Laundromat

Appendix A. Search Strings
Screening (KQ1, KQ2)
Database: Ovid MEDLINE(R)
Search Strategy:
-------------------------------------------------------------------------------1
exp mass screening/ or screening.tw. or exp early diagnosis/
2
(expression screening or throughput screening or molecular screening or pharmaceutical
screening or mutation screening or genetic screening).tw. or exp genetic screening/ or cancer
screening.tw. or compound screening.tw. or drug screening.tw. or exp drug evaluation,
preclinical/
3
1 not 2
4
(randomized controlled trial or controlled clinical trial).pt. or random*.ti,ab. or
placebo.ab. or exp Double-Blind Method/
5
exp albuminuria/ or exp proteinuria/ or exp glomerular filtration rate/ or exp creatinine/
or exp kidney function tests/ or exp cystatins/ or exp kidney diseases/ or kidney$.ti. or nephr$.ti.
or renal.ti. or exp kidney/
6
3 and 4 and 5
7
exp animals/ not humans.sh.
8
6 not 7
9
limit 8 to english language
10
limit 9 to yr="1985 -Current"
11
limit 10 to "all child (0 to 18 years)"
12
limit 10 to "all adult (19 plus years)"
13
11 not 12
14
10 not 13
Monitoring (KQ3, KQ4)
Database: Ovid MEDLINE(R)
Search Strategy:
-------------------------------------------------------------------------------1
monitoring.tw. or exp disease progression/
2
cardiac monitoring.tw. or exp drug monitoring/ or exp environmental monitoring/ or drug
monitoring.tw. or exp blood glucose self-monitoring/ or exp blood gas monitoring,
transcutaneous/ or exp clinical trials data monitoring committees/ or exp esophageal pH
monitoring/ or exp monitoring, immunologic/ or exp uterine monitoring/ or exp monitoring,
intraoperative/ or exp radiation monitoring/ or exp monitoring, physiologic/
3
1 not 2
4
(randomized controlled trial or controlled clinical trial).pt. or random*.ti,ab. or
placebo.ab. or exp Double-Blind Method/
5
exp albuminuria/ or exp proteinuria/ or exp glomerular filtration rate/ or exp creatinine/
or exp kidney function tests/ or exp cystatins/ or exp kidney diseases/ or kidney$.ti. or nephr$.ti.
or renal.ti. or exp kidney/
A-1
6
7
8
9
10
11
12
13
14
3 and 4 and 5
exp animals/ not humans.sh.
6 not 7
limit 8 to english language
limit 9 to yr="1985 -Current"
limit 10 to "all child (0 to 18 years)"
limit 10 to "all adult (19 plus years)"
11 not 12
10 not 13
Treatment (KQ5, KQ6)
Database: Ovid MEDLINE(R)
Search Strategy:
-------------------------------------------------------------------------------1
exp albuminuria/co, de, dh, dt, mo, pc, th or exp proteinuria/co, de, dh, dt, mo, pc, th or
exp glomerular filtration rate/ or exp kidney diseases/co, de, dh, dt, mo, pc, th or exp kidney/co,
de, dh, dt, mo, pc, th or exp diabetic nephropathies/co, de, dh, dt, mo, pc, th or exp kidney
failure, chronic/co, de, dh, dt, mo, pc, th or exp chronic renal insufficiency/co, de, dh, dt, mo, pc,
th or exp renal insufficiency/co, de, dh, dt, mo, pc, th or exp renal insufficiency, chronic/co, de,
dh, dt, mo, pc, th
2
exp *renal replacement therapy/ or exp renal dialysis/ or exp *kidney neoplasms/ or
*nephritis/ or exp *urinary tract infections/ or exp *urolithiasis/ or exp anuria/ or exp diabetes
insipidus/ or exp fanconi syndrome/ or exp hepatorenal syndrome/ or exp hydronephrosis/ or exp
kidney cortex necrosis/ or exp Kidney Diseases, Cystic/ or kidney papillary necrosis/ or exp
nephritis/ or exp renal artery obstruction/ or exp Renal Tubular Transport, Inborn Errors/ or exp
Tuberculosis, Renal/ or exp Zellweger syndrome/ or exp AIDS-Associated Nephropathy/ or exp
Hyperoxaluria/ or exp Nephrocalcinosis/ or exp Perinephritis/ or exp Renal Osteodystrophy/
3
1 not 2
4
(randomized controlled trial or controlled clinical trial).pt. or random*.ti,ab. or
placebo.ab. or exp Double-Blind Method/ or randomized controlled trials as topic/
5
3 and 4
6
exp animals/ not humans.sh.
7
5 not 6
8
limit 7 to english language
9
limit 8 to yr="1985 -Current"
10
limit 9 to "all child (0 to 18 years)"
11
limit 9 to "all adult (19 plus years)"
12
10 not 11
13
9 not 12
A-2
Appendix B. Excluded Studies
(Note that this set of references is different from those in the text, and the numbers are different.)
CKD screening (KQ1, KQ2)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Microalbuminuria in type I diabetic patients.
Prevalence and clinical characteristics.
Microalbuminuria Collaborative Study Group.
Diabetes Care 1992; 15(4):495-501. Not a
randomized trial
The effect of intensive treatment of diabetes on the
development and progression of long-term
complications in insulin-dependent diabetes mellitus.
The Diabetes Control and Complications Trial
Research Group. New England Journal of Medicine
1993; 329(14):977-86. Not an intervention for
screening for CKD
The relationship of glycemic exposure (HbA1c) to
the risk of development and progression of
retinopathy in the diabetes control and complications
trial. Diabetes 1995; 44(8):968-83. Not a randomized
trial
Effects of ramipril on cardiovascular and
microvascular outcomes in people with diabetes
mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention
Evaluation Study Investigators. Lancet 2000;
355(9200):253-9. Not an intervention for screening
for CKD
Abetimus: Abetimus sodium, LJP 394. Biodrugs
2003; 17(3):212-5. Less than 1000 patients in study
Accetta NA, Gladstone EH, DiSogra C, et al.
Prevalence of estimated GFR reporting among US
clinical laboratories. American Journal of Kidney
Diseases 2008; 52(4):778-87. Not a randomized trial
Adler AI, Stevens RJ, Manley SE, et al.
Development and progression of nephropathy in type
2 diabetes: the United Kingdom Prospective Diabetes
Study (UKPDS 64). Kidney International 2003;
63(1):225-32. Not an intervention for screening for
CKD
Agarwal A, Silver MR, Walczyk M, et al. Oncemonthly darbepoetin alfa for maintaining
hemoglobin levels in older patients with chronic
kidney disease. Journal of the American Medical
Directors Association 2007; 8(2):83-90. Not a
randomized trial
Agodoa LY, Francis ME, Eggers PW. Association of
analgesic use with prevalence of albuminuria and
reduced GFR in US adults. American Journal of
Kidney Diseases 2008; 51(4):573-83. Not a
randomized trial
Agrawal A, Sautter MC, Jones NP. Effects of
rosiglitazone maleate when added to a sulfonylurea
regimen in patients with type 2 diabetes mellitus and
mild to moderate renal impairment: a post hoc
analysis. Clinical Therapeutics 2003; 25(11):275464. Duration of follow-up less than 1 year
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
B-1
Ahmedani MY, Hydrie MZI, Iqbal A, et al.
Prevalence of microalbuminuria in type 2 diabetic
patients in Karachi: Pakistan: a multi-center
study.[Erratum appears in J Pak Med Assoc. 2005
Nov;55(11):523].[Erratum appears in J Pak Med
Assoc. 2005 Dec;55(12):570]. JPMA - Journal of the
Pakistan Medical Association 2005; 55(9):382-6. Not
a randomized trial
Ahn CW, Song YD, Kim JH, et al. The validity of
random urine specimen albumin measurement as a
screening test for diabetic nephropathy. Yonsei
Medical Journal 1999; 40(1):40-5. Less than 1000
patients in study
Akanji AO, Mainasara AS, Akinlade KS. Urinary
iodine excretion in mothers and their breast-fed
children in relation to other childhood nutritional
parameters. European Journal of Clinical Nutrition
1996; 50(3):187-91. Not an intervention for
screening for CKD
Al-Maskari F, El-Sadig M, Obineche E. Prevalence
and determinants of microalbuminuria among
diabetic patients in the United Arab Emirates. BMC
Nephrology 2008; 9:1. Not a randomized trial
Alsuwaida A, Abdulkareem A, Alwakeel J. The Gulf
Survey on Anemia Management (GSAM 2005).
Saudi Journal of Kidney Diseases & Transplantation
2007; 18(2):206-14. Patients already diagnosed with
CKD
Amato D, Alvarez-Aguilar C, Castaneda-Limones R,
et al. Prevalence of chronic kidney disease in an
urban Mexican population. Kidney International Supplement 2005; (97):S11-7. Not a randomized
trial
Andrassy J, Zeier M, Andrassy K. Do we need
screening for thrombophilia prior to kidney
transplantation? Nephrology Dialysis Transplantation
2004; 19 Suppl 4:iv64-8. Not a randomized trial
Atkins RC, Briganti EM, Zimmet PZ, et al.
Association between albuminuria and proteinuria in
the general population: the AusDiab Study.
Nephrology Dialysis Transplantation 2003;
18(10):2170-4. Not a randomized trial
Atthobari J, Asselbergs FW, Boersma C, et al. Costeffectiveness of screening for albuminuria with
subsequent fosinopril treatment to prevent
cardiovascular events: A pharmacoeconomic analysis
linked to the prevention of renal and vascular
endstage disease (PREVEND) study and the
prevention of renal and vascular endstage disease
intervention trial (PREVEND IT). Clinical
Therapeutics 2006; 28(3):432-44. Not an intervention
for screening for CKD
Atthobari J, Brantsma AH, Gansevoort RT, et al. The
effect of statins on urinary albumin excretion and
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
glomerular filtration rate: results from both a
randomized clinical trial and an observational cohort
study. Nephrology Dialysis Transplantation 2006;
21(11):3106-14. Less than 1000 patients in study
Atthobari J, Gansevoort RT, Visser ST, et al. The
effect of screening for cardio-renal risk factors on
drug use in the general population. British Journal of
Clinical Pharmacology 2007; 64(6):810-8. Not an
intervention for screening for CKD
Awai K, Imuta M, Utsunomiya D, et al. Contrast
enhancement for whole-body screening using
multidetector row helical CT: comparison between
uniphasic and biphasic injection protocols. Radiation
Medicine 2004; 22(5):303-9. Less than 1000 patients
in study
Azizi M, Menard J, Peyrard S, et al. Assessment of
patients' and physicians' compliance to an ACE
inhibitor treatment based on urinary N-acetyl SerAsp-Lys-Pro determination in the NoninsulinDependent Diabetes, Hypertension,
Microalbuminuria, Proteinuria, Cardiovascular
Events, and Ramipril (DIABHYCAR) study.
Diabetes Care 2006; 29(6):1331-6. Not a randomized
trial
Bakris G. Inclusion of albuminuria in hypertension
and heart guidelines. Kidney International Supplement 2004; (92):S124-5. Not a randomized
trial
Bakris G, Hester A, Weber M, et al. The diabetes
subgroup baseline characteristics of the Avoiding
Cardiovascular Events Through Combination
Therapy in Patients Living With Systolic
Hypertension (ACCOMPLISH) trial. J Cardiometab
Syndr 2008; 3(4):229-33. Not an intervention for
screening for CKD
Bakris GL, Fonseca V, Katholi RE, et al. Differential
effects of beta-blockers on albuminuria in patients
with type 2 diabetes. Hypertension 2005; 46(6):130915. Not an intervention for screening for CKD
Bang H, Mazumdar M, Newman G, et al. Screening
for kidney disease in vascular patients: SCreening for
Occult REnal Disease (SCORED) experience.
Nephrology Dialysis Transplantation 2009;
24(8):2452-7. Not a randomized trial
Barbanel CS, Winkelman JW, Fischer GA, et al.
Confirmation of the Department of Transportation
criteria for a substituted urine specimen. Journal of
Occupational & Environmental Medicine 2002;
44(5):407-16. Not a randomized trial
Barrett BJ, Katzberg RW, Thomsen HS, et al.
Contrast-induced nephropathy in patients with
chronic kidney disease undergoing computed
tomography: a double-blind comparison of iodixanol
and iopamidol.[Erratum appears in Invest Radiol.
2007 Feb;42(2):94 Note: Ni, Zhao-hui [added]].
Investigative Radiology 2006; 41(11):815-21.
Patients already diagnosed with CKD
Baskar V, Kamalakannan D, Holland MR, et al.
Uncertain clinical utility of contemporary strategies
for microalbuminuria testing. Diabetes, Obesity &
Metabolism 2003; 5(4):262-6. Not a randomized trial
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
B-2
Baxter GM, Aitchison F, Sheppard D, et al. Colour
Doppler ultrasound in renal artery stenosis: intrarenal
waveform analysis. British Journal of Radiology
1996; 69(825):810-5. Not a randomized trial
Beatovic S, Jaksic ED, Han RS. Measurement of
renal function by calculation of fractional uptake of
technetium-99m dimercaptosuccinic acid. Nucl Med
Rev Cent East Eur 2004; 7(1):49-52. Not an
intervention for screening for CKD
Beatty OL, Ritchie CM, Hadden DR, et al. Is a
random urinary albumin concentration a useful
screening test in insulin-treated diabetic patients?
Irish Journal of Medical Science 1994; 163(9):406-9.
Not a randomized trial
Beaulieu AJ, Gohh RY, Han H, et al. Enhanced
reduction of fasting total homocysteine levels with
supraphysiological versus standard multivitamin dose
folic acid supplementation in renal transplant
recipients. Arteriosclerosis, Thrombosis & Vascular
Biology 1999; 19(12):2918-21. Patients already
diagnosed with CKD
Beevers DG, Lip GY. Does non-malignant essential
hypertension cause renal damage? A clinician's view.
Journal of Human Hypertension 1996; 10(10):695-9.
Not a randomized trial
Bellizzi V, Scalfi L, Terracciano V, et al. Early
changes in bioelectrical estimates of body
composition in chronic kidney disease. Journal of the
American Society of Nephrology 2006; 17(5):14817. Not a randomized trial
Beresford TP, Blow FC, Hill E, et al. Comparison of
CAGE questionnaire and computer-assisted
laboratory profiles in screening for covert
alcoholism. Lancet 1990; 336(8713):482-5. Not an
intervention for screening for CKD
Berland LL, Koslin DB, Routh WD, et al. Renal
artery stenosis: prospective evaluation of diagnosis
with color duplex US compared with angiography.
Work in progress. Radiology 1990; 174(2):421-3.
Not a randomized trial
Berthoux P, Dejean C, Cecillon S, et al. High
prevalence of hepatitis G virus (HGV) infection in
renal transplantation. Nephrology Dialysis
Transplantation 1998; 13(11):2909-13. Not a
randomized trial
Beto JA, Bansal VK, Hart J, et al. Hemodialysis
prognostic nutrition index as a predictor for
morbidity and mortality in hemodialysis patients and
its correlation to adequacy of dialysis. Council on
Renal Nutrition National Research Question
Collaborative Study Group. Journal of Renal
Nutrition 1999; 9(1):2-8. Patients already diagnosed
with CKD
Bobrie G, Clerson P, Menard J, et al. Masked
hypertension: a systematic review. Journal of
Hypertension 2008; 26(9):1715-25. Not a
randomized trial
Boero R, Prodi E, Elia F, et al. How well are
hypertension and albuminuria treated in type II
diabetic patients? Journal of Human Hypertension
2003; 17(6):413-8. Less than 1000 patients in study
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
Bosmans JL, De Broe ME. Renovascular
hypertension: diagnostic and therapeutic challenges.
Jbr-Btr: Organe de la Societe Royale Belge de
Radiologie 2004; 87(1):32-5. Not a randomized trial
Bostom AG, Carpenter MA, Kusek JW, et al.
Rationale and design of the Folic Acid for Vascular
Outcome Reduction In Transplantation (FAVORIT)
trial. American Heart Journal 2006; 152(3):448.e1-7.
Patients already diagnosed with CKD
Bostom AG, Shemin D, Gohh RY, et al. Treatment
of hyperhomocysteinemia in hemodialysis patients
and renal transplant recipients. Kidney International Supplement 2001; 78:S246-52. Patients already
diagnosed with CKD
Boucher BA, Coffey BC, Kuhl DA, et al. Algorithm
for assessing renal dysfunction risk in critically ill
trauma patients receiving aminoglycosides.
American Journal of Surgery 1990; 160(5):473-80.
Not a randomized trial
Bouhanick B, Berrut G, Chameau AM, et al.
Predictive value of testing random urine sample to
detect microalbuminuria in diabetic subjects during
outpatient visit. Diabete et Metabolisme 1992;
18(1):54-8. Less than 1000 patients in study
Budde K, L Schmouder R, Nashan B, et al.
Pharmacodynamics of single doses of the novel
immunosuppressant FTY720 in stable renal
transplant patients. American Journal of
Transplantation 2003; 3(7):846-54. Patients already
diagnosed with CKD
Budde RJ, Ke S, Levin VA. Activity of pp60c-src in
60 different cell lines derived from human tumors.
Cancer Biochemistry Biophysics 1994; 14(3):171-5.
Not an intervention for screening for CKD
Budney AJ, Hughes JR, Moore BA, et al. Marijuana
abstinence effects in marijuana smokers maintained
in their home environment. Archives of General
Psychiatry 2001; 58(10):917-24. Not a randomized
trial
Buhimschi CS, Norwitz ER, Funai E, et al. Urinary
angiogenic factors cluster hypertensive disorders and
identify women with severe preeclampsia. American
Journal of Obstetrics & Gynecology 2005;
192(3):734-41. Not a randomized trial
Burrowes JD, Larive B, Chertow GM, et al. Selfreported appetite, hospitalization and death in
haemodialysis patients: findings from the
Hemodialysis (HEMO) Study. Nephrology Dialysis
Transplantation 2005; 20(12):2765-74. Patients
already diagnosed with CKD
Buturovic-Ponikvar J. Renal transplant artery
stenosis. Nephrology Dialysis Transplantation 2003;
18 Suppl 5:v74-7. Not a randomized trial
Buxbaum J, Tagoe C, Gallo G, et al. The
pathogenesis of transthyretin tissue deposition:
lessons from transgenic mice. Amyloid 2003; 10
Suppl 1:2-6. Not a randomized trial
Canani LH, Costa LA, Crispim D, et al. The presence
of allele D of angiotensin-converting enzyme
polymorphism is associated with diabetic
nephropathy in patients with less than 10 years
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
B-3
duration of Type 2 diabetes. Diabetic Medicine 2005;
22(9):1167-72. Not a randomized trial
Cao C, Wan X, Chen Y, et al. Metabolic factors and
microinflammatory state promote kidney injury in
type 2 diabetes mellitus patients. Renal Failure 2009;
31(6):470-4. Not a randomized trial
Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus
sodium for renal flare in systemic lupus
erythematosus: results of a randomized, controlled
phase III trial. Arthritis & Rheumatism 2008;
58(8):2470-80. Not an intervention for screening for
CKD
Carter JL, O'Riordan SE, Eaglestone GL, et al.
Chronic kidney disease prevalence in a UK
residential care home population. Nephrology
Dialysis Transplantation 2008; 23(4):1257-64. Not a
randomized trial
Cathelineau G, de Champvallins M, Bouallouche A,
et al. Management of newly diagnosed non-insulindependent diabetes mellitus in the primary care
setting: effects of 2 years of gliclazide treatment--the
Diadem Study. Metabolism: Clinical & Experimental
1997; 46(12 Suppl 1):31-4. Not a randomized trial
Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence
of kidney damage in Australian adults: The AusDiab
kidney study. Journal of the American Society of
Nephrology 2003; 14(7 Suppl 2):S131-8. Not a
randomized trial
Champion MC, Bending JJ, Rodger NW, et al.
Conference on insulin pump therapy in diabetes.
Multicenter study of effect on microvascular disease.
Recruitment, Randomization, and baseline
characteristics of the treatment groups. Diabetes
1985; 34 Suppl 3:13-6. Less than 1000 patients in
study
Chan JC, So WY, Yeung CY, et al. Effects of
structured versus usual care on renal endpoint in type
2 diabetes: the SURE study: a randomized
multicenter translational study. Diabetes Care 2009;
32(6):977-82. Not an intervention for screening for
CKD
Chan YL, Leung CB, Yu SC, et al. Comparison of
non-breath-hold high resolution gadoliniumenhanced MRA with digital subtraction angiography
in the evaluation on allograft renal artery stenosis.
Clinical Radiology 2001; 56(2):127-32. Patients
already diagnosed with CKD
Charytan DM, Wallentin L, Lagerqvist B, et al. Early
angiography in patients with chronic kidney disease:
a collaborative systematic review. Clinical Journal of
The American Society of Nephrology: CJASN 2009;
4(6):1032-43. Not an intervention for screening for
CKD
Chen N, Wang W, Huang Y, et al. Community-based
study on CKD subjects and the associated risk
factors. Nephrology Dialysis Transplantation 2009;
24(7):2117-23. Not a randomized trial
Chen Y-C, Chiu W-T, Wu M-S. Therapeutic effect
of topical gamma-linolenic acid on refractory uremic
pruritus. American Journal of Kidney Diseases 2006;
48(1):69-76. Patients already diagnosed with CKD
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
Chen Z-h, Wang G-h, Wang X-p, et al. Effects of
warm-supplementing kidney yang (WSKY) capsule
added on risperidone on cognition in chronic
schizophrenic patients: a randomized, double-blind,
placebo-controlled, multi-center clinical trial. Human
Psychopharmacology 2008; 23(6):465-70. Not an
intervention for screening for CKD
Cho ME, Kopp JB. HIV and the kidney: a status
report after 20 years. Current HIV/AIDS Reports
2004; 1(3):109-15. Not a randomized trial
Chow FY, Briganti EM, Kerr PG, et al. Healthrelated quality of life in Australian adults with renal
insufficiency: a population-based study. American
Journal of Kidney Diseases 2003; 41(3):596-604. Not
a randomized trial
Chow J, Bennett L. Pre-training assessment tool
(JPAT)--a pilot study. Edtna-Erca Journal 2001;
27(1):37-41. Not a randomized trial
Christianson TJ, Bryant SC, Weymiller AJ, et al. A
pen-and-paper coronary risk estimator for office use
with patients with type 2 diabetes. Mayo Clin Proc
2006; 81(5):632-6. Not a randomized trial
Chumlea WC, Dwyer J, Bergen C, et al. Nutritional
status assessed from anthropometric measures in the
HEMO study. Journal of Renal Nutrition 2003;
13(1):31-8. Patients already diagnosed with CKD
Cohen A, Basch C. Steady state pharmacokinetics of
naproxen in young and elderly healthy volunteers.
Seminars in Arthritis & Rheumatism 1988; 17(3
Suppl 2):7-11. Not an intervention for screening for
CKD
Cohen SD, Norris L, Acquaviva K, et al. Screening,
diagnosis, and treatment of depression in patients
with end-stage renal disease. Clinical Journal of The
American Society of Nephrology: CJASN 2007;
2(6):1332-42. Patients already diagnosed with CKD
Col M, Ocaktan E, Ozdemir O, et al.
Microalbuminuria: prevalence in hypertensives and
diabetics. Acta Medica Austriaca 2004; 31(1):23-9.
Not a randomized trial
Cole LA, Rinne KM, Mahajan SM, et al. Urinary
screening tests for fetal Down syndrome: I. Fresh
beta-core fragment. Prenatal Diagnosis 1999;
19(4):340-50. Not an intervention for screening for
CKD
Collins AC, Vincent J, Newall RG, et al. An aid to
the early detection and management of diabetic
nephropathy: assessment of a new point of care
microalbuminuria system in the diabetic clinic.
Diabetic Medicine 2001; 18(11):928-32. Less than
1000 patients in study
Constantiner M, Sehgal AR, Humbert L, et al. A
dipstick protein and specific gravity algorithm
accurately predicts pathological proteinuria.
American Journal of Kidney Diseases 2005;
45(5):833-41. Not a randomized trial
Cook JD, Hannon MW, Sr., Vo T, et al. Evaluation
of freezing point depression osmolality for
classifying random urine specimens defined as
substituted under HHS/DOT criteria. Journal of
Analytical Toxicology 2002; 26(7):424-9. Less than
1000 patients in study
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
B-4
Cortes-Sanabria L, Cabrera-Pivaral CE, CuetoManzano AM, et al. Improving care of patients with
diabetes and CKD: a pilot study for a clusterrandomized trial. American Journal of Kidney
Diseases 2008; 51(5):777-88. Not an intervention for
screening for CKD
Craig JC, Barratt A, Cumming R, et al. Feasibility
study of the early detection and treatment of renal
disease by mass screening. Internal Medicine Journal
2002; 32(1-2):6-14. Not an intervention for screening
for CKD
Craig KJ, Donovan K, Munnery M, et al.
Identification and management of diabetic
nephropathy in the diabetes clinic. Diabetes Care
2003; 26(6):1806-11. Not a randomized trial
Cueto-Manzano AM, Cortes-Sanabria L, MartinezRamirez HR, et al. Detection of early nephropathy in
Mexican patients with type 2 diabetes mellitus.
Kidney International - Supplement 2005; (97):S40-5.
Not a randomized trial
Cukor D, Coplan J, Brown C, et al. Anxiety disorders
in adults treated by hemodialysis: a single-center
study. American Journal of Kidney Diseases 2008;
52(1):128-36. Patients already diagnosed with CKD
Curtis JJ, Barbeito R, Pirsch J, et al. Differences in
bioavailability between oral cyclosporine
formulations in maintenance renal transplant patients.
American Journal of Kidney Diseases 1999;
34(5):869-74. Patients already diagnosed with CKD
Cusick M, Meleth AD, Agron E, et al. Associations
of mortality and diabetes complications in patients
with type 1 and type 2 diabetes: early treatment
diabetic retinopathy study report no. 27. Diabetes
Care 2005; 28(3):617-25. Not a randomized trial
Davidson MB, Wong A, Hamrahian AH, et al. Effect
of spironolactone therapy on albuminuria in patients
with type 2 diabetes treated with angiotensinconverting enzyme inhibitors. Endocrine Practice
2008; 14(8):985-92. Less than 1000 patients in study
Davis TM, Beilby J, Davis WA, et al. Prevalence,
characteristics, and prognostic significance of HFE
gene mutations in type 2 diabetes: the Fremantle
Diabetes Study. Diabetes Care 2008; 31(9):1795801. Not a randomized trial
De Cosmo S, Motterlini N, Prudente S, et al. Impact
of the PPAR-gamma2 Pro12Ala polymorphism and
ACE inhibitor therapy on new-onset
microalbuminuria in type 2 diabetes: evidence from
BENEDICT. Diabetes 2009; 58(12):2920-9. Not a
randomized trial
de Silva R, Nikitin NP, Bhandari S, et al.
Atherosclerotic renovascular disease in chronic heart
failure: should we intervene? European Heart Journal
2005; 26(16):1596-605. Not a randomized trial
de Zeeuw D, Parving HH, Henning RH.
Microalbuminuria as an early marker for
cardiovascular disease. Journal of the American
Society of Nephrology 2006; 17(8):2100-5. Not a
randomized trial
Debatin JF, Spritzer CE, Grist TM, et al. Imaging of
the renal arteries: value of MR angiography. AJR
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
1991; American Journal of Roentgenology.
157(5):981-90. Less than 1000 patients in study
Deepa M, Pradeepa R, Rema M, et al. The Chennai
Urban Rural Epidemiology Study (CURES)--study
design and methodology (urban component)
(CURES-I). J Assoc Physicians India 2003; 51:86370. Not a randomized trial
D'Elia JA, Weinrauch LA, Gleason RE, et al.
Preliminary screening of the relationship of serum
lipids to survival of chronic dialysis patients. Renal
Failure 1993; 15(2):203-9. Patients already
diagnosed with CKD
Dennen P, Douglas IS, Anderson R. Acute kidney
injury in the intensive care unit: an update and primer
for the intensivist. Critical Care Medicine; 38(1):26175. Not a randomized trial
Desberg AL, Paushter DM, Lammert GK, et al.
Renal artery stenosis: evaluation with color Doppler
flow imaging. Radiology 1990; 177(3):749-53. Less
than 1000 patients in study
Diaz VA, Mainous AG, 3rd, Carek PJ, et al. The
association of vitamin D deficiency and insufficiency
with diabetic nephropathy: implications for health
disparities. J Am Board Fam Med 2009; 22(5):521-7.
Not a randomized trial
Dieker JW, Sun Y-J, Jacobs CW, et al. Mimotopes
for lupus-derived anti-DNA and nucleosome-specific
autoantibodies selected from random peptide phage
display libraries: facts and follies. Journal of
Immunological Methods 2005; 296(1-2):83-93. Not a
randomized trial
Doig JK, MacFadyen RJ, Sweet CS, et al.
Haemodynamic and renal responses to oral losartan
potassium during salt depletion or salt repletion in
normal human volunteers. Journal of Cardiovascular
Pharmacology 1995; 25(4):511-7. Not an
intervention for screening for CKD
Dunn PJ, Jury DR. Random urine albumin:creatinine
ratio measurements as a screening test for diabetic
microalbuminuria--a five year follow up. New
Zealand Medical Journal 1990; 103(902):562-4. Not
a randomized trial
Ejerblad E, Fored CM, Lindblad P, et al. Obesity and
risk for chronic renal failure. Journal of the American
Society of Nephrology 2006; 17(6):1695-702. Not a
randomized trial
Eleftheriadis T, Tsiaga P, Antoniadi G, et al. The
value of serum antilipoarabinomannan antibody
detection in the diagnosis of latent tuberculosis in
hemodialysis patients. American Journal of Kidney
Diseases 2005; 46(4):706-12. Patients already
diagnosed with CKD
Elkohen M, Beregi JP, Deklunder G, et al. A
prospective study of helical computed tomography
angiography versus angiography for the detection of
renal artery stenoses in hypertensive patients. Journal
of Hypertension 1996; 14(4):525-8. Less than 1000
patients in study
Emamian SA, Nielsen MB, Pedersen JF. Can
dipstick screening for hematuria identify individuals
with structural renal abnormalities? A sonographic
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
B-5
evaluation. Scandinavian Journal of Urology &
Nephrology 1996; 30(1):25-7. Not a randomized trial
Ensom MHH, Chong G, Zhou D, et al. Estradiol in
premenstrual asthma: a double-blind, randomized,
placebo-controlled, crossover study.
Pharmacotherapy 2003; 23(5):561-71. Not an
intervention for screening for CKD
Escobedo J, Rana JS, Lombardero MS, et al.
Association between albuminuria and duration of
diabetes and myocardial dysfunction and peripheral
arterial disease among patients with stable coronary
artery disease in the BARI 2D study. Mayo Clin Proc
2010; 85(1):41-6. Not a randomized trial
Etard JF, Borel E. Epidemiological survey of urinary
schistosomiasis in southeastern Mauritania. Tropical
Medicine & Parasitology 1987; 38(1):27-30. Not an
intervention for screening for CKD
Ethier J, Mendelssohn DC, Elder SJ, et al. Vascular
access use and outcomes: an international perspective
from the Dialysis Outcomes and Practice Patterns
Study. Nephrology Dialysis Transplantation 2008;
23(10):3219-26. Not a randomized trial
Ewald B, Attia J. Which test to detect
microalbuminuria in diabetic patients? A systematic
review. Australian Family Physician 2004;
33(7):565-7. Not a randomized trial
Fabian J, Katz I, Gerntholtz T, et al. Chronic kidney
disease in human immunodeficiency virus infection.
Panminerva Medica 2007; 49(2):51-66. Not a
randomized trial
Fagnani F, Souchet T, Labed D, et al. Management
of hypertension and screening of renal complications
by GPs in diabetic type 2 patients (France--2001).
Diabetes & Metabolism 2003; 29(1):58-64. Not a
randomized trial
Fava S, Azzopardi J, Hattersley AT, et al. Increased
prevalence of proteinuria in diabetic sibs of
proteinuric type 2 diabetic subjects. American
Journal of Kidney Diseases 2000; 35(4):708-12. Less
than 1000 patients in study
Fellstrom B, Holdaas H, Jardine AG, et al. Effect of
rosuvastatin on outcomes in chronic haemodialysis
patients: baseline data from the AURORA study.
Kidney & Blood Pressure Research 2007; 30(5):31422. Patients already diagnosed with CKD
Ferris M, Shoham DA, Pierre-Louis M, et al. High
prevalence of unlabeled chronic kidney disease
among inpatients at a tertiary-care hospital.
American Journal of the Medical Sciences 2009;
337(2):93-7. Not a randomized trial
Fischbacher CM, Bhopal R, Rutter MK, et al.
Microalbuminuria is more frequent in South Asian
than in European origin populations: a comparative
study in Newcastle, UK. Diabetic Medicine 2003;
20(1):31-6. Not a randomized trial
Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet
HCl and concurrent low-dose vitamin D improves
treatment of secondary hyperparathyroidism in
dialysis patients compared with vitamin D alone: the
ACHIEVE study results. Clinical Journal of The
American Society of Nephrology: CJASN 2008;
3(6):1718-25. Patients already diagnosed with CKD
117. Flack JM, Grimm RH, Jr., Staffileno BA, et al. New
salt-sensitivity metrics: variability-adjusted blood
pressure change and the urinary sodium-to-creatinine
ratio. Ethnicity & Disease 2002; 12(1):10-9. Less
than 1000 patients in study
118. Fored CM, Nise G, Ejerblad E, et al. Absence of
association between organic solvent exposure and
risk of chronic renal failure: a nationwide populationbased case-control study. Journal of the American
Society of Nephrology 2004; 15(1):180-6. Not a
randomized trial
119. Frankenfield DL, Rocco MV, Roman SH, et al.
Survival advantage for adult Hispanic hemodialysis
patients? Findings from the end-stage renal disease
clinical performance measures project. Journal of the
American Society of Nephrology 2003; 14(1):180-6.
Patients already diagnosed with CKD
120. Freedman BI, Hicks PJ, Sale MM, et al. A leucine
repeat in the carnosinase gene CNDP1 is associated
with diabetic end-stage renal disease in European
Americans. Nephrology Dialysis Transplantation
2007; 22(4):1131-5. Not a randomized trial
121. Freeman RB, Paya C, Pescovitz MD, et al. Risk
factors for cytomegalovirus viremia and disease
developing after prophylaxis in high-risk solid-organ
transplant recipients. Transplantation 2004;
78(12):1765-73. Not an intervention for screening
for CKD
122. Freemont AJ, Hoyland JA, Denton J, et al. The
effects of lanthanum carbonate and calcium
carbonate on bone abnormalities in patients with endstage renal disease. Clinical Nephrology 2005;
64(6):428-37. Patients already diagnosed with CKD
123. Fujii H, Nakamura S, Kuroda S, et al. Relationship
between renal artery stenosis and intrarenal damage
in autopsy subjects with stroke. Nephrology Dialysis
Transplantation 2006; 21(1):113-9. Not a randomized
trial
124. Galassi A, Brancaccio D, Cozzolino M, et al.
Awareness of hypertension and proteinuria in
randomly selected patients in 11 Italian cities. A
2005 report of the National Kidney Foundation of
Italy. Journal of Clinical Hypertension 2009;
11(3):138-43. Not a randomized trial
125. Gallant JE, Winston JA, DeJesus E, et al. The 3-year
renal safety of a tenofovir disoproxil fumarate vs. a
thymidine analogue-containing regimen in
antiretroviral-naive patients. AIDS 2008;
22(16):2155-63. Not an intervention for screening
for CKD
126. Gansevoort RT, Verhave JC, Hillege HL, et al. The
validity of screening based on spot morning urine
samples to detect subjects with microalbuminuria in
the general population. Kidney International Supplement 2005; (94):S28-35. Not a randomized
trial
127. Garcia-Tsao G, Lim JK, Members of Veterans
Affairs Hepatitis CRCP. Management and treatment
of patients with cirrhosis and portal hypertension:
recommendations from the Department of Veterans
Affairs Hepatitis C Resource Center Program and the
National Hepatitis C Program. American Journal of
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
B-6
Gastroenterology 2009; 104(7):1802-29. Not a
randomized trial
Garg AX, Kiberd BA, Clark WF, et al. Albuminuria
and renal insufficiency prevalence guides population
screening: results from the NHANES III. Kidney
International 2002; 61(6):2165-75. Not a randomized
trial
Gatling W, Knight C, Hill RD. Screening for early
diabetic nephropathy: which sample to detect
microalbuminuria? Diabetic Medicine 1985;
2(6):451-5. Not a randomized trial
Gatling W, Knight C, Mullee MA, et al.
Microalbuminuria in diabetes: a population study of
the prevalence and an assessment of three screening
tests. Diabetic Medicine 1988; 5(4):343-7. Not a
randomized trial
Gazis A, Page SR. Microalbuminuria screening in
the UK: are we meeting European standards?
Diabetic Medicine 1996; 13(8):764-7. Not a
randomized trial
George S, Braithwaite RA. An investigation into the
extent of possible dilution of specimens received for
urinary drugs of abuse screening. Addiction 1995;
90(7):967-70. Not a randomized trial
Gerber LM, Johnston K, Alderman MH. Assessment
of a new dipstick test in screening for
microalbuminuria in patients with hypertension.
American Journal of Hypertension 1998; 11(11 Pt
1):1321-7. Not a randomized trial
Ghahramani N, Shadrou S, Hollenbeak C. A
systematic review of continuous renal replacement
therapy and intermittent haemodialysis in
management of patients with acute renal failure.
Nephrology 2008; 13(7):570-8. Patients already
diagnosed with CKD
Ghandour H, Bagley PJ, Shemin D, et al.
Distribution of plasma folate forms in hemodialysis
patients receiving high daily doses of L-folinic or
folic acid. Kidney International 2002; 62(6):2246-9.
Patients already diagnosed with CKD
Giordano M, Tirelli P, Ciarambino T, et al. Screening
of depressive symptoms in young-old hemodialysis
patients: relationship between Beck Depression
Inventory and 15-item Geriatric Depression Scale.
Nephron 2007; 106(4):c187-92. Patients already
diagnosed with CKD
Giugliani R, Ferrari I, Greene LJ. An evaluation of
four methods for the detection of heterozygous
cystinuria. Clinica Chimica Acta 1987; 164(2):22733. Not a randomized trial
Go RC, Desmond R, Roseman JM, et al. Prevalence
and risk factors of microalbuminuria in a cohort of
African-American women with gestational diabetes.
Diabetes Care 2001; 24(10):1764-9. Not a
randomized trial
Gok MA, Shenton BK, Buckley PE, et al. How to
improve the quality of kidneys from non-heartbeating donors: a randomised controlled trial of
thrombolysis in non-heart-beating donors.
Transplantation 2003; 76(12):1714-9. Not an
intervention for screening for CKD
140. Golan L, Birkmeyer JD, Welch HG. The costeffectiveness of treating all patients with type 2
diabetes with angiotensin-converting enzyme
inhibitors. Annals of Internal Medicine 1999;
131(9):660-7. Not an intervention for screening for
CKD
141. Goldsmith DJ, Covic A. Coronary artery disease in
uremia: Etiology, diagnosis, and therapy. Kidney
International 2001; 60(6):2059-78. Not a randomized
trial
142. Goldsmith DJ, Reidy J, Scoble J. Renal arterial
intervention and angiotensin blockade in
atherosclerotic nephropathy. American Journal of
Kidney Diseases 2000; 36(4):837-43. Not a
randomized trial
143. Groetzner J, Wittwer T, Kaczmarek I, et al.
Conversion to sirolimus and mycophenolate can
attenuate the progression of bronchiolitis obliterans
syndrome and improves renal function after lung
transplantation. Transplantation 2006; 81(3):355-60.
Not a randomized trial
144. Gross JL, Zelmanovitz T, Oliveira J, et al. Screening
for diabetic nephropathy: is measurement of urinary
albumin-to-creatinine ratio worthwhile? Diabetes
Care 1999; 22(9):1599-600. Less than 1000 patients
in study
145. Group B. The BErgamo NEphrologic DIabetes
Complications Trial (BENEDICT): design and
baseline characteristics. Controlled Clinical Trials
2003; 24(4):442-61. Not an intervention for
screening for CKD
146. Gupta R, Birnbaum Y, Uretsky BF. The renal patient
with coronary artery disease: current concepts and
dilemmas. Journal of the American College of
Cardiology 2004; 44(7):1343-53. Not a randomized
trial
147. Hall AM, Edwards SG, Lapsley M, et al. Subclinical
tubular injury in HIV-infected individuals on
antiretroviral therapy: a cross-sectional analysis.
American Journal of Kidney Diseases 2009;
54(6):1034-42. Not a randomized trial
148. Hallan H, Romundstad S, Kvenild K, et al.
Microalbuminuria in diabetic and hypertensive
patients and the general population--consequences of
various diagnostic criteria--the Nord-Trondelag
Health Study (HUNT). Scandinavian Journal of
Urology & Nephrology 2003; 37(2):151-8. Not a
randomized trial
149. Hallett M, Burden S, Stewart D, et al. Sleep apnea in
end-stage renal disease patients on hemodialysis and
continuous ambulatory peritoneal dialysis. ASAIO
Journal 1995; 41(3):M435-41. Patients already
diagnosed with CKD
150. Hara N, Koike H, Ogino S, et al. Application of
serum PSA to identify acute bacterial prostatitis in
patients with fever of unknown origin or symptoms
of acute pyelonephritis. Prostate 2004; 60(4):282-8.
Not a randomized trial
151. Harding GKM, Zhanel GG, Nicolle LE, et al.
Antimicrobial treatment in diabetic women with
asymptomatic bacteriuria. New England Journal of
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
B-7
Medicine 2002; 347(20):1576-83. Not an
intervention for screening for CKD
Haug K, Bakke A, Daae LN, et al. Screening for
hematuria, glucosuria and proteinuria in people aged
55-64. Technical, clinical and cost-benefit experience
from a pilot study. Scandinavian Journal of Primary
Health Care 1985; 3(1):31-4. Not a randomized trial
Herget-Rosenthal S, Marggraf G, Husing J, et al.
Early detection of acute renal failure by serum
cystatin C. Kidney International 2004; 66(3):111522. Not an intervention for screening for CKD
Hindmarsh JT. Microalbuminuria. Clinics in
Laboratory Medicine 1988; 8(3):611-6. Not a
randomized trial
Hor T, Baldwin D. Urinary albumin excretion in
patients with diabetes after renal transplantation.
Transplantation Proceedings 2006; 38(9):2879-82.
Not a randomized trial
Howey JE, Browning MC, Fraser CG. Biologic
variation of urinary albumin: consequences for
analysis, specimen collection, interpretation of
results, and screening programs. American Journal of
Kidney Diseases 1989; 13(1):35-7. Not a randomized
trial
Hoy WE, Wang Z, Baker PRA, et al. Reduction in
natural death and renal failure from a systematic
screening and treatment program in an Australian
Aboriginal community. Kidney International Supplement 2003; (83):S66-73. Not a randomized
trial
Huestis MA, Cone EJ. Differentiating new marijuana
use from residual drug excretion in occasional
marijuana users. Journal of Analytical Toxicology
1998; 22(6):445-54. Not an intervention for
screening for CKD
Hyndman ME, Manns BJ, Snyder FF, et al. Vitamin
B12 decreases, but does not normalize, homocysteine
and methylmalonic acid in end-stage renal disease: a
link with glycine metabolism and possible
explanation of hyperhomocysteinemia in end-stage
renal disease. Metabolism: Clinical & Experimental
2003; 52(2):168-72. Patients already diagnosed with
CKD
Incerti J, Zelmanovitz T, Camargo JL, et al.
Evaluation of tests for microalbuminuria screening in
patients with diabetes. Nephrology Dialysis
Transplantation 2005; 20(11):2402-7. Not a
randomized trial
Investigators RRTT, Bellomo R, Cass A, et al.
Screening and study enrolment in the Randomized
Evaluation of Normal vs. Augmented Level
(RENAL) Replacement Therapy Trial. Blood
Purification 2009; 27(2):199-205. Not an
intervention for screening for CKD
Iso H, Shimamoto T, Yokota K, et al. Communitybased education classes for hypertension control. A
1.5-year randomized controlled trial. Hypertension
1996; 27(4):968-74. Not an intervention for
screening for CKD
Izzedine H, Hulot JS, Vittecoq D, et al. Long-term
renal safety of tenofovir disoproxil fumarate in
antiretroviral-naive HIV-1-infected patients. Data
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
from a double-blind randomized active-controlled
multicentre study. Nephrology Dialysis
Transplantation 2005; 20(4):743-6. Not an
intervention for screening for CKD
Jafar TH, Qadri Z, Hashmi S. Prevalence of
microalbuminuria and associated
electrocardiographic abnormalities in an Indo-Asian
population. Nephrology Dialysis Transplantation
2009; 24(7):2111-6. Not a randomized trial
James MA, Fotherby MD, Potter JF. Screening tests
for microalbuminuria in non-diabetic elderly subjects
and their relation to blood pressure. Clinical Science
1995; 88(2):185-90. Not a randomized trial
Jansen JJ, Maassen JA, van der Woude FJ, et al.
Mutation in mitochondrial tRNA(Leu(UUR)) gene
associated with progressive kidney disease. Journal
of the American Society of Nephrology 1997;
8(7):1118-24. Not a randomized trial
Johnson CA, McCarthy J, Bailie GR, et al. Analysis
of renal bone disease treatment in dialysis patients.
American Journal of Kidney Diseases 2002;
39(6):1270-7. Not a randomized trial
Johnson RK, Mortimer AJ. Routine pre-operative
blood testing: is it necessary? Anaesthesia 2002;
57(9):914-7. Not an intervention for screening for
CKD
Juarez FJ, Barrios Y, Cano L, et al. A randomized
trial comparing two corticosteroid regimens
combined with mycophenolate mofetil and
cyclosporine for prevention of acute renal allograft
rejection. Transplantation Proceedings 2006;
38(9):2866-8. Patients already diagnosed with CKD
Judge JS, Low V, Gajraj H, et al. The value of
technetium-99M renography for the detection of
renal artery stenosis in patients with aortic and lower
limb vascular disease. Australian & New Zealand
Journal of Surgery 1992; 62(4):261-5. Not a
randomized trial
Jurkovitz C, Franch H, Shoham D, et al. Family
members of patients treated for ESRD have high
rates of undetected kidney disease. American Journal
of Kidney Diseases 2002; 40(6):1173-8. Not a
randomized trial
Justesen TI, Petersen JLA, Ekbom P, et al. Albuminto-creatinine ratio in random urine samples might
replace 24-h urine collections in screening for microand macroalbuminuria in pregnant woman with type
1 diabetes. Diabetes Care 2006; 29(4):924-5. Not a
randomized trial
Kale K, Sawant S. Clinical significance and
evaluation of proteinuria in NIDDM patients. Indian
Journal of Medical Sciences 1999; 53(3):103-7. Not
a randomized trial
Kapila K, Nampoory MRN, Johny KV, et al. Role of
urinary cytology in detecting human polyoma bk
virus in kidney transplant recipients. A preliminary
report. Medical Principles & Practice 2007;
16(3):237-9. Not a randomized trial
Karaminia R, Tavallaii SA, Lorgard-Dezfuli-Nejad
M, et al. Anxiety and depression: a comparison
between renal transplant recipients and hemodialysis
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
B-8
patients. Transplantation Proceedings 2007;
39(4):1082-4. Patients already diagnosed with CKD
Kelley DE, Bidot P, Freedman Z, et al. Efficacy and
safety of acarbose in insulin-treated patients with
type 2 diabetes. Diabetes Care 1998; 21(12):2056-61.
Not an intervention for screening for CKD
Kimmel PL, Cukor D, Cohen SD, et al. Depression
in end-stage renal disease patients: a critical review.
Advances in Chronic Kidney Disease 2007;
14(4):328-34. Not a randomized trial
King CH, Wiper DW, 3rd, De Stigter KV, et al.
Dose-finding study for praziquantel therapy of
Schistosoma haematobium in Coast Province, Kenya.
American Journal of Tropical Medicine & Hygiene
1989; 40(5):507-13. Not an intervention for
screening for CKD
Kliewer MA, Tupler RH, Carroll BA, et al. Renal
artery stenosis: analysis of Doppler waveform
parameters and tardus-parvus pattern. Radiology
1993; 189(3):779-87. Not a randomized trial
Kocvara R, Plasgura P, Petrik A, et al. A prospective
study of nonmedical prophylaxis after a first kidney
stone. BJU International 1999; 84(4):393-8. Not an
intervention for screening for CKD
Kouidi EJ, Grekas DM, Deligiannis AP. Effects of
exercise training on noninvasive cardiac measures in
patients undergoing long-term hemodialysis: a
randomized controlled trial. American Journal of
Kidney Diseases 2009; 54(3):511-21. Patients
already diagnosed with CKD
Kovarik JM, Hartmann S, Figueiredo J, et al. Effect
of food on everolimus absorption: quantification in
healthy subjects and a confirmatory screening in
patients with renal transplants. Pharmacotherapy
2002; 22(2):154-9. Not an intervention for screening
for CKD
Kovarik JM, Moore R, Wolf P, et al. Screening for
basiliximab exposure-response relationships in renal
allotransplantation. Clinical Transplantation 1999;
13(1 Pt 1):32-8. Patients already diagnosed with
CKD
Kristal B, Shasha SM, Labin L, et al. Estimation of
quantitative proteinuria by using the proteincreatinine ratio in random urine samples. American
Journal of Nephrology 1988; 8(3):198-203. Not a
randomized trial
Krol E, Rutkowski B, Czarniak P, et al. Early
detection of chronic kidney disease: results of the
PolNef study. American Journal of Nephrology
2009; 29(3):264-73. Not a randomized trial
Kyle PM, Campbell S, Buckley D, et al. A
comparison of the inactive urinary
kallikrein:creatinine ratio and the angiotensin
sensitivity test for the prediction of pre-eclampsia.
British Journal of Obstetrics & Gynaecology 1996;
103(10):981-7. Not an intervention for screening for
CKD
Lafolie P, Beck O, Blennow G, et al. Importance of
creatinine analyses of urine when screening for
abused drugs. Clinical Chemistry 1991; 37(11):192731. Not an intervention for screening for CKD
188. Lauritzen T, Christiansen JS, Brock A, et al.
Repeated screening for albumin-creatinine ratio in an
unselected population. The Ebeltoft Health
Promotion Study, a randomized, population-based
intervention trial on health test and health
conversations with general practitioners. Journal of
Diabetes & its Complications 1994; 8(3):146-9. Not
an intervention for screening for CKD
189. Laville M, Anaemia CiDt. New strategies in anaemia
management: ACORD (Anaemia CORrection in
Diabetes) trial. Acta Diabetologica 2004; 41 Suppl
1:S18-22. Not an intervention for screening for CKD
190. Lawrie AS, McDonald SJ, Purdy G, et al.
Prothrombin time derived fibrinogen determination
on Sysmex CA-6000. Journal of Clinical Pathology
1998; 51(6):462-6. Not an intervention for screening
for CKD
191. Leanos-Miranda A, Marquez-Acosta J, RomeroArauz F, et al. Protein:creatinine ratio in random
urine samples is a reliable marker of increased 24hour protein excretion in hospitalized women with
hypertensive disorders of pregnancy. Clinical
Chemistry 2007; 53(9):1623-8. Not a randomized
trial
192. Leedman PJ, Nankervis A, Goodwin M, et al.
Assessment of the Albuscreen microalbuminuria kit
in diabetic outpatients. Medical Journal of Australia
1987; 147(6):285-6. Not a randomized trial
193. Lehmann R, Borovicka J, Kunz P, et al. Evaluation
of delayed gastric emptying in diabetic patients with
autonomic neuropathy by a new magnetic resonance
imaging technique and radio-opaque markers.
Diabetes Care 1996; 19(10):1075-82. Not an
intervention for screening for CKD
194. Leong SO, Lui KF, Ng WY, et al. The use of semiquantitative urine test-strip (Micral Test) for
microalbuminuria screening in patients with diabetes
mellitus. Singapore Medical Journal 1998;
39(3):101-3. Not a randomized trial
195. Lewis EJ, Hunsicker LG, Rodby RA, et al. A clinical
trial in type 2 diabetic nephropathy. American
Journal of Kidney Diseases 2001; 38(4 Suppl
1):S191-4. Patients already diagnosed with CKD
196. Lewis WH, Yeger H, Bonetta L, et al. Homozygous
deletion of a DNA marker from chromosome 11p13
in sporadic Wilms tumor. Genomics 1988; 3(1):2531. Not a randomized trial
197. Lou HX, Vathsala A. Conversion from
mycophenolate mofetil to azathioprine in high-risk
renal allograft recipients on cyclosporine-based
immunosuppression. Transplantation Proceedings
2004; 36(7):2090-1. Patients already diagnosed with
CKD
198. Lu B, Song X, Dong X, et al. High prevalence of
chronic kidney disease in population-based patients
diagnosed with type 2 diabetes in downtown
Shanghai. Journal of Diabetes & its Complications
2008; 22(2):96-103. Not a randomized trial
199. Lucas P, Blome S, Roche J. Intra-renal Doppler
wave-form analysis as a screening test for renal
artery stenosis. Australasian Radiology 1996;
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
B-9
40(3):276-82. Not an intervention for screening for
CKD
Lum G. How effective are screening tests for
microalbuminuria in random urine specimens?
Annals of Clinical & Laboratory Science 2000;
30(4):406-11. Not a randomized trial
Macdougall IC, Matcham J, Gray SJ, et al.
Correction of anaemia with darbepoetin alfa in
patients with chronic kidney disease receiving
dialysis. Nephrology Dialysis Transplantation 2003;
18(3):576-81. Patients already diagnosed with CKD
Malaguarnera M, Ferlito L, Gulizia G, et al. Use of
interleukin-2 in advanced renal carcinoma: metaanalysis and review of the literature. European
Journal of Clinical Pharmacology 2001; 57(4):26773. Not an intervention for screening for CKD
Malik J, Slavikova M, Svobodova J, et al. Regular
ultrasonographic screening significantly prolongs
patency of PTFE grafts. Kidney International 2005;
67(4):1554-8. Not an intervention for screening for
CKD
Malleson PN, Lockitch G, Mackinnon M, et al. Renal
disease in chronic arthritis of childhood. A study of
urinary N-acetyl-beta-glucosaminidase and beta 2microglobulin excretion. Arthritis & Rheumatism
1990; 33(10):1560-6. Not adult population
Marcus J, Sarnak MJ, Menon V. Homocysteine
lowering and cardiovascular disease risk: lost in
translation. Canadian Journal of Cardiology 2007;
23(9):707-10. Not a randomized trial
Marshall SM. Screening for microalbuminuria:
which measurement? Diabetic Medicine 1991;
8(8):706-11. Not a randomized trial
Matinlauri IH, Kyllonen LEJ, Eklund BH, et al.
Weak humoral posttransplant alloresponse after a
well-HLA-matched cadaveric kidney transplantation.
Transplantation 2004; 78(2):198-204. Patients
already diagnosed with CKD
McClellan WM, Ramirez SPB, Jurkovitz C.
Screening for chronic kidney disease: unresolved
issues. Journal of the American Society of
Nephrology 2003; 14(7 Suppl 2):S81-7. Not a
randomized trial
McCullough PA, Li S, Jurkovitz CT, et al. CKD and
cardiovascular disease in screened high-risk
volunteer and general populations: the Kidney Early
Evaluation Program (KEEP) and National Health and
Nutrition Examination Survey (NHANES) 19992004. American Journal of Kidney Diseases 2008;
51(4 Suppl 2):S38-45. Not a randomized trial
McInnes GT, Semple PF. Hypertension:
investigation, assessment and diagnosis. British
Medical Bulletin 1994; 50(2):443-59. Not a
randomized trial
McParland P, Pearce JM, Chamberlain GV. Doppler
ultrasound and aspirin in recognition and prevention
of pregnancy-induced hypertension. Lancet 1990;
335(8705):1552-5. Not an intervention for screening
for CKD
Moore RR, Jr., Hirata-Dulas CA, Kasiske BL. Use of
urine specific gravity to improve screening for
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
albuminuria. Kidney International 1997; 52(1):240-3.
Not a randomized trial
Morgenstern BZ, Butani L, Wollan P, et al. Validity
of protein-osmolality versus protein-creatinine ratios
in the estimation of quantitative proteinuria from
random samples of urine in children. American
Journal of Kidney Diseases 2003; 41(4):760-6. Not
adult population
Mori S, Satoh T, Koide H, et al. Inhibition of
Ras/Raf interaction by anti-oncogenic mutants of
neurofibromin, the neurofibromatosis type 1 (NF1)
gene product, in cell-free systems. Journal of
Biological Chemistry 1995; 270(48):28834-8. Not an
intervention for screening for CKD
Mori TA, Vandongen R, Masarei JR. Fish oilinduced changes in apolipoproteins in IDDM
subjects. Diabetes Care 1990; 13(7):725-32. Not an
intervention for screening for CKD
Mudun A, Falay O, Eryilmaz A, et al. Can exercise
renography be an alternative to ACE inhibitor
renography in hypertensive patients who are
suspicious for renal artery stenosis? Clinical Nuclear
Medicine 2004; 29(1):27-34. Not a randomized trial
Nakao N, Yoshimura A, Morita H, et al.
Combination treatment of angiotensin-II receptor
blocker and angiotensin-converting-enzyme inhibitor
in non-diabetic renal disease (COOPERATE): a
randomised controlled trial.[Erratum appears in
Lancet. 2003 Apr 5;361(9364):1230].[Retraction in
Lancet. 2009 Oct 10;374(9697):1226; PMID:
19819378]. Lancet 2003; 361(9352):117-24. Less
than 1000 patients in study
Nankivell BJ, Chapman JR. The significance of
subclinical rejection and the value of protocol
biopsies. American Journal of Transplantation 2006;
6(9):2006-12. Patients already diagnosed with CKD
Nathan DM, Zinman B, Cleary PA, et al. Modernday clinical course of type 1 diabetes mellitus after
30 years' duration: the diabetes control and
complications trial/epidemiology of diabetes
interventions and complications and Pittsburgh
epidemiology of diabetes complications experience
(1983-2005). Arch Intern Med 2009; 169(14):130716. Not a randomized trial
Newman DJ, Mattock MB, Dawnay ABS, et al.
Systematic review on urine albumin testing for early
detection of diabetic complications. Health
Technology Assessment 2005; 9(30):iii-vi, xiii-163.
Not a randomized trial
Ng LC, Teng LC, Ng ML, et al. Microalbuminuria
measurements by two in-house ELISA methods.
Malaysian Journal of Pathology 2000; 22(2):73-8.
Not a randomized trial
O'Connor PJ, Spann SJ, Woolf SH. Care of adults
with type 2 diabetes mellitus. A review of the
evidence. Journal of Family Practice 1998; 47(5
Suppl):S13-22. Not an intervention for screening for
CKD
Ogawa H, Xu FH, Uebaba K, et al. Antioxidative
potentiality of a Kampo formulation measured by an
ex vivo study. Journal of Alternative &
224.
225.
226.
227.
228.
229.
230.
231.
232.
233.
234.
235.
236.
B-10
Complementary Medicine 2009; 15(3):267-74. Not
an intervention for screening for CKD
Ohmit SE, Flack JM, Peters RM, et al. Longitudinal
Study of the National Kidney Foundation's (NKF)
Kidney Early Evaluation Program (KEEP). Journal
of the American Society of Nephrology 2003; 14(7
Suppl 2):S117-21. Not a randomized trial
Orakzai N, Hanbury DC, Farrington K. Screening for
biochemical abnormalities in urolithiasis patients.
Journal of Ayub Medical College, Abbottabad:
JAMC 2004; 16(2):60-3. Not a randomized trial
Palmer AJ, Valentine WJ, Chen R, et al. A health
economic analysis of screening and optimal
treatment of nephropathy in patients with type 2
diabetes and hypertension in the USA. Nephrology
Dialysis Transplantation 2008; 23(4):1216-23. Not a
randomized trial
Paranjape SB, Thibonnier M. Development and
therapeutic indications of orally-active non-peptide
vasopressin receptor antagonists. Expert Opinion on
Investigational Drugs 2001; 10(5):825-34. Not a
randomized trial
Parikh CR, Gyamlani GG, Carvounis CP. Screening
for microalbuminuria simplified by urine specific
gravity. American Journal of Nephrology 2002;
22(4):315-9. Less than 1000 patients in study
Parving HH. Is antihypertensive treatment the same
for NIDDM and IDDM patients? Diabetes Research
& Clinical Practice 1998; 39 Suppl:S43-7. Not a
randomized trial
Parving HH. Benefits and cost of antihypertensive
treatment in incipient and overt diabetic nephropathy.
Journal of Hypertension - Supplement 1998;
16(1):S99-101. Not a randomized trial
Parving HH, Rossing P. The use of antihypertensive
agents in prevention and treatment of diabetic
nephropathy. Current Opinion in Nephrology &
Hypertension 1994; 3(3):292-300. Not a randomized
trial
Pegoraro A, Singh A, Bakir AA, et al. Simplified
screening for microalbuminuria. Annals of Internal
Medicine 1997; 127(9):817-9. Not a randomized trial
Perroud B, Lee J, Valkova N, et al. Pathway analysis
of kidney cancer using proteomics and metabolic
profiling. Molecular Cancer 2006; 5:64. Not an
intervention for screening for CKD
Persky AM, Ng C, Song MH, et al. Comparison of
the acute pharmacodynamic responses after single
doses of ephedrine or sibutramine in healthy,
overweight volunteers. International Journal of
Clinical Pharmacology & Therapeutics 2004;
42(8):442-8. Not an intervention for screening for
CKD
Petersson B, Kristenson H, Trell E, et al. Screening
and intervention for alcohol-related disease in
middle-aged men: the Malmo Preventive
Programme. Ciba Foundation Symposium 1985;
110:143-63. Not an intervention for screening for
CKD
Pfab T, Franz U, Herfeld F, et al. Rapid
immunochromatographic strip test for the detection
of albuminuria and brief literature review on
237.
238.
239.
240.
241.
242.
243.
244.
245.
246.
247.
248.
albuminuria screening. European Journal of Medical
Research 2006; 11(1):3-6. Not a randomized trial
Phillips RA, Faulkner M, Gassman J, et al.
Recruitment of African Americans with chronic renal
insufficiency into a multicenter clinical trial: the
african american study of kidney disease and
hypertension. Journal of Clinical Hypertension 2004;
6(8):430-6. Not an intervention for screening for
CKD
Plestina S, Stavljenic A, Ceovic S, et al.
Haematological features of the population of the area
of Croatia, Yugoslavia, endemic for Balkan
nephropathy. IARC Scientific Publications 1991;
(115):43-6. Not a randomized trial
Polkinghorne KR, Lau KKP, Saunder A, et al. Does
monthly native arteriovenous fistula blood-flow
surveillance detect significant stenosis--a randomized
controlled trial. Nephrology Dialysis Transplantation
2006; 21(9):2498-506. Not an intervention for
screening for CKD
Postma CT, van Aalen J, de Boo T, et al. Doppler
ultrasound scanning in the detection of renal artery
stenosis in hypertensive patients. British Journal of
Radiology 1992; 65(778):857-60. Not a randomized
trial
Prodjosudjadi W, Suhardjono, Suwitra K, et al.
Detection and prevention of chronic kidney disease
in Indonesia: initial community screening.
Nephrology 2009; 14(7):669-74. Not a randomized
trial
Pugia MJ, Lott JA, Luke KE, et al. Comparison of
instrument-read dipsticks for albumin and creatinine
in urine with visual results and quantitative methods.
Journal of Clinical Laboratory Analysis 1998;
12(5):280-4. Not a randomized trial
Rabindranath KS, Butler JA, Macleod AM, et al.
Physical measures for treating depression in dialysis
patients. Cochrane Database of Systematic Reviews
2005; (2):CD004541. Patients already diagnosed
with CKD
Ralston SH, Caine N, Richards I, et al. Screening for
proteinuria in a rheumatology clinic: comparison of
dipstick testing, 24 hour urine quantitative protein,
and protein/creatinine ratio in random urine samples.
Annals of the Rheumatic Diseases 1988; 47(9):75963. Not an intervention for screening for CKD
Ravikovich E, Messersmith T, Mick G, et al. Effect
of oral fluid intake on urinary albumin excretion in
diabetes mellitus. Journal of Diabetes & its
Complications 2002; 16(4):310-2. Not a randomized
trial
Reach I, Luong N, Chastang C, et al. Dose effect
relationship of reviparin in chronic hemodialysis: a
crossover study versus nadroparin. Artificial Organs
2001; 25(7):591-5. Not an intervention for screening
for CKD
Reddy PP, Mandell J. Prenatal diagnosis.
Therapeutic implications. Urologic Clinics of North
America 1998; 25(2):171-80. Not adult population
Reeves JH, Cumming AR, Gallagher L, et al. A
controlled trial of low-molecular-weight heparin
(dalteparin) versus unfractionated heparin as
249.
250.
251.
252.
253.
254.
255.
256.
257.
258.
259.
B-11
anticoagulant during continuous venovenous
hemodialysis with filtration. Critical Care Medicine
1999; 27(10):2224-8. Not an intervention for
screening for CKD
Regeniter A, Haenni V, Risch L, et al. Urine analysis
performed by flow cytometry: reference range
determination and comparison to morphological
findings, dipstick chemistry and bacterial culture
results--a multicenter study. Clinical Nephrology
2001; 55(5):384-92. Not a randomized trial
Reid A, Stohr W, Walker AS, et al. Severe renal
dysfunction and risk factors associated with renal
impairment in HIV-infected adults in Africa
initiating antiretroviral therapy. Clinical Infectious
Diseases 2008; 46(8):1271-81. Not a randomized
trial
Ricos C, Jimenez CV, Hernandez A, et al. Biological
variation in urine samples used for analyte
measurements. Clinical Chemistry 1994; 40(3):4727. Not a randomized trial
Roderick PJ, Atkins RJ, Smeeth L, et al. Detecting
chronic kidney disease in older people; what are the
implications?.[Erratum appears in Age Ageing. 2009
Sep;38(5):638 Note: Flectcher, Astrid E [corrected to
Fletcher, Astrid E]]. Age & Ageing 2008; 37(2):17986. Not a randomized trial
Romundstad S, Holmen J, Kvenild K, et al. Clinical
relevance of microalbuminuria screening in selfreported non-diabetic/non-hypertensive persons
identified in a large health screening--the NordTrondelag Health Study (HUNT), Norway. Clinical
Nephrology 2003; 59(4):241-51. Not a randomized
trial
Romundstad S, Holmen J, Kvenild K, et al.
Microalbuminuria and all-cause mortality in 2,089
apparently healthy individuals: a 4.4-year follow-up
study. The Nord-Trondelag Health Study (HUNT),
Norway. American Journal of Kidney Diseases 2003;
42(3):466-73. Not a randomized trial
Sandler DP, Burr FR, Weinberg CR. Nonsteroidal
anti-inflammatory drugs and the risk for chronic
renal disease. Annals of Internal Medicine 1991;
115(3):165-72. Not a randomized trial
Saran AM, DuBose TD, Jr. Cardiovascular disease in
chronic kidney disease. Therapeutic Advances in
Cardiovascular Disease 2008; 2(6):425-34. Not a
randomized trial
Saraux A, Fautrel B, Maillefert JF, et al. Laboratory
and imaging studies used by French rheumatologists
to evaluate patients with early arthritis. Journal of
Rheumatology 2006; 33(5):897-902. Not an
intervention for screening for CKD
Saw J, Levin A, Gin K. Coronary artery disease in
chronic kidney disease patients: assessing the
evidence for diagnosis, screening and
revascularization. Canadian Journal of Cardiology
2004; 20(8):807-13. Not a randomized trial
Sawicki PT, Kaiser S, Heinemann L, et al.
Prevalence of renal artery stenosis in diabetes
mellitus--an autopsy study. Journal of Internal
Medicine 1991; 229(6):489-92. Not a randomized
trial
260. Scheid DC, McCarthy LH, Lawler FH, et al.
Screening for microalbuminuria to prevent
nephropathy in patients with diabetes: a systematic
review of the evidence. Journal of Family Practice
2001; 50(8):661-8. Not an intervention for screening
for CKD
261. Schreij G, van Es PN, Schiffers PM, et al. 'Captopril
test', with blood pressure and peripheral renin as
response variables in hypertensive patients with
suspected renal artery stenosis. Journal of Human
Hypertension 1995; 9(9):741-6. Not an intervention
for screening for CKD
262. Schumacher G, Hilscher W, Mollering H, et al.
Engineering enzymes for clinical diagnosis. Annales
de Biologie Clinique 1993; 51(9):815-9. Not an
intervention for screening for CKD
263. Schwab SJ, Dunn FL, Feinglos MN. Screening for
microalbuminuria. A comparison of single sample
methods of collection and techniques of albumin
analysis. Diabetes Care 1992; 15(11):1581-4. Not a
randomized trial
264. Servois V, Laissy JP, Feger C, et al. Twodimensional time-of-flight magnetic resonance
angiography of renal arteries without maximum
intensity projection: a prospective comparison with
angiography in 21 patients screened for renovascular
hypertension. Cardiovascular & Interventional
Radiology 1994; 17(3):138-42. Not a randomized
trial
265. Shambesh MA, Craig PS, Macpherson CN, et al. An
extensive ultrasound and serologic study to
investigate the prevalence of human cystic
echinococcosis in northern Libya. American Journal
of Tropical Medicine & Hygiene 1999; 60(3):462-8.
Not an intervention for screening for CKD
266. Shionoiri H, Kosaka T, Kita E, et al. Comparison of
long-term therapeutic effect of an ACE inhibitor,
temocapril, with that of a diuretic on
microalbuminuria in non-diabetic essential
hypertension. Hypertension Research - Clinical &
Experimental 2000; 23(6):593-600. Not an
intervention for screening for CKD
267. Siewert-Delle A. Long-term renal function in
primary hypertension. An epidemiological and
pathophysiological study. Scandinavian Journal of
Urology & Nephrology Supplementum 1999; 199:136. Not a randomized trial
268. Sikka R, Waters J, Moore W, et al. Renal assessment
practices and the effect of nurse case management of
health maintenance organization patients with
diabetes. Diabetes Care 1999; 22(1):1-6. Less than
1000 patients in study
269. Singh GR, White AV, Hoy WE. Renal ultrasound
findings in an Australian Aboriginal population with
high rates of renal disease. Nephrology 2005;
10(4):358-61. Not a randomized trial
270. Singh NP, Ingle GK, Saini VK, et al. Prevalence of
low glomerular filtration rate, proteinuria and
associated risk factors in North India using
Cockcroft-Gault and Modification of Diet in Renal
Disease equation: an observational, cross-sectional
271.
272.
273.
274.
275.
276.
277.
278.
279.
280.
281.
282.
B-12
study. BMC Nephrology 2009; 10:4. Not a
randomized trial
Skipper GE, Weinmann W, Thierauf A, et al. Ethyl
glucuronide: a biomarker to identify alcohol use by
health professionals recovering from substance use
disorders. Alcohol & Alcoholism 2004; 39(5):445-9.
Not an intervention for screening for CKD
Smaill F. Antibiotics for asymptomatic bacteriuria in
pregnancy. Cochrane Database of Systematic
Reviews 2001; (2):CD000490. Not an intervention
for screening for CKD
Smaill F, Vazquez JC. Antibiotics for asymptomatic
bacteriuria in pregnancy. Cochrane Database of
Systematic Reviews 2007; (2):CD000490. Not an
intervention for screening for CKD
Smith ML, Barnes AJ, Huestis MA. Identifying new
cannabis use with urine creatinine-normalized
THCCOOH concentrations and time intervals
between specimen collections. Journal of Analytical
Toxicology 2009; 33(4):185-9. Not an intervention
for screening for CKD
Smith-Kielland A, Skuterud B, Olsen KM, et al.
Urinary excretion of diazepam metabolites in healthy
volunteers and drug users. Scandinavian Journal of
Clinical & Laboratory Investigation 2001; 61(3):23746. Not an intervention for screening for CKD
Snyder S, Pendergraph B. Detection and evaluation
of chronic kidney disease. American Family
Physician 2005; 72(9):1723-32. Not a randomized
trial
Soonthornpun S, Leelawattana R, Thamprasit A, et
al. Screening for microalbuminuria in type 2
diabetes: a reconsideration. Journal of the Medical
Association of Thailand 2002; 85(5):604-11. Not a
randomized trial
Springhart WP, Marguet CG, Sur RL, et al. Forced
versus minimal intravenous hydration in the
management of acute renal colic: a randomized trial.
Journal of Endourology 2006; 20(10):713-6. Not an
intervention for screening for CKD
Sumaili EK, Cohen EP, Zinga CV, et al. High
prevalence of undiagnosed chronic kidney disease
among at-risk population in Kinshasa, the
Democratic Republic of Congo. BMC Nephrology
2009; 10:18. Not a randomized trial
Suri RS, Clark WF, Barrowman N, et al. Diabetes
during diarrhea-associated hemolytic uremic
syndrome: a systematic review and meta-analysis.
Diabetes Care 2005; 28(10):2556-62. Not an
intervention for screening for CKD
Takahashi H, Kinouchi M, Wuepper KD, et al.
Cloning of human keratolinin cDNA: keratolinin is
identical with a cysteine proteinase inhibitor, cystatin
A, and is regulated by Ca2+, TPA, and cAMP.
Journal of Investigative Dermatology 1997;
108(6):843-7. Not an intervention for screening for
CKD
Tapp RJ, Shaw JE, Harper CA, et al. The prevalence
of and factors associated with diabetic retinopathy in
the Australian population. Diabetes Care 2003;
26(6):1731-7. Not a randomized trial
283. Thomsen HS, Morcos SK, Erley CM, et al. The
ACTIVE Trial: comparison of the effects on renal
function of iomeprol-400 and iodixanol-320 in
patients with chronic kidney disease undergoing
abdominal computed tomography. Investigative
Radiology 2008; 43(3):170-8. Not an intervention for
screening for CKD
284. Thomsen HS, Sos TA, Nielsen SL. Renovascular
hypertension. Diagnosis and intervention. Acta
Radiologica 1989; 30(2):113-20. Not a randomized
trial
285. Torng S, Rigatto C, Rush DN, et al. The urine protein
to creatinine ratio (P/C) as a predictor of 24-hour
urine protein excretion in renal transplant patients.
Transplantation 2001; 72(8):1453-6. Not a
randomized trial
286. Toussaint ND, Lau KK, Strauss BJ, et al.
Determination and validation of aortic calcification
measurement from lateral bone densitometry in
dialysis patients. Clinical Journal of The American
Society of Nephrology: CJASN 2009; 4(1):119-27.
Patients already diagnosed with CKD
287. Toyoda N, Nagai S, Terashima Y, et al. Analysis of
mRNA with microsomal fractionation using a
SAGE-based DNA microarray system facilitates
identification of the genes encoding secretory
proteins. Genome Research 2003; 13(7):1728-36.
Not an intervention for screening for CKD
288. Tsai S-Y, Tseng H-F, Tan H-F, et al. End-stage renal
disease in Taiwan: a case-control study. Journal of
Epidemiology 2009; 19(4):169-76. Not a randomized
trial
289. Tumlin JA, Finkel KW, Murray PT, et al.
Fenoldopam mesylate in early acute tubular necrosis:
a randomized, double-blind, placebo-controlled
clinical trial. American Journal of Kidney Diseases
2005; 46(1):26-34. Not an intervention for screening
for CKD
290. Tutone VK, Mark PB, Revanur V, et al. Random
blood glucose measurements and survival in
nondiabetic renal transplant recipients.
Transplantation Proceedings 2004; 36(10):3006-11.
Patients already diagnosed with CKD
291. van Kooten F, Ciabattoni G, Koudstaal PJ, et al.
Increased thromboxane biosynthesis is associated
with poststroke dementia. Stroke 1999; 30(8):1542-7.
Not an intervention for screening for CKD
292. Vegter S, Perna A, Hiddema W, et al. Costeffectiveness of ACE inhibitor therapy to prevent
dialysis in nondiabetic nephropathy: influence of the
ACE insertion/deletion polymorphism.
Pharmacogenetics & Genomics 2009; 19(9):695-703.
Not a randomized trial
293. Velazquez Lopez L, Sil Acosta MJ, Goycochea
Robles MV, et al. Effect of protein restriction diet on
renal function and metabolic control in patients with
type 2 diabetes: a randomized clinical trial. Nutricion
Hospitalaria 2008; 23(2):141-7. Not an intervention
for screening for CKD
294. Viberti G, Kahn SE, Greene DA, et al. A diabetes
outcome progression trial (ADOPT): an international
multicenter study of the comparative efficacy of
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
B-13
rosiglitazone, glyburide, and metformin in recently
diagnosed type 2 diabetes. Diabetes Care 2002;
25(10):1737-43. Not an intervention for screening
for CKD
Wachtell K, Olsen MH, Dahlof B, et al.
Microalbuminuria in hypertensive patients with
electrocardiographic left ventricular hypertrophy: the
LIFE study. Journal of Hypertension 2002;
20(3):405-12. Not a randomized trial
Wanner C, Horl WH, Luley CH, et al. Effects of
HMG-CoA reductase inhibitors in
hypercholesterolemic patients on hemodialysis.
Kidney International 1991; 39(4):754-60. Patients
already diagnosed with CKD
Warrington SJ, Ravic M, Dawnay A. Renal and
general tolerability of repeated doses of nimesulide
in normal subjects. Drugs 1993; 46 Suppl 1:263-9.
Not an intervention for screening for CKD
Waterman AD, Browne T, Waterman BM, et al.
Attitudes and behaviors of African Americans
regarding early detection of kidney disease.
American Journal of Kidney Diseases 2008;
51(4):554-62. Not a randomized trial
Watson WJ. Screening for glycosuria during
pregnancy. Southern Medical Journal 1990;
83(2):156-8. Not a randomized trial
Watts GF, Hodgson B, Morris RW, et al. Side-room
tests to screen for microalbuminuria in diabetes
mellitus. Diabetic Medicine 1988; 5(3):298-303. Not
a randomized trial
Webb DJ, Newman DJ, Chaturvedi N, et al. The use
of the Micral-Test strip to identify the presence of
microalbuminuria in people with insulin dependent
diabetes mellitus (IDDM) participating in the
EUCLID study. Diabetes Research & Clinical
Practice 1996; 31(1-3):93-102. Not a randomized
trial
Weger M, Deutschmann H, Weger W, et al.
Incomplete renal tubular acidosis in 'primary'
osteoporosis. Osteoporosis International 1999;
10(4):325-9. Not a randomized trial
Whelton PK, Lee JY, Kusek JW, et al. Recruitment
experience in the African American Study of Kidney
Disease and Hypertension (AASK) Pilot Study.
Controlled Clinical Trials 1996; 17(4 Suppl):17S33S. Not an intervention for screening for CKD
Wilde HM, Banks D, Larsen CL, et al. Evaluation of
the Bayer microalbumin/creatinine urinalysis
dipstick. Clinica Chimica Acta 2008; 393(2):110-3.
Not a randomized trial
Williams BT, Ketchum CH, Robinson CA, et al.
Screening for slight albuminuria: a comparison of
selected commercially available methods. Southern
Medical Journal 1990; 83(12):1447-9. Not a
randomized trial
Wilson RA, Norman DJ, Barry JM, et al.
Noninvasive cardiac testing in the end-stage renal
disease patient. Blood Purification 1994; 12(1):7883. Not an intervention for screening for CKD
Wingo CS, Clapp WL. Proteinuria: potential causes
and approach to evaluation. American Journal of the
308.
309.
310.
311.
312.
313.
314.
315.
316.
Medical Sciences 2000; 320(3):188-94. Not a
randomized trial
Witting M, Kuo D. Screening with blood urea
nitrogen before intravenous contrast. American
Journal of Emergency Medicine 2003; 21(6):494-6.
Not a randomized trial
Womer KL, Huang Y, Herren H, et al. Dendritic cell
deficiency associated with development of BK
viremia and nephropathy in renal transplant
recipients. Transplantation 2010; 89(1):115-23. Not
an intervention for screening for CKD
Woo J, Lau E, Swaminathan R, et al. Biochemical
predictors for osteoporotic fractures in elderly
Chinese--a longitudinal study. Gerontology 1990;
36(1):55-8. Not an intervention for screening for
CKD
Woolhandler S, Pels RJ, Bor DH, et al. Dipstick
urinalysis screening of asymptomatic adults for
urinary tract disorders. I. Hematuria and proteinuria.
JAMA 1989; 262(9):1214-9. Not a randomized trial
Wroe S. Zonisamide and renal calculi in patients
with epilepsy: how big an issue? Current Medical
Research & Opinion 2007; 23(8):1765-73. Not a
randomized trial
Wu SY, Fisher DA, Huang WS, et al. Urinary
compound W in pregnant women is a potential
marker for fetal thyroid function. American Journal
of Obstetrics & Gynecology 1998; 178(5):886-91.
Not an intervention for screening for CKD
Xin G, Wang M, Jiao L-l, et al. Protein-to-creatinine
ratio in spot urine samples as a predictor of
quantitation of proteinuria. Clinica Chimica Acta
2004; 350(1-2):35-9. Not a randomized trial
Yanik B, Bavbek N, Yanik T, et al. The effect of
alendronate, risedronate, and raloxifene on renal
functions, based on the Cockcroft and Gault method,
in postmenopausal women. Renal Failure 2007;
29(4):471-6. Not an intervention for screening for
CKD
Ylinenjarvi K, Widersten M, Bjork I. Hydrophobic
sequences can substitute for the wild-type N-terminal
sequence of cystatin A (stefin A) in tight binding to
cysteine proteinases selection of high-affinity N-
317.
318.
319.
320.
321.
322.
323.
324.
terminal region variants by phage display. European
Journal of Biochemistry 1999; 261(3):682-8. Not an
intervention for screening for CKD
Yocum DE, Furst DE, Bensen WG, et al. Safety of
tacrolimus in patients with rheumatoid arthritis: longterm experience. Rheumatology 2004; 43(8):992-9.
Not an intervention for screening for CKD
Zarif L, Covic A, Iyengar S, et al. Inaccuracy of
clinical phenotyping parameters for hypertensive
nephrosclerosis. Nephrology Dialysis
Transplantation 2000; 15(11):1801-7. Not a
randomized trial
Zeller A, Sigle J-P, Battegay E, et al. Value of a
standard urinary dipstick test for detecting
microalbuminuria in patients with newly diagnosed
hypertension. Swiss Medical Weekly 2005; 135(34):57-61. Not a randomized trial
Zelmanovitz T, Gross JL, Oliveira J, et al.
Proteinuria is still useful for the screening and
diagnosis of overt diabetic nephropathy. Diabetes
Care 1998; 21(7):1076-9. Not a randomized trial
Zelmanovitz T, Gross JL, Oliveira JR, et al. The
receiver operating characteristics curve in the
evaluation of a random urine specimen as a screening
test for diabetic nephropathy. Diabetes Care 1997;
20(4):516-9. Not a randomized trial
Zhang Q, Zhang Z, Xin D, et al. Suppression
subtractive hybridization for identifying differentially
expressed genes in renal cell carcinoma. Chinese
Medical Journal 2001; 114(8):807-12. Not an
intervention for screening for CKD
Zhao H, Li X, Johnson DE, et al. Identification of
protease and rpoN-associated genes of uropathogenic
Proteus mirabilis by negative selection in a mouse
model of ascending urinary tract infection.
Microbiology 1999; 145(Pt 1):185-95. Not a
randomized trial
Ziegler D, Siekierka-Kleiser E, Meyer B, et al.
Validation of a novel screening device (NeuroQuick)
for quantitative assessment of small nerve fiber
dysfunction as an early feature of diabetic
polyneuropathy. Diabetes Care 2005; 28(5):1169-74.
Not an intervention for screening for CKD
CKD monitoring (KQ3, KQ4)
1.
2.
The effect of intensive treatment of diabetes on the
development and progression of long-term
complications in insulin-dependent diabetes mellitus.
The Diabetes Control and Complications Trial
Research Group. New England Journal of Medicine
1993; 329(14):977-86. Intervention not related to
monitoring of CKD
Intensive therapy and progression to clinical
albuminuria in patients with insulin dependent
diabetes mellitus and microalbuminuria.
Microalbuminuria Collaborative Study Group,
United Kingdom. BMJ 1995; 311(7011):973-7.
Intervention not related to monitoring of CKD
3.
4.
5.
B-14
Effect of intensive therapy on the development and
progression of diabetic nephropathy in the Diabetes
Control and Complications Trial. The Diabetes
Control and Complications (DCCT) Research Group.
Kidney International 1995; 47(6):1703-20.
Intervention not related to monitoring of CKD
The absence of a glycemic threshold for the
development of long-term complications: the
perspective of the Diabetes Control and
Complications Trial. Diabetes 1996; 45(10):1289-98.
Intervention not related to monitoring of CKD
Captopril reduces the risk of nephropathy in IDDM
patients with microalbuminuria. The
Microalbuminuria Captopril Study Group.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Diabetologia 1996; 39(5):587-93. Intervention not
related to monitoring of CKD
Randomised placebo-controlled trial of effect of
ramipril on decline in glomerular filtration rate and
risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group (Gruppo
Italiano di Studi Epidemiologici in Nefrologia).
Lancet 1997; 349(9069):1857-63. Intervention not
related to monitoring of CKD
Parenteral cidofovir for cytomegalovirus retinitis in
patients with AIDS: the HPMPC peripheral
cytomegalovirus retinitis trial. A randomized,
controlled trial. Studies of Ocular complications of
AIDS Research Group in Collaboration with the
AIDS Clinical Trials Group. Annals of Internal
Medicine 1997; 126(4):264-74. Intervention not
related to monitoring of CKD
Effects of ramipril on cardiovascular and
microvascular outcomes in people with diabetes
mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention
Evaluation Study Investigators.[Erratum appears in
Lancet 2000 Sep 2;356(9232):860]. Lancet 2000;
355(9200):253-9. Intervention not related to
monitoring of CKD
Retinopathy and nephropathy in patients with type 1
diabetes four years after a trial of intensive therapy.
The Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and
Complications Research Group.[Erratum appears in
N Engl J Med 2000 May 4;342(18):1376]. New
England Journal of Medicine 2000; 342(6):381-9.
Intervention not related to monitoring of CKD
Angiotensin II receptor antagonists and heart failure:
angiotensin-converting-enzyme inhibitors remain the
first-line option. Prescrire International 2005;
14(79):180-6. Intervention not related to monitoring
of CKD
Telmisartan did not prevent renal disease in patients
without proteinuria.[Original report in Ann Intern
Med. 2009 Jul 7;151(1):1-10, W1-2; PMID:
19451556]. Annals of Internal Medicine 2009;
151(1):I28. Intervention not related to monitoring of
CKD
Abe M, Okada K, Kikuchi F, et al. Clinical
investigation of the effects of pioglitazone on the
improvement of insulin resistance and blood pressure
in type 2-diabetic patients undergoing hemodialysis.
Clinical Nephrology 2008; 70(3):220-8. Less than 50
patients in study
Abe M, Okada K, Maruyama T, et al. Comparison of
the antiproteinuric effects of the calcium channel
blockers benidipine and amlodipine administered in
combination with angiotensin receptor blockers to
hypertensive patients with stage 3-5 chronic kidney
disease. Hypertension Research - Clinical &
Experimental 2009; 32(4):270-5. Intervention not
related to monitoring of CKD
Abe M, Okada K, Maruyama T, et al. Antiproteinuric
and blood pressure-lowering effects of a fixed-dose
combination of losartan and hydrochlorothiazide in
hypertensive patients with stage 3 chronic kidney
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
B-15
disease. Pharmacotherapy 2009; 29(9):1061-72.
Duration of follow-up less than 1 year
Abouna GM, al-Abdullah IH, Kelly-Sullivan D, et al.
Randomized clinical trial of antithymocyte globulin
induction in renal transplantation comparing a fixed
daily dose with dose adjustment according to T cell
monitoring. Transplantation 1995; 59(11):1564-8.
Not patients with early CKD
Acone D, Cante D, Cillo F, et al. Blood pressure and
progression of renal failure in the elderly. Kidney
International - Supplement 1996; 55:S75-7. Less than
50 patients in study
Adler AI, Stevens RJ, Manley SE, et al.
Development and progression of nephropathy in type
2 diabetes: the United Kingdom Prospective Diabetes
Study (UKPDS 64). Kidney International 2003;
63(1):225-32. Not a randomized trial
Agarwal R. Reproducibility of renal function
measurements in adult men with diabetic
nephropathy: research and clinical implications.
American Journal of Nephrology 2007; 27(1):92100. Not a randomized trial
Agarwal R. Vitamin D, proteinuria, diabetic
nephropathy, and progression of CKD. Clinical
Journal of The American Society of Nephrology:
CJASN 2009; 4(9):1523-8. Not a randomized trial
Agarwal R. Blood pressure components and the risk
for end-stage renal disease and death in chronic
kidney disease. Clinical Journal of The American
Society of Nephrology: CJASN 2009; 4(4):830-7.
Not a randomized trial
Agarwal R, Acharya M, Tian J, et al. Antiproteinuric
effect of oral paricalcitol in chronic kidney disease.
Kidney International 2005; 68(6):2823-8. Duration
of follow-up less than 1 year
Agha A, Amer W, Anwar E, et al. Reduction of
microalbuminuria by using losartan in normotensive
patients with type 2 diabetes mellitus: A randomized
controlled trial. Saudi Journal of Kidney Diseases &
Transplantation 2009; 20(3):429-35. Duration of
follow-up less than 1 year
Agrawal A, Sautter MC, Jones NP. Effects of
rosiglitazone maleate when added to a sulfonylurea
regimen in patients with type 2 diabetes mellitus and
mild to moderate renal impairment: a post hoc
analysis. Clinical Therapeutics 2003; 25(11):275464. Duration of follow-up less than 1 year
Agrawal RP, Dogra R, Mohta N, et al. Beneficial
effect of camel milk in diabetic nephropathy. Acta
Bio-Medica de l Ateneo Parmense 2009; 80(2):1314. Duration of follow-up less than 1 year
Ahern MJ, Harrison W, Hollingsworth P, et al. A
randomised double-blind trial of cyclosporin and
azathioprine in refractory rheumatoid arthritis.
Australian & New Zealand Journal of Medicine
1991; 21(6):844-9. Intervention not related to
monitoring of CKD
Ahmad J, Shafique S, Abidi SM, et al. Effect of 5year enalapril therapy on progression of
microalbuminuria and glomerular structural changes
in type 1 diabetic subjects. Diabetes Research &
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
Clinical Practice 2003; 60(2):131-8. Intervention not
related to monitoring of CKD
Ahmad J, Siddiqui MA, Ahmad H. Effective
postponement of diabetic nephropathy with enalapril
in normotensive type 2 diabetic patients with
microalbuminuria. Diabetes Care 1997; 20(10):157681. Intervention not related to monitoring of CKD
Aho PS, Niemi T, Lindgren L, et al. Endovascular vs
open AAA repair: similar effects on renal proximal
tubular function. Scandinavian Journal of Surgery:
SJS 2004; 93(1):52-6. Not a randomized trial
Ahsan N, Hricik D, Matas A, et al. Prednisone
withdrawal in kidney transplant recipients on
cyclosporine and mycophenolate mofetil--a
prospective randomized study. Steroid Withdrawal
Study Group. Transplantation 1999; 68(12):1865-74.
Not patients with early CKD
Akesson A, Wollheim FA, Thysell H, et al. Visceral
improvement following combined plasmapheresis
and immunosuppressive drug therapy in progressive
systemic sclerosis. Scandinavian Journal of
Rheumatology 1988; 17(5):313-23. Not a
randomized trial
Akizawa T, Asano Y, Morita S, et al. Effect of a
carbonaceous oral adsorbent on the progression of
CKD: a multicenter, randomized, controlled trial.
American Journal of Kidney Diseases 2009;
54(3):459-67. Intervention not related to monitoring
of CKD
Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline
improves short-term survival in severe acute
alcoholic hepatitis: a double-blind, placebocontrolled trial. Gastroenterology 2000; 119(6):163748. Not patients with early CKD
Albanis S, Ather HM, Papatsoris AG, et al.
Inversion, hydration and diuresis during
extracorporeal shock wave lithotripsy: does it
improve the stone-free rate for lower pole stone
clearance? Urologia Internationalis 2009; 83(2):2116. Not a randomized trial
Albert I, Jais JP. The use of frailty models in genetic
studies: application to the relationship between endstage renal failure and mutation type in Alport
syndrome. European Community Alport Syndrome
Concerted Action Group (ECASCA). Journal of
Epidemiology & Biostatistics 2000; 5(3):169-75. Not
a randomized trial
Albert SG, Shapiro MJ, Brown WW, et al. Analysis
of radiocontrast-induced nephropathy by dual-labeled
radionuclide clearance. Investigative Radiology
1994; 29(6):618-23. Duration of follow-up less than
1 year
Al-Kateb H, Boright AP, Mirea L, et al. Multiple
superoxide dismutase 1/splicing factor serine alanine
15 variants are associated with the development and
progression of diabetic nephropathy: the Diabetes
Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications Genetics
study. Diabetes 2008; 57(1):218-28. Not a
randomized trial
Allon M, Robbin ML. Hemodialysis vascular access
monitoring: current concepts. Hemodialysis
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
B-16
International 2009; 13(2):153-62. Not a randomized
trial
Amato RJ, Jac J, Hernandez-McClain J. Interferonalpha in combination with either imatinib (Gleevec)
or gefitinib (Iressa) in metastatic renal cell
carcinoma: a phase II trial. Anti-Cancer Drugs 2008;
19(5):527-33. Not a randomized trial
Andersen S, Brochner-Mortensen J, Parving HH.
Kidney function during and after withdrawal of longterm irbesartan treatment in patients with type 2
diabetes and microalbuminuria. Diabetes Care 2003;
26(12):3296-302. Duration of follow-up less than 1
year
Ansquer J-C, Foucher C, Rattier S, et al. Fenofibrate
reduces progression to microalbuminuria over 3
years in a placebo-controlled study in type 2
diabetes: results from the Diabetes Atherosclerosis
Intervention Study (DAIS). American Journal of
Kidney Diseases 2005; 45(3):485-93. Intervention
not related to monitoring of CKD
Aoki TT, Grecu EO, Prendergast JJ, et al. Effect of
chronic intermittent intravenous insulin therapy on
antihypertensive medication requirements in IDDM
subjects with hypertension and nephropathy.
Diabetes Care 1995; 18(9):1260-5. Intervention not
related to monitoring of CKD
Appel LJ, Wright JT, Jr., Greene T, et al. Long-term
effects of renin-angiotensin system-blocking therapy
and a low blood pressure goal on progression of
hypertensive chronic kidney disease in African
Americans. Archives of Internal Medicine 2008;
168(8):832-9. Intervention not related to monitoring
of CKD
Artz MA, Hilbrands LB, Borm G, et al. Blockade of
the renin-angiotensin system increases graft survival
in patients with chronic allograft nephropathy.
Nephrology Dialysis Transplantation 2004;
19(11):2852-7. Not patients with early CKD
Assan R, Blanchet F, Feutren G, et al. Normal renal
function 8 to 13 years after cyclosporin A therapy in
285 diabetic patients. Diabetes/Metabolism Research
Reviews 2002; 18(6):464-72. Not a randomized trial
Astobieta A, Calvo R, Aguirre C, et al. Netilmicin
kinetics in urology. International Journal of Clinical
Pharmacology, Therapy, & Toxicology 1993;
31(11):557-60. Not a randomized trial
Atzpodien J, Kirchner H, Rebmann U, et al.
Interleukin-2/interferon-alpha2a/13-retinoic acidbased chemoimmunotherapy in advanced renal cell
carcinoma: results of a prospectively randomised trial
of the German Cooperative Renal Carcinoma
Chemoimmunotherapy Group (DGCIN). British
Journal of Cancer 2006; 95(4):463-9. Intervention
not related to monitoring of CKD
Aulitzky WE, Grosse-Wilde H, Westhoff U, et al.
Enhanced serum levels of soluble HLA class I
molecules are induced by treatment with recombinant
interferon-gamma (IFN-gamma). Clinical &
Experimental Immunology 1991; 86(2):236-9. Not a
randomized trial
Axelsson J, Witasp A, Carrero JJ, et al. Circulating
levels of visfatin/pre-B-cell colony-enhancing factor
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
1 in relation to genotype, GFR, body composition,
and survival in patients with CKD. American Journal
of Kidney Diseases 2007; 49(2):237-44. Not a
randomized trial
Azizi M, Menard J, Peyrard S, et al. Assessment of
patients' and physicians' compliance to an ACE
inhibitor treatment based on urinary N-acetyl SerAsp-Lys-Pro determination in the NoninsulinDependent Diabetes, Hypertension,
Microalbuminuria, Proteinuria, Cardiovascular
Events, and Ramipril (DIABHYCAR) study.
Diabetes Care 2006; 29(6):1331-6. Not a randomized
trial
Bacoyiannis C, Dimopoulos MA, Kalofonos HP, et
al. Vinblastine and interferon-gamma combination
with and without 13-cis retinoic acid for patients with
advanced renal cell carcinoma. Results of two phase
II clinical trials. Oncology 2002; 63(2):130-8. Not a
randomized trial
Baigent C, Landray M, Leaper C, et al. First United
Kingdom Heart and Renal Protection (UK-HARP-I)
study: biochemical efficacy and safety of simvastatin
and safety of low-dose aspirin in chronic kidney
disease. American Journal of Kidney Diseases 2005;
45(3):473-84. Intervention not related to monitoring
of CKD
Baigent C, Landray M, Warren M. Statin therapy in
kidney disease populations: potential benefits beyond
lipid lowering and the need for clinical trials. Current
Opinion in Nephrology & Hypertension 2004;
13(6):601-5. Not a randomized trial
Baker LR, Abrams L, Roe CJ, et al. 1,25(OH)2D3
administration in moderate renal failure: a
prospective double-blind trial. Kidney International
1989; 35(2):661-9. Less than 50 patients in study
Baker LR, Abrams SM, Roe CJ, et al. Early therapy
of renal bone disease with calcitriol: a prospective
double-blind study. Kidney International Supplement 1989; 27:S140-2. Less than 50 patients
in study
Bakir AA, Share DS, Levy PS, et al. Focal segmental
glomerulosclerosis in adult African Americans.
Clinical Nephrology 1996; 46(5):306-11. Not a
randomized trial
Bakris G, Hester A, Weber M, et al. The diabetes
subgroup baseline characteristics of the Avoiding
Cardiovascular Events Through Combination
Therapy in Patients Living With Systolic
Hypertension (ACCOMPLISH) trial. J Cardiometab
Syndr 2008; 3(4):229-33. Intervention not related to
monitoring of CKD
Bakris GL, Copley JB, Vicknair N, et al. Calcium
channel blockers versus other antihypertensive
therapies on progression of NIDDM associated
nephropathy. Kidney International 1996; 50(5):164150. Intervention not related to monitoring of CKD
Bakris GL, Weir MR. Angiotensin-converting
enzyme inhibitor-associated elevations in serum
creatinine: is this a cause for concern? Archives of
Internal Medicine 2000; 160(5):685-93. Intervention
not related to monitoring of CKD
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
B-17
Bakris GL, Weir MR, Shanifar S, et al. Effects of
blood pressure level on progression of diabetic
nephropathy: results from the RENAAL study.
Archives of Internal Medicine 2003; 163(13):155565. Intervention not related to monitoring of CKD
Ballardie FW, Roberts ISD. Controlled prospective
trial of prednisolone and cytotoxics in progressive
IgA nephropathy. Journal of the American Society of
Nephrology 2002; 13(1):142-8. Intervention not
related to monitoring of CKD
Banikazemi M, Bultas J, Waldek S, et al. Agalsidasebeta therapy for advanced Fabry disease: a
randomized trial. Annals of Internal Medicine 2007;
146(2):77-86. Intervention not related to monitoring
of CKD
Bannister KM, Weaver A, Clarkson AR, et al. Effect
of angiotensin-converting enzyme and calcium
channel inhibition on progression of IgA
nephropathy. Contributions to Nephrology 1995;
111:184-92; discussion 92-3. Intervention not related
to monitoring of CKD
Bansal N, Tighiouart H, Weiner D, et al. Anemia as a
risk factor for kidney function decline in individuals
with heart failure. American Journal of Cardiology
2007; 99(8):1137-42. Intervention not related to
monitoring of CKD
Barichella M, Savardi C, Mauri A, et al. Diet with
LPP for renal patients increases daily energy
expenditure and improves motor function in
parkinsonian patients with motor fluctuations.
Nutritional Neuroscience 2007; 10(3-4):129-35.
Duration of follow-up less than 1 year
Barlage S, Hauser IA, Elbracht R, et al. Monitoring
of peripheral blood cytotoxic T-cells under
fluvastatin treatment in renal transplant recipients.
Journal of Biological Regulators & Homeostatic
Agents 2005; 19(3-4):159-68. Not a randomized trial
Barratt J, Feehally J. Treatment of IgA nephropathy.
Kidney International 2006; 69(11):1934-8. Not a
randomized trial
Barrett BJ. Managing progressive renal disease
before dialysis. Canadian Family Physician 1999;
45:977-84. Not a randomized trial
Barrett SV, Paul J, Hay A, et al. Does body mass
index affect progression-free or overall survival in
patients with ovarian cancer? Results from
SCOTROC I trial. Annals of Oncology 2008;
19(5):898-902. Intervention not related to monitoring
of CKD
Basile C, Ruggieri G, Vernaglione L, et al. The
natural history of autogenous radio-cephalic wrist
arteriovenous fistulas of haemodialysis patients: a
prospective observational study. Nephrology Dialysis
Transplantation 2004; 19(5):1231-6. Not patients
with early CKD
Bax L, Mali WPTM, Buskens E, et al. The benefit of
STent placement and blood pressure and lipidlowering for the prevention of progression of renal
dysfunction caused by Atherosclerotic ostial stenosis
of the Renal artery. The STAR-study: rationale and
study design. Journal of Nephrology 2003;
16(6):807-12. Not a randomized trial
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
Bazzato G, Scanferla F. Assessment of the best
compatible dialysis system: feasible application for
bioelectrical impedance. International Journal of
Artificial Organs 1995; 18(11):712-5. Not a
randomized trial
Beatovic S, Jaksic ED, Han RS. Measurement of
renal function by calculation of fractional uptake of
technetium-99m dimercaptosuccinic acid. Nucl Med
Rev Cent East Eur 2004; 7(1):49-52. Not adult
population
Bellasi A, Kooienga L, Block GA, et al. How long is
the warranty period for nil or low coronary artery
calcium in patients new to hemodialysis? Journal of
Nephrology 2009; 22(2):255-62. Not a randomized
trial
Bellizzi V, Scalfi L, Terracciano V, et al. Early
changes in bioelectrical estimates of body
composition in chronic kidney disease. Journal of the
American Society of Nephrology 2006; 17(5):14817. Not a randomized trial
Bello E, Caramelo C, Martell N, et al. Impairment of
renal vasodilation with l-arginine is related to more
severe disease in untreated hypertensive patients.
Hypertension 2001; 38(4):907-12. Not a randomized
trial
Bellomo R, Auriemma S, Fabbri A, et al. The
pathophysiology of cardiac surgery-associated acute
kidney injury (CSA-AKI). International Journal of
Artificial Organs 2008; 31(2):166-78. Not a
randomized trial
Ben-Zvi I, Green Y, Nakhoul F, et al. Effects of
diabetes mellitus, chronic renal failure and
hemodialysis on serum and salivary antioxidant
status. Nephron Clin Pract 2007; 105(3):c114-20. Not
a randomized trial
Berenson JR. Recommendations for zoledronic acid
treatment of patients with bone metastases.
Oncologist 2005; 10(1):52-62. Not a randomized
trial
Bergrem H, Goransson LG, Asmundsson P, et al.
The Nephrocare project: referral, patient case-mix,
follow-up and quality of renal care in Nordic renal
centres. Scandinavian Journal of Urology &
Nephrology 2009; 43(4):319-24. Not a randomized
trial
Bertolissi M, Antonucci F, De Monte A, et al. Effects
on renal function of a continuous infusion of
nifedipine during cardiopulmonary bypass. Journal of
Cardiothoracic & Vascular Anesthesia 1996;
10(2):238-42. Less than 50 patients in study
Besarab A, Frinak S, Yee J. What is so bad about a
hemoglobin level of 12 to 13 g/dL for chronic kidney
disease patients anyway? Advances in Chronic
Kidney Disease 2009; 16(2):131-42. Not a
randomized trial
Bhandari S, Brownjohn A, Turney J. Effective
utilization of erythropoietin with intravenous iron
therapy. Journal of Clinical Pharmacy &
Therapeutics 1998; 23(1):73-8. Not a randomized
trial
Bianchi S, Bigazzi R, Caiazza A, et al. A controlled,
prospective study of the effects of atorvastatin on
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
B-18
proteinuria and progression of kidney
disease.[Erratum appears in Am J Kidney Dis. 2004
Jan;43(1):193]. American Journal of Kidney
Diseases 2003; 41(3):565-70. Intervention not
related to monitoring of CKD
Bianchi S, Bigazzi R, Campese VM. Antagonists of
aldosterone and proteinuria in patients with CKD: an
uncontrolled pilot study. American Journal of Kidney
Diseases 2005; 46(1):45-51. Duration of follow-up
less than 1 year
Biancofiore G, Esposito M, Bindi L, et al. Regional
filter heparinization for continuous veno-venous
hemofiltration in liver transplant recipients. Minerva
Anestesiologica 2003; 69(6):527-34; 34-8. Not a
randomized trial
Bibi G, Green Y, Nagler RM. Compositional and
oxidative analysis in the saliva and serum of
predialysis chronic kidney disease patients and endstage renal failure patients on peritoneal dialysis.
Therapeutic Apheresis & Dialysis: Official PeerReviewed Journal of the International Society for
Apheresis, the Japanese Society for Apheresis, the
Japanese Society for Dialysis Therapy 2008;
12(2):164-70. Not a randomized trial
Bilous R. Microvascular disease: what does the
UKPDS tell us about diabetic nephropathy? Diabetic
Medicine 2008; 25 Suppl 2:25-9. Not a randomized
trial
Birnbaum BA, Jacobs JE, Langlotz CP, et al.
Assessment of a bolus-tracking technique in helical
renal CT to optimize nephrographic phase imaging.
Radiology 1999; 211(1):87-94. Not a randomized
trial
Ble A, Fink JC, Woodman RC, et al. Renal function,
erythropoietin, and anemia of older persons: the
InCHIANTI study. Archives of Internal Medicine
2005; 165(19):2222-7. Not a randomized trial
Blohme I, Idstrom JP, Andersson T. A study of the
interaction between omeprazole and cyclosporine in
renal transplant patients. British Journal of Clinical
Pharmacology 1993; 35(2):156-60. Intervention not
related to monitoring of CKD
Boccardo F, Rubagotti A, Canobbio L, et al.
Interleukin-2, interferon-alpha and interleukin-2 plus
interferon-alpha in renal cell carcinoma. A
randomized phase II trial. Tumori 1998; 84(5):534-9.
Intervention not related to monitoring of CKD
Body J-J, Diel I, Bell R. Profiling the safety and
tolerability of bisphosphonates. Seminars in
Oncology 2004; 31(5 Suppl 10):73-8. Not a
randomized trial
Boger RH, Schwedhelm E, Maas R, et al. ADMA
and oxidative stress may relate to the progression of
renal disease: rationale and design of the VIVALDI
study. Vasc Med 2005; 10 Suppl 1:S97-102. Not a
randomized trial
Bohler T, Waiser J, Schutz M, et al. FTY 720A
mediates reduction of lymphocyte counts in human
renal allograft recipients by an apoptosis-independent
mechanism. Transplant International 2000; 13 Suppl
1:S311-3. Not a randomized trial
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
Boldt J, Brosch C, Piper SN, et al. Influence of
prophylactic use of pentoxifylline on postoperative
organ function in elderly cardiac surgery patients.
Critical Care Medicine 2001; 29(5):952-8.
Intervention not related to monitoring of CKD
Bolondi L, Piscaglia F, Gatta A, et al. Effect of
potassium canrenoate, an anti-aldosterone agent, on
incidence of ascites and variceal progression in
cirrhosis. Clinical Gastroenterology & Hepatology
2006; 4(11):1395-402. Intervention not related to
monitoring of CKD
Bolton WK, Cattran DC, Williams ME, et al.
Randomized trial of an inhibitor of formation of
advanced glycation end products in diabetic
nephropathy. American Journal of Nephrology 2004;
24(1):32-40. Intervention not related to monitoring
of CKD
Bonello M, House AA, Cruz D, et al. Integration of
blood volume, blood pressure, heart rate and
bioimpedance monitoring for the achievement of
optimal dry body weight during chronic
hemodialysis. International Journal of Artificial
Organs 2007; 30(12):1098-108. Not a randomized
trial
Boogaard PJ, Houtsma AT, Journee HL, et al. Effects
of exposure to elemental mercury on the nervous
system and the kidneys of workers producing natural
gas. Archives of Environmental Health 1996;
51(2):108-15. Not a randomized trial
Booth AD, Firth JD, Jayne DRW. Immunotherapy
for autoimmune and inflammatory renal diseases.
Expert Opinion on Biological Therapy 2003;
3(3):487-500. Not a randomized trial
Braden GL, von Oeyen PT, Germain MJ, et al.
Ritodrine- and terbutaline-induced hypokalemia in
preterm labor: mechanisms and consequences.
Kidney International 1997; 51(6):1867-75. Not a
randomized trial
Brennan DC, Barbeito R, Burke J, et al. Safety of
Neoral conversion in maintenance renal transplant
patients: A one-year, double-blind study.
NOVARTIS OLN-353 Study Group. Kidney
International 1999; 56(2):685-91. Not patients with
early CKD
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects
of losartan on renal and cardiovascular outcomes in
patients with type 2 diabetes and nephropathy. New
England Journal of Medicine 2001; 345(12):861-9.
Intervention not related to monitoring of CKD
Bretzel RG. Prevention and slowing down the
progression of the diabetic nephropathy through
antihypertensive therapy. Journal of Diabetes & its
Complications 1997; 11(2):112-22. Not a
randomized trial
Breyer JA, Bain RP, Evans JK, et al. Predictors of
the progression of renal insufficiency in patients with
insulin-dependent diabetes and overt diabetic
nephropathy. The Collaborative Study Group.
Kidney International 1996; 50(5):1651-8. Not a
randomized trial
Brienza N, Giglio MT, Marucci M, et al. Does
perioperative hemodynamic optimization protect
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
B-19
renal function in surgical patients? A meta-analytic
study. Critical Care Medicine 2009; 37(6):2079-90.
Not a randomized trial
Brophy DF, Martin EJ, Gehr TWB, et al. Enhanced
anticoagulant activity of enoxaparin in patients with
ESRD as measured by thrombin generation time.
American Journal of Kidney Diseases 2004;
44(2):270-7. Not a randomized trial
Buargub MA, Nabulsi MF, Shafeh TA. Prevalence
and pattern of renal osteodystrophy in chronic
hemodialysis patients: a cross sectional study of 103
patients. Saudi Journal of Kidney Diseases &
Transplantation 2006; 17(3):401-7. Not a randomized
trial
Budoff MJ, Kessler P, Gao YL, et al. The interscan
variation of CT coronary artery calcification score:
analysis of the Calcium Acetate Renagel Comparison
(CARE)-2 study. Academic Radiology 2008;
15(1):58-61. Intervention not related to monitoring
of CKD
Bukowski RM. Targeted therapy for cytokinerefractory metastatic renal cell carcinoma, and
treatment in the community. Oncology 2006; 20(6
Suppl 5):25-8. Not a randomized trial
Bunke M, Sloan R, Brier M, et al. An improved
glomerular filtration rate in cardiac transplant
recipients with once-a-day cyclosporine dosing.
Transplantation 1995; 59(4):537-40. Intervention not
related to monitoring of CKD
Buraczynska M, Grzebalska A, Spasiewicz D, et al.
Genetic polymorphisms of renin-angiotensin system
and progression of interstitial nephritis. Annales
Universitatis Mariae Curie-Sklodowska - Sectio d Medicina 2002; 57(2):330-6. Not a randomized trial
Burgess E. Conservative treatment to slow
deterioration of renal function: evidence-based
recommendations. Kidney International Supplement 1999; 70:S17-25. Intervention not
related to monitoring of CKD
Bursztyn M, Motro M, Grossman E, et al.
Accelerated coronary artery calcification in mildly
reduced renal function of high-risk hypertensives: a
3-year prospective observation. Journal of
Hypertension 2003; 21(10):1953-9. Not a
randomized trial
Butler JA, Peveler RC, Roderick P, et al. Modifiable
risk factors for non-adherence to
immunosuppressants in renal transplant recipients: a
cross-sectional study. Nephrology Dialysis
Transplantation 2004; 19(12):3144-9. Not a
randomized trial
Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical
trial data on atorvastatin for reducing cardiovascular
events: the clinical impact of atorvastatin. Current
Medical Research & Opinion 2008; 24(4):1217-29.
Not a randomized trial
Calkins DS, Degioanni JJ, Tan MN, et al. Human
performance and physiological function during a 24hr exposure to 1% bromotrifluoromethane (Halon
1301). Fundamental & Applied Toxicology 1993;
20(2):240-7. Not a randomized trial
118. Campbell KL, Ash S, Bauer JD. The impact of
nutrition intervention on quality of life in pre-dialysis
chronic kidney disease patients. Clinical Nutrition
2008; 27(4):537-44. Not a randomized trial
119. Campistol JM, Inigo P, Larios S, et al. Role of
transforming growth factor-beta1 in the progression
of chronic allograft nephropathy. Nephrology
Dialysis Transplantation 2001; 16 Suppl 1:114-6. Not
a randomized trial
120. Cantarovich M. Renal protective strategies in heart
transplant patients. Current Opinion in Cardiology
2007; 22(2):133-8. Not a randomized trial
121. Cantarovich M, Giannetti N, Routy J-P, et al. Longterm immunosuppression with anti-CD25
monoclonal antibodies in heart transplant patients
with chronic kidney disease. Journal of Heart &
Lung Transplantation 2009; 28(9):912-8. Not a
randomized trial
122. Cao C, Wan X, Chen Y, et al. Metabolic factors and
microinflammatory state promote kidney injury in
type 2 diabetes mellitus patients. Renal Failure 2009;
31(6):470-4. Not a randomized trial
123. Carides GW, Shahinfar S, Dasbach EJ, et al. The
impact of losartan on the lifetime incidence of endstage renal disease and costs in patients with type 2
diabetes and nephropathy. Pharmacoeconomics
2006; 24(6):549-58. Not a randomized trial
124. Casey ET, Murad MH, Rizvi AZ, et al. Surveillance
of arteriovenous hemodialysis access: a systematic
review and meta-analysis. Journal of Vascular
Surgery 2008; 48(5 Suppl):48S-54S. Not a
randomized trial
125. Cass LM, Efthymiopoulos C, Marsh J, et al. Effect of
renal impairment on the pharmacokinetics of
intravenous zanamivir. Clinical Pharmacokinetics
1999; 36 Suppl 1:13-9. Not a randomized trial
126. Cathelineau G, de Champvallins M, Bouallouche A,
et al. Management of newly diagnosed non-insulindependent diabetes mellitus in the primary care
setting: effects of 2 years of gliclazide treatment--the
Diadem Study. Metabolism: Clinical & Experimental
1997; 46(12 Suppl 1):31-4. Not a randomized trial
127. Cattran DC. Mycophenolate mofetil and cyclosporine
therapy in membranous nephropathy. Seminars in
Nephrology 2003; 23(3):272-7. Not a randomized
trial
128. Cattran DC. Cyclosporine in the treatment of
idiopathic focal segmental glomerulosclerosis.
Seminars in Nephrology 2003; 23(2):234-41. Not a
randomized trial
129. Cattran DC, Alexopoulos E, Heering P, et al.
Cyclosporin in idiopathic glomerular disease
associated with the nephrotic syndrome : workshop
recommendations. Kidney International 2007;
72(12):1429-47. Not a randomized trial
130. Chan JC, So WY, Yeung CY, et al. Effects of
structured versus usual care on renal endpoint in type
2 diabetes: the SURE study: a randomized
multicenter translational study. Diabetes Care 2009;
32(6):977-82. Intervention not related to monitoring
of CKD
131. Chapman AB. Improving clinical trial design for
inquiries into the mechanisms of cyst growth in
ADPKD. Kidney International 2009; 75(2):139-41.
Not a randomized trial
132. Chaudhary UB, Haldas JR. Long-term complications
of chemotherapy for germ cell tumours. Drugs 2003;
63(15):1565-77. Not a randomized trial
133. Chertow GM, Raggi P, Chasan-Taber S, et al.
Determinants of progressive vascular calcification in
haemodialysis patients. Nephrology Dialysis
Transplantation 2004; 19(6):1489-96. Not a
randomized trial
134. Chesterton LJ, Selby NM, Burton JO, et al. Cool
dialysate reduces asymptomatic intradialytic
hypotension and increases baroreflex variability.
Hemodialysis International 2009; 13(2):189-96. Not
a randomized trial
135. Chiang SS, Chen JB, Yang WC. Lanthanum
carbonate (Fosrenol) efficacy and tolerability in the
treatment of hyperphosphatemic patients with endstage renal disease. Clinical Nephrology 2005;
63(6):461-70. Intervention not related to monitoring
of CKD
136. Chiurchiu C, Remuzzi G, Ruggenenti P.
Angiotensin-converting enzyme inhibition and renal
protection in nondiabetic patients: the data of the
meta-analyses. Journal of the American Society of
Nephrology 2005; 16 Suppl 1:S58-63. Not a
randomized trial
137. Choi KL, Elliott WJ. Antihypertensive,
antiproteinuric therapy and myocardial infarction and
stroke prevention. Current Hypertension Reports
2005; 7(5):367-73. Not a randomized trial
138. Chonchol M, Goldenberg I, Moss AJ, et al. Risk
factors for sudden cardiac death in patients with
chronic renal insufficiency and left ventricular
dysfunction. American Journal of Nephrology 2007;
27(1):7-14. Not a randomized trial
139. Chrysant SG. Angiotensin II receptor blockers in the
treatment of the cardiovascular disease continuum.
Clinical Therapeutics 2008; 30 Pt 2:2181-90. Not a
randomized trial
140. Chrysochou C, Randhawa H, Reeve R, et al.
Determinants of renal functional outcome in lupus
nephritis: a single centre retrospective study. Qjm
2008; 101(4):313-6. Not a randomized trial
141. Chu D, Lacouture ME, Fillos T, et al. Risk of handfoot skin reaction with sorafenib: a systematic review
and meta-analysis. Acta Oncologica 2008; 47(2):17686. Not a randomized trial
142. Chu D, Lacouture ME, Weiner E, et al. Risk of handfoot skin reaction with the multitargeted kinase
inhibitor sunitinib in patients with renal cell and nonrenal cell carcinoma: a meta-analysis. Clinical
Genitourinary Cancer 2009; 7(1):11-9. Not a
randomized trial
143. Cianci R, Gigante A, Polidori L, et al. In-stent
restenosis of the renal artery in a single kidney
patient: the role of ACEI in the therapeutic choice.
Angiology 2009; 60(4):496-503. Not a randomized
trial
B-20
144. Cianciaruso B, Pota A, Bellizzi V, et al. Effect of a
low- versus moderate-protein diet on progression of
CKD: follow-up of a randomized controlled trial.
American Journal of Kidney Diseases 2009;
54(6):1052-61. Intervention not related to monitoring
of CKD
145. Cianciaruso B, Pota A, Pisani A, et al. Metabolic
effects of two low protein diets in chronic kidney
disease stage 4-5--a randomized controlled trial.
Nephrology Dialysis Transplantation 2008;
23(2):636-44. Intervention not related to monitoring
of CKD
146. Cianciaruso B, Ravani P, Barrett BJ, et al. Italian
randomized trial of hemoglobin maintenance to
prevent or delay left ventricular hypertrophy in
chronic kidney disease. J Nephrol 2008; 21(6):86170. Intervention not related to monitoring of CKD
147. Ciancio G, Burke GW, Gaynor JJ, et al. A
randomized trial of three renal transplant induction
antibodies: early comparison of tacrolimus,
mycophenolate mofetil, and steroid dosing, and
newer immune-monitoring. Transplantation 2005;
80(4):457-65. Not patients with early CKD
148. Ciancio G, Burke GW, Gaynor JJ, et al. Randomized
trial of mycophenolate mofetil versus enteric-coated
mycophenolate sodium in primary renal transplant
recipients given tacrolimus and
daclizumab/thymoglobulin: one year follow-up.
Transplantation 2008; 86(1):67-74. Not patients with
early CKD
149. Ciancio G, Burke GW, Gaynor JJ, et al. A
randomized long-term trial of tacrolimus/sirolimus
versus tacrolimums/mycophenolate versus
cyclosporine/sirolimus in renal transplantation: threeyear analysis. Transplantation 2006; 81(6):845-52.
Not patients with early CKD
150. Cicinnati VR, Yu Z, Klein CG, et al. Clinical trial:
switch to combined mycophenolate mofetil and
minimal dose calcineurin inhibitor in stable liver
transplant patients--assessment of renal and allograft
function, cardiovascular risk factors and immune
monitoring. Alimentary Pharmacology &
Therapeutics 2007; 26(9):1195-208. Not patients
with early CKD
151. Cinotti GA, Zucchelli PC, Collaborative Study G.
Effect of Lisinopril on the progression of renal
insufficiency in mild proteinuric non-diabetic
nephropathies. Nephrology Dialysis Transplantation
2001; 16(5):961-6. Intervention not related to
monitoring of CKD
152. Citterio F, Sparacino V, Altieri P, et al. Addition of
sirolimus to cyclosporine in long-term kidney
transplant recipients to withdraw steroid.
Transplantation Proceedings 2005; 37(2):827-9. Not
patients with early CKD
153. Clark JI, Kancharla K, Qamar R, et al. Pilot study of
sequential vinorelbine and cisplatin followed by
docetaxel for selected IIIB and stage IV non-small
cell lung cancer. Lung Cancer 2001; 34(2):271-7.
Not a randomized trial
154. Clark PE, Hall MC, Miller A, et al. Phase II trial of
combination interferon-alpha and thalidomide as
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
B-21
first-line therapy in metastatic renal cell carcinoma.
Urology 2004; 63(6):1061-5. Not a randomized trial
Cleland JG, Dargie HJ, Ball SG, et al. Effects of
enalapril in heart failure: a double blind study of
effects on exercise performance, renal function,
hormones, and metabolic state. British Heart Journal
1985; 54(3):305-12. Not a randomized trial
Coburn JW, Elangovan L. Prevention of metabolic
bone disease in the pre-end-stage renal disease
setting. Journal of the American Society of
Nephrology 1998; 9(12 Suppl):S71-7. Not a
randomized trial
Coburn JW, Maung HM, Elangovan L, et al.
Doxercalciferol safely suppresses PTH levels in
patients with secondary hyperparathyroidism
associated with chronic kidney disease stages 3 and
4. American Journal of Kidney Diseases 2004;
43(5):877-90. Duration of follow-up less than 1 year
Cody J, Daly C, Campbell M, et al. Recombinant
human erythropoietin for chronic renal failure
anaemia in pre-dialysis patients. Cochrane Database
of Systematic Reviews 2001; (4):CD003266. Not a
randomized trial
Cody J, Daly C, Campbell M, et al. Recombinant
human erythropoietin for chronic renal failure
anaemia in pre-dialysis patients. Cochrane Database
of Systematic Reviews 2005; (3):CD003266. Not a
randomized trial
Coen G, Mazzaferro S, Bonucci E, et al. Bone GLA
protein in predialysis chronic renal failure. Effects of
1,25(OH)2D3 administration in a long-term followup. Kidney International 1985; 28(5):783-90. Not a
randomized trial
Coen G, Mazzaferro S, Manni M, et al. No
acceleration and possibly slower progression of renal
failure during calcitriol treatment in predialysis
chronic renal failure. Nephrology Dialysis
Transplantation 1994; 9(10):1520. Intervention not
related to monitoring of CKD
Cofan F, Gilabert R, Zambon D, et al. Effect of
pravastatin treatment on the evolution of
extracoronary atherosclerosis in renal transplant
patients. Transplantation Proceedings 2002;
34(1):384-8. Not patients with early CKD
Colhoun HM, Betteridge DJ, Durrington PN, et al.
Primary prevention of cardiovascular disease with
atorvastatin in type 2 diabetes in the Collaborative
Atorvastatin Diabetes Study (CARDS): multicentre
randomised placebo-controlled trial. Lancet 2004;
364(9435):685-96. Intervention not related to
monitoring of CKD
Collins AC, Vincent J, Newall RG, et al. An aid to
the early detection and management of diabetic
nephropathy: assessment of a new point of care
microalbuminuria system in the diabetic clinic.
Diabetic Medicine 2001; 18(11):928-32. Not a
randomized trial
Conen D, Glynn RJ, Buring JE, et al. Association of
renin-angiotensin and endothelial nitric oxide
synthase gene polymorphisms with blood pressure
progression and incident hypertension: prospective
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
cohort study. Journal of Hypertension 2008;
26(9):1780-6. Not a randomized trial
Conil JM, Georges B, Fourcade O, et al. Intermittent
administration of ceftazidime to burns patients:
influence of glomerular filtration. International
Journal of Clinical Pharmacology & Therapeutics
2007; 45(3):133-42. Intervention not related to
monitoring of CKD
Cooper CJ, Murphy TP, Matsumoto A, et al. Stent
revascularization for the prevention of cardiovascular
and renal events among patients with renal artery
stenosis and systolic hypertension: rationale and
design of the CORAL trial. American Heart Journal
2006; 152(1):59-66. Intervention not related to
monitoring of CKD
Coppo R, Peruzzi L, Amore A, et al. IgACE: a
placebo-controlled, randomized trial of angiotensinconverting enzyme inhibitors in children and young
people with IgA nephropathy and moderate
proteinuria. Journal of the American Society of
Nephrology 2007; 18(6):1880-8. Not adult
population
Cortes-Sanabria L, Cabrera-Pivaral CE, CuetoManzano AM, et al. Improving care of patients with
diabetes and CKD: a pilot study for a clusterrandomized trial. American Journal of Kidney
Diseases 2008; 51(5):777-88. Intervention not
related to monitoring of CKD
Cotter G, Dittrich HC, Weatherley BD, et al. The
PROTECT pilot study: a randomized, placebocontrolled, dose-finding study of the adenosine A1
receptor antagonist rolofylline in patients with acute
heart failure and renal impairment. Journal of
Cardiac Failure 2008; 14(8):631-40. Intervention not
related to monitoring of CKD
Couchoud C, Labeeuw M, Moranne O, et al. A
clinical score to predict 6-month prognosis in elderly
patients starting dialysis for end-stage renal disease.
Nephrology Dialysis Transplantation 2009;
24(5):1553-61. Not a randomized trial
Coyle D, Rodby R, Soroka S, et al. Costeffectiveness of irbesartan 300 mg given early versus
late in patients with hypertension and a history of
type 2 diabetes and renal disease: a Canadian
perspective. Clinical Therapeutics 2007; 29(7):150823. Not a randomized trial
Coyne D, Acharya M, Qiu P, et al. Paricalcitol
capsule for the treatment of secondary
hyperparathyroidism in stages 3 and 4 CKD.
American Journal of Kidney Diseases 2006;
47(2):263-76. Intervention not related to monitoring
of CKD
Cravedi P, Ruggenenti P, Remuzzi G. Intensified
inhibition of renin-angiotensin system: a way to
improve renal protection? Current Hypertension
Reports 2007; 9(5):430-6. Not a randomized trial
Crepaldi G, Carta Q, Deferrari G, et al. Effects of
lisinopril and nifedipine on the progression to overt
albuminuria in IDDM patients with incipient
nephropathy and normal blood pressure. The Italian
Microalbuminuria Study Group in IDDM. Diabetes
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
B-22
Care 1998; 21(1):104-10. Intervention not related to
monitoring of CKD
Cronberg S, Nordstrom L. Simplified monitoring of
aminoglycoside treatment. Scandinavian Journal of
Infectious Diseases Supplement 1990; 74:274-9.
Intervention not related to monitoring of CKD
Cruzado JM, Rico J, Grinyo JM. The renin
angiotensin system blockade in kidney
transplantation: pros and cons. Transplant
International 2008; 21(4):304-13. Not a randomized
trial
Culp K, Flanigan M, Lowrie EG, et al. Modeling
mortality risk in hemodialysis patients using
laboratory values as time-dependent covariates.
American Journal of Kidney Diseases 1996;
28(5):741-6. Not a randomized trial
Cummings DM, Amadio P, Jr., Nettler S, et al.
Office-based evaluation of renal function in elderly
patients receiving nonsteroidal anti-inflammatory
drugs. Journal of the American Board of Family
Practice 1988; 1(2):77-80. Intervention not related to
monitoring of CKD
Cummings ST, Fraser CG. Total amylase and
pancreatic isoamylase in serum and urine:
considerations from data on biological variation.
Annals of Clinical Biochemistry 1989; 26(Pt 4):33540. Not a randomized trial
Cunningham MA, Huang XR, Dowling JP, et al.
Prominence of cell-mediated immunity effectors in
"pauci-immune" glomerulonephritis. Journal of the
American Society of Nephrology 1999; 10(3):499506. Not a randomized trial
Cupisti A, Licitra R, Chisari C, et al. Skeletal muscle
and nutritional assessment in chronic renal failure
patients on a protein-restricted diet. Journal of
Internal Medicine 2004; 255(1):115-24. Not a
randomized trial
Czupryniak L, Pawlowski M, Saryusz-Wolska M, et
al. Circadian blood pressure variation and
antihypertensive medication adjustment in
normoalbuminuric type 2 diabetes patients. Kidney
& Blood Pressure Research 2007; 30(3):182-6. Not a
randomized trial
Dailey GE, Boden GH, Creech RH, et al. Effects of
pulsatile intravenous insulin therapy on the
progression of diabetic nephropathy. Metabolism:
Clinical & Experimental 2000; 49(11):1491-5.
Intervention not related to monitoring of CKD
D'Amico G, Gentile MG, Fellin G, et al. Effect of
dietary protein restriction on the progression of renal
failure: a prospective randomized trial. Nephrology
Dialysis Transplantation 1994; 9(11):1590-4.
Intervention not related to monitoring of CKD
Damman K, Navis G, Voors AA, et al. Worsening
renal function and prognosis in heart failure:
systematic review and meta-analysis. Journal of
Cardiac Failure 2007; 13(8):599-608. Intervention
not related to monitoring of CKD
Daumit GL, Hermann JA, Coresh J, et al. Use of
cardiovascular procedures among black persons and
white persons: a 7-year nationwide study in patients
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
with renal disease. Annals of Internal Medicine 1999;
130(3):173-82. Not a randomized trial
Daumit GL, Hermann JA, Powe NR. Relation of
gender and health insurance to cardiovascular
procedure use in persons with progression of chronic
renal disease. Medical Care 2000; 38(4):354-65. Not
a randomized trial
Davidson MB, Karlan VJ, Hair TL. Effect of a
pharmacist-managed diabetes care program in a free
medical clinic. American Journal of Medical Quality
2000; 15(4):137-42. Not a randomized trial
Davis ID, MacRae Dell K, Sweeney WE, et al. Can
progression of autosomal dominant or autosomal
recessive polycystic kidney disease be prevented?
Seminars in Nephrology 2001; 21(5):430-40. Not a
randomized trial
Davis NB, Taber DA, Ansari RH, et al. Phase II trial
of PS-341 in patients with renal cell cancer: a
University of Chicago phase II consortium study.
Journal of Clinical Oncology 2004; 22(1):115-9. Not
a randomized trial
Davis R, Faulds D. Nadroparin calcium. A review of
its pharmacology and clinical use in the prevention
and treatment of thromboembolic disorders. Drugs &
Aging 1997; 10(4):299-322. Intervention not related
to monitoring of CKD
de Brito-Ashurst I, Varagunam M, Raftery MJ, et al.
Bicarbonate supplementation slows progression of
CKD and improves nutritional status. Journal of the
American Society of Nephrology 2009; 20(9):207584. Intervention not related to monitoring of CKD
de Denus S, Tardif J-C, White M, et al.
Quantification of the risk and predictors of
hyperkalemia in patients with left ventricular
dysfunction: a retrospective analysis of the Studies of
Left Ventricular Dysfunction (SOLVD) trials.
American Heart Journal 2006; 152(4):705-12. Not a
randomized trial
de Denus S, Tardif J-C, White M, et al. Temporal
variations in hematocrit values in patients with left
ventricular dysfunction: Relationship with causespecific mortality and morbidity and optimal
monitoring--further insights from SOLVD. Canadian
Journal of Cardiology 2008; 24(1):45-8. Not a
randomized trial
de la Sierra A, Lluch MM, Coca A, et al. Fluid, ionic
and hormonal changes induced by high salt intake in
salt-sensitive and salt-resistant hypertensive patients.
Clinical Science 1996; 91(2):155-61. Intervention not
related to monitoring of CKD
De Marchi S, Cecchin E. Hepatic computed
tomography for monitoring the iron status of
haemodialysis patients with haemosiderosis treated
with recombinant human erythropoietin. Clinical
Science 1991; 81(1):113-21. Not a randomized trial
De Palo EF, Gatti R, Lancerin F, et al. Urinary
insulin-like growth factor I in athletes, before and
after physical exercise, and in sedentary subjects.
Clinica Chimica Acta 2002; 322(1-2):51-7. Not a
randomized trial
De Sadeleer C, Piepsz A, Ham HR. How good is the
slope on the second exponential for estimating 51Cr-
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
B-23
EDTA renal clearance? A Monte Carlo simulation.
Nuclear Medicine Communications 2000; 21(5):4558. Not a randomized trial
de Silva R, Nikitin NP, Bhandari S, et al.
Atherosclerotic renovascular disease in chronic heart
failure: should we intervene? European Heart Journal
2005; 26(16):1596-605. Not a randomized trial
De Vane GW, Czekala NM, Shideler SE, et al.
Monitoring gonadotropin-releasing hormone
administration by measurement of urinary steroid
conjugates. Obstetrics & Gynecology 1986;
67(5):710-7. Not a randomized trial
de Vinuesa SG, Goicoechea M, Kanter J, et al.
Insulin resistance, inflammatory biomarkers, and
adipokines in patients with chronic kidney disease:
effects of angiotensin II blockade. Journal of the
American Society of Nephrology 2006; 17(12 Suppl
3):S206-12. Not a randomized trial
de Vries PJ, Verkooyen RP, Leguit P, et al.
Prospective randomized study of once-daily versus
thrice-daily netilmicin regimens in patients with
intraabdominal infections. European Journal of
Clinical Microbiology & Infectious Diseases 1990;
9(3):161-8. Not patients with early CKD
Deehan DJ, Heys SD, Broom J, et al. Renal
impairment associated with the pre-operative
administration of recombinant interleukin-2. Clinical
Science 1994; 87(5):513-8. Not patients with early
CKD
Deicher R, Horl WH. Anaemia as a risk factor for the
progression of chronic kidney disease. Current
Opinion in Nephrology & Hypertension 2003;
12(2):139-43. Not a randomized trial
Delmez JA, Yan G, Bailey J, et al. Cerebrovascular
disease in maintenance hemodialysis patients: results
of the HEMO Study. American Journal of Kidney
Diseases 2006; 47(1):131-8. Not patients with early
CKD
Dember LM, Hawkins PN, Hazenberg BPC, et al.
Eprodisate for the treatment of renal disease in AA
amyloidosis. New England Journal of Medicine
2007; 356(23):2349-60. Intervention not related to
monitoring of CKD
Depner TA, Keshaviah PR, Ebben JP, et al.
Multicenter clinical validation of an on-line monitor
of dialysis adequacy. Journal of the American
Society of Nephrology 1996; 7(3):464-71. Not
patients with early CKD
Detournay B, Cros S, Charbonnel B, et al. Managing
type 2 diabetes in France: the ECODIA survey.
Diabetes & Metabolism 2000; 26(5):363-9. Not a
randomized trial
Devins GM, Hollomby DJ, Barre PE, et al. Longterm knowledge retention following predialysis
psychoeducational intervention. Nephron 2000;
86(2):129-34. Not a randomized trial
Devins GM, Mendelssohn DC, Barre PE, et al.
Predialysis psychoeducational intervention and
coping styles influence time to dialysis in chronic
kidney disease. American Journal of Kidney
Diseases 2003; 42(4):693-703. Intervention not
related to monitoring of CKD
212. Devins GM, Mendelssohn DC, Barre PE, et al.
Predialysis psychoeducational intervention extends
survival in CKD: a 20-year follow-up. American
Journal of Kidney Diseases 2005; 46(6):1088-98.
Intervention not related to monitoring of CKD
213. Dijkman GA, Fernandez del Moral P, Debruyne FM,
et al. Improved subjective responses to orchiectomy
plus nilutamide (anandron) in comparison to
orchiectomy plus placebo in metastatic prostate
cancer. International Anandron Study Group.
European Urology 1995; 27(3):196-201. Not a
randomized trial
214. Dimopoulos MA, Richardson PG, Schlag R, et al.
VMP (Bortezomib, Melphalan, and Prednisone) is
active and well tolerated in newly diagnosed patients
with multiple myeloma with moderately impaired
renal function, and results in reversal of renal
impairment: cohort analysis of the phase III VISTA
study. Journal of Clinical Oncology 2009;
27(36):6086-93. Intervention not related to
monitoring of CKD
215. Dittrich S, Kurschat K, Dahnert I, et al. Cyanotic
nephropathy and use of non-ionic contrast agents
during cardiac catherization in patients with cyanotic
congenital heart disease. Cardiology in the Young
2000; 10(1):8-14. Not a randomized trial
216. Doehn C, Richter A, Lehmacher W, et al. Adjuvant
autologous tumour cell-lysate vaccine versus no
adjuvant treatment in patients with M0 renal cell
carcinoma after radical nephrectomy: 3-year interim
analysis of a German multicentre phase-III trial.
Folia Biologica 2003; 49(2):69-73. Intervention not
related to monitoring of CKD
217. Donadio JV, Bergstralh EJ, Bibus DM, et al. Is body
size a biomarker for optimizing dosing of omega-3
polyunsaturated fatty acids in the treatment of
patients with IgA nephropathy? Clinical Journal of
The American Society of Nephrology: CJASN 2006;
1(5):933-9. Intervention not related to monitoring of
CKD
218. Donadio JV, Grande JP. The role of fish oil/omega-3
fatty acids in the treatment of IgA nephropathy.
Seminars in Nephrology 2004; 24(3):225-43. Not a
randomized trial
219. Donadio JV, Jr., Grande JP, Bergstralh EJ, et al. The
long-term outcome of patients with IgA nephropathy
treated with fish oil in a controlled trial. Mayo
Nephrology Collaborative Group. Journal of the
American Society of Nephrology 1999; 10(8):17727. Intervention not related to monitoring of CKD
220. Donskov F. Interleukin-2 based immunotherapy in
patients with metastatic renal cell carcinoma. Danish
Medical Bulletin 2007; 54(4):249-65. Not a
randomized trial
221. Dougados M, Awada H, Amor B. Cyclosporin in
rheumatoid arthritis: a double blind, placebo
controlled study in 52 patients. Annals of the
Rheumatic Diseases 1988; 47(2):127-33.
Intervention not related to monitoring of CKD
222. Dougados M, Duchesne L, Awada H, et al.
Assessment of efficacy and acceptability of low dose
cyclosporin in patients with rheumatoid arthritis.
223.
224.
225.
226.
227.
228.
229.
230.
231.
232.
233.
234.
B-24
Annals of the Rheumatic Diseases 1989; 48(7):5506. Not patients with early CKD
Douglas K, O'Malley PG, Jackson JL. Meta-analysis:
the effect of statins on albuminuria. Annals of
Internal Medicine 2006; 145(2):117-24. Not a
randomized trial
Dries DL, Exner DV, Domanski MJ, et al. The
prognostic implications of renal insufficiency in
asymptomatic and symptomatic patients with left
ventricular systolic dysfunction. Journal of the
American College of Cardiology 2000; 35(3):681-9.
Not a randomized trial
Drueke TB, Locatelli F, Clyne N, et al.
Normalization of hemoglobin level in patients with
chronic kidney disease and anemia. New England
Journal of Medicine 2006; 355(20):2071-84. Not a
randomized trial
Dummer CD, Thome FS, Zingano B, et al. Acute
effect of simvastatin on inflammation and oxidative
stress in chronic kidney disease. Journal of
Nephrology 2008; 21(6):900-8. Duration of followup less than 1 year
Dundas S, Todd WT. Clinical presentation,
complications and treatment of infection with
verocytotoxin-producing Escherichia coli.
Challenges for the clinician. Symposium Series/The
Society for Applied Microbiology 2000; (29):24S30S. Not a randomized trial
Dworkin LD, Gong R, Tolbert E, et al. Hepatocyte
growth factor ameliorates progression of interstitial
fibrosis in rats with established renal injury. Kidney
International 2004; 65(2):409-19. Not human study
Eardley KS, Lipkin GW. Atherosclerotic renal artery
stenosis: is it worth diagnosing? Journal of Human
Hypertension 1999; 13(4):217-20. Not a randomized
trial
Ebbehoj E, Arildsen H, Hansen KW, et al. Effects of
metoprolol on QT interval and QT dispersion in Type
1 diabetic patients with abnormal albuminuria.
Diabetologia 2004; 47(6):1009-15. Intervention not
related to monitoring of CKD
Ebbehoj E, Poulsen PL, Hansen KW, et al. Effects on
heart rate variability of metoprolol supplementary to
ongoing ACE-inhibitor treatment in Type I diabetic
patients with abnormal albuminuria. Diabetologia
2002; 45(7):965-75. Duration of follow-up less than
1 year
Economides PA, Khaodhiar L, Caselli A, et al. The
effect of vitamin E on endothelial function of microand macrocirculation and left ventricular function in
type 1 and type 2 diabetic patients. Diabetes 2005;
54(1):204-11. Intervention not related to monitoring
of CKD
Edwards MS, Corriere MA. Contemporary
management of atherosclerotic renovascular disease.
Journal of Vascular Surgery 2009; 50(5):1197-210.
Not a randomized trial
Eidemak I, Haaber AB, Feldt-Rasmussen B, et al.
Exercise training and the progression of chronic renal
failure. Nephron 1997; 75(1):36-40. Not a
randomized trial
235. Eitner F, Ackermann D, Hilgers R-D, et al.
Supportive Versus Immunosuppressive Therapy of
Progressive IgA nephropathy (STOP) IgAN trial:
rationale and study protocol. Journal of Nephrology
2008; 21(3):284-9. Not a randomized trial
236. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and
risk for chronic renal failure. Journal of the American
Society of Nephrology 2006; 17(6):1695-702. Not a
randomized trial
237. El Kossi MMH, Ibrahim A, Lock TJ, et al. Impact of
cardiac transplantation on kidney function: a singlecenter experience. Transplantation Proceedings 2003;
35(4):1527-31. Not a randomized trial
238. Elsasser-Beile U, Kolble N, Grussenmeyer T, et al.
Correlation of clinical and immunological parameters
of metastatic renal cell carcinoma patients
undergoing therapy with interleukin 2, interferonalpha and retinoic acid. Anticancer Research 1998;
18(3B):1883-90. Not a randomized trial
239. El-Sehemy MS, Al-Saaran AM, Baddour NM, et al.
Comparative clinical prospective therapeutic study
between cyclophosphamide, cyclosporine and
azathioprine in the treatment of lupus nephritis.
Egyptian Journal of Immunology/Egyptian
Association of Immunologists 2006; 13(1):39-52.
Less than 50 patients in study
240. Endo K, Miyashita Y, Sasaki H, et al. Probucol
delays progression of diabetic nephropathy. Diabetes
Research & Clinical Practice 2006; 71(2):156-63.
Intervention not related to monitoring of CKD
241. Epstein M. The benefits of ACE inhibitors and
calcium antagonists in slowing progressive renal
failure: focus on fixed-dose combination
antihypertensive therapy. Renal Failure 1996;
18(6):813-32. Not a randomized trial
242. Epstein M. Calcium antagonists and renal protection:
emerging perspectives. Journal of Hypertension Supplement 1998; 16(4):S17-25. Not a randomized
trial
243. Epstein M. Aldosterone as a mediator of progressive
renal dysfunction: evolving perspectives. Internal
Medicine 2001; 40(7):573-83. Not a randomized trial
244. Epstein M. Aldosterone and the hypertensive kidney:
its emerging role as a mediator of progressive renal
dysfunction: a paradigm shift. Journal of
Hypertension 2001; 19(5):829-42. Not a randomized
trial
245. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in
advanced clear-cell renal-cell carcinoma.[Erratum
appears in N Engl J Med. 2007 Jul 12;357(2):203].
New England Journal of Medicine 2007; 356(2):12534. Intervention not related to monitoring of CKD
246. Esmail ZN, Loewen PS. Losartan as an alternative to
ACE inhibitors in patients with renal dysfunction.
Annals of Pharmacotherapy 1998; 32(10):1096-8.
Not a randomized trial
247. Estacio RO, Coll JR, Tran ZV, et al. Effect of
intensive blood pressure control with valsartan on
urinary albumin excretion in normotensive patients
with type 2 diabetes. American Journal of
Hypertension 2006; 19(12):1241-8. Intervention not
related to monitoring of CKD
248. Ewald B, Attia J. Which test to detect
microalbuminuria in diabetic patients? A systematic
review. Aust Fam Physician 2004; 33(7):565-7, 71.
Not a randomized trial
249. Facchini FS, Saylor KL. A low-iron-available,
polyphenol-enriched, carbohydrate-restricted diet to
slow progression of diabetic nephropathy. Diabetes
2003; 52(5):1204-9. Intervention not related to
monitoring of CKD
250. Fagnani F, Souchet T, Labed D, et al. Management
of hypertension and screening of renal complications
by GPs in diabetic type 2 patients (France--2001).
Diabetes & Metabolism 2003; 29(1):58-64. Not a
randomized trial
251. Farace F, Pallardy M, Angevin E, et al. Metastatic
renal-cell carcinoma patients treated with interleukin
2 or interleukin 2 plus interferon gamma:
immunological monitoring. International Journal of
Cancer 1994; 57(6):814-21. Not a randomized trial
252. Farbakhsh K, Kasiske BL. Dyslipidemias in patients
who have chronic kidney disease. Medical Clinics of
North America 2005; 89(3):689-99. Not a
randomized trial
253. Fassett RG, Ball MJ, Robertson IK, et al. The Lipid
lowering and Onset of Renal Disease (LORD) Trial:
a randomized double blind placebo controlled trial
assessing the effect of atorvastatin on the progression
of kidney disease. BMC Nephrology 2008; 9:4. Not a
randomized trial
254. Faull RJ, Russ GR. Tubular expression of
intercellular adhesion molecule-1 during renal
allograft rejection. Transplantation 1989; 48(2):22630. Not a randomized trial
255. Fayers PM, Cook PA, Machin D, et al. On the
development of the Medical Research Council trial
of alpha-interferon in metastatic renal carcinoma.
Urological Working Party Renal Carcinoma
Subgroup. Statistics in Medicine 1994; 13(21):224960. Not a randomized trial
256. Ferramosca E, Burke S, Chasan-Taber S, et al.
Potential antiatherogenic and anti-inflammatory
properties of sevelamer in maintenance hemodialysis
patients. American Heart Journal 2005; 149(5):8205. Intervention not related to monitoring of CKD
257. Ficarra V, Galfano A, Novara G, et al. Risk
stratification and prognostication of renal cell
carcinoma. World Journal of Urology 2008;
26(2):115-25. Not a randomized trial
258. Fifer MA, Molina CR, Quiroz AC, et al.
Hemodynamic and renal effects of atrial natriuretic
peptide in congestive heart failure. American Journal
of Cardiology 1990; 65(3):211-6. Intervention not
related to monitoring of CKD
259. Figlin RA, Thompson JA, Bukowski RM, et al.
Multicenter, randomized, phase III trial of CD8(+)
tumor-infiltrating lymphocytes in combination with
recombinant interleukin-2 in metastatic renal cell
carcinoma. Journal of Clinical Oncology 1999;
17(8):2521-9. Intervention not related to monitoring
of CKD
260. Finn WF, Joy MS, Group LAMS. A long-term, openlabel extension study on the safety of treatment with
B-25
261.
262.
263.
264.
265.
266.
267.
268.
269.
270.
271.
272.
273.
lanthanum carbonate, a new phosphate binder, in
patients receiving hemodialysis. Current Medical
Research & Opinion 2005; 21(5):657-64. Not
patients with early CKD
Fischer U, Salzsieder E, Menzel R, et al. Primary
health care of diabetic patients in a specialized
outpatient setting: a DIABCARE-based analysis.
Diabete et Metabolisme 1993; 19(1 Pt 2):188-94. Not
a randomized trial
Fitts SS, Guthrie MR, Blagg CR. Exercise coaching
and rehabilitation counseling improve quality of life
for predialysis and dialysis patients. Nephron 1999;
82(2):115-21. Less than 50 patients in study
Flaherty KT. Sorafenib in renal cell carcinoma.
Clinical Cancer Research 2007; 13(2 Pt 2):747s-52s.
Not a randomized trial
Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot
study of DCE-MRI to predict progression-free
survival with sorafenib therapy in renal cell
carcinoma. Cancer Biology & Therapy 2008;
7(4):496-501. Not a randomized trial
Flechner SM. Sirolimus in kidney transplantation
indications and practical guidelines: de novo
sirolimus-based therapy without calcineurin
inhibitors. Transplantation 2009; 87(8 Suppl):S1-6.
Not a randomized trial
Fliser D, Haller H. Angiotensin II subtype 1-receptor
antagonists in the treatment of diabetic nephropathy.
Journal of Hypertension - Supplement 2001;
19(1):S57-60. Not a randomized trial
Floege J, Eitner F. Present and future therapy options
in IgA-nephropathy. Journal of Nephrology 2005;
18(4):354-61. Not a randomized trial
Forastiere AA, Belliveau JF, Goren MP, et al.
Pharmacokinetic and toxicity evaluation of five-day
continuous infusion versus intermittent bolus cisdiamminedichloroplatinum(II) in head and neck
cancer patients. Cancer Research 1988; 48(13):386974. Not a randomized trial
Fouque D, Aparicio M. Eleven reasons to control the
protein intake of patients with chronic kidney
disease. Nature Clinical Practice Nephrology 2007;
3(7):383-92. Not a randomized trial
Fouque D, Laville M. Low protein diets for chronic
kidney disease in non diabetic adults. Cochrane
Database of Systematic Reviews 2009;
(3):CD001892. Intervention not related to
monitoring of CKD
Fouque D, Laville M, Boissel JP. Low protein diets
for chronic kidney disease in non diabetic adults.
Cochrane Database of Systematic Reviews 2006;
(2):CD001892. Intervention not related to
monitoring of CKD
Fox CH, Brooks A, Zayas LE, et al. Primary care
physicians' knowledge and practice patterns in the
treatment of chronic kidney disease: an Upstate New
York Practice-based Research Network (UNYNET)
study. Journal of the American Board of Family
Medicine: JABFM 2006; 19(1):54-61. Not a
randomized trial
Freedman BI, Hicks PJ, Sale MM, et al. A leucine
repeat in the carnosinase gene CNDP1 is associated
274.
275.
276.
277.
278.
279.
280.
281.
282.
283.
B-26
with diabetic end-stage renal disease in European
Americans. Nephrology Dialysis Transplantation
2007; 22(4):1131-5. Not a randomized trial
Fried LF, Duckworth W, Zhang JH, et al. Design of
combination angiotensin receptor blocker and
angiotensin-converting enzyme inhibitor for
treatment of diabetic nephropathy (VA NEPHROND). Clinical Journal of The American Society of
Nephrology: CJASN 2009; 4(2):361-8. Not a
randomized trial
Fried LF, Forrest KY, Ellis D, et al. Lipid
modulation in insulin-dependent diabetes mellitus:
effect on microvascular outcomes. Journal of
Diabetes & its Complications 2001; 15(3):113-9.
Intervention not related to monitoring of CKD
Fung MA, Warnock GL, Ao Z, et al. The effect of
medical therapy and islet cell transplantation on
diabetic nephropathy: an interim report.
Transplantation 2007; 84(1):17-22. Not a randomized
trial
Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect
of renin-angiotensin-aldosterone system triple
blockade on non-diabetic renal disease: addition of
an aldosterone blocker, spironolactone, to
combination treatment with an angiotensinconverting enzyme inhibitor and angiotensin II
receptor blocker. Hypertension Research - Clinical &
Experimental 2008; 31(1):59-67. Intervention not
related to monitoring of CKD
Furuta T, Hotta O, Horigome I, et al. Decreased CD4
lymphocyte count as a marker predicting high
mortality rate in managing ANCA related rapidly
progressive glomerulonephritis. Nephron 2002;
91(4):601-5. Not a randomized trial
Gaede P, Hansen HP, Parving H-H, et al. Impact of
low-dose acetylsalicylic acid on kidney function in
type 2 diabetic patients with elevated urinary
albumin excretion rate. Nephrology Dialysis
Transplantation 2003; 18(3):539-42. Duration of
follow-up less than 1 year
Gaede P, Vedel P, Parving HH, et al. Intensified
multifactorial intervention in patients with type 2
diabetes mellitus and microalbuminuria: the Steno
type 2 randomised study. Lancet 1999;
353(9153):617-22. Intervention not related to
monitoring of CKD
Gainer JV, Lipkowitz MS, Yu C, et al. Association
of a CYP4A11 variant and blood pressure in black
men. Journal of the American Society of Nephrology
2008; 19(8):1606-12. Intervention not related to
monitoring of CKD
Garcia-Tsao G, Lim JK, Members of Veterans
Affairs Hepatitis CRCP. Management and treatment
of patients with cirrhosis and portal hypertension:
recommendations from the Department of Veterans
Affairs Hepatitis C Resource Center Program and the
National Hepatitis C Program. American Journal of
Gastroenterology 2009; 104(7):1802-29. Not a
randomized trial
Gemperle O, Neuweiler J, Reutter FW, et al. Familial
glomerulopathy with giant fibrillar (fibronectinpositive) deposits: 15-year follow-up in a large
284.
285.
286.
287.
288.
289.
290.
291.
292.
293.
294.
295.
kindred. American Journal of Kidney Diseases 1996;
28(5):668-75. Not a randomized trial
Germain DP, Waldek S, Banikazemi M, et al.
Sustained, long-term renal stabilization after 54
months of agalsidase beta therapy in patients with
Fabry disease. Journal of the American Society of
Nephrology 2007; 18(5):1547-57. Intervention not
related to monitoring of CKD
Gerth WC, Remuzzi G, Viberti G, et al. Losartan
reduces the burden and cost of ESRD: public health
implications from the RENAAL study for the
European Union. Kidney International - Supplement
2002; (82):S68-72. Not a randomized trial
Giatras I, Lau J, Levey AS. Effect of angiotensinconverting enzyme inhibitors on the progression of
nondiabetic renal disease: a meta-analysis of
randomized trials. Angiotensin-Converting-Enzyme
Inhibition and Progressive Renal Disease Study
Group. Annals of Internal Medicine 1997;
127(5):337-45. Not a randomized trial
Gillis BP, Caggiula AW, Chiavacci AT, et al.
Nutrition intervention program of the Modification of
Diet in Renal Disease Study: a self-management
approach. Journal of the American Dietetic
Association 1995; 95(11):1288-94. Intervention not
related to monitoring of CKD
Glassock RJ. Glomerular therapeutics: looking back,
looking forward. Heart Disease 2001; 3(4):276-81.
Not a randomized trial
Gleave ME, Elhilali M, Fradet Y, et al. Interferon
gamma-1b compared with placebo in metastatic
renal-cell carcinoma. Canadian Urologic Oncology
Group. New England Journal of Medicine 1998;
338(18):1265-71. Intervention not related to
monitoring of CKD
Gonwa T, Mendez R, Yang HC, et al. Randomized
trial of tacrolimus in combination with sirolimus or
mycophenolate mofetil in kidney transplantation:
results at 6 months. Transplantation 2003;
75(8):1213-20. Not patients with early CKD
Gonzalez Vitores AM, Encabo Duro G, Bermejo
Fraile B, et al. Utility of tumor marker CA 72.4 in
patients with chronic renal failure. International
Journal of Biological Markers 1999; 14(2):118-21.
Not a randomized trial
Gonzalgo ML, Eisenberger CF, Lee SM, et al.
Prognostic significance of preoperative molecular
serum analysis in renal cancer. Clinical Cancer
Research 2002; 8(6):1878-81. Not a randomized trial
Gore ME, Escudier B. Emerging efficacy endpoints
for targeted therapies in advanced renal cell
carcinoma. Oncology 2006; 20(6 Suppl 5):19-24. Not
a randomized trial
Gouva C, Nikolopoulos P, Ioannidis JPA, et al.
Treating anemia early in renal failure patients slows
the decline of renal function: a randomized
controlled trial. Kidney International 2004;
66(2):753-60. Intervention not related to monitoring
of CKD
Grabe DW, Garrison GD. Comparison of natural
product use between primary care and nephrology
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
B-27
patients. Annals of Pharmacotherapy 2004; 38(78):1169-72. Not a randomized trial
Gray DW, Richardson A, Hughes D, et al. A
prospective, randomized, blind comparison of three
biopsy techniques in the management of patients
after renal transplantation. Transplantation 1992;
53(6):1226-32. Not patients with early CKD
Groetzner J, Wittwer T, Kaczmarek I, et al.
Conversion to sirolimus and mycophenolate can
attenuate the progression of bronchiolitis obliterans
syndrome and improves renal function after lung
transplantation. Transplantation 2006; 81(3):355-60.
Not a randomized trial
Grootscholten C, Bajema IM, Florquin S, et al.
Treatment with cyclophosphamide delays the
progression of chronic lesions more effectively than
does treatment with azathioprine plus
methylprednisolone in patients with proliferative
lupus nephritis. Arthritis & Rheumatism 2007;
56(3):924-37. Intervention not related to monitoring
of CKD
Grootscholten C, Dieker JWC, McGrath FD, et al. A
prospective study of anti-chromatin and anti-C1q
autoantibodies in patients with proliferative lupus
nephritis treated with cyclophosphamide pulses or
azathioprine/methylprednisolone. Annals of the
Rheumatic Diseases 2007; 66(5):693-6. Intervention
not related to monitoring of CKD
Group ACEIiDNT. Should all patients with type 1
diabetes mellitus and microalbuminuria receive
angiotensin-converting enzyme inhibitors? A metaanalysis of individual patient data. Annals of Internal
Medicine 2001; 134(5):370-9. Not a randomized trial
Guitterez NV, Diaz A, Timmis GC, et al.
Determinants of serum creatinine trajectory in acute
contrast nephropathy. Journal of Interventional
Cardiology 2002; 15(5):349-54. Intervention not
related to monitoring of CKD
Gurley SB, Coffman TM. The renin-angiotensin
system and diabetic nephropathy. Seminars in
Nephrology 2007; 27(2):144-52. Not a randomized
trial
Guy JM, Brammah TB, Holt L, et al. Urinary
excretion of albumin and retinol binding protein in
systemic lupus erythematosus. Annals of Clinical
Biochemistry 1997; 34(Pt 6):668-74. Not a
randomized trial
Guy M, Newall R, Borzomato J, et al. Use of a firstline urine protein-to-creatinine ratio strip test on
random urines to rule out proteinuria in patients with
chronic kidney disease. Nephrology Dialysis
Transplantation 2009; 24(4):1189-93. Not a
randomized trial
Haider DG, Fuhrmann H, Kovarik J, et al.
Postprandial intradialytic dysglycaemia and diabetes
in maintenance haemodialysis patients. European
Journal of Clinical Investigation 2008; 38(10):721-7.
Not a randomized trial
Hall AM, Edwards SG, Lapsley M, et al. Subclinical
tubular injury in HIV-infected individuals on
antiretroviral therapy: a cross-sectional analysis.
307.
308.
309.
310.
311.
312.
313.
314.
315.
316.
317.
318.
American Journal of Kidney Diseases 2009;
54(6):1034-42. Not a randomized trial
Halstenson CE, Wong MO, Herman CS, et al. Effect
of concomitant administration of piperacillin on the
dispositions of isepamicin and gentamicin in patients
with end-stage renal disease. Antimicrobial Agents &
Chemotherapy 1992; 36(9):1832-6. Not a
randomized trial
Han H, Bleyer AJ, Houser RF, et al. Dialysis and
nutrition practices in Korean hemodialysis centers.
Journal of Renal Nutrition 2002; 12(1):42-8. Not a
randomized trial
Hansen HP, Gaede PH, Jensen BR, et al. Lack of
impact of low-dose acetylsalicylic acid on kidney
function in type 1 diabetic patients with
microalbuminuria. Diabetes Care 2000; 23(12):17425. Duration of follow-up less than 1 year
Harris DCH, Rangan GK. Retardation of kidney
failure -- applying principles to practice. Annals of
the Academy of Medicine, Singapore 2005;
34(1):16-23. Not a randomized trial
Haupt MT, Jastremski MS, Clemmer TP, et al. Effect
of ibuprofen in patients with severe sepsis: a
randomized, double-blind, multicenter study. The
Ibuprofen Study Group. Critical Care Medicine
1991; 19(11):1339-47. Intervention not related to
monitoring of CKD
Havenetidis K, Bourdas D. Creatine
supplementation: effects on urinary excretion and
anaerobic performance. Journal of Sports Medicine
& Physical Fitness 2003; 43(3):347-55. Less than 50
patients in study
Hayes JK, Stanley TH, Lind GH, et al. A doubleblind study to evaluate the safety of recombinant
human hemoglobin in surgical patients during
general anesthesia. Journal of Cardiothoracic &
Vascular Anesthesia 2001; 15(5):593-602.
Intervention not related to monitoring of CKD
Hebert LA, Kusek JW, Greene T, et al. Effects of
blood pressure control on progressive renal disease in
blacks and whites. Modification of Diet in Renal
Disease Study Group. Hypertension 1997; 30(3 Pt
1):428-35. Intervention not related to monitoring of
CKD
Hebert LA, Wilmer WA, Falkenhain ME, et al.
Renoprotection: one or many therapies? Kidney
International 2001; 59(4):1211-26. Intervention not
related to monitoring of CKD
Hedayat S, Kershner RP, Su G. Relationship of
whole-blood FK506 concentrations to rejection and
toxicity in liver and kidney transplants. Journal of
Biopharmaceutical Statistics 1996; 6(4):411-24. Not
patients with early CKD
Heering P, Morgera S, Schmitz FJ, et al. Cytokine
removal and cardiovascular hemodynamics in septic
patients with continuous venovenous hemofiltration.
Intensive Care Medicine 1997; 23(3):288-96. Not a
randomized trial
Herlitz H, Harris K, Risler T, et al. The effects of an
ACE inhibitor and a calcium antagonist on the
progression of renal disease: the Nephros Study.
Nephrology Dialysis Transplantation 2001;
319.
320.
321.
322.
323.
324.
325.
326.
327.
328.
329.
330.
331.
B-28
16(11):2158-65. Intervention not related to
monitoring of CKD
Hernandez-Herrera G, Martin-Malo A, Rodriguez M,
et al. Assessment of the length of each hemodialysis
session by on-line dialysate urea monitoring.
Nephron 2001; 89(1):37-42. Not patients with early
CKD
Higashihara E, Nutahara K, Horie S, et al. The effect
of eicosapentaenoic acid on renal function and
volume in patients with ADPKD. Nephrology
Dialysis Transplantation 2008; 23(9):2847-52.
Intervention not related to monitoring of CKD
Hilton R, Tong CYW. Antiviral therapy for
polyomavirus-associated nephropathy after renal
transplantation. Journal of Antimicrobial
Chemotherapy 2008; 62(5):855-9. Not a randomized
trial
Himmelfarb J, Tolkoff Rubin N, Chandran P, et al. A
multicenter comparison of dialysis membranes in the
treatment of acute renal failure requiring dialysis.
Journal of the American Society of Nephrology
1998; 9(2):257-66. Not a randomized trial
Hiremath S, Fergusson D, Doucette S, et al. Renin
angiotensin system blockade in kidney
transplantation: a systematic review of the evidence.
American Journal of Transplantation 2007;
7(10):2350-60. Not a randomized trial
Hirth RA, Turenne MN, Wheeler JRC, et al. Provider
monitoring and pay-for-performance when multiple
providers affect outcomes: An application to renal
dialysis. Health Services Research 2009; 44(5 Pt
1):1585-602. Not a randomized trial
Hogan TJ, Elliott WJ, Seto AH, et al.
Antihypertensive treatment with and without
benazepril in patients with chronic renal
insufficiency: a US economic evaluation.
Pharmacoeconomics 2002; 20(1):37-47. Not a
randomized trial
Hollenberg NK. Aldosterone in the development and
progression of renal injury. Kidney International
2004; 66(1):1-9. Not a randomized trial
Holm T, Andreassen AK, Aukrust P, et al. Omega-3
fatty acids improve blood pressure control and
preserve renal function in hypertensive heart
transplant recipients. European Heart Journal 2001;
22(5):428-36. Less than 50 patients in study
Hong SJ, Cho KS, Cho HY, et al. A prospective,
multicenter, open-label trial of zoledronic acid in
patients with hormone refractory prostate cancer.
Yonsei Medical Journal 2007; 48(6):1001-8. Not a
randomized trial
Hor T, Baldwin D. Urinary albumin excretion in
patients with diabetes after renal transplantation.
Transplantation Proceedings 2006; 38(9):2879-82.
Not patients with early CKD
Hou FF, Zhang X, Zhang GH, et al. Efficacy and
safety of benazepril for advanced chronic renal
insufficiency. New England Journal of Medicine
2006; 354(2):131-40. Intervention not related to
monitoring of CKD
Hu W, Liu C, Xie H, et al. Mycophenolate mofetil
versus cyclophosphamide for inducing remission of
332.
333.
334.
335.
336.
337.
338.
339.
340.
341.
342.
ANCA vasculitis with moderate renal involvement.
Nephrology Dialysis Transplantation 2008;
23(4):1307-12. Less than 50 patients in study
Huland E, Heinzer H, Huland H. Treatment of
pulmonary metastatic renal-cell carcinoma in 116
patients using inhaled interleukin-2 (IL-2).
Anticancer Research 1999; 19(4A):2679-83. Not a
randomized trial
Hunsicker LG, Adler S, Caggiula A, et al. Predictors
of the progression of renal disease in the
Modification of Diet in Renal Disease Study. Kidney
International 1997; 51(6):1908-19. Not a randomized
trial
Huskey J, Lindenfeld J, Cook T, et al. Effect of
simvastatin on kidney function loss in patients with
coronary heart disease: findings from the
Scandinavian Simvastatin Survival Study (4S).
Atherosclerosis 2009; 205(1):202-6. Intervention not
related to monitoring of CKD
Hutson TE, Davis ID, Machiels JP, et al. Efficacy
and safety of pazopanib in patients with metastatic
renal cell carcinoma. Journal of Clinical Oncology
2010; 28(3):475-80. Not a randomized trial
Iaria G, Pisani F, Iorio B, et al. Long-term results of
kidney transplantation with cyclosporine- and
everolimus-based immunosuppression.
Transplantation Proceedings 2006; 38(4):1018-9. Not
patients with early CKD
Ibsen H, Olsen MH, Wachtell K, et al. Reduction in
albuminuria translates to reduction in cardiovascular
events in hypertensive patients: losartan intervention
for endpoint reduction in hypertension study.
Hypertension 2005; 45(2):198-202. Intervention not
related to monitoring of CKD
Ideura T, Shimazui M, Morita H, et al. Protein intake
of more than 0.5 g/kg BW/day is not effective in
suppressing the progression of chronic renal failure.
Contributions to Nephrology 2007; 155:40-9. Not a
randomized trial
Ihle BU, Whitworth JA, Shahinfar S, et al.
Angiotensin-converting enzyme inhibition in
nondiabetic progressive renal insufficiency: a
controlled double-blind trial. American Journal of
Kidney Diseases 1996; 27(4):489-95. Intervention
not related to monitoring of CKD
Ikuerowo SO, Kuczyk MA, Mengel M, et al.
Alteration of subcellular and cellular expression
patterns of cyclin B1 in renal cell carcinoma is
significantly related to clinical progression and
survival of patients. International Journal of Cancer
2006; 119(4):867-74. Not a randomized trial
Imamura R, Ichimaru N, Moriyama T, et al. Long
term efficacy of simvastatin in renal transplant
recipients treated with cyclosporine or tacrolimus.
Clinical Transplantation 2005; 19(5):616-21. Not a
randomized trial
Inoue S, Tomino Y. Effects of calcium antagonists in
hypertensive patients with renal dysfunction: a
prospective, randomized, parallel trial comparing
benidipine and nifedipine. Nephrology 2004;
9(5):265-71. Intervention not related to monitoring
of CKD
343. Inrig JK, Patel UD, Gillespie BS, et al. Relationship
between interdialytic weight gain and blood pressure
among prevalent hemodialysis patients. American
Journal of Kidney Diseases 2007; 50(1):108-18. Not
a randomized trial
344. Investigators RS, Bellomo R, Cass A, et al. Design
and challenges of the Randomized Evaluation of
Normal versus Augmented Level Replacement
Therapy (RENAL) Trial: high-dose versus standarddose hemofiltration in acute renal failure. Blood
Purification 2008; 26(5):407-16. Not patients with
early CKD
345. Ishani A, Grandits GA, Grimm RH, et al. Association
of single measurements of dipstick proteinuria,
estimated glomerular filtration rate, and hematocrit
with 25-year incidence of end-stage renal disease in
the multiple risk factor intervention trial. Journal of
the American Society of Nephrology 2006;
17(5):1444-52. Not a randomized trial
346. Ishani A, Paudel M, Taylor BC, et al. Renal function
and rate of hip bone loss in older men: the
Osteoporotic Fractures in Men Study. Osteoporosis
International 2008; 19(11):1549-56. Not a
randomized trial
347. Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney
injury increases risk of ESRD among elderly. Journal
of the American Society of Nephrology 2009;
20(1):223-8. Not a randomized trial
348. Ishida H, Satou T, Tsuji K, et al. The breath
ammonia measurement of the hemodialysis with a
QCM-NH3 sensor. Bio-Medical Materials &
Engineering 2008; 18(2):99-106. Not a randomized
trial
349. Ishikawa J, Hoshide S, Shibasaki S, et al. The Japan
Morning Surge-1 (JMS-1) study: protocol
description.[Erratum appears in Hypertens Res. 2006
Sep;29(9):739]. Hypertension Research - Clinical &
Experimental 2006; 29(3):153-9. Intervention not
related to monitoring of CKD
350. Ix JH, Shlipak MG, Sarnak MJ, et al. Fetuin-A is not
associated with mortality in chronic kidney disease.
Kidney International 2007; 72(11):1394-9. Not a
randomized trial
351. Jacobs C, Frei D, Perkins AC. Results of the
European Survey on Anaemia Management 2003
(ESAM 2003): current status of anaemia
management in dialysis patients, factors affecting
epoetin dosage and changes in anaemia management
over the last 5 years. Nephrology Dialysis
Transplantation 2005; 20 Suppl 3:iii3-24. Not a
randomized trial
352. Jafar TH, Schmid CH, Landa M, et al. Angiotensinconverting enzyme inhibitors and progression of
nondiabetic renal disease. A meta-analysis of patientlevel data.[Erratum appears in Ann Intern Med 2002
Aug 20;137(4):299]. Annals of Internal Medicine
2001; 135(2):73-87. Intervention not related to
monitoring of CKD
353. Jafar TH, Schmid CH, Stark PC, et al. The rate of
progression of renal disease may not be slower in
women compared with men: a patient-level meta-
B-29
354.
355.
356.
357.
358.
359.
360.
361.
362.
363.
364.
365.
366.
analysis. Nephrology Dialysis Transplantation 2003;
18(10):2047-53. Not a randomized trial
Jafar TH, Stark PC, Schmid CH, et al. Progression of
chronic kidney disease: the role of blood pressure
control, proteinuria, and angiotensin-converting
enzyme inhibition: a patient-level meta-analysis.
Annals of Internal Medicine 2003; 139(4):244-52.
Intervention not related to monitoring of CKD
Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as
a modifiable risk factor for the progression of nondiabetic renal disease. Kidney International 2001;
60(3):1131-40. Intervention not related to monitoring
of CKD
Jain L, Venitz J, Figg WD. Randomized
discontinuation trial of sorafenib (BAY 43-9006).
Cancer Biology & Therapy 2006; 5(10):1270-2. Not
a randomized trial
Jandeleit-Dahm K, Cao Z, Cox AJ, et al. Role of
hyperlipidemia in progressive renal disease: focus on
diabetic nephropathy. Kidney International Supplement 1999; 71:S31-6. Not human study
Jayne D. Challenges in the management of
microscopic polyangiitis: past, present and future.
Current Opinion in Rheumatology 2008; 20(1):3-9.
Not a randomized trial
Jensen NF, Todd MM, Block RI, et al. The efficacy
of routine central venous monitoring in major head
and neck surgery: a retrospective review. Journal of
Clinical Anesthesia 1995; 7(2):119-25. Not a
randomized trial
Jeon SH, Chang SG, Kim JI. The role of adjuvant
immunotherapy after radical nephrectomy and
prognostic factors in pT3N0M0 renal cell carcinoma.
Anticancer Research 1999; 19(6C):5593-7. Not
patients with early CKD
Jerums G, Allen TJ, Campbell DJ, et al. Long-term
renoprotection by perindopril or nifedipine in nonhypertensive patients with Type 2 diabetes and
microalbuminuria. Diabetic Medicine 2004;
21(11):1192-9. Intervention not related to monitoring
of CKD
Jin K-K, Chen L, Pan J-Y, et al. Acupressure therapy
inhibits the development of diabetic complications in
Chinese patients with type 2 diabetes. Journal of
Alternative & Complementary Medicine 2009;
15(9):1027-32. Intervention not related to monitoring
of CKD
Johnson CA, McCarthy J, Bailie GR, et al. Analysis
of renal bone disease treatment in dialysis patients.
American Journal of Kidney Diseases 2002;
39(6):1270-7. Not a randomized trial
Johnson DW. Evidence-based guide to slowing the
progression of early renal insufficiency. Internal
Medicine Journal 2004; 34(1-2):50-7. Intervention
not related to monitoring of CKD
Johnson DW. Dietary protein restriction as a
treatment for slowing chronic kidney disease
progression: the case against. Nephrology 2006;
11(1):58-62. Not a randomized trial
Jorres A. Acute renal failure. Extracorporeal
treatment strategies. Minerva Medica 2002;
93(5):329-4. Not a randomized trial
367. Jorres A. Extracorporeal treatment strategy in acute
renal failure. International Journal of Artificial
Organs 2002; 25(5):391-6. Not a randomized trial
368. Jose P, Skali H, Anavekar N, et al. Increase in
creatinine and cardiovascular risk in patients with
systolic dysfunction after myocardial infarction.
Journal of the American Society of Nephrology
2006; 17(10):2886-91. Intervention not related to
monitoring of CKD
369. Joss N, Jardine A, Gaffney D, et al. Influence of
apolipoprotein E genotype on progression of diabetic
nephropathy. Nephron. Experimental Nephrology
2005; 101(4):e127-33. Not a randomized trial
370. Jungers P, Choukroun G, Oualim Z, et al. Beneficial
influence of recombinant human erythropoietin
therapy on the rate of progression of chronic renal
failure in predialysis patients. Nephrology Dialysis
Transplantation 2001; 16(2):307-12. Not a
randomized trial
371. Kadowaki D, Anraku M, Tasaki Y, et al. Effect of
olmesartan on oxidative stress in hemodialysis
patients. Hypertension Research - Clinical &
Experimental 2007; 30(5):395-402. Not patients with
early CKD
372. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and
intrasubject variability in cyclosporine
pharmacokinetics in renal transplant recipients
treated with a microemulsion formulation in
conjunction with fasting, low-fat meals, or high-fat
meals. Transplantation 1995; 59(4):505-11. Not
patients with early CKD
373. Kalpoe JS, Schippers EF, Eling Y, et al. Similar
reduction of cytomegalovirus DNA load by oral
valganciclovir and intravenous ganciclovir on preemptive therapy after renal and renal-pancreas
transplantation. Antiviral Therapy 2005; 10(1):11923. Not a randomized trial
374. Kamgar M, Nobakhthaghighi N, Shamshirsaz AA, et
al. Impaired fibrinolytic activity in type II diabetes:
correlation with urinary albumin excretion and
progression of renal disease. Kidney International
2006; 69(10):1899-903. Not a randomized trial
375. Kamper AL, Holstein-Rathlou NH, Leyssac PP, et al.
The influence of angiotensin-converting enzyme
inhibition on renal tubular function in progressive
chronic nephropathy. American Journal of Kidney
Diseases 1996; 28(6):822-31. Intervention not
related to monitoring of CKD
376. Kaneko K, Someya T, Nishizaki N, et al. Simplified
quantification of urinary protein excretion using a
novel dipstick in children. Pediatric Nephrology
2005; 20(6):834-6. Not adult population
377. Kanno Y, Okada H, Yamaji Y, et al. Angiotensinconverting-enzyme inhibitors slow renal decline in
IgA nephropathy, independent of tubulointerstitial
fibrosis at presentation. Qjm 2005; 98(3):199-203.
Intervention not related to monitoring of CKD
378. Kaplan AA. Therapeutic apheresis for cancer related
hemolytic uremic syndrome. Therapeutic Apheresis
2000; 4(3):201-6. Intervention not related to
monitoring of CKD
B-30
379. Kaplan B, Wang Z, Keilani T, et al. The specificity
of monoclonal fluorescence polarization
immunoassay for cyclosporine in recipients of
simultaneous pancreas-kidney transplants.
Therapeutic Drug Monitoring 1995; 17(5):499-503.
Intervention not related to monitoring of CKD
380. Kasahara J, Kobayashi K, Maeshima Y, et al.
Clinical significance of serum oxidized low-density
lipoprotein/beta2-glycoprotein I complexes in
patients with chronic renal diseases. Nephron 2004;
98(1):c15-24. Intervention not related to monitoring
of CKD
381. Kasimu H, Jakai T, Qilong C, et al. A brief
evaluation for pre-estimating the severity of gallstone
pancreatitis. Jop: Journal of the Pancreas [Electronic
Resource] 2009; 10(2):147-51. Intervention not
related to monitoring of CKD
382. Kasiske BL, Heim-Duthoy K, Rao KV, et al. The
relationship between cyclosporine pharmacokinetic
parameters and subsequent acute rejection in renal
transplant recipients. Transplantation 1988;
46(5):716-22. Not patients with early CKD
383. Kasiske BL, Lakatua JD. The effects of dietary
protein restriction on chronic progressive renal
disease. Mineral & Electrolyte Metabolism 1997;
23(3-6):296-300. Not a randomized trial
384. Kasiske BL, Lakatua JD, Ma JZ, et al. A metaanalysis of the effects of dietary protein restriction on
the rate of decline in renal function. American
Journal of Kidney Diseases 1998; 31(6):954-61. Not
a randomized trial
385. Katz-Brull R, Rofsky NM, Morrin MM, et al.
Decreases in free cholesterol and fatty acid
unsaturation in renal cell carcinoma demonstrated by
breath-hold magnetic resonance spectroscopy.
American Journal of Physiology - Renal Physiology
2005; 288(4):F637-41. Intervention not related to
monitoring of CKD
386. Kaufman JS, O'Connor TZ, Zhang JH, et al.
Randomized controlled trial of clopidogrel plus
aspirin to prevent hemodialysis access graft
thrombosis. Journal of the American Society of
Nephrology 2003; 14(9):2313-21. Not patients with
early CKD
387. Kaver I, Pecht M, Trainin N, et al. T lymphocyte
subsets and function in the peripheral blood of
patients with urological cancer. Oncology 1992;
49(2):108-13. Not a randomized trial
388. Kawasaka K, Tatsumi N. D-amino acid oxidase
activity in urine obtained from patients with renal
disorders. Clinical Nephrology 1998; 49(4):214-20.
Not a randomized trial
389. Kell MJ. Utilization of plasma and urine methadone
concentrations to optimize treatment in maintenance
clinics: I. Measurement techniques for a clinical
setting. Journal of Addictive Diseases 1994; 13(1):526. Not a randomized trial
390. Kent DM, Jafar TH, Hayward RA, et al. Progression
risk, urinary protein excretion, and treatment effects
of angiotensin-converting enzyme inhibitors in
nondiabetic kidney disease. Journal of the American
391.
392.
393.
394.
395.
396.
397.
398.
399.
400.
401.
B-31
Society of Nephrology 2007; 18(6):1959-65. Not a
randomized trial
Kershner RP, Fitzsimmons WE. Relationship of
FK506 whole blood concentrations and efficacy and
toxicity after liver and kidney transplantation.
Transplantation 1996; 62(7):920-6. Not patients with
early CKD
Khan DA, Ahmad TM, Qureshil AH, et al.
Assessment of proteinuria by using protein:
creatinine index in random urine sample. JPMA Journal of the Pakistan Medical Association 2005;
55(10):428-31. Not a randomized trial
Khanna D, Clements PJ, Furst DE, et al.
Recombinant human relaxin in the treatment of
systemic sclerosis with diffuse cutaneous
involvement: a randomized, double-blind, placebocontrolled trial. Arthritis & Rheumatism 2009;
60(4):1102-11. Intervention not related to monitoring
of CKD
Khoury JA, Storch GA, Bohl DL, et al. Prophylactic
versus preemptive oral valganciclovir for the
management of cytomegalovirus infection in adult
renal transplant recipients. American Journal of
Transplantation 2006; 6(9):2134-43. Intervention not
related to monitoring of CKD
Kimmel M, Butscheid M, Brenner S, et al. Improved
estimation of glomerular filtration rate by serum
cystatin C in preventing contrast induced
nephropathy by N-acetylcysteine or zinc-preliminary results. Nephrology Dialysis
Transplantation 2008; 23(4):1241-5. Intervention not
related to monitoring of CKD
Kimmel PL, Mishkin GJ, Umana WO. Captopril and
renal survival in patients with human
immunodeficiency virus nephropathy. American
Journal of Kidney Diseases 1996; 28(2):202-8. Not a
randomized trial
Kincaid-Smith P, Fairley KF, Farish S, et al.
Reduction of proteinuria by rosiglitazone in nondiabetic renal disease. Nephrology 2008; 13(1):5862. Intervention not related to monitoring of CKD
Kincaid-Smith P, Fairley KF, Packham D. Dual
blockade of the renin-angiotensin system compared
with a 50% increase in the dose of angiotensinconverting enzyme inhibitor: effects on proteinuria
and blood pressure. Nephrology Dialysis
Transplantation 2004; 19(9):2272-4. Intervention not
related to monitoring of CKD
Kinouchi T, Sakamoto J, Tsukamoto T, et al.
Prospective randomized trial of natural interferonalpha versus natural interferon-alpha plus cimetidine
in advanced renal cell carcinoma with pulmonary
metastasis. Journal of Cancer Research & Clinical
Oncology 2006; 132(8):499-504. Not patients with
early CKD
Klahr S. Role of dietary protein and blood pressure in
the progression of renal disease. Kidney International
1996; 49(6):1783-6. Not a randomized trial
Klahr S. Prevention of progression of nephropathy.
Nephrology Dialysis Transplantation 1997; 12 Suppl
2:63-6. Not a randomized trial
402. Klahr S, Breyer JA, Beck GJ, et al. Dietary protein
restriction, blood pressure control, and the
progression of polycystic kidney disease.
Modification of Diet in Renal Disease Study
Group.[Erratum appears in J Am Soc Nephrol 1995
Oct;6(4):1318]. Journal of the American Society of
Nephrology 1995; 5(12):2037-47. Not a randomized
trial
403. Kliem V, Fricke L, Wollbrink T, et al. Improvement
in long-term renal graft survival due to CMV
prophylaxis with oral ganciclovir: results of a
randomized clinical trial. American Journal of
Transplantation 2008; 8(5):975-83. Intervention not
related to monitoring of CKD
404. Kobayashi Y, Hiki Y, Kokubo T, et al. Steroid
therapy during the early stage of progressive IgA
nephropathy. A 10-year follow-up study. Nephron
1996; 72(2):237-42. Not patients with early CKD
405. Koc E, Tunca M, Akgul EO, et al. Effects of
etanercept on urine neopterin levels in patients with
psoriasis in a controlled, open-label study. Journal of
Dermatology 2009; 36(4):191-6. Not patients with
early CKD
406. Koch KM, Koene RA, Messinger D, et al. The use of
epoetin beta in anemic predialysis patients with
chronic renal failure.[Erratum appears in Clin
Nephrol 1995 Oct;44(4):278]. Clinical Nephrology
1995; 44(3):201-8. Intervention not related to
monitoring of CKD
407. Kohen JA, Whitley KY, Kjellstrand CM. Continuous
arteriovenous hemofiltration: a comparison with
hemodialysis in acute renal failure. Transactions American Society for Artificial Internal Organs
1985; 31:169-75. Not patients with early CKD
408. Kopple JD, Greene T, Chumlea WC, et al.
Relationship between nutritional status and the
glomerular filtration rate: results from the MDRD
study. Kidney International 2000; 57(4):1688-703.
Not a randomized trial
409. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al.
Association of activated vitamin D treatment and
mortality in chronic kidney disease. Archives of
Internal Medicine 2008; 168(4):397-403. Not a
randomized trial
410. Kowey PR, Dickson TZ, Zhang Z, et al. Losartan and
end-organ protection--lessons from the RENAAL
study. Clinical Cardiology 2005; 28(3):136-42. Not a
randomized trial
411. Koya D, Haneda M, Inomata S, et al. Long-term
effect of modification of dietary protein intake on the
progression of diabetic nephropathy: a randomised
controlled trial. Diabetologia 2009; 52(10):2037-45.
Intervention not related to monitoring of CKD
412. Krairittichai U, Chaisuvannarat V. Effects of dual
blockade of renin-angiotensin system in type 2
diabetes mellitus patients with diabetic nephropathy.
Journal of the Medical Association of Thailand 2009;
92(5):611-7. Intervention not related to monitoring
of CKD
413. Kralovicova K, Spanik S, Halko J, et al. Do
vancomycin serum levels predict failures of
vancomycin therapy or nephrotoxicity in cancer
414.
415.
416.
417.
418.
419.
420.
421.
422.
423.
424.
425.
B-32
patients? Journal of Chemotherapy 1997; 9(6):420-6.
Intervention not related to monitoring of CKD
Kramer BK, Neumayer HH, Stahl R, et al. Graft
function, cardiovascular risk factors, and sex
hormones in renal transplant recipients on an
immunosuppressive regimen of everolimus, reduced
dose of cyclosporine, and basiliximab.
Transplantation Proceedings 2005; 37(3):1601-4. Not
patients with early CKD
Krane V, Wanner C. Dyslipidaemia in chronic
kidney disease. Minerva Urologica e Nefrologica
2007; 59(3):299-316. Not a randomized trial
Kroencke TJ, Wasser MN, Pattynama PMT, et al.
Gadobenate dimeglumine-enhanced MR angiography
of the abdominal aorta and renal arteries. AJR 2002;
American Journal of Roentgenology. 179(6):157382. Intervention not related to monitoring of CKD
Kshirsagar AV, Joy MS, Hogan SL, et al. Effect of
ACE inhibitors in diabetic and nondiabetic chronic
renal disease: a systematic overview of randomized
placebo-controlled trials. American Journal of
Kidney Diseases 2000; 35(4):695-707. Not a
randomized trial
Kumar MSA, Xiao S-G, Fyfe B, et al. Steroid
avoidance in renal transplantation using basiliximab
induction, cyclosporine-based immunosuppression
and protocol biopsies. Clinical Transplantation 2005;
19(1):61-9. Not patients with early CKD
Kuntz RA, Holt DW, Turner S, et al. Effects of
conventional ultrafiltration on renal performance
during adult cardiopulmonary bypass procedures.
Journal of Extra-Corporeal Technology 2006;
38(2):144-53. Intervention not related to monitoring
of CKD
Kuriyama S, Tomonari H, Yoshida H, et al. Reversal
of anemia by erythropoietin therapy retards the
progression of chronic renal failure, especially in
nondiabetic patients. Nephron 1997; 77(2):176-85.
Intervention not related to monitoring of CKD
Kutner NG. Quality of life and daily hemodialysis.
Seminars in Dialysis 2004; 17(2):92-8. Not patients
with early CKD
Laczika K, Staudinger T, Hollenstein U, et al. Renal
tolerability of four different once-daily dose regimen
of netilmicin in critical care patients. Wiener
Klinische Wochenschrift 1997; 109(21):840-4.
Intervention not related to monitoring of CKD
Laffel LM, McGill JB, Gans DJ. The beneficial
effect of angiotensin-converting enzyme inhibition
with captopril on diabetic nephropathy in
normotensive IDDM patients with microalbuminuria.
North American Microalbuminuria Study Group.
American Journal of Medicine 1995; 99(5):497-504.
Intervention not related to monitoring of CKD
Laing C, Unwin RJ. Are calcium antagonists
effective in preventing complications of hypertension
and progression of renal disease? Current Opinion in
Nephrology & Hypertension 2000; 9(5):489-95. Not
a randomized trial
Lalezari JP, Holland GN, Kramer F, et al.
Randomized, controlled study of the safety and
efficacy of intravenous cidofovir for the treatment of
426.
427.
428.
429.
430.
431.
432.
433.
434.
435.
relapsing cytomegalovirus retinitis in patients with
AIDS. Journal of Acquired Immune Deficiency
Syndromes & Human Retrovirology 1998;
17(4):339-44. Intervention not related to monitoring
of CKD
Lamuraglia M, Escudier B, Chami L, et al. To
predict progression-free survival and overall survival
in metastatic renal cancer treated with sorafenib:
pilot study using dynamic contrast-enhanced Doppler
ultrasound.[Erratum appears in Eur J Cancer. 2007
May;43(8):1336]. European Journal of Cancer 2006;
42(15):2472-9. Not patients with early CKD
Lara PN, Jr., Quinn DI, Margolin K, et al. SU5416
plus interferon alpha in advanced renal cell
carcinoma: a phase II California Cancer Consortium
Study with biological and imaging correlates of
angiogenesis inhibition. Clinical Cancer Research
2003; 9(13):4772-81. Intervention not related to
monitoring of CKD
Laufs U, Custodis F, Bohm M. Who does not need a
statin: too late in end-stage renal disease or heart
failure? Heart 2008; 94(9):1138-40. Not a
randomized trial
Lawrie AS, McDonald SJ, Purdy G, et al.
Prothrombin time derived fibrinogen determination
on Sysmex CA-6000. Journal of Clinical Pathology
1998; 51(6):462-6. Intervention not related to
monitoring of CKD
Le Meur Y, Buchler M, Thierry A, et al.
Individualized mycophenolate mofetil dosing based
on drug exposure significantly improves patient
outcomes after renal transplantation. American
Journal of Transplantation 2007; 7(11):2496-503.
Not patients with early CKD
Lea J, Cheek D, Thornley-Brown D, et al. Metabolic
syndrome, proteinuria, and the risk of progressive
CKD in hypertensive African Americans. American
Journal of Kidney Diseases 2008; 51(5):732-40.
Intervention not related to monitoring of CKD
Lea J, Greene T, Hebert L, et al. The relationship
between magnitude of proteinuria reduction and risk
of end-stage renal disease: results of the African
American study of kidney disease and hypertension.
Archives of Internal Medicine 2005; 165(8):947-53.
Intervention not related to monitoring of CKD
Lee CP, Patel PM, Selby PJ, et al. Randomized phase
II study comparing thalidomide with
medroxyprogesterone acetate in patients with
metastatic renal cell carcinoma. Journal of Clinical
Oncology 2006; 24(6):898-903. Not patients with
early CKD
Lee D, Levin A, Roger SD, et al. Longitudinal
analysis of performance of estimated glomerular
filtration rate as renal function declines in chronic
kidney disease. Nephrology Dialysis Transplantation
2009; 24(1):109-16. Not a randomized trial
Lee JY, Kusek JW, Greene PG, et al. Assessing
medication adherence by pill count and electronic
monitoring in the African American Study of Kidney
Disease and Hypertension (AASK) Pilot Study.
American Journal of Hypertension 1996; 9(8):71925. Intervention not related to monitoring of CKD
436. Leenen FHH, Coletta E, Davies RA. Prevention of
renal dysfunction and hypertension by amlodipine
after heart transplant. American Journal of
Cardiology 2007; 100(3):531-5. Intervention not
related to monitoring of CKD
437. Lehmkuhl HB, Arizon J, Vigano M, et al.
Everolimus with reduced cyclosporine versus MMF
with standard cyclosporine in de novo heart
transplant recipients. Transplantation 2009;
88(1):115-22. Not patients with early CKD
438. Lely AT, van der Kleij FGH, Kistemaker TJ, et al.
Impact of the preintervention rate of renal function
decline on outcome of renoprotective intervention.
Clinical Journal of The American Society of
Nephrology: CJASN 2008; 3(1):54-60. Intervention
not related to monitoring of CKD
439. Lemley KV, Abdullah I, Myers BD, et al. Evolution
of incipient nephropathy in type 2 diabetes
mellitus.[Erratum appears in Kidney Int 2000
Nov;58(5):2257]. Kidney International 2000;
58(3):1228-37. Not a randomized trial
440. Levey AS, Adler S, Caggiula AW, et al. Effects of
dietary protein restriction on the progression of
advanced renal disease in the Modification of Diet in
Renal Disease Study. American Journal of Kidney
Diseases 1996; 27(5):652-63. Intervention not
related to monitoring of CKD
441. Levey AS, Greene T, Sarnak MJ, et al. Effect of
dietary protein restriction on the progression of
kidney disease: long-term follow-up of the
Modification of Diet in Renal Disease (MDRD)
Study. American Journal of Kidney Diseases 2006;
48(6):879-88. Intervention not related to monitoring
of CKD
442. Levin NW, Fishbane S, Canedo FV, et al.
Intravenous methoxy polyethylene glycol-epoetin
beta for haemoglobin control in patients with chronic
kidney disease who are on dialysis: a randomised
non-inferiority trial (MAXIMA).[Erratum appears in
Lancet. 2008 Feb 2;371(9610):386]. Lancet 2007;
370(9596):1415-21. Not patients with early CKD
443. Levine RJ, Hauth JC, Curet LB, et al. Trial of
calcium to prevent preeclampsia. New England
Journal of Medicine 1997; 337(2):69-76. Intervention
not related to monitoring of CKD
444. Lewis EJ. The role of angiotensin II receptor
blockers in preventing the progression of renal
disease in patients with type 2 diabetes. American
Journal of Hypertension 2002; 15(10 Pt 2):123S-8S.
Not a randomized trial
445. Lewis EJ, Hunsicker LG, Rodby RA, et al. A clinical
trial in type 2 diabetic nephropathy. American
Journal of Kidney Diseases 2001; 38(4 Suppl
1):S191-4. Intervention not related to monitoring of
CKD
446. Lezaic VD, Marinkovic J, Ristic S, et al. Conversion
of azathioprine to mycophenolate mofetil and chronic
graft failure progression. Transplantation
Proceedings 2005; 37(2):734-6. Not patients with
early CKD
447. Li PK, Mak TW, Wang AY, et al. The interaction of
fluvastatin and cyclosporin A in renal transplant
B-33
448.
449.
450.
451.
452.
453.
454.
455.
456.
457.
458.
patients. International Journal of Clinical
Pharmacology & Therapeutics 1995; 33(4):246-8.
Not patients with early CKD
Lievre M, Marre M, Chatellier G, et al. The noninsulin-dependent diabetes, hypertension,
microalbuminuria or proteinuria, cardiovascular
events, and ramipril (DIABHYCAR) study: design,
organization, and patient recruitment. DIABHYCAR
Study Group. Controlled Clinical Trials 2000;
21(4):383-96. Intervention not related to monitoring
of CKD
Lin JL, Lin-Tan DT, Yu CC, et al. Environmental
exposure to lead and progressive diabetic
nephropathy in patients with type II diabetes. Kidney
International 2006; 69(11):2049-56. Not a
randomized trial
Lin J-L, Lin-Tan D-T, Hsu K-H, et al. Environmental
lead exposure and progression of chronic renal
diseases in patients without diabetes. New England
Journal of Medicine 2003; 348(4):277-86.
Intervention not related to monitoring of CKD
Lin S-L, Chen Y-M, Chiang W-C, et al. Effect of
pentoxifylline in addition to losartan on proteinuria
and GFR in CKD: a 12-month randomized trial.
American Journal of Kidney Diseases 2008;
52(3):464-74. Intervention not related to monitoring
of CKD
Lin-Tan D-T, Lin J-L, Yen T-H, et al. Long-term
outcome of repeated lead chelation therapy in
progressive non-diabetic chronic kidney diseases.
Nephrology Dialysis Transplantation 2007;
22(10):2924-31. Intervention not related to
monitoring of CKD
Lipton A. The safety of zoledronic acid. Expert
Opinion on Drug Safety 2007; 6(3):305-13.
Intervention not related to monitoring of CKD
Lipton A, Zheng M, Seaman J. Zoledronic acid
delays the onset of skeletal-related events and
progression of skeletal disease in patients with
advanced renal cell carcinoma. Cancer 2003;
98(5):962-9. Intervention not related to monitoring
of CKD
Littlewood KJ, Greiner W, Baum D, et al. Adjunctive
treatment with moxonidine versus nitrendipine for
hypertensive patients with advanced renal failure: a
cost-effectiveness analysis. BMC Nephrology 2007;
8:9. Not a randomized trial
Liu K-P, Lin C-Y, Chen H-J, et al. Renin-angiotensin
system polymorphisms in Taiwanese primary
vesicoureteral reflux. Pediatric Nephrology 2004;
19(6):594-601. Not a randomized trial
Liu M, Zhang W, Gu M, et al. Protective effects of
sirolimus by attenuating connective tissue growth
factor expression in human chronic allograft
nephropathy. Transplantation Proceedings 2007;
39(5):1410-5. Not patients with early CKD
Llewelyn DEH, Garcia-Puig J. How different urinary
albumin excretion rates can predict progression to
nephropathy and the effect of treatment in
hypertensive diabetics. Journal of the ReninAngiotensin-Aldosterone System 2004; 5(3):141-5.
Intervention not related to monitoring of CKD
459. Lobo PI, Cortez MS, Stevenson W, et al.
Normocalcemic hyperparathyroidism associated with
relatively low 1:25 vitamin D levels post-renal
transplant can be successfully treated with oral
calcitriol. Clinical Transplantation 1995; 9(4):27781. Not a randomized trial
460. Locatelli F, Carbarns IR, Maschio G, et al. Longterm progression of chronic renal insufficiency in the
AIPRI Extension Study. The AngiotensinConverting-Enzyme Inhibition in Progressive Renal
Insufficiency Study Group. Kidney International Supplement 1997; 63:S63-6. Intervention not related
to monitoring of CKD
461. Locatelli F, Del Vecchio L, Andrulli S, et al. The role
of underlying nephropathy in the progression of renal
disease. Kidney International - Supplement 2000;
75:S49-55. Not a randomized trial
462. Locatelli F, Del Vecchio L, Pozzoni P. Clinical
benefits of slowing the progression of renal failure.
Kidney International - Supplement 2005; (99):S1526. Not a randomized trial
463. Locatelli F, Del Vecchio L, Pozzoni P, et al. Is it the
agent or the blood pressure level that matters for
renal and vascular protection in chronic
nephropathies? Kidney International - Supplement
2005; (93):S15-9. Not a randomized trial
464. Locatelli F, Manzoni C, Marcelli D. Factors affecting
progression of renal insufficiency. Mineral &
Electrolyte Metabolism 1997; 23(3-6):301-5. Not a
randomized trial
465. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria
and blood pressure as causal components of
progression to end-stage renal failure. Northern
Italian Cooperative Study Group. Nephrology
Dialysis Transplantation 1996; 11(3):461-7.
Intervention not related to monitoring of CKD
466. Locatelli F, Pozzi C, Del Vecchio L, et al. Role of
proteinuria reduction in the progression of IgA
nephropathy. Renal Failure 2001; 23(3-4):495-505.
Not patients with early CKD
467. Locatelli F, Vecchio LD, Pozzi C. IgA
glomerulonephritis: beyond angiotensin-converting
enzyme inhibitors. Nature Clinical Practice
Nephrology 2006; 2(1):24-31. Not a randomized trial
468. Locatelli F, Vecchio LD, Pozzoni P. The importance
of early detection of chronic kidney disease.
Nephrology Dialysis Transplantation 2002; 17 Suppl
11:2-7. Not a randomized trial
469. Lombardo F, Frijia F, Bongioanni P, et al. Diffusion
tensor MRI and MR spectroscopy in long lasting
upper motor neuron involvement in amyotrophic
lateral sclerosis. Archives Italiennes de Biologie
2009; 147(3):69-82. Intervention not related to
monitoring of CKD
470. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril
and vitamin E on atherosclerosis: the study to
evaluate carotid ultrasound changes in patients
treated with ramipril and vitamin E (SECURE).
Circulation 2001; 103(7):919-25. Intervention not
related to monitoring of CKD
471. Lopes RJ, Lourenco AP, Mascarenhas J, et al. Safety
of spironolactone use in ambulatory heart failure
B-34
472.
473.
474.
475.
476.
477.
478.
479.
480.
481.
482.
patients. Clinical Cardiology 2008; 31(11):509-13.
Intervention not related to monitoring of CKD
Lorber MI, Mulgaonkar S, Butt KMH, et al.
Everolimus versus mycophenolate mofetil in the
prevention of rejection in de novo renal transplant
recipients: a 3-year randomized, multicenter, phase
III study. Transplantation 2005; 80(2):244-52. Not
patients with early CKD
Louis S, Audrain M, Cantarovich D, et al. Long-term
cell monitoring of kidney recipients after an
antilymphocyte globulin induction with and without
steroids. Transplantation 2007; 83(6):712-21. Not
patients with early CKD
Loukovaara S, Immonen I, Teramo KA, et al.
Progression of retinopathy during pregnancy in type
1 diabetic women treated with insulin lispro.
Diabetes Care 2003; 26(4):1193-8. Intervention not
related to monitoring of CKD
Low CL, Bailie G, Morgan S, et al. Effect of a
sliding scale protocol for heparin on the ability to
maintain whole blood activated partial
thromboplastin times within a desired range in
hemodialysis patients. Clinical Nephrology 1996;
45(2):120-4. Not patients with early CKD
Luchner A, Hengstenberg C, Lowel H, et al. Effect
of compensated renal dysfunction on approved heart
failure markers: direct comparison of brain
natriuretic peptide (BNP) and N-terminal pro-BNP.
Hypertension 2005; 46(1):118-23. Not a randomized
trial
Lumlertgul D, Noppakun K, Rojanasthien N, et al.
Pharmacokinetic study of the combination of
tacrolimus and fluconazole in renal transplant
patients. Journal of the Medical Association of
Thailand 2006; 89 Suppl 2:S73-8. Not patients with
early CKD
MacDonald AS, Group RGS. A worldwide, phase
III, randomized, controlled, safety and efficacy study
of a sirolimus/cyclosporine regimen for prevention of
acute rejection in recipients of primary mismatched
renal allografts. Transplantation 2001; 71(2):271-80.
Not patients with early CKD
MacGregor MS, Deighan CJ, Rodger RSC, et al. A
prospective open-label randomised trial of quinapril
and/or amlodipine in progressive non-diabetic renal
failure. Nephron 2005; 101(3):c139-49. Intervention
not related to monitoring of CKD
Magee GM, Bilous RW, Cardwell CR, et al. Is
hyperfiltration associated with the future risk of
developing diabetic nephropathy? A meta-analysis.
Diabetologia 2009; 52(4):691-7. Not a randomized
trial
Mahalati K, Lawen J, Kiberd B, et al. Is 3-hour
cyclosporine blood level superior to trough level in
early post-renal transplantation period? Journal of
Urology 2000; 163(1):37-41. Not patients with early
CKD
Mak G, Tan CY, Ben Khiaron O, et al. An evaluation
of the effects of renal artery stenting in renovascular
hypertension. Irish Medical Journal 2007;
100(3):397-8. Not a randomized trial
483. Makino H, Haneda M, Babazono T, et al.
Microalbuminuria reduction with telmisartan in
normotensive and hypertensive Japanese patients
with type 2 diabetes: a post-hoc analysis of The
Incipient to Overt: Angiotensin II Blocker,
Telmisartan, Investigation on Type 2 Diabetic
Nephropathy (INNOVATION) study. Hypertension
Research - Clinical & Experimental 2008; 31(4):65764. Intervention not related to monitoring of CKD
484. Malik J, Slavikova M, Svobodova J, et al. Regular
ultrasonographic screening significantly prolongs
patency of PTFE grafts. Kidney International 2005;
67(4):1554-8. Not patients with early CKD
485. Mallett C, House AA, Spence JD, et al. Longitudinal
ultrasound evaluation of carotid atherosclerosis in
one, two and three dimensions. Ultrasound in
Medicine & Biology 2009; 35(3):367-75.
Intervention not related to monitoring of CKD
486. Mallikaarjun S, Shoaf SE, Boulton DW, et al. Effects
of hepatic or renal impairment on the
pharmacokinetics of aripiprazole. Clinical
Pharmacokinetics 2008; 47(8):533-42. Intervention
not related to monitoring of CKD
487. Mancini D, Pinney S, Burkhoff D, et al. Use of
rapamycin slows progression of cardiac
transplantation vasculopathy. Circulation 2003;
108(1):48-53. Intervention not related to monitoring
of CKD
488. Mani S, Poo WJ. Single institution experience with
recombinant gamma-interferon in the treatment of
patients with metastatic renal cell carcinoma.
American Journal of Clinical Oncology 1996;
19(2):149-53. Not a randomized trial
489. Manikandan R, Srinivasan V, Rane A. Which is the
real gold standard for small-volume renal tumors?
Radical nephrectomy versus nephron-sparing
surgery. Journal of Endourology 2004; 18(1):39-44.
Not a randomized trial
490. Manley HJ. Role of angiotensin-converting-enzyme
inhibition in patients with renal disease. American
Journal of Health-System Pharmacy 2000; 57 Suppl
1:S12-8. Not a randomized trial
491. Mann JFE, Gerstein HC, Yi Q-L, et al. Progression
of renal insufficiency in type 2 diabetes with and
without microalbuminuria: results of the Heart
Outcomes and Prevention Evaluation (HOPE)
randomized study. American Journal of Kidney
Diseases 2003; 42(5):936-42. Not a randomized trial
492. Mann JFE, Gerstein HC, Yi Q-L, et al. Development
of renal disease in people at high cardiovascular risk:
results of the HOPE randomized study. Journal of the
American Society of Nephrology 2003; 14(3):641-7.
Not a randomized trial
493. Mann JFE, Schmieder RE, Dyal L, et al. Effect of
telmisartan on renal outcomes: a randomized
trial.[Summary for patients in Ann Intern Med. 2009
Jul 7;151(1):I28; PMID: 19451555]. Annals of
Internal Medicine 2009; 151(1):1-10. Intervention
not related to monitoring of CKD
494. Manno C, Strippoli GFM, D'Altri C, et al. A novel
simpler histological classification for renal survival
in IgA nephropathy: a retrospective study. American
B-35
495.
496.
497.
498.
499.
500.
501.
502.
503.
504.
505.
Journal of Kidney Diseases 2007; 49(6):763-75. Not
a randomized trial
Marcantoni C, Zanoli L, Rastelli S, et al. Stenting of
renal artery stenosis in coronary artery disease (RASCAD) study: a prospective, randomized trial. Journal
of Nephrology 2009; 22(1):13-6. Intervention not
related to monitoring of CKD
Mariappan P, Smith G, Moussa SA, et al. One week
of ciprofloxacin before percutaneous
nephrolithotomy significantly reduces upper tract
infection and urosepsis: a prospective controlled
study. BJU International 2006; 98(5):1075-9.
Intervention not related to monitoring of CKD
Markowitz CE, Spitsin S, Zimmerman V, et al. The
treatment of multiple sclerosis with inosine. Journal
of Alternative & Complementary Medicine 2009;
15(6):619-25. Intervention not related to monitoring
of CKD
Martin PJ, Nelson BJ, Appelbaum FR, et al.
Evaluation of a CD5-specific immunotoxin for
treatment of acute graft-versus-host disease after
allogeneic marrow transplantation. Blood 1996;
88(3):824-30. Intervention not related to monitoring
of CKD
Martinez-Castelao A, Sarrias X, Bestard O, et al.
Arterial elasticity measurement in renal transplant
patients under anticalcineurin immunosuppression.
Transplantation Proceedings 2005; 37(9):3788-90.
Not patients with early CKD
Marto N, Bertolaccini ML, Calabuig E, et al. AntiC1q antibodies in nephritis: correlation between titres
and renal disease activity and positive predictive
value in systemic lupus erythematosus. Annals of the
Rheumatic Diseases 2005; 64(3):444-8. Not a
randomized trial
Mas VR, Mas LA, Archer KJ, et al. Evaluation of
gene panel mRNAs in urine samples of kidney
transplant recipients as a non-invasive tool of graft
function. Molecular Medicine 2007; 13(5-6):315-24.
Not a randomized trial
Maschio G, Alberti D, Janin G, et al. Effect of the
angiotensin-converting-enzyme inhibitor benazepril
on the progression of chronic renal insufficiency. The
Angiotensin-Converting-Enzyme Inhibition in
Progressive Renal Insufficiency Study Group. New
England Journal of Medicine 1996; 334(15):939-45.
Intervention not related to monitoring of CKD
Masuda S-i, Tamura K, Wakui H, et al. Effects of
angiotensin II type 1 receptor blocker on ambulatory
blood pressure variability in hypertensive patients
with overt diabetic nephropathy. Hypertension
Research - Clinical & Experimental 2009;
32(11):950-5. Intervention not related to monitoring
of CKD
Matsumura C, Kemmotsu O, Kawano Y, et al. Serum
and urine inorganic fluoride levels following
prolonged low-dose sevoflurane anesthesia combined
with epidural block. Journal of Clinical Anesthesia
1994; 6(5):419-24. Intervention not related to
monitoring of CKD
Matthews DR, Stratton IM, Aldington SJ, et al. Risks
of progression of retinopathy and vision loss related
506.
507.
508.
509.
510.
511.
512.
513.
514.
515.
B-36
to tight blood pressure control in type 2 diabetes
mellitus: UKPDS 69. Archives of Ophthalmology
2004; 122(11):1631-40. Intervention not related to
monitoring of CKD
Mauer M, Zinman B, Gardiner R, et al. Renal and
retinal effects of enalapril and losartan in type 1
diabetes. New England Journal of Medicine 2009;
361(1):40-51. Intervention not related to monitoring
of CKD
McClellan WM, Hodgin E, Pastan S, et al. A
randomized evaluation of two health care quality
improvement program (HCQIP) interventions to
improve the adequacy of hemodialysis care of ESRD
patients: feedback alone versus intensive
intervention. Journal of the American Society of
Nephrology 2004; 15(3):754-60. Not patients with
early CKD
McClellan WM, Langston RD, Presley R. Medicare
patients with cardiovascular disease have a high
prevalence of chronic kidney disease and a high rate
of progression to end-stage renal disease. Journal of
the American Society of Nephrology 2004;
15(7):1912-9. Not a randomized trial
McClellan WM, Soucie JM, Krisher J, et al.
Improving the care of patients treated with
hemodialysis: a report from the Health Care
Financing Administration's ESRD Core Indicators
Project. American Journal of Kidney Diseases 1998;
31(4):584-92. Not patients with early CKD
McCormack PM, Cox JP, Marron J, et al. The
antihypertensive efficacy of ketanserin in the elderly
evaluated by ambulatory blood pressure
measurement. Journal of Human Hypertension 1990;
4(5):565-70. Intervention not related to monitoring
of CKD
McCormick PA, Greenslade L, Kibbler CC, et al. A
prospective randomized trial of ceftazidime versus
netilmicin plus mezlocillin in the empirical therapy
of presumed sepsis in cirrhotic patients. Hepatology
1997; 25(4):833-6. Intervention not related to
monitoring of CKD
McCullough PA, Agrawal V, Danielewicz E, et al.
Accelerated atherosclerotic calcification and
Monckeberg's sclerosis: a continuum of advanced
vascular pathology in chronic kidney disease.
Clinical Journal of The American Society of
Nephrology: CJASN 2008; 3(6):1585-98. Not a
randomized trial
McCullough PA, Bakris GL, Owen WF, Jr., et al.
Slowing the progression of diabetic nephropathy and
its cardiovascular consequences. American Heart
Journal 2004; 148(2):243-51. Not a randomized trial
McDonald RA, Smith JM, Ho M, et al. Incidence of
PTLD in pediatric renal transplant recipients
receiving basiliximab, calcineurin inhibitor, sirolimus
and steroids. American Journal of Transplantation
2008; 8(5):984-9. Not adult population
McGill JB. Improving microvascular outcomes in
patients with diabetes through management of
hypertension. Postgraduate Medicine 2009;
121(2):89-101. Not a randomized trial
516. McMahon LP, Roger SD, Levin A, et al.
Development, prevention, and potential reversal of
left ventricular hypertrophy in chronic kidney
disease. Journal of the American Society of
Nephrology 2004; 15(6):1640-7. Intervention not
related to monitoring of CKD
517. Melis D, Parenti G, Gatti R, et al. Efficacy of ACEinhibitor therapy on renal disease in glycogen storage
disease type 1: a multicentre retrospective study.
Clinical Endocrinology 2005; 63(1):19-25. Not a
randomized trial
518. Menon V, Wang X, Sarnak MJ, et al. Long-term
outcomes in nondiabetic chronic kidney disease.
Kidney International 2008; 73(11):1310-5. Not a
randomized trial
519. Mezzano D, Tagle R, Pais E, et al. Endothelial cell
markers in chronic uremia: relationship with
hemostatic defects and severity of renal failure.
Thrombosis Research 1997; 88(6):465-72. Not a
randomized trial
520. Midtvedt K, Fauchald P, Lien B, et al. Individualized
T cell monitored administration of ATG versus
OKT3 in steroid-resistant kidney graft rejection.
Clinical Transplantation 2003; 17(1):69-74. Not
patients with early CKD
521. Milas NC, Nowalk MP, Akpele L, et al. Factors
associated with adherence to the dietary protein
intervention in the Modification of Diet in Renal
Disease Study. Journal of the American Dietetic
Association 1995; 95(11):1295-300. Not a
randomized trial
522. Miller PD, Bilezikian JP, Diaz-Curiel M, et al.
Occurrence of hypercalciuria in patients with
osteoporosis treated with teriparatide. Journal of
Clinical Endocrinology & Metabolism 2007;
92(9):3535-41. Not patients with early CKD
523. Miyazaki Y, Cersosimo E, Triplitt C, et al.
Rosiglitazone decreases albuminuria in type 2
diabetic patients. Kidney International 2007;
72(11):1367-73. Intervention not related to
monitoring of CKD
524. Modine T, Decoene C, Al-Ruzzeh S, et al.
Dobutamine improves thoracic aortic blood flow
during off-pump coronary artery bypass surgery:
results of a prospective randomised controlled trial.
European Journal of Cardio-Thoracic Surgery 2005;
27(2):289-95. Intervention not related to monitoring
of CKD
525. Mohanram A, Zhang Z, Shahinfar S, et al. Anemia
and end-stage renal disease in patients with type 2
diabetes and nephropathy. Kidney International
2004; 66(3):1131-8. Not a randomized trial
526. Moist LM, Churchill DN, House AA, et al. Regular
monitoring of access flow compared with monitoring
of venous pressure fails to improve graft survival.
Journal of the American Society of Nephrology
2003; 14(10):2645-53. Not patients with early CKD
527. Monier-Faugere MC, Malluche HH. Calcitriol pulse
therapy in patients with end-stage renal failure.
Current Opinion in Nephrology & Hypertension
1994; 3(6):615-9. Not patients with early CKD
528. Morita S, Fukuhara S, Akizawa T, et al. Prognostic
factors for a composite end-point of renal outcomes
in patients with chronic kidney disease. Therapeutic
Apheresis & Dialysis: Official Peer-Reviewed
Journal of the International Society for Apheresis, the
Japanese Society for Apheresis, the Japanese Society
for Dialysis Therapy 2006; 10(1):72-7. Not a
randomized trial
529. Mosca A, Paleari R, Ceriotti F, et al. Biological
variability of albumin excretion rate and albumin-tocreatinine ratio in hypertensive type 2 diabetic
patients. Clinical Chemistry & Laboratory Medicine
2003; 41(9):1229-33. Intervention not related to
monitoring of CKD
530. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib
versus interferon alfa in metastatic renal-cell
carcinoma. New England Journal of Medicine 2007;
356(2):115-24. Not patients with early CKD
531. Mpoy M, Vandeleene B, Ketelslegers JM, et al.
Treatment of systemic hypertension in insulin-treated
diabetes mellitus with rilmenidine. American Journal
of Cardiology 1988; 61(7):91D-4D. Intervention not
related to monitoring of CKD
532. Muhlhauser I, Bender R, Bott U, et al. Cigarette
smoking and progression of retinopathy and
nephropathy in type 1 diabetes. Diabetic Medicine
1996; 13(6):536-43. Not a randomized trial
533. Mulgaonkar S, Tedesco H, Oppenheimer F, et al.
FTY720/cyclosporine regimens in de novo renal
transplantation: a 1-year dose-finding study.[Erratum
appears in Am J Transplant. 2006 Dec;6(12):3044].
American Journal of Transplantation 2006;
6(8):1848-57. Not patients with early CKD
534. Munger MA, Gardner SF, Ateshkadi A, et al.
Misoprostol effects on diclofenac-induced
cardiorenal changes in salt-sensitive patients with
hypertension: the MEDIC Study. Pharmacotherapy
2008; 28(7):834-42. Intervention not related to
monitoring of CKD
535. Myrup B, Mathiesen ER, Ronn B, et al. Endothelial
function and serum lipids in the course of developing
microalbuminuria in insulin-dependent diabetes
mellitus. Diabetes Research 1994; 26(1):33-9. Not a
randomized trial
536. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of
pitavastatin on urinary liver-type fatty-acid-binding
protein in patients with nondiabetic mild chronic
kidney disease. American Journal of Nephrology
2006; 26(1):82-6. Intervention not related to
monitoring of CKD
537. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of
pitavastatin on urinary liver-type fatty acid-binding
protein levels in patients with early diabetic
nephropathy. Diabetes Care 2005; 28(11):2728-32.
Intervention not related to monitoring of CKD
538. Nakano S, Ishii T, Kitazawa M, et al. Altered
circadian blood pressure rhythm and progression of
diabetic nephropathy in non-insulin dependent
diabetes mellitus subjects: an average three year
follow-up study. Journal of Investigative Medicine
1996; 44(5):247-53. Not a randomized trial
B-37
539. Nakao T, Kanazawa Y, Nagaoka Y, et al. Body
protein index based on bioelectrical impedance
analysis is a useful new marker assessing nutritional
status: applications to patients with chronic renal
failure on maintenance dialysis. Contributions to
Nephrology 2007; 155:18-28. Not patients with early
CKD
540. Nakao T, Yoshino M, Matsumoto H, et al. Lowdensity lipoprotein apheresis retards the progression
of hyperlipidemic overt diabetic nephropathy.
Kidney International - Supplement 1999; 71:S206-9.
Not a randomized trial
541. Narenpitak S, Narenpitak A. Prevalence of chronic
kidney disease in type 2 diabetes in primary health
care unit of Udon Thani province, Thailand. Journal
of the Medical Association of Thailand 2008;
91(10):1505-13. Not a randomized trial
542. Navaneethan SD, Nigwekar SU, Sehgal AR, et al.
Aldosterone antagonists for preventing the
progression of chronic kidney disease. Cochrane
Database of Systematic Reviews 2009;
(3):CD007004. Not a randomized trial
543. Navaneethan SD, Nigwekar SU, Sehgal AR, et al.
Aldosterone antagonists for preventing the
progression of chronic kidney disease: a systematic
review and meta-analysis. Clinical Journal of The
American Society of Nephrology: CJASN 2009;
4(3):542-51. Not a randomized trial
544. Navaneethan SD, Pansini F, Perkovic V, et al. HMG
CoA reductase inhibitors (statins) for people with
chronic kidney disease not requiring dialysis.
Cochrane Database of Systematic Reviews 2009;
(2):CD007784. Not a randomized trial
545. Negrier S, Escudier B, Lasset C, et al. Recombinant
human interleukin-2, recombinant human interferon
alfa-2a, or both in metastatic renal-cell carcinoma.
Groupe Francais d'Immunotherapie. New England
Journal of Medicine 1998; 338(18):1272-8. Not
patients with early CKD
546. Neuhaus P, Blumhardt G, Bechstein WO, et al.
Comparison of FK506- and cyclosporine-based
immunosuppression in primary orthotopic liver
transplantation. A single center experience.
Transplantation 1995; 59(1):31-40. Intervention not
related to monitoring of CKD
547. Neverov NI, Kaysen GA, Tareyeva IE. Effect of
lipid-lowering therapy on the progression of renal
disease in nondiabetic nephrotic patients.
Contributions to Nephrology 1997; 120:68-78.
Intervention not related to monitoring of CKD
548. Newman DJ, Mattock MB, Dawnay ABS, et al.
Systematic review on urine albumin testing for early
detection of diabetic complications. Health
Technology Assessment 2005; 9(30):iii-vi, xiii-163.
Not a randomized trial
549. Ng CS, Wang X, Faria SC, et al. Perfusion CT in
patients with metastatic renal cell carcinoma treated
with interferon. AJR 2010; 194(1):166-71. Not
patients with early CKD
550. Nielsen FS, Jorgensen LN, Ipsen M, et al. Long-term
comparison of human insulin analogue B10Asp and
soluble human insulin in IDDM patients on a
551.
552.
553.
554.
555.
556.
557.
558.
559.
560.
B-38
basal/bolus insulin regimen. Diabetologia 1995;
38(5):592-8. Intervention not related to monitoring
of CKD
Niwa T, Aoyama I, Takayama F, et al. Urinary
indoxyl sulfate is a clinical factor that affects the
progression of renal failure. Mineral & Electrolyte
Metabolism 1999; 25(1-2):118-22. Not a randomized
trial
Niwa T, Tsukushi S, Ise M, et al. Indoxyl sulfate and
progression of renal failure: effects of a low-protein
diet and oral sorbent on indoxyl sulfate production in
uremic rats and undialyzed uremic patients. Mineral
& Electrolyte Metabolism 1997; 23(3-6):179-84. Not
human study
Nohria A, Hasselblad V, Stebbins A, et al.
Cardiorenal interactions: insights from the ESCAPE
trial. Journal of the American College of Cardiology
2008; 51(13):1268-74. Intervention not related to
monitoring of CKD
Norris KC, Greene T, Kopple J, et al. Baseline
predictors of renal disease progression in the African
American Study of Hypertension and Kidney
Disease. Journal of the American Society of
Nephrology 2006; 17(10):2928-36. Intervention not
related to monitoring of CKD
Northridge DB, Jardine AG, Findlay IN, et al.
Inhibition of the metabolism of atrial natriuretic
factor causes diuresis and natriuresis in chronic heart
failure. American Journal of Hypertension 1990;
3(9):682-7. Intervention not related to monitoring of
CKD
Obialo CI, Conner AC, Lebon LF. Maintaining
patency of tunneled hemodialysis catheters--efficacy
of aspirin compared to warfarin. Scandinavian
Journal of Urology & Nephrology 2003; 37(2):172-6.
Intervention not related to monitoring of CKD
O'Hare AM, Kaufman JS, Covinsky KE, et al.
Current guidelines for using angiotensin-converting
enzyme inhibitors and angiotensin II-receptor
antagonists in chronic kidney disease: is the evidence
base relevant to older adults? Annals of Internal
Medicine 2009; 150(10):717-24. Not a randomized
trial
Oliveras A, Hurtado S, Vazquez S, et al. Efficacy
and safety of doxazosin GITS in hypertensive renal
transplant patients: comparison of 8 and 4 mg.
Transplantation Proceedings 2003; 35(5):1732-5. Not
patients with early CKD
Onuigbo MAC. Does concurrent renin-angiotensinaldosterone blockade in (older) chronic kidney
disease patients play a role in the acute renal failure
epidemic in US hospitalized patients?--Three cases
of severe acute renal failure encountered in a
northwestern Wisconsin Nephrology practice.
Hemodialysis International 2009; 13 Suppl 1:S24-9.
Not a randomized trial
Onuigbo MAC. Reno-prevention vs. reno-protection:
a critical re-appraisal of the evidence-base from the
large RAAS blockade trials after ONTARGET--a
call for more circumspection. Qjm 2009; 102(3):15567. Not a randomized trial
561. Orth SR, Hallan SI. Smoking: a risk factor for
progression of chronic kidney disease and for
cardiovascular morbidity and mortality in renal
patients--absence of evidence or evidence of
absence? Clinical Journal of The American Society
of Nephrology: CJASN 2008; 3(1):226-36. Not a
randomized trial
562. Ortiz MA, De Prado A, Donate T, et al. Angiotensinconverting enzyme polymorphism gene and
evolution of nephropathy to end-stage renal disease.
Nephrology 2003; 8(4):171-6. Not a randomized trial
563. Oudemans-van Straaten HM, Wester JPJ, de Pont
ACJM, et al. Anticoagulation strategies in continuous
renal replacement therapy: can the choice be
evidence based? Intensive Care Medicine 2006;
32(2):188-202. Not a randomized trial
564. Oue T, Namba M, Nakajima H, et al. Risk factors for
the progression of microalbuminuria in Japanese type
2 diabetic patients--a 10 year follow-up study.
Diabetes Research & Clinical Practice 1999;
46(1):47-55. Not a randomized trial
565. Owada A, Nakao M, Koike J, et al. Effects of oral
adsorbent AST-120 on the progression of chronic
renal failure: a randomized controlled study. Kidney
International - Supplement 1997; 63:S188-90.
Intervention not related to monitoring of CKD
566. Owada A, Suda S, Hata T. Antiproteinuric effect of
niceritrol, a nicotinic acid derivative, in chronic renal
disease with hyperlipidemia: a randomized trial.
American Journal of Medicine 2003; 114(5):347-53.
Intervention not related to monitoring of CKD
567. Oyibo SO, Pritchard GM, McLay L, et al. Blood
glucose overestimation in diabetic patients on
continuous ambulatory peritoneal dialysis for endstage renal disease. Diabetic Medicine 2002;
19(8):693-6. Not patients with early CKD
568. Paap CM, Simpson KS, Horton MW, et al. Multipledose pharmacokinetics of pentoxifylline and its
metabolites during renal insufficiency. Annals of
Pharmacotherapy 1996; 30(7-8):724-9. Intervention
not related to monitoring of CKD
569. Padrik P, Leppik K, Arak A. Combination therapy
with capecitabine and interferon alfa-2A in patients
with advanced renal cell carcinoma: a phase II study.
Urologic Oncology 2004; 22(5):387-92. Not patients
with early CKD
570. Pakfetrat M, Nikoo MH, Malekmakan L, et al. A
comparison of sodium bicarbonate infusion versus
normal saline infusion and its combination with oral
acetazolamide for prevention of contrast-induced
nephropathy: a randomized, double-blind trial.
International Urology & Nephrology 2009;
41(3):629-34. Intervention not related to monitoring
of CKD
571. Paoletti E, Amidone M, Cassottana P, et al. Effect of
sirolimus on left ventricular hypertrophy in kidney
transplant recipients: a 1-year nonrandomized
controlled trial. American Journal of Kidney
Diseases 2008; 52(2):324-30. Not a randomized trial
572. Paoletti E, Cannella G. Update on erythropoietin
treatment: should hemoglobin be normalized in
patients with chronic kidney disease? Journal of the
573.
574.
575.
576.
577.
578.
579.
580.
581.
582.
583.
584.
B-39
American Society of Nephrology 2006; 17(4 Suppl
2):S74-7. Not a randomized trial
Park CW, Yun SN, Yang CW, et al. Serum and urine
soluble HLA class I antigen concentrations are
increased in patients with hemorrhagic fever with
renal syndrome. Korean Journal of Internal Medicine
1997; 12(1):52-7. Not a randomized trial
Parving HH. Is antihypertensive treatment the same
for NIDDM and IDDM patients? Diabetes Research
& Clinical Practice 1998; 39 Suppl:S43-7. Not a
randomized trial
Parving HH. Benefits and cost of antihypertensive
treatment in incipient and overt diabetic nephropathy.
Journal of Hypertension - Supplement 1998;
16(1):S99-101. Not a randomized trial
Parving HH, Lehnert H, Brochner-Mortensen J, et al.
The effect of irbesartan on the development of
diabetic nephropathy in patients with type 2 diabetes.
New England Journal of Medicine 2001;
345(12):870-8. Intervention not related to monitoring
of CKD
Parving HH, Lewis JB, Ravid M, et al. Prevalence
and risk factors for microalbuminuria in a referred
cohort of type II diabetic patients: a global
perspective. Kidney International 2006; 69(11):205763. Not a randomized trial
Parving HH, Rossing P. The use of antihypertensive
agents in prevention and treatment of diabetic
nephropathy. Current Opinion in Nephrology &
Hypertension 1994; 3(3):292-300. Not a randomized
trial
Pasero G, Priolo F, Marubini E, et al. Slow
progression of joint damage in early rheumatoid
arthritis treated with cyclosporin A. Arthritis &
Rheumatism 1996; 39(6):1006-15. Intervention not
related to monitoring of CKD
Pecherstorfer M, Rivkin S, Body J-J, et al. Long-term
safety of intravenous ibandronic acid for up to 4
years in metastatic breast cancer: an open-label trial.
Clinical Drug Investigation 2006; 26(6):315-22.
Intervention not related to monitoring of CKD
Pedrinelli R, Dell'Omo G, Giampietro O, et al.
Dissociation between albuminuria and insulinaemia
in hypertensive and atherosclerotic men. Journal of
Human Hypertension 1999; 13(2):129-34. Not a
randomized trial
Pedrini MT, Levey AS, Lau J, et al. The effect of
dietary protein restriction on the progression of
diabetic and nondiabetic renal diseases: a metaanalysis. Annals of Internal Medicine 1996;
124(7):627-32. Not a randomized trial
Penno G, Chaturvedi N, Talmud PJ, et al. Effect of
angiotensin-converting enzyme (ACE) gene
polymorphism on progression of renal disease and
the influence of ACE inhibition in IDDM patients:
findings from the EUCLID Randomized Controlled
Trial. EURODIAB Controlled Trial of Lisinopril in
IDDM. Diabetes 1998; 47(9):1507-11. Not a
randomized trial
Pereira TV, Nunes ACF, Rudnicki M, et al. Influence
of ACE I/D gene polymorphism in the progression of
renal failure in autosomal dominant polycystic
585.
586.
587.
588.
589.
590.
591.
592.
593.
594.
595.
kidney disease: a meta-analysis. Nephrology Dialysis
Transplantation 2006; 21(11):3155-63. Not a
randomized trial
Perkins RM, Aboudara MC, Uy AL, et al. Effect of
pentoxifylline on GFR decline in CKD: a pilot,
double-blind, randomized, placebo-controlled trial.
American Journal of Kidney Diseases 2009;
53(4):606-16. Intervention not related to monitoring
of CKD
Perrin NESS, Jaremko GA, Berg UB. The effects of
candesartan on diabetes glomerulopathy: a doubleblind, placebo-controlled trial. Pediatric Nephrology
2008; 23(6):947-54. Intervention not related to
monitoring of CKD
Persson F, Rossing P, Hovind P, et al. Endothelial
dysfunction and inflammation predict development
of diabetic nephropathy in the Irbesartan in Patients
with Type 2 Diabetes and Microalbuminuria (IRMA
2) study. Scandinavian Journal of Clinical &
Laboratory Investigation 2008; 68(8):731-8.
Intervention not related to monitoring of CKD
Pescovitz MD. A cost too high to bear? Prophylaxis
versus preemptive therapy to prevent posttransplantation cytomegalovirus. Kidney
International 2007; 72(8):912-3. Not patients with
early CKD
Petersen LJ, Petersen JR, Talleruphuus U, et al. A
randomized and double-blind comparison of
isradipine and spirapril as monotherapy and in
combination on the decline in renal function in
patients with chronic renal failure and hypertension.
Clinical Nephrology 2001; 55(5):375-83.
Intervention not related to monitoring of CKD
Peterson GE, de Backer T, Gabriel A, et al.
Prevalence and correlates of left ventricular
hypertrophy in the African American Study of
Kidney Disease Cohort Study. Hypertension 2007;
50(6):1033-9. Not a randomized trial
Peterson JC, Adler S, Burkart JM, et al. Blood
pressure control, proteinuria, and the progression of
renal disease. The Modification of Diet in Renal
Disease Study. Annals of Internal Medicine 1995;
123(10):754-62. Intervention not related to
monitoring of CKD
Pfaller W, Thorwartl U, Nevinny-Stickel M, et al.
Clinical value of fructose 1,6 bisphosphatase in
monitoring renal proximal tubular injury. Kidney
International - Supplement 1994; 47:S68-75.
Intervention not related to monitoring of CKD
Pham P-TT, Pham P-CT, Wilkinson AH.
Management of renal dysfunction in the liver
transplant recipient. Current Opinion in Organ
Transplantation 2009; 14(3):231-9. Not a randomized
trial
Phillips CA, Molitch ME. The relationship between
glucose control and the development and progression
of diabetic nephropathy. Current Diabetes Reports
2002; 2(6):523-9. Not a randomized trial
Pierce HL, Stevermer JJ. Does losartan (Cozaar)
slow the progression of renal disease in patients with
type 2 diabetes and nephropathy? Journal of Family
596.
597.
598.
599.
600.
601.
602.
603.
604.
605.
606.
607.
608.
B-40
Practice 2001; 50(12):1083. Intervention not related
to monitoring of CKD
Pimenta E, Gaddam KK, Oparil S, et al. Effects of
dietary sodium reduction on blood pressure in
subjects with resistant hypertension: results from a
randomized trial. Hypertension 2009; 54(3):475-81.
Intervention not related to monitoring of CKD
Pioro EP, Antel JP, Cashman NR, et al. Detection of
cortical neuron loss in motor neuron disease by
proton magnetic resonance spectroscopic imaging in
vivo. Neurology 1994; 44(10):1933-8. Intervention
not related to monitoring of CKD
Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced
thrombotic microangiopathy: incidence, prevention
and management. Drug Safety 2001; 24(7):491-501.
Intervention not related to monitoring of CKD
Plantinga LC, Jaar BG. Preventing repeat
hospitalizations in dialysis patients: a call for action.
Kidney International 2009; 76(3):249-51. Not
patients with early CKD
Poirier LA, Brown AT, Fink LM, et al. Blood Sadenosylmethionine concentrations and lymphocyte
methylenetetrahydrofolate reductase activity in
diabetes mellitus and diabetic nephropathy.
Metabolism: Clinical & Experimental 2001;
50(9):1014-8. Not a randomized trial
Polkinghorne KR, Lau KKP, Saunder A, et al. Does
monthly native arteriovenous fistula blood-flow
surveillance detect significant stenosis--a randomized
controlled trial. Nephrology Dialysis Transplantation
2006; 21(9):2498-506. Not patients with early CKD
Ponticelli C, Rivolta E. Ciclosporin in minimalchange glomerulopathy and in focal segmental
glomerular sclerosis. American Journal of
Nephrology 1990; 10 Suppl 1:105-9. Not a
randomized trial
Pontrelli P, Rossini M, Infante B, et al. Rapamycin
inhibits PAI-1 expression and reduces interstitial
fibrosis and glomerulosclerosis in chronic allograft
nephropathy. Transplantation 2008; 85(1):125-34.
Not patients with early CKD
Porta C. Maintenance biotherapy with interleukin-2
and interferon for metastatic renal cell cancer. Expert
Review of Anticancer Therapy 2006; 6(1):141-52.
Not a randomized trial
Portaluppi F, Vergnani L, Manfredini R, et al. Timedependent effect of isradipine on the nocturnal
hypertension in chronic renal failure. American
Journal of Hypertension 1995; 8(7):719-26.
Intervention not related to monitoring of CKD
Poschel KA, Bucha E, Esslinger HU, et al.
Pharmacodynamics and pharmacokinetics of
polyethylene glycol-hirudin in patients with chronic
renal failure. Kidney International 2000; 58(6):247884. Intervention not related to monitoring of CKD
Poulsen PL, Ebbehoj E, Hansen KW, et al. High
normo- or low microalbuminuria: basis for
intervention in insulin-dependent diabetes mellitus.
Kidney International - Supplement 1997; 63:S15-8.
Intervention not related to monitoring of CKD
Poulsen PL, Hansen KW, Mogensen CE.
Ambulatory blood pressure in the transition from
609.
610.
611.
612.
613.
614.
615.
616.
617.
618.
619.
620.
normo- to microalbuminuria. A longitudinal study in
IDDM patients. Diabetes 1994; 43(10):1248-53. Not
a randomized trial
Pozzi C, Andrulli S, Del Vecchio L, et al.
Corticosteroid effectiveness in IgA nephropathy:
long-term results of a randomized, controlled trial.
Journal of the American Society of Nephrology
2004; 15(1):157-63. Not patients with early CKD
Pozzi C, Del Vecchio L, Locatelli F. Can
immunosuppressive therapy be useful in IgA
nephropathy when the 'Point of No Return' has
already been exceeded? Nephron 2002; 92(3):699701. Not a randomized trial
Prisant LM, Loebl DH, Mulloy LL. Scleroderma
renal crisis. Journal of Clinical Hypertension 2003;
5(2):168-70. Not a randomized trial
Rachmani R, Slavachevski I, Berla M, et al.
Teaching and motivating patients to control their risk
factors retards progression of cardiovascular as well
as microvascular sequelae of Type 2 diabetes
mellitus- a randomized prospective 8 years follow-up
study. Diabetic Medicine 2005; 22(4):410-4.
Intervention not related to monitoring of CKD
Rahman M, Baimbridge C, Davis BR, et al.
Progression of kidney disease in moderately
hypercholesterolemic, hypertensive patients
randomized to pravastatin versus usual care: a report
from the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT).
American Journal of Kidney Diseases 2008;
52(3):412-24. Intervention not related to monitoring
of CKD
Ramin SM, Vidaeff AC, Yeomans ER, et al. Chronic
renal disease in pregnancy. Obstetrics & Gynecology
2006; 108(6):1531-9. Not a randomized trial
Rammohan C, Fintel D. Dosing considerations and
monitoring of low molecular weight heparins and
glycoprotein IIb/IIIa antagonists in patients with
renal insufficiency. Current Cardiology Reports
2003; 5(4):303-9. Not a randomized trial
Ranich T, Bhathena SJ, Velasquez MT. Protective
effects of dietary phytoestrogens in chronic renal
disease. Journal of Renal Nutrition 2001; 11(4):18393. Not a randomized trial
Rasche FM, Keller F, Lepper PM, et al. High-dose
intravenous immunoglobulin pulse therapy in
patients with progressive immunoglobulin A
nephropathy: a long-term follow-up. Clinical &
Experimental Immunology 2006; 146(1):47-53. Not
a randomized trial
Rasmussen K, Pedersen E. Monitoring of renal
allografts by Doppler ultrasound: precision and
reference values. Scandinavian Journal of Clinical &
Laboratory Investigation 1990; 50(1):51-5.
Intervention not related to monitoring of CKD
Ravid M, Neumann L, Lishner M. Plasma lipids and
the progression of nephropathy in diabetes mellitus
type II: effect of ACE inhibitors. Kidney
International 1995; 47(3):907-10. Intervention not
related to monitoring of CKD
Reach I, Luong N, Chastang C, et al. Dose effect
relationship of reviparin in chronic hemodialysis: a
621.
622.
623.
624.
625.
626.
627.
628.
629.
630.
631.
632.
B-41
crossover study versus nadroparin. Artificial Organs
2001; 25(7):591-5. Not patients with early CKD
Redman BG, Flaherty L, Martino S, et al. Effect of
calcium replacement on the hemodynamic changes
associated with high dose interleukin-2 therapy.
American Journal of Clinical Oncology 1992;
15(4):340-3. Intervention not related to monitoring
of CKD
Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical
pharmacokinetics of tacrolimus in heart transplant
recipients. Therapeutic Drug Monitoring 1999;
21(1):2-7. Not patients with early CKD
Reichard P. Are there any glycemic thresholds for
the serious microvascular diabetic complications?
Journal of Diabetes & its Complications 1995;
9(1):25-30. Intervention not related to monitoring of
CKD
Reichert LJ, Koene RA, Wetzels JF. Urinary
excretion of beta 2-microglobulin predicts renal
outcome in patients with idiopathic membranous
nephropathy. Journal of the American Society of
Nephrology 1995; 6(6):1666-9. Not a randomized
trial
Reilly JP, Ramee SR. Vascular brachytherapy in
renal artery restenosis. Current Opinion in
Cardiology 2004; 19(4):332-5. Not a randomized
trial
Remuzzi G, Macia M, Ruggenenti P. Prevention and
treatment of diabetic renal disease in type 2 diabetes:
the BENEDICT study. Journal of the American
Society of Nephrology 2006; 17(4 Suppl 2):S90-7.
Intervention not related to monitoring of CKD
Remuzzi G, Perico N, Gotti E, et al. The kidney
transplant program at the Bergamo Center. Clinical
Transplants 2000:179-91. Not a randomized trial
Repmann R, Goldschmidt AJW, Richter A. Adjuvant
therapy of renal cell carcinoma patients with an
autologous tumor cell lysate vaccine: a 5-year
follow-up analysis.[Erratum appears in Anticancer
Res. 2003;23:5370]. Anticancer Research 2003;
23(2A):969-74. Not patients with early CKD
Richer M, Robert S, Lebel M. Renal hemodynamics
during norepinephrine and low-dose dopamine
infusions in man. Critical Care Medicine 1996;
24(7):1150-6. Intervention not related to monitoring
of CKD
Ricos C, Jimenez CV, Hernandez A, et al. Biological
variation in urine samples used for analyte
measurements. Clinical Chemistry 1994; 40(3):4727. Not a randomized trial
Riess FC, Moshar S, Bader R, et al. Clinical outcome
of patients with and without renal impairment
undergoing a minimally invasive LIMA-to-LAD
bypass operation. Heart Surgery Forum 2000;
3(4):313-8. Intervention not related to monitoring of
CKD
Rini BI, Halabi S, Taylor J, et al. Cancer and
Leukemia Group B 90206: A randomized phase III
trial of interferon-alpha or interferon-alpha plus antivascular endothelial growth factor antibody
(bevacizumab) in metastatic renal cell carcinoma.
633.
634.
635.
636.
637.
638.
639.
640.
641.
642.
643.
644.
645.
Clinical Cancer Research 2004; 10(8):2584-6. Not
patients with early CKD
Rizzoni D, Porteri E, Boari GEM, et al. Prognostic
significance of small-artery structure in hypertension.
Circulation 2003; 108(18):2230-5. Not a randomized
trial
Roderick PJ, Atkins RJ, Smeeth L, et al. Detecting
chronic kidney disease in older people; what are the
implications?.[Erratum appears in Age Ageing. 2009
Sep;38(5):638 Note: Flectcher, Astrid E [corrected to
Fletcher, Astrid E]]. Age & Ageing 2008; 37(2):17986. Not a randomized trial
Rodger RS, Muralikrishna GS, Halls DJ, et al.
Ranitidine suppresses aluminium absorption in man.
Clinical Science 1991; 80(5):505-8. Not patients with
early CKD
Rodger RS, Sheldon WL, Watson MJ, et al. Zinc
deficiency and hyperprolactinaemia are not
reversible causes of sexual dysfunction in uraemia.
Nephrology Dialysis Transplantation 1989;
4(10):888-92. Intervention not related to monitoring
of CKD
Ronco C, Brendolan A, Milan M, et al. Impact of
biofeedback-induced cardiovascular stability on
hemodialysis tolerance and efficiency. Kidney
International 2000; 58(2):800-8. Not patients with
early CKD
Rosner GL, Stadler W, Ratain MJ. Randomized
discontinuation design: application to cytostatic
antineoplastic agents. Journal of Clinical Oncology
2002; 20(22):4478-84. Intervention not related to
monitoring of CKD
Rossert J, Froissart M, Jacquot C. Anemia
management and chronic renal failure progression.
Kidney International - Supplement 2005; (99):S7681. Not a randomized trial
Rossert J, Levin A, Roger SD, et al. Effect of early
correction of anemia on the progression of CKD.
American Journal of Kidney Diseases 2006;
47(5):738-50. Intervention not related to monitoring
of CKD
Rossert JA, McClellan WM, Roger SD, et al.
Contribution of anaemia to progression of renal
disease: a debate. Nephrology Dialysis
Transplantation 2002; 17 Suppl 1:60-6. Not a
randomized trial
Roux C. The methodology of clinical trials of oral
tiludronate in Paget's disease of bone. Bone 1995;
17(5 Suppl):497S-9S. Not a randomized trial
Roy JN, Barama A, Poirier C, et al. Cyp3A4,
Cyp3A5, and MDR-1 genetic influences on
tacrolimus pharmacokinetics in renal transplant
recipients. Pharmacogenetics & Genomics 2006;
16(9):659-65. Not a randomized trial
Rudberg S, Rasmussen LM, Bangstad HJ, et al.
Influence of insertion/deletion polymorphism in the
ACE-I gene on the progression of diabetic
glomerulopathy in type 1 diabetic patients with
microalbuminuria. Diabetes Care 2000; 23(4):544-8.
Not a randomized trial
Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing
microalbuminuria in type 2 diabetes. New England
646.
647.
648.
649.
650.
651.
652.
653.
654.
655.
B-42
Journal of Medicine 2004; 351(19):1941-51.
Intervention not related to monitoring of CKD
Ruggenenti P, Gaspari F, Perna A, et al. Cross
sectional longitudinal study of spot morning urine
protein:creatinine ratio, 24 hour urine protein
excretion rate, glomerular filtration rate, and end
stage renal failure in chronic renal disease in patients
without diabetes.[Erratum appears in BMJ 1998 Nov
28;317(7171):1491]. BMJ 1998; 316(7130):504-9.
Not a randomized trial
Ruggenenti P, Pagano E, Tammuzzo L, et al.
Ramipril prolongs life and is cost effective in chronic
proteinuric nephropathies. Kidney International
2001; 59(1):286-94. Intervention not related to
monitoring of CKD
Ruggenenti P, Perna A, Gherardi G, et al. Chronic
proteinuric nephropathies: outcomes and response to
treatment in a prospective cohort of 352 patients with
different patterns of renal injury. American Journal
of Kidney Diseases 2000; 35(6):1155-65.
Intervention not related to monitoring of CKD
Ruggenenti P, Perna A, Lesti M, et al. Pretreatment
blood pressure reliably predicts progression of
chronic nephropathies. GISEN Group. Kidney
International 2000; 58(5):2093-101. Not a
randomized trial
Ruggenenti P, Perna A, Loriga G, et al. Bloodpressure control for renoprotection in patients with
non-diabetic chronic renal disease (REIN-2):
multicentre, randomised controlled trial. Lancet
2005; 365(9463):939-46. Intervention not related to
monitoring of CKD
Ruggenenti P, Perna A, Mosconi L, et al. Proteinuria
predicts end-stage renal failure in non-diabetic
chronic nephropathies. The "Gruppo Italiano di Studi
Epidemiologici in Nefrologia" (GISEN). Kidney
International - Supplement 1997; 63:S54-7. Not
patients with early CKD
Ruggenenti P, Perna A, Remuzzi G, et al. Retarding
progression of chronic renal disease: the neglected
issue of residual proteinuria. Kidney International
2003; 63(6):2254-61. Not patients with early CKD
Ruggenenti P, Perna A, Zoccali C, et al. Chronic
proteinuric nephropathies. II. Outcomes and response
to treatment in a prospective cohort of 352 patients:
differences between women and men in relation to
the ACE gene polymorphism. Gruppo Italiano di
Studi Epidemologici in Nefrologia (Gisen). Journal
of the American Society of Nephrology 2000;
11(1):88-96. Intervention not related to monitoring
of CKD
Ruilope LM, Casal MC, Guerrero L, et al. Sodium
intake does not influence the effect of verapamil in
hypertensive patients with mild renal insufficiency.
Drugs 1992; 44 Suppl 1:94-8. Intervention not
related to monitoring of CKD
Ruiz JC, Campistol JM, Grinyo JM, et al. Early
cyclosporine a withdrawal in kidney-transplant
recipients receiving sirolimus prevents progression of
chronic pathologic allograft lesions. Transplantation
2004; 78(9):1312-8. Not patients with early CKD
656. Ruiz JC, Campistol JM, Mota A, et al. Early
elimination of cyclosporine in kidney transplant
recipients receiving sirolimus prevents progression of
chronic pathologic allograft lesions. Transplantation
Proceedings 2003; 35(5):1669-70. Not patients with
early CKD
657. Rush DN, Cockfield SM, Nickerson PW, et al.
Factors associated with progression of interstitial
fibrosis in renal transplant patients receiving
tacrolimus and mycophenolate mofetil.
Transplantation 2009; 88(7):897-903. Not patients
with early CKD
658. Ruzicka M, Burns KD, Culleton B, et al. Treatment
of hypertension in patients with nondiabetic chronic
kidney disease. Canadian Journal of Cardiology
2007; 23(7):595-601. Not a randomized trial
659. Sagawa M, Oka M, Chaboyer W. The utility of
cognitive behavioural therapy on chronic
haemodialysis patients' fluid intake: a preliminary
examination. International Journal of Nursing Studies
2003; 40(4):367-73. Not patients with early CKD
660. Sahadevan M, Kasiske BL. Hyperlipidemia in kidney
disease: causes and consequences. Current Opinion
in Nephrology & Hypertension 2002; 11(3):323-9.
Not a randomized trial
661. Saidi JA, Newhouse JH, Sawczuk IS. Radiologic
follow-up of patients with T1-3a,b,c or T4N+M0
renal cell carcinoma after radical nephrectomy.
Urology 1998; 52(6):1000-3. Not patients with early
CKD
662. Salako BL, Finomo FO, Kadiri S, et al. Comparative
effect of lisinopril and lacidipine on urinary albumin
excretion in patients with type 11 diabetic
nephropathy. African Journal of Medicine & Medical
Sciences 2002; 31(1):53-7. Intervention not related
to monitoring of CKD
663. Sands JJ, Jabyac PA, Miranda CL, et al. Intervention
based on monthly monitoring decreases hemodialysis
access thrombosis. ASAIO Journal 1999; 45(3):14750. Not patients with early CKD
664. Sarapa N, Wickremasingha P, Ge N, et al. Lack of
effect of DX-619, a novel des-fluoro(6)-quinolone,
on glomerular filtration rate measured by serum
clearance of cold iohexol. Antimicrobial Agents &
Chemotherapy 2007; 51(6):1912-7. Intervention not
related to monitoring of CKD
665. Sarnak MJ, Greene T, Wang X, et al. The effect of a
lower target blood pressure on the progression of
kidney disease: long-term follow-up of the
modification of diet in renal disease study. Annals of
Internal Medicine 2005; 142(5):342-51. Intervention
not related to monitoring of CKD
666. Sattler FR, Cowan R, Nielsen DM, et al.
Trimethoprim-sulfamethoxazole compared with
pentamidine for treatment of Pneumocystis carinii
pneumonia in the acquired immunodeficiency
syndrome. A prospective, noncrossover study.
Annals of Internal Medicine 1988; 109(4):280-7.
Intervention not related to monitoring of CKD
667. Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a
difference between the allergic potencies of the iron
sucrose and low molecular weight iron dextran?
668.
669.
670.
671.
672.
673.
674.
675.
676.
677.
678.
B-43
Renal Failure 2007; 29(4):423-6. Intervention not
related to monitoring of CKD
Sawicki PT, Muhlhauser I, Didjurgeit U, et al.
Intensified antihypertensive therapy is associated
with improved survival in type 1 diabetic patients
with nephropathy. Journal of Hypertension 1995;
13(8):933-8. Intervention not related to monitoring
of CKD
Sawicki PT, Muhlhauser I, Didjurgeit U, et al.
Effects of intensification of antihypertensive care in
diabetic nephropathy. Journal of Diabetes & its
Complications 1995; 9(4):315-7. Intervention not
related to monitoring of CKD
Scarpioni R, Michieletti E, Cristinelli L, et al.
Atherosclerotic renovascular disease: medical
therapy versus medical therapy plus renal artery
stenting in preventing renal failure progression: the
rationale and study design of a prospective,
multicenter and randomized trial (NITER). Journal of
Nephrology 2005; 18(4):423-8. Intervention not
related to monitoring of CKD
Schadewaldt P, Killius S, Kamalanathan L, et al.
Renal excretion of galactose and galactitol in patients
with classical galactosaemia, obligate heterozygous
parents and healthy subjects. Journal of Inherited
Metabolic Disease 2003; 26(5):459-79. Not patients
with early CKD
Schaeffner ES, Kurth T, Bowman TS, et al. Blood
pressure measures and risk of chronic kidney disease
in men. Nephrology Dialysis Transplantation 2008;
23(4):1246-51. Not a randomized trial
Schetz M, Bove T, Morelli A, et al. Prevention of
cardiac surgery-associated acute kidney injury.
International Journal of Artificial Organs 2008;
31(2):179-89. Intervention not related to monitoring
of CKD
Schiele J, Nowack R, Julian BA, et al. Treatment of
immunoglobulin A nephropathy. Annales de
Medecine Interne 1999; 150(2):127-36. Intervention
not related to monitoring of CKD
Schjoedt KJ, Hansen HP, Tarnow L, et al. Long-term
prevention of diabetic nephropathy: an audit.
Diabetologia 2008; 51(6):956-61. Not a randomized
trial
Schlosser K, Scigalla P. Biochemical markers as
surrogates in clinical trials in patients with metastatic
bone disease and osteoporosis. Scandinavian Journal
of Clinical and Laboratory Investigation Supplement
1997; 227:21-8. Intervention not related to
monitoring of CKD
Schluchter MD, Greene T, Beck GJ. Analysis of
change in the presence of informative censoring:
application to a longitudinal clinical trial of
progressive renal disease. Statistics in Medicine
2001; 20(7):989-1007. Not a randomized trial
Schmieder RE, Langenfeld MR, Gatzka CD, et al.
Impact of alpha- versus beta-blockers on
hypertensive target organ damage: results of a
double-blind, randomized, controlled clinical trial.
American Journal of Hypertension 1997; 10(9 Pt
1):985-91. Intervention not related to monitoring of
CKD
679. Schoffski P, Guillem V, Garcia M, et al. Phase II
randomized study of Plitidepsin (Aplidin), alone or in
association with L-carnitine, in patients with
unresectable advanced renal cell carcinoma. Marine
Drugs 2009; 7(1):57-70. Intervention not related to
monitoring of CKD
680. Schrier RW. Treating high-risk diabetic hypertensive
patients with comorbid conditions. American Journal
of Kidney Diseases 2000; 36(3 Suppl 1):S10-7. Not a
randomized trial
681. Schrier RW, Estacio RO. The effect of angiotensinconverting enzyme inhibitors on the progression of
nondiabetic renal disease: a pooled analysis of
individual-patient data from 11 randomized,
controlled trials. Annals of Internal Medicine 2001;
135(2):138-9. Intervention not related to monitoring
of CKD
682. Schrier RW, Estacio RO, Esler A, et al. Effects of
aggressive blood pressure control in normotensive
type 2 diabetic patients on albuminuria, retinopathy
and strokes. Kidney International 2002; 61(3):108697. Intervention not related to monitoring of CKD
683. Schwartz MM, Korbet SM, Lewis EJ, et al. The
prognosis and pathogenesis of severe lupus
glomerulonephritis. Nephrology Dialysis
Transplantation 2008; 23(4):1298-306. Not a
randomized trial
684. Senitzer D, Greenstein SM, Louis P, et al.
Monitoring serum IL-2R levels in cadaver renal
transplantation: a prospective, blinded study.
Transplantation Proceedings 1991; 23(1 Pt 2):127981. Not patients with early CKD
685. Seron D, Oppenheimer F, Pallardo LM, et al.
Fluvastatin in the prevention of renal transplant
vasculopathy: results of a prospective, randomized,
double-blind, placebo-controlled trial.
Transplantation 2008; 86(1):82-7. Not patients with
early CKD
686. Shah A, Lettieri J, Blum R, et al. Pharmacokinetics
of intravenous ciprofloxacin in normal and renally
impaired subjects. Journal of Antimicrobial
Chemotherapy 1996; 38(1):103-16. Not a
randomized trial
687. Shah S, Paparello J, Danesh FR. Effects of statin
therapy on the progression of chronic kidney disease.
Advances in Chronic Kidney Disease 2005;
12(2):187-95. Not a randomized trial
688. Sharma M, Rao M, Jacob S, et al. A controlled trial
of intermittent enteral nutrient supplementation in
maintenance hemodialysis patients. Journal of Renal
Nutrition 2002; 12(4):229-37. Not patients with early
CKD
689. Shen Y, Fleming TR. Assessing effects on long-term
survival after early termination of randomized trials.
Lifetime Data Analysis 1999; 5(1):55-66. Not a
randomized trial
690. Shigenaga A-i, Tamura K, Dejima T, et al. Effects of
angiotensin II type 1 receptor blocker on blood
pressure variability and cardiovascular remodeling in
hypertensive patients on chronic peritoneal dialysis.
Nephron 2009; 112(1):c31-40. Not patients with
early CKD
691. Shin YS, Yang CW, Ahn HJ, et al. Clinical
significance of anti-endothelial cell antibody in renal
transplant recipients. Korean Journal of Internal
Medicine 2001; 16(1):24-9. Not patients with early
CKD
692. Siddiqi N, El Shahat O, Bokhari E, et al. The effect
of use of dates on serum potassium in nondiabetic
hemodialysis patients. Saudi Journal of Kidney
Diseases & Transplantation 2009; 20(6):1018-22.
Not patients with early CKD
693. Simeckova A, Zamrazil V, Cerovska J, et al. Does a
relationship exist between ioduria, magnesiuria and
calciuria? Journal of Trace Elements in Medicine &
Biology 2000; 14(1):28-30. Not a randomized trial
694. Sinert R, Doty CI. Evidence-based emergency
medicine review. Prevention of contrast-induced
nephropathy in the emergency department. Annals of
Emergency Medicine 2007; 50(3):335-45. Not a
randomized trial
695. Singh-Franco D, Machado C, Tuteja S, et al.
Trospium chloride for the treatment of overactive
bladder with urge incontinence. Clinical Therapeutics
2005; 27(5):511-30. Not a randomized trial
696. Sirken GR, Shah C, Raja R. Slow-flow venous
pressure for detection of arteriovenous graft
malfunction. Kidney International 2003; 63(5):18948. Not a randomized trial
697. Siu Y-P, Leung K-T, Tong MK-H, et al. Use of
allopurinol in slowing the progression of renal
disease through its ability to lower serum uric acid
level. American Journal of Kidney Diseases 2006;
47(1):51-9. Intervention not related to monitoring of
CKD
698. Skipper GE, Weinmann W, Thierauf A, et al. Ethyl
glucuronide: a biomarker to identify alcohol use by
health professionals recovering from substance use
disorders. Alcohol & Alcoholism 2004; 39(5):445-9.
Intervention not related to monitoring of CKD
699. Slowik MM. Early education of patients with chronic
renal insufficiency: the Healthy Start program. Case
study of the anemic patient. Nephrology Nursing
Journal: Journal of the American Nephrology Nurses'
Association 2001; 28(6):643-6. Not a randomized
trial
700. Smith RJH, Alexander J, Barlow PN, et al. New
approaches to the treatment of dense deposit disease.
Journal of the American Society of Nephrology
2007; 18(9):2447-56. Not a randomized trial
701. Smulders YM, van Eeden AE, Stehouwer CD, et al.
Can reduction in hypertriglyceridaemia slow
progression of microalbuminuria in patients with
non-insulin-dependent diabetes mellitus? European
Journal of Clinical Investigation 1997; 27(12):9971002. Intervention not related to monitoring of CKD
702. Snyder S, Pendergraph B. Detection and evaluation
of chronic kidney disease. American Family
Physician 2005; 72(9):1723-32. Not a randomized
trial
703. Solomkin JS, Fant WK, Rivera JO, et al.
Randomized trial of imipenem/cilastatin versus
gentamicin and clindamycin in mixed flora
infections. American Journal of Medicine 1985;
B-44
704.
705.
706.
707.
708.
709.
710.
711.
712.
713.
714.
78(6A):85-91. Intervention not related to monitoring
of CKD
Solomon LR, Hendler ED. Prospective controlled
study of androgen therapy in the anemia of chronic
renal disease: effects on iron kinetics. Acta
Haematologica 1988; 79(1):12-9. Not a randomized
trial
Soroka N, Silverberg DS, Greemland M, et al.
Comparison of a vegetable-based (soya) and an
animal-based low-protein diet in predialysis chronic
renal failure patients. Nephron 1998; 79(2):173-80.
Not patients with early CKD
Souchet T, Durand Zaleski I, Hannedouche T, et al.
An economic evaluation of Losartan therapy in type
2 diabetic patients with nephropathy: an analysis of
the RENAAL study adapted to France. Diabetes &
Metabolism 2003; 29(1):29-35. Not patients with
early CKD
Sozen S, Gurocak S, Erdem O, et al.
Cyclooxygenase-2 expression: does it have a
probable role in tumorigenesis mechanisms of renal
cell carcinoma? International Urology & Nephrology
2008; 40(2):295-301. Not a randomized trial
Stefoni S, Mosconi G, La Manna G, et al. Lowdosage ibopamine treatment in progressive renal
failure: a long-term multicentre trial. American
Journal of Nephrology 1996; 16(6):489-99.
Intervention not related to monitoring of CKD
Stein WD, Yang J, Bates SE, et al. Bevacizumab
reduces the growth rate constants of renal
carcinomas: a novel algorithm suggests early
discontinuation of bevacizumab resulted in a lack of
survival advantage. Oncologist 2008; 13(10):105562. Intervention not related to monitoring of CKD
Stevenson JC, Hillard TC, Lees B, et al.
Postmenopausal bone loss: does HRT always work?
International Journal of Fertility & Menopausal
Studies 1993; 38 Suppl 2:88-91. Intervention not
related to monitoring of CKD
Stoves J, Inglis H, Newstead CG. A randomized
study of oral vs intravenous iron supplementation in
patients with progressive renal insufficiency treated
with erythropoietin. Nephrology Dialysis
Transplantation 2001; 16(5):967-74. Not patients
with early CKD
Stoves J, Newstead CG, Baczkowski AJ, et al. A
randomized controlled trial of immunosuppression
conversion for the treatment of chronic allograft
nephropathy. Nephrology Dialysis Transplantation
2004; 19(8):2113-20. Not patients with early CKD
Strippoli GFM, Bonifati C, Craig M, et al.
Angiotensin converting enzyme inhibitors and
angiotensin II receptor antagonists for preventing the
progression of diabetic kidney disease. Cochrane
Database of Systematic Reviews 2006;
(4):CD006257. Not a randomized trial
Strippoli GFM, Craig MC, Schena FP, et al. Role of
blood pressure targets and specific antihypertensive
agents used to prevent diabetic nephropathy and
delay its progression. Journal of the American
Society of Nephrology 2006; 17(4 Suppl 2):S153-5.
Not a randomized trial
715. Studies of Ocular Complications of ARGTACTG.
The ganciclovir implant plus oral ganciclovir versus
parenteral cidofovir for the treatment of
cytomegalovirus retinitis in patients with acquired
immunodeficiency syndrome: The Ganciclovir
Cidofovir Cytomegalovirus Retinitis Trial. American
Journal of Ophthalmology 2001; 131(4):457-67.
Intervention not related to monitoring of CKD
716. Sumethkul V, Changsirikulchai S, Lothuvachai T, et
al. Sirolimus attenuates the rate of progression of
early chronic allograft nephropathy. Transplantation
Proceedings 2006; 38(10):3470-2. Not patients with
early CKD
717. Sundaram S, Mainali R, Norfolk ER, et al. Fibrillary
glomerulopathy secondary to light chain deposition
disease in a patient with monoclonal gammopathy.
Annals of Clinical & Laboratory Science 2007;
37(4):370-4. Intervention not related to monitoring
of CKD
718. Sunder-Plassmann G, Horl WH. Importance of iron
supply for erythropoietin therapy. Nephrology
Dialysis Transplantation 1995; 10(11):2070-6. Not
patients with early CKD
719. Sussman SK. Nonvascular intervention in the
genitourinary tract. Current Opinion in Radiology
1991; 3(5):669-80. Intervention not related to
monitoring of CKD
720. Suzuki H, Moriwaki K, Nakamoto H, et al. Blood
pressure reduction in the morning yields beneficial
effects on progression of chronic renal insufficiency
with regression of left ventricular hypertrophy.
Clinical & Experimental Hypertension 2002; 24(12):51-63. Intervention not related to monitoring of
CKD
721. Svensson M, Gustafsson F, Galatius S, et al. How
prevalent is hyperkalemia and renal dysfunction
during treatment with spironolactone in patients with
congestive heart failure? Journal of Cardiac Failure
2004; 10(4):297-303. Not a randomized trial
722. Tabaei BP, Al-Kassab AS, Ilag LL, et al. Does
microalbuminuria predict diabetic nephropathy?
Diabetes Care 2001; 24(9):1560-6. Not a randomized
trial
723. Takahashi T, Reed SD, Schulman KA. Costeffectiveness of the oral adsorbent AST-120 versus
placebo for chronic kidney disease. Nephrology
2008; 13(5):419-27. Not a randomized trial
724. Takei T, Otsubo S, Uchida K, et al. Effects of
sevelamer on the progression of vascular
calcification in patients on chronic haemodialysis.
Nephron 2008; 108(4):c278-83. Not patients with
early CKD
725. Talaulikar GS, Gallagher MP, Carney GM, et al.
Switchover to generic cyclosporine in stable renal
transplant recipients: a single unit experience.
Nephrology 2004; 9(6):418-21. Not patients with
early CKD
726. Tamura S, Ueki K, Ideura H, et al. Corticosteroid
therapy in patients with IgA nephropathy and
impaired renal function. Clinical Nephrology 2001;
55(3):192-5. Not a randomized trial
B-45
727. Tang IY, Murray PT. Prevention of perioperative
acute renal failure: what works? Best Practice &
Research 2004; Clinical Anaesthesiology. 18(1):91111. Intervention not related to monitoring of CKD
728. Tang S, Ho YW, Leung CY, et al. Mycophenolate
mofetil in the treatment of steroid-resistant primary
focal segmental glomerulosclerosis. Journal of
Nephrology 2005; 18(4):429-32. Not patients with
early CKD
729. Teachey DT, Seif AE, Brown VI, et al. Targeting
Notch signaling in autoimmune and
lymphoproliferative disease. Blood 2008;
111(2):705-14. Not human study
730. Tedesco-Silva H, Jr., Vitko S, Pascual J, et al. 12month safety and efficacy of everolimus with
reduced exposure cyclosporine in de novo renal
transplant recipients. Transplant International 2007;
20(1):27-36. Not patients with early CKD
731. Teschan PE, Beck GJ, Dwyer JT, et al. Effect of a
ketoacid-aminoacid-supplemented very low protein
diet on the progression of advanced renal disease: a
reanalysis of the MDRD feasibility study. Clinical
Nephrology 1998; 50(5):273-83. Not patients with
early CKD
732. Textor SC. Renovascular hypertension update.
Current Hypertension Reports 2006; 8(6):521-7. Not
a randomized trial
733. Thall PF, Wooten LH, Tannir NM. Monitoring event
times in early phase clinical trials: some practical
issues. Clinical Trials 2005; 2(6):467-78. Not a
randomized trial
734. Thomas DH, Taylor JD, Barnaby OS, et al.
Determination of free catecholamines in urine by
tandem affinity/ion-pair chromatography and flow
injection analysis. Clinica Chimica Acta 2008;
398(1-2):63-9. Intervention not related to monitoring
of CKD
735. Thomsen HS, Hvid-Jacobsen K, Nielsen SL.
Alternating use of 123I and 131I hippuran for routine
postoperative monitoring of transplanted kidneys is
impracticable. Acta Radiologica 1987; 28(3):365-7.
Not patients with early CKD
736. Tiseo M, Martelli O, Mancuso A, et al. Short
hydration regimen and nephrotoxicity of intermediate
to high-dose cisplatin-based chemotherapy for
outpatient treatment in lung cancer and
mesothelioma. Tumori 2007; 93(2):138-44. Not a
randomized trial
737. Tobe S, Epstein M. The use of calcium antagonists in
the treatment of hypertensive persons with kidney
disease. Current Hypertension Reports 2002;
4(3):191-4. Not a randomized trial
738. Tobita I, Suzuki S, Kobayashi T, et al. A programme
to encourage participation of haemodialysis patients
in an exercise regimen. Journal of Renal Care 2009;
35(1):48-53. Not patients with early CKD
739. Tod M, Minozzi C, Beaucaire G, et al. Isepamicin in
intensive care unit patients with nosocomial
pneumonia: population pharmacokineticpharmacodynamic study. Journal of Antimicrobial
Chemotherapy 1999; 44(1):99-108. Not patients with
early CKD
740. Tofe Povedano S, Garcia De La Villa B. 24-hour and
nighttime blood pressures in type 2 diabetic
hypertensive patients following morning or evening
administration of olmesartan. Journal of Clinical
Hypertension 2009; 11(8):426-31. Intervention not
related to monitoring of CKD
741. Tominaga Y, Kohara S, Namii Y, et al. Clonal
analysis of nodular parathyroid hyperplasia in renal
hyperparathyroidism. World Journal of Surgery
1996; 20(7):744-50; discussion 50-2. Not a
randomized trial
742. Tonelli M, Sacks F, Pfeffer M, et al. Biomarkers of
inflammation and progression of chronic kidney
disease. Kidney International 2005; 68(1):237-45.
Intervention not related to monitoring of CKD
743. Tong PCY, Ko GTC, Chan WB, et al. The efficacy
and tolerability of fosinopril in Chinese type 2
diabetic patients with moderate renal insufficiency.
Diabetes, Obesity & Metabolism 2006; 8(3):342-7.
Intervention not related to monitoring of CKD
744. Toto RD. Lessons from the African-American Study
of Kidney Disease and Hypertension: an update.
Current Hypertension Reports 2006; 8(5):409-12.
Intervention not related to monitoring of CKD
745. Trask PC, Bushmakin AG, Cappelleri JC, et al.
Health-related quality of life during treatment for
renal cell carcinoma: results from a phase II study of
axitinib. Acta Oncologica 2008; 47(5):843-51. Not
patients with early CKD
746. Trivedi H, Lu N, Andresen BT, et al. Slower decline
of renal function after initiation of rosiglitazone in
diabetics -- a pilot study. Clinical Nephrology 2009;
72(3):181-5. Intervention not related to monitoring
of CKD
747. Tugwell P, Bombardier C, Gent M, et al. Low-dose
cyclosporin versus placebo in patients with
rheumatoid arthritis. Lancet 1990; 335(8697):1051-5.
Intervention not related to monitoring of CKD
748. Tugwell P, Ludwin D, Gent M, et al. Interaction
between cyclosporin A and nonsteroidal
antiinflammatory drugs. Journal of Rheumatology
1997; 24(6):1122-5. Intervention not related to
monitoring of CKD
749. Tumlin JA, Finkel KW, Murray PT, et al.
Fenoldopam mesylate in early acute tubular necrosis:
a randomized, double-blind, placebo-controlled
clinical trial. American Journal of Kidney Diseases
2005; 46(1):26-34. Intervention not related to
monitoring of CKD
750. Turner R. Hepatic and renal tolerability of long-term
naproxen treatment in patients with rheumatoid
arthritis. Seminars in Arthritis & Rheumatism 1988;
17(3 Suppl 2):29-35. Intervention not related to
monitoring of CKD
751. Twyman S, Rowe D, Mansell P, et al. Longitudinal
study of urinary albumin excretion in young diabetic
patients--Wessex Diabetic Nephropathy Project.
Diabetic Medicine 2001; 18(5):402-8. Not a
randomized trial
752. Tylicki L, Rutkowski P, Renke M, et al. Triple
pharmacological blockade of the renin-angiotensinaldosterone system in nondiabetic CKD: an open-
B-46
753.
754.
755.
756.
757.
758.
759.
760.
761.
762.
label crossover randomized controlled trial.
American Journal of Kidney Diseases 2008;
52(3):486-93. Intervention not related to monitoring
of CKD
Ulrich C, Bichel J, Euvrard S, et al. Topical
immunomodulation under systemic
immunosuppression: results of a multicentre,
randomized, placebo-controlled safety and efficacy
study of imiquimod 5% cream for the treatment of
actinic keratoses in kidney, heart, and liver transplant
patients. British Journal of Dermatology 2007; 157
Suppl 2:25-31. Intervention not related to monitoring
of CKD
van Essen GG, Apperloo AJ, Rensma PL, et al. Are
angiotensin converting enzyme inhibitors superior to
beta blockers in retarding progressive renal function
decline? Kidney International - Supplement 1997;
63:S58-62. Intervention not related to monitoring of
CKD
Van Poppel H, Da Pozzo L, Albrecht W, et al. A
prospective randomized EORTC intergroup phase 3
study comparing the complications of elective
nephron-sparing surgery and radical nephrectomy for
low-stage renal cell carcinoma. European Urology
2007; 51(6):1606-15. Intervention not related to
monitoring of CKD
Vasavada N, Saha C, Agarwal R. A double-blind
randomized crossover trial of two loop diuretics in
chronic kidney disease. Kidney International 2003;
64(2):632-40. Intervention not related to monitoring
of CKD
Vegter S, Perna A, Hiddema W, et al. Costeffectiveness of ACE inhibitor therapy to prevent
dialysis in nondiabetic nephropathy: influence of the
ACE insertion/deletion polymorphism.
Pharmacogenetics & Genomics 2009; 19(9):695-703.
Not a randomized trial
Vercauteren SB, Bosmans JL, Elseviers MM, et al. A
meta-analysis and morphological review of
cyclosporine-induced nephrotoxicity in auto-immune
diseases. Kidney International 1998; 54(2):536-45.
Not a randomized trial
Vezyroglou G, Mitropoulos A, Antoniadis C. A
metabolic syndrome in diffuse idiopathic skeletal
hyperostosis. A controlled study.[Erratum appears in
J Rheumatol 1997 Aug;24(8):1665]. Journal of
Rheumatology 1996; 23(4):672-6. Intervention not
related to monitoring of CKD
Viberti G, Kahn SE, Greene DA, et al. A diabetes
outcome progression trial (ADOPT): an international
multicenter study of the comparative efficacy of
rosiglitazone, glyburide, and metformin in recently
diagnosed type 2 diabetes. Diabetes Care 2002;
25(10):1737-43. Intervention not related to
monitoring of CKD
Vidt DG, Cressman MD, Harris S, et al.
Rosuvastatin-induced arrest in progression of renal
disease. Cardiology 2004; 102(1):52-60. Intervention
not related to monitoring of CKD
Vincenti F, Lantz M, Birnbaum J, et al. A phase I
trial of humanized anti-interleukin 2 receptor
763.
764.
765.
766.
767.
768.
769.
770.
771.
772.
773.
B-47
antibody in renal transplantation. Transplantation
1997; 63(1):33-8. Not patients with early CKD
Vincenti F, Rostaing L, investigators D. Rationale
and design of the DIRECT study: a comparative
assessment of the hyperglycemic effects of
tacrolimus and cyclosporine following renal
transplantation. Contemporary Clinical Trials 2005;
26(1):17-24. Not patients with early CKD
Vitko S, Margreiter R, Weimar W, et al. Three-year
efficacy and safety results from a study of everolimus
versus mycophenolate mofetil in de novo renal
transplant patients.[Erratum appears in Am J
Transplant. 2006 Jan;6(1):243]. American Journal of
Transplantation 2005; 5(10):2521-30. Not patients
with early CKD
Vitko S, Tedesco H, Eris J, et al. Everolimus with
optimized cyclosporine dosing in renal transplant
recipients: 6-month safety and efficacy results of two
randomized studies. American Journal of
Transplantation 2004; 4(4):626-35. Not patients with
early CKD
Vogt L, Kocks MJA, Laverman GD, et al.
Renoprotection by blockade of the renin-angiotensinaldosterone system in diabetic and non-diabetic
chronic kidney disease. Specific involvement of
intra-renal angiotensin-converting enzyme activity in
therapy resistance? Minerva Medica 2004;
95(5):395-409. Not a randomized trial
Vonend O, Marsalek P, Russ H, et al. Moxonidine
treatment of hypertensive patients with advanced
renal failure. Journal of Hypertension 2003;
21(9):1709-17. Not patients with early CKD
Wade VL, Gleason BL. Dual blockade of the reninangiotensin system in diabetic nephropathy. Annals
of Pharmacotherapy 2004; 38(7-8):1278-82. Not a
randomized trial
Wahbah AM, el-Hefny MO, Wafa EM, et al.
Perioperative renal protection in patients with
obstructive jaundice using drug combinations.
Hepato-Gastroenterology 2000; 47(36):1691-4.
Intervention not related to monitoring of CKD
Wallen NH, Andersson A, Hjemdahl P. Effects of
treatment with oral isosorbide dinitrate on platelet
function in vivo; a double-blind placebo-controlled
study in patients with stable angina pectoris. British
Journal of Clinical Pharmacology 1994; 38(1):63-70.
Intervention not related to monitoring of CKD
Walser M, Hill S. Effect of ketoconazole plus lowdose prednisone on progression of chronic renal
failure. American Journal of Kidney Diseases 1997;
29(4):503-13. Intervention not related to monitoring
of CKD
Walters MR, Bolster A, Dyker AG, et al. Effect of
perindopril on cerebral and renal perfusion in stroke
patients with carotid disease. Stroke 2001; 32(2):4738. Intervention not related to monitoring of CKD
Wang G, Lai FM-M, Lai K-B, et al. Urinary
messenger RNA expression of podocyte-associated
molecules in patients with diabetic nephropathy
treated by angiotensin-converting enzyme inhibitor
and angiotensin receptor blocker. European Journal
774.
775.
776.
777.
778.
779.
780.
781.
782.
783.
of Endocrinology 2008; 158(3):317-22. Intervention
not related to monitoring of CKD
Warrier I, Lusher JM. Development of anaphylactic
shock in haemophilia B patients with inhibitors.
Blood Coagulation & Fibrinolysis 1998; 9 Suppl
1:S125-8. Intervention not related to monitoring of
CKD
Webb DJ, Newman DJ, Chaturvedi N, et al. The use
of the Micral-Test strip to identify the presence of
microalbuminuria in people with insulin dependent
diabetes mellitus (IDDM) participating in the
EUCLID study. Diabetes Research & Clinical
Practice 1996; 31(1-3):93-102. Not a randomized
trial
Webb JG, Pate GE, Humphries KH, et al. A
randomized controlled trial of intravenous Nacetylcysteine for the prevention of contrast-induced
nephropathy after cardiac catheterization: lack of
effect. American Heart Journal 2004; 148(3):422-9.
Intervention not related to monitoring of CKD
Weimer R, Susal C, Yildiz S, et al. Post-transplant
sCD30 and neopterin as predictors of chronic
allograft nephropathy: impact of different
immunosuppressive regimens. American Journal of
Transplantation 2006; 6(8):1865-74. Intervention not
related to monitoring of CKD
Weinrauch LA, Bayliss G, Gleason RE, et al. A pilot
study to assess utility of changes in elements of the
Diabetes Impact Management Scale in evaluating
diabetic patients for progressive nephropathy.
Metabolism: Clinical & Experimental 2009;
58(4):492-6. Intervention not related to monitoring
of CKD
Weinrauch LA, Burger AJ, Aepfelbacher F, et al. A
pilot study to test the effect of pulsatile insulin
infusion on cardiovascular mechanisms that might
contribute to attenuation of renal compromise in type
1 diabetes mellitus patients with proteinuria.
Metabolism: Clinical & Experimental 2007;
56(11):1453-7. Intervention not related to monitoring
of CKD
Weinrauch LA, Kennedy FJ, Burger A, et al.
Prospective evaluation of autonomic dysfunction in
aggressive management of diabetic microangiopathy.
American Journal of Hypertension 1999; 12(11 Pt
1):1135-9. Intervention not related to monitoring of
CKD
Weir MR, Dengel DR, Behrens MT, et al. Saltinduced increases in systolic blood pressure affect
renal hemodynamics and proteinuria. Hypertension
1995; 25(6):1339-44. Intervention not related to
monitoring of CKD
Weir MR, Fink JC, Hanes DS, et al. Chronic
allograft nephropathy: effect of cyclosporine
reduction and addition of mycophenolate mofetil on
progression of renal disease. Transplantation
Proceedings 1999; 31(1-2):1286-7. Intervention not
related to monitoring of CKD
Weiss MF, Rodby RA, Justice AC, et al. Free
pentosidine and neopterin as markers of progression
rate in diabetic nephropathy. Collaborative Study
784.
785.
786.
787.
788.
789.
790.
791.
792.
793.
794.
795.
B-48
Group. Kidney International 1998; 54(1):193-202.
Not a randomized trial
Welage LS, Mason NA, Hoffman EJ, et al. Influence
of cellulose triacetate hemodialyzers on vancomycin
pharmacokinetics. Journal of the American Society
of Nephrology 1995; 6(4):1284-90. Not patients with
early CKD
Wexler D, Silverberg D, Blum M, et al. Anaemia as a
contributor to morbidity and mortality in congestive
heart failure. Nephrology Dialysis Transplantation
2005; 20 Suppl 7:vii11-5. Not a randomized trial
White M, Lepage S, Lavoie J, et al. Effects of
combined candesartan and ACE inhibitors on BNP,
markers of inflammation and oxidative stress, and
glucose regulation in patients with symptomatic heart
failure. Journal of Cardiac Failure 2007; 13(2):86-94.
Intervention not related to monitoring of CKD
Wiegmann TB, Herron KG, Chonko AM, et al.
Effect of angiotensin-converting enzyme inhibition
on renal function and albuminuria in normotensive
type I diabetic patients. Diabetes 1992; 41(1):62-7.
Intervention not related to monitoring of CKD
Wiland P, Szechcinski J. Proximal tubule damage in
patients treated with gentamicin or amikacin. Polish
Journal of Pharmacology 2003; 55(4):631-7.
Intervention not related to monitoring of CKD
Williams ME, Lacson E, Jr., Teng M, et al.
Hemodialyzed type I and type II diabetic patients in
the US: Characteristics, glycemic control, and
survival. Kidney International 2006; 70(8):1503-9.
Not patients with early CKD
Wilmer WA, Hebert LA, Lewis EJ, et al. Remission
of nephrotic syndrome in type 1 diabetes: long-term
follow-up of patients in the Captopril Study.
American Journal of Kidney Diseases 1999;
34(2):308-14. Not patients with early CKD
Wilson J, Wahbha MM, Martin PG, et al. The effect
of nisoldipine on renal function in the long-term
treatment of hypertension in patients with and
without renal impairment. European Journal of
Clinical Pharmacology 1989; 37(5):437-41.
Intervention not related to monitoring of CKD
Wirta OR, Pasternack AI, Mustonen JT, et al.
Urinary albumin excretion rate and its determinants
after 6 years in non-insulin-dependent diabetic
patients. Nephrology Dialysis Transplantation 1996;
11(3):449-56. Not a randomized trial
Womer KL, Huang Y, Herren H, et al. Dendritic cell
deficiency associated with development of BK
viremia and nephropathy in renal transplant
recipients. Transplantation 2010; 89(1):115-23. Not
patients with early CKD
Woo J, Sea MMM, Tong P, et al. Effectiveness of a
lifestyle modification programme in weight
maintenance in obese subjects after cessation of
treatment with Orlistat. Journal of Evaluation in
Clinical Practice 2007; 13(6):853-9. Intervention not
related to monitoring of CKD
Woo KT, Lau YK, Chan CM, et al. ATRA therapy
restores normal renal function and renal reserve and
prevents renal failure. Annals of the Academy of
796.
797.
798.
799.
800.
801.
802.
803.
804.
805.
806.
Medicine, Singapore 2005; 34(1):52-9. Not a
randomized trial
Woo KT, Lau YK, Zhao Y, et al. Disease
progression, response to ACEI/ATRA therapy and
influence of ACE gene in IgA nephritis. Cellular &
Molecular Immunology 2007; 4(3):227-32. Not
patients with early CKD
Woolerton J, Jury DR, Dunn PJ, et al. Urine albumin
creatinine ratio and clinical correlates in a diabetic
population. New Zealand Medical Journal 1987;
100(819):130-4. Not a randomized trial
Woolfson RG, Neild GH. Cyclosporin nephrotoxicity
following cardiac transplantation. Nephrology
Dialysis Transplantation 1997; 12(10):2054-6. Not
patients with early CKD
Work J. Does vascular access monitoring work?
Advances in Renal Replacement Therapy 2002;
9(2):85-90. Not patients with early CKD
Wright JT, Jr., Bakris G, Greene T, et al. Effect of
blood pressure lowering and antihypertensive drug
class on progression of hypertensive kidney disease:
results from the AASK trial.[Erratum appears in
JAMA. 2006 Jun 21;295(23):2726]. JAMA 2002;
288(19):2421-31. Intervention not related to
monitoring of CKD
Wright S, Bogan A, Chokshi A. DaVita program
advocates self-management of CKD. Nephrol News
Issues 2009; 23(13):28-9. Not a randomized trial
Xu J, Lee ET, Devereux RB, et al. A longitudinal
study of risk factors for incident albuminuria in
diabetic American Indians: the Strong Heart Study.
American Journal of Kidney Diseases 2008;
51(3):415-24. Not a randomized trial
Xu X, Wu Z, Zhou Q, et al. The role of determining
the levels of serum collagen type IV in diagnosing
early diabetic nephropathy. Renal Failure 2002;
24(6):747-53. Intervention not related to monitoring
of CKD
Yang CW, Kim YO, Kim YS, et al. Clinical course
of cytomegalovirus (CMV) viremia with and without
ganciclovir treatment in CMV-seropositive kidney
transplant recipients. Longitudinal follow-up of
CMV pp65 antigenemia assay. American Journal of
Nephrology 1998; 18(5):373-8. Intervention not
related to monitoring of CKD
Yang JC, Haworth L, Sherry RM, et al. A
randomized trial of bevacizumab, an anti-vascular
endothelial growth factor antibody, for metastatic
renal cancer. New England Journal of Medicine
2003; 349(5):427-34. Intervention not related to
monitoring of CKD
Yee CS, Gordon C, Dostal C, et al. EULAR
randomised controlled trial of pulse
cyclophosphamide and methylprednisolone versus
continuous cyclophosphamide and prednisolone
807.
808.
809.
810.
811.
812.
813.
814.
815.
816.
B-49
followed by azathioprine and prednisolone in lupus
nephritis. Annals of the Rheumatic Diseases 2004;
63(5):525-9. Intervention not related to monitoring
of CKD
Yorioka N, Kiribayashi K, Naito T, et al. An oral
adsorbent, AST-120, combined with a low-protein
diet and RAS blocker, for chronic kidney disease.
Journal of Nephrology 2008; 21(2):213-20.
Intervention not related to monitoring of CKD
Zanardo G, Michielon P, Rosi P, et al. Effects of a
continuous diltiazem infusion on renal function
during cardiac surgery. Journal of Cardiothoracic &
Vascular Anesthesia 1993; 7(6):711-6. Intervention
not related to monitoring of CKD
Zhang A, Vertommen J, Van Gaal L, et al. Effects of
pravastatin on lipid levels, in vitro oxidizability of
non-HDL lipoproteins and microalbuminuria in
IDDM patients. Diabetes Research & Clinical
Practice 1995; 29(3):189-94. Intervention not related
to monitoring of CKD
Zhang J, Ding EL, Song Y. Adverse effects of
cyclooxygenase 2 inhibitors on renal and arrhythmia
events: meta-analysis of randomized trials. JAMA
2006; 296(13):1619-32. Not a randomized trial
Zhu S, Liu Y, Wang L, et al. Transforming growth
factor-beta1 is associated with kidney damage in
patients with essential hypertension: renoprotective
effect of ACE inhibitor and/or angiotensin II receptor
blocker. Nephrology Dialysis Transplantation 2008;
23(9):2841-6. Intervention not related to monitoring
of CKD
Zhu X, Stergiopoulos K, Wu S. Risk of hypertension
and renal dysfunction with an angiogenesis inhibitor
sunitinib: systematic review and meta-analysis. Acta
Oncologica 2009; 48(1):9-17. Not a randomized trial
Ziakka S, Ursu M, Poulikakos D, et al. Predictive
factors and therapeutic approach of renovascular
disease: four years' follow-up. Renal Failure 2008;
30(10):965-70. Not a randomized trial
Zucchelli P, Cagnoli L, Pasquali S, et al. Clinical and
morphologic evolution of idiopathic membranous
nephropathy. Clinical Nephrology 1986; 25(6):282-8.
Not a randomized trial
Zucchelli P, Ponticelli C, Cagnoli L, et al. Prognostic
value of T lymphocyte subset ratio in idiopathic
membranous nephropathy. American Journal of
Nephrology 1988; 8(1):15-20. Duration of follow-up
less than 1 year
Zucchelli P, Zuccala A, Gaggi R. Comparison of the
effects of ACE inhibitors and calcium channel
blockers on the progression of renal failure.
Nephrology Dialysis Transplantation 1995; 10 Suppl
9:46-51. Intervention not related to monitoring of
CKD
CKD treatment (KQ5, KQ6)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
The Diabetes Control and Complications Trial
(DCCT). Design and methodologic considerations
for the feasibility phase. The DCCT Research Group.
Diabetes 1986; 35(5):530-45. Not CKD treatment
Dietary compliance in the trial of the European Study
Group. A preliminary analysis. European Study
Group for the Conservative Management of Chronic
Renal Failure. Contributions to Nephrology 1990;
81:61-70. Not CKD treatment
Comparative study of the efficacy of dipyrone,
diclofenac sodium and pethidine in acute renal colic.
Collaborative Group of the Spanish Society of
Clinical Pharmacology. European Journal of Clinical
Pharmacology 1991; 40(6):543-6. Not CKD
treatment
Effect of enalapril on survival in patients with
reduced left ventricular ejection fractions and
congestive heart failure. The SOLVD Investigators.
New England Journal of Medicine 1991; 325(5):293302. Not CKD treatment
Comparison between perindopril and nifedipine in
hypertensive and normotensive diabetic patients with
microalbuminuria. Melbourne Diabetic Nephropathy
Study Group. BMJ 1991; 302(6770):210-6. Not
relevant to key questions
Dietary compliance in the trial of the European Study
Group. An interim analysis. European Study Group
for the Conservative Management of Chronic Renal
Failure. Contributions to Nephrology 1992; 98:13341. Not CKD treatment
Effect of enalapril on mortality and the development
of heart failure in asymptomatic patients with
reduced left ventricular ejection fractions. The
SOLVD Investigattors.[Erratum appears in N Engl J
Med 1992 Dec 10;327(24):1768]. New England
Journal of Medicine 1992; 327(10):685-91. Not CKD
treatment
The Modification of Diet in Renal Disease Study:
design, methods, and results from the feasibility
study. American Journal of Kidney Diseases 1992;
20(1):18-33. Not relevant to key questions
The effect of intensive treatment of diabetes on the
development and progression of long-term
complications in insulin-dependent diabetes mellitus.
The Diabetes Control and Complications Trial
Research Group. New England Journal of Medicine
1993; 329(14):977-86. Not early CKD
Results of the North American trial of
piperacillin/tazobactam compared with clindamycin
and gentamicin in the treatment of severe intraabdominal infections. Investigators of the
Piperacillin/Tazobactam Intra-abdominal Infection
Study Group. European Journal of Surgery, Acta
Chirurgica, Supplement 1994; (573):61-6. Not early
CKD
Reduction of dietary protein and phosphorus in the
Modification of Diet in Renal Disease Feasibility
Study. The MDRD Study Group. Journal of the
American Dietetic Association 1994; 94(9):986-90;
quiz 91-2. Not CKD treatment
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
B-50
The effect of age and renal function on the efficacy
and toxicity of methotrexate in rheumatoid arthritis.
Rheumatoid Arthritis Clinical Trial Archive Group.
Journal of Rheumatology 1995; 22(2):218-23. Not
CKD treatment
SOCA research group stops enrollment. Studies of
the Ocular Complications of AIDS. AIDS Patient
Care & Stds 1996; 10(3):188. Not early CKD
Effects of dietary protein restriction on the
progression of moderate renal disease in the
Modification of Diet in Renal Disease
Study.[Erratum appears in J Am Soc Nephrol 1997
Mar;8(3):493]. Journal of the American Society of
Nephrology 1996; 7(12):2616-26. Not early CKD
Short-term effects of protein intake, blood pressure,
and antihypertensive therapy on glomerular filtration
rate in the Modification of Diet in Renal Disease
Study. Journal of the American Society of
Nephrology 1996; 7(10):2097-109. Not RCT or
controlled trial
Captopril reduces the risk of nephropathy in IDDM
patients with microalbuminuria. The
Microalbuminuria Captopril Study Group.
Diabetologia 1996; 39(5):587-93. Not relevant to key
questions
Effects of diet and antihypertensive therapy on
creatinine clearance and serum creatinine
concentration in the Modification of Diet in Renal
Disease Study.[Erratum appears in J Am Soc
Nephrol 1997 Aug;8(8):1354]. Journal of the
American Society of Nephrology 1996; 7(4):556-66.
Not RCT or controlled trial
Randomised placebo-controlled trial of lisinopril in
normotensive patients with insulin-dependent
diabetes and normoalbuminuria or microalbuminuria.
The EUCLID Study Group. Lancet 1997;
349(9068):1787-92. Not relevant to key questions
Heart failure treatment with angiotensin-converting
enzyme inhibitors in hospitalized Medicare patients
in 10 large states. The Large State Peer Review
Organization Consortium. Archives of Internal
Medicine 1997; 157(10):1103-8. Not RCT or
controlled trial
Parenteral cidofovir for cytomegalovirus retinitis in
patients with AIDS: the HPMPC peripheral
cytomegalovirus retinitis trial. A randomized,
controlled trial. Studies of Ocular complications of
AIDS Research Group in Collaboration with the
AIDS Clinical Trials Group. Annals of Internal
Medicine 1997; 126(4):264-74. Not CKD treatment
Benazepril and the kidney: new indication. No better
than the other ACE inhibitors. Prescrire International
1998; 7(38):174-6. Not relevant to key questions
NESP researchers present latest data at ASN.
Nephrology News & Issues 2000; 14(12):56. Not
RCT or controlled trial
Summaries for patients. Weight-training exercises to
counteract the negative effects of low-protein diets in
people with kidney disease. Annals of Internal
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Medicine 2001; 135(11):S-60. Not relevant to key
questions
Summaries for patients. Trial of a drug to decrease
the risk for heart disease in patients with mild kidney
failure. Annals of Internal Medicine 2001; 134(8):S96. Not RCT or controlled trial
Effect of 3 years of antihypertensive therapy on renal
structure in type 1 diabetic patients with albuminuria:
the European Study for the Prevention of Renal
Disease in Type 1 Diabetes (ESPRIT). Diabetes
2001; 50(4):843-50. Sample size less than 50 patients
Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS
Pharmaceuticals, KRN 1493, NPS 1493. Drugs in R
& D 2003; 4(6):349-51. Sample size less than 50
patients
Summaries for patients. Oral administration of an
antibiotic (norfloxacin) may help treat the cardiac
and circulatory complications of liver failure. Annals
of Internal Medicine 2003; 139(3):I62. Not RCT or
controlled trial
Summaries for patients. Effects of blood pressure
drugs in patients with diabetes and kidney
disease.[Original report in Ann Intern Med. 2003 Apr
1;138(7):542-9; PMID: 12667024]. Annals of
Internal Medicine 2003; 138(7):I43. Not RCT or
controlled trial
Summaries for patients. Treating cholesterol in
patients with mild kidney disease.[Original report in
Ann Intern Med. 2003 Jan 21;138(2):98-104; PMID:
12529091]. Annals of Internal Medicine 2003;
138(2):I28. Not RCT or controlled trial
Bevacizumab (Avastin). Medical Letter on Drugs &
Therapeutics 2004; 46(1184):47-8. Not CKD
treatment
New Premier study suggest Preterax as a first-line
antihypertensive. Cardiovascular Journal of Southern
Africa 2004; 15(1):40-1. Not CKD treatment
Summaries for patients. Do the effects of blood
pressure drugs differ by kidney function?.[Original
report in Ann Intern Med. 2006 Feb 7;144(3):172-80;
PMID: 16461961]. Annals of Internal Medicine
2006; 144(3):I33. Not RCT or controlled trial
Sorafenib: new drug. Second-line treatment of
kidney cancer: better evaluated than sunitinib.
Prescrire International 2007; 16(90):141-3. Not
relevant to key questions
Sunitinib: new drug. For some gastrointestinal
stromal tumours. Prescrire International 2007;
16(90):138-41. Not early CKD
Ruboxistaurin: LY 333531. Drugs in R & D 2007;
8(3):193-9. Not RCT or controlled trial
Type 2 diabetes and HbA1c targets. Prescrire
International 2008; 17(98):254. Not CKD treatment
Telmisartan did not prevent renal disease in patients
without proteinuria.[Original report in Ann Intern
Med. 2009 Jul 7;151(1):1-10, W1-2; PMID:
19451556]. Annals of Internal Medicine 2009;
151(1):I28. Not relevant to key questions
Anti-HIV agents. Treatment interruption uncovers
HIV's attack on the kidneys. Treatment Update 2009;
21(2):5-6. Not early CKD
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
B-51
Aarnoutse RE, Wasmuth J-C, Fatkenheuer G, et al.
Administration of indinavir and low-dose ritonavir
(800/100 mg twice daily) with food reduces
nephrotoxic peak plasma levels of indinavir.
Antiviral Therapy 2003; 8(4):309-14. Not CKD
treatment
Abassi Z, Winaver J, Feuerstein GZ. The
biochemical pharmacology of renin inhibitors:
implications for translational medicine in
hypertension, diabetic nephropathy and heart failure:
expectations and reality. Biochemical Pharmacology
2009; 78(8):933-40. Not RCT or controlled trial
Abbott K, Basta E, Bakris GL. Blood pressure
control and nephroprotection in diabetes. Journal of
Clinical Pharmacology 2004; 44(4):431-8. Not early
CKD
Abbott K, Smith A, Bakris GL. Effects of
dihydropyridine calcium antagonists on albuminuria
in patients with diabetes. Journal of Clinical
Pharmacology 1996; 36(3):274-9. Sample size less
than 50 patients
Abbott KC, Bakris GL. Treatment of the diabetic
patient: focus on cardiovascular and renal risk
reduction. Progress in Brain Research 2002;
139:289-98. Not RCT or controlled trial
Abbott KC, Bakris GL. What have we learned from
the current trials? Medical Clinics of North America
2004; 88(1):189-207. Not RCT or controlled trial
Abboud H, Coyne D, Smolenski O, et al. A
comparison of dosing regimens of paricalcitol
capsule for the treatment of secondary
hyperparathyroidism in CKD stages 3 and 4.
American Journal of Nephrology 2006; 26(1):10514. Sample size less than 50 patients
Abdel-Raheem MM, Hebert B, Potti A, et al.
Hyperhomocysteinemia and the risk of
thromboembolic phenomenon in patients with
chronic renal failure. Thrombosis Research 2002;
105(4):299-302. Not RCT or controlled trial
Abdel-Rahman E, Bolton WK. Pimagedine: a novel
therapy for diabetic nephropathy. Expert Opinion on
Investigational Drugs 2002; 11(4):565-74. Not
relevant to key questions
Abe K, Fujino Y, Sakakibara T. The effect of
prostaglandin E1 during cardiopulmonary bypass on
renal function after cardiac surgery. European
Journal of Clinical Pharmacology 1993; 45(3):21720. Not CKD treatment
Abe K, Sakakibara T, Yoshiya I. The effect of
prostaglandin E1 on renal function after cardiac
surgery involving cardiopulmonary bypass.
Prostaglandins Leukotrienes & Essential Fatty Acids
1993; 49(2):627-31. Sample size less than 50 patients
Abe M, Okada K, Maruyama T, et al. Comparison of
the antiproteinuric effects of the calcium channel
blockers benidipine and amlodipine administered in
combination with angiotensin receptor blockers to
hypertensive patients with stage 3-5 chronic kidney
disease. Hypertension Research - Clinical &
Experimental 2009; 32(4):270-5. Follow-up less than
6 months
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
Abe M, Okada K, Maruyama T, et al. Antiproteinuric
and blood pressure-lowering effects of a fixed-dose
combination of losartan and hydrochlorothiazide in
hypertensive patients with stage 3 chronic kidney
disease. Pharmacotherapy 2009; 29(9):1061-72.
Follow-up less than 6 months
Abels R. Rate of progression of chronic renal failure
in predialysis patients treated with erythropoietin.
Seminars in Nephrology 1990; 10(2 Suppl 1):20-5.
Not CKD treatment
Abitbol CL, Chandar J, Onder AM, et al. Profiling
proteinuria in pediatric patients. Pediatric
Nephrology 2006; 21(7):995-1002. Not RCT or
controlled trial
Abizaid AS, Clark CE, Mintz GS, et al. Effects of
dopamine and aminophylline on contrast-induced
acute renal failure after coronary angioplasty in
patients with preexisting renal insufficiency.
American Journal of Cardiology 1999; 83(2):260-3.
Not CKD treatment
Abosaif NY, Tolba YA, Heap M, et al. The outcome
of acute renal failure in the intensive care unit
according to RIFLE: model application, sensitivity,
and predictability. American Journal of Kidney
Diseases 2005; 46(6):1038-48. Not relevant to key
questions
Abouljoud MS, Levy MF, Klintmalm GB.
Hyperlipidemia after liver transplantation: long-term
results of the FK506/cyclosporine A US Multicenter
Trial. US Multicenter Study Group. Transplantation
Proceedings 1995; 27(1):1121-3. Not early CKD
Abouljoud MS, Levy MF, Klintmalm GB.
Hyperlipidemia after liver transplantation: long-term
results of the FK506/cyclosporine a US Multicenter
trial. US Multicenter Study Group. Transplantation
Proceedings 1995; 27(1):1121-3. Not early CKD
Abraham PA, Halstenson CE, Matzke GR, et al.
Comparison of antihypertensive, renal hemodynamic,
and humoral effects of pinacidil and hydralazine
monotherapy. Journal of Clinical Hypertension 1987;
3(4):439-51. Sample size less than 50 patients
Abuissa H, O'Keefe J, Jr. The role of reninangiotensin-aldosterone system-based therapy in
diabetes prevention and cardiovascular and renal
protection. Diabetes, Obesity & Metabolism 2008;
10(12):1157-66. Not relevant to key questions
Acanfora D, Lowenthal DT, Furgi G, et al. The
effects of delapril in combination with indapamide
on glomerular filtration rate in elderly hypertensive
patients. American Journal of Therapeutics 1997;
4(11-12):405-8. Sample size less than 50 patients
Acbay O. Effects of low-dose losartan treatment on
persistent microalbuminuria in normotensive type 1
diabetic subjects. Journal of Endocrinological
Investigation 2001; 24(8):608-11. Sample size less
than 50 patients
Accetta NA, Gladstone EH, DiSogra C, et al.
Prevalence of estimated GFR reporting among US
clinical laboratories. American Journal of Kidney
Diseases 2008; 52(4):778-87. Not CKD treatment
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
B-52
Acchiardo SR, Hayden AJ. Is Na+ modeling
necessary in high flux dialysis? ASAIO Transactions
1991; 37(3):M135-7. Not CKD treatment
Acharya GP, Davis TM, Ho M, et al. Factors
affecting the pharmacokinetics of parenteral
chloramphenicol in enteric fever. Journal of
Antimicrobial Chemotherapy 1997; 40(1):91-8.
Sample size less than 50 patients
Acker CG, Singh AR, Flick RP, et al. A trial of
thyroxine in acute renal failure. Kidney International
2000; 57(1):293-8. Not CKD treatment
Ackerman Z, Cominelli F, Reynolds TB. Effect of
misoprostol on ibuprofen-induced renal dysfunction
in patients with decompensated cirrhosis: results of a
double-blind placebo-controlled parallel group study.
American Journal of Gastroenterology 2002;
97(8):2033-9. Not CKD treatment
Acton KJ, Shields R, Rith-Najarian S, et al. Applying
the diabetes quality improvement project indicators
in the Indian Health Service primary care setting.
Diabetes Care 2001; 24(1):22-6. Not RCT or
controlled trial
Adabag AS, Ishani A, Bloomfield HE, et al. Efficacy
of N-acetylcysteine in preventing renal injury after
heart surgery: a systematic review of randomized
trials. European Heart Journal 2009; 30(15):1910-7.
Not early CKD
Adabag AS, Ishani A, Koneswaran S, et al. Utility of
N-acetylcysteine to prevent acute kidney injury after
cardiac surgery: a randomized controlled trial.
American Heart Journal 2008; 155(6):1143-9. Not
early CKD
Adler AI, Stevens RJ, Manley SE, et al.
Development and progression of nephropathy in type
2 diabetes: the United Kingdom Prospective Diabetes
Study (UKPDS 64). Kidney International 2003;
63(1):225-32. Not CKD treatment
Adnan T, Elif AA, Ayse K, et al. Clonidine as an
adjuvant for lidocaine in axillary brachial plexus
block in patients with chronic renal failure. Acta
Anaesthesiologica Scandinavica 2005; 49(4):563-8.
Not relevant to key questions
Adolph E, Holdt-Lehmann B, Chatterjee T, et al.
Renal Insufficiency Following Radiocontrast
Exposure Trial (REINFORCE): a randomized
comparison of sodium bicarbonate versus sodium
chloride hydration for the prevention of contrastinduced nephropathy. Coronary Artery Disease 2008;
19(6):413-9. Not CKD treatment
Agarwal A, Silver MR, Walczyk M, et al. Oncemonthly darbepoetin alfa for maintaining
hemoglobin levels in older patients with chronic
kidney disease. Journal of the American Medical
Directors Association 2007; 8(2):83-90. Not RCT or
controlled trial
Agarwal R. Add-on angiotensin receptor blockade
with maximized ACE inhibition. Kidney
International 2001; 59(6):2282-9. Sample size less
than 50 patients
Agarwal R. Is i.v. iron really superior in CKD
patients not on dialysis? Kidney International 2006;
70(6):1188; author reply -9. Not CKD treatment
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
Agarwal R. Effects of statins on renal function.
American Journal of Cardiology 2006; 97(5):748-55.
Not relevant to key questions
Agarwal R. Anti-inflammatory effects of short-term
pioglitazone therapy in men with advanced diabetic
nephropathy. American Journal of Physiology Renal Physiology 2006; 290(3):F600-5. Follow-up
less than 6 months
Agarwal R. Nonhematological benefits of iron.
American Journal of Nephrology 2007; 27(6):56571. Sample size less than 50 patients
Agarwal R. Reproducibility of renal function
measurements in adult men with diabetic
nephropathy: research and clinical implications.
American Journal of Nephrology 2007; 27(1):92100. Not RCT or controlled trial
Agarwal R. Vitamin D, proteinuria, diabetic
nephropathy, and progression of CKD. Clinical
Journal of The American Society of Nephrology:
CJASN 2009; 4(9):1523-8. Not RCT or controlled
trial
Agarwal R. Blood pressure components and the risk
for end-stage renal disease and death in chronic
kidney disease. Clinical Journal of The American
Society of Nephrology: CJASN 2009; 4(4):830-7.
Not CKD treatment
Agarwal R, Acharya M, Tian J, et al. Antiproteinuric
effect of oral paricalcitol in chronic kidney disease.
Kidney International 2005; 68(6):2823-8. Sample
size less than 50 patients
Agarwal R, Curley TM. The role of statins in chronic
kidney disease. American Journal of the Medical
Sciences 2005; 330(2):69-81. Follow-up less than 6
months
Agarwal R, Gorski JC, Sundblad K, et al. Urinary
protein binding does not affect response to
furosemide in patients with nephrotic syndrome.
Journal of the American Society of Nephrology
2000; 11(6):1100-5. Sample size less than 50 patients
Agarwal R, Light RP. Physical activity and
hemodynamic reactivity in chronic kidney disease.
Clinical Journal of The American Society of
Nephrology: CJASN 2008; 3(6):1660-8. Not CKD
treatment
Agarwal R, Rizkala AR, Bastani B, et al. A
randomized controlled trial of oral versus intravenous
iron in chronic kidney disease. American Journal of
Nephrology 2006; 26(5):445-54. Follow-up less than
6 months
Agarwal R, Rizkala AR, Kaskas MO, et al. Iron
sucrose causes greater proteinuria than ferric
gluconate in non-dialysis chronic kidney disease.
Kidney International 2007; 72(5):638-42. Not RCT
or controlled trial
Agarwal R, Saha C, Battiwala M, et al. A pilot
randomized controlled trial of renal protection with
pioglitazone in diabetic nephropathy. Kidney
International 2005; 68(1):285-92. Not relevant to key
questions
Agarwal R, Siva S, Dunn SR, et al. Add-on
angiotensin II receptor blockade lowers urinary
transforming growth factor-beta levels. American
Journal of Kidney Diseases 2002; 39(3):486-92.
Sample size less than 50 patients
90. Agarwal R, Vasavada N, Sachs NG, et al. Oxidative
stress and renal injury with intravenous iron in
patients with chronic kidney disease. Kidney
International 2004; 65(6):2279-89. Not relevant to
key questions
91. Agarwal SK, Irshad M, Dash SC. Comparison of two
schedules of hepatitis B vaccination in patients with
mild, moderate and severe renal failure. Journal of
the Association of Physicians of India 1999;
47(2):183-5. Not CKD treatment
92. Agewall S, Wikstrand J, Ljungman S, et al. Urinary
albumin excretion is associated with the intimamedia thickness of the carotid artery in hypertensive
males with non-insulin-dependent diabetes mellitus.
Journal of Hypertension 1995; 13(4):463-9. Not CKD
treatment
93. Aggarwal HK, Nand N, Singh S, et al. Comparison
of oral versus intravenous iron therapy in predialysis
patients of chronic renal failure receiving
recombinant human erythropoietin. Journal of the
Association of Physicians of India 2003; 51:170-4.
Sample size less than 50 patients
94. Agha A, Amer W, Anwar E, et al. Reduction of
microalbuminuria by using losartan in normotensive
patients with type 2 diabetes mellitus: A randomized
controlled trial. Saudi Journal of Kidney Diseases &
Transplantation 2009; 20(3):429-35. Not CKD
treatment
95. Agnes E, Prost JF, Laher MS. Additional benefits of
combining beta-blockade and renal vasodilation in
the treatment of mild to moderate hypertension:
Tertatolol International Multicentre Study results.
Journal of Hypertension - Supplement 1989;
7(6):S270-1. Not early CKD
96. Agnoli GC, Borgatti R, Cacciari M, et al.
Antagonistic effects of sulpiride--racemic and
enantiomers--on renal response to low-dose
dopamine infusion in normal women. Nephron 1989;
51(4):491-8. Sample size less than 50 patients
97. Agnoli GC, Borgatti R, Cacciari M, et al. Interactions
between the renin-angiotensin system and
prostanoids in modulating renal function in
potassium-depleted healthy women. Prostaglandins
Leukotrienes & Essential Fatty Acids 1994;
50(6):347-52. Not CKD treatment
98. Agnoli GC, Borgatti R, Cacciari M, et al. Urinary
prostanoid excretion in healthy women with different
degrees of induced potassium depletion.
Prostaglandins Leukotrienes & Essential Fatty Acids
1992; 46(1):21-6. Not CKD treatment
99. Agnoli GC, Borgatti R, Cacciari M, et al. Renal
function and urinary prostanoid excretions in saltdepleted women: comparative effects of enalapril and
indomethacin treatments. Prostaglandins
Leukotrienes & Essential Fatty Acids 1999;
60(2):87-93. Not CKD treatment
100. Agodoa L. Acute renal failure in the PACU. Journal
of PeriAnesthesia Nursing 2002; 17(6):377-83. Not
CKD treatment
B-53
101. Agodoa LY, Francis ME, Eggers PW. Association of
analgesic use with prevalence of albuminuria and
reduced GFR in US adults. American Journal of
Kidney Diseases 2008; 51(4):573-83. Not CKD
treatment
102. Agrawal RP, Dogra R, Mohta N, et al. Beneficial
effect of camel milk in diabetic nephropathy. Acta
Bio-Medica de l Ateneo Parmense 2009; 80(2):1314. Sample size less than 50 patients
103. Aguilar D, Goldhaber SZ, Gans DJ, et al. Clinically
unrecognized Q-wave myocardial infarction in
patients with diabetes mellitus, systemic
hypertension, and nephropathy. American Journal of
Cardiology 2004; 94(3):337-9. Not relevant to key
questions
104. Ahlmen M, Ahlmen J, Svalander C, et al. Cytotoxic
drug treatment of reactive amyloidosis in rheumatoid
arthritis with special reference to renal insufficiency.
Clinical Rheumatology 1987; 6(1):27-38. Sample
size less than 50 patients
105. Ahmad J, Shafique S, Abidi SMA, et al. Effect of 5year enalapril therapy on progression of
microalbuminuria and glomerular structural changes
in type 1 diabetic subjects. Diabetes Research &
Clinical Practice 2003; 60(2):131-8. Not relevant to
key questions
106. Ahmad J, Siddiqui MA, Ahmad H. Effective
postponement of diabetic nephropathy with enalapril
in normotensive type 2 diabetic patients with
microalbuminuria. Diabetes Care 1997; 20(10):157681. Not relevant to key questions
107. Ahmadi J, Benrazavi L. Substance use among Iranian
nephrologic patients. American Journal of
Nephrology 2002; 22(1):11-3. Not CKD treatment
108. Ahmed A. Use of angiotensin-converting enzyme
inhibitors in patients with heart failure and renal
insufficiency: how concerned should we be by the
rise in serum creatinine? Journal of the American
Geriatrics Society 2002; 50(7):1297-300. Not
relevant to key questions
109. Ahmed A, Aronow WS, Fleg JL. Higher New York
Heart Association classes and increased mortality
and hospitalization in patients with heart failure and
preserved left ventricular function. American Heart
Journal 2006; 151(2):444-50. Not RCT or controlled
trial
110. Ahmed A, Love TE, Sui X, et al. Effects of
angiotensin-converting enzyme inhibitors in systolic
heart failure patients with chronic kidney disease: a
propensity score analysis. Journal of Cardiac Failure
2006; 12(7):499-506. Not relevant to key questions
111. Ai P, Yong G, Dingkun G, et al. Aqueous extract of
Astragali Radix induces human natriuresis through
enhancement of renal response to atrial natriuretic
peptide. Journal of Ethnopharmacology 2008;
116(3):413-21. Not CKD treatment
112. Aitken HA, Burns JW, McArdle CS, et al. Effects of
ketorolac trometamol on renal function. British
Journal of Anaesthesia 1992; 68(5):481-5. Not CKD
treatment
113. Akcicek F, Yalniz T, Basci A, et al. Diuretic effect of
frusemide in patients with nephrotic syndrome: is it
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
B-54
potentiated by intravenous albumin? BMJ 1995;
310(6973):162-3. Follow-up less than 6 months
Akesson A, Blom-Bulow B, Scheja A, et al. Longterm evaluation of penicillamine or cyclofenil in
systemic sclerosis. Results from a two-year
randomized study. Scandinavian Journal of
Rheumatology 1992; 21(5):238-44. Not CKD
treatment
Akesson-Johansson A, Lernestedt JO, Ringden O, et
al. Sensitivity of cytomegalovirus to intravenous
foscarnet treatment. Bone Marrow Transplantation
1986; 1(2):215-20. Sample size less than 50 patients
Akinsola W, Smith F, Alimi T, et al. Low
protein/high calorie dietary regimen in the
management of chronic renal failure. A preliminary
study of Nigerian patients. African Journal of
Medicine & Medical Sciences 1991; 20(1):53-9.
Sample size less than 50 patients
Akizawa T, Asano Y, Morita S, et al. Effect of a
carbonaceous oral adsorbent on the progression of
CKD: a multicenter, randomized, controlled trial.
American Journal of Kidney Diseases 2009;
54(3):459-67. Not early CKD
Akizawa T, Kino K, Koshikawa S, et al. Efficiency
and biocompatibility of a polyethylene glycol grafted
cellulosic membrane during hemodialysis. ASAIO
Transactions 1989; 35(3):333-5. Not CKD treatment
Al Suwaidi J, Reddan DN, Williams K, et al.
Prognostic implications of abnormalities in renal
function in patients with acute coronary syndromes.
Circulation 2002; 106(8):974-80. Not CKD treatment
Al-Ahmad A, Rand WM, Manjunath G, et al.
Reduced kidney function and anemia as risk factors
for mortality in patients with left ventricular
dysfunction. Journal of the American College of
Cardiology 2001; 38(4):955-62. Not RCT or
controlled trial
Alaupovic P, Attman PO, Knight-Gibson C, et al.
Effect of fluvastatin on apolipoprotein-defined
lipoprotein subclasses in patients with chronic renal
insufficiency. Kidney International 2006;
69(10):1865-71. Sample size less than 50 patients
Al-Badr W, Martin KJ. Vitamin D and kidney
disease. Clinical Journal of The American Society of
Nephrology: CJASN 2008; 3(5):1555-60. Not human
studies
Albers M, Romiti M, Braganca Pereira CA, et al. A
meta-analysis of infrainguinal arterial reconstruction
in patients with end-stage renal disease. European
Journal of Vascular & Endovascular Surgery 2001;
22(4):294-300. Not RCT or controlled trial
Albers M, Romiti M, De Luccia N, et al. An updated
meta-analysis of infrainguinal arterial reconstruction
in patients with end-stage renal disease. Journal of
Vascular Surgery 2007; 45(3):536-42. Follow-up less
than 6 months
Albert JM, Gadbury GL, Mascha EJ. Assessing
treatment effect heterogeneity in clinical trials with
blocked binary outcomes. Biometrical Journal 2005;
47(5):662-73. Not relevant to key questions
Albert SG, Shapiro MJ, Brown WW, et al. Analysis
of radiocontrast-induced nephropathy by dual-labeled
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
radionuclide clearance. Investigative Radiology
1994; 29(6):618-23. Not CKD treatment
Alberti D, Locatelli F, Graziani G, et al.
Hypertension and chronic renal insufficiency: the
experience of the Northern Italian Cooperative Study
Group. American Journal of Kidney Diseases 1993;
21(5 Suppl 2):124-30. Not RCT or controlled trial
Albillos A, Garcia-Pagan JC, Iborra J, et al.
Propranolol plus prazosin compared with propranolol
plus isosorbide-5-mononitrate in the treatment of
portal hypertension. Gastroenterology 1998;
115(1):116-23. Not CKD treatment
Albillos A, Lledo JL, Rossi I, et al. Continuous
prazosin administration in cirrhotic patients: effects
on portal hemodynamics and on liver and renal
function. Gastroenterology 1995; 109(4):1257-65.
Follow-up less than 6 months
Alborzi P, Patel NA, Peterson C, et al. Paricalcitol
reduces albuminuria and inflammation in chronic
kidney disease: a randomized double-blind pilot trial.
Hypertension 2008; 52(2):249-55. Sample size less
than 50 patients
Al-Dameh A, Bedford JJ, Leader JP, et al. Urinary
aquaporin-2 levels in healthy volunteers. Nephrology
2003; 8(3):139-41. Follow-up less than 6 months
Alexander CM, Lyle PA, Keane WF, et al. Losartan
and the United States costs of end-stage renal disease
by baseline albuminuria in patients with type 2
diabetes and nephropathy. Kidney International Supplement 2004; (92):S115-7. Not RCT or
controlled trial
Ali A, Asif N, Yaqub S, et al. Spot urine protein:
creatinine ratio versus 24 hour urine protein at
various levels of GFR patients referred to a tertiary
care hospital of Pakistan. JPMA - Journal of the
Pakistan Medical Association 2008; 58(9):476-9. Not
relevant to key questions
Ali ZA, Callaghan CJ, Lim E, et al. Remote ischemic
preconditioning reduces myocardial and renal injury
after elective abdominal aortic aneurysm repair: a
randomized controlled trial. Circulation 2007; 116(11
Suppl):I98-105. Not CKD treatment
Alimchandani A, Pai-dhungat JV. A study of gastric
emptying in chronic renal failure. Journal of the
Association of Physicians of India 1997; 45(11):8358. Sample size less than 50 patients
Al-Kateb H, Boright AP, Mirea L, et al. Multiple
superoxide dismutase 1/splicing factor serine alanine
15 variants are associated with the development and
progression of diabetic nephropathy: the Diabetes
Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications Genetics
study. Diabetes 2008; 57(1):218-28. Not RCT or
controlled trial
Allaqaband S, Tumuluri R, Malik AM, et al.
Prospective randomized study of N-acetylcysteine,
fenoldopam, and saline for prevention of
radiocontrast-induced nephropathy. Catheterization
& Cardiovascular Interventions 2002; 57(3):279-83.
Not CKD treatment
Allen MJ, Ang VT, Bennett ED. Domperidone, a
DA2-specific dopamine antagonist, has no effect on
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
B-55
the renal or haemodynamic response to atrial
natriuretic peptide in man. Clinical Science 1988;
75(6):569-75. Sample size less than 50 patients
Allen SJ, McBride WT, McMurray TJ, et al. Cell
salvage alters the systemic inflammatory response
after off-pump coronary artery bypass grafting
surgery. Annals of Thoracic Surgery 2007;
83(2):578-85. Sample size less than 50 patients
Alli C, Lombardo M, Zanni D, et al. Albuminuria
and transferrinuria in essential hypertension. Effects
of antihypertensive therapy. American Journal of
Hypertension 1996; 9(11):1068-76. Sample size less
than 50 patients
Allison NL, Dubb JW, Ziemniak JA, et al. The effect
of fenoldopam, a dopaminergic agonist, on renal
hemodynamics. Clinical Pharmacology &
Therapeutics 1987; 41(3):282-8. Sample size less
than 50 patients
Al-Maskari F, El-Sadig M. Prevalence of risk factors
for diabetic foot complications. BMC Family
Practice 2007; 8:59. Not RCT or controlled trial
Almquist T, Forslund L, Rehnqvist N, et al.
Prognostic implications of renal dysfunction in
patients with stable angina pectoris. Journal of
Internal Medicine 2006; 260(6):537-44. Not CKD
treatment
al-Nahhas AM, Nimmon CC, Britton KE, et al. The
effect of ramipril, a new angiotensin-converting
enzyme inhibitor on cortical nephron flow and
effective renal plasma flow in patients with essential
hypertension. Nephron 1990; 54(1):47-52. Sample
size less than 50 patients
Aloia JF. Role of calcitriol in the treatment of
postmenopausal osteoporosis. Metabolism: Clinical
& Experimental 1990; 39(4 Suppl 1):35-8. Not CKD
treatment
Aloia JF, Patel M, Dimaano R, et al. Vitamin D
intake to attain a desired serum 25-hydroxyvitamin D
concentration. American Journal of Clinical Nutrition
2008; 87(6):1952-8. Not CKD treatment
Alonso A, Lau J, Jaber BL, et al. Prevention of
radiocontrast nephropathy with N-acetylcysteine in
patients with chronic kidney disease: a meta-analysis
of randomized, controlled trials. American Journal of
Kidney Diseases 2004; 43(1):1-9. Not RCT or
controlled trial
Alper AB, Jr., Tomlin H, Sadhwani U, et al. Effects
of the selective cyclooxygenase-2 inhibitor analgesic
celecoxib on renal carbonic anhydrase enzyme
activity: a randomized, controlled trial. American
Journal of Therapeutics 2006; 13(3):229-35. Not
adult population
al-Sahlawi KS, Tawfik OM. Comparative study of
the efficacy of lysine acetylsalicylate, indomethacin
and pethidine in acute renal colic. European Journal
of Emergency Medicine 1996; 3(3):183-6. Not CKD
treatment
Altay B, Horasanli K, Sarica K, et al. Double-blind,
placebo-controlled, randomized clinical trial of
sublingual or intramuscular piroxicam in the
treatment of renal colic. A comparative study.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
Urologia Internationalis 2007; 79(1):73-5. Sample
size less than 50 patients
Alvarez L, Puleo J, Balint JA. Investigation of
gastrointestinal bleeding in patients with end stage
renal disease. American Journal of Gastroenterology
1993; 88(1):30-3. Not RCT or controlled trial
Alvelos M, Ferreira A, Bettencourt P, et al. Effect of
saline load and metoclopramide on the renal
dopaminergic system in patients with heart failure
and healthy controls. Journal of Cardiovascular
Pharmacology 2005; 45(3):197-203. Not RCT or
controlled trial
Alvelos M, Ferreira A, Bettencourt P, et al. The
effect of dietary sodium restriction on neurohumoral
activity and renal dopaminergic response in patients
with heart failure. European Journal of Heart Failure
2004; 6(5):593-9. Not CKD treatment
al-Waili NS, Saloom KY. Intravenous tenoxicam to
treat acute renal colic: comparison with buscopan
compositum. JPMA - Journal of the Pakistan Medical
Association 1998; 48(12):370-2. Not CKD treatment
Al-Waili NS, Saloom KY. Intramuscular piroxicam
versus intramuscular diclofenac sodium in the
treatment of acute renal colic: double-blind study.
European Journal of Medical Research 1999;
4(1):23-6. Not CKD treatment
Amador-Licona N, Guizar-Mendoza J, Vargas E, et
al. The short-term effect of a switch from
glibenclamide to metformin on blood pressure and
microalbuminuria in patients with type 2 diabetes
mellitus. Archives of Medical Research 2000;
31(6):571-5. Sample size less than 50 patients
Amano J, Suzuki A, Sunamori M. Salutary effect of
reduced glutathione on renal function in coronary
artery bypass operation. Journal of the American
College of Surgeons 1994; 179(6):714-20. Not CKD
treatment
Amano J, Suzuki A, Sunamori M, et al. Effect of
calcium antagonist diltiazem on renal function in
open heart surgery. Chest 1995; 107(5):1260-5.
Sample size less than 50 patients
Amaral CF, Campolina D, Dias MB, et al.
Tourniquet ineffectiveness to reduce the severity of
envenoming after Crotalus durissus snake bite in
Belo Horizonte, Minas Gerais, Brazil. Toxicon 1998;
36(5):805-8. Not CKD treatment
Amaresan MS, Geetha R. Early diagnosis of CKD
and its prevention. Journal of the Association of
Physicians of India 2008; 56:41-6. Not RCT or
controlled trial
Ambwani J, Ubhrani D, Saad R, et al. Could atrial
natriuretic peptide be a useful drug therapy for highrisk patients after cardiac surgery? Interactive
Cardiovascular & Thoracic Surgery 2009; 8(4):4748. Not CKD treatment
Amini M, Salarifar M, Amirbaigloo A, et al. Nacetylcysteine does not prevent contrast-induced
nephropathy after cardiac catheterization in patients
with diabetes mellitus and chronic kidney disease: a
randomized clinical trial. Trials [Electronic
Resource] 2009; 10:45. Not CKD treatment
163. Aminorroaya A, Janghorbani M, Rezvanian H, et al.
Comparison of the effect of pentoxifylline and
captopril on proteinuria in patients with type 2
diabetes mellitus. Nephron 2005; 99(3):c73-7.
Sample size less than 50 patients
164. Amrein PC, Fabian RL. Treatment of recurrent head
and neck cancer with cisplatin and 5-fluorouracil vs.
the same plus bleomycin and methotrexate.
Laryngoscope 1992; 102(8):901-6. Not CKD
treatment
165. Anand A, Anand A, Anand N. Recombinant human
erythropoietin for the correction of cancer associated
anemia with and without concomitant cytotoxic
chemotherapy. Cancer 1996; 77(9):1960-1. Not RCT
or controlled trial
166. Anastassiades E, Howarth D, Howarth JE, et al.
Influence of azathioprine on the ferrokinetics of
patients with renal failure before and after treatment
with erythropoietin. Nephron 1994; 67(3):291-6.
Sample size less than 50 patients
167. Anavekar NS, McMurray JJV, Velazquez EJ, et al.
Relation between renal dysfunction and
cardiovascular outcomes after myocardial infarction.
New England Journal of Medicine 2004;
351(13):1285-95. Follow-up less than 6 months
168. Anavekar NS, Solomon SD, McMurray JJV, et al.
Comparison of renal function and cardiovascular risk
following acute myocardial infarction in patients
with and without diabetes mellitus. American Journal
of Cardiology 2008; 101(7):925-9. Not CKD
treatment
169. Andel M, Grzeszczak W, Michalek J, et al. A
multinational, multi-centre, observational, crosssectional survey assessing diabetes secondary care in
Central and Eastern Europe (DEPAC Survey).
Diabetic Medicine 2008; 25(10):1195-203. Not early
CKD
170. Anders HJ, Rihl M, Loch O, et al. Prediction of
creatinine clearance from serum creatinine in patients
with rheumatoid arthritis: comparison of six formulae
and one nomogram. Clinical Rheumatology 2000;
19(1):26-9. Not early CKD
171. Andersen GS, Hartling OJ, Hein HO, et al. Changes
in blood pressure, fluid volumes and glomerular
filtration rate during long-term treatment with
prizidilol, an antihypertensive drug with combined
vasodilatator and beta-adrenoceptor blocking actions.
Danish Medical Bulletin 1985; 32(5):280-3. Sample
size less than 50 patients
172. Andersen K, Weinberger MH, Constance CM, et al.
Comparative effects of aliskiren-based and ramiprilbased therapy on the renin system during long-term
(6 months) treatment and withdrawal in patients with
hypertension. Journal of the Renin-AngiotensinAldosterone System 2009; 10(3):157-67. Follow-up
less than 6 months
173. Andersen NH, Mogensen CE. Dual blockade of the
renin angiotensin system in diabetic and nondiabetic
kidney disease. Current Hypertension Reports 2004;
6(5):369-76. Not RCT or controlled trial
174. Andersen PE, Bolstad B, Berg KJ, et al. Iodixanol
and ioxaglate in cardioangiography: a double-blind
B-56
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
randomized phase III study. Clinical Radiology
1993; 48(4):268-72. Not CKD treatment
Andersen S, Blouch K, Bialek J, et al. Glomerular
permselectivity in early stages of overt diabetic
nephropathy. Kidney International 2000; 58(5):212937. Sample size less than 50 patients
Andersen S, Brochner-Mortensen J, Parving H-H, et
al. Kidney function during and after withdrawal of
long-term irbesartan treatment in patients with type 2
diabetes and microalbuminuria. Diabetes Care 2003;
26(12):3296-302. Not RCT or controlled trial
Andersen S, Schalkwijk CG, Stehouwer CD, et al.
Angiotensin II blockade is associated with decreased
plasma leukocyte adhesion molecule levels in
diabetic nephropathy. Diabetes Care 2000;
23(7):1031-2. Not CKD treatment
Andersen S, Tarnow L, Cambien F, et al.
Renoprotective effects of losartan in diabetic
nephropathy: interaction with ACE insertion/deletion
genotype? Kidney International 2002; 62(1):192-8.
Follow-up less than 6 months
Andersen S, Tarnow L, Rossing P, et al.
Renoprotective effects of angiotensin II receptor
blockade in type 1 diabetic patients with diabetic
nephropathy. Kidney International 2000; 57(2):6016. Sample size less than 50 patients
Anderson CM. Sodium chloride treatment of
amphotericin B nephrotoxicity. Standard of care?
Western Journal of Medicine 1995; 162(4):313-7.
Not CKD treatment
Anderson J, Glynn LG, Newell J, et al. The impact of
renal insufficiency and anaemia on survival in
patients with cardiovascular disease: a cohort study.
BMC Cardiovascular Disorders 2009; 9:51. Not RCT
or controlled trial
Anderson JW, Blake JE, Turner J, et al. Effects of
soy protein on renal function and proteinuria in
patients with type 2 diabetes. American Journal of
Clinical Nutrition 1998; 68(6 Suppl):1347S-53S.
Sample size less than 50 patients
Anderson TJ, Sun Y-H, Hubacek J, et al. Effects of
folinic acid on forearm blood flow in patients with
end-stage renal disease. Nephrology Dialysis
Transplantation 2006; 21(7):1927-33. Sample size
less than 50 patients
Andersson LG, Jeppsson A, Bratteby LE, et al. Renal
function during cardiopulmonary bypass: influence
of the calcium entry blocker felodipine. Anesthesia &
Analgesia 1996; 83(1):34-40. Follow-up less than 6
months
Anderton JL, Gill M, Notghi A. Renal
haemodynamic effects of bunazosin retard and
prazosin in mild to moderately hypertensive patients
with normal or moderately impaired renal function.
Nephrology Dialysis Transplantation 1994; 9(6):60712. Follow-up less than 6 months
Anderton JL, Notghi A. An evaluation of the efficacy
and safety of doxazosin in the treatment of
hypertension associated with renal insufficiency.
Journal of Human Hypertension 1990; 4 Suppl 3:527. Sample size less than 50 patients
187. Ando Y, Minami H, Saka H, et al. Pharmacokinetic
study of carboplatin given on a 5-day intravenous
schedule. Japanese Journal of Cancer Research 1997;
88(5):517-21. Not CKD treatment
188. Andrew E, Berg KJ, Nossen JO, et al. Renal effects
of iodixanol in patients: a comparison with other
radiographic contrast media. Academic Radiology
1996; 3 Suppl 2:S440-3. Not RCT or controlled trial
189. Angeli P, Gatta A, Caregaro L, et al. Effects of
iloprost, a prostacyclin analog derivative, on renal
plasma flow, renal function, and renin-aldosterone
system in humans. Clinical Pharmacology &
Therapeutics 1988; 44(2):211-6. Sample size less
than 50 patients
190. Angermann CE, Stork S, Costard-Jackle A, et al.
Reduction of cyclosporine after introduction of
mycophenolate mofetil improves chronic renal
dysfunction in heart transplant recipients--the
IMPROVED multi-centre study. European Heart
Journal 2004; 25(18):1626-34. Not early CKD
191. Angevin E, Valteau-Couanet D, Farace F, et al.
Phase I study of prolonged low-dose subcutaneous
recombinant interleukin-2 (IL-2) in patients with
advanced cancer. Journal of Immunotherapy with
Emphasis on Tumor Immunology 1995; 18(3):18895. Follow-up less than 6 months
192. Angoulvant D, Cucherat M, Rioufol G, et al.
Preventing acute decrease in renal function induced
by coronary angiography (PRECORD): a prospective
randomized trial. Archives of cardiovascular diseases
2009; 102(11):761-7. Not CKD treatment
193. Angstwurm MW, Schottdorf J, Schopohl J, et al.
Selenium replacement in patients with severe
systemic inflammatory response syndrome improves
clinical outcome. Critical Care Medicine 1999;
27(9):1807-13. Sample size less than 50 patients
194. Annuk M, Fellstrom B, Lind L. Cyclooxygenase
inhibition improves endothelium-dependent
vasodilatation in patients with chronic renal failure.
Nephrology Dialysis Transplantation 2002;
17(12):2159-63. Sample size less than 50 patients
195. Anothaisintawee T, Rattanasiri S, Ingsathit A, et al.
Prevalence of chronic kidney disease: a systematic
review and meta-analysis. Clinical Nephrology 2009;
71(3):244-54. Not relevant to key questions
196. Anselmino M, Biondi-Zoccai G, Sheiban I. Letter
regarding article by Solomon et al, "Cardiac
Angiography in REnally Impaired Patients (CARE)
study: a randomized double-blind trial of contrastinduced nephropathy in patients with chronic kidney
disease". Circulation 2008; 117(7):e166; author reply
e7. Not CKD treatment
197. Ansquer JC, Foucher C, Aubonnet P, et al. Fibrates
and microvascular complications in diabetes--insight
from the FIELD study. Current Pharmaceutical
Design 2009; 15(5):537-52. Not CKD treatment
198. Ansquer J-C, Dalton RN, Causse E, et al. Effect of
fenofibrate on kidney function: a 6-week randomized
crossover trial in healthy people. American Journal
of Kidney Diseases 2008; 51(6):904-13. Not CKD
treatment
B-57
199. Ansquer J-C, Foucher C, Rattier S, et al. Fenofibrate
reduces progression to microalbuminuria over 3
years in a placebo-controlled study in type 2
diabetes: results from the Diabetes Atherosclerosis
Intervention Study (DAIS). American Journal of
Kidney Diseases 2005; 45(3):485-93. Not relevant to
key questions
200. Anthony J, Rees AE, Davey DA. Indoramin in the
treatment of pregnancy hypertension. A placebocontrolled trial comparing the efficacy of indoramin
with alpha-methyldopa. South African Medical
Journal 1990; Suid-Afrikaanse Tydskrif Vir
Geneeskunde. 78(8):458-61. Not CKD treatment
201. Antonucci F, Calo L, Rizzolo M, et al. Nifedipine
can preserve renal function in patients undergoing
aortic surgery with infrarenal crossclamping.
Nephron 1996; 74(4):668-73. Not CKD treatment
202. Antrum R, Gorst K, Galvin K, et al. A comparison of
teicoplanin vs. cephradine and metronidazole in
surgical prophylaxis: an interim analysis.
Scandinavian Journal of Infectious Diseases
Supplement 1990; 72:45-53. Not CKD treatment
203. Aoki J, Mintz GS, Weissman NJ, et al. Impact of
mild or moderate renal insufficiency on the
intravascular ultrasonic analysis of chronic vascular
response to paclitaxel-eluting and bare-metal stents
(from the TAXUS IV, V, and VI trials). American
Journal of Cardiology 2008; 102(8):1009-16. Not
CKD treatment
204. Aoki J, Ong ATL, Hoye A, et al. Five year clinical
effect of coronary stenting and coronary artery
bypass grafting in renal insufficient patients with
multivessel coronary artery disease: insights from
ARTS trial. European Heart Journal 2005;
26(15):1488-93. Not RCT or controlled trial
205. Apakkan Aksun S, Ozmen B, Ozmen D, et al. Serum
and urinary nitric oxide in Type 2 diabetes with or
without microalbuminuria: relation to glomerular
hyperfiltration. Journal of Diabetes & its
Complications 2003; 17(6):343-8. Not early CKD
206. Appel GB. COX-2 inhibitors and the kidney. Clinical
& Experimental Rheumatology 2001; 19(6 Suppl
25):S37-40. Not RCT or controlled trial
207. Appel LJ, Middleton J, Miller ER, 3rd, et al. The
rationale and design of the AASK cohort study.
Journal of the American Society of Nephrology
2003; 14(7 Suppl 2):S166-72. Not RCT or controlled
trial
208. Appel LJ, Wright JT, Jr., Greene T, et al. Long-term
effects of renin-angiotensin system-blocking therapy
and a low blood pressure goal on progression of
hypertensive chronic kidney disease in African
Americans. Archives of Internal Medicine 2008;
168(8):832-9. Not CKD treatment
209. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term
antiproteinuric response to antihypertensive
treatment predicts long-term GFR decline in patients
with non-diabetic renal disease. Kidney International
- Supplement 1994; 45:S174-8. Sample size less than
50 patients
210. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term
antihypertensive treatment-induced fall in glomerular
211.
212.
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
B-58
filtration rate predicts long-term stability of renal
function. Kidney International 1997; 51(3):793-7.
Follow-up less than 6 months
Apperloo AJ, de Zeeuw D, Sluiter HE, et al.
Differential effects of enalapril and atenolol on
proteinuria and renal haemodynamics in non-diabetic
renal disease. BMJ 1991; 303(6806):821-4. Sample
size less than 50 patients
Appleby C, Foley RN. Hypertension in end-stage
renal disease. Minerva Urologica e Nefrologica
2002; 54(1):37-43. Not RCT or controlled trial
Apseloff G, Wilner KD, von Deutsch DA, et al.
Tenidap sodium decreases renal clearance and
increases steady-state concentrations of lithium in
healthy volunteers. British Journal of Clinical
Pharmacology 1995; 39 Suppl 1:25S-8S. Sample size
less than 50 patients
Apseloff G, Wilner KD, von Deutsch DA, et al.
Sertraline does not alter steady-state concentrations
or renal clearance of lithium in healthy volunteers.
Journal of Clinical Pharmacology 1992; 32(7):643-6.
Not CKD treatment
Aranda P, Segura J, Ruilope LM, et al. Long-term
renoprotective effects of standard versus high doses
of telmisartan in hypertensive nondiabetic
nephropathies. American Journal of Kidney Diseases
2005; 46(6):1074-9. Sample size less than 50 patients
Arcaro G, Zenere BM, Saggiani F, et al. ACE
inhibitors improve endothelial function in type 1
diabetic patients with normal arterial pressure and
microalbuminuria. Diabetes Care 1999; 22(9):153642. Sample size less than 50 patients
Arguedas JA, Perez MI, Wright JM. Treatment blood
pressure targets for hypertension. Cochrane Database
of Systematic Reviews 2009; (3):CD004349. Not
RCT or controlled trial
Arguedas JA, Perez MI, Wright JM. Treatment blood
pressure targets for hypertension. Cochrane Database
of Systematic Reviews 2009; (3):CD004349. Not
RCT or controlled trial
Arici M, Usalan C, Altun B, et al. Radiocontrastinduced nephrotoxicity and urinary alpha-glutathione
S-transferase levels: effect of amlodipine
administration. International Urology & Nephrology
2003; 35(2):255-61. Not relevant to key questions
Armstrong GD, Rowe PC, Goodyer P, et al. A phase
I study of chemically synthesized verotoxin (Shigalike toxin) Pk-trisaccharide receptors attached to
chromosorb for preventing hemolytic-uremic
syndrome. Journal of Infectious Diseases 1995;
171(4):1042-5. Not RCT or controlled trial
Armstrong LE, Pumerantz AC, Roti MW, et al.
Fluid, electrolyte, and renal indices of hydration
during 11 days of controlled caffeine consumption.
International Journal of Sport Nutrition & Exercise
Metabolism 2005; 15(3):252-65. Not RCT or
controlled trial
Arns W, Gies M, Choi L, et al. Absorption
characteristics of EC-MPS--an enteric-coated
formulation of mycophenolic sodium. International
Journal of Clinical Pharmacology & Therapeutics
2006; 44(8):375-85. Not early CKD
223. Aronoff GR. Therapeutic implications associated
with renal studies of nabumetone. Journal of
Rheumatology - Supplement 1992; 36:25-31. Not
CKD treatment
224. Arora R, Clark L, Taylor M. Treatment of high-risk
African American patients: left ventricular
dysfunction, heart failure, renal disease, and
postmyocardial infarction. Journal of Clinical
Hypertension 2003; 5(1 Suppl 1):26-31. Not RCT or
controlled trial
225. Arora S, Clarke K, Srinivasan V, et al. Effect of
nesiritide on renal function in patients admitted for
decompensated heart failure. Qjm 2007;
100(11):699-706. Follow-up less than 6 months
226. Arredondo A, Burke TA, Carides GW, et al. The
impact of losartan on the lifetime incidence of ESRD
and costs in Mexico. Revista de Investigacion Clinica
2005; 57(3):399-405. Sample size less than 50
patients
227. Arroyo V, Fernandez J, Mas A, et al. Molecular
adsorbents recirculating system (MARS) and the
failing liver: a negative editorial for a positive trial?
Hepatology 2008; 47(6):2143-4. Not CKD treatment
228. Artz AS, Fergusson D, Drinka PJ, et al. Mechanisms
of unexplained anemia in the nursing home. Journal
of the American Geriatrics Society 2004; 52(3):4237. Not CKD treatment
229. Arzilli F, Giovannetti R, Lenzi M, et al. Acute
hemodynamic (systemic and renal) and humoral
effects of three increasing doses of iloprost in
essential hypertensives. American Journal of
Hypertension 1989; 2(11 Pt 1):856-60. Sample size
less than 50 patients
230. Arzilli F, Magagna A, Giovannetti R, et al. Acute
dose-response curve of enalapril in renovascular
hypertensives. American Journal of Hypertension
1988; 1(3 Pt 3):75S-8S. Sample size less than 50
patients
231. Ascione R, Lloyd CT, Underwood MJ, et al. Onpump versus off-pump coronary revascularization:
evaluation of renal function. Annals of Thoracic
Surgery 1999; 68(2):493-8. Follow-up less than 6
months
232. Asif A, Epstein DL, Epstein M. Dopamine-1 receptor
agonist: renal effects and its potential role in the
management of radiocontrast-induced nephropathy.
Journal of Clinical Pharmacology 2004;
44(12):1342-51. Not relevant to key questions
233. Aspelin P, Aubry P, Fransson S-G, et al. Nephrotoxic
effects in high-risk patients undergoing angiography.
New England Journal of Medicine 2003; 348(6):4919. Not CKD treatment
234. Aspelin P, Aubry P, Fransson S-G, et al. Costeffectiveness of iodixanol in patients at high risk of
contrast-induced nephropathy. American Heart
Journal 2005; 149(2):298-303. Not RCT or
controlled trial
235. Assadi F. Acetazolamide for prevention of contrastinduced nephropathy: a new use for an old drug.
Pediatric Cardiology 2006; 27(2):238-42. Not RCT
or controlled trial
236. Assan R, Blanchet F, Feutren G, et al. Normal renal
function 8 to 13 years after cyclosporin A therapy in
285 diabetic patients. Diabetes/Metabolism Research
Reviews 2002; 18(6):464-72. Not CKD treatment
237. Asselbergs FW, van der Harst P, van Roon AM, et al.
Long-term effects of pravastatin and fosinopril on
peripheral endothelial function in albuminuric
subjects. Atherosclerosis 2008; 196(1):349-55. Not
RCT or controlled trial
238. Asselbergs FW, van Gilst WH. Angiotensin
converting enzyme inhibition in cardiovascular risk
populations: a practical approach to identify the
patient who will benefit most. Current Opinion in
Cardiology 2007; 22(4):267-72. Not CKD treatment
239. Asselbergs FW, van Roon AM, Hillege HL, et al.
Effects of fosinopril and pravastatin on carotid
intima-media thickness in subjects with increased
albuminuria. Stroke 2005; 36(3):649-53. Sample size
less than 50 patients
240. Assy N, Kayal M, Mejirisky Y, et al. The changes in
renal function after a single dose of intravenous
furosemide in patients with compensated liver
cirrhosis. BMC Gastroenterology 2006; 6:39. Sample
size less than 50 patients
241. Astor BC, Levey AS, Stevens LA, et al. Method of
glomerular filtration rate estimation affects
prediction of mortality risk. Journal of the American
Society of Nephrology 2009; 20(10):2214-22. Not
RCT or controlled trial
242. Astor BC, Yi S, Hiremath L, et al. N-terminal
prohormone brain natriuretic peptide as a predictor of
cardiovascular disease and mortality in blacks with
hypertensive kidney disease: the African American
Study of Kidney Disease and Hypertension (AASK).
Circulation 2008; 117(13):1685-92. Not CKD
treatment
243. Athyros VG, Mikhailidis DP, Papageorgiou AA, et
al. The effect of statins versus untreated
dyslipidaemia on renal function in patients with
coronary heart disease. A subgroup analysis of the
Greek atorvastatin and coronary heart disease
evaluation (GREACE) study. Journal of Clinical
Pathology 2004; 57(7):728-34. Not relevant to key
questions
244. Athyros VG, Papageorgiou AA, Elisaf M, et al.
Statins and renal function in patients with diabetes
mellitus. Current Medical Research & Opinion 2003;
19(7):615-7. Not CKD treatment
245. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria
reduction and progression to renal failure in patients
with type 2 diabetes mellitus and overt nephropathy.
American Journal of Kidney Diseases 2005;
45(2):281-7. Follow-up less than 6 months
246. Atmaca A, Gedik O. Effects of angiotensinconverting enzyme inhibitors, angiotensin II receptor
blockers, and their combination on microalbuminuria
in normotensive patients with type 2 diabetes.
Advances in Therapy 2006; 23(4):615-22. Not
relevant to key questions
247. Atthobari J, Brantsma AH, Gansevoort RT, et al. The
effect of statins on urinary albumin excretion and
glomerular filtration rate: results from both a
B-59
248.
249.
250.
251.
252.
253.
254.
255.
256.
257.
258.
randomized clinical trial and an observational cohort
study. Nephrology Dialysis Transplantation 2006;
21(11):3106-14. Not RCT or controlled trial
Atthobari J, Gansevoort RT, Visser ST, et al. The
effect of screening for cardio-renal risk factors on
drug use in the general population. British Journal of
Clinical Pharmacology 2007; 64(6):810-8. Not CKD
treatment
Aulitzky WE, Grosse-Wilde H, Westhoff U, et al.
Enhanced serum levels of soluble HLA class I
molecules are induced by treatment with recombinant
interferon-gamma (IFN-gamma). Clinical &
Experimental Immunology 1991; 86(2):236-9. Not
CKD treatment
Aurell M, Bengtsson C, Bjorck S. Enalapril versus
metoprolol in primary hypertension--effects on the
glomerular filtration rate. Nephrology Dialysis
Transplantation 1997; 12(11):2289-94. Not early
CKD
Austen SK, Coombes JS, Fassett RG. Homocysteine
and cardiovascular disease in renal disease.
Nephrology 2003; 8(6):285-95. Not CKD treatment
Autier J, Escudier B, Wechsler J, et al. Prospective
study of the cutaneous adverse effects of sorafenib, a
novel multikinase inhibitor. Archives of
Dermatology 2008; 144(7):886-92. Not CKD
treatment
Aviles RJ, Askari AT, Lindahl B, et al. Troponin T
levels in patients with acute coronary syndromes,
with or without renal dysfunction.[Summary for
patients in CMAJ. 2002 Sep 17;167(6):671; PMID:
12358205]. New England Journal of Medicine 2002;
346(26):2047-52. Not RCT or controlled trial
Axelsson J, Bergsten A, Qureshi AR, et al. Elevated
resistin levels in chronic kidney disease are
associated with decreased glomerular filtration rate
and inflammation, but not with insulin resistance.
Kidney International 2006; 69(3):596-604. Not RCT
or controlled trial
Axelsson J, Witasp A, Carrero JJ, et al. Circulating
levels of visfatin/pre-B-cell colony-enhancing factor
1 in relation to genotype, GFR, body composition,
and survival in patients with CKD. American Journal
of Kidney Diseases 2007; 49(2):237-44. Not RCT or
controlled trial
Aybek Z, Turan T, Yonguc T, et al. Requirement of
analgesia for extracorporeal shock wave lithotripsy
and efficacy of a nonsteroidal antiinflammatory drug:
piroxicam. European Urology 1998; 34(3):207-9. Not
CKD treatment
Azadbakht L, Esmaillzadeh A. Soy-protein
consumption and kidney-related biomarkers among
type 2 diabetics: a crossover, randomized clinical
trial. Journal of Renal Nutrition 2009; 19(6):479-86.
Follow-up less than 6 months
Azadbakht L, Shakerhosseini R, Atabak S, et al.
Beneficiary effect of dietary soy protein on lowering
plasma levels of lipid and improving kidney function
in type II diabetes with nephropathy. European
Journal of Clinical Nutrition 2003; 57(10):1292-4.
Sample size less than 50 patients
259. Azar RR, Prpic R, Ho KK, et al. Impact of end-stage
renal disease on clinical and angiographic outcomes
after coronary stenting. American Journal of
Cardiology 2000; 86(5):485-9. Sample size less than
50 patients
260. Azevedo MJ, Pinotti AF, Gross JL, et al. Preserved
left ventricular systolic and diastolic function in
normoalbuminuric insulin-dependent diabetic
patients with glomerular hyperfiltration. Diabetes
Research & Clinical Practice 1994; 25(2):103-10.
Sample size less than 50 patients
261. Azizi M, Bissery A, Lamarre-Cliche M, et al.
Integrating drug pharmacokinetics for phenotyping
individual renin response to angiotensin II blockade
in humans. Hypertension 2004; 43(4):785-90. Not
relevant to key questions
262. Azmus AD, Gottschall C, Manica A, et al.
Effectiveness of acetylcysteine in prevention of
contrast nephropathy. Journal of Invasive Cardiology
2005; 17(2):80-4. Not RCT or controlled trial
263. Baas AF, Janssen KJM, Prinssen M, et al. The
Glasgow Aneurysm Score as a tool to predict 30-day
and 2-year mortality in the patients from the Dutch
Randomized Endovascular Aneurysm Management
trial. Journal of Vascular Surgery 2008; 47(2):27781. Not CKD treatment
264. Baba S, Group JMS. Nifedipine and enalapril equally
reduce the progression of nephropathy in
hypertensive type 2 diabetics. Diabetes Research &
Clinical Practice 2001; 54(3):191-201. Not early
CKD
265. Baba T, Boku A, Ishizaki T, et al. Renal effects of
nicardipine in patients with mild-to-moderate
essential hypertension. American Heart Journal 1986;
111(3):552-7. Sample size less than 50 patients
266. Baba T, Heinemann L, Berger M, et al. Effect of 4hour hyperglycaemia and hyperinsulinaemia on
plasma atrial natriuretic factor concentrations.
Hormone & Metabolic Research 1995; 27(2):95-9.
Not CKD treatment
267. Baba T, Ishizaki T, Ido Y, et al. Renal effects of
nicardipine, a calcium entry blocker, in hypertensive
type II diabetic patients with nephropathy. Diabetes
1986; 35(11):1206-14. Sample size less than 50
patients
268. Baba T, Ishizaki T, Murabayashi S, et al. Multiple
oral doses of nicardipine, a calcium-entry blocker:
effects on renal function, plasma renin activity, and
aldosterone concentration in mild-to-moderate
essential hypertension. Clinical Pharmacology &
Therapeutics 1987; 42(2):232-9. Follow-up less than
6 months
269. Baba T, Murabayashi S, Aoyagi K, et al. Effects of
dilevalol, an R, R-isomer of labetalol, on blood
pressure and renal function in patients with mild-tomoderate essential hypertension. European Journal of
Clinical Pharmacology 1988; 35(1):9-15. Sample size
less than 50 patients
270. Baba T, Murabayashi S, Takebe K. Comparison of
the renal effects of angiotensin converting enzyme
inhibitor and calcium antagonist in hypertensive type
2 (non-insulin-dependent) diabetic patients with
B-60
271.
272.
273.
274.
275.
276.
277.
278.
279.
280.
281.
282.
microalbuminuria: a randomised controlled trial.
Diabetologia 1989; 32(1):40-4. Sample size less than
50 patients
Baba T, Murabayashi S, Tomiyama T, et al.
Comparison of the renal effects of dilevalol and
carteolol in patients with mild to moderate essential
hypertension. European Journal of Clinical
Pharmacology 1990; 38(3):305-7. Sample size less
than 50 patients
Baba T, Tomiyama T, Murabayashi S, et al. Renal
effects of bunazosin, a new alpha 1-adrenoceptor
blocker, in patients with mild-to-moderate essential
hypertension. Journal of Cardiovascular
Pharmacology 1990; 15(5):826-30. Not relevant to
key questions
Baber U, Toto RD, de Lemos JA. Statins and
cardiovascular risk reduction in patients with chronic
kidney disease and end-stage renal failure. American
Heart Journal 2007; 153(4):471-7. Not relevant to
key questions
Backlund M, Pere P, Lepantalo M, et al. Effect of
intra-aortic magnesium on renal function during and
after abdominal aortic surgery: a pilot study. Acta
Anaesthesiologica Scandinavica 2000; 44(5):605-11.
Not early CKD
Backman L, Ringden O, Tollemar J, et al. An
increased risk of relapse in cyclosporin-treated
compared with methotrexate-treated patients: longterm follow-up of a randomized trial. Bone Marrow
Transplantation 1988; 3(5):463-71. Not CKD
treatment
Badalamenti S, Salerno F, Lorenzano E, et al. Renal
effects of dietary supplementation with fish oil in
cyclosporine-treated liver transplant recipients.
Hepatology 1995; 22(6):1695-71. Follow-up less
than 6 months
Badalamenti S, Salerno F, Salmeron JM, et al. Lack
of renal effects of fish oil administration in patients
with advanced cirrhosis and impaired glomerular
filtration. Hepatology 1997; 25(2):313-6. Follow-up
less than 6 months
Bader BD, Berger ED, Heede MB, et al. What is the
best hydration regimen to prevent contrast mediainduced nephrotoxicity? Clinical Nephrology 2004;
62(1):1-7. Not CKD treatment
Bagshaw SM, Delaney A, Haase M, et al. Loop
diuretics in the management of acute renal failure: a
systematic review and meta-analysis. Critical Care &
Resuscitation 2007; 9(1):60-8. Not RCT or controlled
trial
Bagshaw SM, Delaney A, Jones D, et al. Diuretics in
the management of acute kidney injury: a
multinational survey. Contributions to Nephrology
2007; 156:236-49. Not RCT or controlled trial
Bagshaw SM, Ghali WA. Acetylcysteine for
prevention of contrast-induced nephropathy after
intravascular angiography: a systematic review and
meta-analysis. BMC Medicine 2004; 2:38. Not
relevant to key questions
Bagshaw SM, Ghali WA. Theophylline for
prevention of contrast-induced nephropathy: a
systematic review and meta-analysis. Archives of
283.
284.
285.
286.
287.
288.
289.
290.
291.
292.
293.
294.
295.
B-61
Internal Medicine 2005; 165(10):1087-93. Not early
CKD
Bagshaw SM, McAlister FA, Manns BJ, et al.
Acetylcysteine in the prevention of contrast-induced
nephropathy: a case study of the pitfalls in the
evolution of evidence. Archives of Internal Medicine
2006; 166(2):161-6. Not RCT or controlled trial
Baigent C, Landray M. Which cardiovascular risk
factors matter in chronic kidney disease? Nephrology
Dialysis Transplantation 2007; 22(1):9-11. Not CKD
treatment
Baigent C, Landray M, Warren M. Statin therapy in
kidney disease populations: potential benefits beyond
lipid lowering and the need for clinical trials. Current
Opinion in Nephrology & Hypertension 2004;
13(6):601-5. Not RCT or controlled trial
Bailey RR, Carlson RV, Walker RJ, et al. Effect of
oral penbutolol on renal haemodynamics of
hypertensive patients with renal insufficiency. New
Zealand Medical Journal 1985; 98(785):683-5.
Follow-up less than 6 months
Bailey RR, Nairn PL, Walker RJ. Effect of doxazosin
on blood pressure and renal haemodynamics of
hypertensive patients with renal failure. New Zealand
Medical Journal 1986; 99(815):942-5. Sample size
less than 50 patients
Bailey SR. Past and present attempts to prevent
radiocontrast nephropathy. Reviews in
Cardiovascular Medicine 2001; 2 Suppl 1:S14-8. Not
CKD treatment
Bain R, Rohde R, Hunsicker LG, et al. A controlled
clinical trial of angiotensin-converting enzyme
inhibition in type I diabetic nephropathy: study
design and patient characteristics. The Collaborative
Study Group. Journal of the American Society of
Nephrology 1992; 3(4 Suppl):S97-103. Not RCT or
controlled trial
Bainbridge AD, Meredith PA, Elliott HL. A clinical
pharmacological assessment of doxazosin and
enalapril in combination. British Journal of Clinical
Pharmacology 1993; 36(6):599-602. Sample size less
than 50 patients
Baker CSR, Wragg A, Kumar S, et al. A rapid
protocol for the prevention of contrast-induced renal
dysfunction: the RAPPID study. Journal of the
American College of Cardiology 2003; 41(12):21148. Not CKD treatment
Baker J, Cotter JD, Gerrard DF, et al. Effects of
indomethacin and celecoxib on renal function in
athletes. Medicine & Science in Sports & Exercise
2005; 37(5):712-7. Not RCT or controlled trial
Baker LR, Abrams L, Roe CJ, et al. 1,25(OH)2D3
administration in moderate renal failure: a
prospective double-blind trial. Kidney International
1989; 35(2):661-9. Sample size less than 50 patients
Baker LR, Abrams SM, Roe CJ, et al. Early therapy
of renal bone disease with calcitriol: a prospective
double-blind study. Kidney International Supplement 1989; 27:S140-2. Sample size less than
50 patients
Bakris G. Inclusion of albuminuria in hypertension
and heart guidelines. Kidney International -
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
308.
Supplement 2004; (92):S124-5. Not RCT or
controlled trial
Bakris G, Viberti G, Weston WM, et al.
Rosiglitazone reduces urinary albumin excretion in
type II diabetes. Journal of Human Hypertension
2003; 17(1):7-12. Sample size less than 50 patients
Bakris GL. Effects of diltiazem or lisinopril on
massive proteinuria associated with diabetes mellitus.
Annals of Internal Medicine 1990; 112(9):707-8.
Sample size less than 50 patients
Bakris GL. Role for beta-blockers in the management
of diabetic kidney disease. American Journal of
Hypertension 2003; 16(9 Pt 2):7S-12S. Not RCT or
controlled trial
Bakris GL. ACE inhibitors and ARBs: are they better
than other agents to slow nephropathy progression?
Journal of Clinical Hypertension 2007; 9(6):413-5.
Not relevant to key questions
Bakris GL, Barnhill BW, Sadler R. Treatment of
arterial hypertension in diabetic humans: importance
of therapeutic selection. Kidney International 1992;
41(4):912-9. Sample size less than 50 patients
Bakris GL, Fonseca V, Katholi RE, et al. Differential
effects of beta-blockers on albuminuria in patients
with type 2 diabetes. Hypertension 2005; 46(6):130915. Not relevant to key questions
Bakris GL, Mangrum A, Copley JB, et al. Effect of
calcium channel or beta-blockade on the progression
of diabetic nephropathy in African Americans.
Hypertension 1997; 29(3):744-50. Sample size less
than 50 patients
Bakris GL, Ruilope L, Locatelli F, et al. Treatment of
microalbuminuria in hypertensive subjects with
elevated cardiovascular risk: results of the
IMPROVE trial. Kidney International 2007;
72(7):879-85. Not RCT or controlled trial
Bakris GL, Ruilope L, Locatelli F, et al. Rationale
and design of a study to evaluate management of
proteinuria in patients at high risk for vascular
events: the IMPROVE trial. Journal of Human
Hypertension 2006; 20(9):693-700. Not relevant to
key questions
Bakris GL, Siomos M, Richardson D, et al. ACE
inhibition or angiotensin receptor blockade: impact
on potassium in renal failure. VAL-K Study Group.
Kidney International 2000; 58(5):2084-92. Sample
size less than 50 patients
Bakris GL, Slataper R, Vicknair N, et al. ACE
inhibitor mediated reductions in renal size and
microalbuminuria in normotensive, diabetic subjects.
Journal of Diabetes & its Complications 1994;
8(1):2-6. Sample size less than 50 patients
Bakris GL, Starke U, Heifets M, et al. Renal effects
of oral prostaglandin supplementation after ibuprofen
in diabetic subjects: a double-blind, placebocontrolled, multicenter trial. Journal of the American
Society of Nephrology 1995; 5(9):1684-8. Sample
size less than 50 patients
Bakris GL, Toto RD, McCullough PA. Rationale and
design of a study comparing two fixed-dose
combination regimens to reduce albuminuria in
patients with type II diabetes and hypertension.
309.
310.
311.
312.
313.
314.
315.
316.
317.
318.
319.
320.
B-62
Journal of Human Hypertension 2005; 19(2):139-44.
Not relevant to key questions
Bakris GL, Weir MR. Angiotensin-converting
enzyme inhibitor-associated elevations in serum
creatinine: is this a cause for concern? Archives of
Internal Medicine 2000; 160(5):685-93. Not relevant
to key questions
Bakris GL, Weir MR, DeQuattro V, et al. Effects of
an ACE inhibitor/calcium antagonist combination on
proteinuria in diabetic nephropathy. Kidney
International 1998; 54(4):1283-9. Sample size less
than 50 patients
Bakris GL, Weir MR, Secic M, et al. Differential
effects of calcium antagonist subclasses on markers
of nephropathy progression. Kidney International
2004; 65(6):1991-2002. Not early CKD
Bakris GL, Weir MR, Shanifar S, et al. Effects of
blood pressure level on progression of diabetic
nephropathy: results from the RENAAL study.
Archives of Internal Medicine 2003; 163(13):155565. Not CKD treatment
Bakris GL, Williams M, Dworkin L, et al. Preserving
renal function in adults with hypertension and
diabetes: a consensus approach. National Kidney
Foundation Hypertension and Diabetes Executive
Committees Working Group. American Journal of
Kidney Diseases 2000; 36(3):646-61. Not relevant to
key questions
Balakrishnan VS, Coles GA, Williams JD. A
potential role for endogenous adenosine in control of
human glomerular and tubular function. American
Journal of Physiology 1993; 265(4 Pt 2):F504-10.
Not CKD treatment
Balakrishnan VS, Coles GA, Williams JD.
Functional role of endogenous adenosine in human
chronic renal disease. Experimental Nephrology
1996; 4(1):26-36. Sample size less than 50 patients
Balamuthusamy S, Srinivasan L, Verma M, et al.
Renin angiotensin system blockade and
cardiovascular outcomes in patients with chronic
kidney disease and proteinuria: a metaanalysis.[Erratum appears in Am Heart J. 2009
Mar;157(3):501 Note: Jalandara, Nishant [corrected
to Jalandhara, Nishant]]. American Heart Journal
2008; 155(5):791-805. Not CKD treatment
Balderramo DC, Verdu MB, Ramacciotti CF, et al.
Renoprotective effect of high periprocedural doses of
oral N-acetylcysteine in patients scheduled to
undergo a same-day angiography. Revista de la
Facultad de Ciencias Medicas de Cordoba 2004;
61(2):13-9. Sample size less than 50 patients
Baldwin L, Henderson A, Hickman P. Effect of
postoperative low-dose dopamine on renal function
after elective major vascular surgery. Annals of
Internal Medicine 1994; 120(9):744-7. Not CKD
treatment
Banach M, Mikhailidis DP, Kjeldsen SE, et al. Time
for new indications for statins? Medical Science
Monitor 2009; 15(12):MS1-5. Not RCT or controlled
trial
Banerjee D, Materson BJ. Blood pressureindependent impact of antihypertensive agents on
321.
322.
323.
324.
325.
326.
327.
328.
329.
330.
331.
332.
333.
cardiovascular and renal disease. Current
Hypertension Reports 2002; 4(6):445-52. Not
relevant to key questions
Bangstad HJ, Osterby R, Dahl-Jorgensen K, et al.
Improvement of blood glucose control in IDDM
patients retards the progression of morphological
changes in early diabetic nephropathy. Diabetologia
1994; 37(5):483-90. Sample size less than 50 patients
Bangstad HJ, Osterby R, Dahl-Jorgensen K, et al.
Early glomerulopathy is present in young, type 1
(insulin-dependent) diabetic patients with
microalbuminuria. Diabetologia 1993; 36(6):523-9.
Sample size less than 50 patients
Banikazemi M, Bultas J, Waldek S, et al. Agalsidasebeta therapy for advanced Fabry disease: a
randomized trial. Annals of Internal Medicine 2007;
146(2):77-86. Sample size less than 50 patients
Bansal N, Tighiouart H, Weiner D, et al. Anemia as a
risk factor for kidney function decline in individuals
with heart failure. American Journal of Cardiology
2007; 99(8):1137-42. Not relevant to key questions
Baranska-Kosakowska A, Zakliczynski M,
Przybylski R, et al. Role of N-acetylcysteine on renal
function in patients after orthotopic heart
transplantation undergoing coronary angiography.
Transplantation Proceedings 2007; 39(9):2853-5. Not
CKD treatment
Barba G, Vallance PJ, Strazzullo P, et al. Effects of
sodium intake on the pressor and renal responses to
nitric oxide synthesis inhibition in normotensive
individuals with different sodium sensitivity. Journal
of Hypertension 2000; 18(5):615-21. Sample size less
than 50 patients
Barber TJ, Hughes A, Dinsmore WW, et al. How
does HIV impact on non-AIDS events in the era of
HAART? International Journal of STD & AIDS
2009; 20(1):1-3. Not CKD treatment
Barichella M, Savardi C, Mauri A, et al. Diet with
LPP for renal patients increases daily energy
expenditure and improves motor function in
parkinsonian patients with motor fluctuations.
Nutritional Neuroscience 2007; 10(3-4):129-35. Not
RCT or controlled trial
Barit D, Cooper ME. Diabetic patients and kidney
protection: an attainable target. Journal of
Hypertension - Supplement 2008; 26(2):S3-7. Not
relevant to key questions
Barit D, Cooper ME. Diabetic patients and kidney
protection: an attainable target. Journal of
Hypertension 2008; 26 Suppl 2:S3-7. Follow-up less
than 6 months
Barletta G, Lazzeri C, Vecchiarino S, et al. Low-dose
C-type natriuretic peptide does not affect cardiac and
renal function in humans. Hypertension 1998;
31(3):802-8. Sample size less than 50 patients
Barlovic DP, Zaletel J, Prezelj J. Adipocytokines are
associated with renal function in patients with normal
range glomerular filtration rate and type 2 diabetes.
Cytokine 2009; 46(1):142-5. Not early CKD
Barman Balfour JA, Scott LJ. Cinacalcet
hydrochloride. Drugs 2005; 65(2):271-81. Not CKD
treatment
334. Barnett A. Preventing renal complications in type 2
diabetes: results of the diabetics exposed to
telmisartan and enalapril trial. Journal of the
American Society of Nephrology 2006; 17(4 Suppl
2):S132-5. Not RCT or controlled trial
335. Barnett A. Prevention of loss of renal function over
time in patients with diabetic nephropathy. American
Journal of Medicine 2006; 119(5 Suppl 1):S40-7.
Follow-up less than 6 months
336. Barnett AH. The role of angiotensin II receptor
antagonists in the management of diabetes. Blood
Pressure Supplement 2001; 1:21-6. Not RCT or
controlled trial
337. Barnett AH. Preventing renal complications in
diabetic patients: the Diabetics Exposed to
Telmisartan And enalaprIL (DETAIL) study. Acta
Diabetologica 2005; 42 Suppl 1:S42-9. Not CKD
treatment
338. Baron F, Frere P, Baudoux E, et al. Low incidence of
acute graft-versus-host disease after nonmyeloablative stem cell transplantation with CD8depleted peripheral blood stem cells: an update.
Haematologica 2003; 88(7):835-7. Not CKD
treatment
339. Barone R, Borson-Chazot F, Valkema R, et al.
Patient-specific dosimetry in predicting renal toxicity
with (90)Y-DOTATOC: relevance of kidney volume
and dose rate in finding a dose-effect relationship.
Journal of Nuclear Medicine 2005; 46 Suppl 1:99S106S. Not relevant to key questions
340. Barone R, Pauwels S, De Camps J, et al. Metabolic
effects of amino acid solutions infused for renal
protection during therapy with radiolabelled
somatostatin analogues. Nephrology Dialysis
Transplantation 2004; 19(9):2275-81. Sample size
less than 50 patients
341. Barr J, Zaloga GP, Haupt MT, et al. Cation
metabolism during propofol sedation with and
without EDTA in patients with impaired renal
function. Intensive Care Medicine 2000; 26 Suppl
4:S433-42. Not CKD treatment
342. Barrantes F, Feng Y, Ivanov O, et al. Acute kidney
injury predicts outcomes of non-critically ill patients.
Mayo Clinic Proceedings 2009; 84(5):410-6. Not
CKD treatment
343. Barratt TM, Chantler C, Lederman S, et al.
Assessment of renal function. American Journal of
Kidney Diseases 1986; 7(4):347-9. Not CKD
treatment
344. Barrett BJ. Contrast-induced nephropathy: we need
all the data to discern the truth. American Journal of
Kidney Diseases 2009; 54(4):587-9. Not RCT or
controlled trial
345. Barrett SV, Paul J, Hay A, et al. Does body mass
index affect progression-free or overall survival in
patients with ovarian cancer? Results from
SCOTROC I trial. Annals of Oncology 2008;
19(5):898-902. Not CKD treatment
346. Barri YM, Wilcox CS. Salt intake determines the
renal response to L-arginine infusion in normal
human subjects. Kidney International 1998;
53(5):1299-304. Not CKD treatment
B-63
347. Barton M, Mullins JJ, Bailey MA, et al. Role of
endothelin receptors for renal protection and survival
in hypertension: waiting for clinical trials.
Hypertension 2006; 48(5):834-7. Not RCT or
controlled trial
348. Basic-Jukic N, Kes P, Mokos I, et al. Do we need
more intensive enzyme replacement therapy for
Anderson-Fabry disease? Medical Hypotheses 2009;
72(4):476-7. Not RCT or controlled trial
349. Baskurt M, Okcun B, Abaci O, et al. Nacetylcysteine versus N-acetylcysteine +
theophylline for the prevention of contrast
nephropathy. European Journal of Clinical
Investigation 2009; 39(9):793-9. Not CKD treatment
350. Battershill AJ, Scott LJ. Telmisartan: a review of its
use in the management of hypertension. Drugs 2006;
66(1):51-83. Not RCT or controlled trial
351. Bauer JH, Gaddy P. Effects of enalapril alone, and in
combination with hydrochlorothiazide, on reninangiotensin-aldosterone, renal function, salt and
water excretion, and body fluid composition.
American Journal of Kidney Diseases 1985;
6(4):222-32. Sample size less than 50 patients
352. Bauer JH, Reams G, Gaddy P. Renal function and
hemodynamics during treatment with enalapril in
primary hypertension. Nephron 1986; 44 Suppl 1:836. Sample size less than 50 patients
353. Bauer JH, Reams GP. Hemodynamic and renal
function in essential hypertension during treatment
with enalapril. American Journal of Medicine 1985;
79(3C):10-3. Sample size less than 50 patients
354. Bauer JH, Reams GP, Hewett J, et al. A randomized,
double-blind, placebo-controlled trial to evaluate the
effect of enalapril in patients with clinical diabetic
nephropathy. American Journal of Kidney Diseases
1992; 20(5):443-57. Sample size less than 50 patients
355. Bauer JH, Reams GP, Lau A. A comparison of
betaxolol and nadolol on renal function in essential
hypertension. American Journal of Kidney Diseases
1987; 10(2):109-12. Sample size less than 50 patients
356. Bauer LA, Black DJ, Lill JS, et al. Levofloxacin and
ciprofloxacin decrease procainamide and Nacetylprocainamide renal clearances. Antimicrobial
Agents & Chemotherapy 2005; 49(4):1649-51. Not
RCT or controlled trial
357. Bayerle-Eder M, Fuchsjager-Mayrl G, Sieder A, et
al. Effect of pravastatin on responsiveness to Nmonomethyl-L-arginine in patients with
hypercholesterolaemia. Atherosclerosis 2002;
160(1):177-84. Not early CKD
358. Bayerle-Eder M, Langenberger H, Pleiner J, et al.
Endothelin ETA receptor-subtype specific
antagonism does not mitigate the acute systemic or
renal effects of exogenous angiotensin II in humans.
European Journal of Clinical Investigation 2002;
32(4):230-5. Not early CKD
359. Bayliss J, Canepa-Anson R, Norell M, et al. The
renal response to neuroendocrine inhibition in
chronic heart failure: double-blind comparison of
captopril and prazosin. European Heart Journal 1986;
7(10):877-84. Follow-up less than 6 months
360. Beatty OL, Ritchie CM, Hadden DR, et al. Is a
random urinary albumin concentration a useful
screening test in insulin-treated diabetic patients?
Irish Journal of Medical Science 1994; 163(9):406-9.
Not RCT or controlled trial
361. Bech JN, Nielsen CB, Ivarsen P, et al. Dietary
sodium affects systemic and renal hemodynamic
response to NO inhibition in healthy humans.
American Journal of Physiology 1998; 274(5 Pt
2):F914-23. Not CKD treatment
362. Bech JN, Nielsen CB, Pedersen EB. Effects of
systemic NO synthesis inhibition on RPF, GFR,
UNa, and vasoactive hormones in healthy humans.
American Journal of Physiology 1996; 270(5 Pt
2):F845-51. Not CKD treatment
363. Bech JN, Nielsen EH, Pedersen RS, et al. Enhanced
sodium retention after acute nitric oxide blockade in
mildly sodium loaded patients with essential
hypertension. American Journal of Hypertension
2007; 20(3):287-95. Sample size less than 50 patients
364. Beck GJ, Berg RL, Coggins CH, et al. Design and
statistical issues of the Modification of Diet in Renal
Disease Trial. The Modification of Diet in Renal
Disease Study Group. Controlled Clinical Trials
1991; 12(5):566-86. Not CKD treatment
365. Beckebaum S, Cicinnati V, Brokalaki E, et al. CNIsparing regimens within the liver transplant setting:
experiences of a single center. Clinical Transplants
2004:215-20. Not relevant to key questions
366. Beckebaum S, Cicinnati VR, Klein CG, et al. Impact
of combined mycophenolate mofetil and low-dose
calcineurin inhibitor therapy on renal function,
cardiovascular risk factors, and graft function in liver
transplant patients: preliminary results of an open
prospective study. Transplantation Proceedings 2004;
36(9):2671-4. Sample size less than 50 patients
367. Beckebaum S, Klein CG, Sotiropoulos GC, et al.
Combined mycophenolate mofetil and minimal dose
calcineurin inhibitor therapy in liver transplant
patients: clinical results of a prospective randomized
study. Transplantation Proceedings 2009;
41(6):2567-9. Not CKD treatment
368. Beck-Nielsen H, Olesen T, Mogensen CE, et al.
Effect of near normoglycemia for 5 years on
progression of early diabetic retinopathy and renal
involvement. Diabetes Research 1990; 15(4):185-90.
Sample size less than 50 patients
369. Beck-Nielsen H, Richelsen B, Mogensen CE, et al.
Effect of insulin pump treatment for one year on
renal function and retinal morphology in patients
with IDDM. Diabetes Care 1985; 8(6):585-9. Sample
size less than 50 patients
370. Beeks E, van der Klauw MM, Kroon AA, et al.
Alpha-adducin Gly460Trp polymorphism and renal
hemodynamics in essential hypertension.
Hypertension 2004; 44(4):419-23. Not CKD
treatment
371. Beermann B, Eriksson LO, Kallner M. A double
blind comparison of naproxen and sulindac in female
patients with heart failure. Scandinavian Journal of
Rheumatology - Supplement 1986; 62:32-5. Sample
size less than 50 patients
B-64
372. Beevers DG, Lip GY. The protective effect of
blocking angiotensin in both type I and type II
diabetics with nephropathy. Journal of Human
Hypertension 2001; 15(12):837-9. Not RCT or
controlled trial
373. Behets GJ, Verberckmoes SC, D'Haese PC, et al.
Lanthanum carbonate: a new phosphate binder.
Current Opinion in Nephrology & Hypertension
2004; 13(4):403-9. Not relevant to key questions
374. Bektas F, Eken C, Karadeniz O, et al. Intravenous
paracetamol or morphine for the treatment of renal
colic: a randomized, placebo-controlled trial. Annals
of Emergency Medicine 2009; 54(4):568-74. Not
CKD treatment
375. Bell N, Hawkins V, Holliman D, et al. Trandolapril
and human diabetic neuropathy. Lancet 1999;
353(9156):927. Not RCT or controlled trial
376. Bellinghieri G, Mazzaglia G, Savica V, et al. Effects
of manidipine and nifedipine on blood pressure and
renal function in patients with chronic renal failure: a
multicenter randomized controlled trial. Renal
Failure 2003; 25(5):681-9. Not CKD treatment
377. Bellizzi V, Di Iorio BR, De Nicola L, et al. Very low
protein diet supplemented with ketoanalogs improves
blood pressure control in chronic kidney disease.
Kidney International 2007; 71(3):245-51. Not RCT
or controlled trial
378. Bellizzi V, Scalfi L, Terracciano V, et al. Early
changes in bioelectrical estimates of body
composition in chronic kidney disease. Journal of the
American Society of Nephrology 2006; 17(5):14817. Follow-up less than 6 months
379. Bello E, Caramelo C, Martell N, et al. Impairment of
renal vasodilation with l-arginine is related to more
severe disease in untreated hypertensive patients.
Hypertension 2001; 38(4):907-12. Not CKD
treatment
380. Bellomo R, Auriemma S, Fabbri A, et al. The
pathophysiology of cardiac surgery-associated acute
kidney injury (CSA-AKI). International Journal of
Artificial Organs 2008; 31(2):166-78. Not CKD
treatment
381. Bellomo R, Chapman M, Finfer S, et al. Low-dose
dopamine in patients with early renal dysfunction: a
placebo-controlled randomised trial. Australian and
New Zealand Intensive Care Society (ANZICS)
Clinical Trials Group. Lancet 2000; 356(9248):213943. Follow-up less than 6 months
382. Bellomo R, Ronco C, Kellum JA, et al. Acute renal
failure - definition, outcome measures, animal
models, fluid therapy and information technology
needs: the Second International Consensus
Conference of the Acute Dialysis Quality Initiative
(ADQI) Group. Critical Care 2004; 8(4):R204-12.
Not CKD treatment
383. Belonje AMS, de Boer RA, Voors AA. Recombinant
human Epo treatment: beneficial in chronic kidney
disease, chronic heart failure, or both? Editorial to:
"Correction of anemia with erythropoietin in chronic
kidney disease (stage 3 or 4): effects on cardiac
performance by Pappas et al.". Cardiovascular Drugs
& Therapy 2008; 22(1):1-2. Not CKD treatment
384. Benck U, Clorius JH, Zuna I, et al. Renal
hemodynamic changes during smoking: effects of
adrenoreceptor blockade. European Journal of
Clinical Investigation 1999; 29(12):1010-8. Not CKD
treatment
385. Benck U, Haeckel S, Clorius JH, et al. Proteinurialowering effect of heparin therapy in diabetic
nephropathy without affecting the renin-angiotensinaldosterone system. Clinical Journal of The
American Society of Nephrology: CJASN 2007;
2(1):58-67. Sample size less than 50 patients
386. Bender A, Samtleben W, Elstner M, et al. Long-term
creatine supplementation is safe in aged patients with
Parkinson disease. Nutrition Research 2008;
28(3):172-8. Not CKD treatment
387. Bender R. The effect of cholesterol-lowering therapy
on the progression of diabetic nephropathy is
unproved.[Erratum appears in Diabetologia 1996
Aug;39(8):1004]. Diabetologia 1996; 39(3):368-70.
Not RCT or controlled trial
388. Bending JJ, Dodds RA, Keen H, et al. Renal
response to restricted protein intake in diabetic
nephropathy. Diabetes 1988; 37(12):1641-6. Followup less than 6 months
389. Bending JJ, Viberti GC, Watkins PJ, et al.
Intermittent clinical proteinuria and renal function in
diabetes: evolution and the effect of glycaemic
control. British Medical Journal Clinical Research
Ed. 1986; 292(6513):83-6. Sample size less than 50
patients
390. Benincosa LJ, Sagawa K, Massey LK, et al. Effects
of acute caffeine ingestion and menopause on sulfate
homeostasis in women. Life Sciences 1995;
57(16):1497-505. Sample size less than 50 patients
391. Benndorf RA, Appel D, Maas R, et al. Telmisartan
improves endothelial function in patients with
essential hypertension. Journal of Cardiovascular
Pharmacology 2007; 50(4):367-71. Not RCT or
controlled trial
392. Bennett WM. Side effects of erythropoietin therapy.
American Journal of Kidney Diseases 1991; 18(4
Suppl 1):84-6. Not relevant to key questions
393. Bennett WM. A multicenter clinical trial of epoetin
beta for anemia of end-stage renal disease. Journal of
the American Society of Nephrology 1991; 1(7):9908. Not early CKD
394. Benoehr P, Krueth P, Bokemeyer C, et al.
Nephroprotection by theophylline in patients with
cisplatin chemotherapy: a randomized, singleblinded, placebo-controlled trial. Journal of the
American Society of Nephrology 2005; 16(2):452-8.
Not RCT or controlled trial
395. Benohr P, Grenz A, Hartmann JT, et al. Cystatin C--a
marker for assessment of the glomerular filtration
rate in patients with cisplatin chemotherapy. Kidney
& Blood Pressure Research 2006; 29(1):32-5. Not
relevant to key questions
396. Benzoni D, Geoffroy J, Waeber B, et al. Atrial
natriuretic peptide and urinary prostaglandins in man.
British Journal of Clinical Pharmacology 1989;
28(4):397-402. Sample size less than 50 patients
B-65
397. Berenson JR. Recommendations for zoledronic acid
treatment of patients with bone metastases.
Oncologist 2005; 10(1):52-62. Not RCT or controlled
trial
398. Berg KJ, Forre O, Djoseland O, et al. Renal side
effects of high and low cyclosporin A doses in
patients with rheumatoid arthritis. Clinical
Nephrology 1989; 31(5):232-8. Not CKD treatment
399. Berg KJ, Talseth T. Acute renal effects of sulindac
and indomethacin in chronic renal failure. Clinical
Pharmacology & Therapeutics 1985; 37(4):447-52.
Sample size less than 50 patients
400. Berger ED, Setzler BA, Werz U, et al. Blood
pressure reduction is necessary for the reduction of
proteinuria in diabetic nephropathy--comparison of
different antihypertensive agents. Nephrology
Dialysis Transplantation 1999; 14 Suppl 4:28-9.
Sample size less than 50 patients
401. Berger PB, Best PJM, Topol EJ, et al. The relation of
renal function to ischemic and bleeding outcomes
with 2 different glycoprotein IIb/IIIa inhibitors: the
do Tirofiban and ReoPro Give Similar Efficacy
Outcome (TARGET) trial. American Heart Journal
2005; 149(5):869-75. Not relevant to key questions
402. Berghmans T, Klastersky J, Markiewicz E, et al.
Cisplatin-carboplatin-gemcitabine or ifosfamidegemcitabine in advanced non-small cell lung
carcinoma: two pilot studies. Anticancer Research
1999; 19(6C):5651-5. Not early CKD
403. Bergman A, Odar-Cederlof I, Westman L, et al.
Effects of human atrial natriuretic peptide in patients
after coronary artery bypass surgery. Journal of
Cardiothoracic & Vascular Anesthesia 1996;
10(4):490-6. Sample size less than 50 patients
404. Bergman ASF, Odar-Cederlof I, Westman L, et al.
Diltiazem infusion for renal protection in cardiac
surgical patients with preexisting renal dysfunction.
Journal of Cardiothoracic & Vascular Anesthesia
2002; 16(3):294-9. Follow-up less than 6 months
405. Bergner R, Diel IJ, Henrich D, et al. Differences in
nephrotoxicity of intravenous bisphosphonates for
the treatment of malignancy-related bone disease.
Onkologie 2006; 29(11):534-40. Not relevant to key
questions
406. Bergstrom J, Alvestrand A, Bucht H, et al.
Progression of chronic renal failure in man is
retarded with more frequent clinical follow-ups and
better blood pressure control. Clinical Nephrology
1986; 25(1):1-6. Sample size less than 50 patients
407. Bergstrom J, Alvestrand A, Bucht H, et al. What is
the role of controls in an outpatient department on
progression of renal disease? Blood Purification
1988; 6(6):336-42. Not relevant to key questions
408. Bergstrom J, Alvestrand A, Bucht H, et al.
Stockholm clinical study on progression of chronic
renal failure--an interim report. Kidney International
- Supplement 1989; 27:S110-4. Sample size less than
50 patients
409. Bergstrom J, Alvestrand A, Bucht H, et al. Is chronic
renal disease always progressive? Contributions to
Nephrology 1989; 75:60-7. Sample size less than 50
patients
410. Bergus GR. Pain relief for renal colic. Journal of
Family Practice 1996; 43(5):438-40. Not CKD
treatment
411. Beri A, Sural N, Mahajan SB. Non-atheroprotective
effects of statins: a systematic review. American
Journal of Cardiovascular Drugs 2009; 9(6):361-70.
Not RCT or controlled trial
412. Beringer PM, Hidayat L, Heed A, et al. GFR
estimates using cystatin C are superior to serum
creatinine in adult patients with cystic fibrosis.
Journal of Cystic Fibrosis 2009; 8(1):19-25. Sample
size less than 50 patients
413. Beringer PM, Kriengkauykiat J, Zhang X, et al. Lack
of effect of P-glycoprotein inhibition on renal
clearance of dicloxacillin in patients with cystic
fibrosis. Pharmacotherapy 2008; 28(7):883-94. Not
human studies
414. Berl T, Hunsicker LG, Lewis JB, et al. Impact of
achieved blood pressure on cardiovascular outcomes
in the Irbesartan Diabetic Nephropathy Trial. Journal
of the American Society of Nephrology 2005;
16(7):2170-9. Follow-up less than 6 months
415. Bernard S, Fouque D, Laville M, et al. Effects of
low-protein diet supplemented with ketoacids on
plasma lipids in adult chronic renal failure. Mineral
& Electrolyte Metabolism 1996; 22(1-3):143-6.
Sample size less than 50 patients
416. Bernardi M, De Palma R, Trevisani F, et al. Effects
of a new loop diuretic (muzolimine) in cirrhosis with
ascites: comparison with furosemide. Hepatology
1986; 6(3):400-5. Sample size less than 50 patients
417. Bernardi M, De Palma R, Trevisani F, et al.
Comparative pharmacodynamics of furosemide and
muzolimine in cirrhosis. Study on renal sodium and
potassium handling and renin-aldosterone axis.
Zeitschrift fur Kardiologie 1985; 74 Suppl 2:129-34.
Sample size less than 50 patients
418. Bernardi M, D'Intino PE, Trevisani F, et al. Effects
of prolonged ingestion of graded doses of licorice by
healthy volunteers. Life Sciences 1994; 55(11):86372. Not CKD treatment
419. Bernasconi AR, Liste A, Del Pino N, et al. Folic acid
5 or 15 mg/d similarly reduces plasma homocysteine
in patients with moderate-advanced chronic renal
failure. Nephrology 2006; 11(2):137-41. Not RCT or
controlled trial
420. Bernhard J, Beaufrere B, Laville M, et al. Adaptive
response to a low-protein diet in predialysis chronic
renal failure patients. Journal of the American
Society of Nephrology 2001; 12(6):1249-54. Sample
size less than 50 patients
421. Bersten AD, Holt AW. Vasoactive drugs and the
importance of renal perfusion pressure. New
Horizons 1995; 3(4):650-61. Not RCT or controlled
trial
422. Berthold H, del Pozo E. Antidiuretic effect of
Sandostatin (SMS 201-995) in healthy volunteers.
Acta Endocrinologica 1989; 120(6):708-14. Sample
size less than 50 patients
423. Bertolissi M, Antonucci F, De Monte A, et al. Effects
on renal function of a continuous infusion of
nifedipine during cardiopulmonary bypass. Journal of
B-66
424.
425.
426.
427.
428.
429.
430.
431.
432.
433.
434.
Cardiothoracic & Vascular Anesthesia 1996;
10(2):238-42. Sample size less than 50 patients
Bertolotto M, Quaia E, Gasparini C, et al. Resistive
index in patients with renal colic: differences after
medical treatment with indomethacin and ketorolac.
Radiologia Medica 2003; 106(4):370-5. Not relevant
to key questions
Bertoluci MC, Uebel D, Schmidt A, et al. Urinary
TGF-beta1 reduction related to a decrease of systolic
blood pressure in patients with type 2 diabetes and
clinical diabetic nephropathy. Diabetes Research &
Clinical Practice 2006; 72(3):258-64. Follow-up less
than 6 months
Bertram D, Summers R. Serum creatinine levels
during cardiac surgery: absence of effect by
aminoglycosides. Journal of Clinical Pharmacy &
Therapeutics 1993; 18(3):165-70. Not RCT or
controlled trial
Besarab A, Frinak S, Yee J. What is so bad about a
hemoglobin level of 12 to 13 g/dL for chronic kidney
disease patients anyway? Advances in Chronic
Kidney Disease 2009; 16(2):131-42. Not CKD
treatment
Besarab A, Horl WH, Silverberg D. Iron metabolism,
iron deficiency, thrombocytosis, and the cardiorenal
anemia syndrome. Oncologist 2009; 14 Suppl 1:2233. Not CKD treatment
Best PJM, Berger PB, Davis BR, et al. Impact of
mild or moderate chronic kidney disease on the
frequency of restenosis: results from the PRESTO
trial. Journal of the American College of Cardiology
2004; 44(9):1786-91. Sample size less than 50
patients
Best PJM, Steinhubl SR, Berger PB, et al. The
efficacy and safety of short- and long-term dual
antiplatelet therapy in patients with mild or moderate
chronic kidney disease: results from the Clopidogrel
for the Reduction of Events During Observation
(CREDO) trial. American Heart Journal 2008;
155(4):687-93. Not CKD treatment
Best R, Walker BR. Additional value of
measurement of urinary cortisone and unconjugated
cortisol metabolites in assessing the activity of 11
beta-hydroxysteroid dehydrogenase in vivo. Clinical
Endocrinology 1997; 47(2):231-6. Sample size less
than 50 patients
Bestle MH, Olsen NV, Christensen P, et al.
Cardiovascular, endocrine, and renal effects of
urodilatin in normal humans. American Journal of
Physiology 1999; 276(3 Pt 2):R684-95. Sample size
less than 50 patients
Beyer KH, Jr., Gelarden RT, Vary JE, et al. Novel
multivalent effects of pyrazinoylguanidine in patients
with azotemia. Clinical Pharmacology &
Therapeutics 1990; 47(5):629-38. Not CKD
treatment
Bhatnagar V, O'Connor DT, Brophy VH, et al. Gprotein-coupled receptor kinase 4 polymorphisms
and blood pressure response to metoprolol among
African Americans: sex-specificity and interactions.
American Journal of Hypertension 2009; 22(3):3328. Not CKD treatment
435. Bhatnagar V, O'Connor DT, Schork NJ, et al.
Angiotensin-converting enzyme gene polymorphism
predicts the time-course of blood pressure response
to angiotensin converting enzyme inhibition in the
AASK trial. Journal of Hypertension 2007;
25(10):2082-92. Not early CKD
436. Bhatnagar V, O'Connor DT, Schork NJ, et al.
Angiotensin-converting enzyme gene polymorphism
predicts the time-course of blood pressure response
to angiotensin converting enzyme inhibition in the
AASK trial. Journal of Hypertension 2007;
25(10):2082-92. Follow-up less than 6 months
437. Bhattacharya N. Placental umbilical cord blood
transfusion: a new method of treatment of patients
with diabetes and microalbuminuria in the
background of anemia. Clinical & Experimental
Obstetrics & Gynecology 2006; 33(3):164-8. Not
RCT or controlled trial
438. Bianchi S, Bigazzi R, Baldari G, et al. Long-term
effects of enalapril and nicardipine on urinary
albumin excretion in patients with chronic renal
insufficiency: a 1-year follow-up. American Journal
of Nephrology 1991; 11(2):131-7. Sample size less
than 50 patients
439. Bianchi S, Bigazzi R, Baldari G, et al.
Microalbuminuria in patients with essential
hypertension. Effects of an angiotensin converting
enzyme inhibitor and of a calcium channel blocker.
American Journal of Hypertension 1991; 4(4 Pt
1):291-6. Sample size less than 50 patients
440. Bianchi S, Bigazzi R, Baldari G, et al.
Microalbuminuria in patients with essential
hypertension: effects of several antihypertensive
drugs. American Journal of Medicine 1992;
93(5):525-8. Follow-up less than 6 months
441. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled,
prospective study of the effects of atorvastatin on
proteinuria and progression of kidney
disease.[Erratum appears in Am J Kidney Dis. 2004
Jan;43(1):193]. American Journal of Kidney
Diseases 2003; 41(3):565-70. Not relevant to key
questions
442. Bianchi S, Bigazzi R, Campese VM. Antagonists of
aldosterone and proteinuria in patients with CKD: an
uncontrolled pilot study. American Journal of Kidney
Diseases 2005; 46(1):45-51. Follow-up less than 6
months
443. Bianchi S, Bigazzi R, Campese VM. Long-term
effects of spironolactone on proteinuria and kidney
function in patients with chronic kidney disease.
Kidney International 2006; 70(12):2116-23. Not
relevant to key questions
444. Biancofiore G, Della Rocca G, Bindi L, et al. Use of
fenoldopam to control renal dysfunction early after
liver transplantation. Liver Transplantation 2004;
10(8):986-92. Sample size less than 50 patients
445. Bibbins-Domingo K, Lin F, Vittinghoff E, et al.
Renal insufficiency as an independent predictor of
mortality among women with heart failure. Journal of
the American College of Cardiology 2004;
44(8):1593-600. Not RCT or controlled trial
B-67
446. Bichet DG, Kortas C, Mettauer B, et al. Modulation
of plasma and platelet vasopressin by cardiac
function in patients with heart failure. Kidney
International 1986; 29(6):1188-96. Sample size less
than 50 patients
447. Bichu P, Nistala R, Khan A, et al. Angiotensin
receptor blockers for the reduction of proteinuria in
diabetic patients with overt nephropathy: results from
the AMADEO study. Vascular Health & Risk
Management 2009; 5(1):129-40. Not CKD treatment
448. Bidiville J, Waeber G, Porchet M, et al.
Hemodynamic, renal, and endocrine effects of 4-h
infusions of human atrial natriuretic peptide in
normal volunteers. Fundamental & Clinical
Pharmacology 1988; 2(5):413-29. Sample size less
than 50 patients
449. Bierkens AF, Maes RM, Hendrikx JM, et al. The use
of local anesthesia in second generation
extracorporeal shock wave lithotripsy: eutectic
mixture of local anesthetics. Journal of Urology
1991; 146(2):287-9. Not CKD treatment
450. Bigazzi R, Bianchi S, Baldari D, et al. Long-term
effects of a converting enzyme inhibitor and a
calcium channel blocker on urinary albumin
excretion in patients with essential hypertension.
American Journal of Hypertension 1993; 6(2):10813. Sample size less than 50 patients
451. Billstrom A, Hietala SO, Lithner F, et al.
Nephrotoxicity of contrast media in patients with
diabetes mellitus. A comparative urographic and
angiographic study with iohexol and metrizoate. Acta
Radiologica 1989; 30(5):509-15. Not CKD treatment
452. Bilo H, Kluitman E, van Ballegooie E, et al. Long
term use of captopril or nifedipine in normotensive
microalbuminuric patients with insulin-dependent
diabetes mellitus. Diabetes Research 1993;
23(3):115-22. Sample size less than 50 patients
453. Bilous R. Microvascular disease: what does the
UKPDS tell us about diabetic nephropathy? Diabetic
Medicine 2008; 25 Suppl 2:25-9. Not CKD treatment
454. Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of
candesartan on microalbuminuria and albumin
excretion rate in diabetes: three randomized trials.
Annals of Internal Medicine 2009; 151(1):11-20. Not
RCT or controlled trial
455. Binet I, Wallnofer A, Weber C, et al. Renal
hemodynamics and pharmacokinetics of bosentan
with and without cyclosporine A. Kidney
International 2000; 57(1):224-31. Not CKD treatment
456. Biollaz J, Bidiville J, Diezi J, et al. Site of the action
of a synthetic atrial natriuretic peptide evaluated in
humans. Kidney International 1987; 32(4):537-46.
Sample size less than 50 patients
457. Biollaz J, Nussberger J, Porchet M, et al. Four-hour
infusions of synthetic atrial natriuretic peptide in
normal volunteers. Hypertension 1986; 8(6 Pt
2):II96-105. Sample size less than 50 patients
458. Biondi-Zoccai GGL, Lotrionte M, Abbate A, et al.
Compliance with QUOROM and quality of reporting
of overlapping meta-analyses on the role of
acetylcysteine in the prevention of contrast
459.
460.
461.
462.
463.
464.
465.
466.
467.
468.
469.
470.
471.
B-68
associated nephropathy: case study. BMJ 2006;
332(7535):202-9. Sample size less than 50 patients
Bito H, Ikeda K. Renal and hepatic function in
surgical patients after low-flow sevoflurane or
isoflurane anesthesia. Anesthesia & Analgesia 1996;
82(1):173-6. Not CKD treatment
Bito H, Ikeuchi Y, Ikeda K. Effects of low-flow
sevoflurane anesthesia on renal function: comparison
with high-flow sevoflurane anesthesia and low-flow
isoflurane anesthesia. Anesthesiology 1997;
86(6):1231-7. Not CKD treatment
Bjorck S, Aurell M. Angiotensin-converting enzyme
inhibitors in diabetes: effect on the kidney and on
blood pressure. Journal of the American Society of
Nephrology 1990; 1(5 Suppl 2):S59-63. Not CKD
treatment
Bjorck S, Mulec H, Johnsen SA, et al. Renal
protective effect of enalapril in diabetic nephropathy.
BMJ 1992; 304(6823):339-43. Sample size less than
50 patients
Bjorck S, Mulec H, Johnsen SA, et al. Contrasting
effects of enalapril and metoprolol on proteinuria in
diabetic nephropathy.[Erratum appears in BMJ 1990
May 5;300(6733):1170]. BMJ 1990; 300(6729):9047. Follow-up less than 6 months
Blake GM, Moore AEB, Park-Holohan SJ, et al. A
direct in vivo measurement of 99mTc-methylene
diphosphonate protein binding. Nuclear Medicine
Communications 2003; 24(7):829-35. Not CKD
treatment
Blanchard J, Sawers SJ, Jonkman JH, et al.
Comparison of the urinary metabolite profile of
caffeine in young and elderly males. British Journal
of Clinical Pharmacology 1985; 19(2):225-32.
Sample size less than 50 patients
Blaser J, Simmen HP, Thurnheer U, et al.
Nephrotoxicity, high frequency ototoxicity, efficacy
and serum kinetics of once versus thrice daily dosing
of netilmicin in patients with serious infections.
Journal of Antimicrobial Chemotherapy 1995;
36(5):803-14. Not CKD treatment
Blau A, Herzog D, Shechter P, et al. Calcium
channel blocker nisoldipine in chronic renal failure.
Renal Failure 1990; 12(2):113-9. Not early CKD
Ble A, Fink JC, Woodman RC, et al. Renal function,
erythropoietin, and anemia of older persons: the
InCHIANTI study. Archives of Internal Medicine
2005; 165(19):2222-7. Not relevant to key questions
Bleie O, Semb AG, Grundt H, et al. Homocysteinelowering therapy does not affect inflammatory
markers of atherosclerosis in patients with stable
coronary artery disease. Journal of Internal Medicine
2007; 262(2):244-53. Not CKD treatment
Bliss DZ, Stein TP, Schleifer CR, et al.
Supplementation with gum arabic fiber increases
fecal nitrogen excretion and lowers serum urea
nitrogen concentration in chronic renal failure
patients consuming a low-protein diet. American
Journal of Clinical Nutrition 1996; 63(3):392-8.
Sample size less than 50 patients
Block GA, Persky MS, Ketteler M, et al. A
randomized double-blind pilot study of serum
472.
473.
474.
475.
476.
477.
478.
479.
480.
481.
482.
phosphorus normalization in chronic kidney disease:
a new paradigm for clinical outcomes studies in
nephrology. Hemodialysis International 2009;
13(3):360-2. Not RCT or controlled trial
Boccalandro F, Amhad M, Smalling RW, et al. Oral
acetylcysteine does not protect renal function from
moderate to high doses of intravenous radiographic
contrast. Catheterization & Cardiovascular
Interventions 2003; 58(3):336-41. Not CKD
treatment
Bochud M, Staessen JA, Maillard M, et al. Ethnic
differences in proximal and distal tubular sodium
reabsorption are heritable in black and white
populations. Journal of Hypertension 2009;
27(3):606-12. Not early CKD
Bocksch W, Fateh-Moghadam S, Mueller E, et al.
Percutaneous coronary intervention in patients with
end-stage renal disease. Kidney & Blood Pressure
Research 2005; 28(5-6):275-9. Not relevant to key
questions
Boddy AV, Griffin MJ, Sludden J, et al.
Pharmacological study of paclitaxel duration of
infusion combined with GFR-based carboplatin in
the treatment of ovarian cancer. Cancer
Chemotherapy & Pharmacology 2001; 48(1):15-21.
Not early CKD
Bodei L, Cremonesi M, Zoboli S, et al. Receptormediated radionuclide therapy with 90Y-DOTATOC
in association with amino acid infusion: a phase I
study. European Journal of Nuclear Medicine &
Molecular Imaging 2003; 30(2):207-16. Not CKD
treatment
Bodmer CW, Lake D, Savage MW, et al. Hand vein
responses to noradrenaline in normotensive patients
with insulin-dependent diabetes mellitus and
microalbuminuria: effects of alpha-adrenoceptor
blockade with doxazosin. Current Medical Research
& Opinion 1999; 15(3):169-76. Sample size less than
50 patients
Bodnar L, Wcislo G, Gasowska-Bodnar A, et al.
Renal protection with magnesium subcarbonate and
magnesium sulphate in patients with epithelial
ovarian cancer after cisplatin and paclitaxel
chemotherapy: a randomised phase II study.
European Journal of Cancer 2008; 44(17):2608-14.
Not CKD treatment
Body J-J, Diel I, Bell R. Profiling the safety and
tolerability of bisphosphonates. Seminars in
Oncology 2004; 31(5 Suppl 10):73-8. Follow-up less
than 6 months
Boelaert J, Lijnen P, Robbens E, et al. Impairment of
renal function due to sulphinpyrazone after coronary
artery bypass surgery: a prospective double-blind
study. Journal of Cardiovascular Pharmacology
1986; 8(2):386-91. Not CKD treatment
Boero R, Prodi E, Elia F, et al. How well are
hypertension and albuminuria treated in type II
diabetic patients? Journal of Human Hypertension
2003; 17(6):413-8. Not relevant to key questions
Boero R, Rollino C, Massara C, et al. The verapamil
versus amlodipine in nondiabetic nephropathies
treated with trandolapril (VVANNTT) study.
483.
484.
485.
486.
487.
488.
489.
490.
491.
492.
493.
494.
B-69
American Journal of Kidney Diseases 2003;
42(1):67-75. Not relevant to key questions
Boero R, Rollino C, Massara C, et al. Verapamil
versus amlodipine in proteinuric non-diabetic
nephropathies treated with trandolapril (VVANNTT
study): design of a prospective randomized
multicenter trial. Journal of Nephrology 2001;
14(1):15-8. Not CKD treatment
Boerrigter G, Costello-Boerrigter LC, Abraham WT,
et al. Cardiac resynchronization therapy improves
renal function in human heart failure with reduced
glomerular filtration rate. Journal of Cardiac Failure
2008; 14(7):539-46. Not CKD treatment
Boers M, Bensen WG, Ludwin D, et al. Cyclosporine
nephrotoxicity in rheumatoid arthritis: no effect of
short term misoprostol treatment. Journal of
Rheumatology 1992; 19(4):534-7. Not CKD
treatment
Boers M, Dijkmans BA, Breedveld FC, et al. No
effect of misoprostol on renal function of rheumatoid
patients treated with diclofenac. British Journal of
Rheumatology 1991; 30(1):56-9. Sample size less
than 50 patients
Boers M, Dijkmans BA, van Rijthoven AW, et al.
Reversible nephrotoxicity of cyclosporine in
rheumatoid arthritis. Journal of Rheumatology 1990;
17(1):38-42. Not CKD treatment
Boesgaard S, Aldershvile J, Poulsen HE, et al. Nacetylcysteine inhibits angiotensin converting
enzyme in vivo. Journal of Pharmacology &
Experimental Therapeutics 1993; 265(3):1239-44.
Not human studies
Boesken WH, Kult J. High-dose torasemide, given
once daily intravenously for one week, in patients
with advanced chronic renal failure. Clinical
Nephrology 1997; 48(1):22-8. Sample size less than
50 patients
Boey O, Van Hooland S, Woestenburg A, et al.
Methotrexate should not be used for patients with
end-stage kidney disease. Acta Clinica Belgica 2006;
61(4):166-9. Not CKD treatment
Boger RH, Schwedhelm E, Maas R, et al. ADMA
and oxidative stress may relate to the progression of
renal disease: rationale and design of the VIVALDI
study. Vascular Medicine 2005; 10 Suppl 1:S97-102.
Not RCT or controlled trial
Bog-Hansen E, Lindblad U, Ranstam J, et al.
Impaired glucose metabolism and obesity in Swedish
patients with borderline isolated systolic
hypertension: Skaraborg Hypertension and Diabetes
Project. Diabetes, Obesity & Metabolism 2001;
3(1):25-31. Not RCT or controlled trial
Bohe J, Ding H, Qing DP, et al. IGF-I binding
proteins, IGF-I binding protein mRNA and IGF-I
receptor mRNA in rats with acute renal failure given
IGF-I. Kidney International 1998; 54(4):1070-82.
Not human studies
Bohler J, Woitas R, Keller E, et al. Effect of
nifedipine and captopril on glomerular hyperfiltration
in normotensive man. American Journal of Kidney
Diseases 1992; 20(2):132-9. Sample size less than 50
patients
495. Bokemeyer C, Fels LM, Dunn T, et al. Silibinin
protects against cisplatin-induced nephrotoxicity
without compromising cisplatin or ifosfamide antitumour activity. British Journal of Cancer 1996;
74(12):2036-41. Not CKD treatment
496. Boldt J, Brenner T, Lehmann A, et al. Influence of
two different volume replacement regimens on renal
function in elderly patients undergoing cardiac
surgery: comparison of a new starch preparation with
gelatin. Intensive Care Medicine 2003; 29(5):763-9.
Sample size less than 50 patients
497. Boldt J, Brosch C, Rohm K, et al. Is albumin
administration in hypoalbuminemic elderly cardiac
surgery patients of benefit with regard to
inflammation, endothelial activation, and long-term
kidney function? Anesthesia & Analgesia 2008;
107(5):1496-503. Not RCT or controlled trial
498. Boldt J, Muller M, Heesen M, et al. The effects of
pentoxifylline on circulating adhesion molecules in
critically ill patients with acute renal failure treated
by continuous veno-venous hemofiltration. Intensive
Care Medicine 1996; 22(4):305-11. Not CKD
treatment
499. Boldt J, Suttner S, Brosch C, et al. Cardiopulmonary
bypass priming using a high dose of a balanced
hydroxyethyl starch versus an albumin-based
priming strategy. Anesthesia & Analgesia 2009;
109(6):1752-62. Not CKD treatment
500. Boldt J, Suttner S, Brosch C, et al. The influence of a
balanced volume replacement concept on
inflammation, endothelial activation, and kidney
integrity in elderly cardiac surgery patients. Intensive
Care Medicine 2009; 35(3):462-70. Not CKD
treatment
501. Bolognesi M, Sacerdoti D, Merkel C, et al. Effects of
chronic therapy with nadolol on portal
hemodynamics and on splanchnic impedance indices
using Doppler sonography: comparison between
acute and chronic effects. Journal of Hepatology
1997; 26(2):305-11. Sample size less than 50 patients
502. Bolton WK, Cattran DC, Williams ME, et al.
Randomized trial of an inhibitor of formation of
advanced glycation end products in diabetic
nephropathy. American Journal of Nephrology 2004;
24(1):32-40. Not CKD treatment
503. Bomback AS, Kshirsagar AV, Amamoo MA, et al.
Change in proteinuria after adding aldosterone
blockers to ACE inhibitors or angiotensin receptor
blockers in CKD: a systematic review. American
Journal of Kidney Diseases 2008; 51(2):199-211. Not
CKD treatment
504. Bommer J, Jaber BL. Ultrapure dialysate: facts and
myths. Seminars in Dialysis 2006; 19(2):115-9. Not
early CKD
505. Bond GG, Reeve GR, Ott MG, et al. Mortality
among a sample of chemical company employees.
American Journal of Industrial Medicine 1985;
7(2):109-21. Not early CKD
506. Boner G, Cooper ME, McCarroll K, et al. Adverse
effects of left ventricular hypertrophy in the
reduction of endpoints in NIDDM with the
angiotensin II antagonist losartan (RENAAL) study.
507.
508.
509.
510.
511.
512.
513.
514.
515.
516.
517.
518.
519.
520.
B-70
Diabetologia 2005; 48(10):1980-7. Not RCT or
controlled trial
Bonne JF, Fournier A, Massy Z, et al. Overview of
randomised trials of ACE inhibitors. Lancet 2006;
368(9542):1152-3. Follow-up less than 6 months
Bonner G, Lederle RM, Scholze J, et al. Therapeutic
safety of perindopril in the treatment of mild
hypertension with concomitant nephropathy.
Arzneimittel-Forschung 1993; 43(8):852-5. Followup less than 6 months
Bonney SL, Northington RS, Hedrich DA, et al.
Renal safety of two analgesics used over the counter:
ibuprofen and aspirin. Clinical Pharmacology &
Therapeutics 1986; 40(4):373-7. Not CKD treatment
Boogaard PJ, Houtsma AT, Journee HL, et al. Effects
of exposure to elemental mercury on the nervous
system and the kidneys of workers producing natural
gas. Archives of Environmental Health 1996;
51(2):108-15. Not CKD treatment
Boonen S, Sellmeyer DE, Lippuner K, et al. Renal
safety of annual zoledronic acid infusions in
osteoporotic postmenopausal women. Kidney
International 2008; 74(5):641-8. Not CKD treatment
Borcea V, Morcos M, Isermann B, et al. Influence of
ramipril on the course of plasma thrombomodulin in
patients with diabetes mellitus. Vasa 1999;
28(3):172-80. Not RCT or controlled trial
Borzecki AM, Wong AT, Hickey EC, et al.
Hypertension control: how well are we doing?
Archives of Internal Medicine 2003; 163(22):270511. Not CKD treatment
Boscheri A, Weinbrenner C, Botzek B, et al. Failure
of ascorbic acid to prevent contrast-media induced
nephropathy in patients with renal dysfunction.
Clinical Nephrology 2007; 68(5):279-86. Sample size
less than 50 patients
Bostom AG, Culleton BF. Hyperhomocysteinemia in
chronic renal disease. Journal of the American
Society of Nephrology 1999; 10(4):891-900. Not
RCT or controlled trial
Botker HE, Jensen HK, Krusell LR, et al. Renal
effects of xamoterol in patients with moderate heart
failure. Cardiovascular Drugs & Therapy 1993;
7(1):111-6. Sample size less than 50 patients
Bouhanick B. Equivalent effects of nicardipine and
captopril on urinary albumin excretion of type 2,
non-insulin-dependent diabetic subjects with mild to
moderate hypertension. Therapie 1996; 51(1):41-7.
Follow-up less than 6 months
Boulware LE, Troll MU, Jaar BG, et al.
Identification and referral of patients with
progressive CKD: a national study. American Journal
of Kidney Diseases 2006; 48(2):192-204. Not
relevant to key questions
Bouzas-Mosquera A, Vazquez-Rodriguez JM,
Peteiro J. Sodium bicarbonate vs sodium chloride in
preventing contrast medium-induced nephropathy.
JAMA 2009; 301(4):378-9; author reply 9-80. Not
CKD treatment
Bove T, Landoni G, Calabro MG, et al.
Renoprotective action of fenoldopam in high-risk
patients undergoing cardiac surgery: a prospective,
521.
522.
523.
524.
525.
526.
527.
528.
529.
530.
531.
532.
533.
double-blind, randomized clinical trial. Circulation
2005; 111(24):3230-5. Not CKD treatment
Bowden RG, Wilson RL, Deike E, et al. Fish oil
supplementation lowers C-reactive protein levels
independent of triglyceride reduction in patients with
end-stage renal disease. Nutrition in Clinical Practice
2009; 24(4):508-12. Sample size less than 50 patients
Boyden TF, Gurm HS. Does gadolinium-based
angiography protect against contrast-induced
nephropathy?: a systematic review of the literature.
Catheterization & Cardiovascular Interventions 2008;
71(5):687-93. Not CKD treatment
Boyle JA. Controlled trials of amphotericin B lipid
complex. Clinical Infectious Diseases 2000;
31(4):1117-8. Not relevant to key questions
Braden GL, von Oeyen PT, Germain MJ, et al.
Ritodrine- and terbutaline-induced hypokalemia in
preterm labor: mechanisms and consequences.
Kidney International 1997; 51(6):1867-75. Sample
size less than 50 patients
Bradley RT, Ebbs P, Young WY, et al. Specialty
practice in dietetics: empirical models and
results.[Erratum appears in J Am Diet Assoc 1993
Mar;93(3):271].[Erratum appears in J Am Diet Assoc
1993 Apr;93(4):402]. Journal of the American
Dietetic Association 1993; 93(2):203-10. Not RCT or
controlled trial
Brady CB, Gaziano JM, Cxypoliski RA, et al.
Homocysteine lowering and cognition in CKD: the
Veterans Affairs homocysteine study. American
Journal of Kidney Diseases 2009; 54(3):440-9. Not
early CKD
Braith RW, Mills RM, Wilcox CS, et al. High-dose
angiotensin-converting enzyme inhibition restores
body fluid homeostasis in heart-transplant recipients.
Journal of the American College of Cardiology 2003;
41(3):426-32. Sample size less than 50 patients
Bramlage P, Durand-Zaleski I, Desai N, et al. The
value of irbesartan in the management of
hypertension. Expert Opinion on Pharmacotherapy
2009; 10(11):1817-31. Not RCT or controlled trial
Brancati FL, Cusumano AM. Epidemiology and
prevention of diabetic nephropathy. Current Opinion
in Nephrology & Hypertension 1995; 4(3):223-9. Not
relevant to key questions
Branch RA. Prevention of amphotericin B-induced
renal impairment. A review on the use of sodium
supplementation. Archives of Internal Medicine
1988; 148(11):2389-94. Not CKD treatment
Brandao-Neto J, Silva CA, Shuhama T, et al. Renal
handling of zinc in insulin-dependent diabetes
mellitus patients. BioMetals 2001; 14(1):75-80. Not
CKD treatment
Brandli DW, Sarkissian E, Ng SC, et al. Individual
variability in concentrations of urinary sulindac
sulfide. Clinical Pharmacology & Therapeutics 1991;
50(6):650-5. Not CKD treatment
Brandstrom E, Grzegorczyk A, Jacobsson L, et al.
GFR measurement with iohexol and 51Cr-EDTA. A
comparison of the two favoured GFR markers in
Europe. Nephrology Dialysis Transplantation 1998;
13(5):1176-82. Sample size less than 50 patients
534. Brandt JR, Avner ED, Hickman RO, et al. Safety and
efficacy of erythropoietin in children with chronic
renal failure. Pediatric Nephrology 1999; 13(2):1437. Sample size less than 50 patients
535. Brar SS, Hiremath S, Dangas G, et al. Sodium
bicarbonate for the prevention of contrast inducedacute kidney injury: a systematic review and metaanalysis. Clinical Journal of The American Society of
Nephrology: CJASN 2009; 4(10):1584-92. Not RCT
or controlled trial
536. Brar SS, Shen AY-J, Jorgensen MB, et al. Sodium
bicarbonate vs sodium chloride for the prevention of
contrast medium-induced nephropathy in patients
undergoing coronary angiography: a randomized
trial. JAMA 2008; 300(9):1038-46. Not CKD
treatment
537. Brater DC, Anderson S, Baird B, et al. Effects of
ibuprofen, naproxen, and sulindac on prostaglandins
in men. Kidney International 1985; 27(1):66-73.
Sample size less than 50 patients
538. Brater DC, Leinfelder J, Anderson SA. Clinical
pharmacology of torasemide, a new loop diuretic.
Clinical Pharmacology & Therapeutics 1987;
42(2):187-92. Sample size less than 50 patients
539. Brater DC, Rudy DR, Voelker JR, et al.
Pharmacokinetics and pharmacodynamics of
torasemide in patients with chronic renal
insufficiency--preliminary evaluation.
Cardiovascular Drugs & Therapy 1993; 7 Suppl
1:69-73. Sample size less than 50 patients
540. Braunstein JB, Anderson GF, Gerstenblith G, et al.
Noncardiac comorbidity increases preventable
hospitalizations and mortality among Medicare
beneficiaries with chronic heart failure. Journal of the
American College of Cardiology 2003; 42(7):122633. Not CKD treatment
541. Brenner BM. Remission of renal disease: recounting
the challenge, acquiring the goal. Journal of Clinical
Investigation 2002; 110(12):1753-8. Not RCT or
controlled trial
542. Brenner BM, Cooper ME, de Zeeuw D, et al. The
losartan renal protection study--rationale, study
design and baseline characteristics of RENAAL
(Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan). Journal of the
Renin-Angiotensin-Aldosterone System 2000;
1(4):328-35. Not RCT or controlled trial
543. Brenner P, Meyer M, Reichenspurner H, et al.
Significance of prophylactic urodilatin (INN:
ularitide) infusion for the prevention of acute renal
failure in patients after heart transplantation.
European Journal of Medical Research 1995;
1(3):137-43. Sample size less than 50 patients
544. Brenner RM, Chertow GM. The rise and fall of atrial
natriuretic peptide for acute renal failure. Current
Opinion in Nephrology & Hypertension 1997;
6(5):474-6. Not RCT or controlled trial
545. Bretzel RG. Prevention and slowing down the
progression of the diabetic nephropathy through
antihypertensive therapy. Journal of Diabetes & its
Complications 1997; 11(2):112-22. Not RCT or
controlled trial
B-71
546. Breyer JA, Hunsicker LG, Bain RP, et al.
Angiotensin converting enzyme inhibition in diabetic
nephropathy. The Collaborative Study Group.
Kidney International - Supplement 1994; 45:S15660. Not CKD treatment
547. Brichard S, Ketelslegers JM, Lambert AE. Renal
function, glycemic control and perindopril in diabetic
patients. Clinical & Experimental Hypertension Part A, Theory & Practice 1989; 11 Suppl 2:545-54.
Sample size less than 50 patients
548. Brichard S, Ketelslegers JM, Lambert AE. Renal
function, glycaemic control and perindopril in
diabetic patients. Archives des Maladies du Coeur et
des Vaisseaux 1989; 82 Spec No 1:57-61. Sample
size less than 50 patients
549. Brichard SM, Santoni JP, Thomas JR, et al. Long
term reduction of microalbuminuria after 1 year of
angiotensin converting enzyme inhibition by
perindopril in hypertensive insulin-treated diabetic
patients. Diabete et Metabolisme 1990; 16(1):30-6.
Sample size less than 50 patients
550. Brienza N, Giglio MT, Marucci M, et al. Does
perioperative hemodynamic optimization protect
renal function in surgical patients? A meta-analytic
study. Critical Care Medicine 2009; 37(6):2079-90.
Not CKD treatment
551. Brienza N, Malcangi V, Dalfino L, et al. A
comparison between fenoldopam and low-dose
dopamine in early renal dysfunction of critically ill
patients. Critical Care Medicine 2006; 34(3):707-14.
Sample size less than 50 patients
552. Briganti EM, Branley P, Chadban SJ, et al. Smoking
is associated with renal impairment and proteinuria
in the normal population: the AusDiab kidney study.
Australian Diabetes, Obesity and Lifestyle Study.
American Journal of Kidney Diseases 2002;
40(4):704-12. Not CKD treatment
553. Briggs DE, French JA. Levetiracetam safety profiles
and tolerability in epilepsy patients. Expert Opinion
on Drug Safety 2004; 3(5):415-24. Not CKD
treatment
554. Briguori C, Airoldi F, D'Andrea D, et al. Renal
Insufficiency Following Contrast Media
Administration Trial (REMEDIAL): a randomized
comparison of 3 preventive strategies. Circulation
2007; 115(10):1211-7. Not CKD treatment
555. Briguori C, Colombo A, Airoldi F, et al. NAcetylcysteine versus fenoldopam mesylate to
prevent contrast agent-associated nephrotoxicity.
Journal of the American College of Cardiology 2004;
44(4):762-5. Not CKD treatment
556. Briguori C, Colombo A, Violante A, et al. Standard
vs double dose of N-acetylcysteine to prevent
contrast agent associated nephrotoxicity. European
Heart Journal 2004; 25(3):206-11. Not CKD
treatment
557. Briguori C, Manganelli F, Scarpato P, et al.
Acetylcysteine and contrast agent-associated
nephrotoxicity. Journal of the American College of
Cardiology 2002; 40(2):298-303. Not early CKD
558. Briguori C, Marenzi G. Contrast-induced
nephropathy: pharmacological prophylaxis. Kidney
559.
560.
561.
562.
563.
564.
565.
566.
567.
568.
569.
570.
571.
B-72
International - Supplement 2006; (100):S30-8. Not
relevant to key questions
Brinkmann A, Seeling W, Wolf CF, et al. Ibuprofen
does not impair renal function in patients undergoing
infrarenal aortic surgery with epidural anaesthesia.
Intensive Care Medicine 1998; 24(4):322-8. Sample
size less than 50 patients
Brocco E, Velussi M, Cernigoi AM, et al. Evidence
of a threshold value of glycated hemoglobin to
improve the course of renal function in type 2
diabetes with typical diabetic glomerulopathy.
Journal of Nephrology 2001; 14(6):461-71. Not RCT
or controlled trial
Brockenbrough AT, Dittrich MO, Page ST, et al.
Transdermal androgen therapy to augment EPO in
the treatment of anemia of chronic renal disease.
American Journal of Kidney Diseases 2006;
47(2):251-62. Not relevant to key questions
Bromage PR, el-Faqih S, Husain I, et al. Epinephrine
and fentanyl as adjuvants to 0.5% bupivacaine for
epidural analgesia. Regional Anesthesia 1989;
14(4):189-94. Not CKD treatment
Bronas UG. Exercise training and reduction of
cardiovascular disease risk factors in patients with
chronic kidney disease. Advances in Chronic Kidney
Disease 2009; 16(6):449-58. Not RCT or controlled
trial
Brooks D, Charleston J, Dowie D, et al. Predictors of
participant adherence and retention in the African
American Study of Kidney Disease and
Hypertension. Nephrology Nursing Journal: Journal
of the American Nephrology Nurses' Association
2008; 35(2):133-42. Not RCT or controlled trial
Brow TD, Kakkar VV, Das SK. The significance of
creatine kinase in cardiac patients with acute limb
ischaemia. Journal of Cardiovascular Surgery 1999;
40(5):637-44. Not CKD treatment
Brown J. Effects of interrupting the renin-angiotensin
system on sodium excretion in man. Journal of
Physiology 1988; 395:17-40. Sample size less than
50 patients
Brown J, O'Flynn MA. Acute effects of physiological
increments of alpha-atrial natriuretic peptide in man.
Kidney International 1989; 36(4):645-52. Sample
size less than 50 patients
Brown WV. Safety of statins. Current Opinion in
Lipidology 2008; 19(6):558-62. Not relevant to key
questions
Bruce R, Daniels A, Cundy T. Renal function
changes in diabetic nephropathy induced by
bezafibrate. Nephron 1996; 73(3):490. Sample size
less than 50 patients
Bruce R, Rutland M, Cundy T. Glomerular
hyperfiltration in young Polynesians with type 2
diabetes. Diabetes Research & Clinical Practice
1994; 25(3):155-60. Sample size less than 50 patients
Brugts JJ, Boersma E, Chonchol M, et al. The
cardioprotective effects of the angiotensin-converting
enzyme inhibitor perindopril in patients with stable
coronary artery disease are not modified by mild to
moderate renal insufficiency: insights from the
EUROPA trial. Journal of the American College of
572.
573.
574.
575.
576.
577.
578.
579.
580.
581.
582.
583.
584.
Cardiology 2007; 50(22):2148-55. Not RCT or
controlled trial
Brunton C, Varghese Z, Moorhead JF. Lipopheresis
in the nephrotic syndrome. Kidney International Supplement 1999; 71:S6-9. Sample size less than 50
patients
Bruun NE, Dige-Pedersen H, Skott P. Normal
responses of atrial natriuretic factor and renal tubular
function to sodium loading in hypertension-prone
humans. Blood Pressure 2000; 9(4):206-13. Not early
CKD
Bruun NE, Ibsen H, Nielsen F, et al. Lack of effect of
nifedipine on counterregulatory mechanisms in
essential hypertension. Hypertension 1986; 8(8):65561. Sample size less than 50 patients
Bruun NE, Ibsen H, Skott P, et al. Lithium clearance
and renal tubular sodium handling during acute and
long-term nifedipine treatment in essential
hypertension. Clinical Science 1988; 75(6):609-13.
Follow-up less than 6 months
Bruun NE, Skott P, Giese J. Renal and endocrine
effects of physiological variations of atrial natriuretic
factor in normal humans. American Journal of
Physiology 1991; 260(1 Pt 2):R217-24. Not CKD
treatment
Bryan AG, Bolsin SN, Vianna PT, et al. Modification
of the diuretic and natriuretic effects of a dopamine
infusion by fluid loading in preoperative cardiac
surgical patients. Journal of Cardiothoracic &
Vascular Anesthesia 1995; 9(2):158-63. Follow-up
less than 6 months
Bucchi F, Bodzenta A, de Gaetano G, et al. Effects of
1 gram oral or intravenous aspirin on urinary
excretion of thromboxane B2 and 6-keto-PGF1 alpha
in healthy subjects. Prostaglandins 1986; 32(5):691701. Sample size less than 50 patients
Buchet JP, Lauwerys R, Roels H, et al. Renal effects
of cadmium body burden of the general
population.[Erratum appears in Lancet 1991 Jun
22;337(8756):1554]. Lancet 1990; 336(8717):699702. Not CKD treatment
Buckalew VM, Jr. End-stage renal disease: can
dietary protein restriction prevent it? Southern
Medical Journal 1994; 87(10):1034-7. Not RCT or
controlled trial
Buclin T, Pechere-Bertschi A, Sechaud R, et al.
Sinistrin clearance for determination of glomerular
filtration rate: a reappraisal of various approaches
using a new analytical method. Journal of Clinical
Pharmacology 1997; 37(8):679-92. Sample size less
than 50 patients
Buclin T, Sechaud R, Bertschi AP, et al. Estimation
of glomerular filtration rate by sinistrin clearance
using various approaches. Renal Failure 1998;
20(2):267-76. Not CKD treatment
Budoff MJ, Kessler P, Gao YL, et al. The interscan
variation of CT coronary artery calcification score:
analysis of the Calcium Acetate Renagel Comparison
(CARE)-2 study. Academic Radiology 2008;
15(1):58-61. Not RCT or controlled trial
Bunke M, Sloan R, Brier M, et al. An improved
glomerular filtration rate in cardiac transplant
585.
586.
587.
588.
589.
590.
591.
592.
593.
594.
595.
596.
B-73
recipients with once-a-day cyclosporine dosing.
Transplantation 1995; 59(4):537-40. Sample size less
than 50 patients
Burgess E. Conservative treatment to slow
deterioration of renal function: evidence-based
recommendations. Kidney International Supplement 1999; 70:S17-25. Not RCT or controlled
trial
Burgess ED, Carides GW, Gerth WC, et al. Losartan
reduces the costs associated with nephropathy and
end-stage renal disease from type 2 diabetes:
Economic evaluation of the RENAAL study from a
Canadian perspective. Canadian Journal of
Cardiology 2004; 20(6):613-8. Not CKD treatment
Burgess W, Merten GJ, Rittase RA. Sodium
bicarbonate vs sodium chloride in preventing contrast
medium-induced nephropathy. JAMA 2009;
301(4):377; author reply 9-80. Not CKD treatment
Burnier M, Brunner HR. Angiotensin II receptor
antagonists in hypertension. Kidney International Supplement 1998; 68:S107-11. Not RCT or
controlled trial
Burnier M, Hagman M, Nussberger J, et al. Shortterm and sustained renal effects of angiotensin II
receptor blockade in healthy subjects. Hypertension
1995; 25(4 Pt 1):602-9. Sample size less than 50
patients
Burnier M, Mooser V, Wauters JP, et al. Bolus
injections of synthetic atrial natriuretic peptide in
patients with chronic renal failure or nephrotic
syndrome. Journal of Cardiovascular Pharmacology
1989; 13(5):682-90. Not CKD treatment
Burnier M, Rutschmann B, Nussberger J, et al. Saltdependent renal effects of an angiotensin II
antagonist in healthy subjects. Hypertension 1993;
22(3):339-47. Sample size less than 50 patients
Burns KEA, Chu MWA, Novick RJ, et al.
Perioperative N-acetylcysteine to prevent renal
dysfunction in high-risk patients undergoing cabg
surgery: a randomized controlled trial. JAMA 2005;
294(3):342-50. Not CKD treatment
Bursztyn M, Kobrin I, Fidel J, et al. Improved kidney
function with cilazapril in hypertensive type II
diabetics with chronic renal failure. Journal of
Cardiovascular Pharmacology 1991; 18(3):337-41.
Sample size less than 50 patients
Bursztyn M, Motro M, Grossman E, et al.
Accelerated coronary artery calcification in mildly
reduced renal function of high-risk hypertensives: a
3-year prospective observation. Journal of
Hypertension 2003; 21(10):1953-9. Not CKD
treatment
Burton CJ, Tomson CR. Can the use of low-dose
dopamine for treatment of acute renal failure be
justified? Postgraduate Medical Journal 1999;
75(883):269-74. Not CKD treatment
Bus SA, Maas M, de Lange A, et al. Elevated plantar
pressures in neuropathic diabetic patients with
claw/hammer toe deformity. Journal of
Biomechanics 2005; 38(9):1918-25. Not relevant to
key questions
597. Busch M, Franke S, Wolf G, et al. Serum levels of
the advanced glycation end products Nepsiloncarboxymethyllysine and pentosidine are not
influenced by treatment with the angiotensin receptor
II type 1 blocker irbesartan in patients with type 2
diabetic nephropathy and hypertension. Nephron
2008; 108(4):c291-7. Not early CKD
598. Buter H, Navis G, Dullaart RP, et al. Time course of
the antiproteinuric and renal haemodynamic
responses to losartan in microalbuminuric IDDM.
Nephrology Dialysis Transplantation 2001;
16(4):771-5. Sample size less than 50 patients
599. Butler J, Emerman C, Peacock WF, et al. The
efficacy and safety of B-type natriuretic peptide
(nesiritide) in patients with renal insufficiency and
acutely decompensated congestive heart failure.
Nephrology Dialysis Transplantation 2004;
19(2):391-9. Not relevant to key questions
600. Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical
trial data on atorvastatin for reducing cardiovascular
events: the clinical impact of atorvastatin. Current
Medical Research & Opinion 2008; 24(4):1217-29.
Not CKD treatment
601. Caglar K, Yilmaz MI, Saglam M, et al. Short-term
treatment with sevelamer increases serum fetuin-a
concentration and improves endothelial dysfunction
in chronic kidney disease stage 4 patients. Clinical
Journal of The American Society of Nephrology:
CJASN 2008; 3(1):61-8. Follow-up less than 6
months
602. Cahill CJ, Pain JA, Bailey ME. Bile salts, endotoxin
and renal function in obstructive jaundice. Surgery,
Gynecology & Obstetrics 1987; 165(6):519-22.
Sample size less than 50 patients
603. Caidahl K, Eden S, Bengtsson BA. Cardiovascular
and renal effects of growth hormone. Clinical
Endocrinology 1994; 40(3):393-400. Not CKD
treatment
604. Caillot D, Reny G, Solary E, et al. A controlled trial
of the tolerance of amphotericin B infused in
dextrose or in Intralipid in patients with
haematological malignancies. Journal of
Antimicrobial Chemotherapy 1994; 33(3):603-13.
Not CKD treatment
605. Caimmi P-P, Pagani L, Micalizzi E, et al.
Fenoldopam for renal protection in patients
undergoing cardiopulmonary bypass. Journal of
Cardiothoracic & Vascular Anesthesia 2003;
17(4):491-4. Not CKD treatment
606. Callahan MB, LeSage L, Johnstone S. A model for
patient participation in quality of life measurement to
improve rehabilitation outcomes. Nephrology News
& Issues 1999; 13(1):33-7. Not RCT or controlled
trial
607. Callis A, Magnan de Bornier B, Serrano JJ, et al.
Activity of citrulline malate on acid-base balance and
blood ammonia and amino acid levels. Study in the
animal and in man. Arzneimittel-Forschung 1991;
41(6):660-3. Not CKD treatment
608. Camacho P, Pitale S, Abraira C. Beneficial and
detrimental effects of intensive glycaemic control,
with emphasis on type 2 diabetes mellitus. Drugs &
609.
610.
611.
612.
613.
614.
615.
616.
617.
618.
619.
620.
B-74
Aging 2000; 17(6):463-76. Not relevant to key
questions
Camargo EG, Weinert LS, Lavinsky J, et al. The
effect of aspirin on the antiproteinuric properties of
enalapril in microalbuminuric type 2 diabetic
patients: a randomized, double-blind, placebocontrolled study. Diabetes Care 2007; 30(7):e66.
Sample size less than 50 patients
Camisasca P, Avanzini F, Alli C, et al. Overall
cardiovascular risk still ignored in general practice
care of hypertension. Journal of Cardiovascular Risk
2002; 9(3):147-52. Not relevant to key questions
Camp MJ, Wingard JR, Gilmore CE, et al. Efficacy
of low-dose dopamine in preventing amphotericin B
nephrotoxicity in bone marrow transplant patients
and leukemia patients. Antimicrobial Agents &
Chemotherapy 1998; 42(12):3103-6. Not CKD
treatment
Campbell DR, Flemming BK, Mason WF, et al. A
comparative study of the nephrotoxicity of iohexol,
iopamidol and ioxaglate in peripheral angiography.
Canadian Association of Radiologists Journal 1990;
41(3):133-7. Not CKD treatment
Campbell KL, Ash S, Bauer JD. The impact of
nutrition intervention on quality of life in pre-dialysis
chronic kidney disease patients. Clinical Nutrition
2008; 27(4):537-44. Not early CKD
Campbell KL, Ash S, Davies PSW, et al.
Randomized controlled trial of nutritional counseling
on body composition and dietary intake in severe
CKD. American Journal of Kidney Diseases 2008;
51(5):748-58. Not early CKD
Campbell MS, Rai J, Kozin E, et al. Effects of
sirolimus vs. calcineurin inhibitors on renal
dysfunction after orthotopic liver transplantation.
Clinical Transplantation 2007; 21(3):377-84. Sample
size less than 50 patients
Campbell RC, Sui X, Filippatos G, et al. Association
of chronic kidney disease with outcomes in chronic
heart failure: a propensity-matched study.
Nephrology Dialysis Transplantation 2009;
24(1):186-93. Not CKD treatment
Campbell RC, Sui X, Filippatos G, et al. Association
of chronic kidney disease with outcomes in chronic
heart failure: a propensity-matched study.
Nephrology Dialysis Transplantation 2009;
24(1):186-93. Not CKD treatment
Campbell WW, Joseph LJO, Ostlund RE, Jr., et al.
Resistive training and chromium picolinate: effects
on inositols and liver and kidney functions in older
adults. International Journal of Sport Nutrition &
Exercise Metabolism 2004; 14(4):430-42. Not RCT
or controlled trial
Campo C, Garcia-Vallejo O, Barrios V, et al. The
natriuretic effect of nifedipine gastrointestinal
therapeutic system remains despite the presence of
mild-to-moderate renal failure. Journal of
Hypertension 1997; 15(12 Pt 2):1803-8. Follow-up
less than 6 months
Cangiano JL, Figueroa J, Palmer R. Renal
hemodynamic effects of nabumetone, sulindac, and
placebo in patients with osteoarthritis. Clinical
621.
622.
623.
624.
625.
626.
627.
628.
629.
630.
631.
632.
Therapeutics 1999; 21(3):503-12. Not CKD
treatment
Cantaluppi V, Assenzio B, Pasero D, et al.
Polymyxin-B hemoperfusion inactivates circulating
proapoptotic factors. Intensive Care Medicine 2008;
34(9):1638-45. Not RCT or controlled trial
Cantarovich F, Rangoonwala B, Lorenz H, et al.
High-dose furosemide for established ARF: a
prospective, randomized, double-blind, placebocontrolled, multicenter trial. American Journal of
Kidney Diseases 2004; 44(3):402-9. Not CKD
treatment
Cantarovich M. Renal protective strategies in heart
transplant patients. Current Opinion in Cardiology
2007; 22(2):133-8. Not RCT or controlled trial
Cantarovich M, Besner JG, Fitchett DH, et al.
Efficacy and side-effects of cyclosporine dose
monitoring with levels 6 h after the morning dose in
heart transplant patients. Clinical Transplantation
1997; 11(5 Pt 1):399-405. Sample size less than 50
patients
Cantarovich M, Yoshida EM, Peltekian KM, et al.
Poor prediction of the glomerular filtration rate using
current formulas in de novo liver transplant patients.
Transplantation 2006; 82(3):433-6. Not CKD
treatment
Cantor TL. Lack of evidence for administering
vitamin D analogs to kidney failure patients to
improve survivability. Clinical Nephrology 2009;
72(2):97-104. Not early CKD
Capek M, Schnack C, Ludvik B, et al. Effects of
captopril treatment versus placebo on renal function
in type 2 diabetic patients with microalbuminuria: a
long-term study. Clinical Investigator 1994;
72(12):961-6. Sample size less than 50 patients
Capes SE, Gerstein HC, Negassa A, et al. Enalapril
prevents clinical proteinuria in diabetic patients with
low ejection fraction. Diabetes Care 2000; 23(3):37780. Not CKD treatment
Cappelli P, Di Liberato L, Stuard S, et al. N-3
polyunsaturated fatty acid supplementation in
chronic progressive renal disease. Journal of
Nephrology 1997; 10(3):157-62. Sample size less
than 50 patients
Cappuccio FP, Antonios TF, Markandu ND, et al.
Acute natriuretic effect of nifedipine on different
sodium intakes in essential hypertension: evidence
for distal tubular effect? Journal of Human
Hypertension 1994; 8(8):627-30. Not CKD treatment
Caravaca F, Cubero JJ, Jimenez F, et al. Effect of the
mode of calcitriol administration on PTH-ionized
calcium relationship in uraemic patients with
secondary hyperparathyroidism. Nephrology Dialysis
Transplantation 1995; 10(5):665-70. Sample size less
than 50 patients
Carbonell N, Blasco M, Sanjuan R, et al. Intravenous
N-acetylcysteine for preventing contrast-induced
nephropathy: a randomised trial. International
Journal of Cardiology 2007; 115(1):57-62. Not CKD
treatment
633. Carcoana OV, Hines RL. Is renal dose dopamine
protective or therapeutic? Yes. Critical Care Clinics
1996; 12(3):677-85. Not CKD treatment
634. Carcoana OV, Mathew JP, Davis E, et al. Mannitol
and dopamine in patients undergoing
cardiopulmonary bypass: a randomized clinical trial.
Anesthesia & Analgesia 2003; 97(5):1222-9. Not
CKD treatment
635. Cardiel MH. Abetimus sodium: a new therapy for
delaying the time to, and reducing the incidence of,
renal flare and/or major systemic lupus
erythematosus flares in patients with systemic lupus
erythematosus who have a history of renal disease.
Expert Opinion on Investigational Drugs 2005;
14(1):77-88. Not RCT or controlled trial
636. Carella MJ, Gossain VV, Jones J. The effects of a
low-dose regimen of fosinopril on elevated urinary
albumin excretion in normotensive type 1 diabetic
patients. Journal of Medicine 1999; 30(5-6):305-20.
Sample size less than 50 patients
637. Carides GW, Shahinfar S, Dasbach EJ, et al. The
impact of losartan on the lifetime incidence of endstage renal disease and costs in patients with type 2
diabetes and nephropathy. Pharmacoeconomics
2006; 24(6):549-58. Not relevant to key questions
638. Carlsen JE, Jensen HA, Rehling M, et al. Long term
haemodynamic effects of pinacidil and hydralazine in
arterial hypertension. Drugs 1988; 36 Suppl 7:55-63.
Sample size less than 50 patients
639. Carlson K, Hjorth M, Knudsen LM, et al. Toxicity in
standard melphalan-prednisone therapy among
myeloma patients with renal failure--a retrospective
analysis and recommendations for dose adjustment.
British Journal of Haematology 2005; 128(5):631-5.
Not RCT or controlled trial
640. Carr AA, Kowey PR, Devereux RB, et al.
Hospitalizations for new heart failure among subjects
with diabetes mellitus in the RENAAL and LIFE
studies. American Journal of Cardiology 2005;
96(11):1530-6. Not RCT or controlled trial
641. Carraro M, Malalan F, Antonione R, et al. Effects of
a dimeric vs a monomeric nonionic contrast medium
on renal function in patients with mild to moderate
renal insufficiency: a double-blind, randomized
clinical trial. European Radiology 1998; 8(1):144-7.
Not CKD treatment
642. Carraro M, Mancini W, Artero M, et al. Dose effect
of nitrendipine on urinary enzymes and
microproteins following non-ionic radiocontrast
administration. Nephrology Dialysis Transplantation
1996; 11(3):444-8. Not CKD treatment
643. Carraro M, Stacul F, Collari P, et al. Contrast media
nephrotoxicity: urinary protein and enzyme pattern in
patients with or without saline infusion during digital
subtracting angiography. Contributions to
Nephrology 1993; 101:251-4. Not CKD treatment
644. Carrier M, Leblanc M-H, Perrault LP, et al.
Basiliximab and rabbit anti-thymocyte globulin for
prophylaxis of acute rejection after heart
transplantation: a non-inferiority trial. Journal of
Heart & Lung Transplantation 2007; 26(3):258-63.
Not RCT or controlled trial
B-75
645. Carrier M, Pelletier GB, White M, et al. Effect of
pentoxifylline on renal toxicity of cyclosporine:
preliminary results. Transplantation Proceedings
1994; 26(5):2745-6. Sample size less than 50 patients
646. Carrier M, Pelletier GB, White M, et al. Effect of
pentoxifylline on renal toxicity of cyclosporine:
results of a clinical trial after heart transplantation.
Journal of Heart & Lung Transplantation 1996;
15(12):1179-83. Not CKD treatment
647. Carstens J, Greisen J, Jensen KT, et al. Renal effects
of a urodilatin infusion in patients with liver
cirrhosis, with and without ascites. Journal of the
American Society of Nephrology 1998; 9(8):148998. Not CKD treatment
648. Carstens J, Gronbaek H, Larsen HK, et al. Effects of
urodilatin on natriuresis in cirrhosis patients with
sodium retention. BMC Gastroenterology 2007; 7:1.
Follow-up less than 6 months
649. Carstens J, Jensen KT, Pedersen EB. Effect of
urodilatin infusion on renal haemodynamics, tubular
function and vasoactive hormones. Clinical Science
1997; 92(4):397-407. Sample size less than 50
patients
650. Carstens J, Jensen KT, Pedersen EB. Metabolism and
action of urodilatin infusion in healthy volunteers.
Clinical Pharmacology & Therapeutics 1998;
64(1):73-86. Follow-up less than 6 months
651. Carstens J, Pedersen EB. Renal effects of urodilatin
in healthy subjects are independent of blockade of
the cyclooxygenase and angiotensin II receptor.
Scandinavian Journal of Clinical & Laboratory
Investigation 2008; 68(1):2-10. Not RCT or
controlled trial
652. Carswell CI, Goa KL. Losartan in diabetic
nephropathy. Drugs 2003; 63(4):407-14; discussion
15-6. Not RCT or controlled trial
653. Carter JL, O'Riordan SE, Eaglestone GL, et al.
Chronic kidney disease prevalence in a UK
residential care home population. Nephrology
Dialysis Transplantation 2008; 23(4):1257-64. Not
RCT or controlled trial
654. Caruso D, D'Avino M, Acampora C, et al. Effects of
losartan and chlorthalidone on blood pressure and
renal vascular resistance index in non-diabetic
patients with essential hypertension and normal renal
function. Journal of Cardiovascular Pharmacology
2004; 44(5):520-4. Not RCT or controlled trial
655. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of
inhibitors of the renin-angiotensin system and other
antihypertensive drugs on renal outcomes: systematic
review and meta-analysis. Lancet 2005;
366(9502):2026-33. Not RCT or controlled trial
656. Castaneda C, Gordon PL, Parker RC, et al.
Resistance training to reduce the malnutritioninflammation complex syndrome of chronic kidney
disease. American Journal of Kidney Diseases 2004;
43(4):607-16. Not relevant to key questions
657. Castaneda C, Gordon PL, Uhlin KL, et al. Resistance
training to counteract the catabolism of a low-protein
diet in patients with chronic renal insufficiency. A
randomized, controlled trial. Annals of Internal
658.
659.
660.
661.
662.
663.
664.
665.
666.
667.
668.
669.
B-76
Medicine 2001; 135(11):965-76. Sample size less
than 50 patients
Castellani S, Scarti L, Chen JL, et al. The
antihypertensive and renal activities of potassium
canrenoate are associated with increased renal
prostaglandin excretion. Clinical Science 1989;
77(2):217-22. Sample size less than 50 patients
Castellani S, Scarti L, Masotti G, et al. Selective
stimulation of renal PGE2 by potassium canrenoate
in essential hypertension. Progress in Clinical &
Biological Research 1989; 301:297-301. Sample size
less than 50 patients
Castellano M, Beschi M, Agabiti-Rosei E, et al.
Renal and hemodynamic effects of atrial natriuretic
peptide infusion are not mediated by peripheral
dopaminergic mechanisms. American Journal of
Hypertension 1991; 4(4 Pt 1):385-8. Not CKD
treatment
Castellino P, Hunt W, DeFronzo RA. Regulation of
renal hemodynamics by plasma amino acid and
hormone concentrations. Kidney International Supplement 1987; 22:S15-20. Not relevant to key
questions
Castro-Gonzalez I, Miranda-Becerra D, MontanoBenavides S. Evaluation of phosphorus, protein, and
n-3 fatty-acid content in 15 marine fish species
identifies the species most beneficial to renal
patients. Journal of Renal Nutrition 2009; 19(6):4628. Not human studies
Catella-Lawson F, McAdam B, Morrison BW, et al.
Effects of specific inhibition of cyclooxygenase-2 on
sodium balance, hemodynamics, and vasoactive
eicosanoids. Journal of Pharmacology &
Experimental Therapeutics 1999; 289(2):735-41.
Sample size less than 50 patients
Cattaneo D, Remuzzi G. Lipid oxidative stress and
the anti-inflammatory properties of statins and ACE
inhibitors. Journal of Renal Nutrition 2005; 15(1):716. Sample size less than 50 patients
Cattran DC, Alexopoulos E, Heering P, et al.
Cyclosporin in idiopathic glomerular disease
associated with the nephrotic syndrome : workshop
recommendations. Kidney International 2007;
72(12):1429-47. Not RCT or controlled trial
Cavaliere G, Arrigo G, D'Amico G, et al. Tubular
nephrotoxicity after intravenous urography with ionic
high-osmolal and nonionic low-osmolal contrast
media in patients with chronic renal insufficiency.
Nephron 1987; 46(2):128-33. Sample size less than
50 patients
Cavatorta A, Buzio C, Pucci F, et al. Effects of
antihypertensive drugs on glomerular function in
normotensive and hypertensive subjects: hormonal
aspects. Journal of Hypertension - Supplement 1991;
9(6):S218-9. Sample size less than 50 patients
Cazzola M. Erythropoietin pathophysiology and
erythropoietin deficiency anemia. Hematology
Journal 2004; 5 Suppl 3:S100-3. Sample size less
than 50 patients
Celik JB, Gormus N, Topal A, et al. Effect of offpump and on-pump coronary artery bypass grafting
670.
671.
672.
673.
674.
675.
676.
677.
678.
679.
680.
681.
on renal function. Renal Failure 2005; 27(2):183-8.
Not RCT or controlled trial
Centonza L, Castoldi G, Busca G, et al. Behavioural
stress blunts the creatinine clearance increase
induced by a protein load in healthy subjects. Journal
of Nephrology 2001; 14(5):403-9. Not RCT or
controlled trial
Cetina L, Rivera L, Candelaria M, et al.
Chemoradiation with gemcitabine for cervical cancer
in patients with renal failure. Anti-Cancer Drugs
2004; 15(8):761-6. Not relevant to key questions
Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric
effects of combination therapy with enalapril and
losartan in patients with nephropathy due to type 2
diabetes. International Journal of Clinical Practice
2004; 58(5):432-5. Not CKD treatment
Ceyhan C, Akar H, Tekten T, et al.
Microalbuminuria is associated with reduced cardiac
cyclic variation of integrated backscatter signal in
severe hypertension. Echocardiography 2004;
21(6):495-501. Sample size less than 50 patients
Chalmers J, Joshi R, Kengne A-P, et al. Blood
pressure lowering with fixed combination
perindopril-indapamide: key findings from
ADVANCE. Journal of Hypertension - Supplement
2008; 26(2):S11-5. Not RCT or controlled trial
Chalmers N, Jackson RW. Comparison of iodixanol
and iohexol in renal impairment. British Journal of
Radiology 1999; 72(859):701-3. Not CKD treatment
Chan C, Maurer J, Cardella C, et al. A randomized
controlled trial of verapamil on cyclosporine
nephrotoxicity in heart and lung transplant recipients.
Transplantation 1997; 63(10):1435-40. Sample size
less than 50 patients
Chan JC, Cheung CK, Cheung MY, et al. Abnormal
albuminuria as a predictor of mortality and renal
impairment in Chinese patients with NIDDM.
Diabetes Care 1995; 18(7):1013-6. Not RCT or
controlled trial
Chan JC, Critchley JA, Tomlinson B, et al.
Antihypertensive and anti-albuminuric effects of
losartan potassium and felodipine in Chinese elderly
hypertensive patients with or without non-insulindependent diabetes mellitus. American Journal of
Nephrology 1997; 17(1):72-80. Sample size less than
50 patients
Chan JC, Ko GT, Leung DH, et al. Long-term effects
of angiotensin-converting enzyme inhibition and
metabolic control in hypertensive type 2 diabetic
patients. Kidney International 2000; 57(2):590-600.
Not relevant to key questions
Chan JCN, Scott R, Arjona Ferreira JC, et al. Safety
and efficacy of sitagliptin in patients with type 2
diabetes and chronic renal insufficiency. Diabetes,
Obesity & Metabolism 2008; 10(7):545-55. Not CKD
treatment
Chan JCN, Wat NMS, So W-Y, et al. Renin
angiotensin aldosterone system blockade and renal
disease in patients with type 2 diabetes. An Asian
perspective from the RENAAL Study. Diabetes Care
2004; 27(4):874-9. Not relevant to key questions
682. Chandra P, Binongo JNG, Ziegler TR, et al.
Cholecalciferol (vitamin D3) therapy and vitamin D
insufficiency in patients with chronic kidney disease:
a randomized controlled pilot study. Endocrine
Practice 2008; 14(1):10-7. Not CKD treatment
683. Chang GJ, Mahanty HD, Quan D, et al. Experience
with the use of sirolimus in liver transplantation--use
in patients for whom calcineurin inhibitors are
contraindicated. Liver Transplantation 2000;
6(6):734-40. Not early CKD
684. Chapman JR, Griffiths D, Harding NG, et al.
Reversibility of cyclosporin nephrotoxicity after
three months' treatment. Lancet 1985; 1(8421):12830. Follow-up less than 6 months
685. Charloux A, Chaouat A, Piquard F, et al. Renal
hyporesponsiveness to brain natriuretic peptide: both
generation and renal activity of cGMP are decreased
in patients with pulmonary hypertension. Peptides
2006; 27(11):2993-9. Not relevant to key questions
686. Chartapisak W, Opastiraku S, Willis NS, et al.
Prevention and treatment of renal disease in HenochSchonlein purpura: a systematic review. Archives of
Disease in Childhood 2009; 94(2):132-7. Not CKD
treatment
687. Charytan C, Coburn JW, Chonchol M, et al.
Cinacalcet hydrochloride is an effective treatment for
secondary hyperparathyroidism in patients with CKD
not receiving dialysis. American Journal of Kidney
Diseases 2005; 46(1):58-67. Follow-up less than 6
months
688. Charytan C, Qunibi W, Bailie GR, et al. Comparison
of intravenous iron sucrose to oral iron in the
treatment of anemic patients with chronic kidney
disease not on dialysis. Nephron 2005; 100(3):c5562. Not RCT or controlled trial
689. Charytan D, Forman JP, Cutlip DE. Risk of target
lesion revascularization after coronary stenting in
patients with and without chronic kidney disease.
Nephrology Dialysis Transplantation 2007;
22(9):2578-85. Sample size less than 50 patients
690. Charytan DM, Kuntz RE, Chhabra A, et al.
Relationship of chronic kidney disease to
cardiovascular death and myocardial infarction
following coronary stenting. Journal of Nephrology
2006; 19(6):764-70. Not early CKD
691. Chase HP, Garg SK, Harris S, et al. Angiotensinconverting enzyme inhibitor treatment for young
normotensive diabetic subjects: a two-year trial.
Annals of Ophthalmology 1993; 25(8):284-9. Sample
size less than 50 patients
692. Chattington PD, Anderson JV, Rees LH, et al. Atrial
natriuretic peptide in type 2 diabetes mellitus:
response to a physiological mixed meal and
relationship to renal function. Diabetic Medicine
1998; 15(5):375-9. Sample size less than 50 patients
693. Chaturvedi N. Modulation of the renin-angiotensin
system and retinopathy. Heart 2000; 84 Suppl 1:i2931:discussion i50. Not relevant to key questions
694. Chauveau P, Chadefaux B, Coude M, et al. Longterm folic acid (but not pyridoxine) supplementation
lowers elevated plasma homocysteine level in
chronic renal failure. Mineral & Electrolyte
B-77
695.
696.
697.
698.
699.
700.
701.
702.
703.
704.
705.
706.
707.
Metabolism 1996; 22(1-3):106-9. Sample size less
than 50 patients
Cheer SM, McClellan K. Manidipine: a review of its
use in hypertension. Drugs 2001; 61(12):1777-99.
Not RCT or controlled trial
Chellingsworth MC, Kendall MJ. Effects of
nifedipine, verapamil and diltiazem on renal
function. British Journal of Clinical Pharmacology
1988; 25(5):599-602. Sample size less than 50
patients
Chemla ES, Morsy M. Randomized clinical trial
comparing decellularized bovine ureter with
expanded polytetrafluoroethylene for vascular
access. British Journal of Surgery 2009; 96(1):34-9.
Not CKD treatment
Chen BH. COX-2 inhibitors and renal function in
elderly people. CMAJ Canadian Medical Association
Journal 2000; 163(5):604. Not relevant to key
questions
Chen BH. Combination treatment effective option for
hypertensive, diabetic patients with
microalbuminuria. CMAJ Canadian Medical
Association Journal 2001; 164(6):861. Not RCT or
controlled trial
Chen HC, Hsieh MT, Chang SS, et al. Long-term
reno-cardiovascular effects of orally administered
aconiti tuber in humans. American Journal of
Chinese Medicine 1990; 18(1-2):25-33. Not CKD
treatment
Chen HH, Redfield MM, Nordstrom LJ, et al.
Angiotensin II AT1 receptor antagonism prevents
detrimental renal actions of acute diuretic therapy in
human heart failure. American Journal of Physiology
- Renal Physiology 2003; 284(5):F1115-9. Sample
size less than 50 patients
Chen HH, Sundt TM, Cook DJ, et al. Low dose
nesiritide and the preservation of renal function in
patients with renal dysfunction undergoing
cardiopulmonary-bypass surgery: a double-blind
placebo-controlled pilot study. Circulation 2007;
116(11 Suppl):I134-8. Follow-up less than 6 months
Chen HH, Tarng DC, Lee KF, et al. Epoetin alfa and
darbepoetin alfa: effects on ventricular hypertrophy
in patients with chronic kidney disease. Journal of
Nephrology 2008; 21(4):543-9. Not CKD treatment
Chen HX. Expanding the clinical development of
bevacizumab. Oncologist 2004; 9 Suppl 1:27-35. Not
CKD treatment
Chen JLT, Lerner D, Ruthazer R, et al. Association
of physical activity with mortality in chronic kidney
disease. Journal of Nephrology 2008; 21(2):243-52.
Not early CKD
Chen SL, Zhang J, Yei F, et al. Clinical outcomes of
contrast-induced nephropathy in patients undergoing
percutaneous coronary intervention: a prospective,
multicenter, randomized study to analyze the effect
of hydration and acetylcysteine. International Journal
of Cardiology 2008; 126(3):407-13. Not CKD
treatment
Chen X, Zheng F, Chen P, et al. An open-label,
randomized, controlled, 4-week comparative clinical
trial of barnidipine hydrochloride, a calcium-channel
708.
709.
710.
711.
712.
713.
714.
715.
716.
717.
718.
B-78
blocker, and benazepril, an angiotensin-converting
enzyme inhibitor, in Chinese patients with renal
parenchymal hypertension. Journal of International
Medical Research 2006; 34(2):121-8. Not CKD
treatment
Cheng H-C, Kao A-W, Chuang C-H, et al. The
efficacy of high- and low-dose intravenous
omeprazole in preventing rebleeding for patients with
bleeding peptic ulcers and comorbid illnesses.
Digestive Diseases & Sciences 2005; 50(7):1194201. Not RCT or controlled trial
Cheng IK, Lam KS, Janus ED, et al. Treatment of
hyperlipidaemia in patients with non-insulindependent diabetes mellitus with progressive
nephropathy. Contributions to Nephrology 1997;
120:79-87. Not RCT or controlled trial
Cheng IK, Ma JT, Yeh GR, et al. Comparison of
captopril and enalapril in the treatment of
hypertension in patients with non-insulin dependent
diabetes mellitus and nephropathy. International
Urology & Nephrology 1990; 22(3):295-303. Sample
size less than 50 patients
Cheng JWM. Ambrisentan for the management of
pulmonary arterial hypertension. Clinical
Therapeutics 2008; 30(5):825-33. Not RCT or
controlled trial
Cheng S, Coyne D. Paricalcitol capsules for the
control of secondary hyperparathyroidism in chronic
kidney disease. Expert Opinion on Pharmacotherapy
2006; 7(5):617-21. Not relevant to key questions
Cheng Y-F, Strid S, Borga O, et al. Active renal
secretion of NXY-059, a novel neuroprotectant, is
mediated via an organic acid transporter. Journal of
Clinical Pharmacology 2007; 47(7):909-14. Sample
size less than 50 patients
Chen-Scarabelli C, Scarabelli TM. Chronic renal
insufficiency is an independent predictor of mortality
in implantable cardioverter-defibrillator recipients.
Pacing & Clinical Electrophysiology 2007;
30(3):371-6. Not RCT or controlled trial
Chernausek SD, Backeljauw PF, Frane J, et al. Longterm treatment with recombinant insulin-like growth
factor (IGF)-I in children with severe IGF-I
deficiency due to growth hormone insensitivity.
Journal of Clinical Endocrinology & Metabolism
2007; 92(3):902-10. Not human studies
Cherney DZI, Miller JA, Scholey JW, et al. The
effect of cyclooxygenase-2 inhibition on renal
hemodynamic function in humans with type 1
diabetes. Diabetes 2008; 57(3):688-95. Not RCT or
controlled trial
Chertow GM, Dillon M, Burke SK, et al. A
randomized trial of sevelamer hydrochloride
(RenaGel) with and without supplemental calcium.
Strategies for the control of hyperphosphatemia and
hyperparathyroidism in hemodialysis patients.
Clinical Nephrology 1999; 51(1):18-26. Not early
CKD
Cheung R, Lewanczuk RZ, Rodger NW, et al. The
effect of valsartan and captopril on lipid parameters
in patients with type II diabetes mellitus and
719.
720.
721.
722.
723.
724.
725.
726.
727.
728.
729.
730.
nephropathy. International Journal of Clinical
Practice 1999; 53(8):584-92. Not CKD treatment
Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin
provides increasing benefit with decreasing renal
function: a meta-analysis of randomized trials.
American Journal of Cardiology 2003; 92(8):919-23.
Not CKD treatment
Chew DP, Lincoff AM, Gurm H, et al. Bivalirudin
versus heparin and glycoprotein IIb/IIIa inhibition
among patients with renal impairment undergoing
percutaneous coronary intervention (a subanalysis of
the REPLACE-2 trial). American Journal of
Cardiology 2005; 95(5):581-5. Sample size less than
50 patients
Chi Y. Multiple testing procedures based on
weighted Kaplan-Meier statistics for right-censored
survival data. Statistics in Medicine 2005; 24(1):2335. Not CKD treatment
Chiarelli F, Di Marzio D, Santilli F, et al. Effects of
irbesartan on intracellular antioxidant enzyme
expression and activity in adolescents and young
adults with early diabetic angiopathy. Diabetes Care
2005; 28(7):1690-7. Follow-up less than 6 months
Chin HJ, Song YR, Lee JJ, et al. Moderately
decreased renal function negatively affects the
health-related quality of life among the elderly
Korean population: a population-based study.
Nephrology Dialysis Transplantation 2008;
23(9):2810-7. Not CKD treatment
Chiolero A, Maillard M, Nussberger J, et al.
Proximal sodium reabsorption: An independent
determinant of blood pressure response to salt.
Hypertension 2000; 36(4):631-7. Sample size less
than 50 patients
Chiurchiu C, Remuzzi G, Ruggenenti P.
Angiotensin-converting enzyme inhibition and renal
protection in nondiabetic patients: the data of the
meta-analyses. Journal of the American Society of
Nephrology 2005; 16 Suppl 1:S58-63. Not relevant
to key questions
Chmielewski M, Carrero JJ, Nordfors L, et al. Lipid
disorders in chronic kidney disease: reverse
epidemiology and therapeutic approach. Journal of
Nephrology 2008; 21(5):635-44. Not early CKD
Chmielewski M, Carrero JJ, Stenvinkel P, et al.
Metabolic abnormalities in chronic kidney disease
that contribute to cardiovascular disease, and
nutritional initiatives that may diminish the risk.
Current Opinion in Lipidology 2009; 20(1):3-9.
Follow-up less than 6 months
Cho H-Y, Blum RA, Sunderland T, et al.
Pharmacokinetic and pharmacodynamic modeling of
a copper-selective chelator (TETA) in healthy adults.
Journal of Clinical Pharmacology 2009; 49(8):91628. Not CKD treatment
Cho JE, Shim JK, Chang JH, et al. Effect of
nicardipine on renal function after robot-assisted
laparoscopic radical prostatectomy. Urology 2009;
73(5):1056-60. Not CKD treatment
Chodjania Y, Tharaux P-L, Ragueneau I, et al. Renal
and vascular effects of S21402, a dual inhibitor of
angiotensin-converting enzyme and neutral
731.
732.
733.
734.
735.
736.
737.
738.
739.
740.
741.
742.
B-79
endopeptidase, in healthy subjects with hypovolemia.
Clinical Pharmacology & Therapeutics 2002;
71(6):468-78. Sample size less than 50 patients
Choi KC, Lee J, Kim SW, et al. Cimetidine improves
the accuracy of creatinine clearance as an indicator
for glomerular filtration rate. Korean Journal of
Internal Medicine 1993; 8(1):28-33. Sample size less
than 50 patients
Choi KL, Elliott WJ. Antihypertensive,
antiproteinuric therapy and myocardial infarction and
stroke prevention. Current Hypertension Reports
2005; 7(5):367-73. Follow-up less than 6 months
Chonchol M, Goldenberg I, Moss AJ, et al. Risk
factors for sudden cardiac death in patients with
chronic renal insufficiency and left ventricular
dysfunction. American Journal of Nephrology 2007;
27(1):7-14. Follow-up less than 6 months
Christensen CK, Christiansen JS, Christensen T, et
al. The effect of six months continuous subcutaneous
insulin infusion on kidney function and size in
insulin-dependent diabetics. Diabetic Medicine 1986;
3(1):29-32. Sample size less than 50 patients
Christensen CK, Christiansen JS, Schmitz A, et al.
Effect of continuous subcutaneous insulin infusion
on kidney function and size in IDDM patients: a 2
year controlled study. Journal of Diabetic
Complications 1987; 1(3):91-5. Sample size less than
50 patients
Christensen CK, Krusell LR. Acute and long-term
effect of antihypertensive treatment on exercise
induced microalbuminuria in essential hypertension.
Journal of Clinical Hypertension 1987; 3(4):704-12.
Sample size less than 50 patients
Christensen CK, Mogensen CE. Acute and long-term
effect of antihypertensive treatment on exerciseinduced albuminuria in incipient diabetic
nephropathy. Scandinavian Journal of Clinical &
Laboratory Investigation 1986; 46(6):553-9. Sample
size less than 50 patients
Christensen PK, Akram K, Konig KB, et al.
Autoregulation of glomerular filtration rate in
patients with type 2 diabetes during isradipine
therapy. Diabetes Care 2003; 26(1):156-62. Sample
size less than 50 patients
Christensen PK, Hansen HP, Parving HH. Impaired
autoregulation of GFR in hypertensive non-insulin
dependent diabetic patients. Kidney International
1997; 52(5):1369-74. Sample size less than 50
patients
Christensen PK, Hommel EE, Clausen P, et al.
Impaired autoregulation of the glomerular filtration
rate in patients with nondiabetic nephropathies.
Kidney International 1999; 56(4):1517-23. Sample
size less than 50 patients
Christensen PK, Lund S, Parving HH. Autoregulated
glomerular filtration rate during candesartan
treatment in hypertensive type 2 diabetic patients.
Kidney International 2001; 60(4):1435-42. Sample
size less than 50 patients
Christensen PK, Lund S, Parving HH. The impact of
glycaemic control on autoregulation of glomerular
filtration rate in patients with non-insulin dependent
743.
744.
745.
746.
747.
748.
749.
750.
751.
752.
753.
754.
diabetes. Scandinavian Journal of Clinical &
Laboratory Investigation 2001; 61(1):43-50. Sample
size less than 50 patients
Christiansen H, Segura J, Ruilope LM. Renal
endpoints in hypertension trials. Clinical &
Experimental Hypertension 2004; 26(7-8):721-6. Not
relevant to key questions
Christiansen JS, Feldt-Rasmussen B, Parving HH.
Short-term inhibition of prostaglandin synthesis has
no effect on the elevated glomerular filtration rate of
early insulin-dependent diabetes. Diabetic Medicine
1985; 2(1):17-20. Sample size less than 50 patients
Chrysant SG. Angiotensin II receptor blockers in the
treatment of the cardiovascular disease continuum.
Clinical Therapeutics 2008; 30 Pt 2:2181-90. Not
CKD treatment
Chrysant SG, Chrysant GS. Pharmacological and
clinical profile of moexipril: a concise review.
Journal of Clinical Pharmacology 2004; 44(8):82736. Not CKD treatment
Chrysostomou A, Pedagogos E, MacGregor L, et al.
Double-blind, placebo-controlled study on the effect
of the aldosterone receptor antagonist spironolactone
in patients who have persistent proteinuria and are on
long-term angiotensin-converting enzyme inhibitor
therapy, with or without an angiotensin II receptor
blocker. Clinical Journal of The American Society of
Nephrology: CJASN 2006; 1(2):256-62. Not RCT or
controlled trial
Chu D, Lacouture ME, Fillos T, et al. Risk of handfoot skin reaction with sorafenib: a systematic review
and meta-analysis. Acta Oncologica 2008; 47(2):17686. Not CKD treatment
Chuang F-R, Chen T-C, Wang IK, et al. Comparison
of iodixanol and iohexol in patients undergoing
intravenous pyelography: a prospective controlled
study. Renal Failure 2009; 31(3):181-8. Not CKD
treatment
Chuang LM, Jou TS, Wu HP, et al. Effect of
treatment of borderline hypertension on
microalbuminuria in non-insulin-dependent diabetes
mellitus. Journal of the Formosan Medical
Association 1991; 90(6):531-5. Not relevant to key
questions
Chung F-M, Yang Y-H, Shieh T-Y, et al. Effect of
alcohol consumption on estimated glomerular
filtration rate and creatinine clearance rate.
Nephrology Dialysis Transplantation 2005;
20(8):1610-6. Follow-up less than 6 months
Cianciaruso B, Pota A, Bellizzi V, et al. Effect of a
low- versus moderate-protein diet on progression of
CKD: follow-up of a randomized controlled trial.
American Journal of Kidney Diseases 2009;
54(6):1052-61. Not early CKD
Cianciaruso B, Pota A, Bellizzi V, et al. Effect of a
low- versus moderate-protein diet on progression of
CKD: follow-up of a randomized controlled trial.
American Journal of Kidney Diseases 2009;
54(6):1052-61. Not early CKD
Cianciaruso B, Pota A, Pisani A, et al. Metabolic
effects of two low protein diets in chronic kidney
disease stage 4-5--a randomized controlled trial.
755.
756.
757.
758.
759.
760.
761.
762.
763.
764.
765.
766.
B-80
Nephrology Dialysis Transplantation 2008;
23(2):636-44. Not RCT or controlled trial
Cianciaruso B, Ravani P, Barrett BJ, et al. Italian
randomized trial of hemoglobin maintenance to
prevent or delay left ventricular hypertrophy in
chronic kidney disease. Journal of Nephrology 2008;
21(6):861-70. Follow-up less than 6 months
Cianciolo G, La Manna G, Coli L, et al. 5methyltetrahydrofolate administration is associated
with prolonged survival and reduced inflammation in
ESRD patients. American Journal of Nephrology
2008; 28(6):941-8. Not early CKD
Cianciolo G, La Manna G, Coli L, et al. 5methyltetrahydrofolate administration is associated
with prolonged survival and reduced inflammation in
ESRD patients. American Journal of Nephrology
2008; 28(6):941-8. Not RCT or controlled trial
Ciavarella A, Di Mizio G, Stefoni S, et al. Reduced
albuminuria after dietary protein restriction in
insulin-dependent diabetic patients with clinical
nephropathy. Diabetes Care 1987; 10(4):407-13.
Sample size less than 50 patients
Ciavarella A, Vannini P, Flammini M, et al. Effect of
long-term near-normoglycemia on the progression of
diabetic nephropathy. Diabete et Metabolisme 1985;
11(1):3-8. Sample size less than 50 patients
Ciavarella D. The use of protein A columns in the
treatment of cancer and allied diseases. International
Journal of Clinical & Laboratory Research 1992;
21(3):210-3. Not CKD treatment
Cicconetti A, Bartoli A, Ripari F, et al. COX-2
selective inhibitors: a literature review of analgesic
efficacy and safety in oral-maxillofacial surgery.
Oral Surgery Oral Medicine Oral Pathology Oral
Radiology & Endodontics 2004; 97(2):139-46. Not
CKD treatment
Cicek M, Koroglu A, Demirbilek S, et al.
Comparison of propofol-alfentanil and propofolremifentanil anaesthesia in percutaneous
nephrolithotripsy. European Journal of
Anaesthesiology 2005; 22(9):683-8. Not RCT or
controlled trial
Cicinnati VR, Yu Z, Klein CG, et al. Clinical trial:
switch to combined mycophenolate mofetil and
minimal dose calcineurin inhibitor in stable liver
transplant patients--assessment of renal and allograft
function, cardiovascular risk factors and immune
monitoring. Alimentary Pharmacology &
Therapeutics 2007; 26(9):1195-208. Sample size less
than 50 patients
Cifkova R, Nilsson PM. Statins and hypertension.
Journal of Hypertension 2009; 27(3):662-5. Sample
size less than 50 patients
Cinquegrani MP, Liang CS. Indomethacin attenuates
the hypotensive action of hydralazine. Clinical
Pharmacology & Therapeutics 1986; 39(5):564-70.
Sample size less than 50 patients
Claas GJ, Julg B, Goebel FD, et al. Metabolic and
anthropometric changes one year after switching
from didanosine/stavudine to tenofovir in HIVinfected patients. European Journal of Medical
767.
768.
769.
770.
771.
772.
773.
774.
775.
776.
777.
778.
Research 2007; 12(2):54-60. Sample size less than 50
patients
Claria J, Kent JD, Lopez-Parra M, et al. Effects of
celecoxib and naproxen on renal function in
nonazotemic patients with cirrhosis and ascites.
Hepatology 2005; 41(3):579-87. Not RCT or
controlled trial
Claris-Appiani A, Assael BM, Tirelli AS, et al. Lack
of glomerular hemodynamic stimulation after
infusion of branched-chain amino acids. Kidney
International 1988; 33(1):91-4. Sample size less than
50 patients
Clark WF, Forzley BR, Sontrop JM, et al. TTP/HUS:
observational studies generate hypotheses that lead to
randomized controlled trials. Kidney International Supplement 2009; (112):S50-1. Not early CKD
Clarke WL. The Diabetes Control and Complications
Trial: new challenges for the primary physician.
Virginia Medical Quarterly 1994; 121(3):185-8. Not
RCT or controlled trial
Clasen W, Khartabil T, Imm S, et al. Torasemide for
diuretic treatment of advanced chronic renal failure.
Arzneimittel-Forschung 1988; 38(1A):209-11.
Sample size less than 50 patients
Clavijo LC, Pinto TL, Kuchulakanti PK, et al. Effect
of a rapid intra-arterial infusion of dextrose 5% prior
to coronary angiography on frequency of contrastinduced nephropathy in high-risk patients. American
Journal of Cardiology 2006; 97(7):981-3. Not CKD
treatment
Cleland JG, Dargie HJ, Gillen G, et al. Captopril in
heart failure: a double-blind study of the effects on
renal function. Journal of Cardiovascular
Pharmacology 1986; 8(4):700-6. Sample size less
than 50 patients
Cleland JG, Dargie HJ, Pettigrew A, et al. The
effects of captopril on serum digoxin and urinary
urea and digoxin clearances in patients with
congestive heart failure. American Heart Journal
1986; 112(1):130-5. Sample size less than 50 patients
Cleland JG, Gillen G, Dargie HJ. The effects of
frusemide and angiotensin-converting enzyme
inhibitors and their combination on cardiac and renal
haemodynamics in heart failure. European Heart
Journal 1988; 9(2):132-41. Sample size less than 50
patients
Cleland JG, Shah D, Krikler S, et al. Effects of
lisinopril on cardiorespiratory, neuroendocrine, and
renal function in patients with asymptomatic left
ventricular dysfunction. British Heart Journal 1993;
69(6):512-5. Follow-up less than 6 months
Cleland JG, Shah D, Krikler S, et al. Angiotensinconverting enzyme inhibitors, left ventricular
dysfunction, and early heart failure. American
Journal of Cardiology 1992; 70(10):55C-61C.
Sample size less than 50 patients
Clement JG, Bailey DG, Madill HD, et al. The
acetylcholinesterase oxime reactivator HI-6 in man:
pharmacokinetics and tolerability in combination
with atropine. Biopharmaceutics & Drug Disposition
1995; 16(5):415-25. Sample size less than 50 patients
779. Cleveringa FGW, Welsing PMJ, van den Donk M, et
al. Cost-effectiveness of the diabetes care protocol, a
multifaceted computerized decision support diabetes
management intervention that reduces cardiovascular
risk. Diabetes Care 2010; 33(2):258-63. Not CKD
treatment
780. Clifton GG, Cook ME, Poland M, et al. The renal
function and blood pressure effects of dilevalol in the
normotensive and hypertensive elderly. Journal of
Clinical Pharmacology 1989; 29(7):603-8. Sample
size less than 50 patients
781. Clifton GG, Cook ME, Wallin JD. Effects of
dilevalol on renal function. American Journal of
Cardiology 1989; 63(19):75I-8I. Sample size less
than 50 patients
782. Clyne N, Jogestrand T. Effect of erythropoietin
treatment on physical exercise capacity and on renal
function in predialytic uremic patients. Nephron
1992; 60(4):390-6. Not early CKD
783. Coburn JW, Maung HM. Use of active vitamin D
sterols in patients with chronic kidney disease, stages
3 and 4. Kidney International - Supplement 2003;
(85):S49-53. Not early CKD
784. Coburn JW, Maung HM, Elangovan L, et al.
Doxercalciferol safely suppresses PTH levels in
patients with secondary hyperparathyroidism
associated with chronic kidney disease stages 3 and
4. American Journal of Kidney Diseases 2004;
43(5):877-90. Not CKD treatment
785. Coca A. Manidipine plus delapril in patients with
Type 2 diabetes and hypertension: reducing
cardiovascular risk and end-organ damage. Expert
Review of Cardiovascular Therapy 2007; 5(2):14759. Not RCT or controlled trial
786. Cochrane R, Regan L. Undetected gynaecological
disorders in women with renal disease. Human
Reproduction 1997; 12(4):667-70. Not early CKD
787. Coco M, Glicklich D, Faugere MC, et al. Prevention
of bone loss in renal transplant recipients: a
prospective, randomized trial of intravenous
pamidronate. Journal of the American Society of
Nephrology 2003; 14(10):2669-76. Not early CKD
788. Cody J, Daly C, Campbell M, et al. Recombinant
human erythropoietin for chronic renal failure
anaemia in pre-dialysis patients. Cochrane Database
of Systematic Reviews 2001; (4):CD003266. Not
CKD treatment
789. Cody J, Daly C, Campbell M, et al. Recombinant
human erythropoietin for chronic renal failure
anaemia in pre-dialysis patients. Cochrane Database
of Systematic Reviews 2005; (3):CD003266. Not
relevant to key questions
790. Coen G, Mazzaferro S, Bonucci E, et al. Bone GLA
protein in predialysis chronic renal failure. Effects of
1,25(OH)2D3 administration in a long-term followup. Kidney International 1985; 28(5):783-90. Sample
size less than 50 patients
791. Coggins CH, Breyer Lewis J, Caggiula AW, et al.
Differences between women and men with chronic
renal disease. Nephrology Dialysis Transplantation
1998; 13(6):1430-7. Not relevant to key questions
B-81
792. Coggins CH, Dwyer JT, Greene T, et al. Serum lipid
changes associated with modified protein diets:
results from the feasibility phase of the Modification
of Diet in Renal Disease Study. American Journal of
Kidney Diseases 1994; 23(4):514-23. Not RCT or
controlled trial
793. Cogliati AA, Vellutini R, Nardini A, et al.
Fenoldopam infusion for renal protection in high-risk
cardiac surgery patients: a randomized clinical study.
Journal of Cardiothoracic & Vascular Anesthesia
2007; 21(6):847-50. Not RCT or controlled trial
794. Cohen AF, Harkin N, Posner J. Cardiovascular
effects of a novel enkephalin analogue, 443C81, in
humans. Journal of Cardiovascular Pharmacology
1990; 16(3):455-60. Not CKD treatment
795. Cohen D, Dodds R, Viberti G. Effect of protein
restriction in insulin dependent diabetics at risk of
nephropathy. British Medical Journal Clinical
Research Ed. 1987; 294(6575):795-8. Sample size
less than 50 patients
796. Cohen E, Hafner R, Rotenberg Z, et al. Comparison
of ketorolac and diclofenac in the treatment of renal
colic. European Journal of Clinical Pharmacology
1998; 54(6):455-8. Not CKD treatment
797. Cohen EP, Irving AA, Drobyski WR, et al. Captopril
to mitigate chronic renal failure after hematopoietic
stem cell transplantation: a randomized controlled
trial. International Journal of Radiation Oncology,
Biology, Physics 2008; 70(5):1546-51. Not CKD
treatment
798. Cohen JA, Jeffers BW, Stabler S, et al. Increasing
homocysteine levels and diabetic autonomic
neuropathy. Autonomic Neuroscience-Basic &
Clinical 2001; 87(2-3):268-73. Not early CKD
799. Cohen SD, Norris L, Acquaviva K, et al. Screening,
diagnosis, and treatment of depression in patients
with end-stage renal disease. Clinical Journal of The
American Society of Nephrology: CJASN 2007;
2(6):1332-42. Not relevant to key questions
800. Cole RS, Palfrey EL, Smith SE, et al. Indomethacin
as prophylaxis against ureteral colic following
extracorporeal shock wave lithotripsy. Journal of
Urology 1989; 141(1):9-12. Not CKD treatment
801. Collins AC, Vincent J, Newall RG, et al. An aid to
the early detection and management of diabetic
nephropathy: assessment of a new point of care
microalbuminuria system in the diabetic clinic.
Diabetic Medicine 2001; 18(11):928-32. Not CKD
treatment
802. Colson P, Capdevilla X, Barlet H, et al. Effects of
halothane and isoflurane on transient renal
dysfunction associated with infrarenal aortic crossclamping. Journal of Cardiothoracic & Vascular
Anesthesia 1992; 6(3):295-8. Not CKD treatment
803. Colson P, Capdevilla X, Cuchet D, et al. Does choice
of the anesthetic influence renal function during
infrarenal aortic surgery? Anesthesia & Analgesia
1992; 74(4):481-5. Not CKD treatment
804. Colson P, Ribstein J, Mimran A, et al. Effect of
angiotensin converting enzyme inhibition on blood
pressure and renal function during open heart
805.
806.
807.
808.
809.
810.
811.
812.
813.
814.
815.
816.
817.
B-82
surgery. Anesthesiology 1990; 72(1):23-7. Not CKD
treatment
Colson P, Ribstein J, Seguin JR, et al. Mechanisms
of renal hemodynamic impairment during infrarenal
aortic cross-clamping. Anesthesia & Analgesia 1992;
75(1):18-23. Not CKD treatment
Compton A. A practical cost analysis of bivalirudin.
Pharmacotherapy 2002; 22(6 Pt 2):119S-27S. Not
early CKD
Conant EF, Fox KR, Miller WT. Pulmonary edema
as a complication of interleukin-2 therapy. AJR
1989; American Journal of Roentgenology.
152(4):749-52. Sample size less than 50 patients
Conen D, Buerkle G, Perruchoud AP, et al.
Hypertension is an independent risk factor for
contrast nephropathy after percutaneous coronary
intervention. International Journal of Cardiology
2006; 110(2):237-41. Sample size less than 50
patients
Conen D, Glynn RJ, Buring JE, et al. Association of
renin-angiotensin and endothelial nitric oxide
synthase gene polymorphisms with blood pressure
progression and incident hypertension: prospective
cohort study. Journal of Hypertension 2008;
26(9):1780-6. Not RCT or controlled trial
Conil JM, Georges B, Fourcade O, et al. Intermittent
administration of ceftazidime to burns patients:
influence of glomerular filtration. International
Journal of Clinical Pharmacology & Therapeutics
2007; 45(3):133-42. Not RCT or controlled trial
Connell JM, Whitworth JA, Davies DL, et al. Effects
of ACTH and cortisol administration on blood
pressure, electrolyte metabolism, atrial natriuretic
peptide and renal function in normal man. Journal of
Hypertension 1987; 5(4):425-33. Sample size less
than 50 patients
Constantiner M, Sehgal AR, Humbert L, et al. A
dipstick protein and specific gravity algorithm
accurately predicts pathological proteinuria.
American Journal of Kidney Diseases 2005;
45(5):833-41. Not relevant to key questions
Conte G, Dal Canton A, Imperatore P, et al. Acute
increase in plasma osmolality as a cause of
hyperkalemia in patients with renal failure. Kidney
International 1990; 38(2):301-7. Sample size less
than 50 patients
Contreras F, de la Parte MA, Cabrera J, et al. Role of
angiotensin II AT1 receptor blockers in the treatment
of arterial hypertension. American Journal of
Therapeutics 2003; 10(6):401-8. Not CKD treatment
Contreras G, Greene T, Agodoa LY, et al. Blood
pressure control, drug therapy, and kidney disease.
Hypertension 2005; 46(1):44-50. Not early CKD
Contreras I, Reiser KM, Martinez N, et al. Effects of
aspirin or basic amino acids on collagen cross-links
and complications in NIDDM. Diabetes Care 1997;
20(5):832-5. Follow-up less than 6 months
Conway SP, Pond MN, Watson A, et al. Intravenous
colistin sulphomethate in acute respiratory
exacerbations in adult patients with cystic fibrosis.
Thorax 1997; 52(11):987-93. Not CKD treatment
818. Conzen PF, Kharasch ED, Czerner SFA, et al. Lowflow sevoflurane compared with low-flow isoflurane
anesthesia in patients with stable renal insufficiency.
Anesthesiology 2002; 97(3):578-84. Not CKD
treatment
819. Conzen PF, Nuscheler M, Melotte A, et al. Renal
function and serum fluoride concentrations in
patients with stable renal insufficiency after
anesthesia with sevoflurane or enflurane. Anesthesia
& Analgesia 1995; 81(3):569-75. Sample size less
than 50 patients
820. Cook DJ, Crowther MA. Thromboprophylaxis in the
intensive care unit: focus on medical-surgical
patients. Critical Care Medicine 2010; 38(2
Suppl):S76-82. Not RCT or controlled trial
821. Cook ME, Wallin JD, Clifton GG, et al. Renal
function effects of dilevalol, a nonselective betaadrenergic blocking drug with beta-2 agonist activity.
Clinical Pharmacology & Therapeutics 1988;
43(4):393-9. Not relevant to key questions
822. Cook ME, Wallin JD, Thakur VD, et al. Comparative
effects of nabumetone, sulindac, and ibuprofen on
renal function. Journal of Rheumatology 1997;
24(6):1137-44. Sample size less than 50 patients
823. Cook RJ, Neerhut R, Thomas DG. Does combined
epidural lignocaine and fentanyl provide better
anaesthesia for ESWL than lignocaine alone?
Anaesthesia & Intensive Care 1991; 19(3):357-64.
Not CKD treatment
824. Cooper ME. Renal protection and angiotensin
converting enzyme inhibition in microalbuminuric
type I and type II diabetic patients. Journal of
Hypertension - Supplement 1996; 14(6):S11-4. Not
RCT or controlled trial
825. Copley JB, Rosario R. Hypertension: a review and
rationale of treatment. Disease-A-Month 2005;
51(10-11):548-614. Follow-up less than 6 months
826. Cordell WH, Larson TA, Lingeman JE, et al.
Indomethacin suppositories versus intravenously
titrated morphine for the treatment of ureteral colic.
Annals of Emergency Medicine 1994; 23(2):262-9.
Not CKD treatment
827. Cordell WH, Wright SW, Wolfson AB, et al.
Comparison of intravenous ketorolac, meperidine,
and both (balanced analgesia) for renal colic. Annals
of Emergency Medicine 1996; 28(2):151-8. Not CKD
treatment
828. Cordonnier DJ, Pinel N, Barro C, et al. Expansion of
cortical interstitium is limited by converting enzyme
inhibition in type 2 diabetic patients with
glomerulosclerosis. The Diabiopsies Group. Journal
of the American Society of Nephrology 1999;
10(6):1253-63. Sample size less than 50 patients
829. Coresh J, Astor BC, McQuillan G, et al. Calibration
and random variation of the serum creatinine assay as
critical elements of using equations to estimate
glomerular filtration rate. American Journal of
Kidney Diseases 2002; 39(5):920-9. Not RCT or
controlled trial
830. Coresh J, Toto RD, Kirk KA, et al. Creatinine
clearance as a measure of GFR in screenees for the
African-American Study of Kidney Disease and
831.
832.
833.
834.
835.
836.
837.
838.
839.
840.
841.
B-83
Hypertension pilot study. American Journal of
Kidney Diseases 1998; 32(1):32-42. Not CKD
treatment
Cornish SM, Candow DG, Jantz NT, et al.
Conjugated linoleic acid combined with creatine
monohydrate and whey protein supplementation
during strength training. International Journal of
Sport Nutrition & Exercise Metabolism 2009;
19(1):79-96. Not CKD treatment
Cortes-Sanabria L, Cabrera-Pivaral CE, CuetoManzano AM, et al. Improving care of patients with
diabetes and CKD: a pilot study for a clusterrandomized trial. American Journal of Kidney
Diseases 2008; 51(5):777-88. Not CKD treatment
Cosenzi A, Carraro M, Sacerdote A, et al. Nifedipine
reduces postexercise proteinuria in young volunteers.
Renal Physiology & Biochemistry 1995; 18(6):30610. Sample size less than 50 patients
Cosgrove SE, Vigliani GA, Fowler VG, Jr., et al.
Initial low-dose gentamicin for Staphylococcus
aureus bacteremia and endocarditis is nephrotoxic.
Clinical Infectious Diseases 2009; 48(6):713-21. Not
RCT or controlled trial
Cosman F, Nieves J, Herbert J, et al. High-dose
glucocorticoids in multiple sclerosis patients exert
direct effects on the kidney and skeleton. Journal of
Bone & Mineral Research 1994; 9(7):1097-105. Not
CKD treatment
Costa P, Ottino GM, Matani A, et al. Low-dose
dopamine during cardiopulmonary bypass in patients
with renal dysfunction. Journal of Cardiothoracic
Anesthesia 1990; 4(4):469-73. Sample size less than
50 patients
Costa S, Nucci M. Can we decrease amphotericin
nephrotoxicity? Current Opinion in Critical Care
2001; 7(6):379-83. Not early CKD
Costello-Boerrigter LC, Smith WB, Boerrigter G, et
al. Vasopressin-2-receptor antagonism augments
water excretion without changes in renal
hemodynamics or sodium and potassium excretion in
human heart failure. American Journal of Physiology
- Renal Physiology 2006; 290(2):F273-8. Sample size
less than 50 patients
Cotter G, Dittrich HC, Weatherley BD, et al. The
PROTECT pilot study: a randomized, placebocontrolled, dose-finding study of the adenosine A1
receptor antagonist rolofylline in patients with acute
heart failure and renal impairment. Journal of
Cardiac Failure 2008; 14(8):631-40. Not CKD
treatment
Cotter G, Metra M, Weatherley BD, et al. Physiciandetermined worsening heart failure: a novel
definition for early worsening heart failure in patients
hospitalized for acute heart failure--association with
signs and symptoms, hospitalization duration, and
60-day outcomes. Cardiology 2010; 115(1):29-36.
Not CKD treatment
Cotter G, Weissgarten J, Metzkor E, et al. Increased
toxicity of high-dose furosemide versus low-dose
dopamine in the treatment of refractory congestive
heart failure. Clinical Pharmacology & Therapeutics
1997; 62(2):187-93. Sample size less than 50 patients
842. Courtney AE, Maxwell AP. Critiques of clinical
guidelines in nephrology: anaemia. Nephron 2008;
110(2):c115-25. Not CKD treatment
843. Couverchel L, Maugars Y, Prost A. Outcomes of
thirty-four rheumatoid arthritis patients with renal
amyloidosis, including twelve given alkylating
agents. Revue du Rhumatisme 1995; 62(2):79-85.
Not RCT or controlled trial
844. Cox JP, O'Boyle CA, Mee F, et al. The
antihypertensive efficacy of verapamil in the elderly
evaluated by ambulatory blood pressure
measurement. Journal of Human Hypertension 1988;
2(1):41-7. Sample size less than 50 patients
845. Coyle LC, Rodriguez A, Jeschke RE, et al.
Acetylcysteine In Diabetes (AID): a randomized
study of acetylcysteine for the prevention of contrast
nephropathy in diabetics. American Heart Journal
2006; 151(5):1032.e9-12. Sample size less than 50
patients
846. Coyne D, Acharya M, Qiu P, et al. Paricalcitol
capsule for the treatment of secondary
hyperparathyroidism in stages 3 and 4 CKD.
American Journal of Kidney Diseases 2006;
47(2):263-76. Not relevant to key questions
847. Coyne DW. From anemia trials to clinical practice:
understanding the risks and benefits when setting
goals for therapy. Seminars in Dialysis 2008;
21(3):212-6. Not relevant to key questions
848. Coyne DW. Managing anemia in for-profit dialysis
chains: when ethics and business conflict. Seminars
in Dialysis 2009; 22(1):18-21. Not CKD treatment
849. Coyne T, Olson M, Bradham K, et al. Dietary
satisfaction correlated with adherence in the
Modification of Diet in Renal Disease Study. Journal
of the American Dietetic Association 1995;
95(11):1301-6. Not CKD treatment
850. Craig JC. Can ACE inhibitor therapy prevent endstage renal failure? Medical Journal of Australia
2001; 175(5):276. Not RCT or controlled trial
851. Craig JC, Barratt A, Cumming R, et al. Feasibility
study of the early detection and treatment of renal
disease by mass screening. Internal Medicine Journal
2002; 32(1-2):6-14. Not RCT or controlled trial
852. Craig JC, Irwig LM, Knight JF, et al. Does treatment
of vesicoureteric reflux in childhood prevent endstage renal disease attributable to reflux
nephropathy? Pediatrics 2000; 105(6):1236-41. Not
adult population
853. Craig KJ, Donovan K, Munnery M, et al.
Identification and management of diabetic
nephropathy in the diabetes clinic. Diabetes Care
2003; 26(6):1806-11. Not CKD treatment
854. Cravedi P, Remuzzi G. Treating the kidney to cure
the heart. Kidney International - Supplement 2008;
(111):S2-3. Not CKD treatment
855. Cravedi P, Ruggenenti P, Remuzzi G. Intensified
inhibition of renin-angiotensin system: a way to
improve renal protection? Current Hypertension
Reports 2007; 9(5):430-6. Not CKD treatment
856. Cribier B, Couilliet D, Meyer P, et al. The severity of
histopathological changes of leukocytoclastic
vasculitis is not predictive of extracutaneous
857.
858.
859.
860.
861.
862.
863.
864.
865.
866.
867.
868.
869.
B-84
involvement. American Journal of Dermatopathology
1999; 21(6):532-6. Not CKD treatment
Crofford LJ. Specific cyclooxygenase-2 inhibitors:
what have we learned since they came into
widespread clinical use? Current Opinion in
Rheumatology 2002; 14(3):225-30. Not RCT or
controlled trial
Crofford OB. Diabetes control and complications.
Annual Review of Medicine 1995; 46:267-79. Not
CKD treatment
Cronberg S, Nordstrom L. Simplified monitoring of
aminoglycoside treatment. Scandinavian Journal of
Infectious Diseases Supplement 1990; 74:274-9. Not
CKD treatment
Crook ED, Preddie DC. Therapeutic controversies in
hypertension management: angiotensin converting
enzyme (ACE) inhibitors or angiotensin receptor
blockers for diabetic nephropathy? A case for ACE
inhibitors. Ethnicity & Disease 2002; 12(4):S3-4952. Not RCT or controlled trial
Crook ED, Velusamy L. Are low target blood
pressure goals justified in persons with diabetes
mellitus? Current Hypertension Reports 2003;
5(3):231-8. Not RCT or controlled trial
Croom KF, Curran MP, Goa KL, et al. Irbesartan: a
review of its use in hypertension and in the
management of diabetic nephropathy. Drugs 2004;
64(9):999-1028. Not RCT or controlled trial
Crowe AV, Howse M, Vinjamuri S, et al. The
antiproteinuric effect of losartan is systemic blood
pressure dependent. Nephrology Dialysis
Transplantation 2003; 18(10):2160-4. Sample size
less than 50 patients
Crowther MA, Cook DJ. Preventing venous
thromboembolism in critically ill patients. Seminars
in Thrombosis & Hemostasis 2008; 34(5):469-74.
Not CKD treatment
Cruickshank JK, Anderson NM, Wadsworth J, et al.
Treating hypertension in black compared with white
non-insulin dependent diabetics: a double blind trial
of verapamil and metoprolol. BMJ 1988;
297(6657):1155-9. Follow-up less than 6 months
Cruickshanks KJ, Ritter LL, Klein R, et al. The
association of microalbuminuria with diabetic
retinopathy. The Wisconsin Epidemiologic Study of
Diabetic Retinopathy. Ophthalmology 1993;
100(6):862-7. Not RCT or controlled trial
Cserti C, Haspel R, Stowell C, et al. Light-chain
removal by plasmapheresis in myeloma-associated
renal failure. Transfusion 2007; 47(3):511-4. Not
RCT or controlled trial
Cuculich PS, Sanchez JM, Kerzner R, et al. Poor
prognosis for patients with chronic kidney disease
despite ICD therapy for the primary prevention of
sudden death. Pacing & Clinical Electrophysiology
2007; 30(2):207-13. Sample size less than 50 patients
Cummings DM, Amadio P, Jr., Nettler S, et al.
Office-based evaluation of renal function in elderly
patients receiving nonsteroidal anti-inflammatory
drugs. Journal of the American Board of Family
Practice 1988; 1(2):77-80. Follow-up less than 6
months
870. Cummings MH, Watts GF, Tavakolian A, et al.
Prevalence of microalbuminuria, lipoprotein (a) and
coronary artery disease in the lipid clinic. Journal of
Clinical Pathology 1996; 49(1):19-23. Not RCT or
controlled trial
871. Cunningham J, Danese M, Olson K, et al. Effects of
the calcimimetic cinacalcet HCl on cardiovascular
disease, fracture, and health-related quality of life in
secondary hyperparathyroidism. Kidney International
2005; 68(4):1793-800. Sample size less than 50
patients
872. Cuocolo A, Volpe M, Mele AF, et al. Effects of atrial
natriuretic peptide on glomerular filtration rate in
essential hypertension: a radionuclide study.
European Journal of Nuclear Medicine 1991;
18(1):32-7. Sample size less than 50 patients
873. Curry C, Kelly AM. Intravenous tenoxicam for the
treatment of renal colic. New Zealand Medical
Journal 1995; 108(1001):229-30. Not CKD treatment
874. Curtis JJ, Laskow DA, Jones PA, et al. Captoprilinduced fall in glomerular filtration rate in
cyclosporine-treated hypertensive patients. Journal of
the American Society of Nephrology 1993;
3(9):1570-4. Follow-up less than 6 months
875. Curtis JR. Interventions in chronic renal failure. BMJ
1990; 301(6753):622-4. Not RCT or controlled trial
876. Curtis JR. Randomised controlled trial of
hydroquinine in muscle cramps. Lancet 1997;
349(9061):1325; author reply 6. Not RCT or
controlled trial
877. Curtiss FR. Antihypertensive drug effects on renal
function and myocardial infarction and implications
of the ALLHAT study results. Journal of Managed
Care Pharmacy 2003; 9(1):93-4. Not CKD treatment
878. Curtiss FR, Fairman KA. No TREATment with
darbepoetin dosed to hemoglobin 13 grams per
deciliter in type 2 diabetes with pre-dialysis chronic
kidney disease--safety warnings for erythropoiesisstimulating agents. Journal of Managed Care
Pharmacy 2009; 15(9):759-65. Not RCT or
controlled trial
879. Cushner HM, Copley JB, Lindberg JS, et al. Calcium
citrate, a nonaluminum-containing phosphate-binding
agent for treatment of CRF.[Erratum appears in
Kidney Int 1988 May;33(5):1047]. Kidney
International 1988; 33(1):95-9. Follow-up less than 6
months
880. Cusson JR, du Souich P, Le Morvan P, et al. Effect
of ketoprofen on blood pressure, endocrine and renal
responses to chronic dosing with captopril in patients
with essential hypertension. Blood Pressure 1992;
1(3):162-7. Sample size less than 50 patients
881. Czapla K, Rodger RS, Halls DJ, et al. Ranitidine
reduces aluminium toxicity in patients with renal
failure. Nephrology Dialysis Transplantation 1992;
7(12):1246-8. Not CKD treatment
882. Czupryniak L, Pawlowski M, Saryusz-Wolska M, et
al. Circadian blood pressure variation and
antihypertensive medication adjustment in
normoalbuminuric type 2 diabetes patients. Kidney
& Blood Pressure Research 2007; 30(3):182-6.
Sample size less than 50 patients
883. Dahl-Jorgensen K, Bjoro T, Kierulf P, et al. Longterm glycemic control and kidney function in insulindependent diabetes mellitus. Kidney International
1992; 41(4):920-3. Sample size less than 50 patients
884. Dailey GE, Boden GH, Creech RH, et al. Effects of
pulsatile intravenous insulin therapy on the
progression of diabetic nephropathy. Metabolism:
Clinical & Experimental 2000; 49(11):1491-5.
Sample size less than 50 patients
885. Dal Canton A, Fuiano G, Conte G, et al. Mechanism
of increased plasma urea after diuretic therapy in
uraemic patients. Clinical Science 1985; 68(3):25561. Follow-up less than 6 months
886. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of
lercanidipine compared with ramipril on albumin
excretion rate in hypertensive Type 2 diabetic
patients with microalbuminuria: DIAL study
(diabete, ipertensione, albuminuria, lercanidipina).
Diabetes, Nutrition & Metabolism - Clinical &
Experimental 2004; 17(5):259-66. Follow-up less
than 6 months
887. Damasceno A, Santos A, Pestana M, et al. Acute
hypotensive, natriuretic, and hormonal effects of
nifedipine in salt-sensitive and salt-resistant black
normotensive and hypertensive subjects. Journal of
Cardiovascular Pharmacology 1999; 34(3):346-53.
Sample size less than 50 patients
888. D'Ambra MN, Akins CW, Blackstone EH, et al.
Aprotinin in primary valve replacement and
reconstruction: a multicenter, double-blind, placebocontrolled trial. Journal of Thoracic &
Cardiovascular Surgery 1996; 112(4):1081-9. Not
CKD treatment
889. D'Amico G, Gentile MG. Pharmacological and
dietary treatment of lipid abnormalities in nephrotic
patients. Kidney International - Supplement 1991;
31:S65-9. Not RCT or controlled trial
890. D'Amico G, Gentile MG. Effect of dietary
manipulation on the lipid abnormalities and urinary
protein loss in nephrotic patients. Mineral &
Electrolyte Metabolism 1992; 18(2-5):203-6. Sample
size less than 50 patients
891. Damman K, Navis G, Voors AA, et al. Worsening
renal function and prognosis in heart failure:
systematic review and meta-analysis. Journal of
Cardiac Failure 2007; 13(8):599-608. Sample size
less than 50 patients
892. Dana R, Kachhwaha VS. Comparison of oral and
intravenous hydration and diuretic, choice for
protecting cisplatin induced nephrotoxicity. Indian
Journal of Cancer 1996; 33(4):168-70. Not CKD
treatment
893. Darko W, Medicis JJ, Smith A, et al. Mississippi
mud no more: cost-effectiveness of pharmacokinetic
dosage adjustment of vancomycin to prevent
nephrotoxicity. Pharmacotherapy 2003; 23(5):64350. Not CKD treatment
894. Darling JR, Murray JM, McBride DR, et al. Serum
glutathione S-transferase concentrations and
creatinine clearance after sevoflurane anaesthesia.
Anaesthesia 1997; 52(2):121-6. Not CKD treatment
B-85
895. Darragh AS. The effects of isoxicam and piroxicam
on renal function in healthy subjects. British Journal
of Clinical Practice 1985; 39(4):144-7. Not early
CKD
896. Dasgupta A, Steinhubl SR, Bhatt DL, et al. Clinical
outcomes of patients with diabetic nephropathy
randomized to clopidogrel plus aspirin versus aspirin
alone (a post hoc analysis of the clopidogrel for high
atherothrombotic risk and ischemic stabilization,
management, and avoidance [CHARISMA] trial).
American Journal of Cardiology 2009;
103(10):1359-63. Not CKD treatment
897. Daumit GL, Hermann JA, Coresh J, et al. Use of
cardiovascular procedures among black persons and
white persons: a 7-year nationwide study in patients
with renal disease. Annals of Internal Medicine 1999;
130(3):173-82. Not RCT or controlled trial
898. Daumit GL, Hermann JA, Powe NR. Relation of
gender and health insurance to cardiovascular
procedure use in persons with progression of chronic
renal disease. Medical Care 2000; 38(4):354-65. Not
early CKD
899. Daumit GL, Powe NR. Factors influencing access to
cardiovascular procedures in patients with chronic
kidney disease: race, sex, and insurance. Seminars in
Nephrology 2001; 21(4):367-76. Not RCT or
controlled trial
900. Davidson IJ. Renal impact of fluid management with
colloids: a comparative review. European Journal of
Anaesthesiology 2006; 23(9):721-38. Follow-up less
than 6 months
901. Davidson MB, Karlan VJ, Hair TL. Effect of a
pharmacist-managed diabetes care program in a free
medical clinic. American Journal of Medical Quality
2000; 15(4):137-42. Sample size less than 50 patients
902. Davidson MB, Wong A, Hamrahian AH, et al. Effect
of spironolactone therapy on albuminuria in patients
with type 2 diabetes treated with angiotensinconverting enzyme inhibitors. Endocrine Practice
2008; 14(8):985-92. Not RCT or controlled trial
903. Davis KL, Nappi JM. The cardiovascular effects of
eplerenone, a selective aldosterone-receptor
antagonist. Clinical Therapeutics 2003; 25(11):264768. Not relevant to key questions
904. Davis ME, Pemberton CJ, Yandle TG, et al.
Urocortin 2 infusion in healthy humans:
hemodynamic, neurohormonal, and renal responses.
Journal of the American College of Cardiology 2007;
49(4):461-71. Not relevant to key questions
905. Davis ME, Pemberton CJ, Yandle TG, et al.
Urocortin 2 infusion in human heart failure.
European Heart Journal 2007; 28(21):2589-97. Not
early CKD
906. de Boer IH, Kestenbaum B. Vitamin D in chronic
kidney disease: is the jury in? Kidney International
2008; 74(8):985-7. Not CKD treatment
907. de Brito-Ashurst I, Varagunam M, Raftery MJ, et al.
Bicarbonate supplementation slows progression of
CKD and improves nutritional status. Journal of the
American Society of Nephrology 2009; 20(9):207584. Not CKD treatment
908. De Caprio L, De Rosa ML, Di Palma A, et al.
Regression of left ventricular hypertrophy and
improvement of renal hemodynamics in hypertensive
patients treated with quinapril. Cardiovascular Drugs
& Therapy 1994; 8(5):735-40. Follow-up less than 6
months
909. De Cesaris R, Ranieri G, Andriani A, et al. Effects of
benazepril and nicardipine on microalbuminuria in
normotensive and hypertensive patients with
diabetes. Clinical Pharmacology & Therapeutics
1996; 60(4):472-8. Not relevant to key questions
910. De Cesaris R, Ranieri G, Filitti V, et al. Effects of
atenolol and enalapril on kidney function in
hypertensive diabetic patients. Journal of
Cardiovascular Pharmacology 1993; 22(2):208-14.
Sample size less than 50 patients
911. De Cosmo S, Earle K, Morocutti A, et al. Glucoseinduced changes in renal haemodynamics in
proteinuric type 1 (insulin-dependent) diabetic
patients: inhibition by acetylsalicilic acid infusion.
Diabetologia 1993; 36(7):622-7. Sample size less
than 50 patients
912. De Cosmo S, Motterlini N, Prudente S, et al. Impact
of the PPAR-gamma2 Pro12Ala polymorphism and
ACE inhibitor therapy on new-onset
microalbuminuria in type 2 diabetes: evidence from
BENEDICT. Diabetes 2009; 58(12):2920-9. Not
CKD treatment
913. de Denus S, Tardif J-C, White M, et al. Temporal
variations in hematocrit values in patients with left
ventricular dysfunction: Relationship with causespecific mortality and morbidity and optimal
monitoring--further insights from SOLVD. Canadian
Journal of Cardiology 2008; 24(1):45-8. Not CKD
treatment
914. De Feo ML, La Villa G, Lazzeri C, et al. Urinary
endothelin-1 excretion is enhanced by low-dose
infusion of brain natriuretic peptide in normal
humans. Hypertension 1997; 29(1 Pt 1):70-4. Sample
size less than 50 patients
915. de Gaetano G, Bucchi F, Gambino MC, et al. Does
oral aspirin spare the kidney? Lancet 1986;
1(8483):736. Not RCT or controlled trial
916. de Galan BE, Perkovic V, Ninomiya T, et al.
Lowering blood pressure reduces renal events in type
2 diabetes. Journal of the American Society of
Nephrology 2009; 20(4):883-92. Follow-up less than
6 months
917. de Graeff PA, Kingma JH, Viersma JW, et al. Acute
and chronic effects of ramipril and captopril in
congestive heart failure. International Journal of
Cardiology 1989; 23(1):59-67. Sample size less than
50 patients
918. De Jager J, Kooy A, Lehert P, et al. Effects of shortterm treatment with metformin on markers of
endothelial function and inflammatory activity in
type 2 diabetes mellitus: a randomized, placebocontrolled trial. Journal of Internal Medicine 2005;
257(1):100-9. Follow-up less than 6 months
919. De Jong PE, Navis G, de Zeeuw D. Renoprotective
therapy: titration against urinary protein excretion.
B-86
920.
921.
922.
923.
924.
925.
926.
927.
928.
929.
930.
931.
Lancet 1999; 354(9176):352-3. Not RCT or
controlled trial
de la Rosette JJMCH, Tsakiris P, Ferrandino MN, et
al. Beyond prone position in percutaneous
nephrolithotomy: a comprehensive review. European
Urology 2008; 54(6):1262-9. Not RCT or controlled
trial
de La Sierra A, Ruilope LM. Treatment of
hypertension in diabetes mellitus. Current
Hypertension Reports 2000; 2(3):335-42. Not RCT or
controlled trial
de Lasson L, Hansen HE, Juhl B, et al. A
randomised, clinical study of the effect of low-dose
dopamine on central and renal haemodynamics in
infrarenal aortic surgery.[Erratum appears in Eur J
Vasc Endovasc Surg 1997 Oct;14(4):323]. European
Journal of Vascular & Endovascular Surgery 1995;
10(1):82-90. Sample size less than 50 patients
de Lasson L, Hansen HE, Juhl B, et al. Effect of
felodipine on renal function and vasoactive hormones
in infrarenal aortic surgery. British Journal of
Anaesthesia 1997; 79(6):719-25. Sample size less
than 50 patients
de Leeuw PW. Renal function in the elderly: results
from the European Working Party on High Blood
Pressure in the Elderly trial. American Journal of
Medicine 1991; 90(3A):45S-9S. Not CKD treatment
de Leeuw PW, Ruilope LM, Palmer CR, et al.
Clinical significance of renal function in
hypertensive patients at high risk: results from the
INSIGHT trial. Archives of Internal Medicine 2004;
164(22):2459-64. Not RCT or controlled trial
De Leeuw PW, Thijs L, Birkenhager WH, et al.
Prognostic significance of renal function in elderly
patients with isolated systolic hypertension: results
from the Syst-Eur trial. Journal of the American
Society of Nephrology 2002; 13(9):2213-22. Not
CKD treatment
de Mello VDF, Zelmanovitz T, Azevedo MJ, et al.
Long-term effect of a chicken-based diet versus
enalapril on albuminuria in type 2 diabetic patients
with microalbuminuria. Journal of Renal Nutrition
2008; 18(5):440-7. Not CKD treatment
de Mello VDF, Zelmanovitz T, Perassolo MS, et al.
Withdrawal of red meat from the usual diet reduces
albuminuria and improves serum fatty acid profile in
type 2 diabetes patients with macroalbuminuria.
American Journal of Clinical Nutrition 2006;
83(5):1032-8. Not RCT or controlled trial
De Nicola L, Bellizzi V, Minutolo R, et al.
Randomized, double-blind, placebo-controlled study
of arginine supplementation in chronic renal failure.
Kidney International 1999; 56(2):674-84. Sample
size less than 50 patients
De Nicola L, Libetta C, Memoli B, et al. Acute renal
and immunological effects of low-dose cyclosporin
in humans. Nephrology Dialysis Transplantation
1995; 10(9):1739-44. Not CKD treatment
de Pablos-Velasco PL, Pazos Toral F, Esmatjes JE, et
al. Losartan titration versus diuretic combination in
type 2 diabetic patients. Journal of Hypertension
2002; 20(4):715-9. Follow-up less than 6 months
932. De Rosa ML, Cardace P, Rossi M, et al. Comparative
effects of chronic ACE inhibition and AT1 receptor
blocked losartan on cardiac hypertrophy and renal
function in hypertensive patients. Journal of Human
Hypertension 2002; 16(2):133-40. Not early CKD
933. De Rosa ML, de Cristofaro A, Rossi M, et al.
Irbesartan effects on renal function in patients with
renal impairment and hypertension: a drugwithdrawal study. Journal of Cardiovascular
Pharmacology 2001; 38(3):482-9. Not CKD
treatment
934. De Rosa ML, Maddaluno G, Lionetti F, et al. Effects
of enalapril and isradipine alone and in combination
on blood pressure, renal function and
echocardiographic parameters in mild hypertension.
International Journal of Cardiology 2000; 74(1):7784. Not early CKD
935. de Saint-Aurin RG, Kloeckner M, Annane D.
Crystalloids versus colloids for fluid resuscitation in
critically-ill patients. Acta Clinica Belgica Supplementum 2007; (2):412-6. Not CKD treatment
936. De Santo NG, Anastasio P, Spitali L, et al. Renal
reserve is normal in adults born with unilateral renal
agenesis and is not related to hyperfiltration or renal
failure. Mineral & Electrolyte Metabolism 1997;
23(3-6):283-6. Sample size less than 50 patients
937. De Shong D, Mathis AS. Lessons in formulary
management: the case of fenoldopam for
radiographic contrast material-induced nephropathy.
Pharmacotherapy 2004; 24(6):819-20; author reply
20. Follow-up less than 6 months
938. de Smet MD, Rubin BI, Whitcup SM, et al.
Combined use of cyclosporine and ketoconazole in
the treatment of endogenous uveitis. American
Journal of Ophthalmology 1992; 113(6):687-90. Not
CKD treatment
939. de Vinuesa SG, Goicoechea M, Kanter J, et al.
Insulin resistance, inflammatory biomarkers, and
adipokines in patients with chronic kidney disease:
effects of angiotensin II blockade. Journal of the
American Society of Nephrology 2006; 17(12 Suppl
3):S206-12. Follow-up less than 6 months
940. de Vries PJ, Verkooyen RP, Leguit P, et al.
Prospective randomized study of once-daily versus
thrice-daily netilmicin regimens in patients with
intraabdominal infections. European Journal of
Clinical Microbiology & Infectious Diseases 1990;
9(3):161-8. Not CKD treatment
941. De Vriese AS, Coster RV, Smet J, et al. Linezolidinduced inhibition of mitochondrial protein synthesis.
Clinical Infectious Diseases 2006; 42(8):1111-7.
Sample size less than 50 patients
942. De Vriese AS, Verbeke F, Schrijvers BF, et al. Is
folate a promising agent in the prevention and
treatment of cardiovascular disease in patients with
renal failure? Kidney International 2002; 61(4):1199209. Not RCT or controlled trial
943. de Vroege R, Stooker W, van Oeveren W, et al. The
impact of heparin coated circuits upon metabolism in
vital organs: effect upon cerebral and renal function
during and after cardiopulmonary bypass. ASAIO
Journal 2005; 51(1):103-9. Not CKD treatment
B-87
944. de Zeeuw D, Gansevoort RT, Dullaart RP, et al.
Angiotensin II antagonism improves the lipoprotein
profile in patients with nephrotic syndrome. Journal
of Hypertension - Supplement 1995; 13(1):S53-8.
Follow-up less than 6 months
945. de Zeeuw D, Remuzzi G, Parving H-H, et al.
Albuminuria, a therapeutic target for cardiovascular
protection in type 2 diabetic patients with
nephropathy. Circulation 2004; 110(8):921-7. Not
relevant to key questions
946. de Zeeuw D, Remuzzi G, Parving H-H, et al.
Proteinuria, a target for renoprotection in patients
with type 2 diabetic nephropathy: lessons from
RENAAL. Kidney International 2004; 65(6):230920. Not CKD treatment
947. Decatris M, Santhanam S, O'Byrne K. Potential of
interferon-alpha in solid tumours: part 1. Biodrugs
2002; 16(4):261-81. Not CKD treatment
948. Dedov I, Shestakova M, Vorontzov A, et al. A
randomized, controlled study of sulodexide therapy
for the treatment of diabetic nephropathy.
Nephrology Dialysis Transplantation 1997;
12(11):2295-300. Sample size less than 50 patients
949. Deehan DJ, Heys SD, Broom J, et al. Pre-operative
recombinant interleukin-2 and increased
nephrotoxicity. Biochemical Society Transactions
1994; 22(4):425S. Not RCT or controlled trial
950. Deehan DJ, Heys SD, Broom J, et al. Renal
impairment associated with the pre-operative
administration of recombinant interleukin-2. Clinical
Science 1994; 87(5):513-8. Follow-up less than 6
months
951. Deerochanawong C, Kornthong P, Phongwiratchai S,
et al. Effects on urinary albumin excretion and renal
function changes by delapril and manidipine in
normotensive type 2 diabetic patients with
microalbuminuria. Journal of the Medical
Association of Thailand 2001; 84(2):234-41. Sample
size less than 50 patients
952. Deferrari G, Ravera M, Deferrari L, et al. Renal and
cardiovascular protection in type 2 diabetes mellitus:
angiotensin II receptor blockers. Journal of the
American Society of Nephrology 2002; 13 Suppl
3:S224-9. Not RCT or controlled trial
953. Degiannis D, Mowat AM, Tsakiris D, et al. The
effect of random blood transfusions on
immunoglobulin production by peripheral blood
mononuclear cells from uraemic patients. Clinical &
Experimental Immunology 1988; 73(1):155-9. Not
RCT or controlled trial
954. Dehne MG, Klein TF, Muhling J, et al. Impairment
of renal function after cardiopulmonary bypass is not
influenced by dopexamine. Renal Failure 2001;
23(2):217-30. Not CKD treatment
955. Dehne MG, Muhling J, Sablotzki A, et al.
Hydroxyethyl starch (HES) does not directly affect
renal function in patients with no prior renal
impairment. Journal of Clinical Anesthesia 2001;
13(2):103-11. Not early CKD
956. Deicher R, Horl WH. Differentiating factors between
erythropoiesis-stimulating agents: a guide to
957.
958.
959.
960.
961.
962.
963.
964.
965.
966.
967.
968.
B-88
selection for anaemia of chronic kidney disease.
Drugs 2004; 64(5):499-509. Not CKD treatment
Deighan CJ, Caslake MJ, McConnell M, et al.
Comparative effects of cerivastatin and fenofibrate
on the atherogenic lipoprotein phenotype in
proteinuric renal disease. Journal of the American
Society of Nephrology 2001; 12(2):341-8. Sample
size less than 50 patients
Del Vecchio L, Pozzi M, Salvetti A, et al. Efficacy
and tolerability of manidipine in the treatment of
hypertension in patients with non-diabetic chronic
kidney disease without glomerular disease.
Prospective, randomized, double-blind study of
parallel groups in comparison with enalapril. Journal
of Nephrology 2004; 17(2):261-9. Not relevant to key
questions
Delahanty LM. Implications of the diabetes control
and complications trial for renal outcomes and
medical nutrition therapy. Journal of Renal Nutrition
1998; 8(2):59-63. Not relevant to key questions
Delic-Brkljacic D, Galesic K, Ivanac G, et al.
Influence of ATII blockers and calcium channel
blockers on renal vascular resistance in patients with
essential hypertension. Collegium Antropologicum
2009; 33(4):1129-38. Not RCT or controlled trial
Delles C, Jacobi J, Schlaich MP, et al. Assessment of
endothelial function of the renal vasculature in
human subjects. American Journal of Hypertension
2002; 15(1 Pt 1):3-9. Not early CKD
Delles C, Klingbeil AU, Schneider MP, et al. Direct
comparison of the effects of valsartan and
amlodipine on renal hemodynamics in human
essential hypertension. American Journal of
Hypertension 2003; 16(12):1030-5. Sample size less
than 50 patients
Delmas A, Leone M, Rousseau S, et al. Clinical
review: Vasopressin and terlipressin in septic shock
patients. Critical Care 2005; 9(2):212-22. Not CKD
treatment
DeMarco PJ, Weisman MH, Seibold JR, et al.
Predictors and outcomes of scleroderma renal crisis:
the high-dose versus low-dose D-penicillamine in
early diffuse systemic sclerosis trial. Arthritis &
Rheumatism 2002; 46(11):2983-9. Not RCT or
controlled trial
Demarie BK, Bakris GL. Effects of different calcium
antagonists on proteinuria associated with diabetes
mellitus. Annals of Internal Medicine 1990;
113(12):987-8. Sample size less than 50 patients
Dember LM, Hawkins PN, Hazenberg BPC, et al.
Eprodisate for the treatment of renal disease in AA
amyloidosis. New England Journal of Medicine
2007; 356(23):2349-60. Not RCT or controlled trial
Dengel DR, Brown MD, Ferrell RE, et al. A
preliminary study on T-786C endothelial nitric oxide
synthase gene and renal hemodynamic and blood
pressure responses to dietary sodium. Physiological
Research 2007; 56(4):393-401. Not relevant to key
questions
Denig P, Haaijer-Ruskamp FM, Zijsling DH. Impact
of a drug bulletin on the knowledge, perception of
969.
970.
971.
972.
973.
974.
975.
976.
977.
978.
979.
980.
981.
drug utility, and prescribing behavior of physicians.
DICP 1990; 24(1):87-93. Not CKD treatment
Dennis VW. Decoding the modification of diet in
renal disease study. Cleveland Clinic Journal of
Medicine 1994; 61(4):254-7. Not RCT or controlled
trial
Deo R, Lin F, Vittinghoff E, et al. Kidney
dysfunction and sudden cardiac death among women
with coronary heart disease. Hypertension 2008;
51(6):1578-82. Not CKD treatment
Depre M, Van Hecken A, Verbesselt R, et al.
Pharmacokinetic and pharmacodynamic interaction
between the lipoxygenase inhibitor MK-0591 and the
cyclooxygenase inhibitor ibuprofen in man.
International Journal of Clinical Pharmacology
Research 1998; 18(2):53-61. Sample size less than 50
patients
DeQuattro V, Lee DP. Equivalent reduction of
proteinuria in hypertensives by either nifedipine
GITS or enalapril: disparate effects on
neurohormones and ambulatory blood pressure and
the influence of salt. Cardiology 1997; 88 Suppl
3:38-42. Sample size less than 50 patients
Deray G. Amphotericin B nephrotoxicity. Journal of
Antimicrobial Chemotherapy 2002; 49 Suppl 1:3741. Not early CKD
Deray G, Bellin MF, Boulechfar H, et al.
Nephrotoxicity of contrast media in high-risk patients
with renal insufficiency: comparison of low- and
high-osmolar contrast agents. American Journal of
Nephrology 1991; 11(4):309-12. Not CKD treatment
Deray G, Khayat D, Cacoub P, et al. The effects of
diltiazem on methotrexate-induced nephrotoxicity.
European Journal of Clinical Pharmacology 1989;
37(4):337-40. Not CKD treatment
Derlatka P, Bidzinski M, Stachurska E, et al.
Nadroparine activated fibrinolysis and improvement
of glomerular filtration rate in patients with FIGO
IIB-IIIB cervical cancer treated with
radiochemotherapy. Gynecologic Oncology 2007;
104(1):24-31. Not relevant to key questions
Despas F, Detis N, Dumonteil N, et al. Excessive
sympathetic activation in heart failure with chronic
renal failure: role of chemoreflex activation. Journal
of Hypertension 2009; 27(9):1849-54. Follow-up less
than 6 months
Detrenis S, Meschi M, del Mar Jordana Sanchez M,
et al. Contrast medium induced nephropathy in
urological practice. Journal of Urology 2007; 178(4
Pt 1):1164-70. Follow-up less than 6 months
Deyneli O, Yavuz D, Velioglu A, et al. Effects of
ACE inhibition and angiotensin II receptor blockade
on glomerular basement membrane protein excretion
and charge selectivity in type 2 diabetic patients.
Journal of the Renin-Angiotensin-Aldosterone
System 2006; 7(2):98-103. Not early CKD
Dhaene M, Sabot JP, Philippart Y, et al. Effects of
acute protein loads of different sources on glomerular
filtration rate. Kidney International - Supplement
1987; 22:S25-8. Sample size less than 50 patients
D'Haens G, Lemmens L, Geboes K, et al.
Intravenous cyclosporine versus intravenous
982.
983.
984.
985.
986.
987.
988.
989.
990.
991.
992.
993.
B-89
corticosteroids as single therapy for severe attacks of
ulcerative colitis. Gastroenterology 2001;
120(6):1323-9. Not early CKD
Dharmarajan TS. Anemia and response to epoetin
alfa: the cause of anemia matters! Journal of the
American Geriatrics Society 2008; 56(8):1574-5. Not
relevant to key questions
Dharmarajan TS, Widjaja D. Adverse consequences
with use of erythropoiesis-stimulating agents in
anemia prompt release of guidelines to ensure safe
use and maximize benefit. Geriatrics 2008; 63(6):1329. Not CKD treatment
Dhaun N, Macintyre IM, Melville V, et al. Blood
pressure-independent reduction in proteinuria and
arterial stiffness after acute endothelin-a receptor
antagonism in chronic kidney disease. Hypertension
2009; 54(1):113-9. Sample size less than 50 patients
Di Iorio B, Gaudiano G, Altieri C, et al. Aluminum
urinary excretion in patients with chronic renal
failure in treatment with conservative conventional
therapy and with ketoanalogs: research on fasting
patients and after a pharmacological load. Nephron
1995; 71(3):371-2. Not CKD treatment
Di Iorio BR, Minutolo R, De Nicola L, et al.
Supplemented very low protein diet ameliorates
responsiveness to erythropoietin in chronic renal
failure. Kidney International 2003; 64(5):1822-8. Not
early CKD
Di Lullo L, Addesse R, Comegna C, et al. Effects of
fluvastatin treatment on lipid profile, C-reactive
protein trend, and renal function in dyslipidemic
patients with chronic renal failure. Advances in
Therapy 2005; 22(6):601-12. Sample size less than
50 patients
Di Mario U, Bacci S, Morano S, et al. Selective
decrement of anionic immunoglobulin clearance after
induced renal hemodynamic changes in diabetic
patients. American Journal of Physiology 1992;
262(3 Pt 2):F381-8. Not CKD treatment
Diabetes Prevention Program Research G. Changes
in albumin excretion in the diabetes prevention
program. Diabetes Care 2009; 32(4):720-5. Not RCT
or controlled trial
Diaz-Mitoma F, Harding GK, Louie TJ, et al.
Prospective randomized comparison of
imipenem/cilastatin and cefotaxime for treatment of
lung, soft tissue, and renal infections. Reviews of
Infectious Diseases 1985; 7 Suppl 3:S452-7. Sample
size less than 50 patients
Diaz-Sandoval LJ, Kosowsky BD, Losordo DW.
Acetylcysteine to prevent angiography-related renal
tissue injury (the APART trial). American Journal of
Cardiology 2002; 89(3):356-8. Not early CKD
Dick IM, St John A, Heal S, et al. The effect of
estrogen deficiency on bone mineral density, renal
calcium and phosphorus handling and calcitropic
hormones in the rat. Calcified Tissue International
1996; 59(3):174-8. Sample size less than 50 patients
Didjurgeit U, Kruse J, Schmitz N, et al. A timelimited, problem-orientated psychotherapeutic
intervention in Type 1 diabetic patients with
complications: a randomized controlled trial.
Diabetic Medicine 2002; 19(10):814-21. Sample size
less than 50 patients
994. DiDomenico RJ, Eyrich HM. Did contrast
nephropathyin RAPPID really occur? Journal of the
American College of Cardiology 2003; 42(12):2167;
author reply -9. Not CKD treatment
995. Diercks GF, Janssen WM, van Boven AJ, et al.
Rationale, design, and baseline characteristics of a
trial of prevention of cardiovascular and renal disease
with fosinopril and pravastatin in nonhypertensive,
nonhypercholesterolemic subjects with
microalbuminuria (the Prevention of REnal and
Vascular ENdstage Disease Intervention Trial
[PREVEND IT]). American Journal of Cardiology
2000; 86(6):635-8. Not RCT or controlled trial
996. Dilek K, Usta M, Ersoy A, et al. Long-term effects of
losartan on proteinuria and renal function in patients
with renal amyloidosis. Scandinavian Journal of
Urology & Nephrology 2002; 36(6):443-6. Sample
size less than 50 patients
997. Dilger K, Herrlinger C, Peters J, et al. Effects of
celecoxib and diclofenac on blood pressure, renal
function, and vasoactive prostanoids in young and
elderly subjects. Journal of Clinical Pharmacology
2002; 42(9):985-94. Not CKD treatment
998. Dillman RO. The clinical experience with
interleukin-2 in cancer therapy. Cancer Biotherapy
1994; 9(3):183-209. Not CKD treatment
999. Dillman RO, Wiemann M, Nayak SK, et al.
Interferon-gamma or granulocyte-macrophage
colony-stimulating factor administered as adjuvants
with a vaccine of irradiated autologous tumor cells
from short-term cell line cultures: a randomized
phase 2 trial of the cancer biotherapy research group.
Journal of Immunotherapy 2003; 26(4):367-73. Not
CKD treatment
1000. Dimopoulos MA, Richardson PG, Schlag R, et al.
VMP (Bortezomib, Melphalan, and Prednisone) is
active and well tolerated in newly diagnosed patients
with multiple myeloma with moderately impaired
renal function, and results in reversal of renal
impairment: cohort analysis of the phase III VISTA
study. Journal of Clinical Oncology 2009;
27(36):6086-93. Not CKD treatment
1001. Dinits-Pensy M, Forrest GN, Cross AS, et al. The use
of vaccines in adult patients with renal disease.
American Journal of Kidney Diseases 2005;
46(6):997-1011. Not relevant to key questions
1002. Dittrich HC, Gupta DK, Hack TC, et al. The effect of
KW-3902, an adenosine A1 receptor antagonist, on
renal function and renal plasma flow in ambulatory
patients with heart failure and renal impairment.
Journal of Cardiac Failure 2007; 13(8):609-17. Not
early CKD
1003. Dittrich S, Kurschat K, Dahnert I, et al. Renal
function after cardiopulmonary bypass surgery in
cyanotic congenital heart disease. International
Journal of Cardiology 2000; 73(2):173-9. Not early
CKD
1004. Dittrich S, Kurschat K, Dahnert I, et al. Cyanotic
nephropathy and use of non-ionic contrast agents
during cardiac catherization in patients with cyanotic
congenital heart disease. Cardiology in the Young
2000; 10(1):8-14. Sample size less than 50 patients
1005. Dixey JJ, Noormohamed FH, Lant AF, et al. The
effects of naproxen and sulindac on renal function
and their interaction with hydrochlorothiazide and
piretanide in man. British Journal of Clinical
Pharmacology 1987; 23(1):55-63. Sample size less
than 50 patients
1006. Dixey JJ, Noormohamed FH, Lant AF, et al. Effect
of maximal hydration on the renal responses to
pretreatment with nonsteroidal anti-inflammatory
drugs and probenecid in man. British Journal of
Clinical Pharmacology 1988; 25(5):614-7. Follow-up
less than 6 months
1007. Dixey JJ, Noormohamed FH, Pawa JS, et al. The
influence of nonsteroidal anti-inflammatory drugs
and probenecid on the renal response to and kinetics
of piretanide in man. Clinical Pharmacology &
Therapeutics 1988; 44(5):531-9. Sample size less
than 50 patients
1008. Doggrell SA. Sarpogrelate: cardiovascular and renal
clinical potential. Expert Opinion on Investigational
Drugs 2004; 13(7):865-74. Not CKD treatment
1009. Dogra G, Irish A, Chan D, et al. A randomized trial
of the effect of statin and fibrate therapy on arterial
function in CKD. American Journal of Kidney
Diseases 2007; 49(6):776-85. Not RCT or controlled
trial
1010. Dogra GK, Watts GF, Chan DC, et al. Statin therapy
improves brachial artery vasodilator function in
patients with Type 1 diabetes and microalbuminuria.
Diabetic Medicine 2005; 22(3):239-42. Not RCT or
controlled trial
1011. Doig JK, MacFadyen RJ, Sweet CS, et al.
Haemodynamic and renal responses to oral losartan
potassium during salt depletion or salt repletion in
normal human volunteers. Journal of Cardiovascular
Pharmacology 1995; 25(4):511-7. Sample size less
than 50 patients
1012. Dolecek TA, Olson MB, Caggiula AW, et al.
Registered dietitian time requirements in the
Modification of Diet in Renal Disease Study. Journal
of the American Dietetic Association 1995;
95(11):1307-12. Not CKD treatment
1013. Dolegowska B, Pikula E, Safranow K, et al.
Metabolism of eicosanoids and their action on renal
function during ischaemia and reperfusion: the effect
of alprostadil. Prostaglandins Leukotrienes &
Essential Fatty Acids 2006; 75(6):403-11. Not RCT
or controlled trial
1014. Don BR, Kaysen GA, Hutchison FN, et al. The effect
of angiotensin-converting enzyme inhibition and
dietary protein restriction in the treatment of
proteinuria. American Journal of Kidney Diseases
1991; 17(1):10-7. Sample size less than 50 patients
1015. Donadio C, Lucchesi A, Tramonti G, et al. Creatinine
clearance can be predicted from plasma creatinine
and body composition analysis by means of electrical
bioimpedance. Renal Failure 1998; 20(2):285-93.
Not CKD treatment
1016. Donadio C, Lucchesi A, Tramonti G, et al.
Glomerular and tubular effects of contrast media
B-90
diatrizoate and iopromide. Renal Failure 1996;
18(4):657-66. Sample size less than 50 patients
1017. Dones L, Wiltshaw E, Birkhead BG, et al. Towards
an assessment of toxicity in the treatment of ovarian
cancer. Cancer Chemotherapy & Pharmacology
1987; 20(3):213-8. Not relevant to key questions
1018. Donnelly R, Elliott HL, Meredith PA, et al. Clinical
studies with the potassium channel activator
cromakalim in normotensive and hypertensive
subjects. Journal of Cardiovascular Pharmacology
1990; 16(5):790-5. Sample size less than 50 patients
1019. Donnelly R, Molyneaux LM, Willey KA, et al.
Comparative effects of indapamide and captopril on
blood pressure and albumin excretion rate in diabetic
microalbuminuria. American Journal of Cardiology
1996; 77(6):26B-30B. Follow-up less than 6 months
1020. Donnelly S. Why is erythropoietin made in the
kidney? The kidney functions as a 'critmeter' to
regulate the hematocrit. Advances in Experimental
Medicine & Biology 2003; 543:73-87. Not CKD
treatment
1021. Donner KM, Hiltunen TP, Suonsyrja T, et al.
CYP2C9 genotype modifies activity of the reninangiotensin-aldosterone system in hypertensive men.
Journal of Hypertension 2009; 27(10):2001-9. Not
CKD treatment
1022. Doorenbos CJ, Iestra JA, Papapoulos SE, et al. Atrial
natriuretic peptide and chronic renal effects of
changes in dietary protein and sodium intake in man.
Clinical Science 1990; 78(6):565-72. Sample size
less than 50 patients
1023. Dorio PJ, Lee FT, Jr., Henseler KP, et al. Using a
saline chaser to decrease contrast media in abdominal
CT. AJR 2003; American Journal of Roentgenology.
180(4):929-34. Not CKD treatment
1024. Dorner GT, Pehamberger H, Kornek G, et al.
Cisplatin-induced renal effects and thromboxane A2
receptor blockade. European Journal of Clinical
Investigation 1997; 27(10):836-9. Not CKD
treatment
1025. Dougados M, Awada H, Amor B. Cyclosporin in
rheumatoid arthritis: a double blind, placebo
controlled study in 52 patients. Annals of the
Rheumatic Diseases 1988; 47(2):127-33. Follow-up
less than 6 months
1026. Dougados M, Duchesne L, Awada H, et al.
Assessment of efficacy and acceptability of low dose
cyclosporin in patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases 1989; 48(7):5506. Not CKD treatment
1027. Doughty RN, White HD. Carvedilol: use in chronic
heart failure. Expert Review of Cardiovascular
Therapy 2007; 5(1):21-31. Not early CKD
1028. Douglas JG, Agodoa L. ACE inhibition is effective
and renoprotective in hypertensive nephrosclerosis:
the African American Study of Kidney Disease and
Hypertension (AASK) trial. Kidney International Supplement 2003; (83):S74-6. Not early CKD
1029. Douglas K, O'Malley PG, Jackson JL. Meta-analysis:
the effect of statins on albuminuria. Annals of
Internal Medicine 2006; 145(2):117-24. Sample size
less than 50 patients
1030. Drager LF, Andrade L, Barros de Toledo JF, et al.
Renal effects of N-acetylcysteine in patients at risk
for contrast nephropathy: decrease in oxidant stressmediated renal tubular injury. Nephrology Dialysis
Transplantation 2004; 19(7):1803-7. Not relevant to
key questions
1031. Dragu R, Behar S, Sandach A, et al. Should primary
percutaneous coronary intervention be the preferred
method of reperfusion therapy for patients with renal
failure and ST-elevation acute myocardial infarction?
American Journal of Cardiology 2006; 97(8):1142-5.
Follow-up less than 6 months
1032. Dreicer R. Locally advanced and metastatic bladder
cancer. Current Treatment Options in Oncology
2001; 2(5):431-6. Not early CKD
1033. Drescher P, Pereira F, Will JA, et al. Nephrotoxicity
from contrast media: attenuation with theophylline.
Radiology 1995; 197(2):547-8. Not RCT or
controlled trial
1034. Drueke TB, Landais P. Paricalcitol for treatment of
secondary hyperparathyroidism in CKD patients.
American Journal of Kidney Diseases 2006;
47(6):1083; author reply -4. Not RCT or controlled
trial
1035. Druml W. Supplements of keto acids in patients with
chronic renal failure--more than modulators of
nitrogen economy. Wiener Klinische Wochenschrift
2001; 113(17-18):638-40. Not relevant to key
questions
1036. Dugandzic RM, Sketris IS, Belitsky P, et al. Effect of
coadministration of acyclovir and cyclosporine on
kidney function and cyclosporine concentrations in
renal transplant patients. DICP 1991; 25(3):316-7.
Not early CKD
1037. Dullaart RP, Beusekamp BJ, Meijer S, et al. Longterm effects of linoleic-acid-enriched diet on
albuminuria and lipid levels in type 1 (insulindependent) diabetic patients with elevated urinary
albumin excretion. Diabetologia 1992; 35(2):165-72.
Sample size less than 50 patients
1038. Dullaart RP, Beusekamp BJ, Meijer S, et al. Longterm effects of protein-restricted diet on albuminuria
and renal function in IDDM patients without clinical
nephropathy and hypertension. Diabetes Care 1993;
16(2):483-92. Sample size less than 50 patients
1039. Dumas M, de Gislain C, d'Athis P, et al. Evaluation
of the effect of furosemide on ultrafilterable platinum
kinetics in patients treated with cisdiamminedichloroplatinum. Cancer Chemotherapy &
Pharmacology 1989; 23(1):37-40. Sample size less
than 50 patients
1040. Dumas M, de Gislain C, d'Athis P, et al. Influence of
hydration on ultrafilterable platinum kinetics and
kidney function in patients treated with cisdiamminedichloroplatinum(II). Cancer
Chemotherapy & Pharmacology 1990; 26(4):278-82.
Not CKD treatment
1041. Dumler F. Dietary sodium intake and arterial blood
pressure. Journal of Renal Nutrition 2009; 19(1):5760. Not CKD treatment
1042. Dummer CD, Thome FS, Zingano B, et al. Acute
effect of simvastatin on inflammation and oxidative
B-91
stress in chronic kidney disease. Journal of
Nephrology 2008; 21(6):900-8. Sample size less than
50 patients
1043. Dunn CJ, Markham A. Epoetin beta. A review of its
pharmacological properties and clinical use in the
management of anaemia associated with chronic
renal failure. Drugs 1996; 51(2):299-318. Not RCT
or controlled trial
1044. Duong MH, MacKenzie TA, Malenka DJ. Nacetylcysteine prophylaxis significantly reduces the
risk of radiocontrast-induced nephropathy:
comprehensive meta-analysis. Catheterization &
Cardiovascular Interventions 2005; 64(4):471-9.
Sample size less than 50 patients
1045. Dupont AG. Effects of carvedilol on renal function.
European Journal of Clinical Pharmacology 1990; 38
Suppl 2:S96-100. Follow-up less than 6 months
1046. Dupont AG, Gerlo E, Van der Niepen P, et al. Renal
pharmacodynamic effects of torasemide and
furosemide in normal man. Arzneimittel-Forschung
1988; 38(1A):172-5. Sample size less than 50
patients
1047. Dupont AG, Van der Niepen P, Taeymans Y, et al.
Effect of carvedilol on ambulatory blood pressure,
renal hemodynamics, and cardiac function in
essential hypertension. Journal of Cardiovascular
Pharmacology 1987; 10 Suppl 11:S130-6. Follow-up
less than 6 months
1048. Dupont AG, Van der Niepen P, Volckaert A, et al.
Improved renal function during chronic lisinopril
treatment in moderate to severe primary
hypertension. Journal of Cardiovascular
Pharmacology 1987; 10 Suppl 7:S148-50. Sample
size less than 50 patients
1049. Dupuis J, Lalonde G, Bichet D, et al. Captopril does
not prevent nitroglycerin tolerance in heart failure.
Canadian Journal of Cardiology 1990; 6(7):281-6.
Not CKD treatment
1050. Dural O, Kanbak M, Ciliv G, et al. Comparison of
halothane, enflurane and isoflurane kidney effects
through alanine aminopeptidase/urine creatinine
values. Anaesthesia & Intensive Care 1995;
23(2):162-4. Sample size less than 50 patients
1051. Durand D, Ader JL, Rey JP, et al. Inducing
hyperkalemia by converting enzyme inhibitors and
heparin. Kidney International - Supplement 1988;
25:S196-7. Sample size less than 50 patients
1052. Duranteau J, Pussard E, Edouard A, et al.
Flosequinan does not affect systemic and regional
vascular responses to simulated orthostatic stress in
healthy volunteers. British Journal of Clinical
Pharmacology 1992; 34(3):207-14. Not CKD
treatment
1053. Durham JD, Caputo C, Dokko J, et al. A randomized
controlled trial of N-acetylcysteine to prevent
contrast nephropathy in cardiac angiography. Kidney
International 2002; 62(6):2202-7. Not CKD treatment
1054. Durie BGM, Kyle RA, Belch A, et al. Myeloma
management guidelines: a consensus report from the
Scientific Advisors of the International Myeloma
Foundation. Hematology Journal 2003; 4(6):379-98.
Sample size less than 50 patients
1055. Dussaule JC, Michel C, Peraldi MN, et al. Inhibition
of neutral endopeptidase stimulates renal sodium
excretion in patients with chronic renal failure.
Clinical Science 1993; 84(1):31-9. Sample size less
than 50 patients
1056. Dussol B, Morange S, Loundoun A, et al. A
randomized trial of saline hydration to prevent
contrast nephropathy in chronic renal failure patients.
Nephrology Dialysis Transplantation 2006;
21(8):2120-6. Not CKD treatment
1057. Dyadyk AI, Bagriy AE, Lebed IA, et al. ACE
inhibitors captopril and enalapril induce regression of
left ventricular hypertrophy in hypertensive patients
with chronic renal failure. Nephrology Dialysis
Transplantation 1997; 12(5):945-51. Not CKD
treatment
1058. Eadington DW, Freestone S, Waugh CJ, et al.
Lithium pretreatment affects renal and systemic
responses to angiotensin II infusion in normal man.
Clinical Science 1992; 82(5):543-9. Sample size less
than 50 patients
1059. Eadington DW, Frier BM, Swainson CP. Renal
tubular responses to low-dose infusion of angiotensin
II in type 1 diabetes mellitus; relation to chronic
glycaemic control. Nephrology Dialysis
Transplantation 1994; 9(9):1264-70. Sample size less
than 50 patients
1060. Eadington DW, Swainson CP, Lee MR. Oral
carbidopa has no effect on the renal response to
angiotensin II in normal man. Clinical Science 1991;
80(2):149-54. Sample size less than 50 patients
1061. Easthope SE, Jarvis B. Candesartan cilexetil: an
update of its use in essential hypertension. Drugs
2002; 62(8):1253-87. Not relevant to key questions
1062. Ebbehoj E, Arildsen H, Hansen KW, et al. Effects of
metoprolol on QT interval and QT dispersion in Type
1 diabetic patients with abnormal albuminuria.
Diabetologia 2004; 47(6):1009-15. Not relevant to
key questions
1063. Ebbehoj E, Poulsen PL, Hansen KW, et al. Effects on
heart rate variability of metoprolol supplementary to
ongoing ACE-inhibitor treatment in Type I diabetic
patients with abnormal albuminuria. Diabetologia
2002; 45(7):965-75. Sample size less than 50 patients
1064. Ebell MH. NSAIDs vs. opiates for pain in acute renal
colic. American Family Physician 2004; 70(9):1682.
Sample size less than 50 patients
1065. Ebert TJ, Arain SR. Renal responses to low-flow
desflurane, sevoflurane, and propofol in patients.
Anesthesiology 2000; 93(6):1401-6. Not early CKD
1066. Ebert TJ, Groban L, Muzi M, et al. ANP-mediated
volume depletion attenuates renal responses in
humans. American Journal of Physiology 1992;
263(6 Pt 2):R1303-8. Sample size less than 50
patients
1067. Ecder T. Influence of protein-restricted diets on
proteinuria and endothelial dysfunction. Journal of
Renal Nutrition 2009; 19(5 Suppl):S13-4. Not RCT
or controlled trial
1068. Echevarria J, Seas C, Cruz M, et al. Oral rehydration
solution to prevent nephrotoxicity of amphotericin B.
B-92
American Journal of Tropical Medicine & Hygiene
2006; 75(6):1108-12. Not RCT or controlled trial
1069. Eckardt KU. Anaemia in end-stage renal disease:
pathophysiological considerations. Nephrology
Dialysis Transplantation 2001; 16 Suppl 7:2-8. Not
RCT or controlled trial
1070. Eckardt KU, Cardiovascular risk Reduction by Early
Anemia Treatment with Epoetin Beta T. The
CREATE trial--building the evidence. Nephrology
Dialysis Transplantation 2001; 16 Suppl 2:16-8. Not
CKD treatment
1071. Edwards NC, Steeds RP, Ferro CJ, et al. The
treatment of coronary artery disease in patients with
chronic kidney disease. Qjm 2006; 99(11):723-36.
Not RCT or controlled trial
1072. Edwards NC, Steeds RP, Stewart PM, et al. Effect of
spironolactone on left ventricular mass and aortic
stiffness in early-stage chronic kidney disease: a
randomized controlled trial. Journal of the American
College of Cardiology 2009; 54(6):505-12. Not CKD
treatment
1073. Efrati S, Dishy V, Averbukh M, et al. The effect of
N-acetylcysteine on renal function, nitric oxide, and
oxidative stress after angiography. Kidney
International 2003; 64(6):2182-7. Not relevant to key
questions
1074. Egan B, Gleim G, Panish J. Use of losartan in
diabetic patients in the primary care setting: review
of the results in LIFE and RENAAL. Current
Medical Research & Opinion 2004; 20(12):1909-17.
Not RCT or controlled trial
1075. Eggers KM, Lagerqvist B, Venge P, et al. Prognostic
value of biomarkers during and after non-STsegment elevation acute coronary syndrome. Journal
of the American College of Cardiology 2009;
54(4):357-64. Not CKD treatment
1076. Egleston BL, Wong Y-N. Sensitivity analysis to
investigate the impact of a missing covariate on
survival analyses using cancer registry data. Statistics
in Medicine 2009; 28(10):1498-511. Not CKD
treatment
1077. Eguchi A, Takei T, Yoshida T, et al. Combined
cyclosporine and prednisolone therapy in adult
patients with the first relapse of minimal-change
nephrotic syndrome. Nephrology Dialysis
Transplantation 2010; 25(1):124-9. Follow-up less
than 6 months
1078. Ehrich JHH, Geerlings C, Zivicnjak M, et al. Steroidresistant idiopathic childhood nephrosis:
overdiagnosed and undertreated. Nephrology
Dialysis Transplantation 2007; 22(8):2183-93. Not
RCT or controlled trial
1079. Ehrlich M, Grabenwoger M, Cartes-Zumelzu F, et al.
Operations on the thoracic aorta and hypothermic
circulatory arrest: is aprotinin safe? Journal of
Thoracic & Cardiovascular Surgery 1998;
115(1):220-5. Sample size less than 50 patients
1080. Eidemak I, Haaber AB, Feldt-Rasmussen B, et al.
Exercise training and the progression of chronic renal
failure. Nephron 1997; 75(1):36-40. Sample size less
than 50 patients
1081. Eijkelkamp WBA, Zhang Z, Brenner BM, et al.
Renal function and risk for cardiovascular events in
type 2 diabetic patients with hypertension: the
RENAAL and LIFE studies. Journal of Hypertension
2007; 25(4):871-6. Not RCT or controlled trial
1082. Eijkelkamp WBA, Zhang Z, Remuzzi G, et al.
Albuminuria is a target for renoprotective therapy
independent from blood pressure in patients with
type 2 diabetic nephropathy: post hoc analysis from
the Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan (RENAAL) trial.
Journal of the American Society of Nephrology
2007; 18(5):1540-6. Not RCT or controlled trial
1083. Eikelboom JW, Hankey GJ. Associations of
homocysteine, C-reactive protein and cardiovascular
disease in patients with renal disease. Current
Opinion in Nephrology & Hypertension 2001;
10(3):377-83. Not CKD treatment
1084. Eisenberger U, Sollinger D, Stickel F, et al.
Relationship between renal resistance index and renal
function in liver transplant recipients after cessation
of calcineurin inhibitor. Clinical Transplantation
2009; 23(4):499-504. Not CKD treatment
1085. Eisenstein EL. DRIVE it home: making the case for
prospective economic data collection in randomized
clinical trials. Kidney International 2008;
74(12):1507-9. Not RCT or controlled trial
1086. Eiskjaer H, Nielsen CB, Pedersen EB. Pressuredependent, enhanced natriuretic response to lowdose, atrial natriuretic peptide infusion in essential
hypertension. Journal of Internal Medicine 1994;
236(6):665-74. Not RCT or controlled trial
1087. Eiskjaer H, Nielsen CB, Pedersen EB. Pressuredependent distal tubular action of atrial natriuretic
peptide in healthy humans. Journal of Hypertension
1996; 14(1):99-106. Not early CKD
1088. Eiskjaer H, Nielsen CB, Sorensen SS, et al. Renal
and hormonal actions of atrial natriuretic peptide
during angiotensin II or noradrenaline infusion in
man. European Journal of Clinical Investigation
1996; 26(7):584-95. Not CKD treatment
1089. Eiskjaer H, Pedersen EB. Dose-response study of
atrial natriuretic peptide bolus injection in healthy
man. European Journal of Clinical Investigation
1993; 23(1):37-45. Follow-up less than 6 months
1090. Eiskjaer H, Pedersen EB, Rasmussen LM, et al.
Sustained release verapamil in renal hypertension.
European Journal of Clinical Pharmacology 1988;
33(6):549-55. Sample size less than 50 patients
1091. Eiskjaer H, Pedersen EB, Rasmussen LM, et al.
Verapamil sustained-release in renal parenchymal
hypertension: effect on blood pressure, kidney
function, angiotensin II, aldosterone, arginine
vasopressin, atrial natriuretic peptide, and
lipoproteins. Journal of Cardiovascular
Pharmacology 1989; 13 Suppl 4:S17-22. Sample size
less than 50 patients
1092. Eiskjaer H, Schmiegelow M, Jespersen B, et al.
Renal and hormonal effects and tolerance of an ANP
analogue in healthy man. European Journal of
Clinical Pharmacology 1991; 41(6):547-54. Sample
size less than 50 patients
B-93
of Medicine 1991; 324(5):277-84. Not CKD
treatment
1106. Ellis M, Bernsen R, Ali-Zadeh H, et al. A safety and
feasibility study comparing an intermittent high dose
with a daily standard dose of liposomal amphotericin
B for persistent neutropenic fever. Journal of Medical
Microbiology 2009; 58(Pt 11):1474-85. Not CKD
treatment
1107. el-Sayed YM. Correlation between nephrotoxicity
and pharmacokinetic parameters of gentamicin.
Journal of Clinical Pharmacy & Therapeutics 1994;
19(4):267-71. Not CKD treatment
1108. Elsendoorn TJ, Weijl NI, Mithoe S, et al.
Chemotherapy-induced chromosomal damage in
peripheral blood lymphocytes of cancer patients
supplemented with antioxidants or placebo. Mutation
Research 2001; 498(1-2):145-58. Not early CKD
1109. Elseviers MM, Waller I, Nenoy D, et al. Evaluation
of diagnostic criteria for analgesic nephropathy in
patients with end-stage renal failure: results of the
ANNE study. Analgesic Nephropathy Network of
Europe. Nephrology Dialysis Transplantation 1995;
10(6):808-14. Follow-up less than 6 months
1110. el-Sherif AE, Foda R, Norlen LJ, et al. Treatment of
renal colic by prostaglandin synthetase inhibitors and
avafortan (analgesic antispasmodic). British Journal
of Urology 1990; 66(6):602-5. Not CKD treatment
1111. Elung-Jensen T, Heisterberg J, Kamper A-L, et al.
Blood pressure response to conventional and lowdose enalapril in chronic renal failure. British Journal
of Clinical Pharmacology 2003; 55(2):139-46.
Sample size less than 50 patients
1112. Elung-Jensen T, Heisterberg J, Sonne J, et al.
Enalapril dosage in progressive chronic nephropathy:
a randomised, controlled trial. European Journal of
Clinical Pharmacology 2005; 61(2):87-96. Not
relevant to key questions
1113. Elung-Jensen T, Strandgaard S, Kamper A-L.
Longitudinal observations on circadian blood
pressure variation in chronic kidney disease stages 35. Nephrology Dialysis Transplantation 2008;
23(9):2873-8. Sample size less than 50 patients
1114. Elving LD, Wetzels JF, van Lier HJ, et al. Captopril
and atenolol are equally effective in retarding
progression of diabetic nephropathy. Results of a 2year prospective, randomized study. Diabetologia
1994; 37(6):604-9. Sample size less than 50 patients
1115. Ely H. Is pentoxifylline the drug of the decade?
Journal of the American Academy of Dermatology
1994; 30(4):639-42. Not RCT or controlled trial
1116. Emery P. Cyclooxygenase-2: a major therapeutic
advance? American Journal of Medicine 2001;
110(1A):42S-5S. Not RCT or controlled trial
1117. Endemann D, Marienhagen J, Stubanus M, et al.
Volume independent stimulation of renin secretion
by a single dose of amiloride in man. ArzneimittelForschung 2002; 52(9):677-83. Sample size less than
50 patients
1118. Engeler DS, Ackermann DK, Osterwalder JJ, et al. A
double-blind, placebo controlled comparison of the
morphine sparing effect of oral rofecoxib and
1093. Eiskjaer H, Sorensen SS, Danielsen H, et al.
Glomerular and tubular antinatriuretic actions of lowdose angiotensin II infusion in man. Journal of
Hypertension 1992; 10(9):1033-40. Sample size less
than 50 patients
1094. Ejaz AA, Beaver TM, Shimada M, et al. Uric acid: a
novel risk factor for acute kidney injury in high-risk
cardiac surgery patients? American Journal of
Nephrology 2009; 30(5):425-9. Not RCT or
controlled trial
1095. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and
risk for chronic renal failure. Journal of the American
Society of Nephrology 2006; 17(6):1695-702.
Sample size less than 50 patients
1096. Ekinci EI, Thomas G, Thomas D, et al. Effects of salt
supplementation on the albuminuric response to
telmisartan with or without hydrochlorothiazide
therapy in hypertensive patients with type 2 diabetes
are modulated by habitual dietary salt intake.
Diabetes Care 2009; 32(8):1398-403. Follow-up less
than 6 months
1097. Eknoyan G. Emergence of quantification in clinical
investigation and the quest for certainty in
therapeutics: the road from Hammurabi to Kefauver.
Advances in Chronic Kidney Disease 2005;
12(1):88-95. Not RCT or controlled trial
1098. Ekundayo OJ, Muchimba M, Aban IB, et al.
Multimorbidity due to diabetes mellitus and chronic
kidney disease and outcomes in chronic heart failure.
American Journal of Cardiology 2009; 103(1):88-92.
Not CKD treatment
1099. Ekundayo OJ, Muchimba M, Aban IB, et al.
Multimorbidity due to diabetes mellitus and chronic
kidney disease and outcomes in chronic heart failure.
American Journal of Cardiology 2009; 103(1):88-92.
Not CKD treatment
1100. El Kossi MMH, Ibrahim A, Lock TJ, et al. Impact of
cardiac transplantation on kidney function: a singlecenter experience. Transplantation Proceedings 2003;
35(4):1527-31. Not CKD treatment
1101. Elapavaluru S, Kellum JA. Why do patients die of
acute kidney injury? Acta Clinica Belgica Supplementum 2007; (2):326-31. Not CKD treatment
1102. Eliahou HE, Cohen D, Ben-David A, et al. The
calcium channel blocker nisoldipine delays
progression of chronic renal failure in humans
(preliminary communication). Cardiovascular Drugs
& Therapy 1988; 1(5):523-8. Sample size less than
50 patients
1103. Eliahou HE, Cohen D, Hellberg B, et al. Effect of the
calcium channel blocker nisoldipine on the
progression of chronic renal failure in man.
American Journal of Nephrology 1988; 8(4):285-90.
Sample size less than 50 patients
1104. Elkayam U, Janmohamed M, Hatamizadeh P, et al.
Impact of acute serum creatinine elevation in patients
treated with nesiritide. Clinical Cardiology 2009;
32(4):215-9. Not CKD treatment
1105. Ellis CN, Fradin MS, Messana JM, et al.
Cyclosporine for plaque-type psoriasis. Results of a
multidose, double-blind trial. New England Journal
B-94
diclofenac for acute renal colic. Journal of Urology
2005; 174(3):933-6. Not relevant to key questions
1119. Ensrud KE, Lui L-Y, Taylor BC, et al. Renal
function and risk of hip and vertebral fractures in
older women. Archives of Internal Medicine 2007;
167(2):133-9. Not CKD treatment
1120. Epstein M. Effects of ACE inhibitors and calcium
antagonists on progression of chronic renal disease.
Blood Pressure Supplement 1995; 2:108-12. Not
CKD treatment
1121. Epstein M. The benefits of ACE inhibitors and
calcium antagonists in slowing progressive renal
failure: focus on fixed-dose combination
antihypertensive therapy. Renal Failure 1996;
18(6):813-32. Not RCT or controlled trial
1122. Epstein M. Calcium antagonists and renal protection:
emerging perspectives. Journal of Hypertension Supplement 1998; 16(4):S17-25. Not RCT or
controlled trial
1123. Epstein M. Aldosterone as a determinant of
cardiovascular and renal dysfunction. Journal of the
Royal Society of Medicine 2001; 94(8):378-83. Not
RCT or controlled trial
1124. Epstein M. Aldosterone as a mediator of progressive
renal disease: pathogenetic and clinical implications.
American Journal of Kidney Diseases 2001;
37(4):677-88. Not RCT or controlled trial
1125. Epstein M. Recent landmark clinical trials: how do
they modify the therapeutic paradigm? American
Journal of Hypertension 2002; 15(7 Pt 2):82S-4S.
Not RCT or controlled trial
1126. Epstein M, Campese VM. Evolving role of calcium
antagonists in the management of hypertension.
Medical Clinics of North America 2004; 88(1):14965. Not relevant to key questions
1127. Epstein M, Leary E, Laskey R, et al. Atorvastatin
does not induce glomerular or tubular dysfunction
even at high doses. Journal of the CardioMetabolic
Syndrome 2007; 2(3):163-7. Sample size less than 50
patients
1128. Epstein M, Tobe S. What is the optimal strategy to
intensify blood pressure control and prevent
progression of renal failure? Current Hypertension
Reports 2001; 3(5):422-8. Not RCT or controlled
trial
1129. Epstein M, Williams GH, Weinberger M, et al.
Selective aldosterone blockade with eplerenone
reduces albuminuria in patients with type 2 diabetes.
Clinical Journal of The American Society of
Nephrology: CJASN 2006; 1(5):940-51. Follow-up
less than 6 months
1130. Eray O, Cete Y, Oktay C, et al. Intravenous singledose tramadol versus meperidine for pain relief in
renal colic. European Journal of Anaesthesiology
2002; 19(5):368-70. Not CKD treatment
1131. Erdine S, Ari O, Zanchetti A, et al. ESH-ESC
guidelines for the management of hypertension. Herz
2006; 31(4):331-8. Not early CKD
1132. Erdogan A, Davidson CJ. Recent clinical trials of
iodixanol. Reviews in Cardiovascular Medicine
2003; 4 Suppl 5:S43-50. Not CKD treatment
1133. Eriksson LO, Beermann B, Kallner M. Renal
function and tubular transport effects of sulindac and
naproxen in chronic heart failure. Clinical
Pharmacology & Therapeutics 1987; 42(6):646-54.
Sample size less than 50 patients
1134. Eriksson LO, Sturfelt G, Thysell H, et al. Effects of
sulindac and naproxen on prostaglandin excretion in
patients with impaired renal function and rheumatoid
arthritis. American Journal of Medicine 1990;
89(3):313-21. Not CKD treatment
1135. Erley CM, Bader B, Scheu M, et al. Renal
hemodynamics in essential hypertensives treated
with losartan. Clinical Nephrology 1995; 43 Suppl
1:S8-11. Sample size less than 50 patients
1136. Erley CM, Duda SH, Rehfuss D, et al. Prevention of
radiocontrast-media-induced nephropathy in patients
with pre-existing renal insufficiency by hydration in
combination with the adenosine antagonist
theophylline. Nephrology Dialysis Transplantation
1999; 14(5):1146-9. Follow-up less than 6 months
1137. Erley CM, Duda SH, Schlepckow S, et al. Adenosine
antagonist theophylline prevents the reduction of
glomerular filtration rate after contrast media
application. Kidney International 1994; 45(5):142531. Not CKD treatment
1138. Erley CM, Haefele U, Heyne N, et al.
Microalbuminuria in essential hypertension.
Reduction by different antihypertensive drugs.
Hypertension 1993; 21(6 Pt 1):810-5. Sample size
less than 50 patients
1139. Erley CM, Harrer U, Kramer BK, et al. Renal
hemodynamics and reduction of proteinuria by a
vasodilating beta blocker versus an ACE inhibitor.
Kidney International 1992; 41(5):1297-303. Sample
size less than 50 patients
1140. Ermolenko VM, Kukhtevich AV, Dedov II, et al.
Parlodel treatment of uremic hypogonadism in men.
Nephron 1986; 42(1):19-22. Sample size less than 50
patients
1141. Erstad BL, Gales BJ, Rappaport WD. The use of
albumin in clinical practice. Archives of Internal
Medicine 1991; 151(5):901-11. Not CKD treatment
1142. Eschbach JW, Abdulhadi MH, Browne JK, et al.
Recombinant human erythropoietin in anemic
patients with end-stage renal disease. Results of a
phase III multicenter clinical trial. Annals of Internal
Medicine 1989; 111(12):992-1000. Not early CKD
1143. Escobedo J, Rana JS, Lombardero MS, et al.
Association between albuminuria and duration of
diabetes and myocardial dysfunction and peripheral
arterial disease among patients with stable coronary
artery disease in the BARI 2D study. Mayo Clinic
Proceedings 2010; 85(1):41-6. Not CKD treatment
1144. Escudier B, Lethiec JL, Angevin E, et al. Totally
implanted catheters to reduce catheter-related
infections in patients receiving interleukin-2: a 2-year
experience. Supportive Care in Cancer 1995;
3(5):297-300. Not CKD treatment
1145. Eskens FALM, Sleijfer S. The use of bevacizumab in
colorectal, lung, breast, renal and ovarian cancer:
where does it fit? European Journal of Cancer 2008;
44(16):2350-6. Not CKD treatment
B-95
1146. Esmail ZN, Loewen PS. Losartan as an alternative to
ACE inhibitors in patients with renal dysfunction.
Annals of Pharmacotherapy 1998; 32(10):1096-8.
Not RCT or controlled trial
1147. Esnault VL, Potiron-Josse M, Testa A, et al.
Captopril but not acebutolol, prazosin or
indomethacin decreases postexercise proteinuria.
Nephron 1991; 58(4):437-42. Sample size less than
50 patients
1148. Esnault VLM. Radiocontrast media-induced
nephrotoxicity in patients with renal failure: rationale
for a new double-blind, prospective, randomized trial
testing calcium channel antagonists. Nephrology
Dialysis Transplantation 2002; 17(8):1362-4. Not
RCT or controlled trial
1149. Esnault VLM, Brown EA, Apetrei E, et al. The
effects of amlodipine and enalapril on renal function
in adults with hypertension and nondiabetic
nephropathies: a 3-year, randomized, multicenter,
double-blind, placebo-controlled study. Clinical
Therapeutics 2008; 30(3):482-98. Not CKD
treatment
1150. Esnault VLM, Ekhlas A, Delcroix C, et al. Diuretic
and enhanced sodium restriction results in improved
antiproteinuric response to RAS blocking agents.
Journal of the American Society of Nephrology
2005; 16(2):474-81. Not relevant to key questions
1151. Estacio RO, Coll JR, Tran ZV, et al. Effect of
intensive blood pressure control with valsartan on
urinary albumin excretion in normotensive patients
with type 2 diabetes. American Journal of
Hypertension 2006; 19(12):1241-8. Not CKD
treatment
1152. Estacio RO, Regensteiner JG, Wolfel EE, et al. The
association between diabetic complications and
exercise capacity in NIDDM patients. Diabetes Care
1998; 21(2):291-5. Not RCT or controlled trial
1153. Estacio RO, Savage S, Nagel NJ, et al. Baseline
characteristics of participants in the Appropriate
Blood Pressure Control in Diabetes trial. Controlled
Clinical Trials 1996; 17(3):242-57. Not RCT or
controlled trial
1154. Evans DA, Buring J, Mayrent S, et al. Qualitative
overview of randomized trials of aminoglycosides.
American Journal of Medicine 1986; 80(6B):39-43.
Not relevant to key questions
1155. Fabrizi F, Ganeshan SV, Dixit V, et al. Metaanalysis: the adjuvant role of granulocyte
macrophage-colony stimulating factor on
immunological response to hepatitis B virus vaccine
in end-stage renal disease. Alimentary Pharmacology
& Therapeutics 2006; 24(5):789-96. Sample size less
than 50 patients
1156. Faddy SC. Significant statistical heterogeneity in a
meta-analysis of the usefulness of acetylcysteine for
prevention of contrast nephropathy. American
Journal of Cardiology 2004; 94(3):414. Not relevant
to key questions
1157. Faenza A, Catena F, Nardo B, et al. Kidney
preservation with university of Wisconsin and
Celsior solution: a prospective multicenter
randomized study. Transplantation 2001; 72(7):12747. Not CKD treatment
1158. Fagher B, Henningsen N, Hulthen L, et al.
Antihypertensive and renal effects of enalapril and
slow-release verapamil in essential hypertension. A
double-blind, randomized study. European Journal of
Clinical Pharmacology 1990; 39 Suppl 1:S41-3.
Sample size less than 50 patients
1159. Fagnani F, Souchet T, Labed D, et al. Management
of hypertension and screening of renal complications
by GPs in diabetic type 2 patients (France--2001).
Diabetes & Metabolism 2003; 29(1):58-64. Not RCT
or controlled trial
1160. Fakeye TO, Adegoke AO, Omoyeni OC, et al.
Effects of water extract of Hibiscus sabdariffa, Linn
(Malvaceae) 'Roselle' on excretion of a diclofenac
formulation. Phytotherapy Research 2007; 21(1):968. Not relevant to key questions
1161. Falardeau P, Champagne P, Poyet P, et al. Neovastat,
a naturally occurring multifunctional antiangiogenic
drug, in phase III clinical trials. Seminars in
Oncology 2001; 28(6):620-5. Not early CKD
1162. Falkiewicz K, Nahaczewska W, Boratynska M, et al.
Tacrolimus decreases tubular phosphate wasting in
renal allograft recipients. Transplantation
Proceedings 2003; 35(6):2213-5. Not CKD treatment
1163. Fallo F, Gregianin M, Bui F, et al. Comparison of the
antihypertensive and renal effects of tertatolol and
nadolol in hypertensive patients with mild renal
impairment. European Journal of Clinical
Pharmacology 1991; 40(3):309-11. Follow-up less
than 6 months
1164. Fanti P, Asmis R, Stephenson TJ, et al. Positive
effect of dietary soy in ESRD patients with systemic
inflammation--correlation between blood levels of
the soy isoflavones and the acute-phase reactants.
Nephrology Dialysis Transplantation 2006;
21(8):2239-46. Not RCT or controlled trial
1165. Farbakhsh K, Kasiske BL. Dyslipidemias in patients
who have chronic kidney disease. Medical Clinics of
North America 2005; 89(3):689-99. Not RCT or
controlled trial
1166. Farbom P, Wahlstrand B, Almgren P, et al.
Interaction between renal function and
microalbuminuria for cardiovascular risk in
hypertension: the nordic diltiazem study.
Hypertension 2008; 52(1):115-22. Not early CKD
1167. Farkas G, Degi R, Voros P. Long-term effects of
fetal islet transplantation on complication of diabetes,
as compared with effects of intensive insulin therapy.
Transplantation Proceedings 1995; 27(6):3145. Not
RCT or controlled trial
1168. Farker K, Merkel U, Schweer H, et al. Effects of
short-term treatment with diclofenac-colestyramine
on renal function and urinary prostanoid excretion in
patients with type-2 diabetes. European Journal of
Clinical Pharmacology 2002; 58(2):85-91. Sample
size less than 50 patients
1169. Farker K, Nassr N, Huck F, et al. Dipyrone and
diclofenac do not influence creatinine-clearance,
inulin-clearance or PAH-clearance in healthy male
volunteers. International Journal of Clinical
B-96
Pharmacology & Therapeutics 1995; 33(3):125-30.
Sample size less than 50 patients
1170. Farquhar W, Kenney L. Renal effects of ibuprofen
during sodium restriction in the aged. Journal of the
American Geriatrics Society 2000; 48(1):106-8. Not
CKD treatment
1171. Farquhar WB, Kenney WL. Age and renal
prostaglandin inhibition during exercise and heat
stress. Journal of Applied Physiology 1999;
86(6):1936-43. Not CKD treatment
1172. Farquhar WB, Morgan AL, Zambraski EJ, et al.
Effects of acetaminophen and ibuprofen on renal
function in the stressed kidney. Journal of Applied
Physiology 1999; 86(2):598-604. Not CKD treatment
1173. Farvid MS, Jalali M, Siassi F, et al. Comparison of
the effects of vitamins and/or mineral
supplementation on glomerular and tubular
dysfunction in type 2 diabetes. Diabetes Care 2005;
28(10):2458-64. Sample size less than 50 patients
1174. Fassbinder W, Quarder O, Waltz A. Treatment with
carvedilol is associated with a significant reduction
in microalbuminuria: a multicentre randomised
study. International Journal of Clinical Practice 1999;
53(7):519-22. Follow-up less than 6 months
1175. Fassett RG, Ball MJ, Robertson IK, et al. Baseline
serum lipids and renal function in chronic kidney
disease patients entering the LORD trial.
International Journal of Clinical Pharmacology &
Therapeutics 2006; 44(11):580-8. Not early CKD
1176. Fassett RG, Ball MJ, Robertson IK, et al. The Lipid
lowering and Onset of Renal Disease (LORD) Trial:
a randomized double blind placebo controlled trial
assessing the effect of atorvastatin on the progression
of kidney disease. BMC Nephrology 2008; 9:4. Not
relevant to key questions
1177. Fauli A, Gomar C, Campistol JM, et al. Kidneyspecific proteins in patients receiving aprotinin at
high- and low-dose regimens during coronary artery
bypass graft with cardiopulmonary bypass. European
Journal of Anaesthesiology 2005; 22(9):666-71.
Sample size less than 50 patients
1178. Fauvel JP, Najem R, Maakel N, et al. Effects of
moxonidine on stress-induced peak blood pressure
and renal function: a randomized, double-blind,
placebo-controlled crossover study. Journal of
Cardiovascular Pharmacology 1998; 32(3):495-9.
Follow-up less than 6 months
1179. Fauvel JP, Najem R, Ryon B, et al. Effects of
rilmenidine on stress-induced peak blood pressure
and renal function. Journal of Cardiovascular
Pharmacology 1999; 34(1):41-5. Follow-up less than
6 months
1180. Fauvel JP, Velon S, Berra N, et al. Effects of losartan
on renal function in patients with essential
hypertension. Journal of Cardiovascular
Pharmacology 1996; 28(2):259-63. Sample size less
than 50 patients
1181. Fava S, Azzopardi J, Hattersley AT, et al. Increased
prevalence of proteinuria in diabetic sibs of
proteinuric type 2 diabetic subjects. American
Journal of Kidney Diseases 2000; 35(4):708-12. Not
RCT or controlled trial
1182. Favre H, Miescher PA, Lemoine R. Use of
cyclosporine in the treatment of autoimmune
disorders. Transplantation Proceedings 1994;
26(6):3194-6. Not RCT or controlled trial
1183. Fedoruk LM, Wang H, Conaway MR, et al. Statin
therapy improves outcomes after valvular heart
surgery. Annals of Thoracic Surgery 2008;
85(5):1521-5; discussion 5-6. Not CKD treatment
1184. Feindt PR, Walcher S, Volkmer I, et al. Effects of
high-dose aprotinin on renal function in
aortocoronary bypass grafting. Annals of Thoracic
Surgery 1995; 60(4):1076-80. Sample size less than
50 patients
1185. Feiten SF, Draibe SA, Watanabe R, et al. Short-term
effects of a very-low-protein diet supplemented with
ketoacids in nondialyzed chronic kidney disease
patients. European Journal of Clinical Nutrition
2005; 59(1):129-36. Not CKD treatment
1186. Feldt-Rasmussen B. The development of
nephropathy in insulin-dependent diabetes mellitus is
associated with poor glycemic control.
Transplantation Proceedings 1994; 26(2):371-2.
Sample size less than 50 patients
1187. Feldt-Rasmussen B, El Nahas M. Potential role of
growth factors with particular focus on growth
hormone and insulin-like growth factor-1 in the
management of chronic kidney disease. Seminars in
Nephrology 2009; 29(1):50-8. Not relevant to key
questions
1188. Feldt-Rasmussen B, Jensen T, Dieperink H, et al.
Nephrotoxicity of cyclosporin A in patients with
newly diagnosed type 1 diabetes mellitus. Diabetic
Medicine 1990; 7(5):429-33. Sample size less than
50 patients
1189. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect
of two years of strict metabolic control on
progression of incipient nephropathy in insulindependent diabetes. Lancet 1986; 2(8519):1300-4.
Sample size less than 50 patients
1190. Feldt-Rasmussen B, Mathiesen ER, Hegedus L, et al.
Kidney function during 12 months of strict metabolic
control in insulin-dependent diabetic patients with
incipient nephropathy. New England Journal of
Medicine 1986; 314(11):665-70. Sample size less
than 50 patients
1191. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is
more effective than is ampicillin-tobramycin in
cirrhotics with severe infections. Hepatology 1985;
5(3):457-62. Not early CKD
1192. Fellstrom B, Holdaas H, Jardine AG, et al.
Cardiovascular disease in patients with renal disease:
the role of statins. Current Medical Research &
Opinion 2009; 25(1):271-85. Follow-up less than 6
months
1193. Ferder L, Daccordi H, Martello M, et al. Angiotensin
converting enzyme inhibitors versus calcium
antagonists in the treatment of diabetic hypertensive
patients. Hypertension 1992; 19(2 Suppl):II237-42.
Sample size less than 50 patients
1194. Ferdinand KC, Taylor C. The management of
hypertension with angiotensin receptor blockers in
B-97
special populations. Clinical Cornerstone 2009; 9
Suppl 3:S5-17. Not CKD treatment
1195. Ferguson JA, Sundblad KJ, Becker PK, et al. Role of
duration of diuretic effect in preventing sodium
retention. Clinical Pharmacology & Therapeutics
1997; 62(2):203-8. Sample size less than 50 patients
1196. Fernandez PG, Snedden W, Vasdev S, et al.
Bevantolol attenuates thiazide stimulated renin
secretion and catecholamine release in diuretic
resistant hypertensives. Canadian Journal of
Cardiology 1989; 5(2):93-7. Sample size less than 50
patients
1197. Fernandez R, Puig JG, Rodriguez-Perez JC, et al.
Effect of two antihypertensive combinations on
metabolic control in type-2 diabetic hypertensive
patients with albuminuria: a randomised, doubleblind study. Journal of Human Hypertension 2001;
15(12):849-56. Follow-up less than 6 months
1198. Fernandez-Andrade C, Russo D, Iversen B, et al.
Comparison of losartan and amlodipine in renally
impaired hypertensive patients. Kidney International
- Supplement 1998; 68:S120-4. Sample size less than
50 patients
1199. Ferrari P, Gadient G, Cozzio A, et al. Reduced
plasma cyclic GMP but normal renal responses to
atrial natriuretic factor in pre-hypertension. Blood
Pressure 1996; 5(1):16-26. Follow-up less than 6
months
1200. Ferrari P, Marti H-P, Pfister M, et al. Additive
antiproteinuric effect of combined ACE inhibition
and angiotensin II receptor blockade. Journal of
Hypertension 2002; 20(1):125-30. Sample size less
than 50 patients
1201. Ferrario F, Barone MT, Landoni G, et al.
Acetylcysteine and non-ionic isosmolar contrastinduced nephropathy--a randomized controlled study.
Nephrology Dialysis Transplantation 2009;
24(10):3103-7. Not CKD treatment
1202. Ferretti A, Judd JT, Ballard-Barbash R, et al. Effect
of fish oil supplementation on the excretion of the
major metabolite of prostaglandin E in healthy male
subjects. Lipids 1991; 26(7):500-3. Not CKD
treatment
1203. Ferri C, Baldoncini R, Bellini C, et al. Hormonal and
renal responses to atrial natriuretic peptide infusion
in low-renin hypertension. American Journal of
Nephrology 1995; 15(3):222-9. Sample size less than
50 patients
1204. Ferris M, Shoham DA, Pierre-Louis M, et al. High
prevalence of unlabeled chronic kidney disease
among inpatients at a tertiary-care hospital.
American Journal of the Medical Sciences 2009;
337(2):93-7. Not CKD treatment
1205. Feutren G, von Graffenried B. Pharmacology of
cyclosporin A (Sandimmun) and clinical experience
in inflammatory bowel diseases. Schweizerische
Medizinische Wochenschrift 1991; Journal Suisse de
Medecine. 121(20):748-53. Not CKD treatment
1206. Fiaccadori E, Maggiore U, Rotelli C, et al. Effects of
different energy intakes on nitrogen balance in
patients with acute renal failure: a pilot study.
Nephrology Dialysis Transplantation 2005;
20(9):1976-80. Not relevant to key questions
1207. Field TS, Rochon P, Lee M, et al. Computerized
clinical decision support during medication ordering
for long-term care residents with renal insufficiency.
Journal of the American Medical Informatics
Association 2009; 16(4):480-5. Not CKD treatment
1208. Field TS, Rochon P, Lee M, et al. Computerized
clinical decision support during medication ordering
for long-term care residents with renal insufficiency.
Journal of the American Medical Informatics
Association 2009; 16(4):480-5. Not CKD treatment
1209. Fifer MA, Molina CR, Quiroz AC, et al.
Hemodynamic and renal effects of atrial natriuretic
peptide in congestive heart failure. American Journal
of Cardiology 1990; 65(3):211-6. Not CKD treatment
1210. Fine J-D, Johnson LB, Weiner M, et al. Causespecific risks of childhood death in inherited
epidermolysis bullosa. Journal of Pediatrics 2008;
152(2):276-80. Not CKD treatment
1211. Fischbach R, Landwehr P, Lackner K, et al.
Iodixanol vs iopamidol in intravenous DSA of the
abdominal aorta and lower extremity arteries: a
comparative phase-III trial. European Radiology
1996; 6(1):9-13. Not CKD treatment
1212. Fischer D, Cline K, Plone MA, et al. Results of a
randomized crossover study comparing once-daily
and thrice-daily sevelamer dosing. American Journal
of Kidney Diseases 2006; 48(3):437-44. Not relevant
to key questions
1213. Fischer U, Salzsieder E, Menzel R, et al. Primary
health care of diabetic patients in a specialized
outpatient setting: a DIABCARE-based analysis.
Diabete et Metabolisme 1993; 19(1 Pt 2):188-94. Not
RCT or controlled trial
1214. Fischer UM, Tossios P, Mehlhorn U. Renal
protection by radical scavenging in cardiac surgery
patients. Current Medical Research & Opinion 2005;
21(8):1161-4. Not relevant to key questions
1215. Fishbane S, Chittineni H, Packman M, et al. Oral
paricalcitol in the treatment of patients with CKD
and proteinuria: a randomized trial. American
Journal of Kidney Diseases 2009; 54(4):647-52. Not
early CKD
1216. Fishbane S, Pannier A, Liogier X, et al.
Pharmacokinetic and pharmacodynamic properties of
methoxy polyethylene glycol-epoetin beta are
unaffected by the site of subcutaneous
administration. Journal of Clinical Pharmacology
2007; 47(11):1390-7. Not RCT or controlled trial
1217. Fisher AR, Jones P, Barlow P, et al. The influence of
mannitol on renal function during and after openheart surgery. Perfusion 1998; 13(3):181-6. Not CKD
treatment
1218. Fisher CJ, Jr., Opal SM, Lowry SF, et al. Role of
interleukin-1 and the therapeutic potential of
interleukin-1 receptor antagonist in sepsis.
Circulatory Shock 1994; 44(1):1-8. Not RCT or
controlled trial
1219. Fitchett D. Have angiotensin receptor blockers lived
up to expectations? Canadian Journal of Cardiology
2005; 21(7):569-75. Sample size less than 50 patients
B-98
Transplantation 1995; 10(5):643-7. Sample size less
than 50 patients
1233. Fliser D, Ritz E. Serum cystatin C concentration as a
marker of renal dysfunction in the elderly. American
Journal of Kidney Diseases 2001; 37(1):79-83. Not
RCT or controlled trial
1234. Fliser D, Schroter M, Neubeck M, et al.
Coadministration of thiazides increases the efficacy
of loop diuretics even in patients with advanced renal
failure. Kidney International 1994; 46(2):482-8. Not
early CKD
1235. Fliser D, Zurbruggen I, Mutschler E, et al.
Coadministration of albumin and furosemide in
patients with the nephrotic syndrome. Kidney
International 1999; 55(2):629-34. Sample size less
than 50 patients
1236. Flordal PA, Ljungstrom KG. Renal effects of high
dose desmopressin and dextran. A study in normal
subjects and in patients undergoing total hip
replacement. Acta Anaesthesiologica Scandinavica
1993; 37(1):1-6. Sample size less than 50 patients
1237. Fluck RJ, Raine AE. ACE inhibitors in non-diabetic
renal disease. British Heart Journal 1994; 72(3
Suppl):S46-51. Not RCT or controlled trial
1238. Fogari R, Corradi L, Zoppi A, et al. Addition of
manidipine improves the antiproteinuric effect of
candesartan in hypertensive patients with type II
diabetes and microalbuminuria. American Journal of
Hypertension 2007; 20(10):1092-6. Not RCT or
controlled trial
1239. Fogari R, Derosa G, Zoppi A, et al. Effect of
telmisartan-amlodipine combination at different
doses on urinary albumin excretion in hypertensive
diabetic patients with microalbuminuria. American
Journal of Hypertension 2007; 20(4):417-22. Not
CKD treatment
1240. Fogari R, Mugellini A, Zoppi A, et al. Effect of
successful hypertension control by manidipine or
lisinopril on albuminuria and left ventricular mass in
diabetic hypertensive patients with
microalbuminuria. European Journal of Clinical
Pharmacology 2005; 61(7):483-90. Not CKD
treatment
1241. Fogari R, Zoppi A, Corradi L, et al. Long-term
effects of ramipril and nitrendipine on albuminuria in
hypertensive patients with type II diabetes and
impaired renal function. Journal of Human
Hypertension 1999; 13(1):47-53. Not relevant to key
questions
1242. Foley RN. Do we know the correct hemoglobin
target for anemic patients with chronic kidney
disease? Clinical Journal of The American Society of
Nephrology: CJASN 2006; 1(4):678-84. Not relevant
to key questions
1243. Foley RN. Target hemoglobin trials in chronic
kidney disease: design and interpretation issues.
Pediatric Nephrology 2009; 24(12):2279-85. Not
CKD treatment
1244. Fontsere N, Bonal J, Navarro M, et al. A comparison
of prediction equations for estimating glomerular
filtration rate in adult patients with chronic kidney
disease stages 4-5. Effect of nutritional status and
1220. Flaa A, Aksnes TA, Strand A, et al. Complications of
hypertension and the role of angiotensin receptor
blockers in hypertension trials. Expert Review of
Cardiovascular Therapy 2007; 5(3):451-61. Not
human studies
1221. Flaa A, Kjeldsen SE. Are all the hypertensives made
equal? Herz 2006; 31(4):323-30. Not RCT or
controlled trial
1222. Flack JM. Effect of ramipril versus amlodipine on
renal outcomes in hypertensive nephrosclerosis.
Current Hypertension Reports 2002; 4(3):183-4. Not
RCT or controlled trial
1223. Flack JM. Maximising antihypertensive effects of
angiotensin II receptor blockers with thiazide diuretic
combination therapy: focus on
irbesartan/hydrochlorothiazide. International Journal
of Clinical Practice 2007; 61(12):2093-102. Not
relevant to key questions
1224. Flack JR, Molyneaux L, Willey K, et al. Regression
of microalbuminuria: results of a controlled study,
indapamide versus captopril. Journal of
Cardiovascular Pharmacology 1993; 22 Suppl 6:S757. Follow-up less than 6 months
1225. Flapan AD, Davies E, Waugh C, et al. Posture
determines the nature of the interaction between
angiotensin converting enzyme inhibitors and loop
diuretics in patients with chronic cardiac failure.
International Journal of Cardiology 1991; 33(3):37783. Follow-up less than 6 months
1226. Fleisch M, Sutsch G, Yan XW, et al. Systemic,
pulmonary, and renal hemodynamic effects of
endothelin ET(A/B)-receptor blockade in patients
with maintained left ventricular function. Journal of
Cardiovascular Pharmacology 2000; 36(3):302-9.
Not early CKD
1227. Fleming JS, Persaud L, Zivanovic MA. A general
equation for estimating glomerular filtration rate
from a single plasma sample.[Erratum appears in
Nucl Med Commun. 2005 Oct;26(10):933]. Nuclear
Medicine Communications 2005; 26(8):743-8.
Sample size less than 50 patients
1228. Fleming JS, Persaud L, Zivanovic MA. Quality
control of slope-intercept measurements of
glomerular filtration rate using single-sample
estimates. Nuclear Medicine Communications 2005;
26(8):737-42. Follow-up less than 6 months
1229. Flesch M, Knipp S, Kessler G, et al. ARTA: AT1receptor blocker therapy in patients undergoing
coronary artery bypass grafting. Clinical Research in
Cardiology 2009; 98(1):33-43. Not CKD treatment
1230. Fliser D, Dikow R, Demukaj S, et al. Opposing
effects of angiotensin II on muscle and renal blood
flow under euglycemic conditions. Journal of the
American Society of Nephrology 2000; 11(11):20016. Sample size less than 50 patients
1231. Fliser D, Haller H. Angiotensin II subtype 1-receptor
antagonists in the treatment of diabetic nephropathy.
Journal of Hypertension - Supplement 2001;
19(1):S57-60. Not RCT or controlled trial
1232. Fliser D, Rett K, Hubinger A, et al. Influence of ACE
inhibition on glucose tolerance in patients with stable
chronic renal failure. Nephrology Dialysis
B-99
age. Nephron 2006; 104(4):c160-8. Not RCT or
controlled trial
1245. Forbes JM, Soulis T, Thallas V, et al. Renoprotective
effects of a novel inhibitor of advanced glycation.
Diabetologia 2001; 44(1):108-14. Not human studies
1246. Ford I, Bezlyak V, Stott DJ, et al. Reduced
glomerular filtration rate and its association with
clinical outcome in older patients at risk of vascular
events: secondary analysis. PLoS Medicine / Public
Library of Science 2009; 6(1):e16. Not CKD
treatment
1247. Foreman BH, Chambliss ML. Clinical inquiries. Are
ARBs or ACE inhibitors preferred for nephropathy in
diabetes? Journal of Family Practice 2004;
53(3):241-2. Not early CKD
1248. Fornos JA, Andres NF, Andres JC, et al. A
pharmacotherapy follow-up program in patients with
type-2 diabetes in community pharmacies in Spain.
Pharmacy World & Science 2006; 28(2):65-72. Not
relevant to key questions
1249. Forsblom C, Hiukka A, Leinonen ES, et al. Effects of
long-term fenofibrate treatment on markers of renal
function in type 2 diabetes: the FIELD Helsinki
substudy. Diabetes Care 2010; 33(2):215-20. Not
CKD treatment
1250. Forsyth DR, Roberts CJ. Nitrendipine and renal
tubular function in human volunteers. Journal of
Clinical Pharmacology 1992; 32(3):284-9. Not CKD
treatment
1251. Forzley BR, Sontrop JM, Macnab JJ, et al. Treating
TTP/HUS with plasma exchange: a single centre's
25-year experience. British Journal of Haematology
2008; 143(1):100-6. Not CKD treatment
1252. Foucan L, Bourhis V, Bangou J, et al. A randomized
trial of captopril for microalbuminuria in
normotensive adults with sickle cell anemia.
American Journal of Medicine 1998; 104(4):339-42.
Sample size less than 50 patients
1253. Fouque D, Aparicio M. Eleven reasons to control the
protein intake of patients with chronic kidney
disease. Nature Clinical Practice Nephrology 2007;
3(7):383-92. Not CKD treatment
1254. Fouque D, Guebre-Egziabher F. Do low-protein diets
work in chronic kidney disease patients? Seminars in
Nephrology 2009; 29(1):30-8. Not RCT or controlled
trial
1255. Fouque D, Laville M. Low protein diets for chronic
kidney disease in non diabetic adults. Cochrane
Database of Systematic Reviews 2009;
(3):CD001892. Not RCT or controlled trial
1256. Fouque D, Laville M, Boissel JP. Low protein diets
for chronic kidney disease in non diabetic adults.
Cochrane Database of Systematic Reviews 2006;
(2):CD001892. Not RCT or controlled trial
1257. Fouque D, Le Bouc Y, Laville M, et al. Insulin-like
growth factor-1 and its binding proteins during a
low-protein diet in chronic renal failure. Journal of
the American Society of Nephrology 1995;
6(5):1427-33. Sample size less than 50 patients
1258. Fouque D, Wang P, Laville M, et al. Low protein
diets delay end-stage renal disease in non-diabetic
adults with chronic renal failure. Nephrology
Dialysis Transplantation 2000; 15(12):1986-92. Not
relevant to key questions
1259. Fouque D, Wang P, Laville M, et al. Low protein
diets delay end-stage renal disease in non diabetic
adults with chronic renal failure. Cochrane Database
of Systematic Reviews 2000; (2):CD001892. Not
relevant to key questions
1260. Fouque D, Wang P, Laville M, et al. Low protein
diets for chronic renal failure in non diabetic adults.
Cochrane Database of Systematic Reviews 2001;
(2):CD001892. Not relevant to key questions
1261. Fournier A, Moriniere PH, Oprisiu R, et al. 1-alphaHydroxyvitamin D3 derivatives in the treatment of
renal bone diseases: justification and optimal
modalities of administration. Nephron 1995;
71(3):254-83. Not CKD treatment
1262. Fox CH, Brooks A, Zayas LE, et al. Primary care
physicians' knowledge and practice patterns in the
treatment of chronic kidney disease: an Upstate New
York Practice-based Research Network (UNYNET)
study. Journal of the American Board of Family
Medicine: JABFM 2006; 19(1):54-61. Follow-up less
than 6 months
1263. Fox KAA, Antman EM, Montalescot G, et al. The
impact of renal dysfunction on outcomes in the
ExTRACT-TIMI 25 trial. Journal of the American
College of Cardiology 2007; 49(23):2249-55.
Follow-up less than 6 months
1264. Fox KAA, Bassand J-P, Mehta SR, et al. Influence of
renal function on the efficacy and safety of
fondaparinux relative to enoxaparin in non STsegment elevation acute coronary syndromes. Annals
of Internal Medicine 2007; 147(5):304-10. Not CKD
treatment
1265. Franceschini N, Joy MS, Kshirsagar A. Cinacalcet
HCl: a calcimimetic agent for the management of
primary and secondary hyperparathyroidism. Expert
Opinion on Investigational Drugs 2003; 12(8):141321. Not CKD treatment
1266. Frank H, Schobel H-P, Vitkowsky J, et al. Effects of
angiotensin II receptor antagonism on the renal
hemodynamic response to cardiovascular stress.
Kidney International 2003; 63(2):617-23. Sample
size less than 50 patients
1267. Frank H, Werner D, Lorusso V, et al. Simultaneous
hemodialysis during coronary angiography fails to
prevent radiocontrast-induced nephropathy in chronic
renal failure. Clinical Nephrology 2003; 60(3):17682. Not CKD treatment
1268. Franklin SC, Moulton M, Sicard GA, et al. Insulinlike growth factor I preserves renal function
postoperatively. American Journal of Physiology
1997; 272(2 Pt 2):F257-9. Follow-up less than 6
months
1269. Franklin SS, Smith RD. Comparison of effects of
enalapril plus hydrochlorothiazide versus standard
triple therapy on renal function in renovascular
hypertension. American Journal of Medicine 1985;
79(3C):14-23. Follow-up less than 6 months
1270. Franklin SS, Smith RD. A comparison of enalapril
plus hydrochlorothiazide with standard triple therapy
B-100
in renovascular hypertension. Nephron 1986; 44
Suppl 1:73-82. Not CKD treatment
1271. Frassetto LA, Nash E, Morris RC, Jr., et al.
Comparative effects of potassium chloride and
bicarbonate on thiazide-induced reduction in urinary
calcium excretion. Kidney International 2000;
58(2):748-52. Not early CKD
1272. Frederick PR, Frankenfield DL, Biddle MG, et al.
Changes in dialysis units' quality improvement
practices from 1994 to 1996. Anna Journal 1998;
25(5):469-78. Not RCT or controlled trial
1273. Fredman B, Jedeikin R, Olsfanger D, et al. The
opioid-sparing effect of diclofenac sodium in
outpatient extracorporeal shock wave lithotripsy
(ESWL). Journal of Clinical Anesthesia 1993;
5(2):141-4. Not CKD treatment
1274. Fredman B, Zohar E, Golan E, et al. Diclofenac does
not decrease renal blood flow or glomerular filtration
in elderly patients undergoing orthopedic surgery.
Anesthesia & Analgesia 1999; 88(1):149-54. Not
CKD treatment
1275. Freedman BI, Wuerth JP, Cartwright K, et al. Design
and baseline characteristics for the aminoguanidine
Clinical Trial in Overt Type 2 Diabetic Nephropathy
(ACTION II). Controlled Clinical Trials 1999;
20(5):493-510. Not RCT or controlled trial
1276. Freeman RV, Mehta RH, Al Badr W, et al. Influence
of concurrent renal dysfunction on outcomes of
patients with acute coronary syndromes and
implications of the use of glycoprotein IIb/IIIa
inhibitors. Journal of the American College of
Cardiology 2003; 41(5):718-24. Not CKD treatment
1277. Freestone S, Jeffrey RF, Bonner CV, et al. Effect of
lithium on the renal actions of alpha-human atrial
natriuretic peptide in normal man. Clinical Science
1990; 78(4):371-5. Sample size less than 50 patients
1278. Freestone S, McAuslane JA, Prescott LF. Effects of
tenoxicam on renal function and the disposition of
inulin and p-aminohippurate in healthy volunteers
and patients with chronic renal failure. British
Journal of Clinical Pharmacology 1991; 32(4):495500. Sample size less than 50 patients
1279. Frei U, Wagner K. Renal function in liver transplant
patients receiving FK506 or cyclosporin A
immunosuppressive therapy. Transplantation
Proceedings 1994; 26(6):3270-1. Not early CKD
1280. Freidlin B, Korn EL. A testing procedure for survival
data with few responders. Statistics in Medicine
2002; 21(1):65-78. Not RCT or controlled trial
1281. Frenken LA, van Lier HJ, Jordans JG, et al.
Identification of the component part in an epoetin
alfa preparation that causes pain after subcutaneous
injection. American Journal of Kidney Diseases
1993; 22(4):553-6. Sample size less than 50 patients
1282. Freudenberger RS, Kim J, Tawfik I, et al. Optimal
medical therapy is superior to transplantation for the
treatment of class I, II, and III heart failure: a
decision analytic approach. Circulation 2006; 114(1
Suppl):I62-6. Not RCT or controlled trial
1283. Freudenthaler S, Benohr P, Grenz A, et al. Do
alterations of endogenous angiotensin II levels
regulate erythropoietin production in humans?
British Journal of Clinical Pharmacology 2003;
56(4):378-87. Sample size less than 50 patients
1284. Fricker AF, Nussberger J, Meilenbrock S, et al.
Effect of indomethacin on the renal response to
angiotensin II receptor blockade in healthy subjects.
Kidney International 1998; 54(6):2089-97. Sample
size less than 50 patients
1285. Fridman K, Andersson OK, Wysocki M, et al. Acute
effects of candesartan cilexetil (the new angiotensin
II antagonist) on systemic and renal haemodynamics
in hypertensive patients. European Journal of
Clinical Pharmacology 1998; 54(7):497-501. Sample
size less than 50 patients
1286. Fried LF, Forrest KY, Ellis D, et al. Lipid
modulation in insulin-dependent diabetes mellitus:
effect on microvascular outcomes. Journal of
Diabetes & its Complications 2001; 15(3):113-9.
Sample size less than 50 patients
1287. Friedman AN, Hunsicker LG, Selhub J, et al. Creactive protein as a predictor of total arteriosclerotic
outcomes in type 2 diabetic nephropathy. Kidney
International 2005; 68(2):773-8. Not relevant to key
questions
1288. Friedrich JO, Adhikari N, Herridge MS, et al. Metaanalysis: low-dose dopamine increases urine output
but does not prevent renal dysfunction or death.
Annals of Internal Medicine 2005; 142(7):510-24.
Not relevant to key questions
1289. Frohling PT, Krupki F, Kokot F, et al. What are the
most important factors in the progression of renal
failure? Kidney International - Supplement 1989;
27:S106-9. Not early CKD
1290. Frossard V, Ketterer N, Rosselet A, et al. Early
intensification and autologous stem cell
transplantation in patients with systemic AL
amyloidosis: a single-centre experience. Annals of
Hematology 2009; 88(7):681-5. Not CKD treatment
1291. Frumento RJ, Logginidou HG, Wahlander S, et al.
Dexmedetomidine infusion is associated with
enhanced renal function after thoracic surgery.
Journal of Clinical Anesthesia 2006; 18(6):422-6.
Not early CKD
1292. Fuiano G, Esposito C, Sepe V, et al. Effects of
hypercholesterolemia of renal hemodynamics: study
in patients with nephrotic syndrome. Nephron 1996;
73(3):430-5. Sample size less than 50 patients
1293. Fuiano G, Mancuso D, Indolfi C, et al. Early
detection of progressive renal dysfunction in patients
with coronary artery disease. Kidney International
2005; 68(6):2773-80. Not relevant to key questions
1294. Fujii N, Hamano T, Mikami S, et al. Risedronate, an
effective treatment for glucocorticoid-induced bone
loss in CKD patients with or without concomitant
active vitamin D (PRIUS-CKD). Nephrology
Dialysis Transplantation 2007; 22(6):1601-7. Not
RCT or controlled trial
1295. Fujisaki T, Hida M, Hiraga S, et al. Cellular
proliferation and secretion in secondary
hyperparathyroidism during renal failure. Nephron
1997; 77(1):68-75. Sample size less than 50 patients
1296. Fujita T, Ando K, Nishimura H, et al. Antiproteinuric
effect of the calcium channel blocker cilnidipine
B-101
added to renin-angiotensin inhibition in hypertensive
patients with chronic renal disease. Kidney
International 2007; 72(12):1543-9. Not RCT or
controlled trial
1297. Fukuoka N, Aibiki M. Recommended dose of
arbekacin, an aminoglycoside against methicillinresistant Staphylococcus aureus, does not achieve
desired serum concentration in critically ill patients
with lowered creatinine clearance. Journal of Clinical
Pharmacy & Therapeutics 2008; 33(5):521-7. Not
CKD treatment
1298. Fullerton T, Sica DA, Blum RA. Evaluation of the
renal protective effect of misoprostol in elderly,
osteoarthritic patients at risk for nonsteroidal antiinflammatory drug-induced renal dysfunction.
Journal of Clinical Pharmacology 1993;
33(12):1225-32. Not CKD treatment
1299. Fung JWH, Szeto CC, Chan WWM, et al. Effect of
N-acetylcysteine for prevention of contrast
nephropathy in patients with moderate to severe renal
insufficiency: a randomized trial. American Journal
of Kidney Diseases 2004; 43(5):801-8. Not early
CKD
1300. Fung MA, Warnock GL, Ao Z, et al. The effect of
medical therapy and islet cell transplantation on
diabetic nephropathy: an interim report.
Transplantation 2007; 84(1):17-22. Sample size less
than 50 patients
1301. Furey SA, Vargas R, McMahon FG. Renovascular
effects of nonprescription ibuprofen in elderly
hypertensive patients with mild renal impairment.
Pharmacotherapy 1993; 13(2):143-8. Not CKD
treatment
1302. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect
of renin-angiotensin-aldosterone system triple
blockade on non-diabetic renal disease: addition of
an aldosterone blocker, spironolactone, to
combination treatment with an angiotensinconverting enzyme inhibitor and angiotensin II
receptor blocker. Hypertension Research - Clinical &
Experimental 2008; 31(1):59-67. Not CKD treatment
1303. Gabrielsen A, Bie P, Holstein-Rathlou NH, et al.
Neuroendocrine and renal effects of intravascular
volume expansion in compensated heart failure.
American Journal of Physiology - Regulatory
Integrative & Comparative Physiology 2001;
281(2):R459-67. Not early CKD
1304. Gadano A, Moreau R, Vachiery F, et al. Natriuretic
response to the combination of atrial natriuretic
peptide and terlipressin in patients with cirrhosis and
refractory ascites. Journal of Hepatology 1997;
26(6):1229-34. Not CKD treatment
1305. Gaede P, Hansen HP, Parving H-H, et al. Impact of
low-dose acetylsalicylic acid on kidney function in
type 2 diabetic patients with elevated urinary
albumin excretion rate. Nephrology Dialysis
Transplantation 2003; 18(3):539-42. Sample size less
than 50 patients
1306. Gaede P, Poulsen HE, Parving HH, et al. Doubleblind, randomised study of the effect of combined
treatment with vitamin C and E on albuminuria in
Type 2 diabetic patients. Diabetic Medicine 2001;
18(9):756-60. Sample size less than 50 patients
1307. Gaede P, Vedel P, Parving HH, et al. Elevated levels
of plasma von Willebrand factor and the risk of
macro- and microvascular disease in type 2 diabetic
patients with microalbuminuria. Nephrology Dialysis
Transplantation 2001; 16(10):2028-33. Not RCT or
controlled trial
1308. Gaedeke J, Neumayer H-H, Peters H.
Pharmacological management of renal fibrotic
disease. Expert Opinion on Pharmacotherapy 2006;
7(4):377-86. Not relevant to key questions
1309. Gainer JV, Morrow JD, Loveland A, et al. Effect of
bradykinin-receptor blockade on the response to
angiotensin-converting-enzyme inhibitor in
normotensive and hypertensive subjects. New
England Journal of Medicine 1998; 339(18):1285-92.
Sample size less than 50 patients
1310. Galassi A, Brancaccio D, Cozzolino M, et al.
Awareness of hypertension and proteinuria in
randomly selected patients in 11 Italian cities. A
2005 report of the National Kidney Foundation of
Italy. Journal of Clinical Hypertension 2009;
11(3):138-43. Not CKD treatment
1311. Gall MA, Rossing P, Skott P, et al. Placebocontrolled comparison of captopril, metoprolol, and
hydrochlorothiazide therapy in non-insulindependent diabetic patients with primary
hypertension. American Journal of Hypertension
1992; 5(5 Pt 1):257-65. Sample size less than 50
patients
1312. Gallagher DJ, Milowsky MI, Iasonos A, et al.
Sequential adjuvant chemotherapy after surgical
resection of high-risk urothelial carcinoma. Cancer
2009; 115(22):5193-201. Not CKD treatment
1313. Gallagher JC, Rapuri P, Smith L. Falls are associated
with decreased renal function and insufficient
calcitriol production by the kidney. Journal of Steroid
Biochemistry & Molecular Biology 2007; 103(35):610-3. Not RCT or controlled trial
1314. Gallagher PM, Carrithers JA, Godard MP, et al.
Beta-hydroxy-beta-methylbutyrate ingestion, part II:
effects on hematology, hepatic and renal function.
Medicine & Science in Sports & Exercise 2000;
32(12):2116-9. Not early CKD
1315. Gallant JE, Winston JA, DeJesus E, et al. The 3-year
renal safety of a tenofovir disoproxil fumarate vs. a
thymidine analogue-containing regimen in
antiretroviral-naive patients. AIDS 2008;
22(16):2155-63. Not CKD treatment
1316. Galsky MD, Iasonos A, Mironov S, et al. Phase II
trial of dose-dense doxorubicin plus gemcitabine
followed by paclitaxel plus carboplatin in patients
with advanced urothelial carcinoma and impaired
renal function. Cancer 2007; 109(3):549-55. Not
CKD treatment
1317. Gambaro G, Kinalska I, Oksa A, et al. Oral
sulodexide reduces albuminuria in microalbuminuric
and macroalbuminuric type 1 and type 2 diabetic
patients: the Di.N.A.S. randomized trial. Journal of
the American Society of Nephrology 2002;
13(6):1615-25. Not CKD treatment
B-102
Pharmacotherapy 2005; 6(9):1587-96. Sample size
less than 50 patients
1331. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal
effect of low-dose dopamine in high-risk patients
undergoing coronary angiography. Journal of the
American College of Cardiology 1999; 34(6):1682-8.
Not CKD treatment
1332. Garg AX, Kiberd BA, Clark WF, et al. Albuminuria
and renal insufficiency prevalence guides population
screening: results from the NHANES III. Kidney
International 2002; 61(6):2165-75. Not relevant to
key questions
1333. Garg JP, Ellis R, Elliott WJ, et al. Angiotensin
receptor blockade and arterial compliance in chronic
kidney disease: a pilot study. American Journal of
Nephrology 2005; 25(4):393-9. Not relevant to key
questions
1334. Garini G, Mazzi A, Allegri L, et al. Effectiveness of
dietary protein augmentation associated with
angiotensin-converting enzyme inhibition in the
management of the nephrotic syndrome. Mineral &
Electrolyte Metabolism 1996; 22(1-3):123-7. Sample
size less than 50 patients
1335. Garneata L. Pharmaco-economic evaluation of keto
acid/amino acid-supplemented protein-restricted
diets. Journal of Renal Nutrition 2009; 19(5
Suppl):S19-21. Not early CKD
1336. Garovic V, Textor SC. Renovascular hypertension:
current concepts. Seminars in Nephrology 2005;
25(4):261-71. Sample size less than 50 patients
1337. Garty M, Perry G, Shmueli H, et al. Effect of
cimetidine on digoxin disposition in peptic ulcer
patients. European Journal of Clinical Pharmacology
1986; 30(4):489-91. Sample size less than 50 patients
1338. Garufi C, Levi F, Giunta S, et al. Chronomodulated
5-day infusion of floxuridine and L-folinic acid in
patients with advanced malignancies: a feasibility
and tolerability study. Journal of Infusional
Chemotherapy 1995; 5(3 Suppl 1):134-7. Sample size
less than 50 patients
1339. Garwood S, Swamidoss CP, Davis EA, et al. A case
series of low-dose fenoldopam in seventy cardiac
surgical patients at increased risk of renal
dysfunction. Journal of Cardiothoracic & Vascular
Anesthesia 2003; 17(1):17-21. Not RCT or controlled
trial
1340. Gaspari F, Perico N, Ruggenenti P, et al. Plasma
clearance of nonradioactive iohexol as a measure of
glomerular filtration rate. Journal of the American
Society of Nephrology 1995; 6(2):257-63. Sample
size less than 50 patients
1341. Gassman JJ, Greene T, Wright JT, Jr., et al. Design
and statistical aspects of the African American Study
of Kidney Disease and Hypertension (AASK).
Journal of the American Society of Nephrology
2003; 14(7 Suppl 2):S154-65. Not relevant to key
questions
1342. Gates GF. Filtration fraction and its implications for
radionuclide renography using
diethylenetriaminepentaacetic acid and
mercaptoacetyltriglycine. Clinical Nuclear Medicine
2004; 29(4):231-7. Sample size less than 50 patients
1318. Gambini G, Rossi S, Valori C. Absence of effects of
ketanserin on renal prostacyclin and thromboxane A2
in essential hypertension. European Heart Journal
1991; 12(4):550-3. Sample size less than 50 patients
1319. Gandhi MR, Brown P, Romanowski CA, et al. The
use of theophylline, an adenosine antagonist in the
prevention of contrast media induced
nephrotoxicity.[Republished from Br J Radiol 1992
May;65(773):459]. British Journal of Radiology
1992; 65(777):838. Not RCT or controlled trial
1320. Gandhi SK, Ryder DH, Brown NJ. Losartan blocks
aldosterone and renal vascular responses to
angiotensin II in humans. Hypertension 1996;
28(6):961-6. Sample size less than 50 patients
1321. Ganguli A, Kohli HS, Khullar M, et al. Lipid
peroxidation products formation with various
intravenous iron preparations in chronic kidney
disease. Renal Failure 2009; 31(2):106-10. Not CKD
treatment
1322. Gansevoort RT, de Zeeuw D, de Jong PE. Is the
antiproteinuric effect of ACE inhibition mediated by
interference in the renin-angiotensin system? Kidney
International 1994; 45(3):861-7. Not relevant to key
questions
1323. Gansevoort RT, de Zeeuw D, de Jong PE. Additive
antiproteinuric effect of ACE inhibition and a lowprotein diet in human renal disease. Nephrology
Dialysis Transplantation 1995; 10(4):497-504.
Sample size less than 50 patients
1324. Gansevoort RT, de Zeeuw D, Shahinfar S, et al.
Effects of the angiotensin II antagonist losartan in
hypertensive patients with renal disease. Journal of
Hypertension - Supplement 1994; 12(2):S37-42.
Follow-up less than 6 months
1325. Gansevoort RT, Verhave JC, Hillege HL, et al. The
validity of screening based on spot morning urine
samples to detect subjects with microalbuminuria in
the general population. Kidney International Supplement 2005; (94):S28-35. Not CKD treatment
1326. Gao Y, Lu R, Wang X, et al. A clinical trial of tang
shen ning for treatment of diabetic nephropathy.
Journal of Traditional Chinese Medicine 1998;
18(4):247-52. Not relevant to key questions
1327. Garattini L, Brunetti M, Salvioni F, et al. Economic
evaluation of ACE inhibitor treatment of
nephropathy in patients with insulin-dependent
diabetes mellitus in Italy. Pharmacoeconomics 1997;
12(1):67-75. Not RCT or controlled trial
1328. Garcia CA, Abell-Aleff PC, Gamb SI, et al.
Ultrastructural analysis of amyloidoma.
Ultrastructural Pathology 2009; 33(3):123-7. Not
CKD treatment
1329. Garcia de Vinuesa S, Luno J, Gomez-Campdera F, et
al. Effect of strict blood pressure control on
proteinuria in renal patients treated with different
antihypertensive drugs. Nephrology Dialysis
Transplantation 2001; 16 Suppl 1:78-81. Sample size
less than 50 patients
1330. Garcia-Donaire JA, Segura J, Ruilope LM. An
update of irbesartan and renin-angiotensin system
blockade in diabetic nephropathy. Expert Opinion on
B-103
1343. Gatling W, Knight C, Hill RD. Screening for early
diabetic nephropathy: which sample to detect
microalbuminuria? Diabetic Medicine 1985;
2(6):451-5. Not RCT or controlled trial
1344. Gatot I, Abramov D, Tsodikov V, et al. Should we
give prophylactic renal-dose dopamine after coronary
artery bypass surgery? Journal of Cardiac Surgery
2004; 19(2):128-33. Not relevant to key questions
1345. Gatti AM, Rivasi F. Biocompatibility of micro- and
nanoparticles. Part I: in liver and kidney.
Biomaterials 2002; 23(11):2381-7. Not CKD
treatment
1346. Gaudry SE, Sitar DS, Smyth DD, et al. Gender and
age as factors in the inhibition of renal clearance of
amantadine by quinine and quinidine. Clinical
Pharmacology & Therapeutics 1993; 54(1):23-7.
Follow-up less than 6 months
1347. Gaweda AE, Jacobs AA, Aronoff GR, et al. Model
predictive control of erythropoietin administration in
the anemia of ESRD. American Journal of Kidney
Diseases 2008; 51(1):71-9. Not early CKD
1348. Gayet-Ageron A, Ananworanich J, Jupimai T, et al.
No change in calculated creatinine clearance after
tenofovir initiation among Thai patients. Journal of
Antimicrobial Chemotherapy 2007; 59(5):1034-7.
Not CKD treatment
1349. Gazis A, Page SR. Microalbuminuria screening in
the UK: are we meeting European standards?
Diabetic Medicine 1996; 13(8):764-7. Not RCT or
controlled trial
1350. Gelber RP, Kurth T, Kausz AT, et al. Association
between body mass index and CKD in apparently
healthy men. American Journal of Kidney Diseases
2005; 46(5):871-80. Not RCT or controlled trial
1351. Geluk CA, Asselbergs FW, Hillege HL, et al. Impact
of statins in microalbuminuric subjects with the
metabolic syndrome: a substudy of the PREVEND
Intervention Trial. European Heart Journal 2005;
26(13):1314-20. Sample size less than 50 patients
1352. Gentile MG, Ciceri R, Manna GM, et al. The role of
fibre in the treatment of secondary hyperlipidaemia
in nephrotic patients. European Journal of Clinical
Nutrition 1995; 49 Suppl 3:S239-41. Sample size less
than 50 patients
1353. Gentilini P, La Villa G, Marra F, et al.
Pharmacokinetics and pharmacodynamics of
torasemide and furosemide in patients with diuretic
resistant ascites. Journal of Hepatology 1996;
25(4):481-90. Sample size less than 50 patients
1354. Gentilini P, Romanelli RG, La Villa G, et al. Effects
of low-dose captopril on renal hemodynamics and
function in patients with cirrhosis of the liver.
Gastroenterology 1993; 104(2):588-94. Follow-up
less than 6 months
1355. Genuth S. Insights from the diabetes control and
complications trial/epidemiology of diabetes
interventions and complications study on the use of
intensive glycemic treatment to reduce the risk of
complications of type 1 diabetes. Endocrine Practice
2006; 12 Suppl 1:34-41. Not relevant to key
questions
1356. Georges B, Conil J-M, Seguin T, et al. Population
pharmacokinetics of ceftazidime in intensive care
unit patients: influence of glomerular filtration rate,
mechanical ventilation, and reason for admission.
Antimicrobial Agents & Chemotherapy 2009;
53(10):4483-9. Sample size less than 50 patients
1357. Gerbes AL, Gulberg V, Gines P, et al. Therapy of
hyponatremia in cirrhosis with a vasopressin receptor
antagonist: a randomized double-blind multicenter
trial. Gastroenterology 2003; 124(4):933-9. Not CKD
treatment
1358. Gerhardt T, Terjung B, Knipper P, et al. Renal
impairment after liver transplantation - a pilot trial of
calcineurin inhibitor-free vs. calcineurin inhibitor
sparing immunosuppression in patients with mildly
impaired renal function after liver transplantation.
European Journal of Medical Research 2009;
14(5):210-5. Sample size less than 50 patients
1359. Germain DP, Waldek S, Banikazemi M, et al.
Sustained, long-term renal stabilization after 54
months of agalsidase beta therapy in patients with
Fabry disease. Journal of the American Society of
Nephrology 2007; 18(5):1547-57. Follow-up less
than 6 months
1360. Gerrah R, Ehrlich S, Tshori S, et al. Beneficial effect
of aspirin on renal function in patients with renal
insufficiency postcardiac surgery. Journal of
Cardiovascular Surgery 2004; 45(6):545-50. Not
CKD treatment
1361. Gerstein HC. Diabetes and the HOPE study:
implications for macrovascular and microvascular
disease. International Journal of Clinical Practice
2001; Supplement.(117):8-12. Not CKD treatment
1362. Gerstein HC. Reduction of cardiovascular events and
microvascular complications in diabetes with ACE
inhibitor treatment: HOPE and MICRO-HOPE.
Diabetes/Metabolism Research Reviews 2002; 18
Suppl 3:S82-5. Not relevant to key questions
1363. Gerstein HC, Bosch J, Pogue J, et al. Rationale and
design of a large study to evaluate the renal and
cardiovascular effects of an ACE inhibitor and
vitamin E in high-risk patients with diabetes. The
MICRO-HOPE Study. Microalbuminuria,
cardiovascular, and renal outcomes. Heart Outcomes
Prevention Evaluation. Diabetes Care 1996;
19(11):1225-8. Not RCT or controlled trial
1364. Gerth WC, Remuzzi G, Viberti G, et al. Losartan
reduces the burden and cost of ESRD: public health
implications from the RENAAL study for the
European Union. Kidney International - Supplement
2002; (82):S68-72. Not CKD treatment
1365. Gheith O, Sheashaa H, Abdelsalam M, et al. Efficacy
and safety of Monascus purpureus Went rice in
subjects with secondary hyperlipidemia. Clinical &
Experimental Nephrology 2008; 12(3):189-94. Not
CKD treatment
1366. Gheith O, Sheashaa H, Abdelsalam M, et al. Efficacy
and safety of Monascus purpureus Went rice in
children and young adults with secondary
hyperlipidemia: a preliminary report. European
Journal of Internal Medicine 2009; 20(3):e57-61. Not
CKD treatment
B-104
1367. Gheith OA, Sobh MA-K, Mohamed KE-S, et al.
Impact of treatment of dyslipidemia on renal
function, fat deposits and scarring in patients with
persistent nephrotic syndrome. Nephron 2002;
91(4):612-9. Sample size less than 50 patients
1368. Giamarellou H, Yiallouros K, Petrikkos G, et al.
Comparative kinetics and efficacy of amikacin
administered once or twice daily in the treatment of
systemic gram-negative infections. Journal of
Antimicrobial Chemotherapy 1991; 27 Suppl C:73-9.
Not CKD treatment
1369. Giannini C, Lombardo F, Curro F, et al. Effects of
high-dose vitamin E supplementation on oxidative
stress and microalbuminuria in young adult patients
with childhood onset type 1 diabetes mellitus.
Diabetes/Metabolism Research Reviews 2007;
23(7):539-46. Not RCT or controlled trial
1370. Giatras I, Lau J, Levey AS. Effect of angiotensinconverting enzyme inhibitors on the progression of
nondiabetic renal disease: a meta-analysis of
randomized trials. Angiotensin-Converting-Enzyme
Inhibition and Progressive Renal Disease Study
Group. Annals of Internal Medicine 1997;
127(5):337-45. Not RCT or controlled trial
1371. Gibson CM, Dumaine RL, Gelfand EV, et al.
Association of glomerular filtration rate on
presentation with subsequent mortality in non-STsegment elevation acute coronary syndrome;
observations in 13,307 patients in five TIMI trials.
European Heart Journal 2004; 25(22):1998-2005.
Sample size less than 50 patients
1372. Gilbert DN, Lee BL, Dworkin RJ, et al. A
randomized comparison of the safety and efficacy of
once-daily gentamicin or thrice-daily gentamicin in
combination with ticarcillin-clavulanate. American
Journal of Medicine 1998; 105(3):182-91. Not CKD
treatment
1373. Gilbert RE, Kim SA, Tuttle KR, et al. Effect of
ruboxistaurin on urinary transforming growth factorbeta in patients with diabetic nephropathy and type 2
diabetes. Diabetes Care 2007; 30(4):995-6. Not CKD
treatment
1374. Gilbert S, Zuo C, Epstein FH. Effect of specific and
non-specific inhibition of COX-2 on renal
oxygenation before and after water diuresis.
Nephron. Physiology 2005; 99(4):p101-4. Not
relevant to key questions
1375. Gille J, Spieth K, Kaufmann R. Metronomic lowdose chemotherapy as antiangiogenic therapeutic
strategy for cancer. Journal der Deutschen
Dermatologischen Gesellschaft 2005; 3(1):26-32.
Not RCT or controlled trial
1376. Gillespie EA, Gillespie BW, Stevens MJ. Painful
diabetic neuropathy: impact of an alternative
approach. Diabetes Care 2007; 30(4):999-1001. Not
RCT or controlled trial
1377. Gillis BP, Averbach FM, Caggiula AW, et al.
Features of the nutrient database and analysis system
for the Modification of Diet in Renal Disease
Study.[Erratum appears in Control Clin Trials 1994
Aug;15(4):326]. Controlled Clinical Trials 1994;
15(1):44-58. Not RCT or controlled trial
1378. Gillis BP, Caggiula AW, Chiavacci AT, et al.
Nutrition intervention program of the Modification of
Diet in Renal Disease Study: a self-management
approach. Journal of the American Dietetic
Association 1995; 95(11):1288-94. Not CKD
treatment
1379. Ginifer C, Kelly AM. Administration of rectal
indomethacin does not reduce the requirement for
intravenous narcotic analgesia in acute renal colic.
European Journal of Emergency Medicine 1996;
3(2):92-4. Not CKD treatment
1380. Ginsberg AM, Laurenzi MW, Rouse DJ, et al.
Assessment of the effects of the nitroimidazooxazine PA-824 on renal function in healthy subjects.
Antimicrobial Agents & Chemotherapy 2009;
53(9):3726-33. Follow-up less than 6 months
1381. Giordano M, Castellino P, McConnell EL, et al.
Effect of amino acid infusion on renal
hemodynamics in humans: a dose-response study.
American Journal of Physiology 1994; 267(5 Pt
2):F703-8. Sample size less than 50 patients
1382. Giordano M, Sanders LR, Castellino P, et al. Effect
of alpha-adrenergic blockers, ACE inhibitors, and
calcium channel antagonists on renal function in
hypertensive non-insulin-dependent diabetic patients.
Nephron 1996; 72(3):447-53. Sample size less than
50 patients
1383. Giovannetti S, Barsotti G, Cupisti A, et al. Oral
activated charcoal in patients with uremic pruritus.
Nephron 1995; 70(2):193-6. Sample size less than 50
patients
1384. Girbes AR, Smit AJ, Meijer S, et al. Lithium and the
renal response to gludopa, fenoldopam and
dopamine. British Journal of Clinical Pharmacology
1990; 30(4):652-3. Not RCT or controlled trial
1385. Girbes AR, Smit AJ, Meijer S, et al. Renal and
endocrine effects of fenoldopam and metoclopramide
in normal man. Nephron 1990; 56(2):179-85. Sample
size less than 50 patients
1386. Girbes AR, van Veldhuisen DJ, Smit AJ, et al. Renal
and neurohumoral effects of ibopamine and
metoclopramide in normal man. British Journal of
Clinical Pharmacology 1991; 31(6):701-4. Sample
size less than 50 patients
1387. Girndt M, Pietsch M, Kohler H. Tetanus
immunization and its association to hepatitis B
vaccination in patients with chronic renal failure.
American Journal of Kidney Diseases 1995;
26(3):454-60. Sample size less than 50 patients
1388. Gisclon LG, Boyd RA, Williams RL, et al. The effect
of probenecid on the renal elimination of cimetidine.
Clinical Pharmacology & Therapeutics 1989;
45(4):444-52. Not RCT or controlled trial
1389. Giugliano D, Acampora R, Marfella R, et al.
Hemodynamic and metabolic effects of transdermal
clonidine in patients with hypertension and noninsulin-dependent diabetes mellitus. American
Journal of Hypertension 1998; 11(2):184-9. Sample
size less than 50 patients
1390. Giustina A, Bossoni S, Cimino A, et al. Picotamide, a
dual TXB synthetase inhibitor and TXB receptor
antagonist, reduces exercise-induced albuminuria in
B-105
microalbuminuric patients with NIDDM. Diabetes
1993; 42(1):178-82. Sample size less than 50 patients
1391. Giustina A, Bossoni S, Macca C, et al. Isradipine
decreases exercise-induced albuminuria in patients
with essential hypertension. Renal Failure 1993;
15(4):509-14. Sample size less than 50 patients
1392. Giustina A, Perini P, Desenzani P, et al. Long-term
treatment with the dual antithromboxane agent
picotamide decreases microalbuminuria in
normotensive type 2 diabetic patients. Diabetes 1998;
47(3):423-30. Sample size less than 50 patients
1393. Givertz MM, Massie BM, Fields TK, et al. The
effects of KW-3902, an adenosine A1-receptor
antagonist,on diuresis and renal function in patients
with acute decompensated heart failure and renal
impairment or diuretic resistance. Journal of the
American College of Cardiology 2007; 50(16):155160. Not CKD treatment
1394. Glasser SP. Angiotensin converting enzyme
inhibitors: are they preferred first-line therapy?
Current Hypertension Reports 2000; 2(4):392-7. Not
RCT or controlled trial
1395. Gleiter CH, Becker T, Schreeb KH, et al. Fenoterol
but not dobutamine increases erythropoietin
production in humans. Clinical Pharmacology &
Therapeutics 1997; 61(6):669-76. Sample size less
than 50 patients
1396. Glorioso N, Manunta P, Troffa C, et al. Effects of
nitrendipine on blood pressure, renin-angiotensin
system, and kidney function in essential
hypertension. Journal of Cardiovascular
Pharmacology 1988; 12 Suppl 4:S142-5. Sample size
less than 50 patients
1397. Glynn LG, Buckley B, Reddan D, et al.
Multimorbidity and risk among patients with
established cardiovascular disease: a cohort study.
British Journal of General Practice 2008;
58(552):488-94. Not CKD treatment
1398. Glynn LG, Reddan D, Newell J, et al. Chronic
kidney disease and mortality and morbidity among
patients with established cardiovascular disease: a
West of Ireland community-based cohort study.
Nephrology Dialysis Transplantation 2007;
22(9):2586-94. Sample size less than 50 patients
1399. Gobburu JVS, Sekar VJ. Application of modeling
and simulation to integrate clinical pharmacology
knowledge across a new drug application.
International Journal of Clinical Pharmacology &
Therapeutics 2002; 40(7):281-8. Not early CKD
1400. Goddard J, Johnston NR, Cumming AD, et al.
Fractional urinary excretion of endothelin-1 is
reduced by acute ETB receptor blockade. American
Journal of Physiology - Renal Physiology 2007;
293(5):F1433-8. Not relevant to key questions
1401. Goddard J, Johnston NR, Hand MF, et al.
Endothelin-A receptor antagonism reduces blood
pressure and increases renal blood flow in
hypertensive patients with chronic renal failure: a
comparison of selective and combined endothelin
receptor blockade. Circulation 2004; 109(9):1186-93.
Not CKD treatment
1402. Goenka N, Kotonya C, Penney MD, et al.
Thiazolidinediones and the renal and hormonal
response to water immersion-induced volume
expansion in type 2 diabetes mellitus. American
Journal of Physiology - Endocrinology &
Metabolism 2008; 294(4):E733-9. Not CKD
treatment
1403. Goeters C, Reinhardt C, Gronau E, et al. Minimal
flow sevoflurane and isoflurane anaesthesia and
impact on renal function. European Journal of
Anaesthesiology 2001; 18(1):43-50. Not early CKD
1404. Goicoechea M, de Vinuesa SG, Lahera V, et al.
Effects of atorvastatin on inflammatory and
fibrinolytic parameters in patients with chronic
kidney disease. Journal of the American Society of
Nephrology 2006; 17(12 Suppl 3):S231-5. Not
relevant to key questions
1405. Goicoechea M, Liu S, Best B, et al. Greater
tenofovir-associated renal function decline with
protease inhibitor-based versus nonnucleoside
reverse-transcriptase inhibitor-based therapy. Journal
of Infectious Diseases 2008; 197(1):102-8. Followup less than 6 months
1406. Golan L, Birkmeyer JD, Welch HG. The costeffectiveness of treating all patients with type 2
diabetes with angiotensin-converting enzyme
inhibitors. Annals of Internal Medicine 1999;
131(9):660-7. Not CKD treatment
1407. Goldberg DI, Dillon MA, Slatopolsky EA, et al.
Effect of RenaGel, a non-absorbed, calcium- and
aluminium-free phosphate binder, on serum
phosphorus, calcium, and intact parathyroid hormone
in end-stage renal disease patients. Nephrology
Dialysis Transplantation 1998; 13(9):2303-10.
Follow-up less than 6 months
1408. Goldenberg I, Chonchol M, Guetta V. Reversible
acute kidney injury following contrast exposure and
the risk of long-term mortality. American Journal of
Nephrology 2009; 29(2):136-44. Not CKD treatment
1409. Goldenberg I, Moss AJ, McNitt S, et al. Relations
among renal function, risk of sudden cardiac death,
and benefit of the implanted cardiac defibrillator in
patients with ischemic left ventricular dysfunction.
American Journal of Cardiology 2006; 98(4):485-90.
Not RCT or controlled trial
1410. Goldenberg I, Shechter M, Matetzky S, et al. Oral
acetylcysteine as an adjunct to saline hydration for
the prevention of contrast-induced nephropathy
following coronary angiography. A randomized
controlled trial and review of the current literature.
European Heart Journal 2004; 25(3):212-8. Not CKD
treatment
1411. Goldfarb B, Pardoux CM. Exploring series of
multivariate censored temporal data through fuzzy
coding and correspondence analysis. Statistics in
Medicine 2006; 25(10):1741-50. Not RCT or
controlled trial
1412. Goldfarb S, Spinler S, Berns JS, et al. Lowosmolality contrast media and the risk of contrastassociated nephrotoxicity. Investigative Radiology
1993; 28 Suppl 5:S7-10; discussion S1-2. Not CKD
treatment
B-106
1413. Goldfarb S, Walker BR, Agus ZS. The uricosuric
effect of oxaprozin in humans. Journal of Clinical
Pharmacology 1985; 25(2):144-8. Sample size less
than 50 patients
1414. Goldfarb-Rumyantzev AS, Pappas L. Prediction of
renal insufficiency in Pima Indians with nephropathy
of type 2 diabetes mellitus. American Journal of
Kidney Diseases 2002; 40(2):252-64. Not CKD
treatment
1415. Goldsmith DJ, Covic A. Coronary artery disease in
uremia: Etiology, diagnosis, and therapy. Kidney
International 2001; 60(6):2059-78. Not early CKD
1416. Goldstein DJ, Wang O, Gitter BD, et al. Doseresponse study of the analgesic effect of lanepitant in
patients with painful diabetic neuropathy. Clinical
Neuropharmacology 2001; 24(1):16-22. Not CKD
treatment
1417. Golightly LK, O'Fallon CL, Moran WD, et al.
Pharmacist monitoring of drug therapy in patients
with abnormal serum creatinine levels. Hospital
Pharmacy 1993; 28(8):725-7. Sample size less than
50 patients
1418. Golper TA, Illingworth DR, Morris CD, et al.
Lovastatin in the treatment of multifactorial
hyperlipidemia associated with proteinuria.
American Journal of Kidney Diseases 1989;
13(4):312-20. Sample size less than 50 patients
1419. Gomes VO, Poli de Figueredo CE, Caramori P, et al.
N-acetylcysteine does not prevent contrast induced
nephropathy after cardiac catheterisation with an
ionic low osmolality contrast medium: a multicentre
clinical trial. Heart 2005; 91(6):774-8. Not relevant
to key questions
1420. Gonzalez GL, Manrique CM, Sowers JR. High
cardiovascular risk in patients with diabetes and the
cardiometabolic syndrome: mandate for statin
therapy. Journal of the CardioMetabolic Syndrome
2006; 1(3):178-83. Not RCT or controlled trial
1421. Gonzalez RP, Falimirski M, Holevar MR, et al.
Surgical management of renal trauma: is vascular
control necessary? Journal of Trauma-Injury
Infection & Critical Care 1999; 47(6):1039-42;
discussion 42-4. Not CKD treatment
1422. Gonzalez-Abraldes J, Albillos A, Banares R, et al.
Randomized comparison of long-term losartan versus
propranolol in lowering portal pressure in cirrhosis.
Gastroenterology 2001; 121(2):382-8. Not early
CKD
1423. Gonzalez-Ortiz M, Mora-Martinez JM, MartinezAbundis E, et al. Effect of valsartan on renal
handling of uric acid in healthy subjects. Journal of
Nephrology 2000; 13(2):126-8. Not early CKD
1424. Good J, Frost G, Oakley CM, et al. The renal effects
of dopamine and dobutamine in stable chronic heart
failure. Postgraduate Medical Journal 1992; 68 Suppl
2:S7-11. Not CKD treatment
1425. Good JM, Brady AJ, Noormohamed FH, et al. Effect
of intense angiotensin II suppression on the diuretic
response to furosemide during chronic ACE
inhibition. Circulation 1994; 90(1):220-4. Sample
size less than 50 patients
1426. Goodman WG, Frazao JM, Goodkin DA, et al. A
calcimimetic agent lowers plasma parathyroid
hormone levels in patients with secondary
hyperparathyroidism. Kidney International 2000;
58(1):436-45. Not early CKD
1427. Goonasekera CD, Dillon MJ. Random zero
sphygmomanometer versus automatic oscillometric
blood pressure monitor; is either the instrument of
choice? Journal of Human Hypertension 1995;
9(11):885-9. Not CKD treatment
1428. Gordon EJ, Prohaska TR, Gallant MP, et al.
Longitudinal analysis of physical activity, fluid
intake, and graft function among kidney transplant
recipients. Transplant International 2009;
22(10):990-8. Not RCT or controlled trial
1429. Gorse GJ, Bernstein JM, Cronin RE, et al. A
comparison of netilmicin and tobramycin therapy in
patients with renal impairment. Scandinavian Journal
of Infectious Diseases 1992; 24(4):503-14. Not CKD
treatment
1430. Goswami K, Gachhui R, Bandopadhyay A.
Hepatorenal dysfunctions in lead pollution. Journal
of Environmental Science & Engineering 2005;
47(1):75-80. Sample size less than 50 patients
1431. Goto F, Kato S, Sudo I. Treatment of intraoperative
hypertension with enflurane, nicardipine, or human
atrial natriuretic peptide: haemodynamic and renal
effects. Canadian Journal of Anaesthesia 1992;
39(9):932-7. Not CKD treatment
1432. Gottesman RF, Sozio SM. Management of
symptomatic carotid stenosis in individuals with
CKD. Journal of the American Society of
Nephrology 2010; 21(1):9-11. Not RCT or controlled
trial
1433. Gottlieb SS. Adenosine A1 antagonists and the
cardiorenal syndrome. Current Heart Failure Reports
2008; 5(2):105-9. Not CKD treatment
1434. Gottlieb SS, Brater DC, Thomas I, et al. BG9719
(CVT-124), an A1 adenosine receptor antagonist,
protects against the decline in renal function
observed with diuretic therapy.[Erratum appears in
Circulation 2002 Sep 24;106(13):1743]. Circulation
2002; 105(11):1348-53. Follow-up less than 6
months
1435. Gottlieb SS, Skettino SL, Wolff A, et al. Effects of
BG9719 (CVT-124), an A1-adenosine receptor
antagonist, and furosemide on glomerular filtration
rate and natriuresis in patients with congestive heart
failure. Journal of the American College of
Cardiology 2000; 35(1):56-9. Sample size less than
50 patients
1436. Gould MM, Mohamed-Ali V, Goubet SA, et al.
Associations of urinary albumin excretion rate with
vascular disease in europid nondiabetic subjects.
Journal of Diabetes & its Complications 1994;
8(3):180-8. Not RCT or controlled trial
1437. Gouva C, Nikolopoulos P, Ioannidis JPA, et al.
Treating anemia early in renal failure patients slows
the decline of renal function: a randomized
controlled trial. Kidney International 2004;
66(2):753-60. Not relevant to key questions
B-107
1438. Govindarajan G, Saab G, Whaley-Connell A.
Outcomes of carotid revascularization in patients
with chronic kidney disease. Advances in Chronic
Kidney Disease 2008; 15(4):347-54. Not CKD
treatment
1439. Graber SE, Krantz SB. Erythropoietin: biology and
clinical use. Hematology - Oncology Clinics of North
America 1989; 3(3):369-400. Not relevant to key
questions
1440. Gradman AH. Evolving understanding of the reninangiotensin-aldosterone system: pathophysiology and
targets for therapeutic intervention. American Heart
Journal 2009; 157(6 Suppl):S1-6. Not RCT or
controlled trial
1441. Graiff C, Bezza M, Ziller F, et al. Caerulein in the
treatment of biliary and renal colic. Peptides 1985; 6
Suppl 3:47-51. Not CKD treatment
1442. Grande L, Rimola A, Cugat E, et al. Effect of
venovenous bypass on perioperative renal function in
liver transplantation: results of a randomized,
controlled trial. Hepatology 1996; 23(6):1418-28.
Not CKD treatment
1443. Grant MC, Kon Z, Joshi A, et al. Is aprotinin safe to
use in a cohort at increased risk for thrombotic
events: results from a randomized, prospective trial
in off-pump coronary artery bypass. Annals of
Thoracic Surgery 2008; 86(3):815-22; discussion 22. Sample size less than 50 patients
1444. Gras J, Llenas J, Jansat JM, et al. Almotriptan, a new
anti-migraine agent: a review. CNS Drug Reviews
2002; 8(3):217-34. Not CKD treatment
1445. Grases F, Garcia-Gonzalez R, Redondo E, et al.
Effects of escin on indinavir crystallization time in
the urine of patients with HIV-I infection: a
multicenter, randomized, open-label, controlled,
four-period crossover trial. Clinical Therapeutics
2004; 26(12):2045-55. Follow-up less than 6 months
1446. Grassegger A, Schuler G, Hessenberger G, et al.
Interferon-gamma in the treatment of systemic
sclerosis: a randomized controlled multicentre trial.
British Journal of Dermatology 1998; 139(4):639-48.
Sample size less than 50 patients
1447. Greenbaum R, Zucchelli P, Caspi A, et al.
Comparison of the pharmacokinetics of fosinoprilat
with enalaprilat and lisinopril in patients with
congestive heart failure and chronic renal
insufficiency. British Journal of Clinical
Pharmacology 2000; 49(1):23-31. Follow-up less
than 6 months
1448. Greenberg B, Thomas I, Banish D, et al. Effects of
multiple oral doses of an A1 adenosine antagonist,
BG9928, in patients with heart failure: results of a
placebo-controlled, dose-escalation study. Journal of
the American College of Cardiology 2007;
50(7):600-6. Not RCT or controlled trial
1449. Greene T, Daugirdas JT, Depner TA, et al. Solute
clearances and fluid removal in the frequent
hemodialysis network trials. American Journal of
Kidney Diseases 2009; 53(5):835-44. Not early CKD
1450. Greenstone MA, Shaw AB. Alternate day
corticosteroid causes alternate day hyperglycaemia.
Postgraduate Medical Journal 1987; 63(743):761-4.
Not RCT or controlled trial
1451. Greenwood V. ARBs vs ACE inhibitors for
preventing diabetic nephropathy. Journal of Family
Practice 2005; 54(5):453; discussion -4. Not RCT or
controlled trial
1452. Gregory DD, Sarnak MJ, Konstam MA, et al. Impact
of chronic kidney disease and anemia on
hospitalization expense in patients with left
ventricular dysfunction. American Journal of
Cardiology 2003; 92(11):1300-5. Not CKD treatment
1453. Greminger P, Foerster E, Vetter H, et al. Minoxidil
and captopril in severe hypertension. Klinische
Wochenschrift 1986; 64(7):327-32. Sample size less
than 50 patients
1454. Gretz N, Strauch M. Statistical problems in
designing, conducting, and analysing nutritional
trials in patients with chronic renal failure.
Contributions to Nephrology 1986; 53:82-91. Not
RCT or controlled trial
1455. Grima KM. Therapeutic apheresis in hematological
and oncological diseases. Journal of Clinical
Apheresis 2000; 15(1-2):28-52. Not relevant to key
questions
1456. Grimm RH, Jr., Svendsen KH, Kasiske B, et al.
Proteinuria is a risk factor for mortality over 10 years
of follow-up. MRFIT Research Group. Multiple Risk
Factor Intervention Trial. Kidney International Supplement 1997; 63:S10-4. Not RCT or controlled
trial
1457. Groban L, Ebert TJ, Kreis DU, et al. Hemodynamic,
renal, and hormonal responses to incremental ANF
infusions in humans. American Journal of
Physiology 1989; 256(5 Pt 2):F780-6. Sample size
less than 50 patients
1458. Groetzner J, Kaczmarek I, Landwehr P, et al. Renal
recovery after conversion to a calcineurin inhibitorfree immunosuppression in late cardiac transplant
recipients. European Journal of Cardio-Thoracic
Surgery 2004; 25(3):333-41. Sample size less than 50
patients
1459. Groetzner J, Kaczmarek I, Schulz U, et al.
Mycophenolate and sirolimus as calcineurin
inhibitor-free immunosuppression improves renal
function better than calcineurin inhibitor-reduction in
late cardiac transplant recipients with chronic renal
failure.[Erratum appears in Transplantation. 2009
Apr 27;87(8):1264]. Transplantation 2009;
87(5):726-33. Not CKD treatment
1460. Groetzner J, Meiser B, Landwehr P, et al.
Mycophenolate mofetil and sirolimus as calcineurin
inhibitor-free immunosuppression for late cardiactransplant recipients with chronic renal failure.
Transplantation 2004; 77(4):568-74. Not CKD
treatment
1461. Groetzner J, Meiser BM, Schirmer J, et al.
Tacrolimus or cyclosporine for immunosuppression
after cardiac transplantation: which treatment reveals
more side effects during long-term follow-up?
Transplantation Proceedings 2001; 33(1-2):1461-4.
Not CKD treatment
B-108
1462. Groetzner J, Wittwer T, Kaczmarek I, et al.
Conversion to sirolimus and mycophenolate can
attenuate the progression of bronchiolitis obliterans
syndrome and improves renal function after lung
transplantation. Transplantation 2006; 81(3):355-60.
Sample size less than 50 patients
1463. Groggel GC, Cheung AK, Ellis-Benigni K, et al.
Treatment of nephrotic hyperlipoproteinemia with
gemfibrozil. Kidney International 1989; 36(2):26671. Sample size less than 50 patients
1464. Gross AS, McLachlan AJ, Minns I, et al.
Simultaneous administration of a cocktail of markers
to measure renal drug elimination pathways: absence
of a pharmacokinetic interaction between fluconazole
and sinistrin, p-aminohippuric acid and pindolol.
British Journal of Clinical Pharmacology 2001;
51(6):547-55. Not CKD treatment
1465. Gross JL, Zelmanovitz T, Moulin CC, et al. Effect of
a chicken-based diet on renal function and lipid
profile in patients with type 2 diabetes: a randomized
crossover trial. Diabetes Care 2002; 25(4):645-51.
Sample size less than 50 patients
1466. Grossman E, Messerli FH. Why beta-blockers are not
cardioprotective in elderly patients with
hypertension. Current Cardiology Reports 2002;
4(6):468-73. Not RCT or controlled trial
1467. Grossman PD, Burroughs M, Guthmann RA. Clinical
inquiries. What interventions reduce the risk of
contrast nephropathy for high-risk patients? Journal
of Family Practice 2005; 54(4):365-7. Not RCT or
controlled trial
1468. Grossman RM, Chevret S, Abi-Rached J, et al. Longterm safety of cyclosporine in the treatment of
psoriasis. Archives of Dermatology 1996;
132(6):623-9. Not CKD treatment
1469. Grostern RJ, Bryar PJ, Zimbric ML, et al. Toxicity
and dose-response studies of 1alpha-hydroxyvitamin
D2 in a retinoblastoma xenograft model. Archives of
Ophthalmology 2002; 120(5):607-12. Not human
studies
1470. Groth S, Nielsen H, Sorensen JB, et al. Acute and
long-term nephrotoxicity of cis-platinum in man.
Cancer Chemotherapy & Pharmacology 1986;
17(2):191-6. Not CKD treatment
1471. Group ACEIiPRDS. Summaries for patients. Using a
type of blood pressure medicine, angiotensinconverting enzyme inhibitors, to prevent worsening
of kidney disease unrelated to diabetes. Annals of
Internal Medicine 2001; 135(2):S-21. Not RCT or
controlled trial
1472. Group ACEIiDNT. Should all patients with type 1
diabetes mellitus and microalbuminuria receive
angiotensin-converting enzyme inhibitors? A metaanalysis of individual patient data. Annals of Internal
Medicine 2001; 134(5):370-9. Not relevant to key
questions
1473. Group B. The BErgamo NEphrologic DIabetes
Complications Trial (BENEDICT): design and
baseline characteristics. Controlled Clinical Trials
2003; 24(4):442-61. Not RCT or controlled trial
1474. Group PS. Dissociation between blood pressure
reduction and fall in proteinuria in primary renal
disease: a randomized double-blind trial. Journal of
Hypertension 2002; 20(4):729-37. Not CKD
treatment
1475. Grover-Paez F, Villegas Rivera G, Guillen Ortiz R.
Sildenafil citrate diminishes microalbuminuria and
the percentage of A1c in male patients with type 2
diabetes. Diabetes Research & Clinical Practice
2007; 78(1):136-40. Follow-up less than 6 months
1476. Gruberg L, Waksman R, Ajani AE, et al. The effect
of intracoronary radiation for the treatment of
recurrent in-stent restenosis in patients with chronic
renal failure. Journal of the American College of
Cardiology 2001; 38(4):1049-53. Not RCT or
controlled trial
1477. Gruss E, Tomas JF, Bernis C, et al. Nephroprotective
effect of cilastatin in allogeneic bone marrow
transplantation. Results from a retrospective analysis.
Bone Marrow Transplantation 1996; 18(4):761-5.
Not RCT or controlled trial
1478. Gualano B, Ugrinowitsch C, Novaes RB, et al.
Effects of creatine supplementation on renal
function: a randomized, double-blind, placebocontrolled clinical trial. European Journal of Applied
Physiology 2008; 103(1):33-40. Not CKD treatment
1479. Guasch A, Parham M, Zayas CF, et al. Contrasting
effects of calcium channel blockade versus
converting enzyme inhibition on proteinuria in
African Americans with non-insulin-dependent
diabetes mellitus and nephropathy. Journal of the
American Society of Nephrology 1997; 8(5):793-8.
Sample size less than 50 patients
1480. Guastalla JP, Vermorken JB, Wils JA, et al. Phase II
trial for intraperitoneal cisplatin plus intravenous
sodium thiosulphate in advanced ovarian carcinoma
patients with minimal residual disease after cisplatinbased chemotherapy--a phase II study of the EORTC
Gynaecological Cancer Cooperative Group.
European Journal of Cancer 1994; 30A(1):45-9. Not
CKD treatment
1481. Gubern JM, Sancho JJ, Simo J, et al. A randomized
trial on the effect of mannitol on postoperative renal
function in patients with obstructive jaundice.
Surgery 1988; 103(1):39-44. Sample size less than 50
patients
1482. Gudbjornsdottir S, Friberg P, Elam M, et al. The
effect of metformin and insulin on sympathetic nerve
activity, norepinephrine spillover and blood pressure
in obese, insulin resistant, normoglycemic,
hypertensive men. Blood Pressure 1994; 3(6):394403. Sample size less than 50 patients
1483. Guerin C, Girard R, Selli JM, et al. Initial versus
delayed acute renal failure in the intensive care unit.
A multicenter prospective epidemiological study.
Rhone-Alpes Area Study Group on Acute Renal
Failure.[Erratum appears in Am J Respir Crit Care
Med 2001 Mar;163(3 Pt 1):793-4]. American Journal
of Respiratory & Critical Care Medicine 2000; 161(3
Pt 1):872-9. Not RCT or controlled trial
1484. Guerra JG, Casalino E, Palomino JC, et al.
Imipenem/cilastatin vs. gentamicin/clindamycin for
the treatment of moderate to severe infections in
B-109
Cardiology 2004; 44(7):1343-53. Follow-up less than
6 months
1498. Gupta RK, Kapoor A, Tewari S, et al. Captopril for
prevention of contrast-induced nephropathy in
diabetic patients: a randomised study. Indian Heart
Journal 1999; 51(5):521-6. Not early CKD
1499. Gupta RK, Kjeldsen SE, Krause L, et al.
Hemodynamic effects of quinapril, a novel
angiotensin-converting enzyme inhibitor. Clinical
Pharmacology & Therapeutics 1990; 48(1):41-9.
Sample size less than 50 patients
1500. Gupta SK, Parker RA, Robbins GK, et al. The effects
of highly active antiretroviral therapy on albuminuria
in HIV-infected persons: results from a randomized
trial. Nephrology Dialysis Transplantation 2005;
20(10):2237-42. Not CKD treatment
1501. Gupta SK, Smurzynski M, Franceschini N, et al. The
effects of HIV type-1 viral suppression and non-viral
factors on quantitative proteinuria in the highly
active antiretroviral therapy era. Antiviral Therapy
2009; 14(4):543-9. Not RCT or controlled trial
1502. Gurley SB, Coffman TM. The renin-angiotensin
system and diabetic nephropathy. Seminars in
Nephrology 2007; 27(2):144-52. Not RCT or
controlled trial
1503. Gurm HS, Lincoff AM, Kleiman NS, et al. Double
jeopardy of renal insufficiency and anemia in
patients undergoing percutaneous coronary
interventions. American Journal of Cardiology 2004;
94(1):30-4. Not CKD treatment
1504. Guru V, Fremes SE. The role of N-acetylcysteine in
preventing radiographic contrast-induced
nephropathy. Clinical Nephrology 2004; 62(2):77-83.
Not CKD treatment
1505. Gutzwiller J-P, Tschopp S, Bock A, et al. Glucagonlike peptide 1 induces natriuresis in healthy subjects
and in insulin-resistant obese men. Journal of
Clinical Endocrinology & Metabolism 2004;
89(6):3055-61. Not relevant to key questions
1506. Guy M, Newall R, Borzomato J, et al. Use of a firstline urine protein-to-creatinine ratio strip test on
random urines to rule out proteinuria in patients with
chronic kidney disease. Nephrology Dialysis
Transplantation 2009; 24(4):1189-93. Not CKD
treatment
1507. Guy M, Newall R, Borzomato J, et al. Diagnostic
accuracy of the urinary albumin: creatinine ratio
determined by the CLINITEK Microalbumin and
DCA 2000+ for the rule-out of albuminuria in
chronic kidney disease. Clinica Chimica Acta 2009;
399(1-2):54-8. Not CKD treatment
1508. Guy M, Newall R, Borzomato J, et al. Use of a firstline urine protein-to-creatinine ratio strip test on
random urines to rule out proteinuria in patients with
chronic kidney disease. Nephrology Dialysis
Transplantation 2009; 24(4):1189-93. Not CKD
treatment
1509. Haase M, Haase-Fielitz A, Bagshaw SM, et al. Phase
II, randomized, controlled trial of high-dose Nacetylcysteine in high-risk cardiac surgery patients.
Critical Care Medicine 2007; 35(5):1324-31. Not
RCT or controlled trial
hospitalized patients. Reviews of Infectious Diseases
1985; 7 Suppl 3:S463-70. Not early CKD
1485. Guerrero-Romero F, Rodriguez-Moran M, PaniaguaSierra JR, et al. Pentoxifylline reduces proteinuria in
insulin-dependent and non insulin-dependent diabetic
patients. Clinical Nephrology 1995; 43(2):116-21.
Follow-up less than 6 months
1486. Guglielmi G, de Terlizzi F, Aucella F, et al.
Quantitative ultrasound technique at the phalanges in
discriminating between uremic and osteoporotic
patients. European Journal of Radiology 2006;
60(1):108-14. Not RCT or controlled trial
1487. Guillet C. Overview of novel renal properties of
tertatolol. Cardiology 1993; 83 Suppl 1:64-9. Sample
size less than 50 patients
1488. Guillevin L, Le Thi Huong Du, Godeau P, et al.
Clinical findings and prognosis of polyarteritis
nodosa and Churg-Strauss angiitis: a study in 165
patients. British Journal of Rheumatology 1988;
27(4):258-64. Not RCT or controlled trial
1489. Guitterez NV, Diaz A, Timmis GC, et al.
Determinants of serum creatinine trajectory in acute
contrast nephropathy. Journal of Interventional
Cardiology 2002; 15(5):349-54. Not CKD treatment
1490. Guizar JM, Kornhauser C, Malacara JM, et al. Renal
functional reserve in patients with recently diagnosed
Type 2 diabetes mellitus with and without
microalbuminuria. Nephron 2001; 87(3):223-30. Not
RCT or controlled trial
1491. Gulel O, Keles T, Eraslan H, et al. Prophylactic
acetylcysteine usage for prevention of contrast
nephropathy after coronary angiography. Journal of
Cardiovascular Pharmacology 2005; 46(4):464-7.
Follow-up less than 6 months
1492. Gulmann C, Rudberg S, Osterby R. Renal arterioles
in patients with type I diabetes and microalbuminuria
before and after treatment with antihypertensive
drugs. Virchows Archiv 1999; 434(6):523-8. Sample
size less than 50 patients
1493. Gunning TC, Brown MR, Swygert TH, et al.
Perioperative renal function in patients undergoing
orthotopic liver transplantation. A randomized trial
of the effects of verapamil. Transplantation 1991;
51(2):422-7. Not CKD treatment
1494. Gunst J, Schetz M. Clinical benefits of tight
glycaemic control: effect on the kidney. Best Practice
& Research 2009; Clinical Anaesthesiology.
23(4):431-9. Not RCT or controlled trial
1495. Guo LL, Pan Y, Jin HM. Adiponectin is positively
associated with insulin resistance in subjects with
type 2 diabetic nephropathy and effects of
angiotensin II type 1 receptor blocker losartan.
Nephrology Dialysis Transplantation 2009;
24(6):1876-83. Not relevant to key questions
1496. Gupta AK, Rocher LL, Schmaltz SP, et al. Shortterm changes in renal function, blood pressure, and
electrolyte levels in patients receiving cyclosporine
for dermatologic disorders. Archives of Internal
Medicine 1991; 151(2):356-62. Not CKD treatment
1497. Gupta R, Birnbaum Y, Uretsky BF. The renal patient
with coronary artery disease: current concepts and
dilemmas. Journal of the American College of
B-110
1510. Haase M, Haase-Fielitz A, Bellomo R, et al. Sodium
bicarbonate to prevent increases in serum creatinine
after cardiac surgery: a pilot double-blind,
randomized controlled trial. Critical Care Medicine
2009; 37(1):39-47. Not RCT or controlled trial
1511. Haase M, Haase-Fielitz A, Ratnaike S, et al. NAcetylcysteine does not artifactually lower plasma
creatinine concentration. Nephrology Dialysis
Transplantation 2008; 23(5):1581-7. Follow-up less
than 6 months
1512. Hadjadj S, Gourdy P, Zaoui P, et al. Effect of
raloxifene -- a selective oestrogen receptor modulator
-- on kidney function in post-menopausal women
with Type 2 diabetes: results from a randomized,
placebo-controlled pilot trial. Diabetic Medicine
2007; 24(8):906-10. Not relevant to key questions
1513. Hadj-Aissa A, Bankir L, Fraysse M, et al. Influence
of the level of hydration on the renal response to a
protein meal. Kidney International 1992; 42(5):120716. Sample size less than 50 patients
1514. Hadjibabaie M, Alimoghaddam K, Shamshiri AR, et
al. Continuous bladder irrigation prevents
hemorrhagic cystitis after allogeneic hematopoietic
cell transplantation. Urologic Oncology 2008;
26(1):43-6. Sample size less than 50 patients
1515. Haffner CA, Kendall MJ, Struthers AD, et al. Effects
of captopril and enalapril on renal function in elderly
patients with chronic heart failure. Postgraduate
Medical Journal 1995; 71(835):287-92. Follow-up
less than 6 months
1516. Hafner J, Keusch G, Wahl C, et al. Uremic smallartery disease with medial calcification and intimal
hyperplasia (so-called calciphylaxis): a complication
of chronic renal failure and benefit from
parathyroidectomy. Journal of the American
Academy of Dermatology 1995; 33(6):954-62. Not
RCT or controlled trial
1517. Hager B, Betschart M, Krapf R. Effect of
postoperative intravenous loop diuretic on renal
function after major surgery. Schweizerische
Medizinische Wochenschrift 1996; Journal Suisse de
Medecine. 126(16):666-73. Follow-up less than 6
months
1518. Hagg E, Carlberg BC, Hillorn VS, et al. Magnesium
therapy in type 1 diabetes. A double blind study
concerning the effects on kidney function and serum
lipid levels. Magnesium Research 1999; 12(2):12330. Sample size less than 50 patients
1519. Haghi D, Papavassiliu T, Hach C, et al. Utility of
combined parameters of common carotid intimamedia thickness or albuminuria in diagnosis of
coronary artery disease in women. International
Journal of Cardiology 2005; 105(2):134-40. Followup less than 6 months
1520. Haight AE, Kaste SC, Goloubeva OG, et al.
Nephrotoxicity of iopamidol in pediatric, adolescent,
and young adult patients who have undergone
allogeneic bone marrow transplantation. Radiology
2003; 226(2):399-404. Not CKD treatment
1521. Hailpern SM, Melamed ML, Cohen HW, et al.
Moderate chronic kidney disease and cognitive
function in adults 20 to 59 years of age: Third
National Health and Nutrition Examination Survey
(NHANES III). Journal of the American Society of
Nephrology 2007; 18(7):2205-13. Not CKD
treatment
1522. Haines AP, Sanders TA, Imeson JD, et al. Effects of
a fish oil supplement on platelet function,
haemostatic variables and albuminuria in insulindependent diabetics. Thrombosis Research 1986;
43(6):643-55. Sample size less than 50 patients
1523. Hale WA, Nashelsky J, Wilson SA. Clinical
inquiries. Does screening for microalbuminuria in
diabetes prevent complications? Journal of Family
Practice 2003; 52(3):229-31. Not RCT or controlled
trial
1524. Halimi JM, Asmar R, Ribstein J. Optimal
nephroprotection: use, misuse and misconceptions
about blockade of the renin-angiotensin system.
Lessons from the ONTARGET and other recent
trials. Diabetes & Metabolism 2009; 35(6):425-30.
Not RCT or controlled trial
1525. Halkin A, Mehran R, Casey CW, et al. Impact of
moderate renal insufficiency on restenosis and
adverse clinical events after paclitaxel-eluting and
bare metal stent implantation: results from the
TAXUS-IV Trial. American Heart Journal 2005;
150(6):1163-70. Not relevant to key questions
1526. Hall AM, Edwards SG, Lapsley M, et al. Subclinical
tubular injury in HIV-infected individuals on
antiretroviral therapy: a cross-sectional analysis.
American Journal of Kidney Diseases 2009;
54(6):1034-42. Not RCT or controlled trial
1527. Hall WD, Kusek JW, Kirk KA, et al. Short-term
effects of blood pressure control and antihypertensive
drug regimen on glomerular filtration rate: the
African-American Study of Kidney Disease and
Hypertension Pilot Study. American Journal of
Kidney Diseases 1997; 29(5):720-8. Follow-up less
than 6 months
1528. Hallab M, Gallois Y, Chatellier G, et al. Comparison
of reduction in microalbuminuria by enalapril and
hydrochlorothiazide in normotensive patients with
insulin dependent diabetes. BMJ 1993;
306(6871):175-82. Sample size less than 50 patients
1529. Hallan H, Romundstad S, Kvenild K, et al.
Microalbuminuria in diabetic and hypertensive
patients and the general population--consequences of
various diagnostic criteria--the Nord-Trondelag
Health Study (HUNT). Scandinavian Journal of
Urology & Nephrology 2003; 37(2):151-8. Not CKD
treatment
1530. Hallen B, Guilbaud O, Stromberg S, et al. Singledose pharmacokinetics of terodiline, including a
stable isotope technique for improvement of
statistical evaluations. Biopharmaceutics & Drug
Disposition 1988; 9(3):229-50. Sample size less than
50 patients
1531. Haller H, Viberti GC, Mimran A, et al. Preventing
microalbuminuria in patients with diabetes: rationale
and design of the Randomised Olmesartan and
Diabetes Microalbuminuria Prevention
(ROADMAP) study. Journal of Hypertension 2006;
24(2):403-8. Not relevant to key questions
B-111
1532. Halpenny M, Lakshmi S, O'Donnell A, et al.
Fenoldopam: renal and splanchnic effects in patients
undergoing coronary artery bypass grafting.
Anaesthesia 2001; 56(10):953-60. Sample size less
than 50 patients
1533. Halpenny M, Rushe C, Breen P, et al. The effects of
fenoldopam on renal function in patients undergoing
elective aortic surgery. European Journal of
Anaesthesiology 2002; 19(1):32-9. Not early CKD
1534. Halperin AK, Cubeddu LX. The role of calcium
channel blockers in the treatment of hypertension.
American Heart Journal 1986; 111(2):363-82. Not
RCT or controlled trial
1535. Halperin M, Lan KK, Wright EC, et al. Stochastic
curtailing for comparison of slopes in longitudinal
studies. Controlled Clinical Trials 1987; 8(4):315-26.
Not RCT or controlled trial
1536. Hamazaki T, Takazakura E, Osawa K, et al.
Reduction in microalbuminuria in diabetics by
eicosapentaenoic acid ethyl ester. Lipids 1990;
25(9):541-5. Sample size less than 50 patients
1537. Hamilton RA, Kane MP, Demers J. Angiotensinconverting enzyme inhibitors and type 2 diabetic
nephropathy: a meta-analysis. Pharmacotherapy
2003; 23(7):909-15. Not RCT or controlled trial
1538. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino
acid infusion blocks renal tubular uptake of an
indium-labelled somatostatin analogue. British
Journal of Cancer 1993; 67(6):1437-9. Not CKD
treatment
1539. Hampl H, Steinmuller T, Frohling P, et al. Long-term
results of total parathyroidectomy without
autotransplantation in patients with and without renal
failure. Mineral & Electrolyte Metabolism 1999;
25(3):161-70. Not early CKD
1540. Haneda M, Kikkawa R, Sakai H, et al.
Antiproteinuric effect of candesartan cilexetil in
Japanese subjects with type 2 diabetes and
nephropathy. Diabetes Research & Clinical Practice
2004; 66(1):87-95. Not relevant to key questions
1541. Hannedouche T, Chanard J, Baumelou B, et al.
Evaluation of the safety and efficacy of telmisartan
and enalapril, with the potential addition of
frusemide, in moderate-renal failure patients with
mild-to-moderate hypertension. Journal of the ReninAngiotensin-Aldosterone System 2001; 2(4):246-54.
Follow-up less than 6 months
1542. Hannedouche T, Natov S, Ikeni A, et al. Does
lithium affect renal sodium handling and renal
haemodynamics in normal man? Nephrology
Dialysis Transplantation 1990; 5(12):1007-12. Not
CKD treatment
1543. Hannedouche TP, Natov S, Boitard C, et al.
Angiotensin converting enzyme inhibition and
chronic cyclosporine-induced renal dysfunction in
type 1 diabetes. Nephrology Dialysis Transplantation
1996; 11(4):673-8. Follow-up less than 6 months
1544. Hannisdal E, Kildahl-Andersen O, Grottum KA, et
al. Prognostic factors in multiple myeloma in a
population-based trial. European Journal of
Haematology 1990; 45(4):198-202. Not CKD
treatment
1545. Hans B, Hans SS, Mittal VK, et al. Renal functional
response to dopamine during and after arteriography
in patients with chronic renal insufficiency.
Radiology 1990; 176(3):651-4. Not CKD treatment
1546. Hans SS, Hans BA, Dhillon R, et al. Effect of
dopamine on renal function after arteriography in
patients with pre-existing renal insufficiency.
American Surgeon 1998; 64(5):432-6. Not CKD
treatment
1547. Hansen HP, Christensen PK, Tauber-Lassen E, et al.
Low-protein diet and kidney function in insulindependent diabetic patients with diabetic
nephropathy. Kidney International 1999; 55(2):6218. Sample size less than 50 patients
1548. Hansen HP, Gaede PH, Jensen BR, et al. Lack of
impact of low-dose acetylsalicylic acid on kidney
function in type 1 diabetic patients with
microalbuminuria. Diabetes Care 2000; 23(12):17425. Sample size less than 50 patients
1549. Hansen HP, Rossing K, Jacobsen P, et al. The acute
effect of smoking on systemic haemodynamics,
kidney and endothelial functions in insulindependent diabetic patients with microalbuminuria.
Scandinavian Journal of Clinical & Laboratory
Investigation 1996; 56(5):393-9. Follow-up less than
6 months
1550. Hansen HP, Rossing P, Tarnow L, et al. Increased
glomerular filtration rate after withdrawal of longterm antihypertensive treatment in diabetic
nephropathy. Kidney International 1995; 47(6):172631. Not relevant to key questions
1551. Hansen JM, Fogh-Andersen N, Christensen NJ, et al.
Cyclosporine-induced hypertension and decline in
renal function in healthy volunteers. Journal of
Hypertension 1997; 15(3):319-26. Sample size less
than 50 patients
1552. Hansen KW, Klein F, Christensen PD, et al. Effects
of captopril on ambulatory blood pressure, renal and
cardiac function in microalbuminuric type 1 diabetic
patients. Diabete et Metabolisme 1994; 20(5):485-93.
Sample size less than 50 patients
1553. Hansen KW, Pedersen MM, Christiansen JS, et al.
Acute renal effects of angiotensin converting enzyme
inhibition in microalbuminuric type 1 diabetic
patients. Acta Diabetologica 1993; 30(3):149-53.
Sample size less than 50 patients
1554. Hansen PM, Mathiesen ER, Kofoed-Enevoldsen A,
et al. Possible effect of angiotensin-converting
enzyme inhibition on glomerular charge selectivity.
Journal of Diabetes & its Complications 1995;
9(3):158-62. Sample size less than 50 patients
1555. Hansen RA, Chin H, Blalock S, et al. Predialysis
chronic kidney disease: evaluation of quality of life
in clinic patients receiving comprehensive anemia
care. Research In Social & Administrative Pharmacy
2009; 5(2):143-53. Not early CKD
1556. Hansen TK, Moller J, Thomsen K, et al. Effects of
growth hormone on renal tubular handling of sodium
in healthy humans. American Journal of Physiology Endocrinology & Metabolism 2001; 281(6):E132632. Not early CKD
B-112
1557. Hanssen KF, Dahl-Jorgensen K, Brinchmann-Hansen
O. The influence of strict control on diabetic
complications. Acta Endocrinologica. Supplementum
1985; 272:57-60. Sample size less than 50 patients
1558. Hansson L. Effects of angiotensin-converting
enzyme inhibition versus conventional
antihypertensive therapy on the glomerular filtration
rate. Cardiology 1995; 86 Suppl 1:30-3. Not CKD
treatment
1559. Hara K, Koga H, Kohno S, et al. The administration
regimen of isepamicin in patients with chronic
respiratory tract infection. Chemotherapy 1995;
41(6):462-9. Sample size less than 50 patients
1560. Hardiek KJ, Katholi RE, Robbs RS, et al. Renal
effects of contrast media in diabetic patients
undergoing diagnostic or interventional coronary
angiography. Journal of Diabetes & its
Complications 2008; 22(3):171-7. Not RCT or
controlled trial
1561. Harding MB, Davidson CJ, Pieper KS, et al.
Comparison of cardiovascular and renal toxicity after
cardiac catheterization using a nonionic versus ionic
radiographic contrast agent. American Journal of
Cardiology 1991; 68(10):1117-9. Not CKD treatment
1562. Haria M, Plosker GL, Markham A.
Felodipine/metoprolol: a review of the fixed dose
controlled release formulation in the management of
essential hypertension. Drugs 2000; 59(1):141-57.
Not CKD treatment
1563. Harman C. Putting clinical trials on trial. Nature
Reviews Nephrology 2009; 5(6):301. Not RCT or
controlled trial
1564. Harman-Boehm I. Angiotensin receptor blockers do
not have an advantage over angiotensin-converting
inhibitors [corrected]. Israel Medical Association
Journal: Imaj 2004; 6(5):296-8. Not CKD treatment
1565. Harmankaya O, Seber S, Yilmaz M. Combination of
pentoxifylline with angiotensin converting enzyme
inhibitors produces an additional reduction in
microalbuminuria in hypertensive type 2 diabetic
patients. Renal Failure 2003; 25(3):465-70. Not
relevant to key questions
1566. Harper PL, Williamson L, Park G, et al. A pilot study
of antithrombin replacement in intensive care
management: the effects on mortality, coagulation
and renal function. Transfusion Medicine 1991;
1(2):121-8. Not CKD treatment
1567. Harris DCH, Rangan GK. Retardation of kidney
failure -- applying principles to practice. Annals of
the Academy of Medicine, Singapore 2005;
34(1):16-23. Not RCT or controlled trial
1568. Harris LE, Luft FC, Rudy DW, et al. Clinical
correlates of functional status in patients with chronic
renal insufficiency. American Journal of Kidney
Diseases 1993; 21(2):161-6. Not RCT or controlled
trial
1569. Harris RZ, Salfi M, Sullivan JT, et al.
Pharmacokinetics of cinacalcet hydrochloride when
administered with ketoconazole. Clinical
Pharmacokinetics 2007; 46(6):495-501. Not relevant
to key questions
1570. Harten J, Crozier JEM, McCreath B, et al. Effect of
intraoperative fluid optimisation on renal function in
patients undergoing emergency abdominal surgery: a
randomised controlled pilot study (ISRCTN
11799696). International Journal Of Surgery 2008;
6(3):197-204. Not CKD treatment
1571. Hartmann JT, Fels LM, Franzke A, et al.
Comparative study of the acute nephrotoxicity from
standard dose cisplatin +/- ifosfamide and high-dose
chemotherapy with carboplatin and ifosfamide.
Anticancer Research 2000; 20(5C):3767-73. Not
RCT or controlled trial
1572. Hartmann JT, Fels LM, Knop S, et al. A randomized
trial comparing the nephrotoxicity of
cisplatin/ifosfamide-based combination
chemotherapy with or without amifostine in patients
with solid tumors. Investigational New Drugs 2000;
18(3):281-9. Not early CKD
1573. Hartmann JT, Knop S, Fels LM, et al. The use of
reduced doses of amifostine to ameliorate
nephrotoxicity of cisplatin/ifosfamide-based
chemotherapy in patients with solid tumors. AntiCancer Drugs 2000; 11(1):1-6. Not early CKD
1574. Harvey JN, Worth DP, Brown J, et al. The effect of
oral fenoldopam (SKF 82526-J), a peripheral
dopamine receptor agonist, on blood pressure and
renal function in normal man. British Journal of
Clinical Pharmacology 1985; 19(1):21-7. Sample size
less than 50 patients
1575. Harvey JN, Worth DP, Brown J, et al. Studies with
fenoldopam, a dopamine receptor DA1 agonist, in
essential hypertension. British Journal of Clinical
Pharmacology 1986; 21(1):53-61. Sample size less
than 50 patients
1576. Harwood PJ, Giannoudis PV. The safety and efficacy
of linezolid in orthopaedic practice for the treatment
of infection due to antibiotic-resistant organisms.
Expert Opinion on Drug Safety 2004; 3(5):405-14.
Not CKD treatment
1577. Hasebe N, Kikuchi K, Group NCS. Controlledrelease nifedipine and candesartan low-dose
combination therapy in patients with essential
hypertension: the NICE Combi (Nifedipine and
Candesartan Combination) Study. Journal of
Hypertension 2005; 23(2):445-53. Sample size less
than 50 patients
1578. Hashim H, Malmberg L, Graugaard-Jensen C, et al.
Desmopressin, as a "designer-drug," in the treatment
of overactive bladder syndrome. Neurourology &
Urodynamics 2009; 28(1):40-6. Not CKD treatment
1579. Hashizume M, Kitano S, Yamaga H, et al.
Haptoglobin to protect against renal damage from
ethanolamine oleate sclerosant. Lancet 1988;
2(8606):340-1. Follow-up less than 6 months
1580. Hassan Y, Al-Ramahi RJ, Aziz NA, et al. Impact of a
renal drug dosing service on dose adjustment in
hospitalized patients with chronic kidney disease.
Annals of Pharmacotherapy 2009; 43(10):1598-605.
Not RCT or controlled trial
1581. Hasselblad V, Gattis Stough W, Shah MR, et al.
Relation between dose of loop diuretics and
outcomes in a heart failure population: results of the
B-113
ESCAPE trial. European Journal of Heart Failure
2007; 9(10):1064-9. Follow-up less than 6 months
1582. Hasselgren B, Edgar B, Johnsson G, et al. The acute
haemodynamic and renal effects of oral felodipine
and ramipril in healthy subjects. European Journal of
Clinical Pharmacology 1993; 45(4):327-32. Sample
size less than 50 patients
1583. Haug K, Bakke A, Daae LN, et al. Screening for
hematuria, glucosuria and proteinuria in people aged
55-64. Technical, clinical and cost-benefit experience
from a pilot study. Scandinavian Journal of Primary
Health Care 1985; 3(1):31-4. Not CKD treatment
1584. Hausmann DF, Nutz V, Rommelsheim K, et al.
Anabolic steroids in polytrauma patients. Influence
on renal nitrogen and amino acid losses: a doubleblind study. Jpen: Journal of Parenteral & Enteral
Nutrition 1990; 14(2):111-4. Not CKD treatment
1585. Hawkey CJ. Cyclooxygenase inhibition: between the
devil and the deep blue sea. Gut 2002; 50 Suppl
3:III25-30. Not early CKD
1586. Hawkins MJ. Interleukin-2 antitumor and effector
cell responses. Seminars in Oncology 1993; 20(6
Suppl 9):52-9. Not RCT or controlled trial
1587. Hawkins RG, Houston MC. Is population-wide
diuretic use directly associated with the incidence of
end-stage renal disease in the United States? A
hypothesis. American Journal of Hypertension 2005;
18(6):744-9. Not relevant to key questions
1588. Hayakawa T, Shouzu A, Nishikawa M, et al. Effects
of beraprost and cilostazol and renal function on
serum thrombomodulin levels in diabetic patients.
Arzneimittel-Forschung 2000; 50(6):535-8. Not CKD
treatment
1589. Hayami S, Ishigooka M, Suzuki Y, et al. Comparison
of the nephrotoxicity between ioversol and iohexol.
International Urology & Nephrology 1996;
28(5):615-9. Sample size less than 50 patients
1590. Hayashi K, Kumagai H, Saruta T. Effect of
efonidipine and ACE inhibitors on proteinuria in
human hypertension with renal impairment.
American Journal of Hypertension 2003; 16(2):11622. Not relevant to key questions
1591. Hayashi K, Matsuda H, Honda M, et al. Impact of
calcium antagonists on bleeding time in patients with
chronic renal failure. Journal of Human Hypertension
2002; 16(3):199-203. Not CKD treatment
1592. Hayashi M, Numaguchi M, Watabe H, et al.
Cisplatin-induced nephrotoxicity and the protective
effect of fosfomycin on it as demonstrated by using a
crossover study of urinary metabolite levels. Acta
Obstetricia et Gynecologica Scandinavica 1997;
76(6):590-5. Not CKD treatment
1593. Hayashi Y, Ohtani M, Sawa Y, et al. Synthetic
human alpha-atrial natriuretic peptide improves the
management of postoperative hypertension and renal
dysfunction after the repair of abdominal aortic
aneurysm. Journal of Cardiovascular Pharmacology
2003; 42(5):636-41. Not CKD treatment
1594. Hayashida N, Isomura T, Sato T, et al. Effects of
minimal-dose aprotinin on coronary artery bypass
grafting. Journal of Thoracic & Cardiovascular
Surgery 1997; 114(2):261-9. Not CKD treatment
1595. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes,
glycaemic control and mortality risk in patients on
haemodialysis: the Japan Dialysis Outcomes and
Practice Pattern Study. Diabetologia 2007;
50(6):1170-7. Not relevant to key questions
1596. Haynes WG. Hyperhomocysteinemia, vascular
function and atherosclerosis: effects of vitamins.
Cardiovascular Drugs & Therapy 2002; 16(5):391-9.
Not RCT or controlled trial
1597. Haynes WG, Hand MF, Dockrell ME, et al.
Physiological role of nitric oxide in regulation of
renal function in humans. American Journal of
Physiology 1997; 272(3 Pt 2):F364-71. Not RCT or
controlled trial
1598. He FJ, Marciniak M, Carney C, et al. Effects of
potassium chloride and potassium bicarbonate on
endothelial function, cardiovascular risk factors, and
bone turnover in mild hypertensives. Hypertension
2010; 55(3):681-8. Follow-up less than 6 months
1599. He J, Whelton PK. Elevated systolic blood pressure
as a risk factor for cardiovascular and renal disease.
Journal of Hypertension - Supplement 1999;
17(2):S7-13. Not RCT or controlled trial
1600. Head JE, Bryant BJ, Grills BL, et al. Effects of shortterm use of ibuprofen or acetaminophen on bone
resorption in healthy men: a double-blind, placebocontrolled pilot study. Bone 2001; 29(5):437-41. Not
early CKD
1601. Heaney RP. Calcium intake and disease prevention.
Arquivos Brasileiros de Endocrinologia e
Metabologia 2006; 50(4):685-93. Not RCT or
controlled trial
1602. Hebert LA. Renoprotective therapy: how good can it
get? Kidney International 2000; 57(1):343-4. Not
RCT or controlled trial
1603. Hebert LA, Bain RP, Verme D, et al. Remission of
nephrotic range proteinuria in type I diabetes.
Collaborative Study Group. Kidney International
1994; 46(6):1688-93. Not relevant to key questions
1604. Hebert LA, Kusek JW, Greene T, et al. Effects of
blood pressure control on progressive renal disease in
blacks and whites. Modification of Diet in Renal
Disease Study Group. Hypertension 1997; 30(3 Pt
1):428-35. Not RCT or controlled trial
1605. Hebert LA, Wilmer WA, Falkenhain ME, et al.
Renoprotection: one or many therapies? Kidney
International 2001; 59(4):1211-26. Not relevant to
key questions
1606. Hebert MJ, Masse M, Vigneault N, et al. Soluble Fas
is a marker of coronary artery disease in patients with
end-stage renal disease. American Journal of Kidney
Diseases 2001; 38(6):1271-6. Not early CKD
1607. Heeg JE, de Jong PE, van der Hem GK, et al.
Efficacy and variability of the antiproteinuric effect
of ACE inhibition by lisinopril. Kidney International
1989; 36(2):272-9. Sample size less than 50 patients
1608. Heeg JE, de Jong PE, van der Hem GK, et al.
Angiotensin II does not acutely reverse the reduction
of proteinuria by long-term ACE inhibition. Kidney
International 1991; 40(4):734-41. Sample size less
than 50 patients
B-114
1609. Heeg JE, de Jong PE, Vriesendorp R, et al. Additive
antiproteinuric effect of the NSAID indomethacin
and the ACE inhibitor lisinopril. American Journal of
Nephrology 1990; 10 Suppl 1:94-7. Sample size less
than 50 patients
1610. Heemskerk S, Masereeuw R, Moesker O, et al.
Alkaline phosphatase treatment improves renal
function in severe sepsis or septic shock patients.
Critical Care Medicine 2009; 37(2):417-23. Not RCT
or controlled trial
1611. Heerspink HL, Greene T, Lewis JB, et al. Effects of
sulodexide in patients with type 2 diabetes and
persistent albuminuria. Nephrology Dialysis
Transplantation 2008; 23(6):1946-54. Not RCT or
controlled trial
1612. Heinemann L, Janicke I, Bender R, et al. Effects of
enalapril and nitrendipine on exercise albuminuria in
normotensive type I diabetic patients with incipient
nephropathy. Hormone & Metabolic Research 1996;
28(10):549-52. Follow-up less than 6 months
1613. Heise D, Waeschle RM, Schlobohm J, et al. Utility
of cystatin C for assessment of renal function after
cardiac surgery. Nephron 2009; 112(2):c107-14. Not
CKD treatment
1614. Heise T, Magnusson K, Grobel B, et al. A cross-over
evaluation of different methods and devices to
measure blood pressure in type 1 diabetic patients
with nephropathy. Blood Pressure Monitoring 2000;
5(3):175-80. Sample size less than 50 patients
1615. Helaly MA, Sheashaa HA, Hatata ESZ, et al.
Endothelial dysfunction in geriatric diabetic patients:
the role of microalbuminuria in elderly type 2
diabetic patients? A randomized controlled study.
International Urology & Nephrology 2007;
39(1):333-8. Follow-up less than 6 months
1616. Helenglass G, Powles RL, McElwain TJ, et al.
Melphalan and total body irradiation (TBI) versus
cyclophosphamide and TBI as conditioning for
allogeneic matched sibling bone marrow transplants
for acute myeloblastic leukaemia in first remission.
Bone Marrow Transplantation 1988; 3(1):21-9.
Sample size less than 50 patients
1617. Hemmelder MH, de Zeeuw D, de Jong PE.
Antiproteinuric efficacy of verapamil in comparison
to trandolapril in non-diabetic renal disease.
Nephrology Dialysis Transplantation 1999; 14(1):98104. Follow-up less than 6 months
1618. Hemmelder MH, de Zeeuw D, Gansevoort RT, et al.
Blood pressure reduction initiates the antiproteinuric
effect of ACE inhibition. Kidney International 1996;
49(1):174-80. Sample size less than 50 patients
1619. Hemmelgarn BR, Ghali WA, Quan H, et al. Poor
long-term survival after coronary angiography in
patients with renal insufficiency. American Journal
of Kidney Diseases 2001; 37(1):64-72. Not RCT or
controlled trial
1620. Hemmelgarn BR, Manns BJ, Zhang J, et al.
Association between multidisciplinary care and
survival for elderly patients with chronic kidney
disease. Journal of the American Society of
Nephrology 2007; 18(3):993-9. Sample size less than
50 patients
1621. Heng AE, Cellarier E, Aublet-Cuvelier B, et al. Is
treatment with N-acetylcysteine to prevent contrastinduced nephropathy when using bicarbonate
hydration out of date? Clinical Nephrology 2008;
70(6):475-84. Not CKD treatment
1622. Henrich WL. Optimal cardiovascular therapy for
patients with ESRD over the next several years.
Clinical Journal of The American Society of
Nephrology: CJASN 2009; 4 Suppl 1:S106-9. Not
RCT or controlled trial
1623. Henry H, 2nd, Nordan J, Tomlin EM. Comparison of
butorphanol tartrate and meperidine in moderate to
severe renal colic. Urology 1987; 29(3):339-45. Not
CKD treatment
1624. Henry HH, 2nd. Urological applications of
butorphanol tartrate: postoperative pain and renal
colic. Acute Care 1988; 12 Suppl 1:22-30. Not RCT
or controlled trial
1625. Herbert MK, Ginzel S, Muhlschlegel S, et al.
Concomitant treatment with urodilatin (ularitide)
does not improve renal function in patients with
acute renal failure after major abdominal surgery--a
randomized controlled trial. Wiener Klinische
Wochenschrift 1999; 111(4):141-7. Sample size less
than 50 patients
1626. Hering R, Wrigge H, Vorwerk R, et al. The effects of
prone positioning on intraabdominal pressure and
cardiovascular and renal function in patients with
acute lung injury. Anesthesia & Analgesia 2001;
92(5):1226-31. Not early CKD
1627. Herlitz H, Harris K, Risler T, et al. The effects of an
ACE inhibitor and a calcium antagonist on the
progression of renal disease: the Nephros Study.
Nephrology Dialysis Transplantation 2001;
16(11):2158-65. Not early CKD
1628. Herman WH, Shahinfar S, Carides GW, et al.
Losartan reduces the costs associated with diabetic
end-stage renal disease: the RENAAL study
economic evaluation. Diabetes Care 2003; 26(3):6837. Not CKD treatment
1629. Hermans MP, Brichard SM, Colin I, et al. Long-term
reduction of microalbuminuria after 3 years of
angiotensin-converting enzyme inhibition by
perindopril in hypertensive insulin-treated diabetic
patients. American Journal of Medicine 1992;
92(4B):102S-7S. Sample size less than 50 patients
1630. Hernandez C, Rodriguez B, Losada E, et al.
Normoalbuminuric type 1 diabetic patients with
retinopathy have an impaired tubular response to
desmopressin: its relationship with plasma
endothelin-1. Journal of Clinical Endocrinology &
Metabolism 2009; 94(6):2060-5. Not RCT or
controlled trial
1631. Hernberg M. Lymphocyte subsets as prognostic
markers for cancer patients receiving
immunomodulative therapy. Medical Oncology
1999; 16(3):145-53. Not CKD treatment
1632. Herselman MG, Albertse EC, Lombard CJ, et al.
Supplemented low-protein diets--are they superior in
chronic renal failure? South African Medical Journal
1995; Suid-Afrikaanse Tydskrif Vir Geneeskunde.
85(5):361-5. Sample size less than 50 patients
B-115
1633. Herzog S, Cunze T, Martin M, et al. Pulsatile vs.
continuous parenteral tocolysis: comparison of side
effects. European Journal of Obstetrics, Gynecology,
& Reproductive Biology 1999; 85(2):199-204. Not
CKD treatment
1634. Hesselvik F, Brodin B, Carlsson C, et al.
Cryoprecipitate infusion fails to improve organ
function in septic shock. Critical Care Medicine
1987; 15(5):475-83. Sample size less than 50 patients
1635. Hetherington JW, Philp NH. Diclofenac sodium
versus pethidine in acute renal colic. British Medical
Journal Clinical Research Ed. 1986; 292(6515):2378. Not CKD treatment
1636. Heydendael VMR, Spuls PI, Ten Berge IJM, et al.
Cyclosporin trough levels: is monitoring necessary
during short-term treatment in psoriasis? A
systematic review and clinical data on trough levels.
British Journal of Dermatology 2002; 147(1):122-9.
Not CKD treatment
1637. Higashi Y, Oshima T, Ono N, et al. Intravenous
administration of L-arginine inhibits angiotensinconverting enzyme in humans. Journal of Clinical
Endocrinology & Metabolism 1995; 80(7):2198-202.
Sample size less than 50 patients
1638. Higashi Y, Oshima T, Sasaki S, et al. Angiotensinconverting enzyme inhibition, but not calcium
antagonism, improves a response of the renal
vasculature to L-arginine in patients with essential
hypertension. Hypertension 1998; 32(1):16-24.
Sample size less than 50 patients
1639. Higuchi H, Arimura S, Sumikura H, et al. Urine
concentrating ability after prolonged sevoflurane
anaesthesia. British Journal of Anaesthesia 1994;
73(2):239-40. Sample size less than 50 patients
1640. Higuchi H, Wada H, Usui Y, et al. Effects of
probenecid on renal function in surgical patients
anesthetized with low-flow sevoflurane.
Anesthesiology 2001; 94(1):21-31. Not early CKD
1641. Hill AJ, Feneck RO, Walesby RK. A comparison of
fenoldopam and nitroprusside in the control of
hypertension following coronary artery surgery.
Journal of Cardiothoracic & Vascular Anesthesia
1993; 7(3):279-84. Sample size less than 50 patients
1642. Hillege HL, Girbes AR, de Kam PJ, et al. Renal
function, neurohormonal activation, and survival in
patients with chronic heart failure. Circulation 2000;
102(2):203-10. Not early CKD
1643. Hillege HL, van Gilst WH, van Veldhuisen DJ, et al.
Accelerated decline and prognostic impact of renal
function after myocardial infarction and the benefits
of ACE inhibition: the CATS randomized trial.
European Heart Journal 2003; 24(5):412-20. Not
early CKD
1644. Hilleman DE. Role of angiotensin-convertingenzyme inhibitors in the treatment of hypertension.
American Journal of Health-System Pharmacy 2000;
57 Suppl 1:S8-11. Not RCT or controlled trial
1645. Hillock RJ, Frampton CM, Yandle TG, et al. B-type
natriuretic peptide infusions in acute myocardial
infarction. Heart 2008; 94(5):617-22. Not early CKD
1646. Himmelfarb J, Hakim RM. Oxidative stress in
uremia. Current Opinion in Nephrology &
Hypertension 2003; 12(6):593-8. Not CKD treatment
1647. Himmelmann A, Hansson L, Hansson BG, et al.
ACE inhibition preserves renal function better than
beta-blockade in the treatment of essential
hypertension. Blood Pressure 1995; 4(2):85-90. Not
CKD treatment
1648. Himmelmann A, Hansson L, Hansson BG, et al.
Long-term renal preservation in essential
hypertension. Angiotensin converting enzyme
inhibition is superior to beta-blockade. American
Journal of Hypertension 1996; 9(9):850-3. Not
relevant to key questions
1649. Hirosawa A, Niitani H, Hayashibara K, et al. Effects
of sodium thiosulfate in combination therapy of cisdichlorodiammineplatinum and vindesine. Cancer
Chemotherapy & Pharmacology 1989; 23(4):255-8.
Not CKD treatment
1650. Hirschberg R. Biologically active peptides in acute
renal failure: recent clinical trials. Nephrology
Dialysis Transplantation 1997; 12(8):1563-6. Not
RCT or controlled trial
1651. Hirschberg R, Brunori G, Kopple JD, et al. Effects of
insulin-like growth factor I on renal function in
normal men. Kidney International 1993; 43(2):38797. Not adult population
1652. Hirschberg R, Kopple JD. Role of growth hormone
in the amino acid-induced acute rise in renal function
in man. Kidney International 1987; 32(3):382-7.
Sample size less than 50 patients
1653. Hirschberg RR, Zipser RD, Slomowitz LA, et al.
Glucagon and prostaglandins are mediators of amino
acid-induced rise in renal hemodynamics. Kidney
International 1988; 33(6):1147-55. Sample size less
than 50 patients
1654. Hjorth M, Holmberg E, Rodjer S, et al. Impact of
active and passive exclusions on the results of a
clinical trial in multiple myeloma. The Myeloma
Group of Western Sweden. British Journal of
Haematology 1992; 80(1):55-61. Not CKD treatment
1655. Hladunewich MA, Derby GC, Lafayette RA, et al.
Effect of L-arginine therapy on the glomerular injury
of preeclampsia: a randomized controlled trial.
Obstetrics & Gynecology 2006; 107(4):886-95.
Sample size less than 50 patients
1656. Hlatky MA. Underuse of evidence-based therapies.
Circulation 2004; 110(6):644-5. Not CKD treatment
1657. Ho J-d, Liou S-W, Lin H-C. Retinal vein occlusion
and the risk of stroke development: a five-year
follow-up study. American Journal of
Ophthalmology 2009; 147(2):283-90.e2. Follow-up
less than 6 months
1658. Ho KM, Morgan DJ. Use of isotonic sodium
bicarbonate to prevent radiocontrast nephropathy in
patients with mild pre-existing renal impairment: a
meta-analysis. Anaesthesia & Intensive Care 2008;
36(5):646-53. Sample size less than 50 patients
1659. Ho KM, Morgan DJR. Meta-analysis of Nacetylcysteine to prevent acute renal failure after
major surgery. American Journal of Kidney Diseases
2009; 53(1):33-40. Not early CKD
B-116
1660. Ho KM, Sheridan DJ. Meta-analysis of frusemide to
prevent or treat acute renal failure. BMJ 2006;
333(7565):420. Not relevant to key questions
1661. Hobbs H, Stevens P, Klebe B, et al. Referral patterns
to renal services: what has changed in the past 4
years? Nephrology Dialysis Transplantation 2009;
24(11):3411-9. Not RCT or controlled trial
1662. Hochman JS, Shah NR. What price pain
relief?.[Erratum appears in Circulation. 2006 Aug
22;114(8):e364]. Circulation 2006; 113(25):2868-70.
Not RCT or controlled trial
1663. Hodge EE, Reich DJ, Clavien PA, et al. Use of
mycophenolate mofetil in liver transplant recipients
experiencing renal dysfunction on cyclosporine or
tacrolimus-randomized, prospective, multicenter
study results. Transplantation Proceedings 2002;
34(5):1546-7. Sample size less than 50 patients
1664. Hoek FJ, Korevaar JC, Dekker FW, et al. Estimation
of residual glomerular filtration rate in dialysis
patients from the plasma cystatin C level.
Nephrology Dialysis Transplantation 2007;
22(6):1633-8. Follow-up less than 6 months
1665. Hoffer LJ, Saboohi F, Golden M, et al. Cobalamin
dose regimen for maximum homocysteine reduction
in end-stage renal disease. Metabolism: Clinical &
Experimental 2005; 54(6):835-40. Not RCT or
controlled trial
1666. Hoffler D, Koeppe P. Temocillin pharmacokinetics
in normal and impaired renal function. Drugs 1985;
29 Suppl 5:135-9. Sample size less than 50 patients
1667. Hogan SE, L'Allier P, Chetcuti S, et al. Current role
of sodium bicarbonate-based preprocedural hydration
for the prevention of contrast-induced acute kidney
injury: a meta-analysis. American Heart Journal
2008; 156(3):414-21. Not CKD treatment
1668. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The
impact of serum uric acid on cardiovascular
outcomes in the LIFE study. Kidney International
2004; 65(3):1041-9. Not early CKD
1669. Hojs R, Bevc S, Ekart R, et al. Serum cystatin Cbased equation compared to serum creatinine-based
equations for estimation of glomerular filtration rate
in patients with chronic kidney disease. Clinical
Nephrology 2008; 70(1):10-7. Sample size less than
50 patients
1670. Holdaas H, Hartmann A, Berg KJ, et al. Contrasting
effects of angiotensin converting inhibitor and alpha1-antagonist on albuminuria in insulin-dependent
diabetes mellitus patients with nephropathy. Journal
of Internal Medicine 1995; 237(1):63-71. Sample size
less than 50 patients
1671. Holdaas H, Hartmann A, Berg KJ, et al. Renal effects
of losartan and amlodipine in hypertensive patients
with non-diabetic nephropathy. Nephrology Dialysis
Transplantation 1998; 13(12):3096-102. Follow-up
less than 6 months
1672. Holdaas H, Hartmann A, Lien MG, et al. Contrasting
effects of lisinopril and nifedipine on albuminuria
and tubular transport functions in insulin dependent
diabetics with nephropathy. Journal of Internal
Medicine 1991; 229(2):163-70. Sample size less than
50 patients
1673. Holdaas H, Wanner C, Abletshauser C, et al. The
renal safety profile of fluvastatin: results of a pooled
analysis. Renal Failure 2006; 28(6):487-92. Not
relevant to key questions
1674. Holdgate A, Oh CM. Is there a role for
antimuscarinics in renal colic? A randomized
controlled trial. Journal of Urology 2005;
174(2):572-5; discussion 5. Sample size less than 50
patients
1675. Holdgate A, Pollock T. Systematic review of the
relative efficacy of non-steroidal anti-inflammatory
drugs and opioids in the treatment of acute renal
colic. BMJ 2004; 328(7453):1401. Not CKD
treatment
1676. Holdgate A, Pollock T. Nonsteroidal antiinflammatory drugs (NSAIDs) versus opioids for
acute renal colic. Cochrane Database of Systematic
Reviews 2004; (1):CD004137. Not RCT or
controlled trial
1677. Holdgate A, Pollock T. Nonsteroidal antiinflammatory drugs (NSAIDs) versus opioids for
acute renal colic. Cochrane Database of Systematic
Reviews 2005; (2):CD004137. Follow-up less than 6
months
1678. Holl MG, Allen LH. Comparative effects of meals
high in protein, sucrose, or starch on human mineral
metabolism and insulin secretion. American Journal
of Clinical Nutrition 1988; 48(5):1219-25. Sample
size less than 50 patients
1679. Hollenberg NK. Non-insulin-dependent diabetes
mellitus, nephropathy, and the renin system. Journal
of Hypertension - Supplement 1997; 15(7):S7-13.
Not RCT or controlled trial
1680. Hollenberg NK, Parving H-H, Viberti G, et al.
Albuminuria response to very high-dose valsartan in
type 2 diabetes mellitus. Journal of Hypertension
2007; 25(9):1921-6. Not relevant to key questions
1681. Holmberg B, Brannstrom M, Bucht B, et al. Safety
and efficacy of atorvastatin in patients with severe
renal dysfunction. Scandinavian Journal of Urology
& Nephrology 2005; 39(6):503-10. Sample size less
than 50 patients
1682. Holmes CL, Walley KR. Bad medicine: low-dose
dopamine in the ICU. Chest 2003; 123(4):1266-75.
Not CKD treatment
1683. Holmes DI, Abdel Wahab N, Mason RM.
Identification of glucose-regulated genes in human
mesangial cells by mRNA differential display.
Biochemical & Biophysical Research
Communications 1997; 238(1):179-84. Not RCT or
controlled trial
1684. Holmes SJ, Espiner EA, Richards AM, et al. Renal,
endocrine, and hemodynamic effects of human brain
natriuretic peptide in normal man. Journal of Clinical
Endocrinology & Metabolism 1993; 76(1):91-6. Not
CKD treatment
1685. Homma K, Hayashi K, Kanda T, et al. Beneficial
action of candesartan cilexetil plus amlodipine or
ACE inhibitors in chronic nondiabetic renal disease.
Journal of Human Hypertension 2004; 18(12):87984. Sample size less than 50 patients
B-117
1686. Hommel E, Andersen P, Gall MA, et al. Plasma
lipoproteins and renal function during simvastatin
treatment in diabetic nephropathy. Diabetologia
1992; 35(5):447-51. Sample size less than 50 patients
1687. Hommel E, Mathiesen E, Arnold-Larsen S, et al.
Effects of indomethacin on kidney function in type 1
(insulin-dependent) diabetic patients with
nephropathy. Diabetologia 1987; 30(2):78-81.
Sample size less than 50 patients
1688. Hommel E, Mathiesen E, Edsberg B, et al. Acute
reduction of arterial blood pressure reduces urinary
albumin excretion in type 1 (insulin-dependent)
diabetic patients with incipient nephropathy.
Diabetologia 1986; 29(4):211-5. Sample size less
than 50 patients
1689. Hommel E, Parving HH, Mathiesen E, et al. Effect of
captopril on kidney function in insulin-dependent
diabetic patients with nephropathy. British Medical
Journal Clinical Research Ed. 1986; 293(6545):46770. Sample size less than 50 patients
1690. Hon G, Vaziri ND, Kaupke CJ, et al. Lack of a fastacting effect of erythropoietin on arterial blood
pressure and endothelin level. Artificial Organs
1995; 19(2):188-91. Sample size less than 50 patients
1691. Honing ML, Hijmering ML, Ballard DE, et al.
Selective ET(A) receptor antagonism with ABT-627
attenuates all renal effects of endothelin in humans.
Journal of the American Society of Nephrology
2000; 11(8):1498-504. Not early CKD
1692. Honore PM, Joannes-Boyau O, Boer W, et al. Acute
kidney injury in the ICU: time has come for an early
biomarker kit! Acta Clinica Belgica - Supplementum
2007; (2):318-21. Not CKD treatment
1693. Hoogenberg K, Sluiter WJ, Navis G, et al.
Exogenous norepinephrine induces an enhanced
microproteinuric response in microalbuminuric
insulin-dependent diabetes mellitus. Journal of the
American Society of Nephrology 1998; 9(4):643-54.
Sample size less than 50 patients
1694. Hoogenberg K, Smit AJ, Girbes AR. Effects of lowdose dopamine on renal and systemic hemodynamics
during incremental norepinephrine infusion in
healthy volunteers. Critical Care Medicine 1998;
26(2):260-5. Not CKD treatment
1695. Hoogeveen EK, Kostense PJ, Jager A, et al. Serum
homocysteine level and protein intake are related to
risk of microalbuminuria: the Hoorn Study. Kidney
International 1998; 54(1):203-9. Not RCT or
controlled trial
1696. Hoogkamer JF, Kleinbloesem CH, Nokhodian A, et
al. Pharmacokinetics of imidapril and its active
metabolite imidaprilat following single dose and
during steady state in patients with chronic renal
failure. European Journal of Clinical Pharmacology
1998; 54(1):59-61. Sample size less than 50 patients
1697. Hoogwerf BJ, Young JB. The HOPE study. Ramipril
lowered cardiovascular risk, but vitamin E did not.
Cleveland Clinic Journal of Medicine 2000;
67(4):287-93. Not early CKD
1698. Hooper AH, Tindall H, Barker MJ, et al. Renal
scintigraphy and survival of indium-111-labelled
platelets in patients with diabetic nephropathy.
Nuclear Medicine Communications 1986; 7(5):34954. Sample size less than 50 patients
1699. Hoos A, Levey DL. Vaccination with heat shock
protein-peptide complexes: from basic science to
clinical applications. Expert Review of Vaccines
2003; 2(3):369-79. Not CKD treatment
1700. Hopper AH, Tindall H, Davies JA. Administration of
aspirin-dipyridamole reduces proteinuria in diabetic
nephropathy. Nephrology Dialysis Transplantation
1989; 4(2):140-3. Sample size less than 50 patients
1701. Hopper AH, Tindall H, Urquhart S, et al. Reduction
of exercise-induced albuminuria by aspirindipyridamole in patients with diabetes mellitus.
Hormone & Metabolic Research 1987; 19(5):201-3.
Sample size less than 50 patients
1702. Hoque R, Rahman MS, Iqbal M. Effect of enalapril
and losartan on proteinuria in type 2 diabetic
nephropathy patients. Bangladesh Medical Research
Council Bulletin 2009; 35(2):44-8. Sample size less
than 50 patients
1703. Horita Y, Hayashida K, Fukuchi K, et al.
Acetazolamide assisted Tc-99m MAG3 renography
to assess renal blood flow reserve. Annals of Nuclear
Medicine 2003; 17(2):139-44. Not CKD treatment
1704. Horl WH. A need for an individualized approach to
end-stage renal disease patients. Nephrology Dialysis
Transplantation 2002; 17 Suppl 6:17-21. Not early
CKD
1705. Horl WH, Steinhauer HB, Riegel W, et al. Effect of
different dialyzer membranes on plasma levels of
granulocyte elastase. Kidney International Supplement 1988; 24:S90-1. Sample size less than 50
patients
1706. Hornberger J, Wrone E. When to base clinical
policies on observational versus randomized trial
data. Annals of Internal Medicine 1997; 127(8 Pt
2):697-703. Not RCT or controlled trial
1707. Hornberger JC, Garber AM, Jeffery JR. Mortality,
hospital admissions, and medical costs of end-stage
renal disease in the United States and Manitoba,
Canada. Medical Care 1997; 35(7):686-700. Not
early CKD
1708. Hou FF, Xie D, Zhang X, et al. Renoprotection of
Optimal Antiproteinuric Doses (ROAD) Study: a
randomized controlled study of benazepril and
losartan in chronic renal insufficiency. Journal of the
American Society of Nephrology 2007; 18(6):188998. Follow-up less than 6 months
1709. Hou FF, Zhang X, Zhang GH, et al. Efficacy and
safety of benazepril for advanced chronic renal
insufficiency. New England Journal of Medicine
2006; 354(2):131-40. Not RCT or controlled trial
1710. Houben AJ, Krekels MM, Schaper NC, et al.
Microvascular effects of atrial natriuretic peptide
(ANP) in man: studies during high and low salt diet.
Cardiovascular Research 1998; 39(2):442-50. Sample
size less than 50 patients
1711. Hovind P, Tarnow L, Parving H-H. Remission and
regression of diabetic nephropathy. Current
Hypertension Reports 2004; 6(5):377-82. Not CKD
treatment
B-118
1712. Hoy W, McDonald SP. Albuminuria: marker or
target in indigenous populations. Kidney
International - Supplement 2004; (92):S25-31. Not
CKD treatment
1713. Hoy WE, Wang Z, Baker PRA, et al. Reduction in
natural death and renal failure from a systematic
screening and treatment program in an Australian
Aboriginal community. Kidney International Supplement 2003; (83):S66-73. Not RCT or
controlled trial
1714. Hoy WE, Wang Z, Baker PRA, et al. Secondary
prevention of renal and cardiovascular disease:
results of a renal and cardiovascular treatment
program in an Australian aboriginal community.
Journal of the American Society of Nephrology
2003; 14(7 Suppl 2):S178-85. Not RCT or controlled
trial
1715. Hoy WE, Wang Z, VanBuynder P, et al. The natural
history of renal disease in Australian Aborigines. Part
1. Changes in albuminuria and glomerular filtration
rate over time. Kidney International 2001; 60(1):2438. Not RCT or controlled trial
1716. Hricik DE, Levine BS, Adrogue HJ, et al. Evaluation
of enalapril/diltiazem ER in hypertensive patients
with coexisting renal dysfunction.
Enalapril/Diltiazem ER in Hypertensive Renal
Disease Group. Journal of Human Hypertension
1996; 10(11):769-74. Follow-up less than 6 months
1717. Hsia HC, Lin HC, Tsai YT, et al. The effects of
chronic administration of indomethacin and
misoprostol on renal function in cirrhotic patients
with and without ascites. Scandinavian Journal of
Gastroenterology 1995; 30(12):1194-9. Sample size
less than 50 patients
1718. Hsu CY. Does treatment of non-malignant
hypertension reduce the incidence of renal
dysfunction? A meta-analysis of 10 randomised,
controlled trials. Journal of Human Hypertension
2001; 15(2):99-106. Not relevant to key questions
1719. Hu YJ, Chen Y, Zhang YQ, et al. The protective role
of selenium on the toxicity of cisplatin-contained
chemotherapy regimen in cancer patients. Biological
Trace Element Research 1997; 56(3):331-41. Sample
size less than 50 patients
1720. Huang M, Yu J, Hu W. Effect of yitangning granule
on glycometabolism and urinary micro albumin of
diabetes B patients. Journal of Traditional Chinese
Medicine 2004; 24(4):270-3. Follow-up less than 6
months
1721. Huber W, Eckel F, Hennig M, et al. Prophylaxis of
contrast material-induced nephropathy in patients in
intensive care: acetylcysteine, theophylline, or both?
A randomized study. Radiology 2006; 239(3):793804. Sample size less than 50 patients
1722. Huber W, Ilgmann K, Page M, et al. Effect of
theophylline on contrast material-nephropathy in
patients with chronic renal insufficiency: controlled,
randomized, double-blinded study. Radiology 2002;
223(3):772-9. Not early CKD
1723. Huber W, Schipek C, Ilgmann K, et al. Effectiveness
of theophylline prophylaxis of renal impairment after
coronary angiography in patients with chronic renal
insufficiency. American Journal of Cardiology 2003;
91(10):1157-62. Not CKD treatment
1724. Huggins JT, Sahn SA. Causes and management of
pleural fibrosis. Respirology 2004; 9(4):441-7. Not
RCT or controlled trial
1725. Huitema AD, Mathot RA, Tibben MM, et al.
Validation of techniques for the prediction of
carboplatin exposure: application of Bayesian
methods. Clinical Pharmacology & Therapeutics
2000; 67(6):621-30. Not RCT or controlled trial
1726. Huledal G, Jonzon B, Malmenas M, et al. Renal
effects of the cyclooxygenase-inhibiting nitric oxide
donator AZD3582 compared with rofecoxib and
naproxen during normal and low sodium intake.
Clinical Pharmacology & Therapeutics 2005;
77(5):437-50. Not CKD treatment
1727. Humphrey LL, Ballard DJ. Renal complications in
non-insulin-dependent diabetes mellitus. Clinics in
Geriatric Medicine 1990; 6(4):807-25. Not relevant
to key questions
1728. Humphreys MR, Lingeman JE, Terry C, et al. Renal
injury and the application of polysaccharide
hemospheres: a laparoscopic experimental model.
Journal of Endourology 2008; 22(6):1375-81. Not
CKD treatment
1729. Hunsicker LG. Emerging trends for prevention and
treatment of diabetic nephropathy: blockade of the
RAAS and BP control. Journal of Managed Care
Pharmacy 2004; 10(5 Suppl A):S12-7. Not RCT or
controlled trial
1730. Hunsicker LG, Adler S, Caggiula A, et al. Predictors
of the progression of renal disease in the
Modification of Diet in Renal Disease Study. Kidney
International 1997; 51(6):1908-19. Not RCT or
controlled trial
1731. Hunter DW, Chamsuddin A, Bjarnason H, et al.
Preventing contrast-induced nephropathy with
fenoldopam. Techniques in Vascular &
Interventional Radiology 2001; 4(1):53-6. Not early
CKD
1732. Huntress JD, Papadakos PJ. The role of calciumchannel antagonists in solid organ transplantation.
New Horizons 1996; 4(1):129-33. Not RCT or
controlled trial
1733. Hurst M, Jarvis B. Perindopril: an updated review of
its use in hypertension. Drugs 2001; 61(6):867-96.
Not RCT or controlled trial
1734. Hussain SA, Moffitt DD, Glaholm JG, et al. A phase
I-II study of synchronous chemoradiotherapy for
poor prognosis locally advanced bladder cancer.
Annals of Oncology 2001; 12(7):929-35. Not early
CKD
1735. Hussain SA, Stocken DD, Riley P, et al. A phase I/II
study of gemcitabine and fractionated cisplatin in an
outpatient setting using a 21-day schedule in patients
with advanced and metastatic bladder cancer. British
Journal of Cancer 2004; 91(5):844-9. Not relevant to
key questions
1736. Huxtable L, Raney CRK, Khera GS. Should
intravenous N-acetylcysteine be considered standard
of care for prevention of radio-contrast-induced
nephropathy? Journal of the American College of
B-119
Cardiology 2003; 42(12):2169; author reply -70. Not
relevant to key questions
1737. Huybregts RAJM, Morariu AM, Rakhorst G, et al.
Attenuated renal and intestinal injury after use of a
mini-cardiopulmonary bypass system. Annals of
Thoracic Surgery 2007; 83(5):1760-6. Not CKD
treatment
1738. Hwang WYK, Koh LP, Ng HJ, et al. A randomized
trial of amifostine as a cytoprotectant for patients
receiving myeloablative therapy for allogeneic
hematopoietic stem cell transplantation. Bone
Marrow Transplantation 2004; 34(1):51-6. Not CKD
treatment
1739. Hyndman ME, Manns BJ, Snyder FF, et al. Vitamin
B12 decreases, but does not normalize, homocysteine
and methylmalonic acid in end-stage renal disease: a
link with glycine metabolism and possible
explanation of hyperhomocysteinemia in end-stage
renal disease. Metabolism: Clinical & Experimental
2003; 52(2):168-72. Not early CKD
1740. Hynes DM, Stroupe KT, Greer JW, et al. Potential
cost savings of erythropoietin administration in endstage renal disease. American Journal of Medicine
2002; 112(3):169-75. Not RCT or controlled trial
1741. Hynninen MS, Niemi TT, Poyhia R, et al. Nacetylcysteine for the prevention of kidney injury in
abdominal aortic surgery: a randomized, doubleblind, placebo-controlled trial. Anesthesia &
Analgesia 2006; 102(6):1638-45. Not relevant to key
questions
1742. Hynynen M, Palojoki R, Heinonen J, et al. Renal and
vascular effects of atrial natriuretic factor during
cardiopulmonary bypass. Chest 1991; 100(5):1203-9.
Not CKD treatment
1743. Ibbotson T, Goa KL. Darbepoetin alfa. Drugs 2001;
61(14):2097-104; discussion 105-6. Not RCT or
controlled trial
1744. Ibrahim A, Scher N, Williams G, et al. Approval
summary for zoledronic acid for treatment of
multiple myeloma and cancer bone metastases.
Clinical Cancer Research 2003; 9(7):2394-9. Not
CKD treatment
1745. Ibrahim H, Mondress M, Tello A, et al. An
alternative formula to the Cockcroft-Gault and the
modification of diet in renal diseases formulas in
predicting GFR in individuals with type 1 diabetes.
Journal of the American Society of Nephrology
2005; 16(4):1051-60. Not relevant to key questions
1746. Ibrahim HN, Rogers T, Tello A, et al. The
performance of three serum creatinine-based
formulas in estimating GFR in former kidney donors.
American Journal of Transplantation 2006;
6(6):1479-85. Not CKD treatment
1747. Ibrahim S, Derde MP, Kaufman L, et al. Safety,
pharmacokinetics and efficacy of once-a-day
netilmicin and amikacin versus their conventional
schedules in patients suffering from pelvic
inflammatory disease. Renal Failure 1990;
12(3):199-203. Not CKD treatment
1748. Ichai C, Passeron C, Carles M, et al. Prolonged lowdose dopamine infusion induces a transient
improvement in renal function in hemodynamically
stable, critically ill patients: a single-blind,
prospective, controlled study. Critical Care Medicine
2000; 28(5):1329-35. Sample size less than 50
patients
1749. Ichai C, Soubielle J, Carles M, et al. Comparison of
the renal effects of low to high doses of dopamine
and dobutamine in critically ill patients: a singleblind randomized study. Critical Care Medicine
2000; 28(4):921-8. Not early CKD
1750. Ichihara A, Kaneshiro Y, Sakoda M, et al. Add-on
amlodipine improves arterial function and structure
in hypertensive patients treated with an angiotensin
receptor blocker. Journal of Cardiovascular
Pharmacology 2007; 49(3):161-6. Follow-up less
than 6 months
1751. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Benefits
of candesartan on arterial and renal damage of nondiabetic hypertensive patients treated with calcium
channel blockers. American Journal of Nephrology
2006; 26(5):462-8. Follow-up less than 6 months
1752. Ifudu O, Dawood M, Homel P. Erythropoietininduced elevation in blood pressure is immediate and
dose dependent. Nephron 1998; 79(4):486-7. Not
RCT or controlled trial
1753. Ifudu O, Homel P. Effect of serum parathyroid
hormone and aluminum levels on the response to
erythropoietin in uremia. Nephron 1998; 79(4):4778. Not RCT or controlled trial
1754. Igarashi M, Hirata A, Kadomoto Y, et al. Dual
blockade of angiotensin II with enalapril and losartan
reduces proteinuria in hypertensive patients with type
2 diabetes. Endocrine Journal 2006; 53(4):493-501.
Sample size less than 50 patients
1755. Iglesias J, Marik PE, Levine JS, et al. Elevated serum
levels of the type I and type II receptors for tumor
necrosis factor-alpha as predictive factors for ARF in
patients with septic shock. American Journal of
Kidney Diseases 2003; 41(1):62-75. Not CKD
treatment
1756. Iguchi M, Katoh Y, Koike H, et al. Randomized trial
of trigger point injection for renal colic. International
Journal of Urology 2002; 9(9):475-9. Not CKD
treatment
1757. Ihle BU, Becker GJ, Whitworth JA, et al. The effect
of protein restriction on the progression of renal
insufficiency. New England Journal of Medicine
1989; 321(26):1773-7. Not early CKD
1758. Ihle BU, Whitworth JA, Shahinfar S, et al.
Angiotensin-converting enzyme inhibition in
nondiabetic progressive renal insufficiency: a
controlled double-blind trial. American Journal of
Kidney Diseases 1996; 27(4):489-95. Not early CKD
1759. Iino Y, Hayashi M, Kawamura T, et al. Interim
evidence of the renoprotective effect of the
angiotensin II receptor antagonist losartan versus the
calcium channel blocker amlodipine in patients with
chronic kidney disease and hypertension: a report of
the Japanese Losartan Therapy Intended for Global
Renal Protection in Hypertensive Patients (JLIGHT)
Study. Clinical & Experimental Nephrology 2003;
7(3):221-30. Not relevant to key questions
B-120
1760. Iino Y, Hayashi M, Kawamura T, et al.
Renoprotective effect of losartan in comparison to
amlodipine in patients with chronic kidney disease
and hypertension--a report of the Japanese Losartan
Therapy Intended for the Global Renal Protection in
Hypertensive Patients (JLIGHT) study. Hypertension
Research - Clinical & Experimental 2004; 27(1):2130. Not relevant to key questions
1761. Ikeda K, Terashima M, Kawamura H, et al.
Pharmacokinetics of cisplatin in combined cisplatin
and 5-fluorouracil therapy: a comparative study of
three different schedules of cisplatin administration.
Japanese Journal of Clinical Oncology 1998;
28(3):168-75. Not CKD treatment
1762. Ikeda T, Nakayama D, Gomi T, et al. Captopril, an
angiotensin I-converting enzyme inhibitor, decreases
proteinuria in hypertensive patients with renal
diseases. Nephron 1989; 52(1):72-5. Sample size less
than 50 patients
1763. Ilag LL, Martin CL, Tabaei BP, et al. Improving
diabetes processes of care in managed care. Diabetes
Care 2003; 26(10):2722-7. Not relevant to key
questions
1764. Imai E, Ito S, Haneda M, et al. Olmesartan reducing
incidence of endstage renal disease in diabetic
nephropathy trial (ORIENT): rationale and study
design. Hypertension Research - Clinical &
Experimental 2006; 29(9):703-9. Not early CKD
1765. Imai H, Hotta O, Yoshimura M, et al.
Deoxyspergualin, an immunosuppressant, in patients
suffering from nephropathies with crescent
formation: an open-label trial to evaluate safety and
efficacy. Clinical & Experimental Nephrology 2006;
10(1):40-54. Sample size less than 50 patients
1766. Imai Y, Suzuki H, Saito T, et al. The effect of
pravastatin on renal function and lipid metabolism in
patients with renal dysfunction with hypertension and
hyperlipidemia. Pravastatin and Renal Function
Research Group. Clinical & Experimental
Hypertension 1999; 21(8):1345-55. Not relevant to
key questions
1767. Imanishi M, Yoshioka K, Okumura M, et al.
Mechanism of decreased albuminuria caused by
angiotensin converting enzyme inhibitor in early
diabetic nephropathy. Kidney International Supplement 1997; 63:S198-200. Sample size less
than 50 patients
1768. Imbasciati E, Gusmano R, Edefonti A, et al.
Controlled trial of methylprednisolone pulses and
low dose oral prednisone for the minimal change
nephrotic syndrome. British Medical Journal Clinical
Research Ed. 1985; 291(6505):1305-8. Not early
CKD
1769. Indermitte J, Burkolter S, Drewe J, et al. Risk factors
associated with a high velocity of the development of
hyperkalaemia in hospitalised patients. Drug Safety
2007; 30(1):71-80. Not relevant to key questions
1770. Innes A, Gemmell HG, Smith FW, et al. The short
term effects of oral labetalol in patients with chronic
renal disease and hypertension. Journal of Human
Hypertension 1992; 6(3):211-4. Follow-up less than
6 months
1771. Inoue S, Tomino Y. Effects of calcium antagonists in
hypertensive patients with renal dysfunction: a
prospective, randomized, parallel trial comparing
benidipine and nifedipine. Nephrology 2004;
9(5):265-71. Not early CKD
1772. Insua A, Ribstein J, Mimran A. Comparative effect
of captopril and nifedipine in normotensive patients
with incipient diabetic nephropathy. Postgraduate
Medical Journal 1988; 64 Suppl 3:59-62; discussion
90-2. Follow-up less than 6 months
1773. Inthorn D, Hoffmann JN, Hartl WH, et al.
Antithrombin III supplementation in severe sepsis:
beneficial effects on organ dysfunction. Shock 1997;
8(5):328-34. Not CKD treatment
1774. Investigators ACTT. Rationale, design, and baseline
characteristics of the Acetylcystein for ContrastInduced nephropaThy (ACT) Trial: a pragmatic
randomized controlled trial to evaluate the efficacy
of acetylcysteine for the prevention of contrastinduced nephropathy. Trials [Electronic Resource]
2009; 10:38. Not CKD treatment
1775. Investigators DT, Dagenais GR, Gerstein HC, et al.
Effects of ramipril and rosiglitazone on
cardiovascular and renal outcomes in people with
impaired glucose tolerance or impaired fasting
glucose: results of the Diabetes REduction
Assessment with ramipril and rosiglitazone
Medication (DREAM) trial. Diabetes Care 2008;
31(5):1007-14. Not CKD treatment
1776. Ip-Yam PC, Murphy S, Baines M, et al. Renal
function and proteinuria after cardiopulmonary
bypass: the effects of temperature and mannitol.
Anesthesia & Analgesia 1994; 78(5):842-7. Sample
size less than 50 patients
1777. Irish A, Dogra G, Mori T, et al. Preventing AVF
thrombosis: the rationale and design of the Omega-3
fatty acids (Fish Oils) and Aspirin in Vascular access
OUtcomes in REnal Disease (FAVOURED) study.
BMC Nephrology 2009; 10:1. Not CKD treatment
1778. Irwin MG, Roulson CJ, Jones RD, et al. Perioperative administration of rectal diclofenac sodium.
The effect on renal function in patients undergoing
minor orthopaedic surgery. European Journal of
Anaesthesiology 1995; 12(4):403-6. Sample size less
than 50 patients
1779. Isakova T, Gutierrez O, Shah A, et al. Postprandial
mineral metabolism and secondary
hyperparathyroidism in early CKD.[Erratum appears
in J Am Soc Nephrol. 2009 Jan;20(1):229]. Journal
of the American Society of Nephrology 2008;
19(3):615-23. Sample size less than 50 patients
1780. Isakova T, Gutierrez OM, Wolf M. A blueprint for
randomized trials targeting phosphorus metabolism
in chronic kidney disease. Kidney International 2009;
76(7):705-16. Not RCT or controlled trial
1781. Isakova T, Gutierrez OM, Wolf M. A blueprint for
randomized trials targeting phosphorus metabolism
in chronic kidney disease. Kidney International 2009;
76(7):705-16. Not RCT or controlled trial
1782. Isbel NM, Haluska B, Johnson DW, et al. Increased
targeting of cardiovascular risk factors in patients
with chronic kidney disease does not improve
B-121
Experimental 2009; 32(11):962-8. Sample size less
than 50 patients
1795. Ishimura E, Nishizawa Y, Okuno S, et al. Diabetes
mellitus increases the severity of anemia in nondialyzed patients with renal failure. Journal of
Nephrology 1998; 11(2):83-6. Sample size less than
50 patients
1796. Isles C, Main J, O'Connell J, et al. Survival
associated with renovascular disease in Glasgow and
Newcastle: a collaborative study. Scottish Medical
Journal 1990; 35(3):70-3. Not RCT or controlled trial
1797. Ismail T, Ayres R, Kiff P, et al. Enisoprost in liver
transplantation. Transplantation 1995; 59(9):1298301. Follow-up less than 6 months
1798. Isnard F, Tilleul P, Laporte J-P, et al. A benefit for
renal function after early switch to liposomal
amphotericin B from conventional formulation in
empirical antifungal treatment. Nephrology Dialysis
Transplantation 2007; 22(10):3090-1. Not relevant to
key questions
1799. Isomaa B, Henricsson M, Almgren P, et al. The
metabolic syndrome influences the risk of chronic
complications in patients with type II diabetes.
Diabetologia 2001; 44(9):1148-54. Not CKD
treatment
1800. Ito S. Usefulness of RAS inhibition depends on
baseline albuminuria. Nature Reviews Nephrology
2010; 6(1):10-1. Not RCT or controlled trial
1801. Ito S, Nakura N, Le Breton S, et al. Efficacy and
safety of aliskiren in Japanese hypertensive patients
with renal dysfunction. Hypertension Research Clinical & Experimental 2010; 33(1):62-6. Followup less than 6 months
1802. Itoh K. Comparison of methods for determination of
glomerular filtration rate: Tc-99m-DTPA
renography, predicted creatinine clearance method
and plasma sample method. Annals of Nuclear
Medicine 2003; 17(7):561-5. Not CKD treatment
1803. Itoh K, Tsushima S, Tsukamoto E, et al. Reappraisal
of single-sample and gamma camera methods for
determination of the glomerular filtration rate with
99mTc-DTPA. Annals of Nuclear Medicine 2000;
14(3):143-50. Not early CKD
1804. Ivanovski O, Nikolov IG, Drueke BT, et al.
Atherosclerosis and vascular calcification in uraemia
- a new experimental model. Makedonska Akademija
na Naukite i Umetnostite Oddelenie Za Bioloshki i
Meditsinski Nauki Prilozi 2007; 28(2):11-24. Not
CKD treatment
1805. Ivanyi B. Development of chronic renal failure in
patients with multiple myeloma. Archives of
Pathology & Laboratory Medicine 1993; 117(8):83740. Sample size less than 50 patients
1806. Ives NJ, Wheatley K, Stowe RL, et al. Continuing
uncertainty about the value of percutaneous
revascularization in atherosclerotic renovascular
disease: a meta-analysis of randomized trials.
Nephrology Dialysis Transplantation 2003;
18(2):298-304. Not relevant to key questions
1807. Ix JH, McCulloch CE, Chertow GM. Theophylline
for the prevention of radiocontrast nephropathy: a
meta-analysis. Nephrology Dialysis Transplantation
atheroma burden or cardiovascular function.
American Heart Journal 2006; 151(3):745-53. Not
relevant to key questions
1783. Iseki K, Osato S, Onoyama K, et al. Role of calcium
supplementation in patients with mild renal failure.
Contributions to Nephrology 1991; 90:155-60.
Sample size less than 50 patients
1784. Isenbarger DW, Kent SM, O'Malley PG. Metaanalysis of randomized clinical trials on the
usefulness of acetylcysteine for prevention of
contrast nephropathy. American Journal of
Cardiology 2003; 92(12):1454-8. Not CKD treatment
1785. Ishani A, Blackwell T, Jamal SA, et al. The effect of
raloxifene treatment in postmenopausal women with
CKD. Journal of the American Society of
Nephrology 2008; 19(7):1430-8. Follow-up less than
6 months
1786. Ishani A, Grandits GA, Grimm RH, et al. Association
of single measurements of dipstick proteinuria,
estimated glomerular filtration rate, and hematocrit
with 25-year incidence of end-stage renal disease in
the multiple risk factor intervention trial. Journal of
the American Society of Nephrology 2006;
17(5):1444-52. Not RCT or controlled trial
1787. Ishani A, Herzog CA, Collins AJ, et al. Cardiac
medications and their association with cardiovascular
events in incident dialysis patients: cause or effect?
Kidney International 2004; 65(3):1017-25. Not
relevant to key questions
1788. Ishani A, Paudel M, Taylor BC, et al. Renal function
and rate of hip bone loss in older men: the
Osteoporotic Fractures in Men Study. Osteoporosis
International 2008; 19(11):1549-56. Not CKD
treatment
1789. Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney
injury increases risk of ESRD among elderly. Journal
of the American Society of Nephrology 2009;
20(1):223-8. Not CKD treatment
1790. Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney
injury increases risk of ESRD among elderly. Journal
of the American Society of Nephrology 2009;
20(1):223-8. Not CKD treatment
1791. Ishibashi F. Glomerular clearance and tubular
reabsorption of transferrin in microtransferrinuric
patients with non-insulin-dependent diabetes.
Diabetes Research & Clinical Practice 1994;
25(3):169-75. Not CKD treatment
1792. Ishikawa J, Hoshide S, Shibasaki S, et al.
Relationship between morning hypertension
identified by home blood pressure monitoring and
brain natriuretic peptide and estimated glomerular
filtration rate: the Japan Morning Surge 1 (JMS-1)
Study. Journal of Clinical Hypertension 2008;
10(1):34-42. Not RCT or controlled trial
1793. Ishimitsu T, Akashiba A, Kameda T, et al.
Benazepril slows progression of renal dysfunction in
patients with non-diabetic renal disease. Nephrology
2007; 12(3):294-8. Not RCT or controlled trial
1794. Ishimitsu T, Numabe A, Masuda T, et al.
Angiotensin-II receptor antagonist combined with
calcium channel blocker or diuretic for essential
hypertension. Hypertension Research - Clinical &
B-122
2004; 19(11):2747-53. Sample size less than 50
patients
1808. Ix JH, Shlipak MG, Sarnak MJ, et al. Fetuin-A is not
associated with mortality in chronic kidney disease.
Kidney International 2007; 72(11):1394-9. Not RCT
or controlled trial
1809. Iyengar A, Damle H, Kulkarni C, et al. Steroid
sparing effect of a herbal preparation in steroiddependent nephrotic syndrome. Pediatric Nephrology
2006; 21(7):1031-3. Sample size less than 50 patients
1810. Iyengar SK, Adler SG. The application of the
HapMap to diabetic nephropathy and other causes of
chronic renal failure. Seminars in Nephrology 2007;
27(2):223-36. Not relevant to key questions
1811. Izhar M, Alausa T, Folker A, et al. Effects of COX
inhibition on blood pressure and kidney function in
ACE inhibitor-treated blacks and hispanics.
Hypertension 2004; 43(3):573-7. Not RCT or
controlled trial
1812. Izumi K, Eishi K, Yamachika S, et al. The efficacy of
human atrial natriuretic peptide in patients with renal
dysfunction undergoing cardiac surgery. Annals of
Thoracic & Cardiovascular Surgery 2008; 14(5):294302. Not CKD treatment
1813. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal
safety of adefovir dipivoxil in patients with chronic
hepatitis B: two double-blind, randomized, placebocontrolled studies. Kidney International 2004;
66(3):1153-8. Not early CKD
1814. Jackson GH. Renal safety of ibandronate. Oncologist
2005; 10 Suppl 1:14-8. Not relevant to key questions
1815. Jacobi J, Schmieder RE. Nephroprotection by
antihypertensive therapy. Basic Research in
Cardiology 1998; 93 Suppl 2:109-19. Not RCT or
controlled trial
1816. Jacobs DR, Jr., Gross MD, Steffen L, et al. The
effects of dietary patterns on urinary albumin
excretion: results of the Dietary Approaches to Stop
Hypertension (DASH) Trial. American Journal of
Kidney Diseases 2009; 53(4):638-46. Not CKD
treatment
1817. Jacobs ML, Derkx FH, Stijnen T, et al. Effect of
long-acting somatostatin analog (Somatulin) on renal
hyperfiltration in patients with IDDM. Diabetes Care
1997; 20(4):632-6. Sample size less than 50 patients
1818. Jacobsen BA, Fjeldborg P. Renal haemodynamics
during propranolol treatment in patients with arterial
hypertension and chronic renal failure. Scandinavian
Journal of Clinical & Laboratory Investigation 1986;
46(3):289-92. Follow-up less than 6 months
1819. Jacobsen P, Andersen S, Jensen BR, et al. Additive
effect of ACE inhibition and angiotensin II receptor
blockade in type I diabetic patients with diabetic
nephropathy. Journal of the American Society of
Nephrology 2003; 14(4):992-9. Sample size less than
50 patients
1820. Jacobsen P, Andersen S, Rossing K, et al. Dual
blockade of the renin-angiotensin system in type 1
patients with diabetic nephropathy. Nephrology
Dialysis Transplantation 2002; 17(6):1019-24.
Follow-up less than 6 months
1821. Jacobsen P, Andersen S, Rossing K, et al. Dual
blockade of the renin-angiotensin system versus
maximal recommended dose of ACE inhibition in
diabetic nephropathy. Kidney International 2003;
63(5):1874-80. Sample size less than 50 patients
1822. Jacobsen P, Parving H-H. Beneficial impact on
cardiovascular risk factors by dual blockade of the
renin-angiotensin system in diabetic nephropathy.
Kidney International - Supplement 2004; (92):S10810. Not CKD treatment
1823. Jacobson P, Uberti J, Davis W, et al. Tacrolimus: a
new agent for the prevention of graft-versus-host
disease in hematopoietic stem cell transplantation.
Bone Marrow Transplantation 1998; 22(3):217-25.
Not CKD treatment
1824. Jacobson SH, Ostenson CG. Effects of alpha 2adrenergic blockade on renal hemodynamics in
patients with insulin dependent diabetes mellitus.
Diabetes Research & Clinical Practice 1991;
14(3):197-203. Sample size less than 50 patients
1825. Jaehde U, Sorgel F, Reiter A, et al. Effect of
probenecid on the distribution and elimination of
ciprofloxacin in humans. Clinical Pharmacology &
Therapeutics 1995; 58(5):532-41. Sample size less
than 50 patients
1826. Jaehde U, Sorgel F, Stephan U, et al. Effect of an
antacid containing magnesium and aluminum on
absorption, metabolism, and mechanism of renal
elimination of pefloxacin in humans. Antimicrobial
Agents & Chemotherapy 1994; 38(5):1129-33.
Follow-up less than 6 months
1827. Jafar TH, Schmid CH, Landa M, et al. Angiotensinconverting enzyme inhibitors and progression of
nondiabetic renal disease. A meta-analysis of patientlevel data.[Erratum appears in Ann Intern Med 2002
Aug 20;137(4):299]. Annals of Internal Medicine
2001; 135(2):73-87. Not relevant to key questions
1828. Jafar TH, Schmid CH, Stark PC, et al. The rate of
progression of renal disease may not be slower in
women compared with men: a patient-level metaanalysis. Nephrology Dialysis Transplantation 2003;
18(10):2047-53. Not RCT or controlled trial
1829. Jafar TH, Stark PC, Schmid CH, et al. Progression of
chronic kidney disease: the role of blood pressure
control, proteinuria, and angiotensin-converting
enzyme inhibition: a patient-level meta-analysis.
Annals of Internal Medicine 2003; 139(4):244-52.
Not RCT or controlled trial
1830. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as
a modifiable risk factor for the progression of nondiabetic renal disease. Kidney International 2001;
60(3):1131-40. Not RCT or controlled trial
1831. Jager A, Kostense PJ, Nijpels G, et al.
Microalbuminuria is strongly associated with
NIDDM and hypertension, but not with the insulin
resistance syndrome: the Hoorn Study. Diabetologia
1998; 41(6):694-700. Not CKD treatment
1832. Jakobsen JA. Renal experience with Visipaque.
European Radiology 1996; 6 Suppl 2:S16-9. Not
RCT or controlled trial
1833. Jakobsen JA, Berg KJ, Brodahl U, et al. Renal effects
of nonionic contrast media after cardioangiography.
B-123
Acta Radiologica 1994; 35(2):191-6. Not CKD
treatment
1834. Jakobsen JA, Berg KJ, Kjaersgaard P, et al.
Angiography with nonionic X-ray contrast media in
severe chronic renal failure: renal function and
contrast retention. Nephron 1996; 73(4):549-56.
Sample size less than 50 patients
1835. Jakobsen JA, Kolbenstvedt AN, Berg KJ. Renal
effects of iopentol and iohexol after intravenous
injection. Acta Radiologica 1991; 32(4):320-4. Not
CKD treatment
1836. Jakobsen JA, Kolbenstvedt AN, Levorstad K, et al.
Renal effects of nonionic contrast media after
intravenous cardiac, and lumbar aortic injections.
Investigative Radiology 1990; 25 Suppl 1:S135-6.
Sample size less than 50 patients
1837. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate
treatment in women with normal to severely
impaired renal function: an analysis of the fracture
intervention trial. Journal of Bone & Mineral
Research 2007; 22(4):503-8. Not relevant to key
questions
1838. Jamal SA, Fitchett D, Lok CE, et al. The effects of
calcium-based versus non-calcium-based phosphate
binders on mortality among patients with chronic
kidney disease: a meta-analysis. Nephrology Dialysis
Transplantation 2009; 24(10):3168-74. Not RCT or
controlled trial
1839. Jamar F, Barone R, Mathieu I, et al. 86Y-DOTA0)D-Phe1-Tyr3-octreotide (SMT487)--a phase 1
clinical study: pharmacokinetics, biodistribution and
renal protective effect of different regimens of amino
acid co-infusion. European Journal of Nuclear
Medicine & Molecular Imaging 2003; 30(4):510-8.
Not CKD treatment
1840. Jamieson MJ, Webster J, Fowler G, et al. A
comparison of the chronic effects of oral xamoterol
and enalapril on blood pressure and renal function in
mild to moderate heart failure. British Journal of
Clinical Pharmacology 1991; 31(3):305-12. Followup less than 6 months
1841. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of
homocysteine lowering on mortality and vascular
disease in advanced chronic kidney disease and endstage renal disease: a randomized controlled
trial.[Erratum appears in JAMA. 2008 Jul
9;300(2):170]. JAMA 2007; 298(10):1163-70.
Sample size less than 50 patients
1842. Jamison RL, Shih M-C, Humphries DE, et al. Effect
of the MTHFR C677T and A1298C polymorphisms
on survival in patients with advanced CKD and
ESRD: a prospective study. American Journal of
Kidney Diseases 2009; 53(5):779-89. Not CKD
treatment
1843. Jandeleit-Dahm K, Cao Z, Cox AJ, et al. Role of
hyperlipidemia in progressive renal disease: focus on
diabetic nephropathy. Kidney International Supplement 1999; 71:S31-6. Not human studies
1844. Jansen JJ, Maassen JA, van der Woude FJ, et al.
Mutation in mitochondrial tRNA(Leu(UUR)) gene
associated with progressive kidney disease. Journal
of the American Society of Nephrology 1997;
8(7):1118-24. Not RCT or controlled trial
1845. Jansen PM, Danser AHJ, Imholz BP, et al.
Aldosterone-receptor antagonism in hypertension.
Journal of Hypertension 2009; 27(4):680-91. Not
RCT or controlled trial
1846. Janssen JJ, Gans RO, van der Meulen J, et al.
Comparison between the effects of amlodipine and
lisinopril on proteinuria in nondiabetic renal failure:
a double-blind, randomized prospective study.
American Journal of Hypertension 1998; 11(9):10749. Sample size less than 50 patients
1847. Janssen van Doorn K, Spapen H, Geers C, et al.
Sepsis-related acute kidney injury: a protective effect
of drotrecogin alpha (activated) treatment?.[Erratum
appears in Acta Anaesthesiol Scand. 2009
Feb;53(2):275. Note: van Doorn, K J [corrected to
Janssen van Doorn, K]]. Acta Anaesthesiologica
Scandinavica 2008; 52(9):1259-64. Sample size less
than 50 patients
1848. Janssen-Heijnen MLG, van Spronsen DJ, Lemmens
VEPP, et al. A population-based study of severity of
comorbidity among patients with non-Hodgkin's
lymphoma: prognostic impact independent of
International Prognostic Index. British Journal of
Haematology 2005; 129(5):597-606. Not relevant to
key questions
1849. Januzzi JL, Cannon CP, DiBattiste PM, et al. Effects
of renal insufficiency on early invasive management
in patients with acute coronary syndromes (The
TACTICS-TIMI 18 Trial). American Journal of
Cardiology 2002; 90(11):1246-9. Not CKD treatment
1850. Januzzi JL, Jr., Snapinn SM, DiBattiste PM, et al.
Benefits and safety of tirofiban among acute
coronary syndrome patients with mild to moderate
renal insufficiency: results from the Platelet Receptor
Inhibition in Ischemic Syndrome Management in
Patients Limited by Unstable Signs and Symptoms
(PRISM-PLUS) trial. Circulation 2002;
105(20):2361-6. Not CKD treatment
1851. Jardine AG, Connell JM, Northridge D, et al. The
atriopeptidase inhibitor UK 69,578 increases atrial
natriuretic factor and causes a natriuresis in normal
humans. American Journal of Hypertension 1990;
3(9):661-7. Not CKD treatment
1852. Jarnberg P-O. Renal protection strategies in the
perioperative period. Best Practice & Research 2004;
Clinical Anaesthesiology. 18(4):645-60. Not RCT or
controlled trial
1853. Jasani NB, O'Conner RE, Bouzoukis JK. Comparison
of hydromorphone and meperidine for ureteral colic.
Academic Emergency Medicine 1994; 1(6):539-43.
Not CKD treatment
1854. Jaschevatzky OE, Rosenberg RP, Shalit A, et al.
Protein/creatinine ratio in random urine specimens
for quantitation of proteinuria in preeclampsia.
Obstetrics & Gynecology 1990; 75(4):604-6. Not
CKD treatment
1855. Jawa A, Nachimuthu S, Pendergrass M, et al. Betablockers have a beneficial effect upon endothelial
function and microalbuminuria in African-American
subjects with diabetes and hypertension. Journal of
B-124
Diabetes & its Complications 2008; 22(5):303-8. Not
CKD treatment
1856. Jean R, Ducasse JL, Montastruc JL, et al. Treatment
of acute renal colic in a French emergency
department: a comparison of simulated cases and real
cases in acute pain assessment and management.
European Journal of Clinical Pharmacology 2001;
57(9):685-9. Not early CKD
1857. Jeevanandam V, Russell H, Mather P, et al. Donor
tricuspid annuloplasty during orthotopic heart
transplantation: long-term results of a prospective
controlled study. Annals of Thoracic Surgery 2006;
82(6):2089-95; discussion 95. Follow-up less than 6
months
1858. Jeffres MN, Isakow W, Doherty JA, et al. A
retrospective analysis of possible renal toxicity
associated with vancomycin in patients with health
care-associated methicillin-resistant Staphylococcus
aureus pneumonia. Clinical Therapeutics 2007;
29(6):1107-15. Follow-up less than 6 months
1859. Jeffrey RF, MacDonald TM, Freestone S, et al. The
effect of carbidopa and lithium on the systemic and
renal response to acute intravenous saline loading in
normal man. Nephrology Dialysis Transplantation
1989; 4(4):271-7. Not CKD treatment
1860. Jeffrey RF, MacDonald TM, Lee MR. A comparison
of the renal actions of gamma-L-glutamyl-L-dopa
and gamma-L-glutamyl-L-tyrosine in normal man.
Clinical Science 1988; 74(1):37-40. Sample size less
than 50 patients
1861. Jenkins DA, Cowan P, Patrick AW, et al. Renal
responses to nifedipine and captopril in hypertensive
insulin-dependent diabetic men: a randomized crossover study. Nephrology Dialysis Transplantation
1993; 8(3):200-5. Follow-up less than 6 months
1862. Jenkins DJ, Kendall CW, Vidgen E, et al. Highprotein diets in hyperlipidemia: effect of wheat
gluten on serum lipids, uric acid, and renal function.
American Journal of Clinical Nutrition 2001;
74(1):57-63. Not early CKD
1863. Jensen HV, Plenge P, Mellerup ET, et al. Lithium
prophylaxis of manic-depressive disorder: daily
lithium dosing schedule versus every second day.
Acta Psychiatrica Scandinavica 1995; 92(1):69-74.
Follow-up less than 6 months
1864. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, et
al. Increased transvascular lipoprotein transport in
diabetes: association with albuminuria and systolic
hypertension. Journal of Clinical Endocrinology &
Metabolism 2005; 90(8):4441-5. Not early CKD
1865. Jensen KT, Carstens J, Pedersen EB. Effect of BNP
on renal hemodynamics, tubular function and
vasoactive hormones in humans. American Journal
of Physiology 1998; 274(1 Pt 2):F63-72. Sample size
less than 50 patients
1866. Jensen T, Stender S, Goldstein K, et al. Partial
normalization by dietary cod-liver oil of increased
microvascular albumin leakage in patients with
insulin-dependent diabetes and albuminuria. New
England Journal of Medicine 1989; 321(23):1572-7.
Sample size less than 50 patients
1867. Jeppsson A, Ekroth R, Friberg P, et al. Renal effects
of amino acid infusion in cardiac surgery. Journal of
Cardiothoracic & Vascular Anesthesia 2000;
14(1):51-5. Sample size less than 50 patients
1868. Jeppsson A, Ekroth R, Friberg P, et al. Renal effects
of alpha-ketoglutarate early after coronary
operations. Annals of Thoracic Surgery 1998;
65(3):684-90. Not CKD treatment
1869. Jeppsson A, Ekroth R, Kirno K, et al. Insulin and
amino acid infusion after cardiac operations: effects
on systemic and renal perfusion. Journal of Thoracic
& Cardiovascular Surgery 1997; 113(3):594-602.
Sample size less than 50 patients
1870. Jerums G, Allen TJ, Campbell DJ, et al. Long-term
renoprotection by perindopril or nifedipine in nonhypertensive patients with Type 2 diabetes and
microalbuminuria. Diabetic Medicine 2004;
21(11):1192-9. Not relevant to key questions
1871. Jerums G, Allen TJ, Campbell DJ, et al. Long-term
comparison between perindopril and nifedipine in
normotensive patients with type 1 diabetes and
microalbuminuria. American Journal of Kidney
Diseases 2001; 37(5):890-9. Sample size less than 50
patients
1872. Jerums G, Allen TJ, Gilbert RE, et al. Natural history
of early diabetic nephropathy: what are the effects of
therapeutic intervention? Melbourne Diabetic
Nephropathy Study Group. Journal of Diabetes & its
Complications 1995; 9(4):308-14. Not RCT or
controlled trial
1873. Jerums G, Murray RM, Seeman E, et al. Lack of
effect of gliclazide on early diabetic nephropathy and
retinopathy: a two-year controlled study. Diabetes
Research & Clinical Practice 1987; 3(2):71-80.
Sample size less than 50 patients
1874. Jespersen B, Randlov A, Abrahamsen J, et al. Acute
cardiovascular effect of 1,25dihydroxycholecalciferol in essential hypertension.
American Journal of Hypertension 1998; 11(6 Pt
1):659-66. Sample size less than 50 patients
1875. Jevnikar AM, Finnie KJ, Dennis B, et al.
Nephrotoxicity of high- and low-osmolality contrast
media. Nephron 1988; 48(4):300-5. Sample size less
than 50 patients
1876. Ji H, Yao S, Luo Q, et al. TCM treatment of
rheumatoid arthritis by supplementing the kidney and
invigorating the blood circulation. Journal of
Traditional Chinese Medicine 2002; 22(4):252-5. Not
RCT or controlled trial
1877. Jiang F, Jones GT, Dusting GJ. Failure of
antioxidants to protect against angiotensin II-induced
aortic rupture in aged apolipoprotein(E)-deficient
mice. British Journal of Pharmacology 2007;
152(6):880-90. Sample size less than 50 patients
1878. Jin HM, Pan Y. Renoprotection provided by losartan
in combination with pioglitazone is superior to
renoprotection provided by losartan alone in patients
with type 2 diabetic nephropathy. Kidney & Blood
Pressure Research 2007; 30(4):203-11. Not RCT or
controlled trial
1879. Jin H-M, Pan Y. Angiotensin type-1 receptor
blockade with losartan increases insulin sensitivity
B-125
and improves glucose homeostasis in subjects with
type 2 diabetes and nephropathy. Nephrology
Dialysis Transplantation 2007; 22(7):1943-9.
Follow-up less than 6 months
1880. Jin K-K, Chen L, Pan J-Y, et al. Acupressure therapy
inhibits the development of diabetic complications in
Chinese patients with type 2 diabetes. Journal of
Alternative & Complementary Medicine 2009;
15(9):1027-32. Not CKD treatment
1881. Jin X. A clinical investigation on 30 cases of senile
benign renal arteriolosclerosis treated by huang qi gu
jing yin. Journal of Traditional Chinese Medicine
2001; 21(3):177-80. Not early CKD
1882. Jin Z. Chai ling tang in the treatment of steroiddependent nephrosis syndrome. Journal of
Traditional Chinese Medicine 1994; 14(4):254-8. Not
CKD treatment
1883. Jindal RM, Popescu I, Emre S, et al. Serum lipid
changes in liver transplant recipients in a prospective
trial of cyclosporine versus FK506. Transplantation
1994; 57(9):1395-8. Not early CKD
1884. Jo S-H, Koo B-K, Park J-S, et al. Prevention of
radiocontrast medium-induced nephropathy using
short-term high-dose simvastatin in patients with
renal insufficiency undergoing coronary angiography
(PROMISS) trial--a randomized controlled study.
American Heart Journal 2008; 155(3):499.e1-8. Not
CKD treatment
1885. Jo S-H, Koo B-K, Park J-S, et al. N-acetylcysteine
versus AScorbic acid for preventing contrast-Induced
nephropathy in patients with renal insufficiency
undergoing coronary angiography NASPI study-a
prospective randomized controlled trial. American
Heart Journal 2009; 157(3):576-83. Not early CKD
1886. Jo S-H, Koo B-K, Youn T-J, et al. Conclusion of
recent 'osmolality trials' in preventing contrastinduced nephropathy by NAC--what is the standard?
Nephrology Dialysis Transplantation 2008;
23(7):2424; author reply -5. Sample size less than 50
patients
1887. Joannidis M. Medical therapy of acute kidney injury.
Acta Clinica Belgica - Supplementum 2007; (2):3536. Not CKD treatment
1888. Jodrell DI. Formula-based dosing for carboplatin.
European Journal of Cancer 1999; 35(9):1299-301.
Not RCT or controlled trial
1889. Joffe HV, Kwong RY, Gerhard-Herman MD, et al.
Beneficial effects of eplerenone versus
hydrochlorothiazide on coronary circulatory function
in patients with diabetes mellitus. Journal of Clinical
Endocrinology & Metabolism 2007; 92(7):2552-8.
Not RCT or controlled trial
1890. Johansson BL, Borg K, Fernqvist-Forbes E, et al.
Beneficial effects of C-peptide on incipient
nephropathy and neuropathy in patients with Type 1
diabetes mellitus. Diabetic Medicine 2000;
17(3):181-9. Sample size less than 50 patients
1891. Johansson BL, Kernell A, Sjoberg S, et al. Influence
of combined C-peptide and insulin administration on
renal function and metabolic control in diabetes type
1. Journal of Clinical Endocrinology & Metabolism
1993; 77(4):976-81. Sample size less than 50 patients
1892. Johnson AG, Crawford GA, Kelly D, et al. Arginine
vasopressin and osmolality in the elderly. Journal of
the American Geriatrics Society 1994; 42(4):399404. Not RCT or controlled trial
1893. Johnson CA. Use of androgens in patients with renal
failure. Seminars in Dialysis 2000; 13(1):36-9. Not
CKD treatment
1894. Johnson DW. Evidence-based guide to slowing the
progression of early renal insufficiency. Internal
Medicine Journal 2004; 34(1-2):50-7. Not CKD
treatment
1895. Johnson DW. Dietary protein restriction as a
treatment for slowing chronic kidney disease
progression: the case against. Nephrology 2006;
11(1):58-62. Not relevant to key questions
1896. Johnson DW, Armstrong K, Campbell SB, et al.
Metabolic syndrome in severe chronic kidney
disease: Prevalence, predictors, prognostic
significance and effects of risk factor modification.
Nephrology 2007; 12(4):391-8. Not RCT or
controlled trial
1897. Johnson DW, Forman C, Vesey DA. Novel
renoprotective actions of erythropoietin: new uses for
an old hormone. Nephrology 2006; 11(4):306-12.
Not CKD treatment
1898. Johnson DW, Hawley CM, Rosser B, et al.
Oxpentifylline versus placebo in the treatment of
erythropoietin-resistant anaemia: a randomized
controlled trial. BMC Nephrology 2008; 9:8. Not
RCT or controlled trial
1899. Johnston CS, Day CS, Swan PD. Postprandial
thermogenesis is increased 100% on a high-protein,
low-fat diet versus a high-carbohydrate, low-fat diet
in healthy, young women. Journal of the American
College of Nutrition 2002; 21(1):55-61. Not early
CKD
1900. Johnston GD, Passmore AP. The effects of cilazapril
alone and in combination with frusemide in healthy
subjects. British Journal of Clinical Pharmacology
1989; 27 Suppl 2:235S-42S. Not CKD treatment
1901. Jones D, Bellomo R. Renal-dose dopamine: from
hypothesis to paradigm to dogma to myth and,
finally, superstition? Journal of Intensive Care
Medicine 2005; 20(4):199-211. Not relevant to key
questions
1902. Jones E, Goldman M. Lipid formulations of
amphotericin B. Cleveland Clinic Journal of
Medicine 1998; 65(8):423-7. Not CKD treatment
1903. Jones M, Ibels L, Schenkel B, et al. Impact of epoetin
alfa on clinical end points in patients with chronic
renal failure: a meta-analysis. Kidney International
2004; 65(3):757-67. Not early CKD
1904. Jones RD, Endre Z, Miles W, et al. Tenoxicam i.v.
for major gynaecological surgery--effects on renal
function. Anaesthesia & Intensive Care 2000;
28(5):501-9. Sample size less than 50 patients
1905. Jones SL, Kontessis P, Wiseman M, et al. Protein
intake and blood glucose as modulators of GFR in
hyperfiltering diabetic patients. Kidney International
1992; 41(6):1620-8. Sample size less than 50 patients
1906. Jonsson O, Herlitz H, Lindholm E, et al. Prophylaxis
against bone loss in Kock reservoir patients with
B-126
reduced glomerular filtration rate. Scandinavian
Journal of Urology & Nephrology 2005; 39(3):200-5.
Sample size less than 50 patients
1907. Jonsson PE, Olsson AM, Petersson BA, et al.
Intravenous indomethacin and oxycone-papaverine in
the treatment of acute renal colic. A double-blind
study. British Journal of Urology 1987; 59(5):396400. Follow-up less than 6 months
1908. Jorgensen JO, Pedersen SA, Thuesen L, et al.
Beneficial effects of growth hormone treatment in
GH-deficient adults. Lancet 1989; 1(8649):1221-5.
Not CKD treatment
1909. Jose P, Skali H, Anavekar N, et al. Increase in
creatinine and cardiovascular risk in patients with
systolic dysfunction after myocardial infarction.
Journal of the American Society of Nephrology
2006; 17(10):2886-91. Sample size less than 50
patients
1910. Joss N, Jardine A, Gaffney D, et al. Influence of
apolipoprotein E genotype on progression of diabetic
nephropathy. Nephron. Experimental Nephrology
2005; 101(4):e127-33. Not CKD treatment
1911. Joy MS. Darbepoetin alfa: a novel erythropoiesisstimulating protein. Annals of Pharmacotherapy
2002; 36(7-8):1183-92. Not RCT or controlled trial
1912. Juergens CP, Winter JP, Nguyen-Do P, et al.
Nephrotoxic effects of iodixanol and iopromide in
patients with abnormal renal function receiving Nacetylcysteine and hydration before coronary
angiography and intervention: a randomized trial.
Internal Medicine Journal 2009; 39(1):25-31. Not
CKD treatment
1913. Juhanson P, Kepp K, Org E, et al. Nacetyltransferase 8, a positional candidate for blood
pressure and renal regulation: resequencing,
association and in silico study. BMC Medical
Genetics 2008; 9:25. Not CKD treatment
1914. Juhlin T, Bjorkman S, Gunnarsson B, et al. Acute
administration of diclofenac, but possibly not long
term low dose aspirin, causes detrimental renal
effects in heart failure patients treated with ACEinhibitors. European Journal of Heart Failure 2004;
6(7):909-16. Not relevant to key questions
1915. Juhlin T, Bjorkman S, Hoglund P. Cyclooxygenase
inhibition causes marked impairment of renal
function in elderly subjects treated with diuretics and
ACE-inhibitors. European Journal of Heart Failure
2005; 7(6):1049-56. Not RCT or controlled trial
1916. Juhlin T, Erhardt LR, Ottosson H, et al. Treatments
with losartan or enalapril are equally sensitive to
deterioration in renal function from cyclooxygenase
inhibition. European Journal of Heart Failure 2007;
9(2):191-6. Not relevant to key questions
1917. Juhlin T, Jonsson BAG, Hoglund P. Renal effects of
aspirin are clearly dose-dependent and are of clinical
importance from a dose of 160 mg. European Journal
of Heart Failure 2008; 10(9):892-8. Not CKD
treatment
1918. Julier K, da Silva R, Garcia C, et al. Preconditioning
by sevoflurane decreases biochemical markers for
myocardial and renal dysfunction in coronary artery
bypass graft surgery: a double-blinded, placebo-
controlled, multicenter study. Anesthesiology 2003;
98(6):1315-27. Not CKD treatment
1919. Jungers P, Chauveau P, Ployard F, et al. Comparison
of ketoacids and low protein diet on advanced
chronic renal failure progression. Kidney
International - Supplement 1987; 22:S67-71. Sample
size less than 50 patients
1920. Jungers P, Choukroun G, Oualim Z, et al. Beneficial
influence of recombinant human erythropoietin
therapy on the rate of progression of chronic renal
failure in predialysis patients. Nephrology Dialysis
Transplantation 2001; 16(2):307-12. Not RCT or
controlled trial
1921. Jungmann E, Haak T, Althoff PH, et al.
Dopaminergic effects on kidney function and
responsiveness of aldosterone, plasma renin activity,
prolactin, catecholamines, and blood pressure to
stimulation in patients with prolactinoma.
Comparison of the efficacy of pergolide and
bromocriptine therapy. Arzneimittel-Forschung
1988; 38(2):296-300. Sample size less than 50
patients
1922. Jungmann E, Malanyn M, Mortasawi N, et al. Effect
of 1-year treatment with nitrendipine versus enalapril
on urinary albumin and alpha 1-microglobulin
excretion in microalbuminuric patients with type 1
diabetes mellitus. A randomized, single-blind
comparative study. Arzneimittel-Forschung 1994;
44(3):313-7. Sample size less than 50 patients
1923. Jungmann E, Usadel KH. Effect of captopril on renal
functional reserve in type 1 (insulin-dependent)
diabetes mellitus. Diabetologia 1991; 34(11):843-4.
Not early CKD
1924. Jungmann E, Walter-Schrader MC, Haak T, et al.
Impaired renal responsiveness to human atrial
natriuretic peptide (hANP) in normotensive patients
with type 1 diabetes mellitus. Klinische
Wochenschrift 1988; 66(12):527-32. Sample size less
than 50 patients
1925. Jurkovitz C, Franch H, Shoham D, et al. Family
members of patients treated for ESRD have high
rates of undetected kidney disease. American Journal
of Kidney Diseases 2002; 40(6):1173-8. Not CKD
treatment
1926. Kaasjager KA, Koomans HA, Rabelink TJ.
Effectiveness of enalapril versus nifedipine to
antagonize blood pressure and the renal response to
endothelin in humans. Hypertension 1995; 25(4 Pt
1):620-5. Not RCT or controlled trial
1927. Kaasjager KA, Koomans HA, Rabelink TJ.
Endothelin-1-induced vasopressor responses in
essential hypertension. Hypertension 1997; 30(1 Pt
1):15-21. Sample size less than 50 patients
1928. Kabat-Koperska J, Motyl W, Domanski L, et al.
Methods of GFR determination--creatinine clearance
after cimetidine administration in clinical practice.
Acta Medica Austriaca 2004; 31(2):51-5. Follow-up
less than 6 months
1929. Kadhim HM, Ismail SH, Hussein KI, et al. Effects of
melatonin and zinc on lipid profile and renal function
in type 2 diabetic patients poorly controlled with
B-127
metformin. Journal of Pineal Research 2006;
41(2):189-93. Not RCT or controlled trial
1930. Kageyama S, Brown J, Causon R, et al. DOPA
decarboxylase inhibition does not influence the
diuretic and natriuretic response to exogenous alphaatrial natriuretic peptide in man. European Journal of
Clinical Pharmacology 1990; 38(3):223-7. Not CKD
treatment
1931. Kahn D, Ben-Haim S, Bushnell DL, et al. Captoprilenhanced 99Tcm-MAG3 renal scintigraphy in
subjects with suspected renovascular hypertension.
Nuclear Medicine Communications 1994; 15(7):51528. Sample size less than 50 patients
1932. Kaisar MO, Isbel NM, Johnson DW. Recent clinical
trials of pharmacologic cardiovascular interventions
in patients with chronic kidney disease. Reviews on
Recent Clinical Trials 2008; 3(2):79-88. Not CKD
treatment
1933. Kalaitzidis RG, Bakris GL. Should proteinuria
reduction be the criterion for antihypertensive drug
selection for patients with kidney disease? Current
Opinion in Nephrology & Hypertension 2009;
18(5):386-91. Not RCT or controlled trial
1934. Kalambokis G, Economou M, Fotopoulos A, et al.
Effects of nitric oxide inhibition by methylene blue
in cirrhotic patients with ascites. Digestive Diseases
& Sciences 2005; 50(10):1771-7. Not relevant to key
questions
1935. Kalambokis G, Fotopoulos A, Economou M, et al.
Effects of a 7-day treatment with midodrine in nonazotemic cirrhotic patients with and without ascites.
Journal of Hepatology 2007; 46(2):213-21. Sample
size less than 50 patients
1936. Kalantarinia K, Okusa MD. The renin-angiotensin
system and its blockade in diabetic renal and
cardiovascular disease. Current Diabetes Reports
2006; 6(1):8-16. Follow-up less than 6 months
1937. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes
with active versus nutritional vitamin D compounds
in chronic kidney disease. Clinical Journal of The
American Society of Nephrology: CJASN 2009;
4(9):1529-39. Not RCT or controlled trial
1938. Kalayjian RC, Franceschini N, Gupta SK, et al.
Suppression of HIV-1 replication by antiretroviral
therapy improves renal function in persons with low
CD4 cell counts and chronic kidney disease. AIDS
2008; 22(4):481-7. Not CKD treatment
1939. Kale K, Sawant S. Clinical significance and
evaluation of proteinuria in NIDDM patients. Indian
Journal of Medical Sciences 1999; 53(3):103-7. Not
relevant to key questions
1940. Kamali F, Edwards C. Possible role of metabolite in
flosequinan-related mortality. Clinical
Pharmacokinetics 1995; 29(6):396-403. Not RCT or
controlled trial
1941. Kamiyama N, Ogawa R, Hamada H, et al. Preventive
effect of N-acetylcysteine on contrast-induced
nephropathy following coronary angiography and
angioplasty. Yakugaku Zasshi - Journal of the
Pharmaceutical Society of Japan 2008; 128(9):13339. Not CKD treatment
1942. Kammerl MC, Grimm D, Nabel C, et al. Effects of
growth hormone on renal renin gene expression in
normal rats and rats with myocardial infarction.
Nephrology Dialysis Transplantation 2000;
15(6):786-90. Not human studies
1943. Kamper AL, Holstein-Rathlou NH, Leyssac PP, et al.
The influence of angiotensin-converting enzyme
inhibition on renal tubular function in progressive
chronic nephropathy. American Journal of Kidney
Diseases 1996; 28(6):822-31. Not RCT or controlled
trial
1944. Kamper AL, Nielsen OJ. Effect of enalapril on
haemoglobin and serum erythropoietin in patients
with chronic nephropathy. Scandinavian Journal of
Clinical & Laboratory Investigation 1990; 50(6):6118. Not relevant to key questions
1945. Kamper AL, Strandgaard S, Leyssac PP. Effect of
enalapril on the progression of chronic renal failure.
A randomized controlled trial. American Journal of
Hypertension 1992; 5(7):423-30. Not relevant to key
questions
1946. Kamper AL, Strandgaard S, Leyssac PP. Late
outcome of a controlled trial of enalapril treatment in
progressive chronic renal failure. Hard end-points
and influence of proteinuria. Nephrology Dialysis
Transplantation 1995; 10(7):1182-8. Not early CKD
1947. Kanbay M, Covic A, Coca SG, et al. Sodium
bicarbonate for the prevention of contrast-induced
nephropathy: a meta-analysis of 17 randomized
trials. International Urology & Nephrology 2009;
41(3):617-27. Sample size less than 50 patients
1948. Kanbay M, Kasapoglu B, Akcay A. Sodium
bicarbonate vs sodium chloride in preventing contrast
medium-induced nephropathy. JAMA 2009;
301(4):378; author reply 9-80. Not CKD treatment
1949. Kandarpa K, Becker GJ, Hunink MG, et al.
Transcatheter interventions for the treatment of
peripheral atherosclerotic lesions: part I. Journal of
Vascular & Interventional Radiology 2001;
12(6):683-95. Not CKD treatment
1950. Kaneshiro Y, Ichihara A, Sakoda M, et al. Add-on
benefits of amlodipine and thiazide in nondiabetic
chronic kidney disease stage 1/2 patients treated with
valsartan. Kidney & Blood Pressure Research 2009;
32(1):51-8. Not early CKD
1951. Kang YS, Han KH, Han SY, et al. Characteristics of
population with normal serum creatinine impaired
renal function and: the validation of a MDRD
formula in a healthy general population. Clinical
Nephrology 2005; 63(4):258-66. Sample size less
than 50 patients
1952. Kanno Y, Takenaka T, Nakamura T, et al. Add-on
angiotensin receptor blocker in patients who have
proteinuric chronic kidney diseases and are treated
with angiotensin-converting enzyme inhibitors.
Clinical Journal of The American Society of
Nephrology: CJASN 2006; 1(4):730-7. Follow-up
less than 6 months
1953. Kantarci F, Mihmanli I, Adaletli I, et al. The effect of
fluid intake on renal length measurement in adults.
Journal of Clinical Ultrasound 2006; 34(3):128-33.
Not relevant to key questions
B-128
Hypertension 1992; 5(10):778-9. Not RCT or
controlled trial
1968. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of
antihypertensive therapy on the kidney in patients
with diabetes: a meta-regression analysis. Annals of
Internal Medicine 1993; 118(2):129-38. Not RCT or
controlled trial
1969. Kasiske BL, Lakatua JD. The effects of dietary
protein restriction on chronic progressive renal
disease. Mineral & Electrolyte Metabolism 1997;
23(3-6):296-300. Not RCT or controlled trial
1970. Kasiske BL, Lakatua JD, Ma JZ, et al. A metaanalysis of the effects of dietary protein restriction on
the rate of decline in renal function. American
Journal of Kidney Diseases 1998; 31(6):954-61. Not
RCT or controlled trial
1971. Kasiske BL, Velosa JA, Halstenson CE, et al. The
effects of lovastatin in hyperlipidemic patients with
the nephrotic syndrome. American Journal of Kidney
Diseases 1990; 15(1):8-15. Sample size less than 50
patients
1972. Kassimatis TI, Konstantinopoulos PA. The role of
statins in chronic kidney disease (CKD): friend or
foe? Pharmacology & Therapeutics 2009;
122(3):312-23. Not early CKD
1973. Katavetin P, Eiam-Ong S, Suwanwalaikorn S.
Pioglitazone reduces urinary protein and urinary
transforming growth factor-beta excretion in patients
with type 2 diabetes and overt nephropathy. Journal
of the Medical Association of Thailand 2006;
89(2):170-7. Not RCT or controlled trial
1974. Katayama K, Nomura S, Ishikawa H, et al.
Comparison between valsartan and valsartan plus
cilnidipine in type II diabetics with normo- and
microalbuminuria. Kidney International 2006;
70(1):151-6. Not CKD treatment
1975. Katayama S, Kawamori R, Iwamoto Y, et al. In half
of hypertensive diabetics, co-administration of a
calcium channel blocker and an angiotensinconverting enzyme inhibitor achieved a target blood
pressure of <130/80 mmHg: the azelnidipine and
temocapril in hypertensive patients with type 2
diabetes (ATTEST) study. Hypertension Research Clinical & Experimental 2008; 31(8):1499-508. Not
CKD treatment
1976. Katayama Y, Haraoka J, Hirabayashi H, et al. A
randomized controlled trial of hydrocortisone against
hyponatremia in patients with aneurysmal
subarachnoid hemorrhage. Stroke 2007; 38(8):23735. Not RCT or controlled trial
1977. Katholi RE, Taylor GJ, McCann WP, et al.
Nephrotoxicity from contrast media: attenuation with
theophylline. Radiology 1995; 195(1):17-22. Not
CKD treatment
1978. Katholi RE, Taylor GJ, Woods WT, et al.
Nephrotoxicity of nonionic low-osmolality versus
ionic high-osmolality contrast media: a prospective
double-blind randomized comparison in human
beings. Radiology 1993; 186(1):183-7. Not CKD
treatment
1979. Katholi RE, Woods WT, Jr., Taylor GJ, et al.
Oxygen free radicals and contrast nephropathy.
1954. Kantor TG. Use of diclofenac in analgesia. American
Journal of Medicine 1986; 80(4B):64-9. Not RCT or
controlled trial
1955. Kaplan AA. Therapeutic apheresis for cancer related
hemolytic uremic syndrome. Therapeutic Apheresis
2000; 4(3):201-6. Not early CKD
1956. Kaplan NM. The place of diuretics in preventing
cardiovascular events. Journal of Human
Hypertension 2004; 18 Suppl 2:S29-32. Not RCT or
controlled trial
1957. Kaplan-Pavlovcic S, Nadja C. Captopril renography
and duplex Doppler sonography in the diagnosis of
renovascular hypertension. Nephrology Dialysis
Transplantation 1998; 13(2):313-7. Sample size less
than 50 patients
1958. Kapoor A, Figlin RA. Targeted inhibition of
mammalian target of rapamycin for the treatment of
advanced renal cell carcinoma. Cancer 2009;
115(16):3618-30. Not CKD treatment
1959. Kapoor A, Kumar S, Gulati S, et al. The role of
theophylline in contrast-induced nephropathy: a casecontrol study. Nephrology Dialysis Transplantation
2002; 17(11):1936-41. Not CKD treatment
1960. Kapoor A, Sinha N, Sharma RK, et al. Use of
dopamine in prevention of contrast induced acute
renal failure--a randomised study. International
Journal of Cardiology 1996; 53(3):233-6. Not CKD
treatment
1961. Karabina SA, Pappas H, Miltiadous G, et al.
Compositional lipoprotein changes and low-density
lipoprotein susceptibility to oxidation in chronic
renal failure patients with heavy proteinuria.
Nephron 2003; 95(3):c77-83. Not CKD treatment
1962. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan
improves arterial stiffness in type 2 diabetes
independently of blood pressure lowering.
Hypertension 2008; 51(6):1617-23. Not CKD
treatment
1963. Kario K, Matsui Y, Shibasaki S, et al. An alphaadrenergic blocker titrated by self-measured blood
pressure recordings lowered blood pressure and
microalbuminuria in patients with morning
hypertension: the Japan Morning Surge-1 Study.
Journal of Hypertension 2008; 26(6):1257-65. Not
CKD treatment
1964. Karnik AM, Bashir R, Khan FA, et al. Renal
involvement in the systemic inflammatory reaction
syndrome. Renal Failure 1998; 20(1):103-16. Not
CKD treatment
1965. Karthik S, Lisbon A. Low-dose dopamine in the
intensive care unit. Seminars in Dialysis 2006;
19(6):465-71. Not RCT or controlled trial
1966. Kasiakou SK, Sermaides GJ, Michalopoulos A, et al.
Continuous versus intermittent intravenous
administration of antibiotics: a meta-analysis of
randomised controlled trials. The Lancet Infectious
Diseases 2005; 5(9):581-9. Follow-up less than 6
months
1967. Kasiske BL. Questions and answers from controlled
clinical trials of antihypertensive therapy in
progressive renal disease. American Journal of
B-129
American Journal of Kidney Diseases 1998;
32(1):64-71. Not CKD treatment
1980. Katiyar CK, Arora D, Mehrotra R, et al. Management
of chronic hepatitis B with New Livfit in end stage
renal disease. Indian Journal of Physiology &
Pharmacology 2005; 49(1):83-8. Sample size less
than 50 patients
1981. Katzman PL, DiBona GF, Hokfelt B, et al. Acute
renal tubular and hemodynamic effects of the
calcium antagonist felodipine in healthy volunteers.
Journal of the American Society of Nephrology
1991; 2(5):1000-6. Sample size less than 50 patients
1982. Katzman PL, Henningsen NC, Fagher B, et al. Renal
and endocrine effects of long-term converting
enzyme inhibition as compared with calcium
antagonism in essential hypertension. Journal of
Cardiovascular Pharmacology 1990; 15(3):360-4.
Sample size less than 50 patients
1983. Kawamori R, Kamado K, Kamada T. Recent
progress in the treatment of diabetic nephropathy:
importance of strict glycemic control on the
regression of diabetic nephropathy. Journal of
Diabetic Complications 1991; 5(2-3):88-90. Sample
size less than 50 patients
1984. Kawamoto R, Kohara K, Tabara Y, et al. An
association between body mass index and estimated
glomerular filtration rate. Hypertension Research Clinical & Experimental 2008; 31(8):1559-64. Not
CKD treatment
1985. Kawamoto R, Kohara K, Tabara Y, et al. An
association between decreased estimated glomerular
filtration rate and arterial stiffness. Internal Medicine
2008; 47(7):593-8. Not CKD treatment
1986. Kay J, Chow WH, Chan TM, et al. Acetylcysteine
for prevention of acute deterioration of renal function
following elective coronary angiography and
intervention: a randomized controlled trial. JAMA
2003; 289(5):553-8. Not CKD treatment
1987. Kaya K, Oguz M, Akar AR, et al. The effect of
sodium nitroprusside infusion on renal function
during reperfusion period in patients undergoing
coronary artery bypass grafting: a prospective
randomized clinical trial. European Journal of
Cardio-Thoracic Surgery 2007; 31(2):290-7. Sample
size less than 50 patients
1988. Kaysen GA, Gambertoglio J, Felts J, et al. Albumin
synthesis, albuminuria and hyperlipemia in nephrotic
patients. Kidney International 1987; 31(6):1368-76.
Sample size less than 50 patients
1989. Keane WF, Hirata-Dulas CA, Bullock ML, et al.
Adjunctive therapy with intravenous human
immunoglobulin G improves survival of patients
with acute renal failure. Journal of the American
Society of Nephrology 1991; 2(4):841-7. Not CKD
treatment
1990. Keane WF, Lyle PA, Reduction of Endpoints in
NwtAIIRALs. Recent advances in management of
type 2 diabetes and nephropathy: lessons from the
RENAAL study. American Journal of Kidney
Diseases 2003; 41(3 Suppl 1):S22-5. Not RCT or
controlled trial
1991. Keeley EC, McCullough PA. Coronary
revascularization in patients with end-stage renal
disease: risks, benefits, and optimal strategies.
Reviews in Cardiovascular Medicine 2003; 4(3):12530. Not CKD treatment
1992. Keeley EC, McCullough PA. Coronary
revascularization in patients with coronary artery
disease and chronic kidney disease. Advances in
Chronic Kidney Disease 2004; 11(3):254-60. Not
CKD treatment
1993. Keeton GR, Smit RvZ, Bryer A. Renal outcome of
type 2 diabetes in South Africa--a 12-year follow-up
study. South African Medical Journal 2004; SuidAfrikaanse Tydskrif Vir Geneeskunde. 94(9):771-5.
Not RCT or controlled trial
1994. Kefer JM, Hanet CE, Boitte S, et al. Acetylcysteine,
coronary procedure and prevention of contrastinduced worsening of renal function: which benefit
for which patient? Acta Cardiologica 2003;
58(6):555-60. Not relevant to key questions
1995. Keilani T, Danesh FR, Schlueter WA, et al. A
subdepressor low dose of ramipril lowers urinary
protein excretion without increasing plasma
potassium. American Journal of Kidney Diseases
1999; 33(3):450-7. Sample size less than 50 patients
1996. Keilani T, Schlueter WA, Levin ML, et al.
Improvement of lipid abnormalities associated with
proteinuria using fosinopril, an angiotensinconverting enzyme inhibitor. Annals of Internal
Medicine 1993; 118(4):246-54. Follow-up less than
6 months
1997. Keithi-Reddy SR, Addabbo F, Patel TV, et al.
Association of anemia and erythropoiesis stimulating
agents with inflammatory biomarkers in chronic
kidney disease. Kidney International 2008;
74(6):782-90. Sample size less than 50 patients
1998. Keithi-Reddy SR, Singh AK. Hemoglobin target in
chronic kidney disease: a pediatric perspective.
Pediatric Nephrology 2009; 24(3):431-4. Sample size
less than 50 patients
1999. Kekec Z, Yilmaz U, Sozuer E. The effectiveness of
tenoxicam vs isosorbide dinitrate plus tenoxicam in
the treatment of acute renal colic. BJU International
2000; 85(7):783-5. Not early CKD
2000. Kell MJ. Utilization of plasma and urine methadone
concentrations to optimize treatment in maintenance
clinics: I. Measurement techniques for a clinical
setting. Journal of Addictive Diseases 1994; 13(1):526. Not RCT or controlled trial
2001. Kellum JA. Prophylactic fenoldopam for renal
protection? No, thank you, not for me--not yet at
least. Critical Care Medicine 2005; 33(11):2681-3.
Not RCT or controlled trial
2002. Kellum JA, Leblanc M, Venkataraman R. Acute
renal failure. Clinical Evidence 2002; (7):757-74. Not
RCT or controlled trial
2003. Kelly AM, Dwamena B, Cronin P, et al. Metaanalysis: effectiveness of drugs for preventing
contrast-induced nephropathy.[Erratum appears in
Ann Intern Med. 2008 Aug 5;149(3):219]. Annals of
Internal Medicine 2008; 148(4):284-94. Not CKD
treatment
B-130
2004. Kelly DJ, Edgley AJ, Zhang Y, et al. Protein kinase
C-beta inhibition attenuates the progression of
nephropathy in non-diabetic kidney disease.
Nephrology Dialysis Transplantation 2009;
24(6):1782-90. Not CKD treatment
2005. Keltai M, Tonelli M, Mann JFE, et al. Renal function
and outcomes in acute coronary syndrome: impact of
clopidogrel. European Journal of Cardiovascular
Prevention & Rehabilitation 2007; 14(2):312-8.
Sample size less than 50 patients
2006. Kemp G, Rose P, Lurain J, et al. Amifostine
pretreatment for protection against
cyclophosphamide-induced and cisplatin-induced
toxicities: results of a randomized control trial in
patients with advanced ovarian cancer. Journal of
Clinical Oncology 1996; 14(7):2101-12. Not CKD
treatment
2007. Kennedy C, Rickards D, Lee S, et al. A double-blind
study comparing the efficiency, tolerance and renal
effects of iopromide and iopamidol. British Journal
of Radiology 1988; 61(724):288-93. Not relevant to
key questions
2008. Kenny GN. Potential renal, haematological and
allergic adverse effects associated with nonsteroidal
anti-inflammatory drugs. Drugs 1992; 44 Suppl 5:316; discussion 7. Not CKD treatment
2009. Kent DM, Jafar TH, Hayward RA, et al. Progression
risk, urinary protein excretion, and treatment effects
of angiotensin-converting enzyme inhibitors in
nondiabetic kidney disease. Journal of the American
Society of Nephrology 2007; 18(6):1959-65. Not
RCT or controlled trial
2010. Kentsch M, Ludwig D, Drummer C, et al.
Haemodynamic and renal effects of urodilatin bolus
injections in patients with congestive heart failure.
European Journal of Clinical Investigation 1992;
22(10):662-9. Sample size less than 50 patients
2011. Kentsch M, Ludwig D, Drummer C, et al.
Haemodynamic and renal effects of urodilatin in
healthy volunteers. European Journal of Clinical
Investigation 1992; 22(5):319-25. Sample size less
than 50 patients
2012. Keown PA. Quality of life in end-stage renal disease
patients during recombinant human erythropoietin
therapy. The Canadian Erythropoietin Study Group.
Contributions to Nephrology 1991; 88:81-6;
discussion 7-9. Not early CKD
2013. Kerstens MN, Buter H, Navis GJ, et al. 11betahydroxysteroid dehydrogenase activity in proteinuric
patients and the effect of angiotensin-II receptor
blockade. European Journal of Clinical Investigation
2002; 32(7):513-8. Sample size less than 50 patients
2014. Kerstetter JE, O'Brien KO, Insogna KL. Dietary
protein affects intestinal calcium absorption.
American Journal of Clinical Nutrition 1998;
68(4):859-65. Sample size less than 50 patients
2015. Kestenbaum B, Gillen DL, Sherrard DJ, et al.
Calcium channel blocker use and mortality among
patients with end-stage renal disease. Kidney
International 2002; 61(6):2157-64. Not early CKD
2016. Khajehdehi P, Roozbeh J, Mostafavi H. A
comparative randomized and placebo-controlled
short-term trial of aspirin and dipyridamole for overt
type-2 diabetic nephropathy. Scandinavian Journal of
Urology & Nephrology 2002; 36(2):145-8. Followup less than 6 months
2017. Khan DA, Ahmad TM, Qureshil AH, et al.
Assessment of proteinuria by using protein:
creatinine index in random urine sample. JPMA Journal of the Pakistan Medical Association 2005;
55(10):428-31. Not relevant to key questions
2018. Khan NA, Hemmelgarn BR, Tonelli M, et al.
Prognostic value of troponin T and I among
asymptomatic patients with end-stage renal disease: a
meta-analysis. Circulation 2005; 112(20):3088-96.
Sample size less than 50 patients
2019. Khan NA, Ma I, Thompson CR, et al. Kidney
function and mortality among patients with left
ventricular systolic dysfunction. Journal of the
American Society of Nephrology 2006; 17(1):24453. Not relevant to key questions
2020. Khan NA, McAlister FA, Rabkin SW, et al. The
2006 Canadian Hypertension Education Program
recommendations for the management of
hypertension: Part II - Therapy. Canadian Journal of
Cardiology 2006; 22(7):583-93. Follow-up less than
6 months
2021. Khan NA, Susa D, van den Berg JW, et al.
Amelioration of renal ischaemia-reperfusion injury
by synthetic oligopeptides related to human chorionic
gonadotropin. Nephrology Dialysis Transplantation
2009; 24(9):2701-8. Not CKD treatment
2022. Khandekar JD, Elson PJ, DeWys WD, et al.
Comparative activity and toxicity of cisdiamminedichloroplatinum (DDP) and a combination
of doxorubicin, cyclophosphamide, and DDP in
disseminated transitional cell carcinomas of the
urinary tract. Journal of Clinical Oncology 1985;
3(4):539-45. Follow-up less than 6 months
2023. Kharasch ED, Frink EJ, Jr., Artru A, et al. Longduration low-flow sevoflurane and isoflurane effects
on postoperative renal and hepatic function.
Anesthesia & Analgesia 2001; 93(6):1511-20. Not
CKD treatment
2024. Kharasch ED, Frink EJ, Jr., Zager R, et al.
Assessment of low-flow sevoflurane and isoflurane
effects on renal function using sensitive markers of
tubular toxicity. Anesthesiology 1997; 86(6):123853. Not CKD treatment
2025. Khoury Z, Schlicht JR, Como J, et al. The effect of
prophylactic nifedipine on renal function in patients
administered contrast media. Pharmacotherapy 1995;
15(1):59-65. Sample size less than 50 patients
2026. Kiberd BA. Atorvastatin has no beneficial effect on
cardiovascular outcomes in patients with advanced
chronic kidney disease. Nature Clinical Practice
Nephrology 2006; 2(7):354-5. Not RCT or controlled
trial
2027. Kielstein JT, Salpeter SR, Bode-Boeger SM, et al.
Symmetric dimethylarginine (SDMA) as endogenous
marker of renal function--a meta-analysis.
Nephrology Dialysis Transplantation 2006;
21(9):2446-51. Follow-up less than 6 months
B-131
2028. Kielstein JT, Simmel S, Bode-Boger SM, et al.
Subpressor dose asymmetric dimethylarginine
modulates renal function in humans through nitric
oxide synthase inhibition. Kidney & Blood Pressure
Research 2004; 27(3):143-7. Not early CKD
2029. Kim H, Rosenberg SA, Steinberg SM, et al. A
randomized double-blinded comparison of the
antiemetic efficacy of ondansetron and droperidol in
patients receiving high-dose interleukin-2. Journal of
Immunotherapy with Emphasis on Tumor
Immunology 1994; 16(1):60-5. Not CKD treatment
2030. Kim JY, Lee KC, Kim HS, et al. Effect of diltiazem
on kidney function during laparoscopic surgery.
Surgical Endoscopy 2009; 23(8):1785-90. Not CKD
treatment
2031. Kim K-S, Fan WH, Kim Y-D, et al. Effectiveness of
open-label losartan/hydrochlorothiazide combination
therapy in Asian patients with hypertension not
controlled with ACE inhibitor or ARB monotherapy.
Hypertension Research - Clinical & Experimental
2009; 32(6):520-6. Not CKD treatment
2032. Kimel M, Leidy NK, Mannix S, et al. Does epoetin
alfa improve health-related quality of life in
chronically ill patients with anemia? Summary of
trials of cancer, HIV/AIDS, and chronic kidney
disease. Value in Health 2008; 11(1):57-75. Followup less than 6 months
2033. Kimmel M, Butscheid M, Brenner S, et al. Improved
estimation of glomerular filtration rate by serum
cystatin C in preventing contrast induced
nephropathy by N-acetylcysteine or zinc-preliminary results. Nephrology Dialysis
Transplantation 2008; 23(4):1241-5. Not RCT or
controlled trial
2034. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and
treatment of HIV-associated renal diseases: lessons
from clinical and animal studies, molecular
pathologic correlations, and genetic investigations.
Annals of Internal Medicine 2003; 139(3):214-26.
Not CKD treatment
2035. Kimmelstiel CD, Perrone R, Kilcoyne L, et al.
Effects of renal neutral endopeptidase inhibition on
sodium excretion, renal hemodynamics and
neurohormonal activation in patients with congestive
heart failure. Cardiology 1996; 87(1):46-53. Sample
size less than 50 patients
2036. Kimura G, Uzu T, Nakamura S, et al. High sodium
sensitivity and glomerular
hypertension/hyperfiltration in primary
aldosteronism. Journal of Hypertension 1996;
14(12):1463-8. Sample size less than 50 patients
2037. Kincaid-Smith P, Fairley K, Packham D.
Randomized controlled crossover study of the effect
on proteinuria and blood pressure of adding an
angiotensin II receptor antagonist to an angiotensin
converting enzyme inhibitor in normotensive patients
with chronic renal disease and proteinuria.[Erratum
appears in Nephrol Dial Transplant 2002
Jun;17(6):1153]. Nephrology Dialysis
Transplantation 2002; 17(4):597-601. Follow-up less
than 6 months
2038. Kincaid-Smith P, Fairley KF, Farish S, et al.
Reduction of proteinuria by rosiglitazone in nondiabetic renal disease. Nephrology 2008; 13(1):5862. Sample size less than 50 patients
2039. Kincaid-Smith P, Fairley KF, Packham D. Dual
blockade of the renin-angiotensin system compared
with a 50% increase in the dose of angiotensinconverting enzyme inhibitor: effects on proteinuria
and blood pressure. Nephrology Dialysis
Transplantation 2004; 19(9):2272-4. Not CKD
treatment
2040. Kindler J, Schunkert H, Gassmann M, et al.
Therapeutic efficacy and tolerance of ramipril in
hypertensive patients with renal failure. Journal of
Cardiovascular Pharmacology 1989; 13 Suppl 3:S558. Sample size less than 50 patients
2041. Kini AA, Sharma SK. Managing the high-risk
patient: experience with fenoldopam, a selective
dopamine receptor agonist, in prevention of
radiocontrast nephropathy during percutaneous
coronary intervention. Reviews in Cardiovascular
Medicine 2001; 2 Suppl 1:S19-25. Not CKD
treatment
2042. Kinoshita Y, Yahata K, Yoshioka T, et al. Long-term
renal preservation after brain death maintained with
vasopressin and epinephrine. Transplant International
1990; 3(1):15-8. Sample size less than 50 patients
2043. Kinouchi K, Ichihara A, Sakoda M, et al. Safety and
benefits of a tablet combining losartan and
hydrochlorothiazide in Japanese diabetic patients
with hypertension. Hypertension Research - Clinical
& Experimental 2009; 32(12):1143-7. Sample size
less than 50 patients
2044. Kirch W, Stroemer K, Hoogkamer JF, et al. The
influence of prostaglandin inhibition by
indomethacin on blood pressure and renal function in
hypertensive patients treated with cilazapril. British
Journal of Clinical Pharmacology 1989; 27 Suppl
2:297S-301S. Sample size less than 50 patients
2045. Kirsten R, Heintz B, Nelson K, et al. Magnesium
pyridoxal 5-phosphate glutamate reduces
hyperlipidaemia in patients with chronic renal
insufficiency. European Journal of Clinical
Pharmacology 1988; 34(2):133-7. Sample size less
than 50 patients
2046. Kitazato H, Fujita H, Shimotomai T, et al. Effects of
chronic intake of vegetable protein added to animal
or fish protein on renal hemodynamics. Nephron
2002; 90(1):31-6. Not early CKD
2047. Kjaersgaard P, Jakobsen JA, Nossen JO, et al.
Determination of glomerular filtration rate with
Visipaque in patients with severely reduced renal
function. European Radiology 1996; 6(6):865-71.
Sample size less than 50 patients
2048. Klag MJ, Whelton PK, Randall BL, et al. End-stage
renal disease in African-American and white men.
16-year MRFIT findings. JAMA 1997;
277(16):1293-8. Not RCT or controlled trial
2049. Klahr S. Primary and secondary results of the
modification of diet in renal disease study. Mineral &
Electrolyte Metabolism 1996; 22(1-3):138-42. Not
relevant to key questions
B-132
2050. Klahr S. Prevention of progression of nephropathy.
Nephrology Dialysis Transplantation 1997; 12 Suppl
2:63-6. Not RCT or controlled trial
2051. Kleber FX. Socioeconomic aspects of ACE
inhibition in the secondary prevention in
cardiovascular diseases. American Journal of
Hypertension 1994; 7(9 Pt 2):112S-6S. Not CKD
treatment
2052. Klein F, Juhl B, Christiansen JS. Unchanged renal
haemodynamics following high dose ascorbic acid
administration in normoalbuminuric IDDM patients.
Scandinavian Journal of Clinical & Laboratory
Investigation 1995; 55(1):53-9. Follow-up less than 6
months
2053. Klein H, Abassi Z, Keiser HR. Effects of angiotensin
II and phenylephrine on urinary endothelin in normal
female volunteers. Metabolism: Clinical &
Experimental 1995; 44(1):115-8. Follow-up less than
6 months
2054. Klein IHHT, Abrahams A, van Ede T, et al. Different
effects of tacrolimus and cyclosporine on renal
hemodynamics and blood pressure in healthy
subjects. Transplantation 2002; 73(5):732-6. Not
early CKD
2055. Klein IHHT, Ligtenberg G, Oey PL, et al. Enalapril
and losartan reduce sympathetic hyperactivity in
patients with chronic renal failure. Journal of the
American Society of Nephrology 2003; 14(2):42530. Sample size less than 50 patients
2056. Klein L, Massie BM, Leimberger JD, et al.
Admission or changes in renal function during
hospitalization for worsening heart failure predict
postdischarge survival: results from the Outcomes of
a Prospective Trial of Intravenous Milrinone for
Exacerbations of Chronic Heart Failure (OPTIMECHF). Circulation: Heart Failure 2008; 1(1):25-33.
Not RCT or controlled trial
2057. Klein R. Is intensive management of blood pressure
to prevent visual loss in persons with type 2 diabetes
indicated? Archives of Ophthalmology 2004;
122(11):1707-9. Not CKD treatment
2058. Klein R, Klein BE, Moss SE, et al. Blood pressure
and hypertension in diabetes. American Journal of
Epidemiology 1985; 122(1):75-89. Not RCT or
controlled trial
2059. Klein R, Moss SE, Sinaiko AR, et al. The relation of
ambulatory blood pressure and pulse rate to
retinopathy in type 1 diabetes mellitus: the reninangiotensin system study. Ophthalmology 2006;
113(12):2231-6. Not CKD treatment
2060. Kloke HJ, Huysmans FT, Wetzels JF, et al.
Antihypertensive effects of nitrendipine and
cilazapril alone, and in combination in hypertensive
patients with chronic renal failure. British Journal of
Clinical Pharmacology 1989; 27 Suppl 2:289S-96S.
Sample size less than 50 patients
2061. Kloke HJ, Wetzels JF, van Hamersvelt HW, et al.
Effects of nitrendipine and cilazapril on renal
hemodynamics and albuminuria in hypertensive
patients with chronic renal failure. Journal of
Cardiovascular Pharmacology 1990; 16(6):924-30.
Follow-up less than 6 months
2062. Klotz U, Arvela P, Rosenkranz B. Famotidine, a new
H2-receptor antagonist, does not affect hepatic
elimination of diazepam or tubular secretion of
procainamide. European Journal of Clinical
Pharmacology 1985; 28(6):671-5. Sample size less
than 50 patients
2063. Klow NE, Levorstad K, Berg KJ, et al. Iodixanol in
cardioangiography in patients with coronary artery
disease. Tolerability, cardiac and renal effects. Acta
Radiologica 1993; 34(1):72-7. Not CKD treatment
2064. Klutsch K, Grosswendt J, Haecker W. Single dose
comparison of torasemide and furosemide in patients
with advanced renal failure. Arzneimittel-Forschung
1988; 38(1A):200-4. Not relevant to key questions
2065. Knauf H, Bailey MA, Hasenfuss G, et al. The
influence of cardiovascular and antiinflammatory
drugs on thiazide-induced hemodynamic and
saluretic effects. European Journal of Clinical
Pharmacology 2006; 62(11):885-92. Not relevant to
key questions
2066. Knauf H, Mutschler E. Diuretic effectiveness of
hydrochlorothiazide and furosemide alone and in
combination in chronic renal failure. Journal of
Cardiovascular Pharmacology 1995; 26(3):394-400.
Sample size less than 50 patients
2067. Knauf H, Wenk E, Scholmerich J, et al. Prediction of
diuretic mobilization of cirrhotic ascites by
pretreatment fractional sodium excretion. Klinische
Wochenschrift 1990; 68(11):545-51. Not CKD
treatment
2068. Knight EL, Glynn RJ, McIntyre KM, et al. Predictors
of decreased renal function in patients with heart
failure during angiotensin-converting enzyme
inhibitor therapy: results from the studies of left
ventricular dysfunction (SOLVD). American Heart
Journal 1999; 138(5 Pt 1):849-55. Not CKD
treatment
2069. Knudsen ST, Andersen NH, Poulsen SH, et al. Pulse
pressure lowering effect of dual blockade with
candesartan and lisinopril vs. high-dose ACE
inhibition in hypertensive type 2 diabetic subjects: a
CALM II study post-hoc analysis. American Journal
of Hypertension 2008; 21(2):172-6. Not CKD
treatment
2070. Knupp CA, Hak LJ, Coakley DF, et al. Disposition
of didanosine in HIV-seropositive patients with
normal renal function or chronic renal failure:
influence of hemodialysis and continuous ambulatory
peritoneal dialysis. Clinical Pharmacology &
Therapeutics 1996; 60(5):535-42. Sample size less
than 50 patients
2071. Ko DT, Juurlink DN, Mamdani MM, et al.
Appropriateness of spironolactone prescribing in
heart failure patients: a population-based study.
Journal of Cardiac Failure 2006; 12(3):205-10. Not
relevant to key questions
2072. Ko GTC, Tsang C-C, Chan HCK. Stabilization and
regression of albuminuria in Chinese patients with
type 2 diabetes: a one-year randomized study of
valsartan versus enalapril. Advances in Therapy
2005; 22(2):155-62. Sample size less than 50 patients
B-133
2073. Ko JS, Gwak MS, Choi SJ, et al. The effects of
desflurane and propofol-remifentanil on
postoperative hepatic and renal functions after right
hepatectomy in liver donors. Liver Transplantation
2008; 14(8):1150-8. Not early CKD
2074. Kobashigawa JA, Meiser BM. Review of major
clinical trials with mycophenolate mofetil in cardiac
transplantation. Transplantation 2005; 80(2
Suppl):S235-43. Follow-up less than 6 months
2075. Kobayashi M, To H, Tokue A, et al. Cisplatininduced vomiting depends on circadian timing.
Chronobiology International 2001; 18(5):851-63. Not
early CKD
2076. Kobayashi M, Wood PA, Hrushesky WJM.
Circadian chemotherapy for gynecological and
genitourinary cancers. Chronobiology International
2002; 19(1):237-51. Not early CKD
2077. Kobayashi S. Applications of LDL-apheresis in
nephrology. Clinical & Experimental Nephrology
2008; 12(1):9-15. Not relevant to key questions
2078. Kober A, Dobrovits M, Djavan B, et al. Local active
warming: an effective treatment for pain, anxiety and
nausea caused by renal colic. Journal of Urology
2003; 170(3):741-4. Not CKD treatment
2079. Kocakulak M, Askin G, Kucukaksu S, et al. Pulsatile
flow improves renal function in high-risk cardiac
operations. Blood Purification 2005; 23(4):263-7.
Not relevant to key questions
2080. Kocakulak M, Kucukaksu S, Piskin E. Pulsatile roller
pump perfusion is safe in high risk patients.
International Journal of Artificial Organs 2004;
27(5):433-9. Not CKD treatment
2081. Koch G, Fransson L, Karlegard L, et al. Responses of
glomerular filtration, renal blood flow and salt-water
handling to acute cardioselective and non-selective
beta-adrenoceptor blockade in essential hypertension.
European Journal of Clinical Pharmacology 1989;
36(4):343-5. Sample size less than 50 patients
2082. Koch JA, Plum J, Grabensee B, et al. Prostaglandin
E1 (PGE1)--prophylaxis against radiocontrastinduced nephrotoxicity in patients with pre-existing
renal dysfunction. PGE1 Study Group. Nephrology
Dialysis Transplantation 1999; 14 Suppl 4:15.
Follow-up less than 6 months
2083. Koch JA, Plum J, Grabensee B, et al. Prostaglandin
E1: a new agent for the prevention of renal
dysfunction in high risk patients caused by
radiocontrast media? PGE1 Study Group.
Nephrology Dialysis Transplantation 2000; 15(1):439. Not CKD treatment
2084. Koch KM, Koene RA, Messinger D, et al. The use of
epoetin beta in anemic predialysis patients with
chronic renal failure.[Erratum appears in Clin
Nephrol 1995 Oct;44(4):278]. Clinical Nephrology
1995; 44(3):201-8. Not RCT or controlled trial
2085. Koenig K, Padalino P, Alexandrides G, et al.
Bioavailability of potassium and magnesium, and
citraturic response from potassium-magnesium
citrate. Journal of Urology 1991; 145(2):330-4. Not
CKD treatment
2086. Kohlmann O, Jr., Roca-Cusachs A, Laurent S, et al.
Fixed-dose manidipine/delapril versus
losartan/hydrochlorothiazide in hypertensive patients
with type 2 diabetes and microalbuminuria.
Advances in Therapy 2009; 26(3):313-24. Not RCT
or controlled trial
2087. Kohzuki M, Yasujima M, Kanazawa M, et al. Effects
of recombinant human erythropoietin on blood
pressure and renal function in SHR with chronic
renal failure. Clinical & Experimental Pharmacology
& Physiology - Supplement 1995; 22(1):S165-6. Not
RCT or controlled trial
2088. Kojima S, Shida M, Yokoyama H. Comparison
between cilnidipine and amlodipine besilate with
respect to proteinuria in hypertensive patients with
renal diseases. Hypertension Research - Clinical &
Experimental 2004; 27(6):379-85. Not early CKD
2089. Kokubo Y, Nakamura S, Okamura T, et al.
Relationship between blood pressure category and
incidence of stroke and myocardial infarction in an
urban Japanese population with and without chronic
kidney disease: the Suita Study. Stroke 2009;
40(8):2674-9. Not RCT or controlled trial
2090. Koller-Strametz J, Wolzt M, Fuchs C, et al. Renal
hemodynamic effects of L-arginine and sodium
nitroprusside in heart transplant recipients. Kidney
International 1999; 55(5):1871-7. Sample size less
than 50 patients
2091. Kolonko A, Wiecek A, Kokot F. The nonselective
adenosine antagonist theophylline does prevent renal
dysfunction induced by radiographic contrast agents.
Journal of Nephrology 1998; 11(3):151-6. Not CKD
treatment
2092. Komajda M, Genevray B, Grosgogeat Y. Long-term
experience with tertatolol in hypertension. American
Journal of Nephrology 1986; 6 Suppl 2:106-12. Not
relevant to key questions
2093. Komajda M, Lutiger B, Madeira H, et al. Tolerability
of carvedilol and ACE-Inhibition in mild heart
failure. Results of CARMEN (Carvedilol ACEInhibitor Remodelling Mild CHF EvaluatioN).
European Journal of Heart Failure 2004; 6(4):467-75.
Not adult population
2094. Komajda M, Wimart MC. Angiotensin converting
enzyme inhibition: from viper to patient. Heart 2000;
84 Suppl 1:i11-4:discussion i50. Not CKD treatment
2095. Komenda P, Zalunardo N, Burnett S, et al.
Conservative outpatient renoprotective protocol in
patients with low GFR undergoing contrast
angiography: a case series. Clinical & Experimental
Nephrology 2007; 11(3):209-13. Not relevant to key
questions
2096. Komers R, Komersova K, Kazdova L, et al. Effect of
ACE inhibition and angiotensin AT1 receptor
blockade on renal and blood pressure response to Larginine in humans. Journal of Hypertension 2000;
18(1):51-9. Sample size less than 50 patients
2097. Komers R, Simkova R, Kazdova L, et al. Effects of
ACE inhibition and AT1-receptor blockade on
haemodynamic responses to L-arginine in Type 1
diabetes. Journal of the Renin-AngiotensinAldosterone System 2004; 5(1):33-8. Not relevant to
key questions
B-134
2098. Komisarof JA, Gilkey GM, Peters DM, et al. Nacetylcysteine for patients with prolonged
hypotension as prophylaxis for acute renal failure
(NEPHRON). Critical Care Medicine 2007;
35(2):435-41. Not CKD treatment
2099. Kong KL, Tyler JE, Willatts SM, et al. Isoflurane
sedation for patients undergoing mechanical
ventilation: metabolism to inorganic fluoride and
renal effects. British Journal of Anaesthesia 1990;
64(2):159-62. Not CKD treatment
2100. Konishi K, Nakano S, Tsuda S-i, et al. AST-120
(Kremezin) initiated in early stage chronic kidney
disease stunts the progression of renal dysfunction in
type 2 diabetic subjects. Diabetes Research &
Clinical Practice 2008; 81(3):310-5. Not CKD
treatment
2101. Kontessis P, Jones S, Dodds R, et al. Renal,
metabolic and hormonal responses to ingestion of
animal and vegetable proteins. Kidney International
1990; 38(1):136-44. Sample size less than 50 patients
2102. Kontessis PA, Bossinakou I, Sarika L, et al. Renal,
metabolic, and hormonal responses to proteins of
different origin in normotensive, nonproteinuric type
I diabetic patients. Diabetes Care 1995; 18(9):1233.
Follow-up less than 6 months
2103. Kontessis PS, Jones SL, Barrow SE, et al. Effect of
selective inhibition of thromboxane synthesis on
renal function in diabetic nephropathy. Journal of
Laboratory & Clinical Medicine 1993; 121(3):41523. Sample size less than 50 patients
2104. Kooienga L, Fried L, Scragg R, et al. The effect of
combined calcium and vitamin D3 supplementation
on serum intact parathyroid hormone in moderate
CKD. American Journal of Kidney Diseases 2009;
53(3):408-16. Not CKD treatment
2105. Kooman JP, Daemen MJ, Wijnen R, et al.
Morphological changes of the venous system in
uremic patients. A histopathologic study. Nephron
1995; 69(4):454-8. Sample size less than 50 patients
2106. Koopmans PP, Thien T, Thomas CM, et al. The
effects of sulindac and indomethacin on the antihypertensive and diuretic action of
hydrochlorothiazide in patients with mild to
moderate essential hypertension. British Journal of
Clinical Pharmacology 1986; 21(4):417-23. Sample
size less than 50 patients
2107. Kopf D, Schmitz H, Beyer J, et al. A double-blind
trial of perindopril and nitrendipine in incipient
diabetic nephropathy. Diabetes, Nutrition &
Metabolism - Clinical & Experimental 2001;
14(5):245-52. Sample size less than 50 patients
2108. Koppert W, Frotsch K, Huzurudin N, et al. The
effects of paracetamol and parecoxib on kidney
function in elderly patients undergoing orthopedic
surgery. Anesthesia & Analgesia 2006; 103(5):11706. Not early CKD
2109. Kopple JD, Berg R, Houser H, et al. Nutritional
status of patients with different levels of chronic
renal insufficiency. Modification of Diet in Renal
Disease (MDRD) Study Group. Kidney International
- Supplement 1989; 27:S184-94. Not relevant to key
questions
2110. Kopple JD, Greene T, Chumlea WC, et al.
Relationship between nutritional status and the
glomerular filtration rate: results from the MDRD
study. Kidney International 2000; 57(4):1688-703.
Not early CKD
2111. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of
chronic metabolic acidosis in patients with chronic
kidney disease. Kidney International - Supplement
2005; (95):S21-7. Not relevant to key questions
2112. Koretz RL. Does nutritional intervention in proteinenergy malnutrition improve morbidity or mortality?
Journal of Renal Nutrition 1999; 9(3):119-21. Not
RCT or controlled trial
2113. Korkor AB, Bretzmann C. Effect of fish oil on
vitamin D absorption. American Journal of Kidney
Diseases 2009; 53(2):356. Not CKD treatment
2114. Kossmann S, Magner-Krezel Z, Sobieraj R, et al. The
assessment of nephrotoxic effect of
organophosphorous pesticides based on the
determination of the activity of some selected
enzymes in urine. Przeglad Lekarski 1997;
54(10):707-11. Not RCT or controlled trial
2115. Kostapanos MS, Milionis HJ, Saougos VG, et al.
Dose-dependent effect of rosuvastatin treatment on
urinary protein excretion. Journal of Cardiovascular
Pharmacology & Therapeutics 2007; 12(4):292-7.
Not CKD treatment
2116. Kotlyar E, Keogh AM, Thavapalachandran S, et al.
Prehydration alone is sufficient to prevent contrastinduced nephropathy after day-only angiography
procedures--a randomised controlled trial. Heart,
Lung & Circulation 2005; 14(4):245-51. Not relevant
to key questions
2117. Koufaki P, Mercer TH, Naish PF. Effects of exercise
training on aerobic and functional capacity of endstage renal disease patients. Clinical Physiology &
Functional Imaging 2002; 22(2):115-24. Not early
CKD
2118. Kovesdy CP, Kalantar-Zadeh K. Why is proteinenergy wasting associated with mortality in chronic
kidney disease? Seminars in Nephrology 2009;
29(1):3-14. Not CKD treatment
2119. Kowey PR, Dickson TZ, Zhang Z, et al. Losartan and
end-organ protection--lessons from the RENAAL
study. Clinical Cardiology 2005; 28(3):136-42. Not
relevant to key questions
2120. Krairittichai U, Chaisuvannarat V. Effects of dual
blockade of renin-angiotensin system in type 2
diabetes mellitus patients with diabetic nephropathy.
Journal of the Medical Association of Thailand 2009;
92(5):611-7. Follow-up less than 6 months
2121. Kramer BK, Preuner J, Ebenburger A, et al. Lack of
renoprotective effect of theophylline during
aortocoronary bypass surgery. Nephrology Dialysis
Transplantation 2002; 17(5):910-5. Not early CKD
2122. Kramer HJ, Uhl W, Ladstetter B, et al. Influence of
asimadoline, a new kappa-opioid receptor agonist, on
tubular water absorption and vasopressin secretion in
man. British Journal of Clinical Pharmacology 2000;
50(3):227-35. Not early CKD
B-135
Urology 2004; 22(3):172-7. Not relevant to key
questions
2136. Kristjansson A, Wallin L, Mansson W. Renal
function up to 16 years after conduit (refluxing or
anti-reflux anastomosis) or continent urinary
diversion. 1. Glomerular filtration rate and patency of
uretero-intestinal anastomosis.[Erratum appears in Br
Urol 1995 Dec;76(6):815]. British Journal of
Urology 1995; 76(5):539-45. Not CKD treatment
2137. Kron BG, Sjostrom PA, Karlberg BE, et al. Acute
tolerance to furosemide. Pretreatment with captopril
or prazosin does not influence diuresis and
natriuresis. Scandinavian Journal of Urology &
Nephrology 1994; 28(4):337-44. Not CKD treatment
2138. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a)
serum concentrations and apolipoprotein(a)
phenotypes in mild and moderate renal failure.
Journal of the American Society of Nephrology
2000; 11(1):105-15. Not RCT or controlled trial
2139. Kruger W, Sobottka I, Stockschlader M, et al. Fatal
outcome of disseminated candidosis after allogeneic
bone marrow transplantation under treatment with
liposomal and conventional amphotericin-B. A report
of 4 cases with determination of the Mic values.
Scandinavian Journal of Infectious Diseases 1996;
28(3):313-6. Not CKD treatment
2140. Krum H, Aw T-J, Liew D, et al. Blood pressure
effects of COX-2 inhibitors. Journal of
Cardiovascular Pharmacology 2006; 47 Suppl 1:S438. Not RCT or controlled trial
2141. Krum H, Schlaich M, Whitbourn R, et al. Catheterbased renal sympathetic denervation for resistant
hypertension: a multicentre safety and proof-ofprinciple cohort study. Lancet 2009;
373(9671):1275-81. Not RCT or controlled trial
2142. Krusell LR, Christensen CK, Pedersen OL. Alphaadrenoceptor blockade in patients with mild to
moderate hypertension: long-term renal effects of
doxazosin. Journal of Cardiovascular Pharmacology
1992; 20(3):440-4. Sample size less than 50 patients
2143. Kshirsagar AV, Joy MS, Hogan SL, et al. Effect of
ACE inhibitors in diabetic and nondiabetic chronic
renal disease: a systematic overview of randomized
placebo-controlled trials. American Journal of
Kidney Diseases 2000; 35(4):695-707. Not relevant
to key questions
2144. Kshirsagar AV, Poole C, Mottl A, et al. Nacetylcysteine for the prevention of radiocontrast
induced nephropathy: a meta-analysis of prospective
controlled trials. Journal of the American Society of
Nephrology 2004; 15(3):761-9. Sample size less than
50 patients
2145. Kshirsagar AV, Shoham DA, Bang H, et al. The
effect of cholesterol reduction with cholestyramine
on renal function. American Journal of Kidney
Diseases 2005; 46(5):812-9. Not RCT or controlled
trial
2146. Kuan Y, Surman J, Frystyk J, et al. Lack of effect of
IGF-I on the glomerular filtration rate in non-diabetic
patients with advanced chronic kidney disease.
Growth Hormone & Igf Research 2009; 19(3):21925. Not CKD treatment
2123. Krantz SB. Review of patients' responses to epoetin
alfa therapy. Pharmacotherapy 1990; 10(2 ( Pt
2)):15S-21S. Not relevant to key questions
2124. Krasuski RA, Beard BM, Geoghagan JD, et al.
Optimal timing of hydration to erase contrastassociated nephropathy: the OTHER CAN study.
Journal of Invasive Cardiology 2003; 15(12):699702. Not CKD treatment
2125. Krekels MM, Spiering W, Schaper NC, et al.
Dissociation between the renal effects of angiotensin
I and II in sodium-restricted normal subjects.
Cardiovascular Research 1998; 38(1):215-20. Sample
size less than 50 patients
2126. Krempf M, Ranganathan S, Remy JP, et al. Effect of
long-acting somatostatin analog (SMS 201-995) on
high glomerular filtration rate in insulin dependent
diabetic patients. International Journal of Clinical
Pharmacology, Therapy, & Toxicology 1990;
28(7):309-11. Sample size less than 50 patients
2127. Krespi PG, Makris TK, Hatzizacharias AN, et al.
Moxonidine effect on microalbuminuria,
thrombomodulin, and plasminogen activator
inhibitor-1 levels in patients with essential
hypertension. Cardiovascular Drugs & Therapy
1998; 12(5):463-7. Not RCT or controlled trial
2128. Kresyn VI, Aryaev VL, Kostev FI. Litonit:
evaluation of clinical effectiveness. Alcohol &
Alcoholism 1993; 28(3):333-7. Not RCT or
controlled trial
2129. Kreutz R, Kruse HJ, Overlack A, et al. Effects of
sympathetic inhibition on blood pressure and renal
responses to central hypervolaemia in normal
humans. Acta Physiologica Scandinavica 1996;
156(1):1-7. Sample size less than 50 patients
2130. Krijnen P, van Jaarsveld BC, Man in 't Veld AJ, et al.
Reproducibility and validity of quality of life
measurements in hypertensive patients on stable
medication. Netherlands Journal of Medicine 1997;
50(4):137-52. Not RCT or controlled trial
2131. Krikken JA, Waanders F, Dallinga-Thie GM, et al.
Antiproteinuric therapy decreases LDL-cholesterol as
well as HDL-cholesterol in non-diabetic proteinuric
patients: relationships with cholesteryl ester transfer
protein mass and adiponectin. Expert Opinion on
Therapeutic Targets 2009; 13(5):497-504. Not CKD
treatment
2132. Krimholtz MJ, Karalliedde J, Thomas S, et al.
Targeting albumin excretion rate in the treatment of
the hypertensive diabetic patient with renal disease.
Journal of the American Society of Nephrology
2005; 16 Suppl 1:S42-7. Not relevant to key
questions
2133. Krishna GG, Kapoor SC. Preservation of renal
reserve in chronic renal disease. American Journal of
Kidney Diseases 1991; 17(1):18-24. Sample size less
than 50 patients
2134. Krishna GG, Newell G, Miller E, et al. Proteininduced glomerular hyperfiltration: role of hormonal
factors. Kidney International 1988; 33(2):578-83.
Sample size less than 50 patients
2135. Kristjansson A, Mansson W. Renal function in the
setting of urinary diversion. World Journal of
B-136
2147. Kuduvalli M, Grayson AD, Au J, et al. A multicentre additive and logistic risk model for in-hospital
mortality following aortic valve replacement.
European Journal of Cardio-Thoracic Surgery 2007;
31(4):607-13. Not RCT or controlled trial
2148. Kulik A, Ruel M. Statins and coronary artery bypass
graft surgery: preoperative and postoperative efficacy
and safety. Expert Opinion on Drug Safety 2009;
8(5):559-71. Not RCT or controlled trial
2149. Kulka PJ, Tryba M, Zenz M. Preoperative alpha2adrenergic receptor agonists prevent the deterioration
of renal function after cardiac surgery: results of a
randomized, controlled trial. Critical Care Medicine
1996; 24(6):947-52. Sample size less than 50 patients
2150. Kult J, Hacker W, Glocke M. Comparison of efficacy
and tolerance of different oral doses of torasemide
and furosemide in patients with advanced chronic
renal failure. Arzneimittel-Forschung 1988;
38(1A):212-4. Follow-up less than 6 months
2151. Kumar A. Influence of radish consumption on
urinary calcium oxalate excretion. Nepal Medical
College Journal: NMCJ 2004; 6(1):41-4. Not
relevant to key questions
2152. Kumar NS, Singh AK, Mishra RN, et al.
Comparative study of angiotensin converting enzyme
inhibitor and calcium channel blocker in the
treatment of steroid-resistant idiopathic nephrotic
syndrome. Journal of the Association of Physicians
of India 2004; 52:454-8. Not early CKD
2153. Kumar R, Kapoor R, Mandhani A, et al. Optimum
duration of splinting after endopyelotomy. Journal of
Endourology 1999; 13(2):89-92. Not CKD treatment
2154. Kunz R, Friedrich C, Wolbers M, et al. Metaanalysis: effect of monotherapy and combination
therapy with inhibitors of the renin angiotensin
system on proteinuria in renal disease. Annals of
Internal Medicine 2008; 148(1):30-48. Not RCT or
controlled trial
2155. Kunz R, Wolbers M, Glass T, et al. The
COOPERATE trial: a letter of concern. Lancet 2008;
371(9624):1575-6. Not CKD treatment
2156. Kuriyama S, Tomonari H, Tokudome G, et al.
Antiproteinuric effects of combined antihypertensive
therapies in patients with overt type 2 diabetic
nephropathy. Hypertension Research - Clinical &
Experimental 2002; 25(6):849-55. Sample size less
than 50 patients
2157. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal
of anemia by erythropoietin therapy retards the
progression of chronic renal failure, especially in
nondiabetic patients. Nephron 1997; 77(2):176-85.
Not early CKD
2158. Kurman MR. Recent clinical trials with levamisole.
Annals of the New York Academy of Sciences 1993;
685:269-77. Not RCT or controlled trial
2159. Kurnik BR, Allgren RL, Genter FC, et al.
Prospective study of atrial natriuretic peptide for the
prevention of radiocontrast-induced nephropathy.
American Journal of Kidney Diseases 1998;
31(4):674-80. Not CKD treatment
2160. Kurnik BR, Weisberg LS, Askenase AD, et al.
Mannitol stimulates atrial natriuretic peptide release
in humans. American Journal of Kidney Diseases
1991; 17(1):62-8. Sample size less than 50 patients
2161. Kurokawa K, Chan JCN, Cooper ME, et al. Renin
angiotensin aldosterone system blockade and renal
disease in patients with type 2 diabetes: a subanalysis
of Japanese patients from the RENAAL study.
Clinical & Experimental Nephrology 2006;
10(3):193-200. Sample size less than 50 patients
2162. Kurth T, de Jong PE, Cook NR, et al. Kidney
function and risk of cardiovascular disease and
mortality in women: a prospective cohort
study.[Erratum appears in BMJ. 2009;339:b2769].
BMJ 2009; 338:b2392. Not RCT or controlled trial
2163. Kurth T, de Jong PE, Cook NR, et al. Kidney
function and risk of cardiovascular disease and
mortality in women: a prospective cohort
study.[Erratum appears in BMJ. 2009;339:b2769].
BMJ 2009; 338:b2392. Not RCT or controlled trial
2164. Kusek JW, Coyne T, de Velasco A, et al.
Recruitment experience in the full-scale phase of the
Modification of Diet in Renal Disease Study.
Controlled Clinical Trials 1993; 14(6):538-57. Not
relevant to key questions
2165. Kusek JW, Hirschman GH, Agodoa L, et al.
Nephrology clinical trials supported by the kidney
programs of the National Institutes of Health.
Clinical Nephrology 1992; 38 Suppl 1:S61-3. Not
CKD treatment
2166. Kusek JW, Lee JY, Charleston J, et al. Participant
satisfaction in the African American Study of Kidney
Disease and Hypertension (AASK) Pilot Study.
Controlled Clinical Trials 1996; 17(4 Suppl):47S54S. Not RCT or controlled trial
2167. Kusek JW, Lee JY, Smith DE, et al. Effect of blood
pressure control and antihypertensive drug regimen
on quality of life: the African American Study of
Kidney Disease and Hypertension (AASK) Pilot
Study. Controlled Clinical Trials 1996; 17(4
Suppl):40S-6S. Not relevant to key questions
2168. Kutner N. Quality of life assessment in a recent
haemoglobin trial in CKD (CHOIR). Nephrology
Dialysis Transplantation 2007; 22(7):2099. Not CKD
treatment
2169. Kutner NG, Johansen KL, Kaysen GA, et al. The
comprehensive dialysis study (CDS): a USRDS
special study. Clinical Journal of The American
Society of Nephrology: CJASN 2009; 4(3):645-50.
Not early CKD
2170. Kvetny J, Gregersen G, Pedersen RS. Randomized
placebo-controlled trial of perindopril in
normotensive, normoalbuminuric patients with type 1
diabetes mellitus. Qjm 2001; 94(2):89-94. Not early
CKD
2171. Kyle RA, Gertz MA, Greipp PR, et al. A trial of
three regimens for primary amyloidosis: colchicine
alone, melphalan and prednisone, and melphalan,
prednisone, and colchicine. New England Journal of
Medicine 1997; 336(17):1202-7. Not CKD treatment
2172. La Villa G, Barletta G, Pantaleo P, et al.
Hemodynamic, renal, and endocrine effects of acute
inhibition of nitric oxide synthase in compensated
B-137
cirrhosis. Hepatology 2001; 34(1):19-27. Not early
CKD
2173. La Villa G, Fronzaroli C, Lazzeri C, et al.
Cardiovascular and renal effects of low dose brain
natriuretic peptide infusion in man. Journal of
Clinical Endocrinology & Metabolism 1994;
78(5):1166-71. Not CKD treatment
2174. La Villa G, Lazzeri C, Pascale A, et al.
Cardiovascular and renal effects of low-dose atrial
natriuretic peptide in compensated cirrhosis.
American Journal of Gastroenterology 1997;
92(5):852-7. Not CKD treatment
2175. La Villa G, Marra F, Laffi G, et al. Effects of rhein
on renal arachidonic acid metabolism and renal
function in patients with congestive heart failure.
European Journal of Clinical Pharmacology 1989;
37(1):1-5. Sample size less than 50 patients
2176. La Villa G, Stefani L, Lazzeri C, et al. Acute effects
of physiological increments of brain natriuretic
peptide in humans. Hypertension 1995; 26(4):62833. Sample size less than 50 patients
2177. Labrecque M, Dostaler LP, Rousselle R, et al.
Efficacy of nonsteroidal anti-inflammatory drugs in
the treatment of acute renal colic. A meta-analysis.
Archives of Internal Medicine 1994; 154(12):1381-7.
Not RCT or controlled trial
2178. Lacourciere Y, Nadeau A, Poirier L, et al.
Comparative effects of converting enzyme inhibition
and conventional therapy in hypertensive non-insulin
dependent diabetics with normal renal function.
Clinical & Investigative Medicine - Medecine
Clinique et Experimentale 1991; 14(6):652-60. Not
early CKD
2179. Laczy B, Cseh J, Mohas M, et al. Effects of
pentoxifylline and pentosan polysulphate
combination therapy on diabetic neuropathy in type 2
diabetes mellitus. Acta Diabetologica 2009;
46(2):105-11. Not CKD treatment
2180. Laerum E, Ommundsen OE, Gronseth JE, et al.
Intramuscular diclofenac versus intravenous
indomethacin in the treatment of acute renal colic.
European Urology 1996; 30(3):358-62. Not CKD
treatment
2181. Laffi G, Marra F, Carloni V, et al. Thromboxanereceptor blockade increases water diuresis in
cirrhotic patients with ascites. Gastroenterology
1992; 103(3):1017-21. Not CKD treatment
2182. Lainchbury JG, Richards AM, Nicholls MG, et al.
The effects of pathophysiological increments in brain
natriuretic peptide in left ventricular systolic
dysfunction. Hypertension 1997; 30(3 Pt 1):398-404.
Follow-up less than 6 months
2183. Lainchbury JG, Troughton RW, Lewis LK, et al.
Hemodynamic, hormonal, and renal effects of shortterm adrenomedullin infusion in healthy volunteers.
Journal of Clinical Endocrinology & Metabolism
2000; 85(3):1016-20. Not early CKD
2184. Laine L, White WB, Rostom A, et al. COX-2
selective inhibitors in the treatment of osteoarthritis.
Seminars in Arthritis & Rheumatism 2008;
38(3):165-87. Not CKD treatment
2185. Laing C, Unwin RJ. Are calcium antagonists
effective in preventing complications of hypertension
and progression of renal disease? Current Opinion in
Nephrology & Hypertension 2000; 9(5):489-95. Not
relevant to key questions
2186. Laisalmi M, Teppo AM, Koivusalo AM, et al. The
effect of ketorolac and sevoflurane anesthesia on
renal glomerular and tubular function. Anesthesia &
Analgesia 2001; 93(5):1210-3. Not early CKD
2187. Laisalmi-Kokki M, Pesonen E, Kokki H, et al.
Potentially detrimental effects of N-acetylcysteine on
renal function in knee arthroplasty. Free Radical
Research 2009; 43(7):691-6. Not CKD treatment
2188. Lajer H, Daugaard G. Cisplatin and
hypomagnesemia. Cancer Treatment Reviews 1999;
25(1):47-58. Not CKD treatment
2189. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(cidofovir): results of a phase I/II study of a novel
antiviral nucleotide analogue. Journal of Infectious
Diseases 1995; 171(4):788-96. Sample size less than
50 patients
2190. Lalezari JP, Holland GN, Kramer F, et al.
Randomized, controlled study of the safety and
efficacy of intravenous cidofovir for the treatment of
relapsing cytomegalovirus retinitis in patients with
AIDS. Journal of Acquired Immune Deficiency
Syndromes & Human Retrovirology 1998;
17(4):339-44. Not CKD treatment
2191. Laliberte M-C, Normandeau M, Lord A, et al. Use of
over-the-counter medications and natural products in
patients with moderate and severe chronic renal
insufficiency. American Journal of Kidney Diseases
2007; 49(2):245-56. Not RCT or controlled trial
2192. Lalonde L, Normandeau M, Lamarre D, et al.
Evaluation of a training and communication-network
nephrology program for community pharmacists.
Pharmacy World & Science 2008; 30(6):924-33. Not
CKD treatment
2193. Lam KS, Cheng IK, Janus ED, et al. Cholesterollowering therapy may retard the progression of
diabetic nephropathy. Diabetologia 1995; 38(5):6049. Sample size less than 50 patients
2194. Lam YW, Boyd RA, Chin SK, et al. Effect of
probenecid on the pharmacokinetics and
pharmacodynamics of procainamide. Journal of
Clinical Pharmacology 1991; 31(5):429-32. Not CKD
treatment
2195. Lamb EJ, Fluck RJ, Venton TR, et al. Effects of
parathyroid hormone and 1,25(OH2)D3 on protein
glycation in moderate uraemia. Nephron 1996;
74(2):295-300. Not RCT or controlled trial
2196. Lambers Heerspink HJ, Agarwal R, Coyne DW, et
al. The selective vitamin D receptor activator for
albuminuria lowering (VITAL) study: study design
and baseline characteristics. American Journal of
Nephrology 2009; 30(3):280-6. Not early CKD
2197. Lambers Heerspink HJ, Fowler MJ, Volgi J, et al.
Rationale for and study design of the sulodexide
trials in Type 2 diabetic, hypertensive patients with
microalbuminuria or overt nephropathy. Diabetic
B-138
Medicine 2007; 24(11):1290-5. Not RCT or
controlled trial
2198. Lambert KE. Recombinant human erythropoietin.
Canadian Nurse 1990; 86(10):27-8. Not early CKD
2199. Lameire N. Contrast-induced nephropathy in the
critically-ill patient: focus on emergency screening
and prevention. Acta Clinica Belgica Supplementum 2007; (2):346-52. Not CKD treatment
2200. Landersdorfer CB, Kirkpatrick CMJ, Kinzig M, et al.
Competitive inhibition of renal tubular secretion of
gemifloxacin by probenecid. Antimicrobial Agents &
Chemotherapy 2009; 53(9):3902-7. Sample size less
than 50 patients
2201. Landersdorfer CB, Kirkpatrick CMJ, Kinzig M, et al.
Inhibition of flucloxacillin tubular renal secretion by
piperacillin. British Journal of Clinical Pharmacology
2008; 66(5):648-59. Not RCT or controlled trial
2202. Landmann R, Keilholz U, Scheibenbogen C, et al.
Relationship between soluble tumor necrosis factor
(TNF) receptors and TNF alpha during
immunotherapy with interleukin-2 and/or interferon
alpha. Cancer Immunology, Immunotherapy 1994;
38(2):113-8. Not CKD treatment
2203. Landoni G, Bignami E, Gonfalini M, et al.
Fenoldopam in cardiac surgery-associated acute
kidney injury. International Journal of Artificial
Organs 2008; 31(6):561. Not CKD treatment
2204. Landoni G, Biondi-Zoccai GGL, Tumlin JA, et al.
Beneficial impact of fenoldopam in critically ill
patients with or at risk for acute renal failure: a metaanalysis of randomized clinical trials. American
Journal of Kidney Diseases 2007; 49(1):56-68. Not
RCT or controlled trial
2205. Landray M, Baigent C, Leaper C, et al. The second
United Kingdom Heart and Renal Protection (UKHARP-II) Study: a randomized controlled study of
the biochemical safety and efficacy of adding
ezetimibe to simvastatin as initial therapy among
patients with CKD. American Journal of Kidney
Diseases 2006; 47(3):385-95. Not RCT or controlled
trial
2206. Lane C, Brown M, Dunsmuir W, et al. Can spot urine
protein/creatinine ratio replace 24 h urine protein in
usual clinical nephrology? Nephrology 2006;
11(3):245-9. Follow-up less than 6 months
2207. Lang CC, Choy AM, Balfour DJ, et al. Prazosin
attenuates the natriuretic response to atrial natriuretic
factor in man. Kidney International 1992; 42(2):43341. Sample size less than 50 patients
2208. Lang CC, Choy AM, Rahman AR, et al. Renal
effects of low dose prazosin in patients with
congestive heart failure. European Heart Journal
1993; 14(9):1245-52. Not CKD treatment
2209. Lang CC, Rahman AR, Balfour DJ, et al. Effect of
noradrenaline on renal sodium and water handling in
euhydrated and overhydrated man. Clinical Science
1993; 85(4):487-94. Not RCT or controlled trial
2210. Lang CC, Rahman AR, Balfour DJ, et al. Enalapril
blunts the antinatriuretic effect of circulating
noradrenaline in man. Journal of Hypertension 1993;
11(5):565-71. Sample size less than 50 patients
2211. Lang CC, Rahman AR, Choy AM, et al. Renal
interactions between the renin-angiotensin system
and the sympathetic nervous system in man. Journal
of Hypertension - Supplement 1991; 9(6):S206-7.
Sample size less than 50 patients
2212. Lang SM, Schiffl H. Losartan and anaemia of endstage renal disease. Lancet 1998; 352(9141):1708.
Not early CKD
2213. Langer M, Junge W, Keysser R, et al. Renal and
hepatic tolerance of nonionic and ionic contrast
media in intravenous digital subtraction angiography.
Fortschritte auf dem Gebiete der Rontgenstrahlen
und der Nuklearmedizin - Erganzungsband 1989;
128:95-100. Not CKD treatment
2214. Langer M, Langer R, Felix R, et al. Analysis of renal
and hepatic impairment by ionic and nonionic
contrast media. Investigative Radiology 1990; 25
Suppl 1:S125-6. Follow-up less than 6 months
2215. Langer M, Langer R, Zwicker C, et al. Clinical and
nephrologic tolerance of iopromide and iotrolan in
computed tomography. Investigative Radiology
1991; 26 Suppl 1:S83-5; discussion S8-91. Sample
size less than 50 patients
2216. Langston RD, Presley R, Flanders WD, et al. Renal
insufficiency and anemia are independent risk factors
for death among patients with acute myocardial
infarction. Kidney International 2003; 64(4):1398405. Not CKD treatment
2217. Langtry HD, Gillis JC, Davis R. Topiramate. A
review of its pharmacodynamic and pharmacokinetic
properties and clinical efficacy in the management of
epilepsy. Drugs 1997; 54(5):752-73. Not CKD
treatment
2218. Larkin JMG, Kaye SB. Potential clinical applications
of epothilones: a review of phase II studies. Annals
of Oncology 2007; 18 Suppl 5:v28-34. Sample size
less than 50 patients
2219. Larochelle P, Cusson JR, du Souich P, et al. Renal
effects of a nonhypotensive i.v. dose of felodipine.
Journal of Clinical Pharmacology 1993; 33(8):732-7.
Sample size less than 50 patients
2220. Larsen M, Hommel E, Parving HH, et al. Protective
effect of captopril on the blood-retina barrier in
normotensive insulin-dependent diabetic patients
with nephropathy and background retinopathy.
Graefes Archive for Clinical & Experimental
Ophthalmology 1990; 228(6):505-9. Sample size less
than 50 patients
2221. Lasaridis AN, Sarafidis PA. Diabetic nephropathy
and antihypertensive treatment: what are the lessons
from clinical trials? American Journal of
Hypertension 2003; 16(8):689-97. Not RCT or
controlled trial
2222. Lash JP, Wang X, Greene T, et al. Quality of life in
the African American Study of Kidney Disease and
Hypertension: effects of blood pressure management.
American Journal of Kidney Diseases 2006;
47(6):956-64. Not CKD treatment
2223. Lassnigg A, Donner E, Grubhofer G, et al. Lack of
renoprotective effects of dopamine and furosemide
during cardiac surgery. Journal of the American
B-139
Society of Nephrology 2000; 11(1):97-104. Not CKD
treatment
2224. Lastra-Gonzalez G, Manrique CM, Govindarajan G,
et al. Insights into the emerging cardiometabolic
prevention and management of diabetes mellitus.
Expert Opinion on Pharmacotherapy 2005;
6(13):2209-21. Not RCT or controlled trial
2225. Laszlo J, Goldstein D, Vugrin D, et al. Does
maintenance therapy with alpha interferon stabilize
cancer growth? A pilot study. Journal of Biological
Response Modifiers 1986; 5(4):294-9. Sample size
less than 50 patients
2226. Latinwo LM, Ikediobi CO, Singh NP, et al.
Comparative studies of in vivo genotoxic effects of
cadmium chloride in rat brain, kidney and liver cells.
Cellular & Molecular Biology 1997; 43(2):203-10.
Not human studies
2227. Lau HS, Hyneck ML, Berardi RR, et al. Kinetics,
dynamics, and bioavailability of bumetanide in
healthy subjects and patients with chronic renal
failure. Clinical Pharmacology & Therapeutics 1986;
39(6):635-45. Sample size less than 50 patients
2228. Lau LL, Halliday MI, Smye MG, et al.
Extraperitoneal approach reduces intestinal and renal
dysfunction in elective abdominal aortic aneurysm
repair. International Angiology 2001; 20(4):282-7.
Not early CKD
2229. Laufs U, Custodis F, Bohm M. Who does not need a
statin: too late in end-stage renal disease or heart
failure? Heart 2008; 94(9):1138-40. Not CKD
treatment
2230. Laufs U, Custodis F, Bohm M. Who does not need a
statin: too late in end-stage renal disease or heart
failure? Postgraduate Medical Journal 2009;
85(1002):187-9. Not RCT or controlled trial
2231. Laurent S. Evidence for benefits of perindopril in
hypertension and its complications. American
Journal of Hypertension 2005; 18(9 Pt 2):155S-62S.
Sample size less than 50 patients
2232. Lauschke A, Teichgraber UKM, Frei U, et al. 'Lowdose' dopamine worsens renal perfusion in patients
with acute renal failure. Kidney International 2006;
69(9):1669-74. Sample size less than 50 patients
2233. Laverman GD, Navis G, Henning RH, et al. Dual
renin-angiotensin system blockade at optimal doses
for proteinuria. Kidney International 2002;
62(3):1020-5. Sample size less than 50 patients
2234. Laviades C, Varo N, Diez J. Transforming growth
factor beta in hypertensives with cardiorenal damage.
Hypertension 2000; 36(4):517-22. Sample size less
than 50 patients
2235. Laville M, Anaemia CiDt. New strategies in anaemia
management: ACORD (Anaemia CORrection in
Diabetes) trial. Acta Diabetologica 2004; 41 Suppl
1:S18-22. Not CKD treatment
2236. Lavrijssen AT, Kroon AA, Fuss-Lejeune M, et al.
Renal haemodynamics and sodium excretory
capacity during urapidil treatment in patients with
essential hypertension. Journal of Hypertension
2000; 18(7):963-9. Sample size less than 50 patients
2237. Lawendy N, Krishnaswami S, Wang R, et al. Effect
of CP-690,550, an orally active janus kinase
inhibitor, on renal function in healthy adult
volunteers. Journal of Clinical Pharmacology 2009;
49(4):423-9. Not early CKD
2238. Lawlor DK, Moist L, DeRose G, et al. Prevention of
contrast-induced nephropathy in vascular surgery
patients. Annals of Vascular Surgery 2007;
21(5):593-7. Follow-up less than 6 months
2239. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al.
Achievement and safety of a low blood pressure goal
in chronic renal disease. The Modification of Diet in
Renal Disease Study Group. Hypertension 1997;
29(2):641-50. Not relevant to key questions
2240. Lazzeri C, Tosti Guerra C, Vecchiarino S, et al. Ctype natriuretic peptide does not affect plasma and
urinary adrenomedullin in man. Clinical Physiology
1999; 19(1):68-75. Sample size less than 50 patients
2241. Lazzeri M, Barbanti G, Beneforti P, et al. Vesicalrenal reflex: diuresis and natriuresis activated by
intravesical capsaicin. Scandinavian Journal of
Urology & Nephrology 1995; 29(1):39-43. Sample
size less than 50 patients
2242. Le Bricon T, Erlich D, Bengoufa D, et al. Sodium
dodecyl sulfate-agarose gel electrophoresis of urinary
proteins: application to multiple myeloma. Clinical
Chemistry 1998; 44(6 Pt 1):1191-7. Not RCT or
controlled trial
2243. Lea J, Greene T, Hebert L, et al. The relationship
between magnitude of proteinuria reduction and risk
of end-stage renal disease: results of the African
American study of kidney disease and hypertension.
Archives of Internal Medicine 2005; 165(8):947-53.
Not RCT or controlled trial
2244. Leary WP. Renal excretory actions of
antihypertensive agents. Effects of rilmenidine.
American Journal of Medicine 1989; 87(3C):63S-6S.
Not relevant to key questions
2245. Leary WP, Reyes AJ, Wynne RD, et al. Renal
excretory actions of furosemide, of
hydrochlorothiazide and of the vasodilator
flosequinan in healthy subjects. Journal of
International Medical Research 1990; 18(2):120-41.
Not CKD treatment
2246. Leavey SF, Weitzel WF. Endocrine abnormalities in
chronic renal failure. Endocrinology & Metabolism
Clinics of North America 2002; 31(1):107-19. Not
RCT or controlled trial
2247. Leblond V, Sutton L, Jacquiaud C, et al. Evaluation
of renal function in 60 long-term survivors of bone
marrow transplantation. Journal of the American
Society of Nephrology 1995; 6(6):1661-5. Not CKD
treatment
2248. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal
protective effects of enalapril in hypertensive
NIDDM: role of baseline albuminuria. Kidney
International - Supplement 1994; 45:S150-5. Not
relevant to key questions
2249. Lecomte JM, Baumer P, Lim C, et al. Stereoselective
protection of exogenous and endogenous atrial
natriuretic factor by enkephalinase inhibitors in mice
and humans. European Journal of Pharmacology
1990; 179(1-2):65-73. Sample size less than 50
patients
B-140
2250. Ledderhos C, Brauer H, Gens A, et al.
Cardiorespiratory and renal responses to arterial
chemoreceptor stimulation in early hypertension.
International Journal of Clinical Pharmacology &
Therapeutics 1996; 34(11):470-6. Sample size less
than 50 patients
2251. Lee A, Cooper MC, Craig JC, et al. Effects of
nonsteroidal anti-inflammatory drugs on postoperative renal function in normal adults. Cochrane
Database of Systematic Reviews 2001;
(2):CD002765. Not CKD treatment
2252. Lee A, Cooper MC, Craig JC, et al. Effects of
nonsteroidal anti-inflammatory drugs on
postoperative renal function in adults with normal
renal function. Cochrane Database of Systematic
Reviews 2004; (2):CD002765. Not CKD treatment
2253. Lee A, Cooper MG, Craig JC, et al. The effects of
nonsteroidal anti-inflammatory drugs (NSAIDs) on
postoperative renal function: a meta-analysis.
Anaesthesia & Intensive Care 1999; 27(6):574-80.
Not RCT or controlled trial
2254. Lee A, Cooper MG, Craig JC, et al. Effects of
nonsteroidal anti-inflammatory drugs on postoperative renal function in adults. Cochrane Database
of Systematic Reviews 2000; (4):CD002765. Not
early CKD
2255. Lee A, Cooper MG, Craig JC, et al. Effects of
nonsteroidal anti-inflammatory drugs on
postoperative renal function in adults with normal
renal function. Cochrane Database of Systematic
Reviews 2007; (2):CD002765. Not relevant to key
questions
2256. Lee C, Gnanasegaram D, Maloba M. Best evidence
topic report. Rectal or intravenous non-steroidal antiinflammatory drugs in acute renal colic. Emergency
Medicine Journal 2005; 22(9):653-4. Not relevant to
key questions
2257. Lee CYW, Chen HH, Lisy O, et al.
Pharmacodynamics of a novel designer natriuretic
peptide, CD-NP, in a first-in-human clinical trial in
healthy subjects. Journal of Clinical Pharmacology
2009; 49(6):668-73. Not CKD treatment
2258. Lee D, Levin A, Roger SD, et al. Longitudinal
analysis of performance of estimated glomerular
filtration rate as renal function declines in chronic
kidney disease. Nephrology Dialysis Transplantation
2009; 24(1):109-16. Not CKD treatment
2259. Lee HC, Mitchell HC, Van Dreal P, et al.
Hyperfiltration and conservation of renal function in
hypertensive nephrosclerosis patients. American
Journal of Kidney Diseases 1993; 21(4 Suppl 1):6874. Not RCT or controlled trial
2260. Lee JY, Greene PG, Douglas M, et al. Appointment
attendance, pill counts, and achievement of goal
blood pressure in the African American Study of
Kidney Disease and Hypertension Pilot Study.
Controlled Clinical Trials 1996; 17(4 Suppl):34S-9S.
Follow-up less than 6 months
2261. Lee JY, Kusek JW, Greene PG, et al. Assessing
medication adherence by pill count and electronic
monitoring in the African American Study of Kidney
Disease and Hypertension (AASK) Pilot Study.
American Journal of Hypertension 1996; 9(8):71925. Follow-up less than 6 months
2262. Lee RT, Lee TH, Poole WK, et al. Rate of
disappearance of creatine kinase-MB after acute
myocardial infarction: clinical determinants of
variability. American Heart Journal 1988; 116(6 Pt
1):1493-9. Follow-up less than 6 months
2263. Lee RWC, Di Giantomasso D, May C, et al.
Vasoactive drugs and the kidney. Best Practice &
Research 2004; Clinical Anaesthesiology. 18(1):5374. Not CKD treatment
2264. Lee T-M, Chang N-C. Effect of nicorandil on
proteinuria in well controlled hypertensive patients.
Journal of Hypertension 2009; 27(3):618-25. Not
RCT or controlled trial
2265. Lee T-M, Lin M-S, Tsai C-H, et al. Add-on and
withdrawal effect of pravastatin on proteinuria in
hypertensive patients treated with AT receptor
blockers. Kidney International 2005; 68(2):779-87.
Not relevant to key questions
2266. Lee T-M, Su S-F, Tsai C-H. Effect of pravastatin on
proteinuria in patients with well-controlled
hypertension. Hypertension 2002; 40(1):67-73. Not
relevant to key questions
2267. Lee VS, Rusinek H, Bokacheva L, et al. Renal
function measurements from MR renography and a
simplified multicompartmental model. American
Journal of Physiology - Renal Physiology 2007;
292(5):F1548-59. Not RCT or controlled trial
2268. Lee WT, Padayachi K, Collins JF, et al. A
comparison of oral and intravenous alfacalcidol in
the treatment of uremic hyperparathyroidism. Journal
of the American Society of Nephrology 1994;
5(6):1344-8. Not early CKD
2269. Lee YH, Lee WC, Chen MT, et al. Acupuncture in
the treatment of renal colic. Journal of Urology 1992;
147(1):16-8. Not CKD treatment
2270. Leehey DJ, Braun BI, Tholl DA, et al. Can
pharmacokinetic dosing decrease nephrotoxicity
associated with aminoglycoside therapy. Journal of
the American Society of Nephrology 1993; 4(1):8190. Sample size less than 50 patients
2271. Leehey DJ, Moinuddin I, Bast JP, et al. Aerobic
exercise in obese diabetic patients with chronic
kidney disease: a randomized and controlled pilot
study. Cardiovascular Diabetology 2009; 8:62.
Follow-up less than 6 months
2272. Leehey DJ, Palubiak DJ, Chebrolu S, et al. Sodium
ferric gluconate causes oxidative stress but not acute
renal injury in patients with chronic kidney disease: a
pilot study. Nephrology Dialysis Transplantation
2005; 20(1):135-40. Not relevant to key questions
2273. Leeman M, van de Borne P, Collart F, et al.
Bisoprolol and atenolol in essential hypertension:
effects on systemic and renal hemodynamics and on
ambulatory blood pressure. Journal of Cardiovascular
Pharmacology 1993; 22(6):785-91. Sample size less
than 50 patients
2274. Leenen FH, Smith DL, Farkas RM, et al.
Cardiovascular effects of indapamide in hypertensive
patients with or without renal failure. A dose-
B-141
response curve. American Journal of Medicine 1988;
84(1B):76-85. Sample size less than 50 patients
2275. Leenen FHH, Coletta E, Davies RA. Prevention of
renal dysfunction and hypertension by amlodipine
after heart transplant. American Journal of
Cardiology 2007; 100(3):531-5. Follow-up less than
6 months
2276. Leenen FHH, Nwachuku CE, Black HR, et al.
Clinical events in high-risk hypertensive patients
randomly assigned to calcium channel blocker versus
angiotensin-converting enzyme inhibitor in the
antihypertensive and lipid-lowering treatment to
prevent heart attack trial. Hypertension 2006;
48(3):374-84. Not RCT or controlled trial
2277. Lefebvre P, Duh MS, Buteau S, et al. Medical costs
of untreated anemia in elderly patients with
predialysis chronic kidney disease. Journal of the
American Society of Nephrology 2006; 17(12):3497502. Sample size less than 50 patients
2278. Lefebvre P, Vekeman F, Sarokhan B, et al.
Relationship between hemoglobin level and quality
of life in anemic patients with chronic kidney disease
receiving epoetin alfa. Current Medical Research &
Opinion 2006; 22(10):1929-37. Not RCT or
controlled trial
2279. Legault L, Ogilvie RI, Cardella CJ, et al. Calcium
antagonists in heart transplant recipients: effects on
cardiac and renal function and cyclosporine
pharmacokinetics. Canadian Journal of Cardiology
1993; 9(5):398-404. Follow-up less than 6 months
2280. Legroux-Crespel E, Cledes J, Misery L. A
comparative study on the effects of naltrexone and
loratadine on uremic pruritus. Dermatology 2004;
208(4):326-30. Sample size less than 50 patients
2281. Lehmkuhl HB, Arizon J, Vigano M, et al.
Everolimus with reduced cyclosporine versus MMF
with standard cyclosporine in de novo heart
transplant recipients. Transplantation 2009;
88(1):115-22. Not early CKD
2282. Leitersdorf E, Muratti EN, Eliav O, et al. Efficacy
and safety of triple therapy (fluvastatin-bezafibratecholestyramine) for severe familial
hypercholesterolemia. American Journal of
Cardiology 1995; 76(2):84A-8A. Follow-up less than
6 months
2283. Lely AT, van der Kleij FGH, Kistemaker TJ, et al.
Impact of the preintervention rate of renal function
decline on outcome of renoprotective intervention.
Clinical Journal of The American Society of
Nephrology: CJASN 2008; 3(1):54-60. Not CKD
treatment
2284. Lema G, Urzua J, Jalil R, et al. Renal protection in
patients undergoing cardiopulmonary bypass with
preoperative abnormal renal function. Anesthesia &
Analgesia 1998; 86(1):3-8. Sample size less than 50
patients
2285. Lemaire SA, Jones MM, Conklin LD, et al.
Randomized comparison of cold blood and cold
crystalloid renal perfusion for renal protection during
thoracoabdominal aortic aneurysm repair. Journal of
Vascular Surgery 2009; 49(1):11-9; discussion 9. Not
CKD treatment
2286. Lemann J, Bidani AK, Bain RP, et al. Use of the
serum creatinine to estimate glomerular filtration rate
in health and early diabetic nephropathy.
Collaborative Study Group of Angiotensin
Converting Enzyme Inhibition in Diabetic
Nephropathy. American Journal of Kidney Diseases
1990; 16(3):236-43. Not CKD treatment
2287. Lemann J, Jr., Pleuss JA, Hornick L, et al. Dietary
NaCl-restriction prevents the calciuria of KCldeprivation and blunts the calciuria of KHCO3deprivation in healthy adults. Kidney International
1995; 47(3):899-906. Sample size less than 50
patients
2288. Lemley KV, Abdullah I, Myers BD, et al. Evolution
of incipient nephropathy in type 2 diabetes
mellitus.[Erratum appears in Kidney Int 2000
Nov;58(5):2257]. Kidney International 2000;
58(3):1228-37. Not RCT or controlled trial
2289. Lemmer JH, Jr., Stanford W, Bonney SL, et al.
Aprotinin for coronary artery bypass grafting: effect
on postoperative renal function. Annals of Thoracic
Surgery 1995; 59(1):132-6. Not CKD treatment
2290. Lemos PA, Arampatzis CA, Hoye A, et al. Impact of
baseline renal function on mortality after
percutaneous coronary intervention with sirolimuseluting stents or bare metal stents. American Journal
of Cardiology 2005; 95(2):167-72. Sample size less
than 50 patients
2291. Lenaerts A, Codden T, Henry J-P, et al. Comparative
pilot study of repeated large volume paracentesis vs
the combination on clonidine-spironolactone in the
treatment of cirrhosis-associated refractory ascites.
Gastroenterologie Clinique et Biologique 2005;
29(11):1137-42. Sample size less than 50 patients
2292. Lennert T, Luft FC. Kidneys on vacation: the notion
of renal work and the introduction of
nonpharmacological therapies. American Journal of
Kidney Diseases 1997; 29(5):777-80. Not RCT or
controlled trial
2293. Leoncini G, Martinoli C, Viazzi F, et al. Changes in
renal resistive index and urinary albumin excretion in
hypertensive patients under long-term treatment with
lisinopril or nifedipine GITS. Nephron 2002;
90(2):169-73. Sample size less than 50 patients
2294. Leopold JA. Small-molecule glycoprotein IIb/IIIa
antagonists and bleeding risk in women: too much of
a good thing? Circulation 2006; 114(13):1344-6. Not
CKD treatment
2295. Lepor NE. A review of contemporary prevention
strategies for radiocontrast nephropathy: a focus on
fenoldopam and N-acetylcysteine. Reviews in
Cardiovascular Medicine 2003; 4 Suppl 1:S15-20.
Not CKD treatment
2296. Lerner SA, Schmitt BA, Seligsohn R, et al.
Comparative study of ototoxicity and nephrotoxicity
in patients randomly assigned to treatment with
amikacin or gentamicin. American Journal of
Medicine 1986; 80(6B):98-104. Not early CKD
2297. Lernfelt B, Landahl S, Johansson P, et al.
Haemodynamic and renal effects of felodipine in
young and elderly subjects. European Journal of
B-142
Clinical Pharmacology 1998; 54(8):595-601. Sample
size less than 50 patients
2298. Leung WYS, So W-Y, Tong PCY, et al. The
renoprotective effects of structured care in a clinical
trial setting in type 2 diabetic patients with
nephropathy. Nephrology Dialysis Transplantation
2004; 19(10):2519-25. Not CKD treatment
2299. Levey AS, Adler S, Caggiula AW, et al. Effects of
dietary protein restriction on the progression of
advanced renal disease in the Modification of Diet in
Renal Disease Study. American Journal of Kidney
Diseases 1996; 27(5):652-63. Not early CKD
2300. Levey AS, Berg RL, Gassman JJ, et al. Creatinine
filtration, secretion and excretion during progressive
renal disease. Modification of Diet in Renal Disease
(MDRD) Study Group. Kidney International Supplement 1989; 27:S73-80. Not relevant to key
questions
2301. Levey AS, Bosch JP, Lewis JB, et al. A more
accurate method to estimate glomerular filtration rate
from serum creatinine: a new prediction equation.
Modification of Diet in Renal Disease Study Group.
Annals of Internal Medicine 1999; 130(6):461-70.
Not RCT or controlled trial
2302. Levey AS, Coresh J, Greene T, et al. Using
standardized serum creatinine values in the
modification of diet in renal disease study equation
for estimating glomerular filtration rate.[Erratum
appears in Ann Intern Med. 2008 Oct 7;149(7):519].
Annals of Internal Medicine 2006; 145(4):247-54.
Not CKD treatment
2303. Levey AS, Gassman JJ, Hall PM, et al. Assessing the
progression of renal disease in clinical studies:
effects of duration of follow-up and regression to the
mean. Modification of Diet in Renal Disease
(MDRD) Study Group. Journal of the American
Society of Nephrology 1991; 1(9):1087-94. Not
relevant to key questions
2304. Levey AS, Greene T, Schluchter MD, et al.
Glomerular filtration rate measurements in clinical
trials. Modification of Diet in Renal Disease Study
Group and the Diabetes Control and Complications
Trial Research Group. Journal of the American
Society of Nephrology 1993; 4(5):1159-71. Not CKD
treatment
2305. Levey AS, Mulrow CD. An editorial update: what
level of blood pressure control in chronic kidney
disease? Annals of Internal Medicine 2005;
143(1):79-81. Not CKD treatment
2306. Levin A. The treatment of anemia in chronic kidney
disease: understandings in 2006. Current Opinion in
Nephrology & Hypertension 2007; 16(3):267-71.
Sample size less than 50 patients
2307. Levin A. Understanding recent haemoglobin trials in
CKD: methods and lesson learned from CREATE
and CHOIR.[Erratum appears in Nephrol Dial
Transplant. 2007 Mar;22(3):977]. Nephrology
Dialysis Transplantation 2007; 22(2):309-12. Not
CKD treatment
2308. Levin A, Duncan L, Djurdjev O, et al. A randomized
placebo-controlled double-blind trial of lipidlowering strategies in patients with renal
insufficiency: diet modification with or without
fenofibrate. Clinical Nephrology 2000; 53(2):140-6.
Sample size less than 50 patients
2309. Levine CB, Fahrbach KR, Frame D, et al. Effect of
amlodipine on systolic blood pressure. Clinical
Therapeutics 2003; 25(1):35-57. Not RCT or
controlled trial
2310. Levy B, Nace L, Bollaert PE, et al. Comparison of
systemic and regional effects of dobutamine and
dopexamine in norepinephrine-treated septic shock.
Intensive Care Medicine 1999; 25(9):942-8. Sample
size less than 50 patients
2311. Levy EM. Angiotensin converting enzyme inhibitors:
first line therapy in patients with diabetic
hypertension? Current Opinion in Nephrology &
Hypertension 1999; 8(3):333-4. Not RCT or
controlled trial
2312. Levy P-Y, Corey R, Berger P, et al. Etiologic
diagnosis of 204 pericardial effusions. Medicine
2003; 82(6):385-91. Not CKD treatment
2313. Levy R, DellaValle A, Atav AS, et al. The
relationship between glomerular filtration rate and
survival in patients treated with an implantable
cardioverter defibrillator. Clinical Cardiology 2008;
31(6):265-9. Not CKD treatment
2314. Lewandowski B, Bernacka K, Kucharewicz B, et al.
Assessment of beta-2-microglobulin concentration in
serum and urine in rheumatoid arthritis. Roczniki
Akademii Medycznej W Bialymstoku 1996;
41(2):482-91. Not CKD treatment
2315. Lewerin C, Ljungman S, Nilsson-Ehle H. Glomerular
filtration rate as measured by serum cystatin C is an
important determinant of plasma homocysteine and
serum methylmalonic acid in the elderly. Journal of
Internal Medicine 2007; 261(1):65-73. Not relevant
to key questions
2316. Lewis EJ. Therapeutic interventions in the
progression of diabetic nephropathy. American
Journal of Hypertension 1994; 7(9 Pt 2):93S-5S. Not
CKD treatment
2317. Lewis EJ. The role of angiotensin II receptor
blockers in preventing the progression of renal
disease in patients with type 2 diabetes. American
Journal of Hypertension 2002; 15(10 Pt 2):123S-8S.
Not RCT or controlled trial
2318. Lewis EJ, Hunsicker LG, Rodby RA, et al. A clinical
trial in type 2 diabetic nephropathy. American
Journal of Kidney Diseases 2001; 38(4 Suppl
1):S191-4. Not RCT or controlled trial
2319. Lewis EJ, Lewis JB. Treatment of diabetic
nephropathy with angiotensin II receptor antagonist.
Clinical & Experimental Nephrology 2003; 7(1):1-8.
Not CKD treatment
2320. Lewis HM, Wilkins MR, Kendall MJ, et al.
Carbidopa does not affect the renal response to atrial
natriuretic factor in man. Clinical Science 1989;
77(3):281-5. Not CKD treatment
2321. Lewis J, Agodoa L, Cheek D, et al. Comparison of
cross-sectional renal function measurements in
African Americans with hypertensive nephrosclerosis
and of primary formulas to estimate glomerular
filtration rate.[Erratum appears in Am J Kidney Dis
B-143
2002 Feb;39(2):444]. American Journal of Kidney
Diseases 2001; 38(4):744-53. Not RCT or controlled
trial
2322. Lewis J, Greene T, Appel L, et al. A comparison of
iothalamate-GFR and serum creatinine-based
outcomes: acceleration in the rate of GFR decline in
the African American Study of Kidney Disease and
Hypertension. Journal of the American Society of
Nephrology 2004; 15(12):3175-83. Sample size less
than 50 patients
2323. Lewis NP, Ferguson DR. The effect of enalapril on
the renal response to tilting in humans. British
Journal of Clinical Pharmacology 1989; 27(2):191-7.
Sample size less than 50 patients
2324. Lherm T, Troche G, Rossignol M, et al. Renal effects
of low-dose dopamine in patients with sepsis
syndrome or septic shock treated with
catecholamines. Intensive Care Medicine 1996;
22(3):213-9. Sample size less than 50 patients
2325. Li G, Yin L, Liu T, et al. Role of probucol in
preventing contrast-induced acute kidney injury after
coronary interventional procedure. American Journal
of Cardiology 2009; 103(4):512-4. Not CKD
treatment
2326. Li J, Schluchter MD. Conditional mixed models
adjusting for non-ignorable drop-out with
administrative censoring in longitudinal studies.
Statistics in Medicine 2004; 23(22):3489-503. Not
RCT or controlled trial
2327. Li Kam Wa TC, Freestone S, Samson RR, et al. A
comparison of the renal and neuroendocrine effects
of two 5-hydroxytryptamine renal prodrugs in normal
man. Clinical Science 1993; 85(5):607-14. Follow-up
less than 6 months
2328. Li Kam Wa TC, Freestone S, Samson RR, et al. The
antinatriuretic action of gamma-L-glutamyl-5hydroxy-L-tryptophan is dependent on its
decarboxylation to 5-hydroxytryptamine in normal
man. British Journal of Clinical Pharmacology 1994;
38(3):265-9. Sample size less than 50 patients
2329. Li Kam Wa TC, Freestone S, Samson RR, et al.
Renal metabolism and effects of the glutamyl
derivatives of L-dopa and 5-hydroxytryptophan in
man. Clinical Science 1996; 91(2):177-85. Not CKD
treatment
2330. Li Q, Zhang C-L, Fu Z-L, et al. Development of
formulae for accurate measurement of the glomerular
filtration rate by renal dynamic imaging. Nuclear
Medicine Communications 2007; 28(5):407-13. Not
CKD treatment
2331. Li X, Tian J, Wu J, et al. A comparison of a standarddose prednisone regimen and mycophenolate mofetil
combined with a lower prednisone dose in Chinese
adults with idiopathic nephrotic syndrome who were
carriers of hepatitis B surface antigen: a prospective
cohort study. Clinical Therapeutics 2009; 31(4):74150. Not RCT or controlled trial
2332. Li X-S, Zheng W-Y, Lou S-X, et al. Effect of Ginkgo
leaf extract on vascular endothelial function in
patients with early stage diabetic nephropathy.
Chinese Journal of Integrative Medicine 2009;
15(1):26-9. Not early CKD
2333. Li X-Y, Xu M, Wang J-G, et al. Serum C-reactive
protein (CRP) and microalbuminuria in relation to
fasting and 2-h postload plasma glucose in a Chinese
population. Clinical Endocrinology 2009; 70(5):6917. Not RCT or controlled trial
2334. Libertino JA, Beckmann CF. Surgery and
percutaneous angioplasty in the management of
renovascular hypertension. Urologic Clinics of North
America 1994; 21(2):235-43. Not RCT or controlled
trial
2335. Licata G, Scaglione R, Ganguzza A, et al. Effects of
amlodipine on renal haemodynamics in mild to
moderate hypertensive patients. A randomized
controlled study versus placebo. European Journal of
Clinical Pharmacology 1993; 45(4):307-11. Sample
size less than 50 patients
2336. Licata G, Scaglione R, Guillet C, et al. Double-blind
controlled study of rilmenidine versus
hydrochlorothiazide in mild hypertension: clinical
and renal haemodynamic evaluation. Journal of
Human Hypertension 1993; 7(2):153-7. Sample size
less than 50 patients
2337. Licker M, Bednarkiewicz M, Neidhart P, et al.
Preoperative inhibition of angiotensin-converting
enzyme improves systemic and renal haemodynamic
changes during aortic abdominal surgery. British
Journal of Anaesthesia 1996; 76(5):632-9. Sample
size less than 50 patients
2338. Lieberman SA, Holloway L, Marcus R, et al.
Interactions of growth hormone and parathyroid
hormone in renal phosphate, calcium, and calcitriol
metabolism and bone remodeling in postmenopausal
women. Journal of Bone & Mineral Research 1994;
9(11):1723-8. Sample size less than 50 patients
2339. Lievre M, Marre M, Chatellier G, et al. The noninsulin-dependent diabetes, hypertension,
microalbuminuria or proteinuria, cardiovascular
events, and ramipril (DIABHYCAR) study: design,
organization, and patient recruitment. DIABHYCAR
Study Group. Controlled Clinical Trials 2000;
21(4):383-96. Not RCT or controlled trial
2340. Ligtenberg G, Blankestijn PJ, Oey PL, et al.
Reduction of sympathetic hyperactivity by enalapril
in patients with chronic renal failure. New England
Journal of Medicine 1999; 340(17):1321-8. Sample
size less than 50 patients
2341. Lim SC, Koh AFY, Goh SK, et al. Angiotensin
receptor antagonist vs. angiotensin-converting
enzyme inhibitor in Asian subjects with type 2
diabetes and albuminuria - a randomized crossover
study. Diabetes, Obesity & Metabolism 2007;
9(4):477-82. Sample size less than 50 patients
2342. Lim VS. Recombinant human erythropoietin in
predialysis patients. American Journal of Kidney
Diseases 1991; 18(4 Suppl 1):34-7. Not relevant to
key questions
2343. Lim VS, DeGowin RL, Zavala D, et al. Recombinant
human erythropoietin treatment in pre-dialysis
patients. A double-blind placebo-controlled trial.
Annals of Internal Medicine 1989; 110(2):108-14.
Follow-up less than 6 months
B-144
2344. Lim VS, Wolfson M, Yarasheski KE, et al. Leucine
turnover in patients with nephrotic syndrome:
evidence suggesting body protein conservation.
Journal of the American Society of Nephrology
1998; 9(6):1067-73. Not RCT or controlled trial
2345. Lim VS, Zavala DC, Flanigan MJ, et al. Blunted
peripheral tissue responsiveness to thyroid hormone
in uremic patients. Kidney International 1987;
31(3):808-14. Sample size less than 50 patients
2346. Lim W, Dentali F, Eikelboom JW, et al. Metaanalysis: low-molecular-weight heparin and bleeding
in patients with severe renal insufficiency. Annals of
Internal Medicine 2006; 144(9):673-84. Not RCT or
controlled trial
2347. Lin C-C, Chuang F-R, Lee C-H, et al. The renalsparing efficacy of basiliximab in adult living donor
liver transplantation. Liver Transplantation 2005;
11(10):1258-64. Follow-up less than 6 months
2348. Lin J, Bonventre JV. Prevention of radiocontrast
nephropathy. Current Opinion in Nephrology &
Hypertension 2005; 14(2):105-10. Not relevant to
key questions
2349. Lin JL, Ho HH, Yu CC. Chelation therapy for
patients with elevated body lead burden and
progressive renal insufficiency. A randomized,
controlled trial. Annals of Internal Medicine 1999;
130(1):7-13. Sample size less than 50 patients
2350. Lin JL, Lin-Tan DT, Yu CC, et al. Environmental
exposure to lead and progressive diabetic
nephropathy in patients with type II diabetes. Kidney
International 2006; 69(11):2049-56. Not relevant to
key questions
2351. Lin JL, Tan DT, Hsu KH, et al. Environmental lead
exposure and progressive renal insufficiency.
Archives of Internal Medicine 2001; 161(2):264-71.
Not CKD treatment
2352. Lin JL, Yu CC, Lin-Tan DT, et al. Lead chelation
therapy and urate excretion in patients with chronic
renal diseases and gout. Kidney International 2001;
60(1):266-71. Sample size less than 50 patients
2353. Lin J-L, Lin-Tan D-T, Hsu K-H, et al. Environmental
lead exposure and progression of chronic renal
diseases in patients without diabetes. New England
Journal of Medicine 2003; 348(4):277-86. Not CKD
treatment
2354. Lin J-L, Lin-Tan D-T, Li Y-J, et al. Low-level
environmental exposure to lead and progressive
chronic kidney diseases. American Journal of
Medicine 2006; 119(8):707.e1-9. Not relevant to key
questions
2355. Lin S. New research areas for keto acid/amino acidsupplemented protein diets. Journal of Renal
Nutrition 2009; 19(5 Suppl):S30-2. Not RCT or
controlled trial
2356. Lin S-L, Chen Y-M, Chiang W-C, et al. Effect of
pentoxifylline in addition to losartan on proteinuria
and GFR in CKD: a 12-month randomized trial.
American Journal of Kidney Diseases 2008;
52(3):464-74. Not RCT or controlled trial
2357. Lind L, Wengle B, Sorensen OH, et al. Delayed
hypersensitivity in primary and secondary
hyperparathyroidism. Treatment with active vitamin
D. Experimental & Clinical Endocrinology 1990;
95(2):271-4. Not CKD treatment
2358. Lindeman RD, Romero L, Liang HC, et al.
Prevalence of proteinuria/microalbuminuria in an
elderly urban, biethnic community. Geriatric
Nephrology & Urology 1998; 8(3):123-30. Not RCT
or controlled trial
2359. Lindenfeld J, Borer J, Armstrong PW. Losartan
potassium (Cozaar). Circulation 2002;
105(16):e9100. Not relevant to key questions
2360. Lindsay RM, Spanner E, Heidenheim AP, et al. A
multicenter study of short hour dialysis using
AN69S. Preliminary results. ASAIO Transactions
1991; 37(3):M465-7. Not CKD treatment
2361. Lindsay RM, Spanner E, Heidenheim AP, et al. The
influence of dialysis membrane upon protein
catabolic rate. ASAIO Transactions 1991;
37(3):M134-5. Not CKD treatment
2362. Linnebjerg H, Kothare PA, Park S, et al. Effect of
renal impairment on the pharmacokinetics of
exenatide. British Journal of Clinical Pharmacology
2007; 64(3):317-27. Sample size less than 50 patients
2363. Lin-Tan D-T, Lin J-L, Yen T-H, et al. Long-term
outcome of repeated lead chelation therapy in
progressive non-diabetic chronic kidney diseases.
Nephrology Dialysis Transplantation 2007;
22(10):2924-31. Not RCT or controlled trial
2364. Lintott CJ, Scott RS, Bremer JM, et al. Fluvastatin
for dyslipoproteinemia, with or without concomitant
chronic renal insufficiency. American Journal of
Cardiology 1995; 76(2):97A-101A. Sample size less
than 50 patients
2365. Liou HH, Chiang SS, Wu SC, et al. Intravenous
infusion or nebulization of salbutamol for treatment
of hyperkalemia in patients with chronic renal
failure. Chung Hua i Hsueh Tsa Chih - Chinese
Medical Journal 1994; 53(5):276-81. Sample size less
than 50 patients
2366. Liou HH, Huang TP, Campese VM. Effect of longterm therapy with captopril on proteinuria and renal
function in patients with non-insulin-dependent
diabetes and with non-diabetic renal diseases.
Nephron 1995; 69(1):41-8. Sample size less than 50
patients
2367. Lipkin GW, Dawnay AB, Harwood SM, et al.
Enhanced natriuretic response to neutral
endopeptidase inhibition in patients with moderate
chronic renal failure. Kidney International 1997;
52(3):792-801. Sample size less than 50 patients
2368. Lips P, Wiersinga A, van Ginkel FC, et al. The effect
of vitamin D supplementation on vitamin D status
and parathyroid function in elderly subjects. Journal
of Clinical Endocrinology & Metabolism 1988;
67(4):644-50. Not CKD treatment
2369. Lipton A. The safety of zoledronic acid. Expert
Opinion on Drug Safety 2007; 6(3):305-13. Sample
size less than 50 patients
2370. Lishner M, Lang R, Jutrin I, et al. Analgesic effect of
ceruletide compared with pentazocine in biliary and
renal colic: a prospective, controlled, double-blind
study. Drug Intelligence & Clinical Pharmacy 1985;
19(6):433-6. Follow-up less than 6 months
B-145
1993; 6(7 Pt 1):554-63. Sample size less than 50
patients
2384. Ljutic D, Perkovic D, Rumboldt Z, et al. Comparison
of ondansetron with metoclopramide in the
symptomatic relief of uremia-induced nausea and
vomiting. Kidney & Blood Pressure Research 2002;
25(1):61-4. Sample size less than 50 patients
2385. Llanos A, Cieza J, Bernardo J, et al. Effect of salt
supplementation on amphotericin B nephrotoxicity.
Kidney International 1991; 40(2):302-8. Not CKD
treatment
2386. Lloret J, Vila A, Puig X, et al. Nifedipine in the
treatment of renal colic. Methods & Findings in
Experimental & Clinical Pharmacology 1986;
8(9):575-9. Sample size less than 50 patients
2387. Locatelli F. Controlled study of protein-restricted
diet in chronic renal failure. Contributions to
Nephrology 1989; 75:141-6. Not relevant to key
questions
2388. Locatelli F. Dietary compliance in patients with
chronic renal failure: experience in a northern Italy
trial. Contributions to Nephrology 1990; 81:102-6.
Not CKD treatment
2389. Locatelli F, Canaud B, Eckardt K-U, et al. Oxidative
stress in end-stage renal disease: an emerging threat
to patient outcome. Nephrology Dialysis
Transplantation 2003; 18(7):1272-80. Not early CKD
2390. Locatelli F, Carbarns IR, Maschio G, et al. Longterm progression of chronic renal insufficiency in the
AIPRI Extension Study. The AngiotensinConverting-Enzyme Inhibition in Progressive Renal
Insufficiency Study Group. Kidney International Supplement 1997; 63:S63-6. Not relevant to key
questions
2391. Locatelli F, Covic A, Macdougall IC, et al. ORAMA:
a study to investigate EBPG impact on renal anaemia
- design and baseline data. Journal of Nephrology
2008; 21(4):592-603. Not CKD treatment
2392. Locatelli F, Del Vecchio L, Andrulli S, et al. The role
of underlying nephropathy in the progression of renal
disease. Kidney International - Supplement 2000;
75:S49-55. Not CKD treatment
2393. Locatelli F, Del Vecchio L, Marai P, et al. The
renoprotective effect of antihypertensive drugs.
Journal of Nephrology 1998; 11(6):330-6. Not RCT
or controlled trial
2394. Locatelli F, Del Vecchio L, Pozzoni P. Clinical
benefits of slowing the progression of renal failure.
Kidney International - Supplement 2005; (99):S1526. Not relevant to key questions
2395. Locatelli F, Del Vecchio L, Pozzoni P. Anemia and
cardiovascular risk: the lesson of the CREATE Trial.
Journal of the American Society of Nephrology
2006; 17(12 Suppl 3):S262-6. Not RCT or controlled
trial
2396. Locatelli F, Del Vecchio L, Pozzoni P. Treating
anemia at different stages of renal disease. Journal of
Nephrology 2007; 20 Suppl 12:S33-8. Not relevant
to key questions
2397. Locatelli F, Del Vecchio L, Pozzoni P, et al. Is it the
agent or the blood pressure level that matters for
renal and vascular protection in chronic
2371. Lissoni P, Malugani F, Malysheva O, et al.
Neuroimmunotherapy of untreatable metastatic solid
tumors with subcutaneous low-dose interleukin-2,
melatonin and naltrexone: modulation of interleukin2-induced antitumor immunity by blocking the
opioid system. Neuroendocrinology Letters 2002;
23(4):341-4. Not CKD treatment
2372. Lit YZ, Meyer T. Managing diabetic nephropathy:
recent studies. Current Opinion in Nephrology &
Hypertension 2006; 15(2):111-6. Not RCT or
controlled trial
2373. Littlewood KJ, Greiner W, Baum D, et al. Adjunctive
treatment with moxonidine versus nitrendipine for
hypertensive patients with advanced renal failure: a
cost-effectiveness analysis. BMC Nephrology 2007;
8:9. Not RCT or controlled trial
2374. Littlewood TJ, Alikhan R. The use of intravenous
iron in patients with cancer-related anaemia. British
Journal of Haematology 2008; 141(6):751-6. Sample
size less than 50 patients
2375. Litz RJ, Hubler M, Lorenz W, et al. Renal responses
to desflurane and isoflurane in patients with renal
insufficiency. Anesthesiology 2002; 97(5):1133-6.
Not CKD treatment
2376. Liu B-C, Chen L, Sun J, et al. Connective tissue
growth factor-mediated angiotensin II-induced
hypertrophy of proximal tubular cells. Nephron.
Experimental Nephrology 2006; 103(1):e16-26. Not
RCT or controlled trial
2377. Liu C, Chen H, Zhou C, et al. Potent potentiating
diuretic effects of prednisone in congestive heart
failure. Journal of Cardiovascular Pharmacology
2006; 48(4):173-6. Not CKD treatment
2378. Liu C, Liu G, Zhou C, et al. Potent diuretic effects of
prednisone in heart failure patients with refractory
diuretic resistance. Canadian Journal of Cardiology
2007; 23(11):865-8. Not RCT or controlled trial
2379. Liu Q, Garner P, Wang Y, et al. Drugs and herbs
given to prevent hepatotoxicity of tuberculosis
therapy: systematic review of ingredients and
evaluation studies. BMC Public Health 2008; 8:365.
Not CKD treatment
2380. Liu R, Nair D, Ix J, et al. N-acetylcysteine for the
prevention of contrast-induced nephropathy. A
systematic review and meta-analysis. Journal of
General Internal Medicine 2005; 20(2):193-200. Not
RCT or controlled trial
2381. Liu X, Du J, Cai J, et al. Clinical systematic
observation of Kangxin capsule curing vascular
dementia of senile kidney deficiency and blood
stagnation type. Journal of Ethnopharmacology 2007;
112(2):350-5. Not RCT or controlled trial
2382. Livio M, Mannucci PM, Vigano G, et al. Conjugated
estrogens for the management of bleeding associated
with renal failure. New England Journal of Medicine
1986; 315(12):731-5. Sample size less than 50
patients
2383. Ljungman S, Wikstrand J, Hartford M, et al. Effects
of long-term antihypertensive treatment and aging on
renal function and albumin excretion in primary
hypertension. American Journal of Hypertension
B-146
nephropathies? Kidney International - Supplement
2005; (93):S15-9. Not RCT or controlled trial
2398. Locatelli F, Manzoni C, Marcelli D. Factors affecting
progression of renal insufficiency. Mineral &
Electrolyte Metabolism 1997; 23(3-6):301-5. Not
RCT or controlled trial
2399. Locatelli F, Manzoni C, Marcelli D. Treatment of
hypertension in chronic renal insufficiency. Journal
of Nephrology 1997; 10(4):220-3. Not RCT or
controlled trial
2400. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria
and blood pressure as causal components of
progression to end-stage renal failure. Northern
Italian Cooperative Study Group. Nephrology
Dialysis Transplantation 1996; 11(3):461-7. Not RCT
or controlled trial
2401. Locatelli F, Marcelli D, Tentori F, et al. Controlled
trials on low-protein diet: effects on chronic renal
insufficiency progression. Renal Failure 1993;
15(3):407-13. Not RCT or controlled trial
2402. Locatelli F, Olivares J, Walker R, et al. Novel
erythropoiesis stimulating protein for treatment of
anemia in chronic renal insufficiency. Kidney
International 2001; 60(2):741-7. Not CKD treatment
2403. Locatelli F, Vecchio LD, Pozzoni P. The importance
of early detection of chronic kidney disease.
Nephrology Dialysis Transplantation 2002; 17 Suppl
11:2-7. Not relevant to key questions
2404. Locatelli MC, D'Antona A, Labianca R, et al. A
phase II study of combination chemotherapy in
advanced ovarian carcinoma with cisplatin and
cyclophosphamide plus reduced glutathione as
potential protective agent against cisplatin toxicity.
Tumori 1993; 79(1):37-9. Not CKD treatment
2405. Lodise TP, Lomaestro B, Graves J, et al. Larger
vancomycin doses (at least four grams per day) are
associated with an increased incidence of
nephrotoxicity. Antimicrobial Agents &
Chemotherapy 2008; 52(4):1330-6. Not CKD
treatment
2406. Loeb M, Neupane B, Walter SD, et al.
Environmental risk factors for community-acquired
pneumonia hospitalization in older adults. Journal of
the American Geriatrics Society 2009; 57(6):103640. Not CKD treatment
2407. Loef BG, Epema AH, Navis G, et al. Off-pump
coronary revascularization attenuates transient renal
damage compared with on-pump coronary
revascularization. Chest 2002; 121(4):1190-4. Not
early CKD
2408. Loef BG, Henning RH, Epema AH, et al. Effect of
dexamethasone on perioperative renal function
impairment during cardiac surgery with
cardiopulmonary bypass. British Journal of
Anaesthesia 2004; 93(6):793-8. Not relevant to key
questions
2409. Logan A. BENEDICT in the treatment of
hypertension. Current Hypertension Reports 2005;
7(2):121-3. Not RCT or controlled trial
2410. London GM. Efficacy of indapamide 1.5 mg,
sustained release, in the lowering of systolic blood
pressure. Journal of Human Hypertension 2004; 18
Suppl 2:S9-S14. Not RCT or controlled trial
2411. London GM, Pannier B, Guerin AP, et al. Cardiac
hypertrophy, aortic compliance, peripheral
resistance, and wave reflection in end-stage renal
disease. Comparative effects of ACE inhibition and
calcium channel blockade. Circulation 1994;
90(6):2786-96. Not early CKD
2412. Lopes NH, da Silva Paulitsch F, Pereira A, et al.
Mild chronic kidney dysfunction and treatment
strategies for stable coronary artery disease. Journal
of Thoracic & Cardiovascular Surgery 2009;
137(6):1443-9. Not CKD treatment
2413. Lopes T, Dias JS, Marcelino J, et al. An assessment
of the clinical efficacy of intranasal desmopressin
spray in the treatment of renal colic. BJU
International 2001; 87(4):322-5. Not CKD treatment
2414. Lopez LM, Santiago TM. Isradipine--another
calcium-channel blocker for the treatment of
hypertension and angina. Annals of Pharmacotherapy
1992; 26(6):789-99. Not relevant to key questions
2415. Lopez MC, Belizan JM, Villar J, et al. The
measurement of diastolic blood pressure during
pregnancy: which Korotkoff phase should be used?
American Journal of Obstetrics & Gynecology 1994;
170(2):574-8. Not RCT or controlled trial
2416. Lorenzano E, Badalamenti S, Scotti A, et al. Renal
effects of imidazole-2-hydroxybenzoate in patients
with compensated liver cirrhosis. International
Journal of Clinical Pharmacology, Therapy, &
Toxicology 1992; 30(7):225-9. Sample size less than
50 patients
2417. Lottenberg R, Hassell KL. An evidence-based
approach to the treatment of adults with sickle cell
disease. Hematology 2005:58-65. Not adult
population
2418. Loudon JAZ, Groom KM, Bennett PR. Prostaglandin
inhibitors in preterm labour. Best Practice &
Research in Clinical Obstetrics & Gynaecology
2003; 17(5):731-44. Not CKD treatment
2419. Loup R, Favre L, Vallotton MB. Effect of
noradrenaline, vasopressin and angiotensin II on
renal prostaglandins in man. Clinical Science 1986;
70(4):371-7. Sample size less than 50 patients
2420. Lovell HG. Angiotensin converting enzyme
inhibitors in normotensive diabetic patients with
microalbuminuria. Cochrane Database of Systematic
Reviews 2000; (2):CD002183. Not relevant to key
questions
2421. Lovell HG. Angiotensin converting enzyme
inhibitors in normotensive diabetic patients with
microalbuminuria. Cochrane Database of Systematic
Reviews 2001; (1):CD002183. Not relevant to key
questions
2422. Lovell HG. WITHDRAWN: Angiotensin converting
enzyme inhibitors in normotensive diabetic patients
with microalbuminuria. Cochrane Database of
Systematic Reviews 2006; (1):CD002183. Sample
size less than 50 patients
2423. Lubrano R, Marandola M, Antonucci A, et al.
Hypotensive anesthesia with propofol and
remifentanil: protective effect of alpha-tocopherol on
B-147
renal function. Journal of Clinical Anesthesia 2008;
20(3):164-9. Not CKD treatment
2424. Lucarini AR, Arrighi P, Favilla S, et al. The
influence of dopamine-1 receptor blockade on the
humoral and renal effects of low-dose atrial
natriuretic factor in human hypertensives. Journal of
Hypertension - Supplement 1989; 7(6):S230-1.
Sample size less than 50 patients
2425. Lucarini AR, Salvetti A. Haemodynamic (systemic
and renal) and humoral interactions between
nicardipine and domperidone in hypertensives.
Journal of Hypertension - Supplement 1987;
5(5):S571-4. Sample size less than 50 patients
2426. Lucarini AR, Salvetti A. Systemic and renal
hemodynamic effects of celiprolol in essential
hypertensives. American Journal of Cardiology 1988;
61(5):45C-8C. Sample size less than 50 patients
2427. Luchner A, Hengstenberg C, Lowel H, et al. Effect
of compensated renal dysfunction on approved heart
failure markers: direct comparison of brain
natriuretic peptide (BNP) and N-terminal pro-BNP.
Hypertension 2005; 46(1):118-23. Not RCT or
controlled trial
2428. Luchsinger A, Velasco M, Urbina A, et al.
Comparative effects of dopaminergic agonists on
cardiovascular, renal, and renin-angiotensin systems
in hypertensive patients. Journal of Clinical
Pharmacology 1992; 32(1):55-60. Sample size less
than 50 patients
2429. Lucker PW, Venitz J, Hey B, et al.
Pharmacodynamic and pharmacokinetic correlation
of muzolimine with and without aluminium
hydroxide. Zeitschrift fur Kardiologie 1985; 74
Suppl 2:141-4. Sample size less than 50 patients
2430. Ludlow M, Luxton G, Mathew T. Effects of
fluoridation of community water supplies for people
with chronic kidney disease. Nephrology Dialysis
Transplantation 2007; 22(10):2763-7. Sample size
less than 50 patients
2431. Luft FC. STOPPING at the CAPPP of good HOPE.
Nephrology Dialysis Transplantation 2000;
15(4):451-2. Not RCT or controlled trial
2432. Luft FC. Hypertensive nephrosclerosis: update.
Current Opinion in Nephrology & Hypertension
2004; 13(2):147-54. Not CKD treatment
2433. Luik PT, Hoogenberg K, Van Der Kleij FGH, et al.
Short-term moderate sodium restriction induces
relative hyperfiltration in normotensive
normoalbuminuric Type I diabetes mellitus.
Diabetologia 2002; 45(4):535-41. Sample size less
than 50 patients
2434. Luippold G, Benohr P, Piesch C, et al. Urinary
dopamine excretion in healthy volunteers: effect of
sodium diet and acute water load. Pflugers Archiv European Journal of Physiology 2000; 440(1):28-33.
Not early CKD
2435. Luippold G, Schneider S, Stefanescu A, et al.
Dopamine D2-like receptors and amino acid-induced
glomerular hyperfiltration in humans. British Journal
of Clinical Pharmacology 2001; 51(5):415-21. Not
early CKD
2436. Luke DR, Sarnoski TP, Bell N, et al. Influence of
pentoxifylline on renal function in HIV-seropositive
patients. Renal Failure 1993; 15(2):181-8. Sample
size less than 50 patients
2437. Luke RG, Boyle JA. Renal effects of amphotericin B
lipid complex. American Journal of Kidney Diseases
1998; 31(5):780-5. Not CKD treatment
2438. Luksch A, Polak K, Matulla B, et al. Glucose and
insulin exert additive ocular and renal vasodilator
effects on healthy humans. Diabetologia 2001;
44(1):95-103. Not early CKD
2439. Lumlertgul D, Keoplung M, Sitprija V, et al.
Furosemide and dopamine in malarial acute renal
failure. Nephron 1989; 52(1):40-4. Not CKD
treatment
2440. Lumlertgul D, Wongmekiat O, Sirivanichai C, et al.
Intrarenal infusion of gallopamil in acute renal
failure. A preliminary report. Drugs 1991; 42 Suppl
1:44-50. Not CKD treatment
2441. Lund B, Hansen OP, Hansen HH, et al. Combination
therapy with
carboplatin/cisplatin/ifosfamide/etoposide in ovarian
cancer. Seminars in Oncology 1992; 19(1 Suppl
1):26-9. Not CKD treatment
2442. Lundby B, Berg KJ, Lien HH, et al. A double blind
study to evaluate the tolerability of gadodiamide
injection and its effect on renal function in patients
undergoing cerebral magnetic resonance imaging.
British Journal of Radiology 1993; 66(790):871-6.
Not CKD treatment
2443. Lungershausen YK, Howe PR, Clifton PM, et al.
Evaluation of an omega-3 fatty acid supplement in
diabetics with microalbuminuria. Annals of the New
York Academy of Sciences 1997; 827:369-81.
Follow-up less than 6 months
2444. Luno J, Barrio V, Goicoechea MA, et al. Effects of
dual blockade of the renin-angiotensin system in
primary proteinuric nephropathies. Kidney
International - Supplement 2002; (82):S47-52.
Sample size less than 50 patients
2445. Luntz SP, Unnebrink K, Seibert-Grafe M, et al.
HEGPOL: randomized, placebo controlled,
multicenter, double-blind clinical trial to investigate
hepatoprotective effects of glycine in the
postoperative phase of liver transplantation
[ISRCTN69350312]. BMC Surgery 2005; 5:18. Not
relevant to key questions
2446. Luss H, Mitrovic V, Seferovic PM, et al. Renal
effects of ularitide in patients with decompensated
heart failure. American Heart Journal 2008;
155(6):1012.e1-8. Not CKD treatment
2447. Luts L, Bergenfelz A, Alumets J, et al. Parathyroid
function and histology in patients with parathyroid
adenoma: correlation of clinical and morphologic
findings. World Journal of Surgery 1997; 21(5):55363. Not RCT or controlled trial
2448. Lynch AI, Boerwinkle E, Davis BR, et al.
Antihypertensive pharmacogenetic effect of
fibrinogen-beta variant -455G>A on cardiovascular
disease, end-stage renal disease, and mortality: the
GenHAT study. Pharmacogenetics & Genomics
2009; 19(6):415-21. Not CKD treatment
B-148
2449. Lyubimova NV, Topchieva SV, Averinova SG, et al.
Modern methods for diagnosis and monitoring of
nephrotoxicity during antitumor therapy with
platinum derivatives. Bulletin of Experimental
Biology & Medicine 2000; 130(9):886-91. Not early
CKD
2450. Ma WW, Jimeno A. Temsirolimus. Drugs of Today
2007; 43(10):659-69. Not RCT or controlled trial
2451. Ma X. Clinical analysis for the acupuncture treatment
in 42 cases of gouty renal damage. Journal of
Traditional Chinese Medicine 2004; 24(3):185-7.
Sample size less than 50 patients
2452. Ma YC, Zuo L, Chen JH, et al. Improved GFR
estimation by combined creatinine and cystatin C
measurements. Kidney International 2007;
72(12):1535-42. Not RCT or controlled trial
2453. Ma Y-C, Zuo L, Chen J-H, et al. Modified
glomerular filtration rate estimating equation for
Chinese patients with chronic kidney
disease.[Erratum appears in J Am Soc Nephrol. 2006
Dec;17(12):3540]. Journal of the American Society
of Nephrology 2006; 17(10):2937-44. Not RCT or
controlled trial
2454. Maccariello ER, Genelhu de Abreu Fagundes V,
Francischetti EA. The effects of isradipine and
spirapril as monotherapy and combined therapy on
blood pressure, renal hemodynamics, natriuresis, and
urinary kallikrein in hypertensive nephropathy.
American Journal of Hypertension 1997; 10(5 Pt
1):541-5. Follow-up less than 6 months
2455. Macdonald JH, Marcora SM, Jibani MM, et al.
Nandrolone decanoate as anabolic therapy in chronic
kidney disease: a randomized phase II dose-finding
study. Nephron 2007; 106(3):c125-35. Follow-up
less than 6 months
2456. MacDonald TM. Metoclopramide, domperidone and
dopamine in man: actions and interactions. European
Journal of Clinical Pharmacology 1991; 40(3):22530. Sample size less than 50 patients
2457. MacDonald TM, Jeffrey RF, Lee MR. The renal and
haemodynamic effects of a 10 h infusion of
glutamyl-L-dopa in normal man. British Journal of
Clinical Pharmacology 1989; 27(6):811-22. Not CKD
treatment
2458. Macdougall IC. How to improve survival in predialysis patients. Nephron 2000; 85 Suppl 1:15-22.
Not RCT or controlled trial
2459. Macdougall IC, Robson R, Opatrna S, et al.
Pharmacokinetics and pharmacodynamics of
intravenous and subcutaneous continuous
erythropoietin receptor activator (C.E.R.A.) in
patients with chronic kidney disease. Clinical Journal
of The American Society of Nephrology: CJASN
2006; 1(6):1211-5. Not RCT or controlled trial
2460. Macdougall IC, Steering Committee of the Ct, Group
CS. CREATE: new strategies for early anaemia
management in renal insufficiency. Nephrology
Dialysis Transplantation 2003; 18 Suppl 2:ii13-6.
Not early CKD
2461. Macdougall IC, Walker R, Provenzano R, et al.
C.E.R.A. corrects anemia in patients with chronic
kidney disease not on dialysis: results of a
randomized clinical trial. Clinical Journal of The
American Society of Nephrology: CJASN 2008;
3(2):337-47. Not CKD treatment
2462. Macedo E, Abdulkader R, Castro I, et al. Lack of
protection of N-acetylcysteine (NAC) in acute renal
failure related to elective aortic aneurysm repair-a
randomized controlled trial. Nephrology Dialysis
Transplantation 2006; 21(7):1863-9. Sample size less
than 50 patients
2463. MacGregor DA, Butterworth JFt, Zaloga CP, et al.
Hemodynamic and renal effects of dopexamine and
dobutamine in patients with reduced cardiac output
following coronary artery bypass grafting. Chest
1994; 106(3):835-41. Sample size less than 50
patients
2464. MacGregor GA. Blood pressure, angiotensinconverting enzyme (ACE) inhibitors, and the kidney.
American Journal of Medicine 1992; 92(4B):20S-7S.
Not relevant to key questions
2465. MacGregor MS, Deighan CJ, Rodger RSC, et al. A
prospective open-label randomised trial of quinapril
and/or amlodipine in progressive non-diabetic renal
failure. Nephron 2005; 101(3):c139-49. Sample size
less than 50 patients
2466. Mackay IG, Macnicol AM, Smith HJ, et al. Intrinsic
sympathomimetic activity of cardioselective betaadrenoceptor blockers and effects on renal function.
British Journal of Clinical Pharmacology 1985;
20(3):197-203. Sample size less than 50 patients
2467. MacKinnon M, Leenen FHH, Ruzicka M. Does
ALLHAT change the management of hypertension in
chronic kidney disease? Current Hypertension
Reports 2005; 7(6):474-83. Not RCT or controlled
trial
2468. MacKinnon M, Shurraw S, Akbari A, et al.
Combination therapy with an angiotensin receptor
blocker and an ACE inhibitor in proteinuric renal
disease: a systematic review of the efficacy and
safety data. American Journal of Kidney Diseases
2006; 48(1):8-20. Not relevant to key questions
2469. MacLean CH, Mojica WA, Morton SC, et al. Effects
of omega-3 fatty acids on lipids and glycemic control
in type II diabetes and the metabolic syndrome and
on inflammatory bowel disease, rheumatoid arthritis,
renal disease, systemic lupus erythematosus, and
osteoporosis. Evidence Report: Technology
Assessment 2004; (89):1-4. Follow-up less than 6
months
2470. MacLeod MJ, McLay J. Drug treatment of
hypertension complicating diabetes mellitus. Drugs
1998; 56(2):189-202. Not RCT or controlled trial
2471. MacNeill BD, Harding SA, Bazari H, et al.
Prophylaxis of contrast-induced nephropathy in
patients undergoing coronary angiography.
Catheterization & Cardiovascular Interventions 2003;
60(4):458-61. Not relevant to key questions
2472. Madero M, Sarnak MJ, Wang X, et al. Uric acid and
long-term outcomes in CKD. American Journal of
Kidney Diseases 2009; 53(5):796-803. Follow-up
less than 6 months
2473. Madero M, Sarnak MJ, Wang X, et al. Body mass
index and mortality in CKD. American Journal of
B-149
Kidney Diseases 2007; 50(3):404-11. Sample size
less than 50 patients
2474. Madkour H, Gadallah M, Riveline B, et al.
Comparison between the effects of indapamide and
hydrochlorothiazide on creatinine clearance in
patients with impaired renal function and
hypertension. American Journal of Nephrology 1995;
15(3):251-5. Not relevant to key questions
2475. Madkour H, Gadallah M, Riveline B, et al.
Indapamide is superior to thiazide in the preservation
of renal function in patients with renal insufficiency
and systemic hypertension. American Journal of
Cardiology 1996; 77(6):23B-5B. Not CKD treatment
2476. Madore F, Lazarus JM, Brady HR. Therapeutic
plasma exchange in renal diseases. Journal of the
American Society of Nephrology 1996; 7(3):367-86.
Not RCT or controlled trial
2477. Madsen JK, Jensen JW, Sandermann J, et al. Effect
of nitrendipine on renal function and on hormonal
parameters after intravascular iopromide. Acta
Radiologica 1998; 39(4):375-80. Sample size less
than 50 patients
2478. Madsen JK, Zachariae H, Pedersen EB. Effects of the
calcium antagonist felodipine on renal
haemodynamics, tubular sodium handling, and blood
pressure in cyclosporin-treated dermatological
patients. Nephrology Dialysis Transplantation 1997;
12(3):480-4. Not CKD treatment
2479. Magee GM, Bilous RW, Cardwell CR, et al. Is
hyperfiltration associated with the future risk of
developing diabetic nephropathy? A meta-analysis.
Diabetologia 2009; 52(4):691-7. Not relevant to key
questions
2480. Mahajan SK, Sharma VK, Thakral S. Effect of
enalapril on renal profile and right ventricular
dimensions in chronic cor pulmonale. Journal of the
Association of Physicians of India 1996; 44(5):3234. Sample size less than 50 patients
2481. Mahesh B, Yim B, Robson D, et al. Does furosemide
prevent renal dysfunction in high-risk cardiac
surgical patients? Results of a double-blinded
prospective randomised trial. European Journal of
Cardio-Thoracic Surgery 2008; 33(3):370-6. Sample
size less than 50 patients
2482. Mahmood A, Gosling P, Vohra RK. Randomized
clinical trial comparing the effects on renal function
of hydroxyethyl starch or gelatine during aortic
aneurysm surgery. British Journal of Surgery 2007;
94(4):427-33. Not relevant to key questions
2483. Mahmud N, O'Toole D, O'Hare N, et al. Evaluation
of renal function following treatment with 5aminosalicylic acid derivatives in patients with
ulcerative colitis. Alimentary Pharmacology &
Therapeutics 2002; 16(2):207-15. Not early CKD
2484. Maillard M, Burnier M. Comparative cardiovascular
safety of traditional nonsteroidal anti-inflammatory
drugs. Expert Opinion on Drug Safety 2006; 5(1):8394. Not relevant to key questions
2485. Mainra R, Gallo K, Moist L. Effect of Nacetylcysteine on renal function in patients with
chronic kidney disease. Nephrology 2007; 12(5):5103. Sample size less than 50 patients
2486. Maioli M, Toso A, Leoncini M, et al. Sodium
bicarbonate versus saline for the prevention of
contrast-induced nephropathy in patients with renal
dysfunction undergoing coronary angiography or
intervention. Journal of the American College of
Cardiology 2008; 52(8):599-604. Not early CKD
2487. Maione A, Nicolucci A, Craig JC, et al. Protocol of
the Long-term Impact of RAS Inhibition on
Cardiorenal Outcomes (LIRICO) randomized trial.
Journal of Nephrology 2007; 20(6):646-55. Not CKD
treatment
2488. Maisch NM, Pezzillo KK. HMG-CoA reductase
inhibitors for the prevention of nephropathy. Annals
of Pharmacotherapy 2004; 38(2):342-5. Sample size
less than 50 patients
2489. Majumdar SR, Kjellstrand CM, Tymchak WJ, et al.
Forced euvolemic diuresis with mannitol and
furosemide for prevention of contrast-induced
nephropathy in patients with CKD undergoing
coronary angiography: a randomized controlled trial.
American Journal of Kidney Diseases 2009;
54(4):602-9. Not CKD treatment
2490. Mak RH, Cheung W. Therapeutic strategy for
cachexia in chronic kidney disease. Current Opinion
in Nephrology & Hypertension 2007; 16(6):542-6.
Not CKD treatment
2491. Maki DD, Ma JZ, Louis TA, et al. Long-term effects
of antihypertensive agents on proteinuria and renal
function. Archives of Internal Medicine 1995;
155(10):1073-80. Not relevant to key questions
2492. Makino H, Haneda M, Babazono T, et al. The
telmisartan renoprotective study from incipient
nephropathy to overt nephropathy--rationale, study
design, treatment plan and baseline characteristics of
the incipient to overt: angiotensin II receptor blocker,
telmisartan, Investigation on Type 2 Diabetic
Nephropathy (INNOVATION) Study. Journal of
International Medical Research 2005; 33(6):677-86.
Not human studies
2493. Makino H, Haneda M, Babazono T, et al.
Microalbuminuria reduction with telmisartan in
normotensive and hypertensive Japanese patients
with type 2 diabetes: a post-hoc analysis of The
Incipient to Overt: Angiotensin II Blocker,
Telmisartan, Investigation on Type 2 Diabetic
Nephropathy (INNOVATION) study. Hypertension
Research - Clinical & Experimental 2008; 31(4):65764. Not CKD treatment
2494. Malaguarnera M, Vacante M, Russo C, et al. A
single dose of rasburicase in elderly patients with
hyperuricaemia reduces serum uric acid levels and
improves renal function. Expert Opinion on
Pharmacotherapy 2009; 10(5):737-42. Not RCT or
controlled trial
2495. Malandrino S, Angelini M, Baldini L, et al. Effects
of suprofen on renal function in patients with
rheumatoid arthritis. International Journal of Clinical
Pharmacology Research 1987; 7(4):259-63. Followup less than 6 months
2496. Malani AK, Ammar H, Yassin MH. Progression of
chronic kidney disease: can it be prevented or
arrested? American Journal of Medicine 2007;
B-150
120(3):e29; author reply e31. Not RCT or controlled
trial
2497. Mallamaci F, Leonardis D, Bellizzi V, et al. Does
high salt intake cause hyperfiltration in patients with
essential hypertension? Journal of Human
Hypertension 1996; 10(3):157-61. Sample size less
than 50 patients
2498. Maller R, Ahrne H, Holmen C, et al. Once- versus
twice-daily amikacin regimen: efficacy and safety in
systemic gram-negative infections. Scandinavian
Amikacin Once Daily Study Group. Journal of
Antimicrobial Chemotherapy 1993; 31(6):939-48.
Not CKD treatment
2499. Maller R, Isaksson B, Nilsson L, et al. A study of
amikacin given once versus twice daily in serious
infections. Journal of Antimicrobial Chemotherapy
1988; 22(1):75-9. Sample size less than 50 patients
2500. Malleson PN, Lockitch G, Mackinnon M, et al. Renal
disease in chronic arthritis of childhood. A study of
urinary N-acetyl-beta-glucosaminidase and beta 2microglobulin excretion. Arthritis & Rheumatism
1990; 33(10):1560-6. Not CKD treatment
2501. Mallett C, House AA, Spence JD, et al. Longitudinal
ultrasound evaluation of carotid atherosclerosis in
one, two and three dimensions. Ultrasound in
Medicine & Biology 2009; 35(3):367-75. Sample
size less than 50 patients
2502. Mallick NP. Dietary protein and progression of
chronic renal disease. BMJ 1994; 309(6962):1101-2.
Not CKD treatment
2503. Malmstrom H, Rasmussen S, Simonsen E.
Intraperitoneal high-dose cisplatin and etoposide
with systemic thiosulfate protection in second-line
treatment of advanced ovarian cancer. Gynecologic
Oncology 1993; 49(2):166-71. Not CKD treatment
2504. Malnick SDH, Somin M. The VALIDD study.
Lancet 2007; 370(9591):931; author reply -2. Sample
size less than 50 patients
2505. Malvy D, Maingourd C, Pengloan J, et al. Effects of
severe protein restriction with ketoanalogues in
advanced renal failure. Journal of the American
College of Nutrition 1999; 18(5):481-6. Not early
CKD
2506. Man in't Veld AJ. Clinical overview of irbesartan:
expanding the therapeutic window in hypertension.
Journal of Hypertension - Supplement 1997;
15(7):S27-33. Not relevant to key questions
2507. Manasia AR, Leibowitz AB, Miller CM, et al.
Postoperative intravenous infusion of alprostadil
(PGE1) does not improve renal function in hepatic
transplant recipients. Journal of the American
College of Surgeons 1996; 182(4):347-52. Sample
size less than 50 patients
2508. Manche A, Galea J, Busuttil W. Tolerance to ACE
inhibitors after cardiac surgery. European Journal of
Cardio-Thoracic Surgery 1999; 15(1):55-60. Not
CKD treatment
2509. Mancia G. ADVANCE: a new era in diabetes and
hypertension. Introduction. Journal of Hypertension Supplement 2008; 26(2):S1. Not RCT or controlled
trial
2510. Mandhani A, Kapoor R, Zaman W, et al. Is a 2-week
duration sufficient for stenting in endopyelotomy?
Journal of Urology 2003; 169(3):886-9. Not CKD
treatment
2511. Manley HJ. Role of angiotensin-converting-enzyme
inhibition in patients with renal disease. American
Journal of Health-System Pharmacy 2000; 57 Suppl
1:S12-8. Not relevant to key questions
2512. Manley KJ, Fraenkel MB, Mayall BC, et al. Probiotic
treatment of vancomycin-resistant enterococci: a
randomised controlled trial. Medical Journal of
Australia 2007; 186(9):454-7. Follow-up less than 6
months
2513. Manlucu J, Tonelli M, Ray JG, et al. Dose-reducing
H2 receptor antagonists in the presence of low
glomerular filtration rate: a systematic review of the
evidence. Nephrology Dialysis Transplantation 2005;
20(11):2376-84. Follow-up less than 6 months
2514. Mann JF. Ace inhibition in chronic renal failure: a
step forward. Nephrology Dialysis Transplantation
1996; 11(6):932-3. Not RCT or controlled trial
2515. Mann JF. What are the short-term and long-term
consequences of anaemia in CRF patients?
Nephrology Dialysis Transplantation 1999; 14 Suppl
2:29-36. Not RCT or controlled trial
2516. Mann JF. Valsartan and the kidney: present and
future. Journal of Cardiovascular Pharmacology
1999; 33 Suppl 1:S37-40; discussion S1-3. Not RCT
or controlled trial
2517. Mann JF. Should the results of the HOPE study
affect nephrological practice? For the HOPE
investigators. Nephrology Dialysis Transplantation
2000; 15(4):453-4. Not relevant to key questions
2518. Mann JF, Gerstein HC, Pogue J, et al. Renal
insufficiency as a predictor of cardiovascular
outcomes and the impact of ramipril: the HOPE
randomized trial. Annals of Internal Medicine 2001;
134(8):629-36. Not relevant to key questions
2519. Mann JF, Hilgers KF, Veelken R, et al. Effect of
antihypertensive therapy on the progression of nondiabetic renal disease. Clinical Nephrology 1992; 38
Suppl 1:S74-7. Not relevant to key questions
2520. Mann JF, Reisch C, Bergbreiter R, et al. Effects of
WY 47987 (atrial natriuretic factor 102-126) in
patients with renal insufficiency: a placebocontrolled, randomised study. Nephrology Dialysis
Transplantation 1989; 4(9):776-81. Sample size less
than 50 patients
2521. Mann JFE. Cardiovascular risk in patients with mild
renal insufficiency: implications for the use of ACE
inhibitors. Presse Medicale 2005; 34(18):1303-8. Not
relevant to key questions
2522. Mann JFE, Gerstein HC, Yi Q-L, et al. Development
of renal disease in people at high cardiovascular risk:
results of the HOPE randomized study. Journal of the
American Society of Nephrology 2003; 14(3):641-7.
Not relevant to key questions
2523. Mann JFE, Green D, Jamerson K, et al. Avosentan
for overt diabetic nephropathy. Journal of the
American Society of Nephrology 2010; 21(3):52735. Not CKD treatment
B-151
2524. Mann JFE, Lonn EM, Yi Q, et al. Effects of vitamin
E on cardiovascular outcomes in people with mildto-moderate renal insufficiency: results of the HOPE
study. Kidney International 2004; 65(4):1375-80. Not
CKD treatment
2525. Manns B, Stevens L, Miskulin D, et al. A systematic
review of sevelamer in ESRD and an analysis of its
potential economic impact in Canada and the United
States. Kidney International 2004; 66(3):1239-47.
Not CKD treatment
2526. Manske CL, Wang Y, Rector T, et al. Coronary
revascularisation in insulin-dependent diabetic
patients with chronic renal failure. Lancet 1992;
340(8826):998-1002. Not CKD treatment
2527. Mansour G, Mansour J. Autoregulated glomerular
filtration rate during candesartan treatment in
hypertensive type 2 diabetic patients. Current
Hypertension Reports 2002; 4(6):437-8. Not RCT or
controlled trial
2528. Mansson W, Ahlgren G, White T. Glomerular
filtration rate up to 10 years after urinary diversion of
different types. A comparative study of ileal and
colonic conduit, refluxing and antirefluxing ureteral
anastomosis and continent caecal reservoir.
Scandinavian Journal of Urology & Nephrology
1989; 23(3):195-200. Not CKD treatment
2529. Mansy H, Goodship TH, Tapson JS, et al. Effect of a
high protein diet in patients with the nephrotic
syndrome. Clinical Science 1989; 77(4):445-51.
Sample size less than 50 patients
2530. Marathias KP, Vassili M, Robola A, et al.
Preoperative intravenous hydration confers
renoprotection in patients with chronic kidney
disease undergoing cardiac surgery. Artificial Organs
2006; 30(8):615-21. Follow-up less than 6 months
2531. Marchais SJ, Boussac I, Guerin AP, et al.
Arteriosclerosis and antihypertensive response to
calcium antagonists in end-stage renal failure.
Journal of Cardiovascular Pharmacology 1991; 18
Suppl 1:S74-8. Not early CKD
2532. Marcus J, Sarnak MJ, Menon V. Homocysteine
lowering and cardiovascular disease risk: lost in
translation. Canadian Journal of Cardiology 2007;
23(9):707-10. Not RCT or controlled trial
2533. Marcus LS, Hart D, Packer M, et al. Hemodynamic
and renal excretory effects of human brain natriuretic
peptide infusion in patients with congestive heart
failure. A double-blind, placebo-controlled,
randomized crossover trial. Circulation 1996;
94(12):3184-9. Not CKD treatment
2534. Marcus R, Butterfield G, Holloway L, et al. Effects
of short term administration of recombinant human
growth hormone to elderly people. Journal of
Clinical Endocrinology & Metabolism 1990;
70(2):519-27. Sample size less than 50 patients
2535. Marenzi G, Assanelli E, Marana I, et al. Nacetylcysteine and contrast-induced nephropathy in
primary angioplasty. New England Journal of
Medicine 2006; 354(26):2773-82. Sample size less
than 50 patients
2536. Marier J-F, Lee J, Kambhampati SRP, et al. Effect of
repeated oral administrations of the oral adsorbent
AST-120 on serum creatinine and other markers of
renal function. A randomized controlled study in
patients with chronic kidney disease. American
Journal of Nephrology 2006; 26(2):136-41. Not RCT
or controlled trial
2537. Marik PE. Low-dose dopamine: a systematic review.
Intensive Care Medicine 2002; 28(7):877-83. Not
early CKD
2538. Marik PE, Iglesias J. Low-dose dopamine does not
prevent acute renal failure in patients with septic
shock and oliguria. NORASEPT II Study
Investigators. American Journal of Medicine 1999;
107(4):387-90. Follow-up less than 6 months
2539. Marin R, Ruilope LM, Aljama P, et al. A random
comparison of fosinopril and nifedipine GITS in
patients with primary renal disease. Journal of
Hypertension 2001; 19(10):1871-6. Not early CKD
2540. Marincola FM, White DE, Wise AP, et al.
Combination therapy with interferon alfa-2a and
interleukin-2 for the treatment of metastatic cancer.
Journal of Clinical Oncology 1995; 13(5):1110-22.
Not RCT or controlled trial
2541. Maroni BJ, Tom K, Masud T, et al. How is lean body
mass conserved with the very-low protein diet
regimen? Mineral & Electrolyte Metabolism 1996;
22(1-3):54-7. Follow-up less than 6 months
2542. Marre M. Microalbuminuria and ACE inhibition in
non-hypertensive diabetics. Journal of Diabetic
Complications 1990; 4(2):84-5. Sample size less than
50 patients
2543. Marre M. Recent advance in the treatment of diabetic
nephropathy: angiotensin I converting enzyme
(ACE) inhibitors. Journal of Diabetic Complications
1991; 5(2-3):91. Sample size less than 50 patients
2544. Marre M, Chatellier G, Leblanc H, et al. Prevention
of diabetic nephropathy with enalapril in
normotensive diabetics with microalbuminuria. BMJ
1988; 297(6656):1092-5. Sample size less than 50
patients
2545. Marre M, Hallab M, Billiard A, et al. Small doses of
ramipril to reduce microalbuminuria in diabetic
patients with incipient nephropathy independently of
blood pressure changes. Journal of Cardiovascular
Pharmacology 1991; 18 Suppl 2:S165-8. Sample size
less than 50 patients
2546. Marre M, Leblanc H, Suarez L, et al. Converting
enzyme inhibition and kidney function in
normotensive diabetic patients with persistent
microalbuminuria. British Medical Journal Clinical
Research Ed. 1987; 294(6585):1448-52. Sample size
less than 50 patients
2547. Marre M, Lievre M, Chatellier G, et al. ACE
inhibitors and diabetics with albuminuria. The
DIABHYCAR Study Group. Lancet 1995;
346(8990):1638. Not RCT or controlled trial
2548. Marre M, Lievre M, Vasmant D, et al. Determinants
of elevated urinary albumin in the 4,937 type 2
diabetic subjects recruited for the DIABHYCAR
Study in Western Europe and North Africa. Diabetes
Care 2000; 23 Suppl 2:B40-8. Not RCT or controlled
trial
B-152
2549. Marrocco-Trischitta MM, Melissano G, Kahlberg A,
et al. Glomerular filtration rate after left renal vein
division and reconstruction during infrarenal aortic
aneurysm repair. Journal of Vascular Surgery 2007;
45(3):481-6. Not RCT or controlled trial
2550. Marsell R, Grundberg E, Krajisnik T, et al. Fibroblast
growth factor-23 is associated with parathyroid
hormone and renal function in a population-based
cohort of elderly men. European Journal of
Endocrinology 2008; 158(1):125-9. Not CKD
treatment
2551. Marshall MR, Song Q, Ma TM, et al. Evolving
connectionist system versus algebraic formulas for
prediction of renal function from serum creatinine.
Kidney International 2005; 67(5):1944-54. Not RCT
or controlled trial
2552. Marshall SM. Screening for microalbuminuria:
which measurement? Diabetic Medicine 1991;
8(8):706-11. Not CKD treatment
2553. Marshall SM. HOPE for all people with diabetes?
Heart Outcomes Prevention Evaluation. Diabetic
Medicine 2000; 17 Suppl 2:9-10. Not relevant to key
questions
2554. Marshall SM, Shearing PA, Shelley JH, et al. The
effect of bromhexine on albumin excretion in insulin
dependent diabetes. Diabete et Metabolisme 1991;
17(3):332-6. Sample size less than 50 patients
2555. Marso SP, Ellis SG, Tuzcu M, et al. The importance
of proteinuria as a determinant of mortality following
percutaneous coronary revascularization in diabetics.
Journal of the American College of Cardiology 1999;
33(5):1269-77. Not RCT or controlled trial
2556. Marti H-P, Frey FJ. Nephrotoxicity of rapamycin: an
emerging problem in clinical medicine. Nephrology
Dialysis Transplantation 2005; 20(1):13-5. Not RCT
or controlled trial
2557. Martin KJ. The first human cell line-derived
erythropoietin, epoetin-delta (Dynepo), in the
management of anemia in patients with chronic
kidney disease. Clinical Nephrology 2007; 68(1):2631. Not RCT or controlled trial
2558. Martin KJ, Gonzalez EA, Gellens ME, et al. Therapy
of secondary hyperparathyroidism with 19-nor1alpha,25-dihydroxyvitamin D2. American Journal
of Kidney Diseases 1998; 32(2 Suppl 2):S61-6.
Sample size less than 50 patients
2559. Martin P, Tindall H, Rice P, et al. Effects of
pimobendan (UDCG 115) on renal function in
healthy volunteers. Journal of International Medical
Research 1992; 20(3):267-72. Sample size less than
50 patients
2560. Martinez I, Saracho R, Montenegro J, et al. The
importance of dietary calcium and phosphorous in
the secondary hyperparathyroidism of patients with
early renal failure. American Journal of Kidney
Diseases 1997; 29(4):496-502. Follow-up less than 6
months
2561. Martinez Martin FJ. Manidipine in hypertensive
patients with metabolic syndrome: the MARIMBA
study. Expert Review of Cardiovascular Therapy
2009; 7(7):863-9. Follow-up less than 6 months
2562. Martinez-Martin FJ, Saiz-Satjes M. Add-on
manidipine versus amlodipine in diabetic patients
with hypertension and microalbuminuria: the
AMANDHA study. Expert Review of Cardiovascular
Therapy 2008; 6(10):1347-55. Not CKD treatment
2563. Martino G, Frusciante V, Varraso A, et al. Efficacy
of 51Cr-EDTA clearance to tailor a carboplatin
therapeutic regimen in ovarian cancer patients.
Anticancer Research 1999; 19(6C):5587-91. Sample
size less than 50 patients
2564. Martins D, Norris K. Combating diabetic
nephropathy with drug therapy. Current Diabetes
Reports 2001; 1(2):148-56. Not RCT or controlled
trial
2565. Masala A, Faedda R, Alagna S, et al. Use of
testosterone to prevent cyclophosphamide-induced
azoospermia. Annals of Internal Medicine 1997;
126(4):292-5. Sample size less than 50 patients
2566. Maschio G, Alberti D, Locatelli F, et al. Angiotensinconverting enzyme inhibitors and kidney protection:
the AIPRI trial. The ACE Inhibition in Progressive
Renal Insufficiency (AIPRI) Study Group. Journal of
Cardiovascular Pharmacology 1999; 33 Suppl 1:S1620; discussion S41-3. Not relevant to key questions
2567. Massarella JW, Nazareno LA, Passe S, et al. The
effect of probenecid on the pharmacokinetics of
zalcitabine in HIV-positive patients. Pharmaceutical
Research 1996; 13(3):449-52. Sample size less than
50 patients
2568. Massy ZA. Therapy of hyperhomocysteinemia in
chronic kidney disease. Seminars in Nephrology
2006; 26(1):24-7. Follow-up less than 6 months
2569. Masud T, Young VR, Chapman T, et al. Adaptive
responses to very low protein diets: the first
comparison of ketoacids to essential amino acids.
Kidney International 1994; 45(4):1182-92. Sample
size less than 50 patients
2570. Masuda M, Yamada T, Mine T, et al. Comparison of
usefulness of sodium bicarbonate versus sodium
chloride to prevent contrast-induced nephropathy in
patients undergoing an emergent coronary procedure.
American Journal of Cardiology 2007; 100(5):781-6.
Not early CKD
2571. Masuda M, Yamada T, Okuyama Y, et al. Sodium
bicarbonate improves long-term clinical outcomes
compared with sodium chloride in patients with
chronic kidney disease undergoing an emergent
coronary procedure. Circulation Journal 2008;
72(10):1610-4. Not CKD treatment
2572. Masuda S-i, Tamura K, Wakui H, et al. Effects of
angiotensin II type 1 receptor blocker on ambulatory
blood pressure variability in hypertensive patients
with overt diabetic nephropathy. Hypertension
Research - Clinical & Experimental 2009;
32(11):950-5. Sample size less than 50 patients
2573. Mathew A, Eliasziw M, Devereaux PJ, et al. Carotid
endarterectomy benefits patients with CKD and
symptomatic high-grade stenosis. Journal of the
American Society of Nephrology 2010; 21(1):14552. Not RCT or controlled trial
2574. Mathew JT, Patni H, Chaudhary AN, et al.
Aldosterone induces mesangial cell apoptosis both in
B-153
vivo and in vitro. American Journal of Physiology Renal Physiology 2008; 295(1):F73-81. Not CKD
treatment
2575. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of
captopril in postponing nephropathy in normotensive
insulin dependent diabetic patients with
microalbuminuria. BMJ 1991; 303(6794):81-7. Not
relevant to key questions
2576. Mathiesen ER, Hommel E, Hansen HP, et al.
Randomised controlled trial of long term efficacy of
captopril on preservation of kidney function in
normotensive patients with insulin dependent
diabetes and microalbuminuria. BMJ 1999;
319(7201):24-5. Sample size less than 50 patients
2577. Mathiesen ER, Hommel E, Olsen UB, et al. Elevated
urinary prostaglandin excretion and the effect of
indomethacin on renal function in incipient diabetic
nephropathy. Diabetic Medicine 1988; 5(2):145-9.
Sample size less than 50 patients
2578. Mathur RP, Dash SC, Gupta N, et al. Effects of
correction of metabolic acidosis on blood urea and
bone metabolism in patients with mild to moderate
chronic kidney disease: a prospective randomized
single blind controlled trial. Renal Failure 2006;
28(1):1-5. Not RCT or controlled trial
2579. Mathur VS. Pathophysiology of radiocontrast
nephropathy and use of fenoldopam for its
prevention. Reviews in Cardiovascular Medicine
2001; 2 Suppl 1:S4-8. Not CKD treatment
2580. Mathur VS. The role of the DA1 receptor agonist
fenoldopam in the management of critically ill,
transplant, and hypertensive patients. Reviews in
Cardiovascular Medicine 2003; 4 Suppl 1:S35-40.
Not CKD treatment
2581. Mathur VS, Swan SK, Lambrecht LJ, et al. The
effects of fenoldopam, a selective dopamine receptor
agonist, on systemic and renal hemodynamics in
normotensive subjects. Critical Care Medicine 1999;
27(9):1832-7. Follow-up less than 6 months
2582. Matin SF. Laparoscopic approaches to urologic
malignancies. Current Treatment Options in
Oncology 2003; 4(5):373-83. Not CKD treatment
2583. Matos JPS, de Lourdes Rodrigues M, Ismerim VL, et
al. Effects of dual blockade of the renin angiotensin
system in hypertensive type 2 diabetic patients with
nephropathy. Clinical Nephrology 2005; 64(3):180-9.
Not RCT or controlled trial
2584. Matsuda H, Hayashi K, Homma K, et al. Differing
anti-proteinuric action of candesartan and losartan in
chronic renal disease. Hypertension Research Clinical & Experimental 2003; 26(11):875-80.
Follow-up less than 6 months
2585. Matsuda H, Hayashi K, Saruta T. Distinct time
courses of renal protective action of angiotensin
receptor antagonists and ACE inhibitors in chronic
renal disease. Journal of Human Hypertension 2003;
17(4):271-6. Not CKD treatment
2586. Matsumoto H, Nakao T, Okada T, et al. Favorable
outcome of low-dose cyclosporine after pulse
methylprednisolone in Japanese adult minimalchange nephrotic syndrome. Internal Medicine 2004;
43(8):668-73. Not RCT or controlled trial
2587. Matsumura C, Kemmotsu O, Kawano Y, et al. Serum
and urine inorganic fluoride levels following
prolonged low-dose sevoflurane anesthesia combined
with epidural block. Journal of Clinical Anesthesia
1994; 6(5):419-24. Sample size less than 50 patients
2588. Matthews DR, Stratton IM, Aldington SJ, et al. Risks
of progression of retinopathy and vision loss related
to tight blood pressure control in type 2 diabetes
mellitus: UKPDS 69. Archives of Ophthalmology
2004; 122(11):1631-40. Not CKD treatment
2589. Matz GJ. Aminoglycoside ototoxicity. American
Journal of Otolaryngology 1986; 7(2):117-9. Not
relevant to key questions
2590. Mauer M, Zinman B, Gardiner R, et al. ACE-I and
ARBs in early diabetic nephropathy. Journal of the
Renin-Angiotensin-Aldosterone System 2002;
3(4):262-9. Not early CKD
2591. Mauer M, Zinman B, Gardiner R, et al. Renal and
retinal effects of enalapril and losartan in type 1
diabetes. New England Journal of Medicine 2009;
361(1):40-51. Not relevant to key questions
2592. Mauer M, Zinman B, Gardiner R, et al. Renal and
retinal effects of enalapril and losartan in type 1
diabetes. New England Journal of Medicine 2009;
361(1):40-51. Not relevant to key questions
2593. Mauri JM, Valles M. Effects of recombinant
interleukin-2 and revaccination for hepatitis B in
previously vaccinated, non-responder, chronic
uraemic patients. Collaborative Group of Girona.
Nephrology Dialysis Transplantation 1997;
12(4):729-32. Not CKD treatment
2594. Mauro LS, Kuhl DA, Kirchhoff JR, et al. Impact of
oral bases on aluminum absorption. American
Journal of Therapeutics 2001; 8(1):21-5. Not early
CKD
2595. Mayer AF, Schroeder C, Heusser K, et al. Influences
of norepinephrine transporter function on the
distribution of sympathetic activity in humans.
Hypertension 2006; 48(1):120-6. Not early CKD
2596. Mayer SA, Solomon RA, Fink ME, et al. Effect of
5% albumin solution on sodium balance and blood
volume after subarachnoid hemorrhage.
Neurosurgery 1998; 42(4):759-67; discussion 67-8.
Not CKD treatment
2597. Mazze RS, Bergenstal R, Ginsberg B. Intensified
diabetes management: lessons from the diabetes
control and complications trial. International Journal
of Clinical Pharmacology & Therapeutics 1995;
33(1):43-51. Not RCT or controlled trial
2598. Mazzeo AT, Brophy GM, Gilman CB, et al. Safety
and tolerability of cyclosporin a in severe traumatic
brain injury patients: results from a prospective
randomized trial. Journal of Neurotrauma 2009;
26(12):2195-206. Not CKD treatment
2599. McAlister FA, Levine M, Zarnke KB, et al. The 2000
Canadian recommendations for the management of
hypertension: Part one--therapy. Canadian Journal of
Cardiology 2001; 17(5):543-59. Not early CKD
2600. McAuliffe AV, Brooks BA, Fisher EJ, et al.
Administration of ascorbic acid and an aldose
reductase inhibitor (tolrestat) in diabetes: effect on
B-154
urinary albumin excretion. Nephron 1998; 80(3):27784. Sample size less than 50 patients
2601. McBride WT, Allen S, Gormley SMC, et al.
Methylprednisolone favourably alters plasma and
urinary cytokine homeostasis and subclinical renal
injury at cardiac surgery. Cytokine 2004; 27(2-3):819. Sample size less than 50 patients
2602. McCance-Katz EF, Rainey PM, Jatlow P, et al.
Methadone effects on zidovudine disposition (AIDS
Clinical Trials Group 262). Journal of Acquired
Immune Deficiency Syndromes & Human
Retrovirology 1998; 18(5):435-43. Not CKD
treatment
2603. McCarthy ML, Stoukides CA. Estrogen therapy of
uremic bleeding. Annals of Pharmacotherapy 1994;
28(1):60-2. Not relevant to key questions
2604. McClean DR, Ikram H, Garlick AH, et al. The
clinical, cardiac, renal, arterial and neurohormonal
effects of omapatrilat, a vasopeptidase inhibitor, in
patients with chronic heart failure. Journal of the
American College of Cardiology 2000; 36(2):479-86.
Not early CKD
2605. McClellan WM, Knight DF, Karp H, et al. Early
detection and treatment of renal disease in
hospitalized diabetic and hypertensive patients:
important differences between practice and published
guidelines. American Journal of Kidney Diseases
1997; 29(3):368-75. Not RCT or controlled trial
2606. McClellan WM, Langston RD, Presley R. Medicare
patients with cardiovascular disease have a high
prevalence of chronic kidney disease and a high rate
of progression to end-stage renal disease. Journal of
the American Society of Nephrology 2004;
15(7):1912-9. Not CKD treatment
2607. McClellan WM, Ramirez SPB, Jurkovitz C.
Screening for chronic kidney disease: unresolved
issues. Journal of the American Society of
Nephrology 2003; 14(7 Suppl 2):S81-7. Not CKD
treatment
2608. McConaghy JR. What is the best treatment for
slowing the progression to end-stage renal disease
(ESRD) in African Americans with hypertensive
nephropathy? Journal of Family Practice 2001;
50(9):744. Not RCT or controlled trial
2609. McCormack PL, Wagstaff AJ. Lacidipine: a review
of its use in the management of hypertension. Drugs
2003; 63(21):2327-56. Not RCT or controlled trial
2610. McCormack PM, Cox JP, Marron J, et al. The
antihypertensive efficacy of ketanserin in the elderly
evaluated by ambulatory blood pressure
measurement. Journal of Human Hypertension 1990;
4(5):565-70. Sample size less than 50 patients
2611. McCormick BB, Sydor A, Akbari A, et al. The effect
of pentoxifylline on proteinuria in diabetic kidney
disease: a meta-analysis. American Journal of
Kidney Diseases 2008; 52(3):454-63. Not CKD
treatment
2612. McCormick PA, Greenslade L, Kibbler CC, et al. A
prospective randomized trial of ceftazidime versus
netilmicin plus mezlocillin in the empirical therapy
of presumed sepsis in cirrhotic patients. Hepatology
1997; 25(4):833-6. Not CKD treatment
2613. McCullough PA. Evaluation and treatment of
coronary artery disease in patients with end-stage
renal disease. Kidney International - Supplement
2005; (95):S51-8. Not RCT or controlled trial
2614. McCullough PA. Multimodality prevention of
contrast-induced acute kidney injury. American
Journal of Kidney Diseases 2008; 51(2):169-72. Not
CKD treatment
2615. McCullough PA, Agrawal V, Danielewicz E, et al.
Accelerated atherosclerotic calcification and
Monckeberg's sclerosis: a continuum of advanced
vascular pathology in chronic kidney disease.
Clinical Journal of The American Society of
Nephrology: CJASN 2008; 3(6):1585-98. Not CKD
treatment
2616. McCullough PA, Bertrand ME, Brinker JA, et al. A
meta-analysis of the renal safety of isosmolar
iodixanol compared with low-osmolar contrast
media. Journal of the American College of
Cardiology 2006; 48(4):692-9. Not relevant to key
questions
2617. McCullough PA, Li S, Jurkovitz CT, et al. CKD and
cardiovascular disease in screened high-risk
volunteer and general populations: the Kidney Early
Evaluation Program (KEEP) and National Health and
Nutrition Examination Survey (NHANES) 19992004. American Journal of Kidney Diseases 2008;
51(4 Suppl 2):S38-45. Not CKD treatment
2618. McDiarmid SV, Colonna JO, 2nd, Shaked A, et al. A
comparison of renal function in cyclosporine- and
FK-506-treated patients after primary orthotopic liver
transplantation. Transplantation 1993; 56(4):847-53.
Follow-up less than 6 months
2619. McDonald V, Leandro M. Rituximab in nonhaematological disorders of adults and its mode of
action. British Journal of Haematology 2009;
146(3):233-46. Not CKD treatment
2620. McGee WT, Mailloux P, Jodka P, et al. The
pulmonary artery catheter in critical care. Seminars
in Dialysis 2006; 19(6):480-91. Follow-up less than
6 months
2621. McGill JB. Improving microvascular outcomes in
patients with diabetes through management of
hypertension. Postgraduate Medicine 2009;
121(2):89-101. Not RCT or controlled trial
2622. McGowan T, Vaccaro NM, Beaver JS, et al.
Pharmacokinetic and pharmacodynamic profiles of
extended dosing of epoetin alfa in anemic patients
who have chronic kidney disease and are not on
dialysis. Clinical Journal of The American Society of
Nephrology: CJASN 2008; 3(4):1006-14. Sample
size less than 50 patients
2623. McGregor DO, Dellow WJ, Robson RA, et al.
Betaine supplementation decreases post-methionine
hyperhomocysteinemia in chronic renal failure.
Kidney International 2002; 61(3):1040-6. Sample
size less than 50 patients
2624. McInnes GT. Angiotensin II antagonism in clinical
practice: experience with valsartan. Journal of
Cardiovascular Pharmacology 1999; 33 Suppl 1:S2932; discussion S41-3. Not RCT or controlled trial
B-155
2625. McInnes GT. The expanding role of angiotensin
receptor blockers in the management of the elderly
hypertensive. Current Medical Research & Opinion
2003; 19(5):452-5. Not relevant to key questions
2626. McKee MD, Cecco SA, Niemela JE, et al. Effects of
interleukin 2 therapy on lymphocyte magnesium
levels. Journal of Laboratory & Clinical Medicine
2002; 139(1):5-12. Not early CKD
2627. McKenna F, Davison AM. Renin and beta-blockade:
prorenin and aldosterone may explain the
controversy. Clinical Nephrology 1986; 25(3):14954. Sample size less than 50 patients
2628. McKenna K, Smith D, Barrett P, et al. Angiotensinconverting enzyme inhibition by quinapril blocks the
albuminuric effect of atrial natriuretic peptide in
Type 1 diabetes and microalbuminuria. Diabetic
Medicine 2000; 17(3):219-24. Sample size less than
50 patients
2629. McKinnon PS, Paladino JA, Schentag JJ. Evaluation
of area under the inhibitory curve (AUIC) and time
above the minimum inhibitory concentration
(T>MIC) as predictors of outcome for cefepime and
ceftazidime in serious bacterial infections.
International Journal of Antimicrobial Agents 2008;
31(4):345-51. Not early CKD
2630. McLachlan S-A, Cameron D, Murray R, et al. Safety
of oral ibandronate in the treatment of bone
metastases from breast cancer : long-term follow-up
experience. Clinical Drug Investigation 2006;
26(1):43-8. Not CKD treatment
2631. McMahon LP, Mason K, Skinner SL, et al. Effects of
haemoglobin normalization on quality of life and
cardiovascular parameters in end-stage renal failure.
Nephrology Dialysis Transplantation 2000;
15(9):1425-30. Sample size less than 50 patients
2632. McMurray J. Angiotensin receptor blockers and
myocardial infarction: analysis of evidence is
incomplete and inaccurate. BMJ 2005;
330(7502):1269; author reply 70-1. Not RCT or
controlled trial
2633. McMurray J, Seidelin PH, Struthers AD. Evidence
for a proximal and distal nephron action of atrial
natriuretic factor in man. Nephron 1989; 51(1):39-43.
Not CKD treatment
2634. McMurray J, Struthers AD. Effects of angiotensin II
and atrial natriuretic peptide alone and in
combination on urinary water and electrolyte
excretion in man. Clinical Science 1988; 74(4):41925. Not RCT or controlled trial
2635. McMurray JJ, Seidelin PH, Brown RA, et al.
Noradrenaline attenuates the natriuretic effect of
atrial natriuretic factor in man. British Journal of
Clinical Pharmacology 1989; 27(1):7-12. Not CKD
treatment
2636. McNabb WR, Noormohamed FH, Lant AF. The
effects of enalapril on blood pressure and the kidney
in normotensive subjects under altered sodium
balance. Journal of Hypertension 1986; 4(1):39-47.
Sample size less than 50 patients
2637. McParland P, Pearce JM, Chamberlain GV. Doppler
ultrasound and aspirin in recognition and prevention
of pregnancy-induced hypertension. Lancet 1990;
335(8705):1552-5. Not early CKD
2638. McQueen MJ, Lonn E, Gerstein HC, et al. The
HOPE (Heart Outcomes Prevention Evaluation)
Study and its consequences. Scandinavian Journal of
Clinical and Laboratory Investigation Supplement
2005; 240:143-56. Not RCT or controlled trial
2639. Mechl Z, Kerpel-Fronius S, Decker A, et al.
Comparative evaluation of two administration
schedules of cis-dichlorodiammineplatinum (DDP) in
ovarian and head and neck cancers: a CMEA
chemotherapy group study. Neoplasma 1987;
34(1):37-43. Follow-up less than 6 months
2640. Medina HJ, Galvin EM, Dirckx M, et al.
Remifentanil as a single drug for extracorporeal
shock wave lithotripsy: a comparison of infusion
doses in terms of analgesic potency and side effects.
Anesthesia & Analgesia 2005; 101(2):365-70.
Follow-up less than 6 months
2641. Mehdi U, Toto RD. Anemia, diabetes, and chronic
kidney disease. Diabetes Care 2009; 32(7):1320-6.
Not RCT or controlled trial
2642. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition
of angiotensin receptor blockade or
mineralocorticoid antagonism to maximal
angiotensin-converting enzyme inhibition in diabetic
nephropathy. Journal of the American Society of
Nephrology 2009; 20(12):2641-50. Duplicate listings
2643. Mehls O, Haas S. Effects of recombinant human
growth hormone in catabolic adults with chronic
renal failure. Growth Hormone & Igf Research 2000;
10 Suppl B:S31-7. Not relevant to key questions
2644. Mehls O, Knoller N, Oh J, et al. Daily but not pulse
calcitriol therapy improves growth in experimental
uremia. Pediatric Nephrology 2000; 14(7):658-63.
Not human studies
2645. Mehran R, Ashby DT. Radiocontrast-induced acute
renal failure: allocations and outcomes. Reviews in
Cardiovascular Medicine 2001; 2 Suppl 1:S9-13. Not
CKD treatment
2646. Mehran R, Nikolsky E, Lansky AJ, et al. Impact of
chronic kidney disease on early (30-day) and late (1year) outcomes of patients with acute coronary
syndromes treated with alternative antithrombotic
treatment strategies: an ACUITY (Acute
Catheterization and Urgent Intervention Triage
strategY) substudy. Jacc: Cardiovascular
Interventions 2009; 2(8):748-57. Not CKD treatment
2647. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic
pharmacokinetic and pharmacodynamic
considerations in critical illness. Intensive Care
Medicine 2004; 30(12):2145-56. Not RCT or
controlled trial
2648. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic
kidney disease, hypovitaminosis D, and mortality in
the United States. Kidney International 2009;
76(9):977-83. Not RCT or controlled trial
2649. Mehta RL, Pascual MT, Soroko S, et al. Diuretics,
mortality, and nonrecovery of renal function in acute
renal failure. JAMA 2002; 288(20):2547-53. Not
CKD treatment
B-156
2650. Meier P, Ko DT, Tamura A, et al. Sodium
bicarbonate-based hydration prevents contrastinduced nephropathy: a meta-analysis. BMC
Medicine 2009; 7:23. Not early CKD
2651. Meisinger E, Strauch M. Controlled trial of two keto
acid supplements on renal function, nutritional status,
and bone metabolism in uremic patients. Kidney
International - Supplement 1987; 22:S170-3. Not
RCT or controlled trial
2652. Melin B, Jimenez C, Koulmann N, et al.
Hyperhydration induced by glycerol ingestion:
hormonal and renal responses. Canadian Journal of
Physiology & Pharmacology 2002; 80(6):526-32.
Not early CKD
2653. Melis D, Parenti G, Gatti R, et al. Efficacy of ACEinhibitor therapy on renal disease in glycogen storage
disease type 1: a multicentre retrospective study.
Clinical Endocrinology 2005; 63(1):19-25. Sample
size less than 50 patients
2654. Mellor JA, Kingdom J, Cafferkey M, et al.
Vancomycin toxicity: a prospective study. Journal of
Antimicrobial Chemotherapy 1985; 15(6):773-80.
Sample size less than 50 patients
2655. Meloni C, Morosetti M, Suraci C, et al. Severe
dietary protein restriction in overt diabetic
nephropathy: benefits or risks? Journal of Renal
Nutrition 2002; 12(2):96-101. Not relevant to key
questions
2656. Meloni C, Tatangelo P, Cipriani S, et al. Adequate
protein dietary restriction in diabetic and nondiabetic
patients with chronic renal failure. Journal of Renal
Nutrition 2004; 14(4):208-13. Not relevant to key
questions
2657. Mena AC, Pulido EG, Guillen-Ponce C.
Understanding the molecular-based mechanism of
action of the tyrosine kinase inhibitor: sunitinib.
Anti-Cancer Drugs 2010; 21 Suppl 1:S3-11. Not
CKD treatment
2658. Mendelssohn DC, Muirhead N, Manns BJ. Managing
anemia. What do we do now? Views from Canada.
Nephrology News & Issues 2007; 21(7):55-7.
Follow-up less than 6 months
2659. Menon V, Greene T, Pereira AA, et al. Glycosylated
hemoglobin and mortality in patients with
nondiabetic chronic kidney disease. Journal of the
American Society of Nephrology 2005; 16(11):34117. Follow-up less than 6 months
2660. Menon V, Greene T, Pereira AA, et al. Relationship
of phosphorus and calcium-phosphorus product with
mortality in CKD. American Journal of Kidney
Diseases 2005; 46(3):455-63. Follow-up less than 6
months
2661. Menon V, Greene T, Wang X, et al. C-reactive
protein and albumin as predictors of all-cause and
cardiovascular mortality in chronic kidney disease.
Kidney International 2005; 68(2):766-72. Not
relevant to key questions
2662. Menon V, Kopple JD, Wang X, et al. Effect of a very
low-protein diet on outcomes: long-term follow-up of
the Modification of Diet in Renal Disease (MDRD)
Study. American Journal of Kidney Diseases 2009;
53(2):208-17. Not CKD treatment
2663. Menon V, Li L, Wang X, et al. Adiponectin and
mortality in patients with chronic kidney disease.
Journal of the American Society of Nephrology
2006; 17(9):2599-606. Sample size less than 50
patients
2664. Menon V, Sarnak MJ, Greene T, et al. Relationship
between homocysteine and mortality in chronic
kidney disease. Circulation 2006; 113(12):1572-7.
Sample size less than 50 patients
2665. Menon V, Shlipak MG, Wang X, et al. Cystatin C as
a risk factor for outcomes in chronic kidney disease.
Annals of Internal Medicine 2007; 147(1):19-27.
Follow-up less than 6 months
2666. Menon V, Wang X, Greene T, et al. Relationship
between C-reactive protein, albumin, and
cardiovascular disease in patients with chronic
kidney disease. American Journal of Kidney
Diseases 2003; 42(1):44-52. Not CKD treatment
2667. Menon V, Wang X, Greene T, et al. Homocysteine in
chronic kidney disease: Effect of low protein diet and
repletion with B vitamins. Kidney International
2005; 67(4):1539-46. Not relevant to key questions
2668. Menon V, Wang X, Sarnak MJ, et al. Long-term
outcomes in nondiabetic chronic kidney disease.
Kidney International 2008; 73(11):1310-5. Not CKD
treatment
2669. Mercieri M, Mercieri A, Tritapepe L, et al. Highdose aprotinin with gentamicin-vancomycin
antibiotic prophylaxis increases blood concentrations
of creatinine and cystatin C in patients undergoing
coronary artery bypass grafting. British Journal of
Anaesthesia 1999; 82(4):531-6. Follow-up less than
6 months
2670. Meredith PA, Elliott HL, Pasanisi F, et al. Verapamil
pharmacokinetics and apparent hepatic and renal
blood flow. British Journal of Clinical Pharmacology
1985; 20(2):101-6. Sample size less than 50 patients
2671. Meredith PA, Pasanisi F, Elliott HL, et al. The effect
of nisoldipine on apparent liver blood flow and
effective renal plasma flow. British Journal of
Clinical Pharmacology 1985; 20(3):235-7. Sample
size less than 50 patients
2672. Merion RM. Prostaglandins in liver transplantation.
Advances in Experimental Medicine & Biology
1997; 433:13-8. Not CKD treatment
2673. Merkel C, Gatta A, Donada C, et al. Long-term effect
of nadolol or nadolol plus isosorbide-5-mononitrate
on renal function and ascites formation in patients
with cirrhosis. GTIP Gruppo Triveneto per
l'Ipertensione Portale. Hepatology 1995; 22(3):80813. Not CKD treatment
2674. Merten GJ, Burgess WP, Gray LV, et al. Prevention
of contrast-induced nephropathy with sodium
bicarbonate: a randomized controlled trial. JAMA
2004; 291(19):2328-34. Not relevant to key questions
2675. Mesotten D, Swinnen JV, Vanderhoydonc F, et al.
Contribution of circulating lipids to the improved
outcome of critical illness by glycemic control with
intensive insulin therapy. Journal of Clinical
Endocrinology & Metabolism 2004; 89(1):219-26.
Not relevant to key questions
B-157
Systematic Reviews 2009; (1):CD003595. Not early
CKD
2689. Michalopoulos A, Geroulanos S, Rosmarakis ES, et
al. Frequency, characteristics, and predictors of
microbiologically documented nosocomial infections
after cardiac surgery. European Journal of CardioThoracic Surgery 2006; 29(4):456-60. Not relevant
to key questions
2690. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Acute
decline in renal function, inflammation, and
cardiovascular risk after an acute coronary syndrome.
Clinical Journal of The American Society of
Nephrology: CJASN 2009; 4(11):1811-7. Not CKD
treatment
2691. Mielniczuk LM, Pfeffer MA, Lewis EF, et al.
Estimated glomerular filtration rate, inflammation,
and cardiovascular events after an acute coronary
syndrome. American Heart Journal 2008;
155(4):725-31. Not CKD treatment
2692. Mihatsch MJ, Helmchen U, Casanova P, et al.
Kidney biopsy findings in cyclosporine-treated
patients with insulin-dependent diabetes mellitus.
Klinische Wochenschrift 1991; 69(8):354-9. Not
CKD treatment
2693. Mihmanli I, Besirli K, Kurugoglu S, et al. Cephalic
vein and hemodialysis fistula: surgeon's observation
versus color Doppler ultrasonographic findings.
Journal of Ultrasound in Medicine 2001; 20(3):21722. Not early CKD
2694. Milas NC, Nowalk MP, Akpele L, et al. Factors
associated with adherence to the dietary protein
intervention in the Modification of Diet in Renal
Disease Study. Journal of the American Dietetic
Association 1995; 95(11):1295-300. Not CKD
treatment
2695. Miller CC, 3rd, Grimm JC, Estrera AL, et al.
Postoperative renal function preservation with
nonischemic femoral arterial cannulation for
thoracoabdominal aortic repair. Journal of Vascular
Surgery 2010; 51(1):38-42. Not RCT or controlled
trial
2696. Miller ER, 3rd, Juraschek SP, Appel LJ, et al. The
effect of n-3 long-chain polyunsaturated fatty acid
supplementation on urine protein excretion and
kidney function: meta-analysis of clinical trials.
American Journal of Clinical Nutrition 2009;
89(6):1937-45. Not CKD treatment
2697. Miller HI, Dascalu A, Rassin TA, et al. Effects of an
acute dose of L-arginine during coronary
angiography in patients with chronic renal failure: a
randomized, parallel, double-blind clinical trial.
American Journal of Nephrology 2003; 23(2):91-5.
Follow-up less than 6 months
2698. Miller JA. Impact of hyperglycemia on the renin
angiotensin system in early human type 1 diabetes
mellitus. Journal of the American Society of
Nephrology 1999; 10(8):1778-85. Sample size less
than 50 patients
2699. Miller MA, Texter M, Gmerek A, et al. Quinapril
hydrochloride effects on renal function in patients
with renal dysfunction and hypertension: a drug-
2676. Messa P, Macario F, Yaqoob M, et al. The OPTIMA
study: assessing a new cinacalcet
(Sensipar/Mimpara) treatment algorithm for
secondary hyperparathyroidism. Clinical Journal of
The American Society of Nephrology: CJASN 2008;
3(1):36-45. Not CKD treatment
2677. Messerli FH. Combinations in the treatment of
hypertension: ACE inhibitors and calcium
antagonists. American Journal of Hypertension 1999;
12(8 Pt 2):86S-90S. Not RCT or controlled trial
2678. Metra M, Dei Cas L. Clinical efficacy of ibopamine
in patients with chronic heart failure. Clinical
Cardiology 1995; 18(3 Suppl I):I22-31. Not CKD
treatment
2679. Metz U, Graben N, Maruhn D, et al. Urinary enzyme
excretion after a single dose of phenacetin and
paracetamol (acetaminophen) during antidiuresis and
during water diuresis. Clinica Chimica Acta 1986;
160(2):151-5. Sample size less than 50 patients
2680. Meyer M, Pfarr E, Schirmer G, et al. Therapeutic use
of the natriuretic peptide ularitide in acute renal
failure. Renal Failure 1999; 21(1):85-100. Not CKD
treatment
2681. Meyer M, Wiebe K, Wahlers T, et al. Urodilatin
(INN:ularitide) as a new drug for the therapy of acute
renal failure following cardiac surgery. Clinical &
Experimental Pharmacology & Physiology 1997;
24(5):374-6. Not CKD treatment
2682. Meyer RD. Risk factors and comparisons of clinical
nephrotoxicity of aminoglycosides. American
Journal of Medicine 1986; 80(6B):119-25. Not
relevant to key questions
2683. Meyrier A, Dratwa M, Sennesael J, et al. Fixed lowdose perindopril-indapamide combination in
hypertensive patients with chronic renal failure.
American Journal of Hypertension 1998; 11(9):108792. Sample size less than 50 patients
2684. Mezzano D, Tagle R, Pais E, et al. Endothelial cell
markers in chronic uremia: relationship with
hemostatic defects and severity of renal failure.
Thrombosis Research 1997; 88(6):465-72. Not RCT
or controlled trial
2685. Miao L, Sun J, Yuan H, et al. Combined therapy of
low-dose tacrolimus and prednisone in nephrotic
syndrome with slight mesangial proliferation.
Nephrology 2006; 11(5):449-54. Not RCT or
controlled trial
2686. Miceli JJ, Wilner KD, Swan SK, et al.
Pharmacokinetics, safety, and tolerability of
intramuscular ziprasidone in healthy volunteers.
Journal of Clinical Pharmacology 2005; 45(6):62030. Not relevant to key questions
2687. Michael M, Elliott EJ, Craig JC, et al. Interventions
for hemolytic uremic syndrome and thrombotic
thrombocytopenic purpura: a systematic review of
randomized controlled trials. American Journal of
Kidney Diseases 2009; 53(2):259-72. Not CKD
treatment
2688. Michael M, Elliott EJ, Ridley GF, et al. Interventions
for haemolytic uraemic syndrome and thrombotic
thrombocytopenic purpura. Cochrane Database of
B-158
withdrawal study. Cardiovascular Drugs & Therapy
1994; 8(2):271-5. Sample size less than 50 patients
2700. Miller PD, Roux C, Boonen S, et al. Safety and
efficacy of risedronate in patients with age-related
reduced renal function as estimated by the Cockcroft
and Gault method: a pooled analysis of nine clinical
trials. Journal of Bone & Mineral Research 2005;
20(12):2105-15. Not RCT or controlled trial
2701. Miller PD, Schwartz EN, Chen P, et al. Teriparatide
in postmenopausal women with osteoporosis and
mild or moderate renal impairment. Osteoporosis
International 2007; 18(1):59-68. Not relevant to key
questions
2702. Miller SB, Moulton M, O'Shea M, et al. Effects of
IGF-I on renal function in end-stage chronic renal
failure. Kidney International 1994; 46(1):201-7. Not
early CKD
2703. Millis JM, McDiarmid SV, Hiatt JR, et al.
Randomized prospective trial of OKT3 for early
prophylaxis of rejection after liver transplantation.
Transplantation 1989; 47(1):82-8. Not CKD
treatment
2704. Millward SF, Burbridge BE, Hartman NG, et al.
Nephrotoxicity of ioxaglate and ioversol assessed by
glomerular filtration rate: a pilot study. Canadian
Association of Radiologists Journal 1996; 47(1):249. Sample size less than 50 patients
2705. Mimran A, Alfaro V. Candesartan: nephroprotective
effects and treatment of diabetic nephropathy. Drugs
of Today 2003; 39(6):439-50. Not RCT or controlled
trial
2706. Mimran A, Insua A, Ribstein J, et al. Comparative
effect of captopril and nifedipine in normotensive
patients with incipient diabetic nephropathy.
Diabetes Care 1988; 11(10):850-3. Follow-up less
than 6 months
2707. Mimran A, Insua A, Ribstein J, et al. Contrasting
effects of captopril and nifedipine in normotensive
patients with incipient diabetic nephropathy. Journal
of Hypertension 1988; 6(11):919-23. Follow-up less
than 6 months
2708. Mimran A, Ribstein J, DuCailar G. Angiotensin II
receptor antagonists and hypertension. Clinical &
Experimental Hypertension 1999; 21(5-6):847-58.
Not RCT or controlled trial
2709. Mimura T, Takenaka T, Kanno Y, et al. Vascular
compliance is secured under angiotensin inhibition in
non-diabetic chronic kidney diseases. Journal of
Human Hypertension 2008; 22(1):38-47. Not RCT or
controlled trial
2710. Miner SES, Dzavik V, Nguyen-Ho P, et al. Nacetylcysteine reduces contrast-associated
nephropathy but not clinical events during long-term
follow-up. American Heart Journal 2004;
148(4):690-5. Not RCT or controlled trial
2711. Mineshita S, Toyoshima A, Yazaki T. Influence of
phenacetin and its metabolites on renal function.
Nippon Jinzo Gakkai Shi 1989; Japanese Journal of
Nephrology. 31(6):629-33. Sample size less than 50
patients
2712. Minetti EE, Cozzi MG, Guidi E. Long- versus shortterm effects of two different ACE inhibitors on renal
haemodynamics: preliminary results from an ongoing
trial. Nephrology Dialysis Transplantation 1995; 10
Suppl 6:18-21. Sample size less than 50 patients
2713. Minutolo R, Andreucci M, Balletta MM, et al. Effect
of posture on sodium excretion and diuretic efficacy
in nephrotic patients. American Journal of Kidney
Diseases 2000; 36(4):719-27. Not RCT or controlled
trial
2714. Miralles R, Cami J, Gutierrez J, et al. Diclofenac
versus dipyrone in acute renal colic: a double-blind
controlled trial. European Journal of Clinical
Pharmacology 1987; 33(5):527-8. Not CKD
treatment
2715. Miranda ME. The influence of allopurinol on renal
deterioration in familial nepropathy associated with
hyperuricemia (FNAH). The Spanish Group for the
Study of FNAH. Advances in Experimental
Medicine & Biology 1994; 370:61-4. Not CKD
treatment
2716. Mircescu G, Garneata L, Stancu SH, et al. Effects of
a supplemented hypoproteic diet in chronic kidney
disease. Journal of Renal Nutrition 2007; 17(3):17988. Not RCT or controlled trial
2717. Misra D, Leibowitz K, Gowda RM, et al. Role of Nacetylcysteine in prevention of contrast-induced
nephropathy after cardiovascular procedures: a metaanalysis. Clinical Cardiology 2004; 27(11):607-10.
Not relevant to key questions
2718. Mitaka C, Kudo T, Jibiki M, et al. Effects of human
atrial natriuretic peptide on renal function in patients
undergoing abdominal aortic aneurysm repair.
Critical Care Medicine 2008; 36(3):745-51. Not RCT
or controlled trial
2719. Mitchell HC, Smith RD, Cutler RE, et al. Racial
differences in the renal response to blood pressure
lowering during chronic angiotensin-converting
enzyme inhibition: a prospective double-blind
randomized comparison of fosinopril and lisinopril in
older hypertensive patients with chronic renal
insufficiency. American Journal of Kidney Diseases
1997; 29(6):897-906. Sample size less than 50
patients
2720. Mitrovic V, Seferovic P, Dodic S, et al. Cardio-renal
effects of the A1 adenosine receptor antagonist
SLV320 in patients with heart failure. Circulation:
Heart Failure 2009; 2(6):523-31. Not CKD treatment
2721. Mittleman KD. Influence of angiotensin II blockade
during exercise in the heat. European Journal of
Applied Physiology & Occupational Physiology
1996; 72(5-6):542-7. Not CKD treatment
2722. Mix TCH, Brenner RM, Cooper ME, et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp
Therapy (TREAT): evolving the management of
cardiovascular risk in patients with chronic kidney
disease.[Erratum appears in Am Heart J. 2005
Jul;150(1):53]. American Heart Journal 2005;
149(3):408-13. Not relevant to key questions
2723. Miyazaki Y, Cersosimo E, Triplitt C, et al.
Rosiglitazone decreases albuminuria in type 2
diabetic patients. Kidney International 2007;
72(11):1367-73. Follow-up less than 6 months
B-159
2724. Miyoshi H, Ohshiba S, Matsumoto A, et al.
Haptoglobin prevents renal dysfunction associated
with intravariceal infusion of ethanolamine oleate.
American Journal of Gastroenterology 1991;
86(11):1638-41. Not CKD treatment
2725. Mocan MZ, Mocan H, Gacar MN, et al. Effect of
essential amino acid supplementation in acute renal
failure. International Urology & Nephrology 1995;
27(4):503-10. Not CKD treatment
2726. Mocroft A, Wyatt C, Szczech L, et al. Interruption of
antiretroviral therapy is associated with increased
plasma cystatin C. AIDS 2009; 23(1):71-82. Not
CKD treatment
2727. Mocroft A, Wyatt C, Szczech L, et al. Interruption of
antiretroviral therapy is associated with increased
plasma cystatin C. AIDS 2009; 23(1):71-82. Not
CKD treatment
2728. Modesti PA, Vanni S, Morabito M, et al. Role of
endothelin-1 in exposure to high altitude: Acute
Mountain Sickness and Endothelin-1 (ACME-1)
study. Circulation 2006; 114(13):1410-6. Sample size
less than 50 patients
2729. Modi GK. The death knell for dopamine? National
Medical Journal of India 2001; 14(2):88-9. Not CKD
treatment
2730. Modi NB, Novotny W, Reimann JD, et al.
Pharmacokinetics and pharmacodynamics of
sibrafiban, an orally administered IIb/IIIa antagonist,
in patients with acute coronary syndrome. Journal of
Clinical Pharmacology 1999; 39(7):675-84. Not CKD
treatment
2731. Moe SM, Cunningham J, Bommer J, et al. Long-term
treatment of secondary hyperparathyroidism with the
calcimimetic cinacalcet HCl. Nephrology Dialysis
Transplantation 2005; 20(10):2186-93. Follow-up
less than 6 months
2732. Mogensen CE. The reno-protective role of AT(1)receptor blockers. Journal of Human Hypertension
2002; 16 Suppl 3:S52-8. Not relevant to key
questions
2733. Mogensen CE, Neldam S, Tikkanen I, et al.
Randomised controlled trial of dual blockade of
renin-angiotensin system in patients with
hypertension, microalbuminuria, and non-insulin
dependent diabetes: the candesartan and lisinopril
microalbuminuria (CALM) study. BMJ 2000;
321(7274):1440-4. Follow-up less than 6 months
2734. Mohammed SF, Korinek J, Chen HH, et al.
Nesiritide in acute decompensated heart failure:
current status and future perspectives. Reviews in
Cardiovascular Medicine 2008; 9(3):151-8. Not CKD
treatment
2735. Mohanram A, Zhang Z, Shahinfar S, et al. Anemia
and end-stage renal disease in patients with type 2
diabetes and nephropathy. Kidney International
2004; 66(3):1131-8. Not CKD treatment
2736. Mohanram A, Zhang Z, Shahinfar S, et al. The effect
of losartan on hemoglobin concentration and renal
outcome in diabetic nephropathy of type 2 diabetes.
Kidney International 2008; 73(5):630-6. Not CKD
treatment
2737. Mohideen P, Bornemann M, Sugihara J, et al. The
metabolic effects of troglitazone in patients with
diabetes and end-stage renal disease. Endocrine
2005; 28(2):181-6. Not relevant to key questions
2738. Mohrke W, Knauf H, Mutschler E. Pharmacokinetics
and pharmacodynamics of triamterene and
hydrochlorothiazide and their combination in healthy
volunteers. International Journal of Clinical
Pharmacology & Therapeutics 1997; 35(10):447-52.
Not CKD treatment
2739. Moist L, Nesrallah G, Kortas C, et al. Plasma
exchange in rapidly progressive renal failure due to
multiple myeloma. A retrospective case series.
American Journal of Nephrology 1999; 19(1):45-50.
Not RCT or controlled trial
2740. Molenaar IQ, Begliomini B, Grazi GL, et al. The
effect of aprotinin on renal function in orthotopic
liver transplantation. Transplantation 2001;
71(2):247-52. Not CKD treatment
2741. Molina CR, Fowler MB, McCrory S, et al.
Hemodynamic, renal and endocrine effects of atrial
natriuretic peptide infusion in severe heart failure.
Journal of the American College of Cardiology 1988;
12(1):175-86. Sample size less than 50 patients
2742. Molitch ME, Steffes MW, Cleary PA, et al. Baseline
analysis of renal function in the Diabetes Control and
Complications Trial. The Diabetes Control and
Complications Trial Research Group
[corrected].[Erratum appears in Kidney Int 1993
May;43(5):1196]. Kidney International 1993;
43(3):668-74. Not RCT or controlled trial
2743. Mollee PN, Wechalekar AD, Pereira DL, et al.
Autologous stem cell transplantation in primary
systemic amyloidosis: the impact of selection criteria
on outcome. Bone Marrow Transplantation 2004;
33(3):271-7. Not CKD treatment
2744. Molnar Z, Szakmany T, Koszegi T. Prophylactic Nacetylcysteine decreases serum CRP but not PCT
levels and microalbuminuria following major
abdominal surgery. A prospective, randomised,
double-blinded, placebo-controlled clinical trial.
Intensive Care Medicine 2003; 29(5):749-55. Not
CKD treatment
2745. Molyneaux LM, Willey KA, Yue DK. Indapamide is
as effective as captopril in the control of
microalbuminuria in diabetes. Journal of
Cardiovascular Pharmacology 1996; 27(3):424-7.
Sample size less than 50 patients
2746. Molzahn AE, Hibbert MP, Gaudet D, et al. Managing
chronic kidney disease in a nurse-run, physicianmonitored clinic: the CanPREVENT experience.
Canadian Journal of Nursing Research 2008;
40(3):96-112. Not RCT or controlled trial
2747. Monaco M, Di Tommaso L, Mottola M, et al.
Clinical outcome for on-pump myocardial
revascularization in patients with mild renal
dysfunction. Thoracic & Cardiovascular Surgeon
2005; 53(1):46-51. Not relevant to key questions
2748. Mondorf A, Mondorf W, Banzer S. A multiple-center
comparative study of the kidney tolerance of
ceftazidime versus cefotaxime and tobramycin.
B-160
Chemioterapia 1987; 6(2 Suppl):331-2. Follow-up
less than 6 months
2749. Mondorf AW, Bonsiepe C, Mondorf W. Randomized
multi center study comparing nephrotoxicity of
ceftazidime versus the combination of piperacillin
and netilmicin with and without furosemide.
Advances in Experimental Medicine & Biology
1989; 252:307-12. Not early CKD
2750. Monier-Faugere MC, Malluche HH. Calcitriol pulse
therapy in patients with end-stage renal failure.
Current Opinion in Nephrology & Hypertension
1994; 3(6):615-9. Not early CKD
2751. Montanari A, Carra N, Perinotto P, et al. Renal
hemodynamic control by endothelin and nitric oxide
under angiotensin II blockade in man. Hypertension
2002; 39(2 Pt 2):715-20. Not early CKD
2752. Montanari A, Tateo E, Fasoli E, et al. Angiotensin II
blockade does not prevent renal effects of L-NAME
in sodium-repleted humans. Hypertension 1997; 30(3
Pt 2):557-62. Sample size less than 50 patients
2753. Montori VM. Should patients with type 2 diabetes
focus on glycemic control to reduce their
cardiovascular risk? Polskie Archiwum Medycyny
Wewnetrznej 2008; 118(9):502-7. Not CKD
treatment
2754. Moore AEB, Hain SF, Blake GM, et al. Validation of
ultrafiltration as a method of measuring free 99mTcMDP. Journal of Nuclear Medicine 2003; 44(6):8917. Not CKD treatment
2755. Moore KB, McKenna K, Tormey WP, et al. The
albuminuric action of atrial natriuretic peptide is not
modified by ACE-inhibition with perindopril in Type
2 diabetes. Diabetic Medicine 2003; 20(9):713-6.
Sample size less than 50 patients
2756. Moore MJ, O'Sullivan B, Tannock IF. Are treatment
strategies of urologic oncologists influenced by the
opinions of their colleagues? British Journal of
Cancer 1990; 62(6):988-91. Not CKD treatment
2757. Moore NN, Lapsley M, Norden AG, et al. Does Nacetylcysteine prevent contrast-induced nephropathy
during endovascular AAA repair? A randomized
controlled pilot study. Journal of Endovascular
Therapy: Official Journal of the International Society
of Endovascular Specialists 2006; 13(5):660-6.
Sample size less than 50 patients
2758. Moore RD, Lerner SA, Levine DP. Nephrotoxicity
and ototoxicity of aztreonam versus aminoglycoside
therapy in seriously ill nonneutropenic patients.
Journal of Infectious Diseases 1992; 165(4):683-8.
Not CKD treatment
2759. Moore RD, Smith CR, Holloway JJ, et al.
Cefotaxime vs nafcillin and tobramycin for the
treatment of serious infection. Comparative costeffectiveness. Archives of Internal Medicine 1986;
146(6):1153-7. Not CKD treatment
2760. Moore RD, Steinberg EP, Powe NR, et al.
Nephrotoxicity of high-osmolality versus lowosmolality contrast media: randomized clinical trial.
Radiology 1992; 182(3):649-55. Not CKD treatment
2761. Moore WV, Donaldson DL, Chonko AM, et al.
Ambulatory blood pressure in type I diabetes
mellitus. Comparison to presence of incipient
nephropathy in adolescents and young adults.
Diabetes 1992; 41(9):1035-41. Not RCT or
controlled trial
2762. Mor E, Patel T, Glabman S, et al. Comparison of
short and long-term renal function in liver transplant
patients receiving cyclosporin or FK 506. Transplant
International 1994; 7 Suppl 1:S77-80. Not RCT or
controlled trial
2763. Mora C, Macia M, Navarro JF. Renal failure,
anaemia, cytokines and inflammation. Nephrology
Dialysis Transplantation 2001; 16(7):1524-5. Not
RCT or controlled trial
2764. Morales E, Valero MA, Leon M, et al. Beneficial
effects of weight loss in overweight patients with
chronic proteinuric nephropathies. American Journal
of Kidney Diseases 2003; 41(2):319-27. Sample size
less than 50 patients
2765. Morales JM, Grinyo JM, Campistol JM, et al.
Improved renal function, with similar proteinuria,
after two years of early tacrolimus withdrawal from a
regimen of sirolimus plus tacrolimus. Transplantation
2008; 86(4):620-2. Not CKD treatment
2766. Morariu AM, Loef BG, Aarts LPHJ, et al.
Dexamethasone: benefit and prejudice for patients
undergoing on-pump coronary artery bypass grafting:
a study on myocardial, pulmonary, renal, intestinal,
and hepatic injury. Chest 2005; 128(4):2677-87. Not
RCT or controlled trial
2767. Morcos M, Borcea V, Isermann B, et al. Effect of
alpha-lipoic acid on the progression of endothelial
cell damage and albuminuria in patients with
diabetes mellitus: an exploratory study. Diabetes
Research & Clinical Practice 2001; 52(3):175-83.
Sample size less than 50 patients
2768. Moreau ME, Garbacki N, Molinaro G, et al. The
kallikrein-kinin system: current and future
pharmacological targets. Journal of Pharmacological
Sciences 2005; 99(1):6-38. Not RCT or controlled
trial
2769. Moreau P, Milpied N, Fayette N, et al. Reduced renal
toxicity and improved clinical tolerance of
amphotericin B mixed with intralipid compared with
conventional amphotericin B in neutropenic patients.
Journal of Antimicrobial Chemotherapy 1992;
30(4):535-41. Sample size less than 50 patients
2770. Moreau R, Lebrec D. Acute kidney injury: new
concepts. Hepatorenal syndrome: the role of
vasopressors. Nephron. Physiology 2008;
109(4):p73-9. Not CKD treatment
2771. Moreira RO, Trujillo FR, Meirelles RM, et al. Use of
optical coherence tomography (OCT) and indirect
ophthalmoscopy in the diagnosis of macular edema
in diabetic patients. International Ophthalmology
2001; 24(6):331-6. Not CKD treatment
2772. Morelli A, Ricci Z, Bellomo R, et al. Prophylactic
fenoldopam for renal protection in sepsis: a
randomized, double-blind, placebo-controlled pilot
trial. Critical Care Medicine 2005; 33(11):2451-6.
Not relevant to key questions
2773. Morgan T, Anderson A, Bertram D, et al. Effect of
candesartan and lisinopril alone and in combination
on blood pressure and microalbuminuria. Journal of
B-161
the Renin-Angiotensin-Aldosterone System 2004;
5(2):64-71. Not CKD treatment
2774. Morganti A. Randomized clinical trials on surrogate
end points: are they useful for evaluating
cardiovascular and renal disease protection in
hypertension? The case for yes. Journal of the
American Society of Nephrology 2006; 17(4 Suppl
2):S141-4. Not relevant to key questions
2775. Morgera S, Woydt R, Kern H, et al. Low-dose
prostacyclin preserves renal function in high-risk
patients after coronary bypass surgery. Critical Care
Medicine 2002; 30(1):107-12. Not early CKD
2776. Mori TA, Burke V, Puddey I, et al. The effects of
[omega]3 fatty acids and coenzyme Q10 on blood
pressure and heart rate in chronic kidney disease: a
randomized controlled trial. Journal of Hypertension
2009; 27(9):1863-72. Follow-up less than 6 months
2777. Morikawa S, Sone T, Tsuboi H, et al. Renal
protective effects and the prevention of contrastinduced nephropathy by atrial natriuretic
peptide.[Erratum appears in J Am Coll Cardiol. 2009
Sep 15;54(12):1122]. Journal of the American
College of Cardiology 2009; 53(12):1040-6. Not
RCT or controlled trial
2778. Morillas RM, Planas R, Cabre E, et al. Propranolol
plus isosorbide-5-mononitrate for portal hypertension
in cirrhosis: long-term hemodynamic and renal
effects. Hepatology 1994; 20(6):1502-8. Not CKD
treatment
2779. Morimoto S, Yano Y, Maki K, et al. Renal and
vascular protective effects of cilnidipine in patients
with essential hypertension. Journal of Hypertension
2007; 25(10):2178-83. Not RCT or controlled trial
2780. Morimoto S, Yano Y, Maki K, et al. Renal and
vascular protective effects of telmisartan in patients
with essential hypertension. Hypertension Research Clinical & Experimental 2006; 29(8):567-72. Not
RCT or controlled trial
2781. Morita S, Fukuhara S, Akizawa T, et al. Study design
and methods for a clinical trial of an oral
carbonaceous adsorbent used to prevent the
progression of chronic kidney disease (CAP-KD).
Clinical & Experimental Nephrology 2005; 9(3):21927. Not CKD treatment
2782. Morris ST, McMurray JJ, Rodger RS, et al. Impaired
endothelium-dependent vasodilatation in uraemia.
Nephrology Dialysis Transplantation 2000;
15(8):1194-200. Sample size less than 50 patients
2783. Mortelmans LJM, Desruelles D, Baert JA, et al. Use
of tramadol drip in controlling renal colic pain.
Journal of Endourology 2006; 20(12):1010-5. Not
RCT or controlled trial
2784. Mortensen BM, Aarseth HP, Ganss R, et al. 24,25dihydroxy vitamin D3 treatment inhibits parathyroidstimulated adenylate cyclase in iliac crest biopsies
from uremic patients. Bone 1993; 14(2):125-31.
Sample size less than 50 patients
2785. Mosconi L, Ruggenenti P, Perna A, et al.
Nitrendipine and enalapril improve albuminuria and
glomerular filtration rate in non-insulin dependent
diabetes. Kidney International - Supplement 1996;
55:S91-3. Sample size less than 50 patients
2786. Motovska Z, Widimsky P, Petr R, et al. Factors
influencing clopidogrel efficacy in patients with
stable coronary artery disease undergoing elective
percutaneous coronary intervention: statin's
advantage and the smoking "paradox". Journal of
Cardiovascular Pharmacology 2009; 53(5):368-72.
Not CKD treatment
2787. Motwani JG, Fenwick MK, McAlpine HM, et al.
Effectiveness of captopril in reversing renal
vasoconstriction after Q-wave acute myocardial
infarction. American Journal of Cardiology 1993;
71(4):281-6. Sample size less than 50 patients
2788. Motwani JG, Fenwick MK, Morton JJ, et al.
Furosemide-induced natriuresis is augmented by
ultra-low-dose captopril but not by standard doses of
captopril in chronic heart failure. Circulation 1992;
86(2):439-45. Sample size less than 50 patients
2789. Motwani JG, Fenwick MK, Morton JJ, et al.
Determinants of the initial effects of captopril on
blood pressure, glomerular filtration rate, and
natriuresis in mild-to-moderate chronic congestive
heart failure secondary to coronary artery disease.
American Journal of Cardiology 1994; 73(16):11916. Sample size less than 50 patients
2790. Motwani JG, Fenwick MK, Struthers AD.
Comparison of three methods of glomerular filtration
rate measurement with and without captopril
pretreatment in groups of patients with left
ventricular dysfunction. European Heart Journal
1992; 13(9):1195-200. Not CKD treatment
2791. Motwani JG, Lang CC, Cramb G, et al. Natriuretic
response to neutral endopeptidase inhibition is
blunted by enalapril in healthy men. Hypertension
1995; 25(4 Pt 1):637-42. Sample size less than 50
patients
2792. Motwani JG, Struthers AD. Interactive effects of
indomethacin, angiotensin II and frusemide on renal
haemodynamics and natriuresis in man. British
Journal of Clinical Pharmacology 1994; 37(4):35561. Not CKD treatment
2793. Moudgal VV, Sobel JD. Selecting antifungal agents
for the treatment of invasive fungal infections in
patients with renal failure. Current Opinion in
Investigational Drugs 2004; 5(8):873-8. Follow-up
less than 6 months
2794. Moulder JE, Fish BL, Cohen EP. ACE inhibitors and
AII receptor antagonists in the treatment and
prevention of bone marrow transplant nephropathy.
Current Pharmaceutical Design 2003; 9(9):737-49.
Not relevant to key questions
2795. Moulin B, Fillastre JP, Godin M, et al. Renal
hemodynamics and sodium excretion after acute and
chronic administration of cicletanine in normotensive
and hypertensive subjects. Journal of Cardiovascular
Pharmacology 1995; 25(2):292-9. Sample size less
than 50 patients
2796. Mourad G, Haecker W, Mion C. Dose-dependent
salidiuretic efficacy of torasemide in comparison to
furosemide and placebo in advanced renal failure.
Arzneimittel-Forschung 1988; 38(1A):205-8. Sample
size less than 50 patients
B-162
2797. Mourad JJ, Le Jeune S. Evaluation of high dose of
perindopril/indapamide fixed combination in
reducing blood pressure and improving end-organ
protection in hypertensive patients. Current Medical
Research & Opinion 2009; 25(9):2271-80. Not RCT
or controlled trial
2798. Moyses C, Higgins TJ. Safety of long-term use of
lisinopril for congestive heart failure. American
Journal of Cardiology 1992; 70(10):91C-7C. Not
CKD treatment
2799. Mueck AO, Seeger H, Petersen G, et al. Effect of two
oral contraceptives with different ethinyl estradiol
and levonorgestrel concentrations on the urinary
excretion of biochemical vasoactive markers.
Contraception 2001; 64(6):357-62. Not early CKD
2800. Mueller AR, Platz KP, Blumhardt G, et al. The
optimal immunosuppressant after liver
transplantation according to diagnosis: cyclosporine
A or FK506? Clinical Transplantation 1995; 9(3 Pt
1):176-84. Not CKD treatment
2801. Mueller C. Prevention of contrast-induced
nephropathy with volume supplementation. Kidney
International - Supplement 2006; (100):S16-9. Not
RCT or controlled trial
2802. Mueller C, Buerkle G, Buettner HJ, et al. Prevention
of contrast media-associated nephropathy:
randomized comparison of 2 hydration regimens in
1620 patients undergoing coronary angioplasty.
Archives of Internal Medicine 2002; 162(3):329-36.
Not early CKD
2803. Mueller C, Buerkle G, Perruchoud AP, et al. Female
sex and risk of contrast nephropathy after
percutaneous coronary intervention. Canadian
Journal of Cardiology 2004; 20(5):505-9. Not
relevant to key questions
2804. Mueller C, Laule-Kilian K, Scholer A, et al. B-type
natriuretic peptide for acute dyspnea in patients with
kidney disease: insights from a randomized
comparison. Kidney International 2005; 67(1):27884. Not CKD treatment
2805. Mueller C, Seidensticker P, Buettner HJ, et al.
Incidence of contrast nephropathy in patients
receiving comprehensive intravenous and oral
hydration. Swiss Medical Weekly 2005; 135(1920):286-90. Follow-up less than 6 months
2806. Muir A, Davidson R, Silverstone T, et al. Two
regimens of lithium prophylaxis and renal function.
Acta Psychiatrica Scandinavica 1989; 80(6):579-83.
Sample size less than 50 patients
2807. Muirhead N. A rationale for an individualized
haemoglobin target. Nephrology Dialysis
Transplantation 2002; 17 Suppl 6:2-7. Not RCT or
controlled trial
2808. Mukhopadhyay S, Singh M, Cater JI, et al. Nebulised
antipseudomonal antibiotic therapy in cystic fibrosis:
a meta-analysis of benefits and risks. Thorax 1996;
51(4):364-8. Not RCT or controlled trial
2809. Mulec H, Johnsen SA, Bjorck S. Long-term enalapril
treatment in diabetic nephropathy. Kidney
International - Supplement 1994; 45:S141-4. Not
relevant to key questions
2810. Mulec H, Johnson SA, Bjorck S. Relation between
serum cholesterol and diabetic nephropathy. Lancet
1990; 335(8704):1537-8. Not RCT or controlled trial
2811. Mulhauser I, Prange K, Sawicki PT, et al. Effects of
dietary sodium on blood pressure in IDDM patients
with nephropathy. Diabetologia 1996; 39(2):212-9.
Sample size less than 50 patients
2812. Munger MA, Gardner SF, Ateshkadi A, et al.
Misoprostol effects on diclofenac-induced
cardiorenal changes in salt-sensitive patients with
hypertension: the MEDIC Study. Pharmacotherapy
2008; 28(7):834-42. Not CKD treatment
2813. Munkhaugen J, Lydersen S, Romundstad PR, et al.
Kidney function and future risk for adverse
pregnancy outcomes: a population-based study from
HUNT II, Norway. Nephrology Dialysis
Transplantation 2009; 24(12):3744-50. Not RCT or
controlled trial
2814. Munoz M, Breymann C, Garcia-Erce JA, et al.
Efficacy and safety of intravenous iron therapy as an
alternative/adjunct to allogeneic blood transfusion.
Vox Sanguinis 2008; 94(3):172-83. Not RCT or
controlled trial
2815. Munoz-Garcia B, Moreno JA, Lopez-Franco O, et al.
Tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) enhances vascular and renal damage
induced by hyperlipidemic diet in ApoE-knockout
mice. Arteriosclerosis, Thrombosis & Vascular
Biology 2009; 29(12):2061-8. Follow-up less than 6
months
2816. Murakami R, Tajima H, Kumazaki T. Effect of
iomeprol on renal function immediately after
abdominal angiography. Acta Radiologica 1996;
37(6):962-5. Sample size less than 50 patients
2817. Murakami R, Tajima H, Kumazaki T, et al. Effect of
iodixanol on renal function immediately after
abdominal angiography. Clinical comparison with
iomeprol and ioxaglate. Acta Radiologica 1998;
39(4):368-71. Sample size less than 50 patients
2818. Murayama S, Hirano T, Sakaue T, et al. Low-dose
candesartan cilexetil prevents early kidney damage in
type 2 diabetic patients with mildly elevated blood
pressure. Hypertension Research - Clinical &
Experimental 2003; 26(6):453-8. Not RCT or
controlled trial
2819. Murdoch D, Sager J. Will targeted therapy hold its
promise? An evidence-based review. Current
Opinion in Oncology 2008; 20(1):104-11. Follow-up
less than 6 months
2820. Murgia MG, Jordan S, Kahan BD. The side effect
profile of sirolimus: a phase I study in quiescent
cyclosporine-prednisone-treated renal transplant
patients. Kidney International 1996; 49(1):209-16.
Not early CKD
2821. Muriel C, Ortiz P. Efficacy of two different
intramuscular doses of dipyrone in acute renal colic.
Cooperative Study Group. Methods & Findings in
Experimental & Clinical Pharmacology 1993;
15(7):465-9. Not CKD treatment
2822. Muriel-Villoria C, Zungri-Telo E, Diaz-Curiel M, et
al. Comparison of the onset and duration of the
analgesic effect of dipyrone, 1 or 2 g, by the
B-163
intramuscular or intravenous route, in acute renal
colic. European Journal of Clinical Pharmacology
1995; 48(2):103-7. Follow-up less than 6 months
2823. Murphy PT, Casey MC, Walker F, et al. The role of
plasmapheresis in myeloma patients with renal
failure. Clinical & Laboratory Haematology 1994;
16(4):407. Not CKD treatment
2824. Murray MD, Black PK, Kuzmik DD, et al. Acute and
chronic effects of nonsteroidal antiinflammatory
drugs on glomerular filtration rate in elderly patients.
American Journal of the Medical Sciences 1995;
310(5):188-97. Sample size less than 50 patients
2825. Murray MD, Greene PK, Brater DC, et al. Effects of
flurbiprofen on renal function in patients with
moderate renal insufficiency. British Journal of
Clinical Pharmacology 1992; 33(4):385-93. Sample
size less than 50 patients
2826. Muscheites J, Wigger M, Drueckler E, et al.
Cinacalcet for secondary hyperparathyroidism in
children with end-stage renal disease. Pediatric
Nephrology 2008; 23(10):1823-9. Not CKD
treatment
2827. Musleh GS, Patel NC, Grayson AD, et al. Off-pump
coronary artery bypass surgery does not reduce
gastrointestinal complications. European Journal of
Cardio-Thoracic Surgery 2003; 23(2):170-4. Not
CKD treatment
2828. Musso P, Cox I, Vidano E, et al. Cardiac troponin
elevations in chronic renal failure: prevalence and
clinical significance. Clinical Biochemistry 1999;
32(2):125-30. Not CKD treatment
2829. Myint L, Tin Nu S, Myint Aye M, et al. Heparin
therapy in Russell's viper bite victims with
impending dic (a controlled trial). Southeast Asian
Journal of Tropical Medicine & Public Health 1989;
20(2):271-7. Sample size less than 50 patients
2830. Myles PS, Buckland MR, Schenk NJ, et al. Effect of
"renal-dose" dopamine on renal function following
cardiac surgery. Anaesthesia & Intensive Care 1993;
21(1):56-61. Not RCT or controlled trial
2831. Myrup B, Hansen PM, Jensen T, et al. Effect of lowdose heparin on urinary albumin excretion in insulindependent diabetes mellitus. Lancet 1995;
345(8947):421-2. Sample size less than 50 patients
2832. Na KY, Han JS, Kim YS, et al. Does albumin
preinfusion potentiate diuretic action of furosemide
in patients with nephrotic syndrome? Journal of
Korean Medical Science 2001; 16(4):448-54. Sample
size less than 50 patients
2833. Naeije R, Degaute JP. Redistribution of cardiac
output to the kidneys by tertatolol does not involve
prostaglandins. American Journal of Hypertension
1989; 2(11 Pt 2):241S-4S. Sample size less than 50
patients
2834. Naeije R, Fiasse A, Carlier E, et al. Systemic and
renal haemodynamic effects of angiotensin
converting enzyme inhibition by zabicipril in young
and in old normal men. European Journal of Clinical
Pharmacology 1993; 44(1):35-9. Sample size less
than 50 patients
2835. Nagai T. The effect of pancreatic elastase on diabetic
nephropathy. Diabetes Research & Clinical Practice
1994; 24(3):161-5. Not RCT or controlled trial
2836. Nagaya N, Miyatake K, Uematsu M, et al.
Hemodynamic, renal, and hormonal effects of ghrelin
infusion in patients with chronic heart failure. Journal
of Clinical Endocrinology & Metabolism 2001;
86(12):5854-9. Sample size less than 50 patients
2837. Nagaya N, Satoh T, Nishikimi T, et al.
Hemodynamic, renal, and hormonal effects of
adrenomedullin infusion in patients with congestive
heart failure. Circulation 2000; 101(5):498-503.
Sample size less than 50 patients
2838. Nagler A, Ackerstein A, Ben-Shahar M, et al.
Continuous interleukin-2 infusion combined with
cyclophosphamide- based combination
chemotherapy in the treatment of hemato-oncological
malignancies. Results of a phase I-II study. Acta
Haematologica 1998; 100(2):63-8. Sample size less
than 50 patients
2839. Nair KS, Pabico RC, Truglia JA, et al. Mechanism of
glomerular hyperfiltration after a protein meal in
humans. Role of hormones and amino acids.
Diabetes Care 1994; 17(7):711-5. Not CKD
treatment
2840. Nakamura K, Okamura T, Hayakawa T, et al.
Chronic kidney disease is a risk factor for
cardiovascular death in a community-based
population in Japan: NIPPON DATA90. Circulation
Journal 2006; 70(8):954-9. Follow-up less than 6
months
2841. Nakamura M, Arakawa N, Kato M. Renal, hormonal,
and hemodynamic effects of low-dose infusion of
atrial natriuretic factor in acute myocardial
infarction. American Heart Journal 1990;
120(5):1078-85. Not CKD treatment
2842. Nakamura T, Fujiwara N, Sugaya T, et al. Effect of
red wine on urinary protein, 8hydroxydeoxyguanosine, and liver-type fatty acidbinding protein excretion in patients with diabetic
nephropathy. Metabolism: Clinical & Experimental
2009; 58(8):1185-90. Sample size less than 50
patients
2843. Nakamura T, Inoue T, Fujiwara N, et al. Additional
renoprotective effects of azelnidipine combined with
angiotensin receptor blockers in patients with
diabetic nephropathy. Clinical Nephrology 2008;
70(5):385-92. Not RCT or controlled trial
2844. Nakamura T, Inoue T, Sugaya T, et al.
Renoprotective effect of telmisartan in patients with
chronic kidney disease. Clinical & Experimental
Hypertension 2008; 30(7):662-72. Sample size less
than 50 patients
2845. Nakamura T, Kanno Y, Takenaka T, et al. An
angiotensin receptor blocker reduces the risk of
congestive heart failure in elderly hypertensive
patients with renal insufficiency. Hypertension
Research - Clinical & Experimental 2005; 28(5):41523. Not relevant to key questions
2846. Nakamura T, Kawagoe Y, Matsuda T, et al. Oral
ADSORBENT AST-120 decreases carotid intimamedia thickness and arterial stiffness in patients with
B-164
with trauma. ASAIO Journal 2002; 48(3):244-8. Not
early CKD
2858. Nakano T, Ninomiya T, Sumiyoshi S, et al.
Association of kidney function with coronary
atherosclerosis and calcification in autopsy samples
from Japanese elders: the Hisayama study. American
Journal of Kidney Diseases 2010; 55(1):21-30. Not
RCT or controlled trial
2859. Nakao N, Seno H, Kasuga H, et al. Effects of
combination treatment with losartan and trandolapril
on office and ambulatory blood pressures in nondiabetic renal disease: a COOPERATE-ABP
substudy. American Journal of Nephrology 2004;
24(5):543-8. Not RCT or controlled trial
2860. Nakao N, Yoshimura A, Morita H, et al.
Combination treatment of angiotensin-II receptor
blocker and angiotensin-converting-enzyme inhibitor
in non-diabetic renal disease (COOPERATE): a
randomised controlled trial.[Erratum appears in
Lancet. 2003 Apr 5;361(9364):1230].[Retraction in
Lancet. 2009 Oct 10;374(9697):1226; PMID:
19819378]. Lancet 2003; 361(9352):117-24. Not
CKD treatment
2861. Nakao N, Yoshimura A, Morita H, et al.
Combination treatment of angiotensin-II receptor
blocker and angiotensin-converting-enzyme inhibitor
in non-diabetic renal disease (COOPERATE): a
randomised controlled trial.[Erratum appears in
Lancet. 2003 Apr 5;361(9364):1230].[Retraction in
Lancet. 2009 Oct 10;374(9697):1226; PMID:
19819378]. Lancet 2003; 361(9352):117-24. Not
CKD treatment
2862. Nakao T, Yoshino M, Matsumoto H, et al. Lowdensity lipoprotein apheresis retards the progression
of hyperlipidemic overt diabetic nephropathy.
Kidney International - Supplement 1999; 71:S206-9.
Sample size less than 50 patients
2863. Nakayama Y, Nonoguchi H, Kohda Y, et al.
Different Mechanisms for the Progression of CKD
with ACE Gene Polymorphisms. Nephron 2009;
111(4):c240-6. Not RCT or controlled trial
2864. Nallamothu BK, Shojania KG, Saint S, et al. Is
acetylcysteine effective in preventing contrast-related
nephropathy? A meta-analysis. American Journal of
Medicine 2004; 117(12):938-47. Not relevant to key
questions
2865. Nalysnyk L, Fahrbach K, Reynolds MW, et al.
Adverse events in coronary artery bypass graft
(CABG) trials: a systematic review and analysis.
Heart 2003; 89(7):767-72. Not CKD treatment
2866. Nanayakkara PWB, Kiefte-de Jong JC, Stehouwer
CDA, et al. Association between global leukocyte
DNA methylation, renal function, carotid intimamedia thickness and plasma homocysteine in patients
with stage 2-4 chronic kidney disease. Nephrology
Dialysis Transplantation 2008; 23(8):2586-92. Not
CKD treatment
2867. Nanayakkara PWB, Kiefte-de Jong JC, ter Wee PM,
et al. Randomized placebo-controlled trial assessing
a treatment strategy consisting of pravastatin, vitamin
E, and homocysteine lowering on plasma asymmetric
dimethylarginine concentration in mild to moderate
chronic renal failure. Kidney & Blood Pressure
Research 2004; 27(2):121-6. Not relevant to key
questions
2847. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of
pioglitazone on carotid intima-media thickness and
arterial stiffness in type 2 diabetic nephropathy
patients. Metabolism: Clinical & Experimental 2004;
53(10):1382-6. Follow-up less than 6 months
2848. Nakamura T, Sato E, Fujiwara N, et al. Comparative
effects of benidipine and amlodipine on proteinuria,
urinary 8-OHdG, urinary L-FABP, and inflammatory
and atherosclerosis markers in early-stage chronic
kidney disease. American Journal of the Medical
Sciences 2010; 339(2):157-63. Sample size less than
50 patients
2849. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of
pitavastatin on urinary liver-type fatty-acid-binding
protein in patients with nondiabetic mild chronic
kidney disease. American Journal of Nephrology
2006; 26(1):82-6. Not RCT or controlled trial
2850. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of
erythropoietin on urinary liver-type fatty-acidbinding protein in patients with chronic renal failure
and anemia. American Journal of Nephrology 2006;
26(3):276-80. Sample size less than 50 patients
2851. Nakamura T, Sugaya T, Kawagoe Y, et al.
Azelnidipine reduces urinary protein excretion and
urinary liver-type fatty acid binding protein in
patients with hypertensive chronic kidney disease.
American Journal of the Medical Sciences 2007;
333(6):321-6. Follow-up less than 6 months
2852. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of
pitavastatin on urinary liver-type fatty acid-binding
protein levels in patients with early diabetic
nephropathy. Diabetes Care 2005; 28(11):2728-32.
Sample size less than 50 patients
2853. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect
of cerivastatin on urinary albumin excretion and
plasma endothelin-1 concentrations in type 2 diabetes
patients with microalbuminuria and dyslipidemia.
American Journal of Nephrology 2001; 21(6):44954. Not relevant to key questions
2854. Nakamura T, Ushiyama C, Osada S, et al.
Pioglitazone reduces urinary podocyte excretion in
type 2 diabetes patients with microalbuminuria.
Metabolism: Clinical & Experimental 2001;
50(10):1193-6. Sample size less than 50 patients
2855. Nakamura T, Ushiyama C, Shimada N, et al. Effect
of the antiplatelet drug dilazep dihydrochloride on
urinary podocytes in patients in the early stage of
diabetic nephropathy. Diabetes Care 2000;
23(8):1168-71. Not RCT or controlled trial
2856. Nakamura T, Ushiyama C, Suzuki S, et al.
Comparison between the angiotensin II receptor
antagonist candesartan cilexetil and the angiotensinconverting enzyme inhibitor trandolapril in
microalbuminuria of patients with early diabetic
nephropathy. Nephron 2000; 86(2):247. Follow-up
less than 6 months
2857. Nakamura T, Ushiyama C, Suzuki Y, et al.
Hemoperfusion with polymyxin B immobilized
fibers for urinary albumin excretion in septic patients
B-165
CKD. American Journal of Kidney Diseases 2009;
53(1):41-50. Not CKD treatment
2868. Nanayakkara PWB, Teerlink T, Stehouwer CDA, et
al. Plasma asymmetric dimethylarginine (ADMA)
concentration is independently associated with
carotid intima-media thickness and plasma soluble
vascular cell adhesion molecule-1 (sVCAM-1)
concentration in patients with mild-to-moderate renal
failure. Kidney International 2005; 68(5):2230-6.
Sample size less than 50 patients
2869. Nanayakkara PWB, van Guldener C, ter Wee PM, et
al. Effect of a treatment strategy consisting of
pravastatin, vitamin E, and homocysteine lowering
on carotid intima-media thickness, endothelial
function, and renal function in patients with mild to
moderate chronic kidney disease: results from the
Anti-Oxidant Therapy in Chronic Renal
Insufficiency (ATIC) Study. Archives of Internal
Medicine 2007; 167(12):1262-70. Not RCT or
controlled trial
2870. Nangaku M, Fliser D. Erythropoiesis-stimulating
agents: past and future. Kidney International Supplement 2007; (107):S1-3. Not RCT or controlled
trial
2871. Nankervis A, Nicholls K, Kilmartin G, et al. Effects
of perindopril on renal histomorphometry in diabetic
subjects with microalbuminuria: a 3-year placebocontrolled biopsy study. Metabolism: Clinical &
Experimental 1998; 47(12 Suppl 1):12-5. Sample size
less than 50 patients
2872. Nash RA, Etzioni R, Storb R, et al. Tacrolimus
(FK506) alone or in combination with methotrexate
or methylprednisolone for the prevention of acute
graft-versus-host disease after marrow
transplantation from HLA-matched siblings: a singlecenter study. Blood 1995; 85(12):3746-53. Sample
size less than 50 patients
2873. Natov S, Hannedouche T, Schmitt F, et al. Are the
renal haemodynamic and natriuretic effects of
calcium antagonists and angiotensin converting
inhibitors additive? Journal of Hypertension Supplement 1991; 9(6):S392-3. Sample size less than
50 patients
2874. Naughton F, Wijeysundera D, Karkouti K, et al. Nacetylcysteine to reduce renal failure after cardiac
surgery: a systematic review and meta-analysis.
Canadian Journal of Anaesthesia 2008; 55(12):82735. Not CKD treatment
2875. Navaneethan SD, Nigwekar SU, Sehgal AR, et al.
Aldosterone antagonists for preventing the
progression of chronic kidney disease. Cochrane
Database of Systematic Reviews 2009;
(3):CD007004. Not RCT or controlled trial
2876. Navaneethan SD, Nigwekar SU, Sehgal AR, et al.
Aldosterone antagonists for preventing the
progression of chronic kidney disease: a systematic
review and meta-analysis. Clinical Journal of The
American Society of Nephrology: CJASN 2009;
4(3):542-51. Follow-up less than 6 months
2877. Navaneethan SD, Pansini F, Strippoli GFM. Statins
in patients with chronic kidney disease: evidence
from systematic reviews and randomized clinical
trials. PLoS Medicine / Public Library of Science
2006; 3(5):e123. Not relevant to key questions
2878. Navaneethan SD, Singh S, Appasamy S, et al.
Sodium bicarbonate therapy for prevention of
contrast-induced nephropathy: a systematic review
and meta-analysis. American Journal of Kidney
Diseases 2009; 53(4):617-27. Not CKD treatment
2879. Navarro JF, Mora C, Muros M, et al. Additive
antiproteinuric effect of pentoxifylline in patients
with type 2 diabetes under angiotensin II receptor
blockade: a short-term, randomized, controlled trial.
Journal of the American Society of Nephrology
2005; 16(7):2119-26. Follow-up less than 6 months
2880. Navarro JF, Mora C, Muros M, et al. Effects of
pentoxifylline administration on urinary N-acetylbeta-glucosaminidase excretion in type 2 diabetic
patients: a short-term, prospective, randomized study.
American Journal of Kidney Diseases 2003;
42(2):264-70. Sample size less than 50 patients
2881. Navarro JF, Mora C, Rivero A, et al. Urinary protein
excretion and serum tumor necrosis factor in diabetic
patients with advanced renal failure: effects of
pentoxifylline administration. American Journal of
Kidney Diseases 1999; 33(3):458-63. Sample size
less than 50 patients
2882. Navis G, de Jong PE, Donker AJ, et al. Moderate
sodium restriction in hypertensive subjects: renal
effects of ACE-inhibition. Kidney International
1987; 31(3):815-9. Follow-up less than 6 months
2883. Naylor CD, Detsky AS, O'Rourke K, et al. Does
treatment with essential amino acids and hypertonic
glucose improve survival in acute renal failure?: A
meta-analysis. Renal Failure 1987; 10(3-4):141-52.
Not relevant to key questions
2884. Nazir FS, Overell JR, Bolster A, et al. Effect of
perindopril on cerebral and renal perfusion on
normotensives in mild early ischaemic stroke: a
randomized controlled trial. Cerebrovascular
Diseases 2005; 19(2):77-83. Follow-up less than 6
months
2885. Nazir FS, Overell JR, Bolster A, et al. The effect of
losartan on global and focal cerebral perfusion and
on renal function in hypertensives in mild early
ischaemic stroke. Journal of Hypertension 2004;
22(5):989-95. Not CKD treatment
2886. Negri AL. Prevention of progressive fibrosis in
chronic renal diseases: antifibrotic agents. Journal of
Nephrology 2004; 17(4):496-503. Not relevant to key
questions
2887. Negrier S, Perol D, Ravaud A, et al. Randomized
study of intravenous versus subcutaneous
interleukin-2, and IFNalpha in patients with good
prognosis metastatic renal cancer. Clinical Cancer
Research 2008; 14(18):5907-12. Not CKD treatment
2888. Nellemann B, Gormsen LC, Dollerup J, et al.
Simvastatin reduces plasma osteoprotegerin in type 2
diabetic patients with microalbuminuria. Diabetes
Care 2007; 30(12):3122-4. Not RCT or controlled
trial
2889. Nelson CE, Nylander C, Olsson AM, et al. Rectal v.
intravenous administration of indomethacin in the
treatment of renal colic. Acta Chirurgica
B-166
Scandinavica 1988; 154(4):253-5. Not relevant to key
questions
2890. Nergelius G, Vinge E, Bengtsson HI, et al. No effect
of diclofenac on the pharmacokinetics of cloxacillin.
Pharmacology & Toxicology 1997; 81(1):26-30. Not
CKD treatment
2891. Neri S, Bruno CM, Leotta C, et al. Early endothelial
alterations in non-insulin-dependent diabetes
mellitus. International Journal of Clinical &
Laboratory Research 1998; 28(2):100-3. Not CKD
treatment
2892. Nesher G, Sonnenblick M, Dwolatzky T. Protective
effect of misoprostol on indomethacin induced renal
dysfunction in elderly patients. Journal of
Rheumatology 1995; 22(4):713-6. Sample size less
than 50 patients
2893. Netelenbos JC, Asscheman H, Lips P, et al. Absence
of effect of 24,25-dihydroxyvitamin D3 in primary
hyperparathyroidism. Journal of Clinical
Endocrinology & Metabolism 1986; 63(1):246-8.
Sample size less than 50 patients
2894. Neuberger JM, Mamelok RD, Neuhaus P, et al.
Delayed introduction of reduced-dose tacrolimus,
and renal function in liver transplantation: the
'ReSpECT' study. American Journal of
Transplantation 2009; 9(2):327-36. Not RCT or
controlled trial
2895. Neuhaus PJ. Optimised first-line FK506-based
protocols in liver transplantation: experience from
the University Hospital Rudolf Virchow, Berlin.
Transplantation Proceedings 1994; 26(6):3264-6. Not
RCT or controlled trial
2896. Neuhofer W, Pittrow D. Endothelin receptor
selectivity in chronic kidney disease: rationale and
review of recent evidence. European Journal of
Clinical Investigation 2009; 39 Suppl 2:50-67. Not
early CKD
2897. Neumann DR, Esselstyn CB, Jr., Madera A, et al.
Parathyroid detection in secondary
hyperparathyroidism with 123I/99mTc-sestamibi
subtraction single photon emission computed
tomography. Journal of Clinical Endocrinology &
Metabolism 1998; 83(11):3867-71. Not CKD
treatment
2898. Neumayer HH, Gellert J, Luft FC. Calcium
antagonists and renal protection. Renal Failure 1993;
15(3):353-8. Not RCT or controlled trial
2899. Neumayer HH, Junge W, Kufner A, et al. Prevention
of radiocontrast-media-induced nephrotoxicity by the
calcium channel blocker nitrendipine: a prospective
randomised clinical trial. Nephrology Dialysis
Transplantation 1989; 4(12):1030-6. Not CKD
treatment
2900. Neumayer HH, Kunzendorf U. Renal protection with
the calcium antagonists. Journal of Cardiovascular
Pharmacology 1991; 18 Suppl 1:S11-8. Not relevant
to key questions
2901. Neuringer JR, Levey AS. Strategies to slow the
progression of renal disease. Seminars in Nephrology
1994; 14(3):261-73. Not RCT or controlled trial
2902. New JP, Marshall SM, Bilous RW. Renal
autoregulation is normal in newly diagnosed,
normotensive, NIDDM patients. Diabetologia 1998;
41(2):206-11. Sample size less than 50 patients
2903. Newell DR, Eeles RA, Gumbrell LA, et al.
Carboplatin and etoposide pharmacokinetics in
patients with testicular teratoma. Cancer
Chemotherapy & Pharmacology 1989; 23(6):367-72.
Not CKD treatment
2904. Newman PJ, Quinn AC, Hall GM, et al. Circulating
fluoride changes and hepatorenal function following
sevoflurane anaesthesia. Anaesthesia 1994;
49(11):936-9. Not CKD treatment
2905. Newman TJ, Dreslinski GR, Tadros SS. Safety
profile of aztreonam in clinical trials. Reviews of
Infectious Diseases 1985; 7 Suppl 4:S648-55. Not
RCT or controlled trial
2906. Ng TMH, Shurmur SW, Silver M, et al. Comparison
of N-acetylcysteine and fenoldopam for preventing
contrast-induced nephropathy (CAFCIN).
International Journal of Cardiology 2006;
109(3):322-8. Follow-up less than 6 months
2907. Ngan HY, Choo YC, Cheung M, et al. A randomized
study of high-dose versus low-dose cis-platinum
combined with cyclophosphamide in the treatment of
advanced ovarian cancer. Hong Kong Ovarian
Carcinoma Study Group. Chemotherapy 1989;
35(3):221-7. Not CKD treatment
2908. Ngugi NN, McLigeyo SO, Kayima JK. Treatment of
hyperkalaemia by altering the transcellular gradient
in patients with renal failure: effect of various
therapeutic approaches. East African Medical Journal
1997; 74(8):503-9. Follow-up less than 6 months
2909. Nguyen M, Chung EP. Telithromycin: the first
ketolide antimicrobial. Clinical Therapeutics 2005;
27(8):1144-63. Not CKD treatment
2910. Nguyen SA, Suranyi P, Ravenel JG, et al. Isoosmolality versus low-osmolality iodinated contrast
medium at intravenous contrast-enhanced CT: effect
on kidney function. Radiology 2008; 248(1):97-105.
Not RCT or controlled trial
2911. Nguyen TC, Stegmayr B, Busund R, et al. Plasma
therapies in thrombotic syndromes. International
Journal of Artificial Organs 2005; 28(5):459-65.
Follow-up less than 6 months
2912. Niccoli L, Bellino S, Cantini F. Renal tolerability of
three commonly employed non-steroidal antiinflammatory drugs in elderly patients with
osteoarthritis. Clinical & Experimental
Rheumatology 2002; 20(2):201-7. Not early CKD
2913. Nicholls MG, Arakawa K. Angiotensin-converting
enzyme inhibitors in congestive heart failure. Journal
of Cardiovascular Pharmacology 1987; 9 Suppl
3:S19-21. Not relevant to key questions
2914. Nicholls SJ, Tuzcu EM, Hsu A, et al. Comparison of
coronary atherosclerotic volume in patients with
glomerular filtration rates < or = 60 versus > 60
ml/min/1.73 m(2): a meta-analysis of intravascular
ultrasound studies. American Journal of Cardiology
2007; 99(6):813-6. Not relevant to key questions
2915. Nichols GA, Arondekar B, Herman WH.
Complications of dysglycemia and medical costs
associated with nondiabetic hyperglycemia.
B-167
American Journal of Managed Care 2008;
14(12):791-8. Not CKD treatment
2916. Nicholson ML, Baker DM, Hopkinson BR, et al.
Randomized controlled trial of the effect of mannitol
on renal reperfusion injury during aortic aneurysm
surgery. British Journal of Surgery 1996; 83(9):12303. Sample size less than 50 patients
2917. Nielsen CB, Bech JN, Pedersen EB. Effects of
prostacyclin on renal haemodynamics, renal tubular
function and vasoactive hormones in healthy
humans. A placebo-controlled dose-response study.
British Journal of Clinical Pharmacology 1997;
44(5):471-6. Sample size less than 50 patients
2918. Nielsen CB, Eiskjaer H, Pedersen EB. Enhanced
renal production of cyclic GMP and reduced free
water clearance during sodium nitroprusside infusion
in healthy man. European Journal of Clinical
Investigation 1993; 23(6):375-81. Sample size less
than 50 patients
2919. Nielsen CB, Pedersen EB. Effect of pinacidil on
renal haemodynamics, tubular function and plasma
levels of angiotensin II, aldosterone and atrial
natriuretic peptide in healthy man. European Journal
of Clinical Pharmacology 1993; 45(1):29-35. Sample
size less than 50 patients
2920. Nielsen CB, Pedersen EB. Abnormal distal tubular
sodium reabsorption during dopamine infusion in
patients with essential hypertension evaluated by the
lithium clearance methods. Clinical Nephrology
1997; 47(5):304-9. Sample size less than 50 patients
2921. Nielsen FS. Diabetic nephropathy in non-insulin
dependent diabetes mellitus. Cardiovascular risk
factors and antihypertensive treatment. Danish
Medical Bulletin 2000; 47(4):249-70. Not relevant to
key questions
2922. Nielsen FS, Gaede P, Vedel P, et al. White coat
hypertension in NIDDM patients with and without
incipient and overt diabetic nephropathy. Diabetes
Care 1997; 20(5):859-63. Follow-up less than 6
months
2923. Nielsen FS, Rossing P, Gall MA, et al. Impact of
lisinopril and atenolol on kidney function in
hypertensive NIDDM subjects with diabetic
nephropathy. Diabetes 1994; 43(9):1108-13. Sample
size less than 50 patients
2924. Nielsen FS, Rossing P, Gall MA, et al. Long-term
effect of lisinopril and atenolol on kidney function in
hypertensive NIDDM subjects with diabetic
nephropathy. Diabetes 1997; 46(7):1182-8. Sample
size less than 50 patients
2925. Nielsen FS, Rossing P, Gall MA, et al. Lisinopril
improves endothelial dysfunction in hypertensive
NIDDM subjects with diabetic nephropathy.
Scandinavian Journal of Clinical & Laboratory
Investigation 1997; 57(5):427-34. Sample size less
than 50 patients
2926. Nielsen HK, Krusell L, Baelum J, et al. Renal effects
of acute exposure to toluene. A controlled clinical
trial. Acta Medica Scandinavica 1985; 218(3):31721. Sample size less than 50 patients
2927. Nielsen HK, Thomsen K, Eriksen EF, et al. The
effects of high-dose glucocorticoid administration on
serum bone gamma carboxyglutamic acid-containing
protein, serum alkaline phosphatase and vitamin D
metabolites in normal subjects. Bone & Mineral
1988; 4(1):105-13. Follow-up less than 6 months
2928. Nielsen OM, Engell HC. Effects of maintaining
normal plasma colloid osmotic pressure on renal
function and excretion of sodium and water after
major surgery. A randomized study. Danish Medical
Bulletin 1985; 32(3):182-5. Sample size less than 50
patients
2929. Nielsen S, Dollerup J, Nielsen B, et al. Losartan
reduces albuminuria in patients with essential
hypertension. An enalapril controlled 3 months
study. Nephrology Dialysis Transplantation 1997; 12
Suppl 2:19-23. Sample size less than 50 patients
2930. Nielsen S, Dollerup J, Nielsen B, et al. Combination
of enalapril and low-dose thiazide reduces
normoalbuminuria in essential hypertension. Journal
of Hypertension 1998; 16(10):1539-44. Follow-up
less than 6 months
2931. Nielsen S, Hove KY, Dollerup J, et al. Losartan
modifies glomerular hyperfiltration and insulin
sensitivity in type 1 diabetes. Diabetes, Obesity &
Metabolism 2001; 3(6):463-71. Sample size less than
50 patients
2932. Nielsen S, Schmitz A, Bacher T, et al. Transcapillary
escape rate and albuminuria in Type II diabetes.
Effects of short-term treatment with low-molecular
weight heparin. Diabetologia 1999; 42(1):60-7. Not
RCT or controlled trial
2933. Nielsen S, Schmitz O, Moller N, et al. Renal function
and insulin sensitivity during simvastatin treatment in
type 2 (non-insulin-dependent) diabetic patients with
microalbuminuria. Diabetologia 1993; 36(10):107986. Sample size less than 50 patients
2934. Nielsen SE, Sugaya T, Tarnow L, et al. Tubular and
glomerular injury in diabetes and the impact of ACE
inhibition. Diabetes Care 2009; 32(9):1684-8. Not
RCT or controlled trial
2935. Nigwekar SU, Kandula P, Hix JK, et al. Off-pump
coronary artery bypass surgery and acute kidney
injury: a meta-analysis of randomized and
observational studies. American Journal of Kidney
Diseases 2009; 54(3):413-23. Not RCT or controlled
trial
2936. Nigwekar SU, Navaneethan SD, Parikh CR, et al.
Atrial natriuretic peptide for preventing and treating
acute kidney injury. Cochrane Database of
Systematic Reviews 2009; (4):CD006028. Not RCT
or controlled trial
2937. Nigwekar SU, Navaneethan SD, Parikh CR, et al.
Atrial natriuretic peptide for management of acute
kidney injury: a systematic review and meta-analysis.
Clinical Journal of The American Society of
Nephrology: CJASN 2009; 4(2):261-72. Not CKD
treatment
2938. Nigwekar SU, Navaneethan SD, Parikh CR, et al.
Atrial natriuretic peptide for management of acute
kidney injury: a systematic review and meta-analysis.
Clinical Journal of The American Society of
Nephrology: CJASN 2009; 4(2):261-72. Not CKD
treatment
B-168
2939. Nikolov IG, Mozar A, Drueke TB, et al. Impact of
disturbances of calcium and phosphate metabolism
on vascular calcification and clinical outcomes in
patients with chronic kidney disease. Blood
Purification 2009; 27(4):350-9. Not CKD treatment
2940. Nikolsky E, Mehran R, Dangas G, et al.
Development and validation of a prognostic risk
score for major bleeding in patients undergoing
percutaneous coronary intervention via the femoral
approach. European Heart Journal 2007;
28(16):1936-45. Follow-up less than 6 months
2941. Nilsen L, Djoseland O, Rootwelt K, et al. Effects of
short-term treatment with naproxen on kidney
function in insulin-dependent diabetic patients with
microalbuminuria. Scandinavian Journal of Clinical
& Laboratory Investigation 1991; 51(7):591-7.
Sample size less than 50 patients
2942. Nilsen OG, Sellevold OF, Romfo OS, et al.
Pharmacokinetics and effects on renal function
following cilazapril and hydrochlorothiazide alone
and in combination in healthy subjects and
hypertensive patients. British Journal of Clinical
Pharmacology 1989; 27 Suppl 2:323S-8S. Not
relevant to key questions
2943. Ninomiya T, Perkovic V, de Galan BE, et al.
Albuminuria and kidney function independently
predict cardiovascular and renal outcomes in
diabetes. Journal of the American Society of
Nephrology 2009; 20(8):1813-21. Not early CKD
2944. Ninomiya T, Perkovic V, Gallagher M, et al. Lower
blood pressure and risk of recurrent stroke in patients
with chronic kidney disease: PROGRESS trial.
Kidney International 2008; 73(8):963-70. Not CKD
treatment
2945. Ninomiya Y, Arakawa M. Renal effects of
prostaglandin E1 in type 2 (non-insulin-dependent)
diabetic patients with subclinical nephropathy.
Diabetes Research 1989; 10(3):129-34. Follow-up
less than 6 months
2946. Nishimura M, Sasaki T, Ohishi A, et al. Angiotensinconverting enzyme inhibitors and probucol suppress
the time-dependent increase in urinary Type IV
collagen excretion of Type II diabetes mellitus
patients with early diabetic nephropathy. Clinical
Nephrology 2001; 56(2):96-103. Not early CKD
2947. Nishizawa Y, Shoji T. Does paricalcitol reduce
proteinuria in patients with chronic kidney disease?
Nature Clinical Practice Nephrology 2006; 2(7):3523. Not RCT or controlled trial
2948. Nissel R, Fischer D-C, Puhlmann A, et al. Short-term
growth hormone treatment and microcirculation:
effects in patients with chronic kidney disease.
Microvascular Research 2009; 78(2):246-52. Not
RCT or controlled trial
2949. Nitsch D, Felber Dietrich D, von Eckardstein A, et
al. Prevalence of renal impairment and its association
with cardiovascular risk factors in a general
population: results of the Swiss SAPALDIA study.
Nephrology Dialysis Transplantation 2006;
21(4):935-44. Not adult population
2950. Nix DE, Thomas JK, Symonds WT, et al.
Assessment of the enzymuria resulting from
gentamicin alone and combinations of gentamicin
with various beta-lactam antibiotics. Annals of
Pharmacotherapy 1997; 31(6):696-703. Not CKD
treatment
2951. Nohria A, Hasselblad V, Stebbins A, et al.
Cardiorenal interactions: insights from the ESCAPE
trial. Journal of the American College of Cardiology
2008; 51(13):1268-74. Not CKD treatment
2952. Nolan CR, Califano JR, Butzin CA. Influence of
calcium acetate or calcium citrate on intestinal
aluminum absorption. Kidney International 1990;
38(5):937-41. Not CKD treatment
2953. Nolasco F, Cameron JS, Heywood EF, et al. Adultonset minimal change nephrotic syndrome: a longterm follow-up. Kidney International 1986;
29(6):1215-23. Follow-up less than 6 months
2954. Noone M, Pomeroy L, Sage R, et al. Prospective
study of amikacin versus netilmicin in the treatment
of severe infection in hospitalized patients. American
Journal of Medicine 1989; 86(6 Pt 2):809-13. Not
CKD treatment
2955. Noormohamed FH, Fuller GN, Lant AF. Effect of
salt balance on the renal and hemodynamic actions of
benazepril in normal men. Journal of Clinical
Pharmacology 1989; 29(10):928-37. Sample size less
than 50 patients
2956. Noormohamed FH, Lant AF. Renal handling of
lithium and the effects of mannitol and arginine
vasopressin in man. Clinical Science 1995; 89(1):2736. Sample size less than 50 patients
2957. Nordal KP, Dahl E. Low dose calcitriol versus
placebo in patients with predialysis chronic renal
failure. Journal of Clinical Endocrinology &
Metabolism 1988; 67(5):929-36. Sample size less
than 50 patients
2958. Nordenstrom E, Westerdahl J, Bergenfelz A. Effect
on bone density of postoperative calcium and
vitamin-D supplementation in patients with primary
hyperparathyroidism: A retrospective study.
Langenbecks Archives of Surgery 2009; 394(3):4617. Not CKD treatment
2959. Norgaard K, Feldt-Rasmussen B. Sodium retention
and insulin treatment in insulin-dependent diabetes
mellitus. Acta Diabetologica 1994; 31(1):19-25.
Sample size less than 50 patients
2960. Norgaard K, Jensen T, Christensen P, et al. A
comparison of spirapril and isradipine in patients
with diabetic nephropathy and hypertension. Blood
Pressure 1993; 2(4):301-8. Sample size less than 50
patients
2961. Norgaard K, Jensen T, Skott P, et al. Effects of
insulin on renal haemodynamics and sodium
handling in normal subjects. Scandinavian Journal of
Clinical & Laboratory Investigation 1991; 51(4):36776. Sample size less than 50 patients
2962. Norlund L, Fex G, Lanke J, et al. Reference intervals
for the glomerular filtration rate and cell-proliferation
markers: serum cystatin C and serum beta 2microglobulin/cystatin C-ratio. Scandinavian Journal
of Clinical & Laboratory Investigation 1997;
57(6):463-70. Not RCT or controlled trial
B-169
2963. Norman RW, Butler GJ, MacDiarmid SA, et al.
111Indium-oxine-labeled leukocytes and 67galliumcitrate as indicators of renal injury following
extracorporeal shock wave lithotripsy. Journal of
Urology 1992; 148(3 Pt 2):1022-4. Sample size less
than 50 patients
2964. Norris K, Vaughn C. The role of renin-angiotensinaldosterone system inhibition in chronic kidney
disease. Expert Review of Cardiovascular Therapy
2003; 1(1):51-63. Not early CKD
2965. Norris KC, Greene T, Kopple J, et al. Baseline
predictors of renal disease progression in the African
American Study of Hypertension and Kidney
Disease. Journal of the American Society of
Nephrology 2006; 17(10):2928-36. Not RCT or
controlled trial
2966. North RA, Taylor RS, Schellenberg JC. Evaluation
of a definition of pre-eclampsia. British Journal of
Obstetrics & Gynaecology 1999; 106(8):767-73. Not
RCT or controlled trial
2967. Northridge DB, Jardine AG, Findlay IN, et al.
Inhibition of the metabolism of atrial natriuretic
factor causes diuresis and natriuresis in chronic heart
failure. American Journal of Hypertension 1990;
3(9):682-7. Not CKD treatment
2968. Nosrati SM, Khwaja S, el-Shahawy M, et al. Effect
of angiotensin converting enzyme inhibition by
perindopril on proteinuria of primary renal diseases.
American Journal of Nephrology 1997; 17(6):511-7.
Sample size less than 50 patients
2969. Nossen JO, Jakobsen JA, Kjaersgaard P, et al.
Elimination of the non-ionic X-ray contrast media
iodixanol and iohexol in patients with severely
impaired renal function. Scandinavian Journal of
Clinical & Laboratory Investigation 1995; 55(4):34150. Sample size less than 50 patients
2970. Notghi A, Fiskerstrand CE, Burnet ME, et al. Effect
of nifedipine and mefruside on renal function and
platelet function in hypertensive patients. Current
Medical Research & Opinion 1987; 10(7):441-9.
Sample size less than 50 patients
2971. Nouri-Majalan N, Ardakani EF, Forouzannia K, et al.
Effects of allopurinol and vitamin E on renal function
in patients with cardiac coronary artery bypass grafts.
Vascular Health & Risk Management 2009;
5(2):489-94. Follow-up less than 6 months
2972. Nowack R, Fliser D, Richter J, et al. Effects of
angiotensin-converting enzyme inhibition on renal
sodium handling after furosemide injection. Clinical
Investigator 1993; 71(8):622-7. Sample size less than
50 patients
2973. Nyberg G, Blohme G, Norden G. Impact of
metabolic control in progression of clinical diabetic
nephropathy. Diabetologia 1987; 30(2):82-6. Sample
size less than 50 patients
2974. Nyman U, Almen T, Aspelin P, et al. Contrastmedium-Induced nephropathy correlated to the ratio
between dose in gram iodine and estimated GFR in
ml/min. Acta Radiologica 2005; 46(8):830-42. Not
RCT or controlled trial
2975. Nyman U, Elmstahl B, Leander P, et al. Are
gadolinium-based contrast media really safer than
iodinated media for digital subtraction angiography
in patients with azotemia? Radiology 2002;
223(2):311-8; discussion 28-9. Not early CKD
2976. Obasaju CK, Johnson SW, Rogatko A, et al.
Evaluation of carboplatin pharmacokinetics in the
absence and presence of paclitaxel. Clinical Cancer
Research 1996; 2(3):549-52. Sample size less than 50
patients
2977. Obata R, Bito H, Ohmura M, et al. The effects of
prolonged low-flow sevoflurane anesthesia on renal
and hepatic function. Anesthesia & Analgesia 2000;
91(5):1262-8. Not early CKD
2978. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated
dosing of N-acetylcysteine prevents contrast-induced
nephropathy after elective and urgent coronary
angiography and intervention. Journal of
Interventional Cardiology 2004; 17(3):159-65. Not
early CKD
2979. O'Connell DP, Ragsdale NV, Boyd DG, et al.
Differential human renal tubular responses to
dopamine type 1 receptor stimulation are determined
by blood pressure status. Hypertension 1997; 29(1 Pt
1):115-22. Sample size less than 50 patients
2980. O'Connell JE, Jardine AG, Davies DL, et al. Renal
and hormonal effects of chronic inhibition of neutral
endopeptidase (EC 3.4.24.11) in normal man.
Clinical Science 1993; 85(1):19-26. Follow-up less
than 6 months
2981. O'Connor PJ, Spann SJ, Woolf SH. Care of adults
with type 2 diabetes mellitus. A review of the
evidence. Journal of Family Practice 1998; 47(5
Suppl):S13-22. Not RCT or controlled trial
2982. Odabas AR, Cetinkaya R, Selcuk Y, et al. Effect of
losartan treatment on the proteinuria in normotensive
patients having proteinuria due to secondary
amyloidosis. Upsala Journal of Medical Sciences
2001; 106(3):183-8. Sample size less than 50 patients
2983. Oddoze C, Morange S, Portugal H, et al. Cystatin C
is not more sensitive than creatinine for detecting
early renal impairment in patients with diabetes.
American Journal of Kidney Diseases 2001;
38(2):310-6. Not RCT or controlled trial
2984. O'Doherty DP, Gertz BJ, Tindale W, et al. Effects of
five daily 1 h infusions of alendronate in Paget's
disease of bone. Journal of Bone & Mineral Research
1992; 7(1):81-7. Not CKD treatment
2985. O'Doherty DP, McCloskey EV, Vasikaran S, et al.
The effects of intravenous alendronate in Paget's
disease of bone. Journal of Bone & Mineral Research
1995; 10(7):1094-100. Sample size less than 50
patients
2986. O'Donnell MJ, Rowe BR, Lawson N, et al.
Comparison of the effects of an angiotensin
converting enzyme inhibitor and a calcium antagonist
in hypertensive, macroproteinuric diabetic patients: a
randomised double-blind study. Journal of Human
Hypertension 1993; 7(4):333-9. Sample size less than
50 patients
2987. O'Donnell MJ, Rowe BR, Lawson N, et al. Placebocontrolled trial of lisinopril in normotensive diabetic
patients with incipient nephropathy. Journal of
B-170
Human Hypertension 1993; 7(4):327-32. Sample size
less than 50 patients
2988. Odvina CV, Mason RP, Pak CYC. Prevention of
thiazide-induced hypokalemia without magnesium
depletion by potassium-magnesium-citrate. American
Journal of Therapeutics 2006; 13(2):101-8. Not RCT
or controlled trial
2989. Ogawa O, Hayashi C, Nakaniwa T, et al. Arterial
stiffness is associated with diabetic retinopathy in
type 2 diabetes. Diabetes Research & Clinical
Practice 2005; 68(2):162-6. Not relevant to key
questions
2990. Ogawa S, Mori T, Nako K, et al. Reduced
albuminuria with sarpogrelate is accompanied by a
decrease in monocyte chemoattractant protein-1
levels in type 2 diabetes. Clinical Journal of The
American Society of Nephrology: CJASN 2008;
3(2):362-8. Not RCT or controlled trial
2991. Ogawa S, Mori T, Nako K, et al. Combination
therapy with renin-angiotensin system inhibitors and
the calcium channel blocker azelnidipine decreases
plasma inflammatory markers and urinary oxidative
stress markers in patients with diabetic nephropathy.
Hypertension Research - Clinical & Experimental
2008; 31(6):1147-55. Sample size less than 50
patients
2992. Ogawa S, Mori T, Nako K, et al. Angiotensin II type
1 receptor blockers reduce urinary oxidative stress
markers in hypertensive diabetic nephropathy.
Hypertension 2006; 47(4):699-705. Follow-up less
than 6 months
2993. Ogawa S, Takeuchi K, Mori T, et al. Spironolactone
further reduces urinary albumin excretion and plasma
B-type natriuretic peptide levels in hypertensive type
II diabetes treated with angiotensin-converting
enzyme inhibitor. Clinical & Experimental
Pharmacology & Physiology 2006; 33(5-6):477-9.
Not RCT or controlled trial
2994. Ogawa Y, Haneda T, Hirayama T, et al. Effects of
lisinopril and nitrendipine on urinary albumin
excretion and renal function in patients with mild to
moderate essential hypertension. Hypertension
Research - Clinical & Experimental 2000; 23(6):60712. Sample size less than 50 patients
2995. Ogihara T, Kaneko Y, Ikeda M, et al. Clinical
evaluation of delapril in Japan. Report from the
Japan Study Group on Delapril. American Journal of
Hypertension 1991; 4(1 Pt 2):42S-5S. Not CKD
treatment
2996. O'Hanlon JJ, Beers H, Huss BK, et al. A comparison
of the effect of intramuscular diclofenac, ketorolac or
piroxicam on post-operative pain following
laparoscopy. European Journal of Anaesthesiology
1996; 13(4):404-7. Not CKD treatment
2997. O'Hara JF, Jr., Hsu THS, Sprung J, et al. The effect
of dopamine on renal function in solitary partial
nephrectomy surgery.[Erratum appears in J Urol
2002 Mar;167(3):1408]. Journal of Urology 2002;
167(1):24-8. Not early CKD
2998. O'Hare AM, Kaufman JS, Covinsky KE, et al.
Current guidelines for using angiotensin-converting
enzyme inhibitors and angiotensin II-receptor
antagonists in chronic kidney disease: is the evidence
base relevant to older adults? Annals of Internal
Medicine 2009; 150(10):717-24. Not RCT or
controlled trial
2999. O'Hare AM, Vittinghoff E, Hsia J, et al. Renal
insufficiency and the risk of lower extremity
peripheral arterial disease: results from the Heart and
Estrogen/Progestin Replacement Study (HERS).
Journal of the American Society of Nephrology
2004; 15(4):1046-51. Not CKD treatment
3000. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive
insulin therapy prevents the progression of diabetic
microvascular complications in Japanese patients
with non-insulin-dependent diabetes mellitus: a
randomized prospective 6-year study. Diabetes
Research & Clinical Practice 1995; 28(2):103-17.
Not CKD treatment
3001. Ohls RK, Dai A. Long-acting erythropoietin: clinical
studies and potential uses in neonates. Clinics in
Perinatology 2004; 31(1):77-89. Sample size less
than 50 patients
3002. Ohmit SE, Flack JM, Peters RM, et al. Longitudinal
Study of the National Kidney Foundation's (NKF)
Kidney Early Evaluation Program (KEEP). Journal
of the American Society of Nephrology 2003; 14(7
Suppl 2):S117-21. Not CKD treatment
3003. Ohnmacht GA, Phan GQ, Mavroukakis SA, et al. A
prospective, randomized, double-blind, placebocontrolled trial evaluating the effect of nystatin on
the development of oral irritation in patients
receiving high-dose intravenous interleukin-2.
Journal of Immunotherapy 2001; 24(2):188-92. Not
CKD treatment
3004. Okamoto H, Nagatomo A, Kunitoh H, et al.
Prediction of carboplatin clearance calculated by
patient characteristics or 24-hour creatinine
clearance: a comparison of the performance of three
formulae. Cancer Chemotherapy & Pharmacology
1998; 42(4):307-12. Not CKD treatment
3005. O'Keefe JH, Bybee KA, Lavie CJ. Intensive lipid
intervention in the post-ENHANCE era. Mayo Clinic
Proceedings 2008; 83(8):867-9. Not CKD treatment
3006. Oksa A, Spustova V, Krivosikova Z, et al. Effects of
long-term cholecalciferol supplementation on
mineral metabolism and calciotropic hormones in
chronic kidney disease. Kidney & Blood Pressure
Research 2008; 31(5):322-9. Not CKD treatment
3007. Olbricht CJ, Wanner C, Thiery J, et al. Simvastatin in
nephrotic syndrome. Simvastatin in Nephrotic
Syndrome Study Group. Kidney International Supplement 1999; 71:S113-6. Not CKD treatment
3008. Oldemeyer JB, Biddle WP, Wurdeman RL, et al.
Acetylcysteine in the prevention of contrast-induced
nephropathy after coronary angiography. American
Heart Journal 2003; 146(6):E23. Not RCT or
controlled trial
3009. Olencki T, Finke J, Tubbs R, et al.
Immunomodulatory effects of interleukin-2 and
interleukin-4 in patients with malignancy. Journal of
Immunotherapy with Emphasis on Tumor
Immunology 1996; 19(1):69-80. Not CKD treatment
B-171
Pharmacology 1997; 43(5):509-20. Sample size less
than 50 patients
3022. Olsen NV, Olsen MH, Fogh-Andersen N, et al.
Lithium clearance method and the renal response to
low-dose dopamine in man: a randomized, controlled
study. Clinical Science 1993; 84(2):237-42. Sample
size less than 50 patients
3023. Olthof MR, Brink EJ, Katan MB, et al. Choline
supplemented as phosphatidylcholine decreases
fasting and postmethionine-loading plasma
homocysteine concentrations in healthy men.
American Journal of Clinical Nutrition 2005;
82(1):111-7. Sample size less than 50 patients
3024. Omar MA, Motala AA, Seedat MA, et al. Effects of
captopril and prazosin on renal function in diabetes.
South African Medical Journal 1993; SuidAfrikaanse Tydskrif Vir Geneeskunde. 83(5):365.
Not RCT or controlled trial
3025. Omari BO, Nelson RJ, Robertson JM. Effect of right
atrial appendectomy on the release of atrial
natriuretic hormone. Journal of Thoracic &
Cardiovascular Surgery 1991; 102(2):272-9. Not
CKD treatment
3026. O'Meara E, Clayton T, McEntegart MB, et al.
Clinical correlates and consequences of anemia in a
broad spectrum of patients with heart failure: results
of the Candesartan in Heart Failure: Assessment of
Reduction in Mortality and Morbidity (CHARM)
Program. Circulation 2006; 113(7):986-94. Not RCT
or controlled trial
3027. Onat A, Hergenc G, Uyarel H, et al. Association
between mild renal dysfunction and insulin resistance
or metabolic syndrome in a random nondiabetic
population sample. Kidney & Blood Pressure
Research 2007; 30(2):88-96. Not relevant to key
questions
3028. Onbasili AO, Yeniceriglu Y, Agaoglu P, et al.
Trimetazidine in the prevention of contrast-induced
nephropathy after coronary procedures. Heart 2007;
93(6):698-702. Not CKD treatment
3029. O'Neill JO, Taylor DO, Starling RC.
Immunosuppression for cardiac transplantation--the
past, present and future. Transplantation Proceedings
2004; 36(2 Suppl):309S-13S. Sample size less than
50 patients
3030. Onorati F, Presta P, Fuiano G, et al. A randomized
trial of pulsatile perfusion using an intra-aortic
balloon pump versus nonpulsatile perfusion on shortterm changes in kidney function during
cardiopulmonary bypass during myocardial
reperfusion. American Journal of Kidney Diseases
2007; 50(2):229-38. Not relevant to key questions
3031. Onuigbo MAC. Does concurrent renin-angiotensinaldosterone blockade in (older) chronic kidney
disease patients play a role in the acute renal failure
epidemic in US hospitalized patients?--Three cases
of severe acute renal failure encountered in a
northwestern Wisconsin Nephrology practice.
Hemodialysis International 2009; 13 Suppl 1:S24-9.
Not CKD treatment
3032. Onuigbo MAC. Reno-prevention vs. reno-protection:
a critical re-appraisal of the evidence-base from the
3010. Olgaard K, Lewin E. Reply to Dr S.C. Palmer and
co-workers. Nephrology Dialysis Transplantation
2008; 23(8):2709-10. Not CKD treatment
3011. Olgaard K, Storm T, van Wowern N, et al.
Glucocorticoid-induced osteoporosis in the lumbar
spine, forearm, and mandible of nephrotic patients: a
double-blind study on the high-dose, long-term
effects of prednisone versus deflazacort. Calcified
Tissue International 1992; 50(6):490-7. Sample size
less than 50 patients
3012. Oliver WC, Jr., Nuttall GA, Cherry KJ, et al. A
comparison of fenoldopam with dopamine and
sodium nitroprusside in patients undergoing crossclamping of the abdominal aorta. Anesthesia &
Analgesia 2006; 103(4):833-40. Not CKD treatment
3013. Olsen KM, Rudis MI, Rebuck JA, et al. Effect of
once-daily dosing vs. multiple daily dosing of
tobramycin on enzyme markers of nephrotoxicity.
Critical Care Medicine 2004; 32(8):1678-82. Not
CKD treatment
3014. Olsen ME, Thomsen T, Hassager C, et al.
Hemodynamic and renal effects of indomethacin in
losartan-treated hypertensive individuals. American
Journal of Hypertension 1999; 12(2 Pt 1):209-16.
Sample size less than 50 patients
3015. Olsen MH, Wachtell K, Bella JN, et al. Albuminuria
predicts cardiovascular events independently of left
ventricular mass in hypertension: a LIFE substudy.
Journal of Human Hypertension 2004; 18(6):453-9.
Not CKD treatment
3016. Olsen MH, Wachtell K, Borch-Johnsen K, et al. A
blood pressure independent association between
glomerular albumin leakage and electrocardiographic
left ventricular hypertrophy. The LIFE Study.
Losartan Intervention For Endpoint reduction.
Journal of Human Hypertension 2002; 16(8):591-5.
Not relevant to key questions
3017. Olsen MH, Wachtell K, Ibsen H, et al. Reductions in
albuminuria and in electrocardiographic left
ventricular hypertrophy independently improve
prognosis in hypertension: the LIFE study. Journal of
Hypertension 2006; 24(4):775-81. Sample size less
than 50 patients
3018. Olsen NV, Fogh-Andersen N, Strandgaard S, et al.
Endogenous versus exogenous lithium clearance for
evaluation of dopamine-induced changes in renal
tubular function. Clinical Science 1996; 90(6):511-5.
Sample size less than 50 patients
3019. Olsen NV, Jensen NG, Hansen JM, et al. Nonsteroidal anti-inflammatory drugs and renal response
to exercise: a comparison of indomethacin and
nabumetone. Clinical Science 1999; 97(4):457-65.
Sample size less than 50 patients
3020. Olsen NV, Lang-Jensen T, Hansen JM, et al. Effects
of acute beta-adrenoceptor blockade with metoprolol
on the renal response to dopamine in normal humans.
British Journal of Clinical Pharmacology 1994;
37(4):347-53. Not CKD treatment
3021. Olsen NV, Olsen MH, Bonde J, et al. Dopamine
natriuresis in salt-repleted, water-loaded humans: a
dose-response study. British Journal of Clinical
B-172
Nephrology 2003; 8(4):171-6. Sample size less than
50 patients
3045. Os I, Gudmundsdottir H, Kjeldsen SE, et al.
Treatment of isolated systolic hypertension in
diabetes mellitus type 2. Diabetes, Obesity &
Metabolism 2006; 8(4):381-7. Not RCT or controlled
trial
3046. Osei SY, Price DA, Laffel LM, et al. Effect of
angiotensin II antagonist eprosartan on
hyperglycemia-induced activation of intrarenal reninangiotensin system in healthy humans. Hypertension
2000; 36(1):122-6. Not early CKD
3047. Oster HS, Hoffman M, Prutchi-Sagiv S, et al.
Erythropoietin in clinical practice: current use, effect
on survival, and future directions. Israel Medical
Association Journal: Imaj 2006; 8(10):703-6. Not
CKD treatment
3048. Ostermann M, Alvarez G, Sharpe MD, et al.
Frusemide administration in critically ill patients by
continuous compared to bolus therapy. Nephron
2007; 107(2):c70-6. Sample size less than 50 patients
3049. Osterziel KJ, Dietz R, Harder K, et al. Comparison of
captopril with enalapril in the treatment of heart
failure: influence on hemodynamics and measures of
renal function. Cardiovascular Drugs & Therapy
1992; 6(2):173-80. Sample size less than 50 patients
3050. Osterziel KJ, Dietz R, Lemmer B. Circadian rhythm
of blood pressure in congestive heart failure and
effects of ACE inhibitors. Chronobiology
International 1991; 8(5):420-31. Sample size less
than 50 patients
3051. O'Toole L, Stewart M, Padfield P, et al. Effect of the
insertion/deletion polymorphism of the angiotensinconverting enzyme gene on response to angiotensinconverting enzyme inhibitors in patients with heart
failure. Journal of Cardiovascular Pharmacology
1998; 32(6):988-94. Sample size less than 50 patients
3052. Ott C, Ritt M, Titze SI, et al. Rosuvastatin does not
affect intrarenal hemodynamics in patients with
hypercholesterolemia. Journal of Nephrology 2009;
22(5):675-81. Sample size less than 50 patients
3053. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, et al.
Effects of a long-acting formulation of octreotide on
renal function and renal sodium handling in cirrhotic
patients with portal hypertension: a randomized,
double-blind, controlled trial. Hepatology 2001;
34(3):471-7. Not early CKD
3054. Oudemans-van Straaten HM. Strategies to prevent
contrast nephropathy. Minerva Cardioangiologica
2005; 53(5):445-63. Sample size less than 50 patients
3055. Oudit GY, Liu GC, Zhong J, et al. Human
recombinant ACE2 reduces the progression of
diabetic nephropathy. Diabetes 2010; 59(2):529-38.
Not human studies
3056. Ovartlarnporn M, Jongjaroenprasert W. Advancing
age and renal impairment as important predisposing
factors of gatifloxacin-induced hyperglycemia in
non-diabetes patients. Journal of the Medical
Association of Thailand 2007; 90(3):569-73. Not
relevant to key questions
large RAAS blockade trials after ONTARGET--a
call for more circumspection. Qjm 2009; 102(3):15567. Not CKD treatment
3033. Onwude JL, Lilford RJ, Hjartardottir H, et al. A
randomised double blind placebo controlled trial of
fish oil in high risk pregnancy. British Journal of
Obstetrics & Gynaecology 1995; 102(2):95-100. Not
CKD treatment
3034. Ooi JSM, Ramzisham ARM, Zamrin MD. Is 6%
hydroxyethyl starch 130/0.4 safe in coronary artery
bypass graft surgery? Asian Cardiovascular &
Thoracic Annals 2009; 17(4):368-72. Not CKD
treatment
3035. Oosterlinck W, Philp NH, Charig C, et al. A doubleblind single dose comparison of intramuscular
ketorolac tromethamine and pethidine in the
treatment of renal colic. Journal of Clinical
Pharmacology 1990; 30(4):336-41. Not CKD
treatment
3036. Ordonez JD, Hiatt RA, Killebrew EJ, et al. The
increased risk of coronary heart disease associated
with nephrotic syndrome. Kidney International 1993;
44(3):638-42. Not RCT or controlled trial
3037. O'Reilly PH, Brooman PJ, Martin PJ, et al. Accuracy
and reproducibility of a new contrast clearance
method for the determination of glomerular filtration
rate. British Medical Journal Clinical Research Ed.
1986; 293(6541):234-6. Follow-up less than 6
months
3038. Oriana S, Bohm S, Spatti G, et al. A preliminary
clinical experience with reduced glutathione as
protector against cisplatin-toxicity. Tumori 1987;
73(4):337-40. Sample size less than 50 patients
3039. O'Riordan E, Foley RN. Effects of anaemia on
cardiovascular status. Nephrology Dialysis
Transplantation 2000; 15 Suppl 3:19-22. Not early
CKD
3040. Orita Y, Okada M, Harada S, et al. Skim soy protein
enhances GFR as much as beefsteak protein in
healthy human subjects. Clinical & Experimental
Nephrology 2004; 8(2):103-8. Not CKD treatment
3041. Ortapamuk H, Naldoken S, Tekdogan UY, et al.
Differential renal function in the prediction of
recovery in adult obstructed kidneys after
pyeloplasty. Annals of Nuclear Medicine 2003;
17(8):663-8. Not CKD treatment
3042. Orth SR, Hallan SI. Smoking: a risk factor for
progression of chronic kidney disease and for
cardiovascular morbidity and mortality in renal
patients--absence of evidence or evidence of
absence? Clinical Journal of The American Society
of Nephrology: CJASN 2008; 3(1):226-36. Not RCT
or controlled trial
3043. Ortiz A, Oliveira JP, Wanner C, et al.
Recommendations and guidelines for the diagnosis
and treatment of Fabry nephropathy in adults. Nature
Clinical Practice Nephrology 2008; 4(6):327-36. Not
CKD treatment
3044. Ortiz MA, De Prado A, Donate T, et al. Angiotensinconverting enzyme polymorphism gene and
evolution of nephropathy to end-stage renal disease.
B-173
3057. Overbosch D, van Gulpen C, Mattie H. Renal
clearance of temocillin in volunteers. Drugs 1985; 29
Suppl 5:128-34. Sample size less than 50 patients
3058. Overman GP, Teter CJ, Guthrie SK. Acamprosate for
the adjunctive treatment of alcohol dependence.
Annals of Pharmacotherapy 2003; 37(7-8):1090-9.
Not CKD treatment
3059. Owada A, Nakao M, Koike J, et al. Effects of oral
adsorbent AST-120 on the progression of chronic
renal failure: a randomized controlled study. Kidney
International - Supplement 1997; 63:S188-90.
Sample size less than 50 patients
3060. Owada A, Suda S, Hata T. Effect of long-term
administration of prostaglandin I(2) in incipient
diabetic nephropathy. Nephron 2002; 92(4):788-96.
Sample size less than 50 patients
3061. Owada A, Suda S, Hata T. Antiproteinuric effect of
niceritrol, a nicotinic acid derivative, in chronic renal
disease with hyperlipidemia: a randomized trial.
American Journal of Medicine 2003; 114(5):347-53.
Sample size less than 50 patients
3062. Owan TE, Chen HH, Frantz RP, et al. The effects of
nesiritide on renal function and diuretic
responsiveness in acutely decompensated heart
failure patients with renal dysfunction. Journal of
Cardiac Failure 2008; 14(4):267-75. Not CKD
treatment
3063. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium
bicarbonate, N-acetylcysteine, and saline for
prevention of radiocontrast-induced nephropathy. A
comparison of 3 regimens for protecting contrastinduced nephropathy in patients undergoing coronary
procedures. A single-center prospective controlled
trial. American Heart Journal 2007; 154(3):539-44.
Follow-up less than 6 months
3064. Ozcan S, Yilmaz E, Buyukkocak U, et al.
Comparison of three analgesics for extracorporeal
shock wave lithotripsy. Scandinavian Journal of
Urology & Nephrology 2002; 36(4):281-5. Not CKD
treatment
3065. Ozdal OL, Ozden C, Benli K, et al. Effect of shortterm finasteride therapy on peroperative bleeding in
patients who were candidates for transurethral
resection of the prostate (TUR-P): a randomized
controlled study. Prostate Cancer & Prostatic
Diseases 2005; 8(3):215-8. Not RCT or controlled
trial
3066. Ozdener F, Ozdemir V. Fasidotril Eli Lilly. Current
Opinion in Investigational Drugs 2003; 4(9):1113-9.
Not CKD treatment
3067. Pacher R, Stanek B, Globits S, et al. Effects of two
different enalapril dosages on clinical,
haemodynamic and neurohumoral response of
patients with severe congestive heart failure.
European Heart Journal 1996; 17(8):1223-32. Not
early CKD
3068. Pacher R, Stanek B, Hulsmann M, et al. Effect of
prostaglandin E1 infusion in severe chronic heart
failure. Prostaglandins 1997; 53(4):221-35. Not CKD
treatment
3069. Packard DP, Milton JE, Shuler LA, et al.
Implications of chronic kidney disease for dietary
treatment in cardiovascular disease. Journal of Renal
Nutrition 2006; 16(3):259-68. Follow-up less than 6
months
3070. Padillo FJ, Briceno J, Cruz A, et al. Randomized
clinical trial of the effect of intravenous fluid
administration on hormonal and renal dysfunction in
patients with obstructive jaundice undergoing
endoscopic drainage. British Journal of Surgery
2005; 92(1):39-43. Sample size less than 50 patients
3071. Pageaux G-P, Rostaing L, Calmus Y, et al.
Mycophenolate mofetil in combination with
reduction of calcineurin inhibitors for chronic renal
dysfunction after liver transplantation. Liver
Transplantation 2006; 12(12):1755-60. Sample size
less than 50 patients
3072. Pagliaro LC, Sharma P. Review of metastatic bladder
cancer. Minerva Urologica e Nefrologica 2006;
58(1):53-71. Not relevant to key questions
3073. Pain JA, Cahill CJ, Gilbert JM, et al. Prevention of
postoperative renal dysfunction in patients with
obstructive jaundice: a multicentre study of bile salts
and lactulose. British Journal of Surgery 1991;
78(4):467-9. Not CKD treatment
3074. Pais RC, Abdel-Mageed A, Ghim TT, et al. Phase I
study of recombinant human interleukin-2 for
pediatric malignancies: feasibility of outpatient
therapy. A Pediatric Oncology Group Study. Journal
of Immunotherapy 1992; 12(2):138-46. Not adult
population
3075. Palazzuoli A, Gallotta M, Iovine F, et al. Anaemia in
heart failure: a common interaction with renal
insufficiency called the cardio-renal anaemia
syndrome. International Journal of Clinical Practice
2008; 62(2):281-6. Not CKD treatment
3076. Palazzuoli A, Silverberg D, Iovine F, et al.
Erythropoietin improves anemia exercise tolerance
and renal function and reduces B-type natriuretic
peptide and hospitalization in patients with heart
failure and anemia. American Heart Journal 2006;
152(6):1096.e9-15. Not CKD treatment
3077. Palla R, Marchitiello M, Tuoni M, et al. Enzymuria
in aminoglycoside-induced kidney damage.
Comparative study of gentamicin, amikacin,
sisomicin and netilmicin. International Journal of
Clinical Pharmacology Research 1985; 5(5):351-5.
Sample size less than 50 patients
3078. Palla R, Parrini M, Panichi V, et al. Acute effects of
calcitonin gene related peptide on renal
haemodynamics and renin and angiotensin II
secretion in patients with renal disease. International
Journal of Tissue Reactions 1995; 17(1):43-9.
Sample size less than 50 patients
3079. Palmas W, Moran A, Pickering T, et al. Ambulatory
pulse pressure and progression of urinary albumin
excretion in older patients with type 2 diabetes
mellitus. Hypertension 2006; 48(2):301-8. Sample
size less than 50 patients
3080. Palmer AJ, Annemans L, Roze S, et al. An economic
evaluation of the Irbesartan in Diabetic Nephropathy
Trial (IDNT) in a UK setting. Journal of Human
Hypertension 2004; 18(10):733-8. Not CKD
treatment
B-174
3081. Palmer AJ, Valentine WJ, Chen R, et al. A health
economic analysis of screening and optimal
treatment of nephropathy in patients with type 2
diabetes and hypertension in the USA. Nephrology
Dialysis Transplantation 2008; 23(4):1216-23.
Sample size less than 50 patients
3082. Palmer AJ, Valentine WJ, Ray JA. Irbesartan
treatment of patients with type 2 diabetes,
hypertension and renal disease: a UK health
economics analysis. International Journal of Clinical
Practice 2007; 61(10):1626-33. Not RCT or
controlled trial
3083. Palmer SC, McGregor DO, Macaskill P, et al. Metaanalysis: vitamin D compounds in chronic kidney
disease. Annals of Internal Medicine 2007;
147(12):840-53. Not relevant to key questions
3084. Palmer SC, Nand K, Strippoli GF. Interventions for
minimal change disease in adults with nephrotic
syndrome. Cochrane Database of Systematic
Reviews 2008; (1):CD001537. Not relevant to key
questions
3085. Palumbo A, Gay F. How to treat elderly patients with
multiple myeloma: combination of therapy or
sequencing. Hematology 2009:566-77. Not RCT or
controlled trial
3086. Pan Y, Guo LL, Jin HM. Low-protein diet for
diabetic nephropathy: a meta-analysis of randomized
controlled trials. American Journal of Clinical
Nutrition 2008; 88(3):660-6. Not CKD treatment
3087. Panetta CJ, Herzog CA, Henry TD. Acute coronary
syndromes in patients with renal disease: what are
the issues? Current Cardiology Reports 2006;
8(4):296-300. Sample size less than 50 patients
3088. Paniagua JA, Lopez-Miranda J, Perez-Martinez P, et
al. Oxidized-LDL levels are changed during shortterm serum glucose variations and lowered with
statin treatment in early Type 2 diabetes: a study of
endothelial function and microalbuminuria. Diabetic
Medicine 2005; 22(12):1647-56. Sample size less
than 50 patients
3089. Paniagua R, Claure R, Amato D, et al. Effects of oral
administration of zinc and diiodohydroxyquinolein
on plasma zinc levels of uremic patients. Nephron
1995; 69(2):147-50. Sample size less than 50 patients
3090. Panichi V, Andreini B, De Pietro S, et al. Calcitriol
oral therapy for the prevention of secondary
hyperparathyroidism in patients with predialytic
renal failure. Clinical Nephrology 1998; 49(4):24550. Sample size less than 50 patients
3091. Panichi V, Paoletti S, Mantuano E, et al. In vivo and
in vitro effects of simvastatin on inflammatory
markers in pre-dialysis patients. Nephrology Dialysis
Transplantation 2006; 21(2):337-44. Not CKD
treatment
3092. Pannu N, Manns B, Lee H, et al. Systematic review
of the impact of N-acetylcysteine on contrast
nephropathy. Kidney International 2004; 65(4):136674. Not relevant to key questions
3093. Pannu N, Tonelli M. Strategies to reduce the risk of
contrast nephropathy: an evidence-based approach.
Current Opinion in Nephrology & Hypertension
2006; 15(3):285-90. Follow-up less than 6 months
3094. Pannu N, Wiebe N, Tonelli M, et al. Prophylaxis
strategies for contrast-induced nephropathy. JAMA
2006; 295(23):2765-79. Not relevant to key questions
3095. Panos GZ, Betsi GI, Falagas ME. Systematic review:
are antibiotics detrimental or beneficial for the
treatment of patients with Escherichia coli O157:H7
infection? Alimentary Pharmacology & Therapeutics
2006; 24(5):731-42. Not RCT or controlled trial
3096. Pantaleo P, Marra F, Vizzutti F, et al. Effects of
dietary supplementation with arachidonic acid on
platelet and renal function in patients with cirrhosis.
Clinical Science 2004; 106(1):27-34. Not CKD
treatment
3097. Paoletti E, Cannella G. Update on erythropoietin
treatment: should hemoglobin be normalized in
patients with chronic kidney disease? Journal of the
American Society of Nephrology 2006; 17(4 Suppl
2):S74-7. Not relevant to key questions
3098. Papaioannou GI, Seip RL, Grey NJ, et al. Brachial
artery reactivity in asymptomatic patients with type 2
diabetes mellitus and microalbuminuria (from the
Detection of Ischemia in Asymptomatic Diabeticsbrachial artery reactivity study). American Journal of
Cardiology 2004; 94(3):294-9. Not CKD treatment
3099. Papavasiliou EC, Gouva C, Siamopoulos KC, et al.
Erythrocyte PAF-acetylhydrolase activity in various
stages of chronic kidney disease: effect of long-term
therapy with erythropoietin. Kidney International
2005; 68(1):246-55. Sample size less than 50 patients
3100. Papavasiliou EC, Gouva C, Siamopoulos KC, et al.
PAF-acetylhydrolase activity in plasma of patients
with chronic kidney disease. Effect of long-term
therapy with erythropoietin. Nephrology Dialysis
Transplantation 2006; 21(5):1270-7. Not RCT or
controlled trial
3101. Pappas KD, Gouva CD, Katopodis KP, et al.
Correction of anemia with erythropoietin in chronic
kidney disease (stage 3 or 4): effects on cardiac
performance. Cardiovascular Drugs & Therapy 2008;
22(1):37-44. Not RCT or controlled trial
3102. Paran H, Neufeld D, Mayo A, et al. Preliminary
report of a prospective randomized study of
octreotide in the treatment of severe acute
pancreatitis. Journal of the American College of
Surgeons 1995; 181(2):121-4. Not CKD treatment
3103. Paredes J, Hong WK, Felder TB, et al. Prospective
randomized trial of high-dose cisplatin and
fluorouracil infusion with or without sodium
diethyldithiocarbamate in recurrent and/or metastatic
squamous cell carcinoma of the head and neck.
Journal of Clinical Oncology 1988; 6(6):955-62. Not
CKD treatment
3104. Parfrey P. Anaemia in chronic renal disease: lessons
learned since Seville 1994. Nephrology Dialysis
Transplantation 2001; 16 Suppl 7:41-5. Not RCT or
controlled trial
3105. Parfrey PS, Harnett JD. The management of cardiac
disease in chronic uremia. Current Opinion in
Nephrology & Hypertension 1994; 3(2):145-54. Not
CKD treatment
3106. Parikh CR, McSweeney P, Schrier RW. Acute renal
failure independently predicts mortality after
B-175
myeloablative allogeneic hematopoietic cell
transplant. Kidney International 2005; 67(5):19992005. Not CKD treatment
3107. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, et al.
Levosimendan: from basic science to clinical
practice. Heart Failure Reviews 2009; 14(4):265-75.
Not CKD treatment
3108. Park GD, Goldberg MJ, Spector R, et al. The effects
of activated charcoal on digoxin and digitoxin
clearance. Drug Intelligence & Clinical Pharmacy
1985; 19(12):937-41. Sample size less than 50
patients
3109. Park JS, Kim SB. C-reactive protein as a
cardiovascular risk factor and its therapeutic
implications in end-stage renal disease patients.
Nephrology 2003; 8 Suppl:S40-4. Not CKD
treatment
3110. Parkash R, Stevenson WG, Epstein LM, et al.
Predicting early mortality after implantable
defibrillator implantation: a clinical risk score for
optimal patient selection. American Heart Journal
2006; 151(2):397-403. Not RCT or controlled trial
3111. Parker MR, Willatts SM. A pilot study to investigate
the effects of an infusion of aminophylline on renal
function following major abdominal surgery.
Anaesthesia 2001; 56(7):670-5. Not RCT or
controlled trial
3112. Parks RW, Diamond T, McCrory DC, et al.
Prospective study of postoperative renal function in
obstructive jaundice and the effect of perioperative
dopamine. British Journal of Surgery 1994;
81(3):437-9. Not CKD treatment
3113. Parrinello G, Paterna S, Torres D, et al. One-year
renal and cardiac effects of bisoprolol versus losartan
in recently diagnosed hypertensive patients: a
randomized, double-blind study. Clinical Drug
Investigation 2009; 29(9):591-600. Not CKD
treatment
3114. Parsons DS, Harris DC. A review of quality of life in
chronic renal failure. Pharmacoeconomics 1997; 12(2
Pt 1):140-60. Not RCT or controlled trial
3115. Parvanova A, Chiurchiu C, Ruggenenti P, et al.
Inhibition of the renin-angiotensin system and
cardio-renal protection: focus on losartan and
angiotensin receptor blockade. Expert Opinion on
Pharmacotherapy 2005; 6(11):1931-42. Not relevant
to key questions
3116. Parvez Z, Ramamurthy S, Patel NB, et al. Enzyme
markers of contrast media-induced renal failure.
Investigative Radiology 1990; 25 Suppl 1:S133-4.
Sample size less than 50 patients
3117. Parving HH. Protein restriction and renal failure in
diabetes mellitus. New England Journal of Medicine
1991; 324(24):1743-4. Not RCT or controlled trial
3118. Parving HH. Is antihypertensive treatment the same
for NIDDM and IDDM patients? Diabetes Research
& Clinical Practice 1998; 39 Suppl:S43-7. Not RCT
or controlled trial
3119. Parving HH. Benefits and cost of antihypertensive
treatment in incipient and overt diabetic nephropathy.
Journal of Hypertension - Supplement 1998;
16(1):S99-101. Not RCT or controlled trial
3120. Parving HH. Diabetic hypertensive patients. Is this a
group in need of particular care and attention?
Diabetes Care 1999; 22 Suppl 2:B76-9. Not RCT or
controlled trial
3121. Parving HH. Blockade of the renin-angiotensinaldosterone system and renal protection in diabetes
mellitus. Journal of the Renin-AngiotensinAldosterone System 2000; 1(1):30-1. Not RCT or
controlled trial
3122. Parving HH, Hommel E, Damkjaer Nielsen M, et al.
Effect of captopril on blood pressure and kidney
function in normotensive insulin dependent diabetics
with nephropathy. BMJ 1989; 299(6698):533-6.
Sample size less than 50 patients
3123. Parving HH, Hommel E, Jensen BR, et al. Long-term
beneficial effect of ACE inhibition on diabetic
nephropathy in normotensive type 1 diabetic patients.
Kidney International 2001; 60(1):228-34. Sample
size less than 50 patients
3124. Parving HH, Hommel E, Smidt UM. Protection of
kidney function and decrease in albuminuria by
captopril in insulin dependent diabetics with
nephropathy. BMJ 1988; 297(6656):1086-91. Sample
size less than 50 patients
3125. Parving HH, Mogensen CE, Thomas MC, et al. Poor
prognosis in proteinuric type 2 diabetic patients with
retinopathy: insights from the RENAAL study. Qjm
2005; 98(2):119-26. Not early CKD
3126. Parving HH, Rossing P. The use of antihypertensive
agents in prevention and treatment of diabetic
nephropathy. Current Opinion in Nephrology &
Hypertension 1994; 3(3):292-300. Not RCT or
controlled trial
3127. Parving HH, Tarnow L, Nielsen FS, et al.
Cyclosporine nephrotoxicity in type 1 diabetic
patients. A 7-year follow-up study. Diabetes Care
1999; 22(3):478-83. Sample size less than 50 patients
3128. Parving HH, Tarnow L, Rossing P. Renal protection
in diabetes: an emerging role for calcium antagonists.
Journal of Hypertension - Supplement 1996;
14(4):S21-5. Not RCT or controlled trial
3129. Parving HH, Tarnow L, Rossing P. Renal protection
in diabetes--an emerging role for calcium
antagonists. Cardiology 1997; 88 Suppl 3:56-62. Not
RCT or controlled trial
3130. Parving H-H, Andersen S, Jacobsen P, et al.
Angiotensin receptor blockers in diabetic
nephropathy: renal and cardiovascular end points.
Seminars in Nephrology 2004; 24(2):147-57. Not
CKD treatment
3131. Parving H-H, Brenner BM, McMurray JJV, et al.
Aliskiren Trial in Type 2 Diabetes Using CardioRenal Endpoints (ALTITUDE): rationale and study
design. Nephrology Dialysis Transplantation 2009;
24(5):1663-71. Not CKD treatment
3132. Parving H-H, de Zeeuw D, Cooper ME, et al. ACE
gene polymorphism and losartan treatment in type 2
diabetic patients with nephropathy. Journal of the
American Society of Nephrology 2008; 19(4):771-9.
Not CKD treatment
3133. Parving H-H, Persson F, Lewis JB, et al. Aliskiren
combined with losartan in type 2 diabetes and
B-176
nephropathy.[Reprint in Ugeskr Laeger. 2009 Mar
9;171(11):881-4; PMID: 19291865]. New England
Journal of Medicine 2008; 358(23):2433-46. Followup less than 6 months
3134. Pasquali S, Cagnoli L, Rovinetti C, et al. Plasma
exchange therapy in rapidly progressive renal failure
due to multiple myeloma. International Journal of
Artificial Organs 1985; 8 Suppl 2:27-30. Sample size
less than 50 patients
3135. Passa P, Chatellier G. The DIAB-HYCAR Study.
Diabetologia 1996; 39(12):1662-7. Not RCT or
controlled trial
3136. Passa P, Leblanc H, Chevrel A, et al. Discontinuing
ACE inhibition in patients with diabetic nephropathy.
BMJ 1991; 302(6777):658. Not RCT or controlled
trial
3137. Passariello N, Sepe J, Marrazzo G, et al. Effect of
aldose reductase inhibitor (tolrestat) on urinary
albumin excretion rate and glomerular filtration rate
in IDDM subjects with nephropathy. Diabetes Care
1993; 16(5):789-95. Sample size less than 50 patients
3138. Passfall J, Pai J, Spies KP, et al. Effect of water and
bicarbonate loading in patients with chronic renal
failure. Clinical Nephrology 1997; 47(2):92-8.
Sample size less than 50 patients
3139. Passmore AP, Copeland S, Johnston GD. The effects
of ibuprofen and indomethacin on renal function in
the presence and absence of frusemide in healthy
volunteers on a restricted sodium diet. British Journal
of Clinical Pharmacology 1990; 29(3):311-9. Not
CKD treatment
3140. Passmore AP, Kondowe GB, Johnston GD. Renal
and cardiovascular effects of caffeine: a doseresponse study. Clinical Science 1987; 72(6):749-56.
Sample size less than 50 patients
3141. Pasternack A, Vanttinen T, Solakivi T, et al.
Normalization of lipoprotein lipase and hepatic lipase
by gemfibrozil results in correction of lipoprotein
abnormalities in chronic renal failure. Clinical
Nephrology 1987; 27(4):163-8. Sample size less than
50 patients
3142. Pastors JG, Franz MJ, Warshaw H, et al. How
effective is medical nutrition therapy in diabetes
care? Journal of the American Dietetic Association
2003; 103(7):827-31. Not RCT or controlled trial
3143. Patel A. Acute renal failure from contrast medium: ...
and remember simple and cheap measures. BMJ
2006; 333(7569):653-4. Not RCT or controlled trial
3144. Patel Z, Bhattacharjee LI, Shah BV. The role of
dietary protein restriction in Indian patients with
chronic renal failure. Journal of the Association of
Physicians of India 2000; 48(11):1078-81. Sample
size less than 50 patients
3145. Paterna S, Parrinello G, Scaglione R, et al. Effect of
long-term losartan administration on renal
haemodynamics and function in hypertensive
patients. Cardiovascular Drugs & Therapy 2000;
14(5):529-32. Sample size less than 50 patients
3146. Patil AJ, Bhagwat VR, Patil JA, et al. Occupational
lead exposure in battery manufacturing workers,
silver jewelry workers, and spray painters in western
Maharashtra (India): effect on liver and kidney
function. Journal of Basic & Clinical Physiology &
Pharmacology 2007; 18(2):87-100. Not RCT or
controlled trial
3147. Patrono C, Davi G. Antiplatelet agents in the
prevention of diabetic vascular complications.
Diabetes-Metabolism Reviews 1993; 9(3):177-88.
Not RCT or controlled trial
3148. Pattou FN, Pellissier LC, Noel C, et al.
Supernumerary parathyroid glands: frequency and
surgical significance in treatment of renal
hyperparathyroidism. World Journal of Surgery
2000; 24(11):1330-4. Not early CKD
3149. Paulsen L, Holm C, Bech JN, et al. Effects of statins
on renal sodium and water handling: acute and shortterm effects of atorvastatin on renal haemodynamics,
tubular function, vasoactive hormones, blood
pressure and pulse rate in healthy,
normocholesterolemic humans. Nephrology Dialysis
Transplantation 2008; 23(5):1556-61. Follow-up less
than 6 months
3150. Paulsen L, Holst LM, Bech JN, et al. Glomerular
filtration rate and blood pressure are unchanged by
increased sodium intake in atorvastatin-treated
healthy men. Scandinavian Journal of Clinical &
Laboratory Investigation 2009; 69(3):323-9. Sample
size less than 50 patients
3151. Pavlik I, Suchy J, Pacik D, et al. Comparison of
cizolirtine citrate and metamizol sodium in the
treatment of adult acute renal colic: a randomized,
double-blind, clinical pilot study. Clinical
Therapeutics 2004; 26(7):1061-72. Sample size less
than 50 patients
3152. Pechere-Bertschi A, Maillard M, Stalder H, et al.
Renal hemodynamic and tubular responses to salt in
women using oral contraceptives. Kidney
International 2003; 64(4):1374-80. Sample size less
than 50 patients
3153. Pecis M, Azevedo MJ, Gross JL. Glomerular
hyperfiltration is associated with blood pressure
abnormalities in normotensive normoalbuminuric
IDDM patients. Diabetes Care 1997; 20(8):1329-33.
Follow-up less than 6 months
3154. Pecis M, de Azevedo MJ, Gross JL. Chicken and fish
diet reduces glomerular hyperfiltration in IDDM
patients. Diabetes Care 1994; 17(7):665-72. Sample
size less than 50 patients
3155. Pedersen EB, Madsen JK, Sorensen SS, et al.
Improvement in renal function by felodipine during
cyclosporine treatment in acute and short-term
studies. Kidney International - Supplement 1996;
55:S94-6. Not early CKD
3156. Pedersen EB, Thomsen IM, Fjordside LS. Effect of
BQ-123, an endothelin antagonist, on renal
hemodynamics, tubular function, vasoactive
hormones, and blood pressure in healthy humans: a
dose response study. American Journal of
Hypertension 2005; 18(12 Pt 1):1578-85. Not
relevant to key questions
3157. Pedersen LM, Milman N. Microalbuminuria in
patients with lung cancer. European Journal of
Cancer 1998; 34(1):76-80. Not CKD treatment
B-177
3158. Pedersen MM, Christiansen JS, Mogensen CE.
Reduction of glomerular hyperfiltration in
normoalbuminuric IDDM patients by 6 mo of aldose
reductase inhibition. Diabetes 1991; 40(5):527-31.
Sample size less than 50 patients
3159. Pedersen MM, Hansen KW, Schmitz A, et al. Effects
of ACE inhibition supplementary to beta blockers
and diuretics in early diabetic nephropathy. Kidney
International 1992; 41(4):883-90. Sample size less
than 50 patients
3160. Pedersen MM, Mogensen CE, Jorgensen FS, et al.
Renal effects from limitation of high dietary protein
in normoalbuminuric diabetic patients. Kidney
International - Supplement 1989; 27:S115-21.
Sample size less than 50 patients
3161. Pedersen MM, Schmitz A, Pedersen EB, et al. Acute
and long-term renal effects of angiotensin converting
enzyme inhibition in normotensive,
normoalbuminuric insulin-dependent diabetic
patients. Diabetic Medicine 1988; 5(6):562-9.
Sample size less than 50 patients
3162. Pedersen RS, Bentzen H, Bech JN, et al. Effect of an
acute oral ibuprofen intake on urinary aquaporin-2
excretion in healthy humans. Scandinavian Journal of
Clinical & Laboratory Investigation 2001; 61(8):63140. Not early CKD
3163. Pedrinelli R, Dell'Omo G, Giampietro O, et al.
Dissociation between albuminuria and insulinaemia
in hypertensive and atherosclerotic men. Journal of
Human Hypertension 1999; 13(2):129-34. Not CKD
treatment
3164. Pedrinelli R, Ebel M, Catapano G, et al. Pressor,
renal and endocrine effects of L-arginine in essential
hypertensives. European Journal of Clinical
Pharmacology 1995; 48(3-4):195-201. Sample size
less than 50 patients
3165. Pedrinelli R, Panarace G, Spessot M, et al. Low dose
atrial natriuretic factor in primary aldosteronism:
renal, hemodynamic, and vascular effects.
Hypertension 1989; 14(2):156-63. Not CKD
treatment
3166. Pedrini MT, Levey AS, Lau J, et al. The effect of
dietary protein restriction on the progression of
diabetic and nondiabetic renal diseases: a metaanalysis. Annals of Internal Medicine 1996;
124(7):627-32. Not RCT or controlled trial
3167. Peixoto AJ, Orias M. Is there a role for direct renin
inhibitors in chronic kidney disease? Current Opinion
in Nephrology & Hypertension 2009; 18(5):397-403.
Not RCT or controlled trial
3168. Peloquin CA, Berning SE, Nitta AT, et al.
Aminoglycoside toxicity: daily versus thrice-weekly
dosing for treatment of mycobacterial diseases.
Clinical Infectious Diseases 2004; 38(11):1538-44.
Not CKD treatment
3169. Peng T, Hu Z, Xia Q, et al. A comparative study of
the renoprotective effects of benidipine and valsartan
in primary hypertensive patients with proteinuria.
Arzneimittel-Forschung 2009; 59(12):647-50. Not
relevant to key questions
3170. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of
angiotensin-converting enzyme (ACE) gene
polymorphism on progression of renal disease and
the influence of ACE inhibition in IDDM patients:
findings from the EUCLID Randomized Controlled
Trial. EURODIAB Controlled Trial of Lisinopril in
IDDM. Diabetes 1998; 47(9):1507-11. Not CKD
treatment
3171. Pentheroudakis G, Twelves C. Capecitabine
(Xeloda): from the laboratory to the patient's home.
Clinical Colorectal Cancer 2002; 2(1):16-23. Not
CKD treatment
3172. Percheron C, Colette C, Astre C, et al. Effects of
moderate changes in protein intake on urinary
albumin excretion in type I diabetic patients.
Nutrition 1995; 11(4):345-9. Sample size less than 50
patients
3173. Pereira CN, Machado FR, Guimaraes HP, et al.
Hemodynamics and renal function during
administration of low-dose dopamine in severely ill
patients. Sao Paulo Medical Journal = Revista
Paulista de Medicina 2004; 122(4):141-6. Not RCT
or controlled trial
3174. Perez J, Taura P, Rueda J, et al. Role of dopamine in
renal dysfunction during laparoscopic surgery.
Surgical Endoscopy 2002; 16(9):1297-301. Not early
CKD
3175. Perez N, Spizzirri F, Rahman R, et al. Steroids in the
hemolytic uremic syndrome. Pediatric Nephrology
1998; 12(2):101-4. Not CKD treatment
3176. Perez-Maraver M, Carrera MJ, Micalo T, et al.
Renoprotective effect of diltiazem in hypertensive
type 2 diabetic patients with persistent
microalbuminuria despite ACE inhibitor treatment.
Diabetes Research & Clinical Practice 2005;
70(1):13-9. Sample size less than 50 patients
3177. Perez-Valdivieso JR, Bes-Rastrollo M, Monedero P,
et al. Prognosis and serum creatinine levels in acute
renal failure at the time of nephrology consultation:
an observational cohort study. BMC Nephrology
2007; 8:14. Not early CKD
3178. Perinotto P, Biggi A, Carra N, et al. Angiotensin II
and prostaglandin interactions on systemic and renal
effects of L-NAME in humans. Journal of the
American Society of Nephrology 2001; 12(8):170612. Not early CKD
3179. Perkins RM, Aboudara MC, Uy AL, et al. Effect of
pentoxifylline on GFR decline in CKD: a pilot,
double-blind, randomized, placebo-controlled trial.
American Journal of Kidney Diseases 2009;
53(4):606-16. Not CKD treatment
3180. Perkovic V, Verdon C, Ninomiya T, et al. The
relationship between proteinuria and coronary risk: a
systematic review and meta-analysis. PLoS Medicine
/ Public Library of Science 2008; 5(10):e207. Not
CKD treatment
3181. Perna A, Ruggenenti P, Testa A, et al. ACE genotype
and ACE inhibitors induced renoprotection in
chronic proteinuric nephropathies1. Kidney
International 2000; 57(1):274-81. Not CKD treatment
3182. Perneger TV, Klag MJ, Whelton PK. Cause of death
in patients with end-stage renal disease: death
certificates vs registry reports. American Journal of
Public Health 1993; 83(12):1735-8. Not early CKD
B-178
3183. Perrin NESS, Jaremko GA, Berg UB. The effects of
candesartan on diabetes glomerulopathy: a doubleblind, placebo-controlled trial. Pediatric Nephrology
2008; 23(6):947-54. Sample size less than 50 patients
3184. Persson B, Andersson OK, Wysocki M, et al. Renal
and hemodynamic effects of isradipine in essential
hypertension. American Journal of Medicine 1989;
86(4A):60-4. Sample size less than 50 patients
3185. Persson B, Andersson OK, Wysocki M, et al.
Calcium antagonism in essential hypertension: effect
on renal haemodynamics and microalbuminuria.
Journal of Internal Medicine 1992; 231(3):247-52.
Sample size less than 50 patients
3186. Persson B, Granerus G, Wysocki M, et al. Acute
systemic and renal haemodynamic effects and longterm antihypertensive action of cadralazine in
patients pretreated with beta-blockers and diuretics.
European Journal of Clinical Pharmacology 1987;
31(5):513-8. Sample size less than 50 patients
3187. Persson F, Rossing P, Hovind P, et al. Endothelial
dysfunction and inflammation predict development
of diabetic nephropathy in the Irbesartan in Patients
with Type 2 Diabetes and Microalbuminuria (IRMA
2) study. Scandinavian Journal of Clinical &
Laboratory Investigation 2008; 68(8):731-8. Not
CKD treatment
3188. Persson F, Rossing P, Reinhard H, et al. Renal
effects of aliskiren compared with and in
combination with irbesartan in patients with type 2
diabetes, hypertension, and albuminuria. Diabetes
Care 2009; 32(10):1873-9. Sample size less than 50
patients
3189. Persson NH, Bergqvist D, Melander A, et al.
Comparison of a narcotic (oxicone) and a nonnarcotic anti-inflammatory analgesic (indoprofen) in
the treatment of renal colic. Acta Chirurgica
Scandinavica 1985; 151(2):105-8. Follow-up less
than 6 months
3190. Perttunen K, Kalso E, Heinonen J, et al. IV
diclofenac in post-thoracotomy pain. British Journal
of Anaesthesia 1992; 68(5):474-80. Not CKD
treatment
3191. Perttunen K, Nilsson E, Kalso E. I.v. diclofenac and
ketorolac for pain after thoracoscopic surgery. British
Journal of Anaesthesia 1999; 82(2):221-7. Not CKD
treatment
3192. Perumal K, Fischer MJ, Mrtek R. Efficacy of
furosemide in ARF. American Journal of Kidney
Diseases 2005; 45(4):786; author reply -7. Follow-up
less than 6 months
3193. Petchey WG, Hickman IJ, Duncan E, et al. The role
of 25-hydroxyvitamin D deficiency in promoting
insulin resistance and inflammation in patients with
chronic kidney disease: a randomised controlled trial.
BMC Nephrology 2009; 10:41. Not RCT or
controlled trial
3194. Peters PJ, Moore DM, Mermin J, et al. Antiretroviral
therapy improves renal function among HIV-infected
Ugandans. Kidney International 2008; 74(7):925-9.
Not early CKD
3195. Peters RM, Flack JM. Salt sensitivity and
hypertension in African Americans: implications for
cardiovascular nurses. Progress in Cardiovascular
Nursing 2000; 15(4):138-44. Not RCT or controlled
trial
3196. Petersen LJ, Petersen JR, Talleruphuus U, et al. A
randomized and double-blind comparison of
isradipine and spirapril as monotherapy and in
combination on the decline in renal function in
patients with chronic renal failure and hypertension.
Clinical Nephrology 2001; 55(5):375-83. Sample size
less than 50 patients
3197. Peterson GE, de Backer T, Gabriel A, et al.
Prevalence and correlates of left ventricular
hypertrophy in the African American Study of
Kidney Disease Cohort Study. Hypertension 2007;
50(6):1033-9. Sample size less than 50 patients
3198. Peterson K. ACE inhibitors and renoprotection.
Journal of Family Practice 1996; 42(5):453. Not RCT
or controlled trial
3199. Petrica L, Petrica M, Vlad A, et al. Nephro- and
neuroprotective effects of rosiglitazone versus
glimepiride in normoalbuminuric patients with type 2
diabetes mellitus: a randomized controlled trial.
Wiener Klinische Wochenschrift 2009; 121(2324):765-75. Sample size less than 50 patients
3200. Petrovich Z, Yu C, Giannotta SL, et al. Survival and
pattern of failure in brain metastasis treated with
stereotactic gamma knife radiosurgery. Journal of
Neurosurgery 2002; 97(5 Suppl):499-506. Not CKD
treatment
3201. Petry A, Wulf H, Baumgartel M. The influence of
ketanserin or urapidil on haemodynamics, stress
response and kidney function during operations for
myocardial revascularisation. Anaesthesia 1995;
50(4):312-6. Sample size less than 50 patients
3202. Pettinger WA, Lee HC, Reisch J, et al. Long-term
improvement in renal function after short-term strict
blood pressure control in hypertensive
nephrosclerosis. Hypertension 1989; 13(6 Pt 2):76672. Not relevant to key questions
3203. Pfaller W, Thorwartl U, Nevinny-Stickel M, et al.
Clinical value of fructose 1,6 bisphosphatase in
monitoring renal proximal tubular injury. Kidney
International - Supplement 1994; 47:S68-75. Not
CKD treatment
3204. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial
of darbepoetin alfa in type 2 diabetes and chronic
kidney disease. New England Journal of Medicine
2009; 361(21):2019-32. Not CKD treatment
3205. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial
of darbepoetin alfa in type 2 diabetes and chronic
kidney disease. New England Journal of Medicine
2009; 361(21):2019-32. Not CKD treatment
3206. Pfeffer MA, Burdmann EA, Chen C-Y, et al.
Baseline characteristics in the Trial to Reduce
Cardiovascular Events With Aranesp Therapy
(TREAT). American Journal of Kidney Diseases
2009; 54(1):59-69. Not CKD treatment
3207. Pfeffer MA, Committee TE. An ongoing study of
anemia correction in chronic kidney disease. New
England Journal of Medicine 2007; 356(9):959-61.
Not relevant to key questions
B-179
Practice 2001; 50(12):1083. Not RCT or controlled
trial
3222. Pieta J, Millar T, Zacharias J, et al. Effect of
pergolide on restless legs and leg movements in sleep
in uremic patients. Sleep 1998; 21(6):617-22. Not
early CKD
3223. Pijls LTJ, de Vries H, van Eijk JTM, et al. Protein
restriction, glomerular filtration rate and albuminuria
in patients with type 2 diabetes mellitus: a
randomized trial. European Journal of Clinical
Nutrition 2002; 56(12):1200-7. Sample size less than
50 patients
3224. Pimenta E, Oparil S. Role of aliskiren in cardio-renal
protection and use in hypertensives with multiple risk
factors. Vascular Health & Risk Management 2009;
5(1):453-63. Not RCT or controlled trial
3225. Pines A, Fisman EZ. ACE Inhibition with moexipril:
a review of potential effects beyond blood pressure
control. American Journal of Cardiovascular Drugs
2003; 3(5):351-60. Follow-up less than 6 months
3226. Pinkau T, Ndrepepa G, Kastrati A, et al.
Glycoprotein IIb/IIIa receptor inhibition with
abciximab during percutaneous coronary
interventions increases the risk of bleeding in
patients with impaired renal function. Cardiology
2008; 111(4):247-53. Follow-up less than 6 months
3227. Pinol C, Cobos A, Cases A, et al. Nitrendipine and
enalapril in the treatment of diabetic hypertensive
patients with microalbuminuria. Kidney International
- Supplement 1996; 55:S85-7. Sample size less than
50 patients
3228. Pinto JR, Bending JJ, Dodds RA, et al. Effect of low
protein diet on the renal response to meat ingestion in
diabetic nephropathy. European Journal of Clinical
Investigation 1991; 21(2):175-83. Sample size less
than 50 patients
3229. Piozzi R, Ribeiro DA, Padovan LEM, et al.
Genotoxicity and cytotoxicity in multiple organs
induced by titanium miniplates in Wistar rats. Journal
of Biomedical Materials Research 2009; Part A.
88(2):342-7. Not early CKD
3230. Piper SN, Kumle B, Maleck WH, et al. Diltiazem
may preserve renal tubular integrity after cardiac
surgery. Canadian Journal of Anaesthesia 2003;
50(3):285-92. Not CKD treatment
3231. Piquard F, Richard R, Charloux A, et al. Hormonal,
renal, hemodynamic responses to acute neutral
endopeptidase inhibition in heart transplant patients.
Journal of Applied Physiology 2002; 93(2):569-75.
Not early CKD
3232. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced
thrombotic microangiopathy: incidence, prevention
and management. Drug Safety 2001; 24(7):491-501.
Not early CKD
3233. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone
improves glomerular hyperfiltration, renal
endothelial dysfunction, and microalbuminuria of
incipient diabetic nephropathy in patients. Diabetes
2005; 54(7):2206-11. Sample size less than 50
patients
3234. Pitt B. Revascularization in patients with chronic
kidney disease: the state of the ARTS. European
3208. Pfeffer MA, Solomon SD, Singh AK, et al.
Uncertainty in the treatment of anemia in chronic
kidney disease. Reviews in Cardiovascular Medicine
2005; 6 Suppl 3:S35-41. Not human studies
3209. Pham P-TT, Pham P-CT, Wilkinson AH.
Management of renal dysfunction in the liver
transplant recipient. Current Opinion in Organ
Transplantation 2009; 14(3):231-9. Not CKD
treatment
3210. Phillips E, Hinck B, Pedro R, et al. Celecoxib in the
management of acute renal colic: a randomized
controlled clinical trial. Urology 2009; 74(5):994-9.
Follow-up less than 6 months
3211. Phillips PJ, Phillipou G, Bowen KM, et al. Diabetic
microalbuminuria and cilazapril. American Journal
of Medicine 1993; 94(4A):58S-60S. Sample size less
than 50 patients
3212. Phillips RA, Faulkner M, Gassman J, et al.
Recruitment of African Americans with chronic renal
insufficiency into a multicenter clinical trial: the
african american study of kidney disease and
hypertension. Journal of Clinical Hypertension 2004;
6(8):430-6. Not CKD treatment
3213. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality
and target haemoglobin concentrations in anaemic
patients with chronic kidney disease treated with
erythropoietin: a meta-analysis. Lancet 2007;
369(9559):381-8. Sample size less than 50 patients
3214. Piccoli A. Elementary clinical decision analysis in
evidence-based nephrology. Journal of Nephrology
2000; 13(6):419-32. Not RCT or controlled trial
3215. Pichler J, Risch L, Hefti U, et al. Glomerular
filtration rate estimates decrease during high altitude
expedition but increase with Lake Louise acute
mountain sickness scores. Acta Physiologica 2008;
192(3):443-50. Not RCT or controlled trial
3216. Pickering TG. Cardiorenal protection in diabetes.
Heart Disease 2000; 2(2):S18-22. Not RCT or
controlled trial
3217. Pickles CJ, Broughton Pipkin F, Symonds EM. A
randomised placebo controlled trial of labetalol in the
treatment of mild to moderate pregnancy induced
hypertension. British Journal of Obstetrics &
Gynaecology 1992; 99(12):964-8. Not CKD
treatment
3218. Pickup JC, Collins AC, Walker JD, et al. Patterns of
hyperinsulinaemia in type 1 diabetic patients with
and without nephropathy. Diabetic Medicine 1989;
6(8):685-91. Sample size less than 50 patients
3219. Pidgeon GB, Richards AM, Nicholls MG, et al.
Acute effects of intravenous ouabain in healthy
volunteers. Clinical Science 1994; 86(4):391-7. Not
CKD treatment
3220. Piecha G, Adamczak M, Chudek J, et al. Indapamide
decreases plasma adiponectin concentration in
patients with essential hypertension. Kidney & Blood
Pressure Research 2007; 30(3):187-94. Sample size
less than 50 patients
3221. Pierce HL, Stevermer JJ. Does losartan (Cozaar)
slow the progression of renal disease in patients with
type 2 diabetes and nephropathy? Journal of Family
B-180
Heart Journal 2005; 26(15):1456-7. Follow-up less
than 6 months
3235. Pitt B, Segal R, Martinez FA, et al. Randomised trial
of losartan versus captopril in patients over 65 with
heart failure (Evaluation of Losartan in the Elderly
Study, ELITE). Lancet 1997; 349(9054):747-52. Not
early CKD
3236. Pivalizza EG, Abramson DC, Harvey A.
Perioperative hypercoagulability in uremic patients: a
viscoelastic study. Journal of Clinical Anesthesia
1997; 9(6):442-5. Sample size less than 50 patients
3237. Platz KP, Mueller AR, Jonas S, et al. Toxicity versus
rejection--or why conversions between cyclosporine
A and FK506 were performed after liver
transplantation. Clinical Transplantation 1995; 9(3 Pt
1):146-54. Not RCT or controlled trial
3238. Plosker GL, Sorkin EM. Quinapril. A reappraisal of
its pharmacology and therapeutic efficacy in
cardiovascular disorders. Drugs 1994; 48(2):227-52.
Not CKD treatment
3239. Plum J, Bunten B, Nemeth R, et al. Effects of the
angiotensin II antagonist valsartan on blood pressure,
proteinuria, and renal hemodynamics in patients with
chronic renal failure and hypertension. Journal of the
American Society of Nephrology 1998; 9(12):222334. Sample size less than 50 patients
3240. Plum J, Bunten B, Nemeth R, et al. Treatment with
the angiotensin II antagonist valsartan in patients
with chronic renal failure and hypertension.
Nephrology Dialysis Transplantation 1999; 14 Suppl
4:25-7. Sample size less than 50 patients
3241. Plusa SM, Clark NW. Prevention of postoperative
renal dysfunction in patients with obstructive
jaundice: a comparison of mannitol-induced diuresis
and oral sodium taurocholate. Journal of the Royal
College of Surgeons of Edinburgh 1991; 36(5):3035. Not CKD treatment
3242. Pohl MA. Changing the course of diabetic
nephropathy: angiotensin-converting enzyme
inhibition in type I diabetic renal disease. Cleveland
Clinic Journal of Medicine 1994; 61(1):38-42. Not
RCT or controlled trial
3243. Pohl MA, Blumenthal S, Cordonnier DJ, et al.
Independent and additive impact of blood pressure
control and angiotensin II receptor blockade on renal
outcomes in the irbesartan diabetic nephropathy trial:
clinical implications and limitations. Journal of the
American Society of Nephrology 2005; 16(10):302737. Not RCT or controlled trial
3244. Poirier SJ. Reducing complications in type 2
diabetes. American Family Physician 1998;
57(6):1238-9. Not RCT or controlled trial
3245. Poletti P-A, Saudan P, Platon A, et al. I.v. Nacetylcysteine and emergency CT: use of serum
creatinine and cystatin C as markers of radiocontrast
nephrotoxicity. AJR 2007; American Journal of
Roentgenology. 189(3):687-92. Not CKD treatment
3246. Polonia J, Boaventura I, Gama G, et al. Influence of
non-steroidal anti-inflammatory drugs on renal
function and 24h ambulatory blood pressurereducing effects of enalapril and nifedipine
gastrointestinal therapeutic system in hypertensive
patients. Journal of Hypertension 1995; 13(8):92531. Follow-up less than 6 months
3247. Pomerleau J, Verdy M, Garrel DR, et al. Effect of
protein intake on glycaemic control and renal
function in type 2 (non-insulin-dependent) diabetes
mellitus. Diabetologia 1993; 36(9):829-34. Sample
size less than 50 patients
3248. Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin
versus cyclophosphamide for patients with steroiddependent and frequently relapsing idiopathic
nephrotic syndrome: a multicentre randomized
controlled trial. Nephrology Dialysis Transplantation
1993; 8(12):1326-32. Not early CKD
3249. Ponticelli C, Rizzoni G, Edefonti A, et al. A
randomized trial of cyclosporine in steroid-resistant
idiopathic nephrotic syndrome. Kidney International
1993; 43(6):1377-84. Sample size less than 50
patients
3250. Pool JL. Is it time to move to multidrug
combinations? American Journal of Hypertension
2003; 16(11 Pt 2):36S-40S. Not CKD treatment
3251. Poortmans JR, Auquier H, Renaut V, et al. Effect of
short-term creatine supplementation on renal
responses in men. European Journal of Applied
Physiology & Occupational Physiology 1997;
76(6):566-7. Sample size less than 50 patients
3252. Porayko MK, Gonwa TA, Klintmalm GB, et al.
Comparing nephrotoxicity of FK 506 and
cyclosporine regimens after liver transplantation:
preliminary results from US Multicenter trial. U.S.
Multicenter Liver Study Group. Transplantation
Proceedings 1995; 27(1):1114-6. Not early CKD
3253. Porayko MK, Textor SC, Krom RA, et al.
Nephrotoxic effects of primary immunosuppression
with FK-506 and cyclosporine regimens after liver
transplantation. Mayo Clinic Proceedings 1994;
69(2):105-11. Sample size less than 50 patients
3254. Porayko MK, Textor SC, Krom RA, et al.
Nephrotoxicity of FK 506 and cyclosporine when
used as primary immunosuppression in liver
transplant recipients. Transplantation Proceedings
1993; 25(1 Pt 1):665-8. Not RCT or controlled trial
3255. Pordy R, Woittiez A. Steady-state trough plasma
mibefradil concentrations and correlation to blood
pressure response in hypertensive patients with
chronic renal disease. International Journal of
Clinical Pharmacology Research 1998; 18(3):105-8.
Not RCT or controlled trial
3256. Portaluppi F, Vergnani L, Manfredini R, et al. Timedependent effect of isradipine on the nocturnal
hypertension in chronic renal failure. American
Journal of Hypertension 1995; 8(7):719-26. Sample
size less than 50 patients
3257. Porter GA. Contrast-associated nephropathy:
presentation, pathophysiology and management.
Mineral & Electrolyte Metabolism 1994; 20(4):23243. Not CKD treatment
3258. Porter GA, Norton TL, Legg V. Using urinary
biomarkers to evaluate renal effects of a Cox-2
NSAID in volunteers. Renal Failure 1999; 21(34):311-7. Sample size less than 50 patients
B-181
3259. Porzano AM, Baldoncini R, De Siati L, et al. Effects
of short-time insulin suppression on renal sodium
excretion in type II diabetic hypertensives. Diabetes
Research 1993; 22(1):3-10. Sample size less than 50
patients
3260. Poschel KA, Bucha E, Esslinger HU, et al.
Pharmacodynamics and pharmacokinetics of
polyethylene glycol-hirudin in patients with chronic
renal failure. Kidney International 2000; 58(6):247884. Not RCT or controlled trial
3261. Posen S, Clifton-Bligh P, Reeve TS, et al. Is
parathyroidectomy of benefit in primary
hyperparathyroidism? Quarterly Journal of Medicine
1985; 54(215):241-51. Not CKD treatment
3262. Postma MJ, Kruidhof H, de Jong-van den Berg
LTW, et al. Pharmacoeconomic aspects of losartan
treatment to delay progression of renal disease in
patients with Type 2 diabetes. Expert Opinion on
Pharmacotherapy 2003; 4(9):1543-50. Not relevant
to key questions
3263. Potena L, Bianchi IG, Magnani G, et al.
Cyclosporine lowering with everolimus or
mycophenolate to preserve renal function in heart
recipients: a randomized study. Transplantation
2010; 89(2):263-5. Sample size less than 50 patients
3264. Potter K, Hankey GJ, Green DJ, et al. Homocysteine
or renal impairment: which is the real cardiovascular
risk factor? Arteriosclerosis, Thrombosis & Vascular
Biology 2008; 28(6):1158-64. Not human studies
3265. Pouleur H. Neurohormonal and hemodynamic effects
of ibopamine. Clinical Cardiology 1995; 18(3 Suppl
I):I17-21. Not CKD treatment
3266. Poulsen PL. ACE inhibitor intervention in Type 1
diabetes with low grade microalbuminuria. Journal of
the Renin-Angiotensin-Aldosterone System 2003;
4(1):17-26. Sample size less than 50 patients
3267. Poulsen PL, Ebbehoj E, Mogensen CE. Lisinopril
reduces albuminuria during exercise in low grade
microalbuminuric type 1 diabetic patients: a double
blind randomized study. Journal of Internal Medicine
2001; 249(5):433-40. Sample size less than 50
patients
3268. Poulsen PL, Ebbehoj E, Nosadini R, et al. Early
ACE-i intervention in microalbuminuric patients
with type 1 diabetes: effects on albumin excretion, 24
h ambulatory blood pressure, and renal function.
Diabetes & Metabolism 2001; 27(2 Pt 1):123-8.
Sample size less than 50 patients
3269. Powe NR. Measuring effectiveness and outcomes of
interventions for renal disease. Current Opinion in
Nephrology & Hypertension 1996; 5(3):230-5. Not
RCT or controlled trial
3270. Powe NR, Moore RD, Steinberg EP. Adverse
reactions to contrast media: factors that determine the
cost of treatment. AJR 1993; American Journal of
Roentgenology. 161(5):1089-95. Not CKD treatment
3271. Power DA, Duggan J, Brady HR. Renal-dose (lowdose) dopamine for the treatment of sepsis-related
and other forms of acute renal failure: ineffective and
probably dangerous. Clinical & Experimental
Pharmacology & Physiology - Supplement 1999;
26:S23-8. Not RCT or controlled trial
3272. Power I, Cumming AD, Pugh GC. Effect of
diclofenac on renal function and prostacyclin
generation after surgery. British Journal of
Anaesthesia 1992; 69(5):451-6. Sample size less than
50 patients
3273. Praga M, Andrade CF, Luno J, et al. Antiproteinuric
efficacy of losartan in comparison with amlodipine in
non-diabetic proteinuric renal diseases: a doubleblind, randomized clinical trial. Nephrology Dialysis
Transplantation 2003; 18(9):1806-13. Follow-up less
than 6 months
3274. Praga M, Hernandez E, Andres A, et al. Effects of
body-weight loss and captopril treatment on
proteinuria associated with obesity. Nephron 1995;
70(1):35-41. Sample size less than 50 patients
3275. Prakash S, Pande DP, Sharma S, et al. Randomized,
double-blind, placebo-controlled trial to evaluate
efficacy of ketodiet in predialytic chronic renal
failure. Journal of Renal Nutrition 2004; 14(2):89-96.
Not CKD treatment
3276. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al.
Management of type 2 diabetes in treatment-naive
elderly patients: benefits and risks of vildagliptin
monotherapy. Diabetes Care 2007; 30(12):3017-22.
Not relevant to key questions
3277. Predel HG, Kuklinski P, Kramer HJ. Intranasal
application of atrial natriuretic peptide and 1deamino-d-arginine vasopressin in healthy
volunteers. Hemodynamic, hormonal, and renal
excretory effects. American Journal of Hypertension
1992; 5(9):657-60. Sample size less than 50 patients
3278. Preiss DJ, Godber IM, Lamb EJ, et al. The influence
of a cooked-meat meal on estimated glomerular
filtration rate. Annals of Clinical Biochemistry 2007;
44(Pt 1):35-42. Not RCT or controlled trial
3279. Prescott LF, Freestone S, McAuslane JA.
Reassessment of the single intravenous injection
method with inulin for measurement of the
glomerular filtration rate in man. Clinical Science
1991; 80(2):167-76. Sample size less than 50 patients
3280. Prescott LF, Mattison P, Menzies DG, et al. The
comparative effects of paracetamol and indomethacin
on renal function in healthy female volunteers.
British Journal of Clinical Pharmacology 1990;
29(4):403-12. Not CKD treatment
3281. Presta P, Onorati F, Fuiano L, et al. Can pulsatile
cardiopulmonary bypass prevent perioperative renal
dysfunction during myocardial revascularization in
elderly patients? Nephron 2009; 111(4):c229-35. Not
CKD treatment
3282. Preston RA, Afshartous D, Alonso AB. Effects of
selective vs. nonselective cyclooxygenase inhibition
on dynamic renal potassium excretion: a randomized
trial. Clinical Pharmacology & Therapeutics 2008;
84(2):208-11. Not CKD treatment
3283. Preston RA, Afshartous D, Garg D, et al.
Mechanisms of impaired potassium handling with
dual renin-angiotensin-aldosterone blockade in
chronic kidney disease. Hypertension 2009;
53(5):754-60. Not CKD treatment
3284. Preston RA, Materson BJ, Reda DJ, et al. Proteinuria
in mild to moderate hypertension: results of the VA
B-182
cooperative study of six antihypertensive agents and
placebo. Department of Veterans Affairs Cooperative
Study Group on Antihypertensive Agents. Clinical
Nephrology 1997; 47(5):310-5. Not early CKD
3285. Price DA, Fisher NDL, Lansang MC, et al. Renal
perfusion in blacks: alterations caused by
insuppressibility of intrarenal renin with salt.
Hypertension 2002; 40(2):186-9. Not CKD treatment
3286. Price DA, Hollenberg NK. Angiotensin receptor
blockers in diabetic nephropathy. Current Diabetes
Reports 2001; 1(3):267-74. Not RCT or controlled
trial
3287. Pridjian AK, Bove EL, Beekman RH, 3rd, et al.
Comparison of a low osmolarity nonionic
radiographic contrast agent with a standard medium
on renal function in cyanotic and normal dogs.
Catheterization & Cardiovascular Diagnosis 1994;
31(1):90-3. Sample size less than 50 patients
3288. Prins JM, Buller HR, Kuijper EJ, et al. Once versus
thrice daily gentamicin in patients with serious
infections. Lancet 1993; 341(8841):335-9. Not CKD
treatment
3289. Prisant LM. Diabetes mellitus and hypertension: a
mandate for intense treatment according to new
guidelines. American Journal of Therapeutics 2003;
10(5):363-9. Not RCT or controlled trial
3290. Prisant LM, Louard RJ. Controversies surrounding
the treatment of the hypertensive patient with
diabetes. Current Hypertension Reports 1999;
1(6):512-20. Not RCT or controlled trial
3291. Pritchard G, Lyons D, Webster J, et al. Do
trandolapril and indomethacin influence renal
function and renal functional reserve in hypertensive
patients? British Journal of Clinical Pharmacology
1997; 44(2):145-9. Follow-up less than 6 months
3292. Prodjosudjadi W, Suhardjono, Suwitra K, et al.
Detection and prevention of chronic kidney disease
in Indonesia: initial community screening.
Nephrology 2009; 14(7):669-74. Not RCT or
controlled trial
3293. Pronovost PH, Brady HR, Gunning ME, et al.
Clinical features, predictors of disease progression
and results of renal transplantation in
fibrillary/immunotactoid glomerulopathy.
Nephrology Dialysis Transplantation 1996;
11(5):837-42. Not RCT or controlled trial
3294. Provenzano R, Bhaduri S, Singh AK, et al. Extended
epoetin alfa dosing as maintenance treatment for the
anemia of chronic kidney disease: the PROMPT
study. Clinical Nephrology 2005; 64(2):113-23. Not
CKD treatment
3295. Provenzano R, Garcia-Mayol L, Suchinda P, et al.
Once-weekly epoetin alfa for treating the anemia of
chronic kidney disease. Clinical Nephrology 2004;
61(6):392-405. Sample size less than 50 patients
3296. Puig JG, Marre M, Kokot F, et al. Efficacy of
indapamide SR compared with enalapril in elderly
hypertensive patients with type 2 diabetes. American
Journal of Hypertension 2007; 20(1):90-7. Not RCT
or controlled trial
3297. Puig JG, Mateos FA, Ramos TH, et al. Albumin
excretion rate and metabolic modifications in patients
with essential hypertension. Effects of two
angiotensin converting enzyme inhibitors. American
Journal of Hypertension 1994; 7(1):46-51. Sample
size less than 50 patients
3298. Puigmule M, Lopez-Hellin J, Sune G, et al.
Differential proteomic analysis of cyclosporine Ainduced toxicity in renal proximal tubule cells.
Nephrology Dialysis Transplantation 2009;
24(9):2672-86. Not CKD treatment
3299. Pull ter Gunne AJ, Bruining HA, Obertop H.
Haemodynamics and 'optimal' hydration in aortic
cross clamping. Netherlands Journal of Surgery
1990; 42(4):113-7. Not CKD treatment
3300. Puolakka PAE, Rintala S, Yli-Hankala A, et al. The
effect of parecoxib on kidney function at
laparoscopic hysterectomy. Renal Failure 2009;
31(4):284-9. Sample size less than 50 patients
3301. Puscas I, Coltau M, Baican M, et al. Omeprazole has
a dual mechanism of action: it inhibits both
H(+)K(+)ATPase and gastric mucosa carbonic
anhydrase enzyme in humans (in vitro and in vivo
experiments). Journal of Pharmacology &
Experimental Therapeutics 1999; 290(2):530-4. Not
CKD treatment
3302. Pylypchuk G, Beaubien E. Diabetic nephropathy.
Prevention and early referral. Canadian Family
Physician 2000; 46:636-42. Not RCT or controlled
trial
3303. Qiu Z, Chen X, Xu M, et al. Evaluation of
preoperative intra-aortic balloon pump in coronary
patients with severe left ventricular dysfunction
undergoing OPCAB surgery: early and mid-term
outcomes. Journal Of Cardiothoracic Surgery 2009;
4:39. Not CKD treatment
3304. Quan DJ, McQueen KD. dDAVP in enuresis. DICP
1990; 24(12):1179-80. Not RCT or controlled trial
3305. Raab C, Weidmann E, Schmidt A, et al. The effects
of interleukin-2 treatment on endothelin and the
activation of the hypothalamic-pituitary-adrenal axis.
Clinical Endocrinology 1999; 50(1):37-44. Not CKD
treatment
3306. Raal FJ, Kalk WJ, Lawson M, et al. Effect of
moderate dietary protein restriction on the
progression of overt diabetic nephropathy: a 6-mo
prospective study. American Journal of Clinical
Nutrition 1994; 60(4):579-85. Sample size less than
50 patients
3307. Rab A, Dallinger S, Polak K, et al. Specific
endothelin ET(A) receptor antagonism does not
modulate insulin-induced hemodynamic effects in
the human kidney, eye, or forearm. Journal of
Pharmacology & Experimental Therapeutics 2004;
309(2):692-6. Not CKD treatment
3308. Rabbani N, Alam SS, Riaz S, et al. High-dose
thiamine therapy for patients with type 2 diabetes and
microalbuminuria: a randomised, double-blind
placebo-controlled pilot study. Diabetologia 2009;
52(2):208-12. Not CKD treatment
3309. Rabelink AJ, Hene RJ, Erkelens DW, et al. Effects of
simvastatin and cholestyramine on lipoprotein profile
in hyperlipidaemia of nephrotic syndrome. Lancet
B-183
1988; 2(8624):1335-8. Sample size less than 50
patients
3310. Rabelink TJ, Kaasjager KA, Boer P, et al. Effects of
endothelin-1 on renal function in humans:
implications for physiology and pathophysiology.
Kidney International 1994; 46(2):376-81. Not RCT
or controlled trial
3311. Rabelink TJ, Koomans HA, van de Stolpe A, et al.
Effects of atrial natriuretic peptide on distal tubule
function in humans. Kidney International 1990;
37(3):996-1001. Not CKD treatment
3312. Rachmani R, Levi Z, Slavachevski I, et al. Teaching
patients to monitor their risk factors retards the
progression of vascular complications in high-risk
patients with Type 2 diabetes mellitus--a randomized
prospective study. Diabetic Medicine 2002;
19(5):385-92. Not early CKD
3313. Rachmani R, Levi Z, Slavachevsky I, et al. Effect of
an alpha-adrenergic blocker, and ACE inhibitor and
hydrochlorothiazide on blood pressure and on renal
function in type 2 diabetic patients with hypertension
and albuminuria. A randomized cross-over study.
Nephron 1998; 80(2):175-82. Follow-up less than 6
months
3314. Rachmani R, Ravid M. Risk factors for nephropathy
in type 2 diabetes mellitus. Comprehensive Therapy
1999; 25(6-7):366-9. Not RCT or controlled trial
3315. Rachmani R, Slavachevski I, Berla M, et al.
Teaching and motivating patients to control their risk
factors retards progression of cardiovascular as well
as microvascular sequelae of Type 2 diabetes
mellitus- a randomized prospective 8 years follow-up
study. Diabetic Medicine 2005; 22(4):410-4. Not
early CKD
3316. Rachmani R, Slavachevsky I, Amit M, et al. The
effect of spironolactone, cilazapril and their
combination on albuminuria in patients with
hypertension and diabetic nephropathy is
independent of blood pressure reduction: a
randomized controlled study.[Retraction in Diabet
Med. 2006 Jul;23(7):818; PMID: 16842490].
Diabetic Medicine 2004; 21(5):471-5. Sample size
less than 50 patients
3317. Radermacher J, Koch KM. Treatment of renal
anemia by erythropoietin substitution. The effects on
the cardiovascular system. Clinical Nephrology
1995; 44 Suppl 1:S56-60. Not early CKD
3318. Radovancevic B, Frazier OH. Treatment of moderate
heart allograft rejection with cyclosporine. Journal of
Heart Transplantation 1986; 5(4):307-11. Sample size
less than 50 patients
3319. Ragsdale NV, Lynd M, Chevalier RL, et al. Selective
peripheral dopamine-1 receptor stimulation.
Differential responses to sodium loading and
depletion in humans. Hypertension 1990; 15(6 Pt
2):914-21. Not CKD treatment
3320. Rahman AR, Motwani JG, Lang CC, et al.
Circulating angiotensin II and renal sodium handling
in man: a dose-response study. Clinical Science
1993; 85(2):147-56. Sample size less than 50 patients
3321. Rahman M. Initial findings of the AASK: African
Americans with hypertensive kidney disease benefit
from an ACE inhibitor. Cleveland Clinic Journal of
Medicine 2003; 70(4):304-5. Not relevant to key
questions
3322. Rahman M, El-Meanawy A, Romanello J. The
African American Study of Kidney Disease: do these
results indicate that 140/90 mm hg is good enough?
Current Hypertension Reports 2005; 7(5):363-6. Not
relevant to key questions
3323. Raimondo ML, Dagher L, Papatheodoridis GV, et al.
Long-term mycophenolate mofetil monotherapy in
combination with calcineurin inhibitors for chronic
renal dysfunction after liver transplantation.
Transplantation 2003; 75(2):186-90. Sample size less
than 50 patients
3324. Ralph CJ, Tanser SJ, Macnaughton PD, et al. A
randomised controlled trial investigating the effects
of dopexamine on gastrointestinal function and organ
dysfunction in the critically ill.[Erratum appears in
Intensive Care Med 2002 Jul;28(7):1001]. Intensive
Care Medicine 2002; 28(7):884-90. Not CKD
treatment
3325. Ram CV. Ketanserin in essential hypertension.
Effects of blood pressure on renal hemodynamics.
American Journal of Hypertension 1988; 1(3 Pt
3):309S-11S. Follow-up less than 6 months
3326. Raman GV, Campbell SK, Farrer A, et al. Modifying
effects of amlodipine on cyclosporin A-induced
changes in renal function in patients with psoriasis.
Journal of Hypertension - Supplement 1998;
16(4):S39-41. Sample size less than 50 patients
3327. Ramel A, Jonsson PV, Bjornsson S, et al. Differences
in the glomerular filtration rate calculated by two
creatinine-based and three cystatin-C-based formulae
in hospitalized elderly patients. Nephron 2008;
108(1):c16-22. Not relevant to key questions
3328. Ramin SM, Vidaeff AC, Yeomans ER, et al. Chronic
renal disease in pregnancy. Obstetrics & Gynecology
2006; 108(6):1531-9. Not relevant to key questions
3329. Ramires JA, Tsanaclis A, Gimenez HC, et al. Acute
effects of dobutamine and dopamine on renal and
respiratory functions in patients on prolonged
mechanical ventilation. Brazilian Journal of Medical
& Biological Research 1991; 24(1):35-42. Sample
size less than 50 patients
3330. Rammohan C, Fintel D. Dosing considerations and
monitoring of low molecular weight heparins and
glycoprotein IIb/IIIa antagonists in patients with
renal insufficiency. Current Cardiology Reports
2003; 5(4):303-9. Not CKD treatment
3331. Randell TT, Hockerstedt KA. Triiodothyronine
treatment in brain-dead multiorgan donors--a
controlled study. Transplantation 1992; 54(4):736-8.
Sample size less than 50 patients
3332. Ranganathan N, Friedman EA, Tam P, et al.
Probiotic dietary supplementation in patients with
stage 3 and 4 chronic kidney disease: a 6-month pilot
scale trial in Canada. Current Medical Research &
Opinion 2009; 25(8):1919-30. Sample size less than
50 patients
3333. Ranganathan S, Krempf M, Feraille E, et al. Short
term effect of an aldose reductase inhibitor on
urinary albumin excretion rate (UAER) and
B-184
glomerular filtration rate (GFR) in type 1 diabetic
patients with incipient nephropathy. Diabete et
Metabolisme 1993; 19(2):257-61. Sample size less
than 50 patients
3334. Rangemark C, Lind H, Lindholm L, et al. Lisinopril
reduces postexercise albuminuria more effectively
than atenolol in primary hypertension. European
Journal of Clinical Pharmacology 1996; 49(4):26771. Follow-up less than 6 months
3335. Ranich T, Bhathena SJ, Velasquez MT. Protective
effects of dietary phytoestrogens in chronic renal
disease. Journal of Renal Nutrition 2001; 11(4):18393. Not CKD treatment
3336. Ranieri G, Andriani A, Lamontanara G, et al. Effects
of lisinopril and amlodipine on microalbuminuria and
renal function in patients with hypertension. Clinical
Pharmacology & Therapeutics 1994; 56(3):323-30.
Sample size less than 50 patients
3337. Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam
prophylaxis of postoperative acute renal failure in
high-risk cardiac surgery patients. Annals of
Thoracic Surgery 2004; 78(4):1332-7; discussion 78. Not RCT or controlled trial
3338. Rapini RP, Herbert AA, Drucker CR. Acquired
perforating dermatosis. Evidence for combined
transepidermal elimination of both collagen and
elastic fibers. Archives of Dermatology 1989;
125(8):1074-8. Sample size less than 50 patients
3339. Rappelli A, Dessi-Fulgheri P, Madeddu P, et al.
Studies on the natriuretic effect of nifedipine in
hypertensive patients: increase in levels of plasma
atrial natriuretic factor without participation of the
renal kallikrein-kinin system. Journal of
Hypertension - Supplement 1987; 5(4):S61-5.
Sample size less than 50 patients
3340. Rasaratnam B, Kaye D, Jennings G, et al. The effect
of selective intestinal decontamination on the
hyperdynamic circulatory state in cirrhosis. A
randomized trial. Annals of Internal Medicine 2003;
139(3):186-93. Not CKD treatment
3341. Rashid ST, Salman M, Myint F, et al. Prevention of
contrast-induced nephropathy in vascular patients
undergoing angiography: a randomized controlled
trial of intravenous N-acetylcysteine. Journal of
Vascular Surgery 2004; 40(6):1136-41. Not relevant
to key questions
3342. Rasmussen A, Jespersen L. Reduced tubular
reabsorption of phosphate during post-operative
glucose infusions in humans. European Journal of
Clinical Investigation 1985; 15(3):157-60. Sample
size less than 50 patients
3343. Rasmussen A, Kimose HH, Hessov I. Severity of
postoperative hypophosphatemia in relation to
glucose administration and renal handling of
phosphate. Acta Chirurgica Scandinavica 1988;
154(11-12):617-21. Follow-up less than 6 months
3344. Rasmussen S, Leth A, Ibsen H, et al. Converting
enzyme inhibition in mild and moderate essential
hypertension. II. Acta Medica Scandinavica 1986;
219(1):29-36. Sample size less than 50 patients
3345. Ratner RE. Diabetes control and complications.
Where do we go from here? Online Journal of
Current Clinical Trials 1993; Doc No 68:[996 words;
6 paragraphs]. Not RCT or controlled trial
3346. Ravera M, Ratto E, Vettoretti S, et al. Prevention and
treatment of diabetic nephropathy: the program for
irbesartan mortality and morbidity evaluation.
Journal of the American Society of Nephrology
2005; 16 Suppl 1:S48-52. Not relevant to key
questions
3347. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to
attenuate decline in renal function in normotensive,
normoalbuminuric patients with type 2 diabetes
mellitus. A randomized, controlled trial. Annals of
Internal Medicine 1998; 128(12 Pt 1):982-8. Not
relevant to key questions
3348. Ravid M, Lang R, Rachmani R, et al. Long-term
renoprotective effect of angiotensin-converting
enzyme inhibition in non-insulin-dependent diabetes
mellitus. A 7-year follow-up study. Archives of
Internal Medicine 1996; 156(3):286-9. Not relevant
to key questions
3349. Ravid M, Neumann L, Lishner M. Plasma lipids and
the progression of nephropathy in diabetes mellitus
type II: effect of ACE inhibitors. Kidney
International 1995; 47(3):907-10. Not CKD treatment
3350. Ravid M, Savin H, Jutrin I, et al. Long-term effect of
ACE inhibition on development of nephropathy in
diabetes mellitus type II. Kidney International Supplement 1994; 45:S161-4. Not relevant to key
questions
3351. Rayner B. Advances in the treatment of diabetic
renal disease: focus on losartan. Current Medical
Research & Opinion 2004; 20(3):333-40. Not RCT or
controlled trial
3352. Rayner BL, Trinder YA, Baines D, et al. Effect of
losartan versus candesartan on uric acid, renal
function, and fibrinogen in patients with
hypertension and hyperuricemia associated with
diuretics. American Journal of Hypertension 2006;
19(2):208-13. Follow-up less than 6 months
3353. Reams G, Villarreal D, Wu Z, et al. Urinary
angiotensin II: a marker of renal tissue activity?
Nephron 1994; 67(4):450-8. Not RCT or controlled
trial
3354. Reams GP, Bauer JH. Enalapril versus triple-drug
therapy in the treatment of renovascular
hypertension. Drugs 1985; 30 Suppl 1:59-69. Sample
size less than 50 patients
3355. Reams GP, Lau A, Bauer JH. Short-term and longterm renal response to nifedipine monotherapy.
American Journal of Hypertension 1989; 2(3 Pt
1):188-90. Not CKD treatment
3356. Reams GP, Lau A, Hamory A, et al. Amlodipine
therapy corrects renal abnormalities encountered in
the hypertensive state. American Journal of Kidney
Diseases 1987; 10(6):446-51. Sample size less than
50 patients
3357. Reddan D, Laville M, Garovic VD. Contrast-induced
nephropathy and its prevention: What do we really
know from evidence-based findings? Journal of
Nephrology 2009; 22(3):333-51. Not RCT or
controlled trial
B-185
3358. Reddan DN, Frankenfield DL, Klassen PS, et al.
Regional variability in anaemia management and
haemoglobin in the US. Nephrology Dialysis
Transplantation 2003; 18(1):147-52. Not early CKD
3359. Reddan DN, O'Shea JC, Sarembock IJ, et al.
Treatment effects of eptifibatide in planned coronary
stent implantation in patients with chronic kidney
disease (ESPRIT Trial). American Journal of
Cardiology 2003; 91(1):17-21. Follow-up less than 6
months
3360. Redman BG, Flaherty L, Martino S, et al. Effect of
calcium replacement on the hemodynamic changes
associated with high dose interleukin-2 therapy.
American Journal of Clinical Oncology 1992;
15(4):340-3. Not CKD treatment
3361. Regamey F, Maillard M, Nussberger J, et al. Renal
hemodynamic and natriuretic effects of concomitant
Angiotensin-converting enzyme and neutral
endopeptidase inhibition in men. Hypertension 2002;
40(3):266-72. Sample size less than 50 patients
3362. Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical
pharmacokinetics of tacrolimus in heart transplant
recipients. Therapeutic Drug Monitoring 1999;
21(1):2-7. Not CKD treatment
3363. Reich DJ, Clavien PA, Hodge EE, et al.
Mycophenolate mofetil for renal dysfunction in liver
transplant recipients on cyclosporine or tacrolimus:
randomized, prospective, multicenter pilot study
results. Transplantation 2005; 80(1):18-25. Followup less than 6 months
3364. Reichard P, Nilsson BY, Rosenqvist U. The effect of
long-term intensified insulin treatment on the
development of microvascular complications of
diabetes mellitus. New England Journal of Medicine
1993; 329(5):304-9. Not early CKD
3365. Reichard P, Pihl M, Rosenqvist U, et al.
Complications in IDDM are caused by elevated
blood glucose level: the Stockholm Diabetes
Intervention Study (SDIS) at 10-year follow up.
Diabetologia 1996; 39(12):1483-8. Sample size less
than 50 patients
3366. Reichard P, Rosenqvist U. Nephropathy is delayed
by intensified insulin treatment in patients with
insulin-dependent diabetes mellitus and retinopathy.
Journal of Internal Medicine 1989; 226(2):81-7. Not
relevant to key questions
3367. Reichel H, Grussinger A, Knehans A, et al. Longterm therapy with cyclosporin A does not influence
serum concentrations of vitamin D metabolites in
patients with multiple sclerosis. Clinical Investigator
1992; 70(7):595-9. Not CKD treatment
3368. Reichert LJ, Koene RA, Wetzels JF. Acute
haemodynamic and proteinuric effects of
prednisolone in patients with a nephrotic syndrome.
Nephrology Dialysis Transplantation 1999; 14(1):917. Sample size less than 50 patients
3369. Reid A, Stohr W, Walker AS, et al. Severe renal
dysfunction and risk factors associated with renal
impairment in HIV-infected adults in Africa
initiating antiretroviral therapy. Clinical Infectious
Diseases 2008; 46(8):1271-81. Not CKD treatment
3370. Reimann IW, Golbs E, Fischer C, et al. Influence of
intravenous acetylsalicylic acid and sodium salicylate
on human renal function and lithium clearance.
European Journal of Clinical Pharmacology 1985;
29(4):435-41. Sample size less than 50 patients
3371. Reisler RB, Han C, Burman WJ, et al. Grade 4 events
are as important as AIDS events in the era of
HAART. Journal of Acquired Immune Deficiency
Syndromes: JAIDS 2003; 34(4):379-86. Not relevant
to key questions
3372. Remuzzi G, Macia M, Ruggenenti P. Prevention and
treatment of diabetic renal disease in type 2 diabetes:
the BENEDICT study. Journal of the American
Society of Nephrology 2006; 17(4 Suppl 2):S90-7.
Sample size less than 50 patients
3373. Remuzzi G, Ruggenenti P, Perna A, et al. Continuum
of renoprotection with losartan at all stages of type 2
diabetic nephropathy: a post hoc analysis of the
RENAAL trial results. Journal of the American
Society of Nephrology 2004; 15(12):3117-25. Not
relevant to key questions
3374. Renke M, Tylicki L, Knap N, et al. Spironolactone
attenuates oxidative stress in patients with chronic
kidney disease. Hypertension 2008; 52(5):e132-3;
author reply e4. Not CKD treatment
3375. Renke M, Tylicki L, Knap N, et al. High-dose
angiotensin-converting enzyme inhibitor attenuates
o